

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:38:23 ; Search time 693 Seconds

(without alignments)
3.951 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatactctctagtgaag.....ttgtaattctagtgctgat 2267

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	44.2	1.9	289	1	ACCESSION:AR162089
C 2	44.2	1.9	289	1	ACCESSION:AR166614
C 3	44.2	1.9	2422	1	ACCESSION:AR030786
C 4	44.2	1.9	2422	1	ACCESSION:AR045090
C 5	44.2	1.9	2422	1	ACCESSION:AR052946
C 6	44.2	1.9	2422	1	ACCESSION:AR122899
C 7	44.2	1.9	2422	1	ACCESSION:AR127821
C 8	44.2	1.9	2462	1	ACCESSION:AR095304
C 9	44.2	1.9	2462	1	ACCESSION:AR103988
C 10	44.2	1.9	2462	1	ACCESSION:AR335083
C 11	44.2	1.9	2462	1	ACCESSION:AR409604
C 12	44.2	1.9	2462	1	ACCESSION:MI1322
C 13	44.2	1.9	2483	1	ACCESSION:E01076
C 14	44.2	1.9	2483	1	ACCESSION:I07990
C 15	44	1.9	2177	1	ACCESSION:E01075
C 16	44	1.9	2438	1	ACCESSION:I07991
C 17	37.4	1.6	1573	1	ACCESSION:BC040125
C 18	32.4	1.4	300	1	ACCESSION:BD211952
C 19	28	1.2	1403	1	ACCESSION:BC009726
C 20	27.2	1.2	1792	1	ACCESSION:BC034377
C 21	25.2	1.1	1843	1	ACCESSION:AR390799
C 22	25.2	1.1	1843	1	ACCESSION:AX411026
C 23	25.2	1.1	1843	1	ACCESSION:X02750
C 24	24.4	1.1	251	1	ACCESSION:AY083553
C 25	24	1.1	1499	1	ACCESSION:DI0445
C 26	24	1.1	1580	1	ACCESSION:AF318182
C 27	24	1.1	1603	1	ACCESSION:BC013896
C 28	23.8	1.0	364	1	ACCESSION:AR425705
C 29	23.8	1.0	364	1	ACCESSION:BD121258
C 30	23.8	1.0	868	1	ACCESSION:BD124660
C 31	23.8	1.0	868	1	ACCESSION:BD126609
C 32	23.6	1.0	1671	1	ACCESSION:AY040345
C 33	23	1.0	364	1	ACCESSION:AR425705

C 34	23	1.0	364	1	BD121258	ACCESSION:BD121258
C 35	23	1.0	394	1	AX839180	ACCESSION:AX839180
C 36	23	1.0	1329	1	AF465274	ACCESSION:AF465274
C 37	23	1.0	1507	1	AX774765	ACCESSION:AX774765
C 38	23	1.0	1507	1	HUMFACX	ACCESSION:M57285
C 39	22.8	1.0	200	1	AX395271	ACCESSION:AX395271
C 40	22.8	1.0	210	1	AB06245853	ACCESSION:AB062462
C 41	22.8	1.0	210	1	AB06245853	ACCESSION:AB062463
C 42	22.2	1.0	223	1	AX908508	ACCESSION:AX908508
C 43	22.2	1.0	223	1	BD044041	ACCESSION:BD044041
C 44	22	1.0	121	1	AX265077	ACCESSION:AX265077
C 45	22	1.0	121	1	AX265078	ACCESSION:AX265078
C 46	22	1.0	121	1	AX265081	ACCESSION:AX265081
C 47	22	1.0	121	1	AX265082	ACCESSION:AX265082
C 48	22	1.0	121	1	AX265085	ACCESSION:AX265085
C 49	22	1.0	121	1	AX265086	ACCESSION:AX265086
C 50	22	1.0	121	1	AX265089	ACCESSION:AX265089
C 51	22	1.0	121	1	AX265090	ACCESSION:AX265090
C 52	22	1.0	121	1	AX265093	ACCESSION:AX265093
C 53	22	1.0	121	1	AX265094	ACCESSION:AX265094
C 54	22	1.0	121	1	AX265073	ACCESSION:AX265073
C 55	22	1.0	121	1	AX265074	ACCESSION:AX265074
C 56	22	1.0	193	1	HUMKALR4	ACCESSION:M33108
C 57	22	1.0	240	1	HUMFIXG3	ACCESSION:K02050
C 58	22	1.0	385	1	AX892787	ACCESSION:AX892787
C 59	22	1.0	385	1	BD028320	ACCESSION:BD028320
C 60	22	1.0	409	1	AX839163	ACCESSION:AX839163
C 61	21.6	1.0	860	1	AF011898	ACCESSION:AF011898
C 62	21.6	1.0	861	1	AF011352	ACCESSION:AF011352
C 63	21.6	1.0	1869	1	BC061149	ACCESSION:BC061149
C 64	21.4	0.9	328	1	AX839181	ACCESSION:AX839181
C 65	21.4	0.9	1129	1	AX464088	ACCESSION:AX464088
C 66	21.4	0.9	1129	1	AY359106	ACCESSION:AY359106
C 67	21.4	0.9	6098	1	AX565990	ACCESSION:AX565990
C 68	21.2	0.9	121	1	AX265101	ACCESSION:AX265101
C 69	21.2	0.9	121	1	AX265102	ACCESSION:AX265102
C 70	21.2	0.9	121	1	AX265097	ACCESSION:AX265097
C 71	21.2	0.9	121	1	AX265098	ACCESSION:AX265098
C 72	21.2	0.9	1541	1	BC046125	ACCESSION:BC046125
C 73	21	0.9	267	1	BD060364	ACCESSION:BD060364
C 74	21	0.9	280	1	AF306917	ACCESSION:AF306917
C 75	21	0.9	280	1	AF306913	ACCESSION:AF306913
C 76	21	0.9	280	1	AF306914	ACCESSION:AF306914
C 77	21	0.9	280	1	AF306915	ACCESSION:AF306915
C 78	21	0.9	280	1	AF306919	ACCESSION:AF306919
C 79	21	0.9	1722	1	AF515269	ACCESSION:AF515269
C 80	20.8	0.9	484	1	RATCFX	ACCESSION:RATCFX
C 81	20.6	0.9	341	1	AX524243	ACCESSION:AX524243
C 82	20.6	0.9	341	1	AX552981	ACCESSION:AX552981
C 83	20.6	0.9	1206	1	E63001	ACCESSION:E63001
C 84	20.6	0.9	1206	1	E63002	ACCESSION:E63002
C 85	20.6	0.9	1221	1	E62997	ACCESSION:E62997
C 86	20.6	0.9	1221	1	E62998	ACCESSION:E62998
C 87	20.6	0.9	1221	1	E62999	ACCESSION:E62999
C 88	20.6	0.9	1221	1	E63000	ACCESSION:E63000
C 89	20.6	0.9	1440	1	AR112953	ACCESSION:AR112953
C 90	20.6	0.9	1440	1	AR112969	ACCESSION:AR112969
C 91	20.6	0.9	1440	1	I19358	ACCESSION:I19358
C 92	20.6	0.9	1440	1	I19360	ACCESSION:I19360
C 93	20.6	0.9	1440	1	BD194674	ACCESSION:BD194674
C 94	20.6	0.9	6098	1	AX565990	ACCESSION:AX565990
C 95	20.4	0.9	394	1	AX839180	ACCESSION:AX839180
C 96	20.4	0.9	1416	1	AF465269	ACCESSION:AF465269
C 97	20.4	0.9	2072	1	AF272774	ACCESSION:AF272774
C 98	20.4	0.9	2078	1	AF272773	ACCESSION:AF272773
C 99	20.2	0.9	183	1	AY155152	ACCESSION:AY155152
C 100	20.2	0.9	214	1	AB083386	ACCESSION:AB083386
C 101	20.2	0.9	214	1	AB084901	ACCESSION:AB084901
C 102	20.2	0.9	227	1	AY022473	ACCESSION:AY022473
C 103	20.2	0.9	227	1	AY023221	ACCESSION:AY023221
C 104	20.2	0.9	272	1	HUMPROS01	ACCESSION:M36551 J
C 105	20.2	0.9	274	1	AF306920	ACCESSION:AF306920
C 106	20.2	0.9	352	1	HUMPS02	ACCESSION:M57841 J

C 107	20.2	0.9	885	1	AR108139	ACCESSION:AR108139	C 180	18.6	0.8	168	1	AR151537	ACCESSION:AR151537
C 108	20.2	0.9	1543	1	AX401899	ACCESSION:AX401899	C 181	18.6	0.8	168	1	I82435	ACCESSION:I82435
C 109	20.2	0.9	1543	1	RNPROC	ACCESSION:Y64336 S	C 182	18.6	0.8	174	1	HUMPRB01	ACCESSION:M36565 J
C 110	20	0.9	855	1	AF011899	ACCESSION:AF011899	C 183	18.6	0.8	189	1	AX135778S1	ACCESSION:AX135778S1
C 111	20	0.9	1130	1	AR234337	ACCESSION:AR234337	C 184	18.6	0.8	189	1	AX135796S1	ACCESSION:AX135796S1
C 112	20	0.9	1142	1	AR219285	ACCESSION:AR219285	C 185	18.6	0.8	200	1	AR047835	ACCESSION:AR047835
C 113	20	0.9	1166	1	AR221273	ACCESSION:AR221273	C 186	18.6	0.8	222	1	AX260845	ACCESSION:AX260845
C 114	20	0.9	1169	1	AR219284	ACCESSION:AR219284	C 187	18.6	0.8	241	1	HS98A12P	ACCESSION:263614
C 115	20	0.9	1722	1	AF515269	ACCESSION:AF515269	C 188	18.6	0.8	289	1	AR162089	ACCESSION:AR162089
C 116	19.8	0.9	254	1	AX587861	ACCESSION:AX587861	C 189	18.6	0.8	289	1	AR166614	ACCESSION:AR166614
C 117	19.8	0.9	268	1	HSUKB1FJ7	ACCESSION:AF055326	C 190	18.6	0.8	427	1	AX524284	ACCESSION:AX524284
C 118	19.8	0.9	384	1	BD095271	ACCESSION:BD095271	C 191	18.6	0.8	427	1	AX553022	ACCESSION:AX553022
C 119	19.8	0.9	394	1	AX814618	ACCESSION:AX814618	C 192	18.6	0.8	439	1	AX277349	ACCESSION:AX277349
C 120	19.8	0.9	535	1	DLA6882	ACCESSION:AJ006882	C 193	18.6	0.8	439	1	AX277375	ACCESSION:AX277375
C 121	19.8	0.9	556	1	BV036036	ACCESSION:BV036036	C 194	18.6	0.8	484	1	MACCFX	ACCESSION:D21214
C 122	19.8	0.9	813	1	P1GFIAX	ACCESSION:M26235	C 195	18.6	0.8	546	1	AX775014	ACCESSION:AX775014
C 123	19.8	0.9	873	1	HUMCFIX	ACCESSION:M35672	C 196	18.6	0.8	624	1	AX335885	ACCESSION:AX335885
C 124	19.8	0.9	1850	1	MMU44795	ACCESSION:U44795	C 197	18.6	0.8	624	1	HUMFX8	ACCESSION:L29433 M
C 125	19.6	0.9	484	1	HAMCFX	ACCESSION:D21216	C 198	18.6	0.8	711	1	BD173590	ACCESSION:BD173590
C 126	19.6	0.9	596	1	AX193364	ACCESSION:AX193364	C 199	18.6	0.8	773	1	AX827818	ACCESSION:AX827818
C 127	19.6	0.9	609	1	AX763043	ACCESSION:AX763043	C 200	18.6	0.8	773	1	RNTRY2	ACCESSION:V01274
C 128	19.6	0.9	882	1	AX675583	ACCESSION:AX675583	C 201	18.6	0.8	819	1	DOGRYPA	ACCESSION:M11589
C 129	19.6	0.9	1442	1	AR219285	ACCESSION:AR219285	C 202	18.6	0.8	854	1	PVTRYP8IN	ACCESSION:X86369
C 130	19.6	0.9	1161	1	AX675581	ACCESSION:AX675581	C 203	18.6	0.8	1278	1	AF465268	ACCESSION:AF465268
C 131	19.6	0.9	1169	1	AR219284	ACCESSION:AR219284	C 204	18.6	0.8	1443	1	HUMFXM	ACCESSION:X03194
C 132	19.6	0.9	1373	1	BOVPBC	ACCESSION:X02435	C 205	18.6	0.8	1467	1	A86859	ACCESSION:A86859
C 133	19.4	0.9	177	1	AR109618	ACCESSION:AR109618	C 206	18.6	0.8	1467	1	A86886	ACCESSION:A86886
C 134	19.4	0.9	177	1	AR150638	ACCESSION:AR150638	C 207	18.6	0.8	1467	1	AR316969	ACCESSION:AR316969
C 135	19.4	0.9	177	1	E16187	ACCESSION:E16187	C 208	18.6	0.8	1467	1	AR340866	ACCESSION:AR340866
C 136	19.4	0.9	177	1	E27213	ACCESSION:E27213	C 209	18.6	0.8	1467	1	AX082959	ACCESSION:AX082959
C 137	19.4	0.9	177	1	E28271	ACCESSION:E28271	C 210	18.6	0.8	1467	1	BD070392	ACCESSION:BD070392
C 138	19.4	0.9	177	1	AR300928	ACCESSION:AR300928	C 211	18.6	0.8	1467	1	BD070435	ACCESSION:BD070435
C 139	19.4	0.9	204	1	AR109885	ACCESSION:AR109885	C 212	18.6	0.8	1514	1	AF191307	ACCESSION:AF191307
C 140	19.4	0.9	204	1	AR150703	ACCESSION:AR150703	C 213	18.4	0.8	193	1	HUMKALR4	ACCESSION:X33108
C 141	19.4	0.9	249	1	AJ586104	ACCESSION:AJ586104	C 214	18.4	0.8	249	1	HUMDPBIA	ACCESSION:N77674
C 142	19.4	0.9	290	1	AX83191	ACCESSION:AX83191	C 215	18.4	0.8	249	1	HUMDPBA	ACCESSION:D10478
C 143	19.4	0.9	352	1	HUMPS02	ACCESSION:M57841 J	C 216	18.4	0.8	249	1	HUMDPBB	ACCESSION:D10479
C 144	19.4	0.9	471	1	DOGA2	ACCESSION:D43751	C 217	18.4	0.8	249	1	HUMMDPBH	ACCESSION:M23680
C 145	19.4	0.9	823	1	SHPP1XA	ACCESSION:M26233	C 218	18.4	0.8	256	1	HUMMDP1H	ACCESSION:M23333
C 146	19.4	0.9	829	1	BC061135	ACCESSION:BC061135	C 219	18.4	0.8	257	1	AF180970	ACCESSION:AF180970
C 147	19.4	0.9	1126	1	AR095306	ACCESSION:AR095306	C 220	18.4	0.8	264	1	HUMDPB1KT	ACCESSION:D10882
C 148	19.4	0.9	1126	1	AR103990	ACCESSION:AR103990	C 221	18.4	0.8	283	1	AF336224	ACCESSION:AF336224
C 149	19.4	0.9	1126	1	HUMFX	ACCESSION:R01886	C 222	18.4	0.8	285	1	AF492638	ACCESSION:AF492638
C 150	19.4	0.9	1404	1	A93124	ACCESSION:A93124	C 223	18.4	0.8	285	1	HUMMDPBZ	ACCESSION:M83912
C 151	19.4	0.9	1414	1	HUMCFX	ACCESSION:M2613	C 224	18.4	0.8	804	1	AF312826	ACCESSION:AF312826
C 152	19.4	0.9	1551	1	AX147505	ACCESSION:AX147505	C 225	18.4	0.8	832	1	SHEFFIXA	ACCESSION:M26233
C 153	19.4	0.9	1850	1	MMU44795	ACCESSION:U44795	C 226	18.4	0.8	832	1	AF011900	ACCESSION:AF011900
C 154	19.4	0.9	1869	1	BC061149	ACCESSION:BC061149	C 227	18.4	0.8	1293	1	AF465275	ACCESSION:AF465275
C 155	19.2	0.8	281	1	MUSACROS02	ACCESSION:M96427 M	C 228	18.4	0.8	1505	1	AX523898	ACCESSION:AX523898
C 156	19.2	0.8	471	1	GOTA3	ACCESSION:D43752	C 229	18.2	0.8	171	1	S78934	ACCESSION:S78934
C 157	19.2	0.8	596	1	BV094002	ACCESSION:BV094002	C 230	18.2	0.8	240	1	AX318568	ACCESSION:AX318568
C 158	19.2	0.8	826	1	RARBTHRO	ACCESSION:M81396	C 231	18.2	0.8	251	1	AY083553	ACCESSION:AY083553
C 159	19.2	0.8	1302	1	AF465270	ACCESSION:AF465270	C 232	18.2	0.8	265	1	HSTCRB9	ACCESSION:X74849
C 160	19.2	0.8	1341	1	AF532184	ACCESSION:AF532184	C 233	18.2	0.8	836	1	AF011901	ACCESSION:AF011901
C 161	19.2	0.8	1619	1	OCU77477	ACCESSION:U77477 S	C 234	18.2	0.8	987	1	AF542056	ACCESSION:AF542056
C 162	19.1	0.8	279	1	AF306907	ACCESSION:AF306907	C 235	18.2	0.8	1558	1	OCU49933	ACCESSION:U49933
C 163	19.1	0.8	279	1	AF306908	ACCESSION:AF306908	C 236	18	0.8	199	1	S68634	ACCESSION:S68634
C 164	19.1	0.8	279	1	AF306912	ACCESSION:AF306912	C 237	18	0.8	276	1	I14646	ACCESSION:I14646
C 165	19	0.8	244	1	HSRCYB2S3	ACCESSION:U72402	C 238	18	0.8	276	1	AY267909S2	ACCESSION:AY267910
C 166	18.8	0.8	340	1	AR263850	ACCESSION:AR263850	C 239	18	0.8	276	1	ASHA507648	ACCESSION:AJ507648
C 167	18.8	0.8	340	1	AR263851	ACCESSION:AR263851	C 240	18	0.8	276	1	HSHLAAGN2	ACCESSION:U90243
C 168	18.8	0.8	352	1	DMU58868	ACCESSION:U58868	C 241	18	0.8	290	1	AR249144	ACCESSION:AR249144
C 169	18.8	0.8	596	1	AX193364	ACCESSION:AX193364	C 242	18	0.8	299	1	AX312474	ACCESSION:AX312474
C 170	18.8	0.8	882	1	AX675583	ACCESSION:AX193364	C 243	18	0.8	302	1	BR2A271156	ACCESSION:AJ271156
C 171	18.8	0.8	1161	1	AX675581	ACCESSION:AX675583	C 244	18	0.8	335	1	FRSPLEX2	ACCESSION:X95338
C 172	18.8	0.8	1505	1	AX523898	ACCESSION:AX523898	C 245	18	0.8	383	1	AF266240	ACCESSION:AF266240
C 173	18.8	0.8	1671	1	AY040345	ACCESSION:AY040345	C 246	18	0.8	815	1	AX921761	ACCESSION:AX921761
C 174	18.6	0.8	168	1	AR077689	ACCESSION:AR077689	C 247	18	0.8	873	1	HUMCFIX	ACCESSION:M35672
C 175	18.6	0.8	168	1	AR081819	ACCESSION:AR081819	C 248	18	0.8	1329	1	AF465274	ACCESSION:AF465274
C 176	18.6	0.8	168	1	AR098999	ACCESSION:AR098999	C 249	18	0.8	1389	1	E02492	ACCESSION:E02492
C 177	18.6	0.8	168	1	AR116830	ACCESSION:AR116830	C 250	17.8	0.8	177	1	AX381010	ACCESSION:AX381010
C 178	18.6	0.8	168	1	AR127061	ACCESSION:AR127061							
C 179	18.6	0.8	168	1	AR141647	ACCESSION:AR141647							

ALIGNMENTS

```
RESULT 1
AR162089/c
LOCUS          AR162089          289 bp      DNA          linear      PAT 17-OCT-2001
DEFINITION     Sequence 17 from patent US 6258558.
ACCESSION      AR162089
VERSION        AR162089.1  GI:16229155
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 289)
AUTHORS        Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE          Method for selection of proteins using RNA-protein fusions
JOURNAL        Patent: US 6258558-A 17 10-JUL-2001;
FEATURES       Location/Qualifiers
source         1..289
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 289;
Best Local Similarity 12.8%; Pred. No. 4.9e-05;
Matches 37; Conservative 105; Mismatches 147; Indels 0; Gaps 0;

Qy 1625 GGTCTTTTGTATGCTTCTTGACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 289 GGTCTTTTGTATGCTTCTTGACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1685 TCTTTTGGTTTCTTGAAAATATTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTTCCCTTCTT 1744
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 229 YAGYCYTYGYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 170
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1745 CTATTCTCTTGGTTTGTGCAATGCTCTGCTGCTTCCCTGATGTTTATGCTGCTGATPAT 1804
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 169 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 110
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1805 TTTAGACTTAACATTTCTTTGACCAAGGATATCCATTTCTTCTATCTTCTTCTTCTTCT 1864
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 109 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 50
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1865 TGAGATTCCTCTTCTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1913
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 49 YGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYCYCY 1
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 2
AR166614/c
LOCUS          AR166614          289 bp      DNA          linear      PAT 17-OCT-2001
DEFINITION     Sequence 17 from patent US 6281344.
ACCESSION      AR166614
VERSION        AR166614.1  GI:16242009
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 289)
AUTHORS        Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE          Nucleic acid-protein fusion molecules and libraries
JOURNAL        Patent: US 6281344-A 17 28-AUG-2001;
FEATURES       Location/Qualifiers
source         1..289
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 289;
Best Local Similarity 12.8%; Pred. No. 4.9e-05;
Matches 37; Conservative 105; Mismatches 147; Indels 0; Gaps 0;

Qy 1625 GGTCTTTTGTATGCTTCTTGACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 289 GGTCTTTTGTATGCTTCTTGACCTTGATAGGATCTCTTCTCAAGGTTAGGAAATTTT 1684
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1685 TCTTTTGGTTTCTTGAAAATATTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTTCCCTTCTT 1744
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 229 YAGYCYTYGYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 170
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1745 CTATTCTCTTGGTTTGTGCAATGCTCTGCTGCTTCCCTGATGTTTATGCTGCTGATPAT 1804
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 169 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 110
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1805 TTTAGACTTAACATTTCTTTGACCAAGGATATCCATTTCTTCTATCTTCTTCTTCTTCT 1864
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 109 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 50
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1865 TGAGATTCCTCTTCTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1913
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 49 YGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYCYCY 1
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 3
AR030786/c
LOCUS          AR030786          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5861374.
ACCESSION      AR030786
VERSION        AR030786.1  GI:5944000
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian. and Hart,C.E.
TITLE          Modified Factor VII
JOURNAL        Patent: US 5861374-A 1 19-JAN-1999;
FEATURES       Location/Qualifiers
source         1..2422
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy 1104 GCATTTGGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1163
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2167 GCACATGTGAGTCAGATCGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2108
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1164 TGTCTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1216
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2107 GGTGTGTGTGCGCACTTGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2055
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 4
AR045090/c
LOCUS          AR045090          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5817788.
ACCESSION      AR045090
VERSION        AR045090.1  GI:5966555
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and
               Bregengaard,C.
TITLE          Modified factor VII
JOURNAL        Patent: US 5817788-A 1 06-OCT-1998;
FEATURES       Location/Qualifiers
source         1..2422
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
```

```
Qy 1685 TCTTTTGGTTTCTTGAAAATATTTTCCCTGCTTGTGACCTGCTTCTTCCCTTCTTCCCTTCTT 1744
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 229 YAGYCYTYGYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 170
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1745 CTATTCTCTTGGTTTGTGCAATGCTCTGCTGCTTCCCTGATGTTTATGCTGCTGATPAT 1804
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 169 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 110
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1805 TTTAGACTTAACATTTCTTTGACCAAGGATATCCATTTCTTCTATCTTCTTCTTCTTCT 1864
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 109 YNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYSYNNYS 50
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 1865 TGAGATTCCTCTTCTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1913
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Qy 49 YGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYAYATYTYGYTYCYCY 1
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 3
AR030786/c
LOCUS          AR030786          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5861374.
ACCESSION      AR030786
VERSION        AR030786.1  GI:5944000
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian. and Hart,C.E.
TITLE          Modified Factor VII
JOURNAL        Patent: US 5861374-A 1 19-JAN-1999;
FEATURES       Location/Qualifiers
source         1..2422
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

Qy 1104 GCATTTGGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1163
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2167 GCACATGTGAGTCAGATCGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2108
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1164 TGTCTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1216
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2107 GGTGTGTGTGCGCACTTGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 2055
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 4
AR045090/c
LOCUS          AR045090          2422 bp      DNA          linear      PAT 29-SEP-1999
DEFINITION     Sequence 1 from patent US 5817788.
ACCESSION      AR045090
VERSION        AR045090.1  GI:5966555
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknow.
REFERENCE      1 (bases 1 to 2422)
AUTHORS        Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and
               Bregengaard,C.
TITLE          Modified factor VII
JOURNAL        Patent: US 5817788-A 1 06-OCT-1998;
FEATURES       Location/Qualifiers
source         1..2422
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      1.9%; Score 44.2; DB 1; Length 2422;
Best Local Similarity 61.9%; Pred. No. 5.7e-05;
Matches 70; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
```



```
KEYWORDS JP 1987000283-A/1.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 2177)
AUTHORS Furederitsuku,E.H., Maaku,J.M., Shiyaaron,J.B., Kiyasuriin,E.B.,
        Maagaratsuto,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.
TITLE DNA ENCODING FACTOR VII
JOURNAL Patent: JP 1987000283-A 1 06-JAN-1987;
        HEMOJENETITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
        TOYO SODA MFG CO LTD
COMMENT OS Human {Homo sapiens}
        PN JP 1987000283-A/1
        PD 06-JAN-1987
        PF 16-APR-1986 JP 1986087861
        PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
        FUREDERITSUKU ESU HAAGEN, MAARU JIEI MARII,
        PI SHIYAARON JIEI BAZUBII,
        PI KIVASURIIN ERU BAAKUNAA, MAAGARETSUTO WAI INSUREE, PI
        RICHIAADO JII UTSUDOBERRII, CHIYAARUZU ERU GUREI PC
        C12N15/00,A61K37/45,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC
        strandedness: Double;
        CC topology: Linear;
        CC hypothetical: No;
        CC anti-sense: No;
        CC *source: tissue type=liver;
        CC *source: library=cDNA library, lambda dt11 cDNA library; CC
        *source: clone=lambdaviI 2115, lambda daviI 1923; FH Key
        Location/Qualifiers
FH CDS 13..1128
FT CDS /product='factor VII peptide' FT
FT polyA_signal 2106..2111
FT exon <1..12
FT 3'UTR 1129..<2177.
FEATURES
source
1..2177
Location/Qualifiers
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'

Query Match 1.9%; Score 44; DB 1; Length 2177;
Best Local Similarity 63.0%; Pred. No. 6.3e-05;
Matches 68; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1080 GTGTTTGGGATCTTGTTATCTTGCACCTTGTGAAGTGTGTGTGTGTGTGTGTG 1139
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1755 GTGTCGCGTGCATTGGCATGTGCGTGCACCTCCATGTGTATATCTGTGTGTCATCTGTGTG 1696
QY 1140 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1187
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1695 TGCATATCTATGTGCGTGTGTCATCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1648

RESULT 16
107991/c
LOCUS
DEFINITION Homo sapiens, similar to coagulation factor X, clone IMAGE:5764698,
        mRNA.
ACCESSION BC040125
VERSION BC040125.1 GI:25455627
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1573)
AUTHORS Strausberg,R.
TITLE Direct Submission
JOURNAL Submitted (22-NOV-2002) National Institutes of Health, Mammalian
        Gene Collection (MGC), Cancer Genomics Office, National Cancer
        Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
        USA
REMARK NHT-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
        Email: cgapbs-remail.nih.gov
        Tissue Procurement: Life Technologies, Inc.
        cDNA Library Preparation: Life Technologies, Inc.
        cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
        DNA Sequencing by: Institute for Systems Biology
        http://www.systemsbio.org
        contact: amadan@systemsbiology.org
        Anup Madan, Jessica Fahey, Erin Helton, Mark Ketterman, Anuradha
        Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
        through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
        Series: IRAP Plate: 84 Row: m Column: 9
        This clone was selected for full length sequencing because it
        passed the following selection criteria: matched mRNA gi: 9961350.
FEATURES
source
1..1573
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='mRNA'
/db_xref='taxon:9606'
/clone='IMAGE:5764698'
/tissue_type='Brain, adult, 6 pooled whole brains'
/clone_lib='NIH MGC_114'
/lab_host='DH10B'
/note='Vector: pCMV-SPORT6'

Query Match 1.6%; Score 37.4; DB 1; Length 1573;
Best Local Similarity 51.5%; Pred. No. 0.0032;
Matches 86; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

QY 1506 TTATATGTTAAATGGTCTTTTTCCTTGCATCTTTAAATATCTTTCTTTGTCATATA 1565
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1564 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1505
QY 1566 CTTTCTAGTATTGATTATTATGCACTGTGGGGAGTTCTTTTCCGTCGAATATTGTG 1625
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1504 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTT 1445
```

[illegible]

[illegible]


```
CDS
Query Match 1.0%; Score 23; DB 1; Length 1329;
Best Local Similarity 74.4%; Pred. No. 17;
Matches 29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1573 TGATTGATTATTATGCACTGTGGGAGTTCTTTCCG 1611
|||||
Db 5 TGATTAGGATTGCTGCACCTGTTGGATTCTCTTTCCG 43

RESULT 37
AX774765/c
LOCUS AX774765 1507 bp DNA linear PAT 09-JUL-2003
DEFINITION Sequence 81 from Patent WO03038129.
ACCESSION AX774765
VERSION AX774765.1 GI:32486281
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Raponi, M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 03038129-A 81 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)
FEATURES
source
1. .1507
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 23; DB 1; Length 1507;
Best Local Similarity 60.3%; Pred. No. 17;
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1622 TTGTGTTTGTATGCTTTGTACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAT 1681
|||||
Db 1506 TTTTGTGTTTGTATGCTTTGTACCTTGATAGGCACTCTTTCTCAAGGTTAGGACGT 1447

QY 1682 TTT 1684
Db 1446 TAT 1444

RESULT 38
HUMFACX/c
LOCUS HUMFACX 1507 bp mRNA linear PRI 08-NOV-1994
DEFINITION Human coagulation factor X (F10) mRNA, complete cds.
ACCESSION M57285
VERSION M57285.1 GI:182389
KEYWORDS coagulation factor X.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Messier, T. L., Pittman, D. D., Long, G. L., Kaufman, R. J. and Church, W. R.
TITLE Cloning and expression in COS-1 cells of a full-length cDNA
JOURNAL encoding human coagulation factor X
MEDLINE Gene 99 (2), 291-294 (1991)
PUBMED 1902434
COMMENT Original source text: Human, cDNA to mRNA.
FEATURES
source
1. .1507
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q14"
/tissue type="liver"
1. .1507
/gene="F10"

gene
```


TITLE
JOURNAL

Direct Submission
Submitted (29-MAY-2001) Yoko Satta, The Graduate University for Advanced Studies, Department of Biosystems Science; 1560-35 Kamiyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:sattay@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)

FEATURES

source Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="P9"
/product="coagulation factor XI"
/number=4

exon

Query Match 1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred.No.17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGGTTTACGAGGCACATATTCCTGGTGTTATGTCTGTGTTTTG 2215
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 133 CCATTTAAACATGGATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 74
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 2216 CTTTGGCATATACCGCTGAG 2237
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 73 AATTGGCAATAAATGCTTAG 52
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 42
AX908508 223 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 24371 from Patent EP1033401.
DEFINITION AX908508
ACCESSION AX908508.1 GI:40064588
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1 Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
Expressed sequence tags and encoded human proteins
Patent: EP 1033401-A 24371 06-SEP-2000;
Genet (FR)

FEATURES

source Location/Qualifiers
1..223
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 22.2; DB 1; Length 223;
Best Local Similarity 54.2%; Pred.No.24;
Matches 45; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 1102 TTGCACCTTGGAAGTG 1161
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 4 TTGCACCTGTTGAGTG 63
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 1162 TGTGTCTGTCTGTGTCTTTGTG 1184
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 64 AGCCACCTTGGCAAGTGCCTGTG 86
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 43
BD044041 223 bp DNA linear PAT 27-AUG-2002
LOCUS Sequence tag and encoded human protein.
DEFINITION BD044041
ACCESSION BD044041.1 GI:22585783
VERSION

[illegible]

	Query Match	1.0%	Score 22;	DB 1;	Length 121;
	Best Local Similarity	53.5%	Pred. No. 26;		
	Matches	46;	Conservative	0;	Mismatches 40;
				Indels	0;
				Gaps	0;
Qy	2156	CTATTGTAATAGGGTTTTACGAGGACATATTCTCGTGTGTTATTGTCTGTGTTTTG	2215		
Db	87	CCATTTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG	28		

Qy	2216	CTTTGGCATATAGACGGCTGAGTTTG	2241
Db			
	27	AATTGGCACGTAAACTGCTTAGAATG	2
RESULT 45			
AX265078			
LOCUS	AX265078	Sequence 2469 from Patent WO0173002.	121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265078		
ACCESSION	AX265078		
VERSION	AX265078.1	GI:16513877	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Knief, E.B., Gamper, H.B. and Rice, M.C.		
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides		
JOURNAL	Patent: WO 0173002-A 2469 04-OCT-2001;		
FEATURES	UNIVERSITY OF DELAWARE (US)		
source	Location/Qualifiers		
	1..121		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	1.0%; Score 22; DB 1; Length 121;		
Best Local Similarity	53.5%; Pred. No. 26;		
Matches	46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;		
Qy	2156	CTATTGTAATAGGGTTTTACGAGGCACATTTGTCCTGGTGTGTTATGCTGTGTTTTG	2215
Db			
	35	CCATTTAAACATGGATTGGACTCACA CTGATCTCCATCTTTGAGATGAGTTAAGAAAATTG	94
Qy	2216	CTTTGGCATATAGACGGCTGAGTTTG	2241
Db			
	95	AATTGGCACGTAACTGCTTAGAATG	120
RESULT 46			
AX265081/c			
LOCUS	AX265081	Sequence 2472 from Patent WO0173002.	121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265081		
ACCESSION	AX265081		
VERSION	AX265081.1	GI:16513880	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Knief, E.B., Gamper, H.B. and Rice, M.C.		
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides		
JOURNAL	Patent: WO 0173002-A 2472 04-OCT-2001;		
FEATURES	UNIVERSITY OF DELAWARE (US)		
source	Location/Qualifiers		
	1..121		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	1.0%; Score 22; DB 1; Length 121;		
Best Local Similarity	53.5%; Pred. No. 26;		
Matches	46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;		
Qy	2156	CTATTGTAATAGGGTTTTACGAGGCACATTTGTCCTGGTGTGTTATGCTGTGTTTTG	2215
Db			
	88	CCATTTAAACATGGATTGGACTCACA CTGATCTCCATCTTTGAGATGAGTTAAGAAAATTG	29
Qy	2216	CTTTGGCATATAGACGGCTGAGTTTG	2241

```
Db 28 AATTGGCAGCTAAACTGCTTAGAATG 3
||||| ||| ||| ||| ||| |||
RESULT 47
AX265082
LOCUS AX265082 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2473 from Patent WO0173002.
ACCESSION AX265082
VERSION AX265082.1 GI:16513881
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2473 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTGGTTGTTATGTCGTGTTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 34 CCATTTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 93
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 94 AATTGGCAGCTAAACTGCTTAGAATG 119
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 48
AX265085/c
LOCUS AX265085 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2476 from Patent WO0173002.
ACCESSION AX265085
VERSION AX265085.1 GI:16513884
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2476 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTGGTTGTTATGTCGTGTTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 89 CCATTTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 30
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 29 AATTGGCAGCTAAACTGCTTAGAATG 4
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 49
AX265086
LOCUS AX265086 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2477 from Patent WO0173002.
ACCESSION AX265086
VERSION AX265086.1 GI:16513885
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2477 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTGGTTGTTATGTCGTGTTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 33 CCATTTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 92
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 93 AATTGGCAGCTAAACTGCTTAGAATG 118
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 50
AX265089/c
LOCUS AX265089 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2480 from Patent WO0173002.
ACCESSION AX265089
VERSION AX265089.1 GI:16513888
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2480 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTCCTGGTTGTTATGTCGTGTTTTTG 2215
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 86 CCATTTAAACATGGAATGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 27
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 26 AATTGGCAGCTAAACTGCTTAGAATG 1
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 51
AX265090
LOCUS AX265090 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2481 from Patent WO0173002.
ACCESSION AX265090
VERSION AX265090.1 GI:16513889
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2481 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 95
QY 2216 CTTTGGCATATAGCGGCTGAGTTTG 2241
DB 96 AATTGGCACGTAACCTGCTTAGAATG 121

RESULT 52
AX265093/c
LOCUS AX265093 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2484 from Patent WO0173002.
ACCESSION AX265093
VERSION AX265093.1 GI:16513892
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2484 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 27
QY 2216 CTTTGGCATATAGCGGCTGAGTTTG 2241
DB 26 AATTGGCACGTAACCTGCTTAGAATG 1
```

```
RESULT 53
AX265094
LOCUS AX265094 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2485 from Patent WO0173002.
ACCESSION AX265094
VERSION AX265094.1 GI:16513893
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2485 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 95
QY 2216 CTTTGGCATATAGCGGCTGAGTTTG 2241
DB 96 AATTGGCACGTAACCTGCTTAGAATG 121

RESULT 54
AX265073/c
LOCUS AX265073 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2464 from Patent WO0173002.
ACCESSION AX265073
VERSION AX265073.1 GI:16513872
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2464 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTAGCAGGACATATTGTCCTGGTGTGTTATTGTCGTGTTTGG 2215
DB 91 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 32
QY 2216 CTTTGGCATATAGCGGCTGAGTTTG 2241
DB 31 AATTGGCACGTAACCTGCTTAGAATG 6
```

```

RESULT 55
AX265074
LOCUS
DEFINITION Sequence 2465 from Patent WO0173002.
ACCESSION AX265074
VERSION AX265074.1 GI:16513873
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kniec,E.B., Ganper,H.B. and Rice,M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2465 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTGGTGTATTGCTGTGTTTGG 2215
Db 31 CCATTAAACATGGATTGGACTCACATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 90
QY 2216 CTTTGGCATATACGCGTCAGTTTG 2241
Db 91 AATTGGCAGCTAAACTGCTTAGAATG 116

RESULT 56
HUMKALR4/c
LOCUS
DEFINITION Human renal kallikrein, exon 4.
ACCESSION M33108
VERSION M33108.1 GI:186648
KEYWORDS kallikrein; kininogenase.
SEGMENT 4 of 5
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N.,
AUTHORS Nakanishi,S., Callen,D.F., Baker,E., Hyland,V.J., Sutherland,G.R.
and Richards,R.I.
TITLE Structure and chromosomal localization of the human renal
JOURNAL kallikrein gene
MEDLINE Biochemistry 27 (9), 3124-3129 (1988)
PUBMED 88269498
COMMENT Original source text: Human parotid gland, cDNA to mRNA.
FEATURES
source
1..193
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="19q13.3"
prim_transcript <1..>193
/gene="KLK1"
/note="kallikrein mRNA and introns"
intron <1..>29
/gene="KLK1"
/note="kallikrein intron C"
exon 30..166
/gene="KLK1"
/note="G00-120-118"

```

```

intron
/number=4
167..>193
/gene="KLK1"
/note="kallikrein intron D"
Query Match 1.0%; Score 22; DB 1; Length 193;
Best Local Similarity 67.4%; Pred. No. 27;
Matches 31; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
QY 953 GTAGGTGTCTTTTGGATGCGACAGTAGGATGAGTCTTGTGTTTC 998
Db 104 GCGAGTGGGGCTTTTTCACATCATCTAGGACGAGGATTTGAGGTC 59

RESULT 57
HUMFIXG3/c
LOCUS
DEFINITION Human factor IX gene, exon 4.
ACCESSION K02050
VERSION K02050.1 GI:182616
KEYWORDS Christmas factor; factor IX.
SEGMENT 3 of 6
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 240)
AUTHORS Anson,D.S., Choo,K.H., Rees,D.J., Giannelli,F., Gould,K.,
Huddleston,J.A. and Brownlee,G.G.
TITLE The gene structure of human anti-haemophilic factor IX
JOURNAL EMBO J. 3 (5), 1053-1060 (1984)
MEDLINE 84236100
PUBMED 6329734
COMMENT Original source text: Human: cDNA to liver mRNA, clones cVII, cVI,
108.1, and DB.1; 4X lymphoblastoid cell line (GM1416B) DNA, clone
lambda-HIX-4; genomic DNA library of Lawn et al., clones
lambda-HIX-1,2,3.
See segment 1
FEATURES
source
1..240
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="Xq26.3-q27.1"
prim_transcript <1..>240
/gene="F9"
/note="fix mRNA"
intron <1..64
/gene="F9"
exon 65..178
/gene="F9"
/note="fix intron 3"
intron <1..>240
/note="G00-119-900"
/number=4
179..>240
/gene="F9"
/note="fix intron 4"
Query Match 1.0%; Score 22; DB 1; Length 240;
Best Local Similarity 53.5%; Pred. No. 27;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGCTGGTGTATTGCTGTGTTTGG 2215
Db 101 CCATTAAACATGGAITGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 42
QY 2216 CTTTGGCATATACGCGTCAGTTTG 2241
Db 41 AATTGGCAGCTAAACTGCTTAGAATG 16

RESULT 58
AX892787/c

```

LOCUS AX892787 385 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8650 from Patent EP1033401.
ACCESSION AX892787
VERSION AX892787.1 GI:40047671
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 8650 06-SEP-2000;
Genset (FR)
FEATURES
Location/Qualifiers
source 1..385
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 385;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTAACTCTGGGCGAGGTAGGGGCACTACCGCATTCCTC 276
DB 135 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGACGATGCACC 76
QY 277 TCTCTTCCAA 286
DB 75 CCACAGACAA 66
RESULT 59
BD028320/c
LOCUS BD028320 385 bp DNA linear PAT 27-AUG-2002
DEFINITION Sequence tag and encoded human protein.
ACCESSION BD028320
VERSION BD028320.1 GI:22570062
KEYWORDS JP 2001269182-A/4566.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 385)
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 4566 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/4566
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PR 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCCLAIR,JEAN YVES
PI JORDAN
PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21,PC
C12N5/10,
PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N15/00,C12N5/00,PC
CC G06F15/40
FH Key Location/Qualifiers.
FEATURES
source 1..385
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 385;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTAACTCTGGGCGAGGTAGGGGCACTACCGCATTCCTC 276

DB 135 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGACGATGCACC 76
QY 277 TCTCTTCCAA 286
DB 75 CCACAGACAA 66
RESULT 60
AX839163/c
LOCUS AX839163 409 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 6 from Patent WO03076610.
ACCESSION AX839163
VERSION AX839163.1 GI:39922612
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Bracco,L., Brinkman,B. and Coignard,F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 6 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
FEATURES
Location/Qualifiers
source 1..409
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 409;
Best Local Similarity 57.1%; Pred. No. 28;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY 217 TCTCTCTCCCTTCTCTAACTCTGGGCGAGGTAGGGGCACTACCGCATTCCTC 276
DB 108 TCTCACTCCAGCTCCCAATCCGAGACTGATGAGGGGCGACCGACGATGCACC 49
QY 277 TCTCTTCCAA 286
DB 48 CCACAGACAA 39
RESULT 61
AF011898/c
LOCUS AF011898 860 bp mRNA linear VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a2 (TRYPA2) mRNA, complete cds.
ACCESSION AF011898
VERSION AF011898.1 GI:2367494
KEYWORDS
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE 1 (bases 1 to 860)
AUTHORS Roach,J.C.
TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 860)
AUTHORS Roach,J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA
FEATURES
Location/Qualifiers
source 1..860
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
1..860
/gene="TRYPA2"
6..749
gene
CDS


```
/tissue_type="Liver, mouse"
/clone_lib="NIH_MGC_177"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
1..1869
/gene="F7"
/notes="synonyms: FVII, mfVII"
/db_xref="LocusID:14068"
/db_xref="MGI:109325"
10..1350
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAH61149.1"
/db_xref="GI:38511702"
/db_xref="LocusID:14068"
/translation="MVPAQHGLLLLCFLQLQPLGTAVFTQERAHGVLRHRRANS
LLEWLPSECEBQCSFEAREIFKSPERTKQFVIYSDGDOCSNPNQGGTC
QHLKSYVCLLEDPEGRNCKEKEQELICANENGDCQYCRDHVGTAKSCHEDT
LQPDVSCPKVPCGRI PVVERKSSRQGRIVGKNVCPKGECPQWALVKINGLL
CGAVLLDARWITAAHCFDNIYKGNITVMGEHDFSEKGDQVRRVTQVIMPKYI
RGKINHDIALLRLHVPVFTDVVPLCLPEKSFSENTIARIFRSVSGWQLLDRGAT
ALELMSIEVPRMLTQDCLHAKHSNTPKITENMFCAGYMDGTACKGDSGGPHAT
YAGTWLTCVSWGSGCAIGHIGVITRVSQIDWLVRHMDSKLQGVRLPFL"
79..264
/notes="Gla; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
268..378
/notes="EGF_CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:cd00054"
589..1302
/notes="Tryp SPG; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 1.0%; Score 21.6; DB 1; Length 1869;
Best Local Similarity 68.2%; Pred. No. 39; Mismatches 0; Gaps 0;
Matches 30; Conservative 0; Indels 14; Indels 0; Gaps 0;

QY 1681 TTTTCTTTTGGTTCTTGAATAATTTCCCTGCTTTGA 1724
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1860 TTTTCTTTTGGTTCTTGAATAATTTCTCATTAATTGA 1817
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 64
AX839181
LOCUS 328 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 24 from Patent WO03076610.
ACCESSION AX839181
VERSION AX839181.1 GI:39922630
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Bracco,L., Brinkman,B. and Coignard,F.
TITLES Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 24 18-SEP-2003;
EXONHIT Therapeutics S.A. (FR)
FEATURES
Location/Qualifiers
1..328
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 328;
Best Local Similarity 52.9%; Pred. No. 40; Mismatches 41; Indels 0; Gaps 0;
Matches 46; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 1681 TTTTCTTTTGGTTCTTGAATAATTTCTCATTAATTGA 1724
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1860 TTTTCTTTTGGTTCTTGAATAATTTCTCATTAATTGA 1817
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 65
AX464088/c
LOCUS 1129 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 221 from Patent WO0140466.
ACCESSION AX464088
VERSION AX464088.1 GI:21899060
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker,K.P., Beresini,M., DeForge,L., Desnoyers,L., Filvaroff,E.,
Gao,W.Q., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L.,
Sherwood,S., Smith,V., Stewart,T.A., Tumas,D., Watanabe,C.K.,
Wood,W.L. and Zhang,Z.
TITLES Secreted and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL Patent: WO 0140466-A 221 07-JUN-2001;
Genentech Inc. (US)
FEATURES
Location/Qualifiers
1..1129
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 43; Mismatches 16; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1975
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1129 TTTTCTTTTGGTTCTTGAATAATTTCTCATTAATTGA 1817
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 66
AX359106/c
LOCUS 1129 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DNA99391 MPN (UNQ1884) mRNA, complete cds.
ACCESSION AY359106
VERSION AY359106.1 GI:37183328
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1129)
AUTHORS Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
Stinson,J., Vagts,A., Vanden,R., Watanabe,C., Wileand,D., Woods,K.,
Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
Goddard,A., Wood,W.L. and Godowski,P.
TITLES The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
JOURNAL Genome Res. 13 (10), 2265-2270 (2003)
PUBMED 12975309
REFERENCE 2 (bases 1 to 1129)
AUTHORS Clark,H.F.
```

<hr/>					
AX265101					
GI:16513900					
Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
1					
Kniec,E.B., Gamber,H.B. and Rice,M.C.					
Targeted chromosomal genomic alterations with modified single					
stranded oligonucleotides					
Patent: WO 0173002-A 2492 04-OCT-2001;					
UNIVERSITY OF DELAWARE (US)					
FEATURES					
source					
1..121					
Location/Qualifiers					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match 0.9%; Score 21.2; DB 1; Length 121;					
Best Local Similarity 53.7%; Pred.No.42;					
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;					
<hr/>					
QY	2156	CTATTGTAATAGGGTTTACGAGGCATAATTCCTCGTGTTATTGTCTGTGTTTTG	2215		
DB	83	CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG	24		
QY	2216	CTTTGGCATATACGCGCTGAG	2237		
DB	23	AATGGCAGTAACCTGCTTAG	2		
<hr/>					
RESULT 69					
AX265102					
LOCUS					
Sequence 2493 from Patent W00173002.					
Accession AX265102					
Version AX265102.1 GI:16513901					
Keywords					
Source					
Organism					
Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
1					
Kniec,E.B., Gamber,H.B. and Rice,M.C.					
Targeted chromosomal genomic alterations with modified single					
stranded oligonucleotides					
Patent: WO 0173002-A 2493 04-OCT-2001;					
UNIVERSITY OF DELAWARE (US)					
FEATURES					
source					
1..121					
Location/Qualifiers					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match 0.9%; Score 21.2; DB 1; Length 121;					
Best Local Similarity 53.7%; Pred.No.42;					
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;					
<hr/>					
QY	2156	CTATTGTAATAGGGTTTACGAGGCATAATTCCTCGTGTTATTGTCTGTGTTTTG	2215		
DB	39	CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG	98		
QY	2216	CTTTGGCATATACGCGCTGAG	2237		
DB	99	AATGGCAGTAACCTGCTTAG	120		
<hr/>					
RESULT 70					
AX265097/c					
LOCUS					
Sequence 2498 from Patent W00173002.					
Definition Accession AX265097					
Keywords					
Source					
Organism					
Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
1					
Kniec,E.B., Gamber,H.B. and Rice,M.C.					
Targeted chromosomal genomic alterations with modified single					
stranded oligonucleotides					
Patent: WO 0173002-A 2498 04-OCT-2001;					
UNIVERSITY OF DELAWARE (US)					
FEATURES					
source					
1..121					
Location/Qualifiers					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match 0.9%; Score 21.2; DB 1; Length 121;					
Best Local Similarity 53.7%; Pred.No.42;					
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;					
<hr/>					
QY	2156	CTATTGTAATAGGGTTTACGAGGCATAATTCCTCGTGTTATTGTCTGTGTTTTG	2215		
DB	39	CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG	98		
QY	2216	CTTTGGCATATACGCGCTGAG	2237		
DB	99	AATGGCAGTAACCTGCTTAG	120		
<hr/>					
RESULT 70					
AX265097/c					
LOCUS					
Sequence 2498 from Patent W00173002.					
Definition Accession AX265097					
Keywords					
Source					
Organism					
Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
1					
Kniec,E.B., Gamber,H.B. and Rice,M.C.					
Targeted chromosomal genomic alterations with modified single					
stranded oligonucleotides					
Patent: WO 0173002-A 2498 04-OCT-2001;					
UNIVERSITY OF DELAWARE (US)					
FEATURES					
source					
1..121					
Location/Qualifiers					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match 0.9%; Score 21.2; DB 1; Length 121;					
Best Local Similarity 53.7%; Pred.No.42;					
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;					
<hr/>					
QY	2156	CTATTGTAATAGGGTTTACGAGGCATAATTCCTCGTGTTATTGTCTGTGTTTTG	2215		
DB	39	CCATTTAAACATGGATTGGACTCACACTGATCCTCATCTTTGAGTAGGTTAAGAATTG	98		
QY	2216	CTTTGGCATATACGCGCTGAG	2237		
DB	99	AATGGCAGTAACCTGCTTAG	120		
<hr/>					
RESULT 70					
AX265097/c					
LOCUS					
Sequence 2498 from Patent W00173002.					
Definition Accession AX265097					
Keywords					
Source					
Organism					
Homo sapiens (human)					
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
1					
Kniec,E.B., Gamber,H.B. and Rice,M.C.					
Targeted chromosomal genomic alterations with modified single					
stranded oligonucleotides					
Patent: WO 0173002-A 2498 04-OCT-2001;					
UNIVERSITY OF DELAWARE (US)					
FEATURES					
source					
1..121					
Location/Qualifiers					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match 0.9%; Score 21.2; DB 1; Length 121;					
Best Local Similarity 53.7%; Pred.No.42;					
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;</					

```

VERSION      AX265097.1  GI:16513896
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE        Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 2488 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 42;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTAGCAGGACATATTGCTCGTGTGTTATTGTCGTGTTTGG 2215
      |||||
Db 84 CCAATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 25
      |||||

QY 2216 CTTTGGCATATAGCGGCTGAG 2237
      |||||
Db 24 AATTGGCAGTAACTGCTTAG 3

RESULT 71
LOCUS      AX265098                      121 bp      DNA      linear      PAT 26-OCT-2001
DEFINITION Sequence 2489 from Patent WO0173002.
ACCESSION  AX265098
VERSION     AX265098.1  GI:16513897
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS      Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE        Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 2489 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 42;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTAGCAGGACATATTGCTCGTGTGTTATTGTCGTGTTTGG 2215
      |||||
Db 38 CCAATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 97
      |||||

QY 2216 CTTTGGCATATAGCGGCTGAG 2237
      |||||
Db 98 AATTGGCAGTAACTGCTTAG 119

RESULT 72
LOCUS      BC046125/c                      1541 bp      mRNA      linear      PRI 07-OCT-2003
DEFINITION Homo sapiens coagulation factor X, mRNA (cDNA clone MGC:57588
              IMAGE:5723510), complete cds.
ACCESSION    BC046125

```

```

VERSION      BC046125.1  GI:28374355
KEYWORDS     MGC.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1 (bases 1 to 1541)
AUTHORS      Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
              Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
              Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
              Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
              Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
              Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
              Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
              Carninci,P., Prange,C., Raha,S., Loquellano,N.A., Peters,G.J.,
              Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J.,
              McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
              Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
              Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
              Fahey,J., Helton,E., Kettelman,M., Madan,A., Rodriguez,S.,
              Sanchez,A., Whitting,M., Madan,A., Young,A.C., Shvchenko,Y.,
              Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
              Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
              Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalusz,D.E.,
              Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
              Generation and initial analysis of more than 15,000 full-length
              human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
REFERENCE    2 (bases 1 to 1541)
AUTHORS      Strausberg,R.
TITLE        Direct Submission
JOURNAL
REMARK
COMMENT      NIH-MGC Project URL: http://mgc.nci.nih.gov
              Contact: MGC help desk
              Email: cgabbs-r@mail.nih.gov
              Tissue Procurement: Invitrogen
              cDNA Library Preparation: Life Technologies, Inc.
              cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
              DNA Sequencing by: Sequencing Group at the Stanford Human Genome
              Center, Stanford University School of Medicine, Stanford, CA 94305
              Web site: http://www-shgc.stanford.edu
              Contact: (Dickson, Mark) mcdexpaxil.stanford.edu
              Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
              R. M.
              Clone distribution: MGC clone distribution information can be found
              through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
              Series: IRAX Plate: 107 Row: h Column: 24
              This clone was selected for full length sequencing because it
              passed the following selection criteria: matched mRNA gi: 9961350.
              Location/Qualifiers
                  1..1541
                  /organism="Homo sapiens"
                  /mol_type="mRNA"
                  /db_xref="taxon:9606"
                  /clone="MGC:57588 IMAGE:5723510"
                  /tissue type="Ovary, pooled from 3 adults"
                  /clone_lib="NIH MGC 125"
                  /lab_host="DH10B"
                  /note="Vector: pCMV-SPORT6"
                  1..1541
                  /gene="F10"
                  /note="synonyms: FX, FXA"
                  /db_xref="LocusID:2159"
                  /db_xref="MIM:227600"
                  39..1505
                  /codon_start=1
                  /product="coagulation factor X precursor"

```

```

/protein_id="AAH46125.1"
/db_xref="GI:28374356"
/db_xref="LocusID:2159"
/translation="MGRPLHLVLLSASLAGLLLGESLFIIRREQANNILARVTRANSF
LEMMKGLHRECEMEETCSYEAREVEDSKTNEFWNKYGDQDQCTSPQNGKCK
DGLGYCTCLGEGKNCLELFRKLCSLDNCDOFCHEQNSVCSARGVTLADN
GKACIPGPVPCGKQTLERKRSVAQATSSGSEAPDSITWKPYDAADLPTENFDLL
DFNQTPERDGNLRLTRVGGQCKDGCPCWQALLINENEGFCGTLISFYILTAAH
CLYQAKRFKVRVGNTEQEGEAVHEVEVINKHNRFTKETYDFDIAVLRLKTPTF
RMNVAPACLFERDWAETLTKTGIYSGFGRTHEKQSTRLKMLRVPYVDNRNSCKL
SSSFIITQNMFCAGYDQKQDAGCGSGSPHVRFKDQYFVTGIVSGEGCARGKYG
IYTKVAFKLWIDRSMKTRGLPKAKSHAPEVITSSPLK"
misc_feature
111..293
/notes="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
318..401
/notes="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
738..1424
/notes="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"
Query Match 0.9%; Score 21.2; DB 1; Length 1541;
Best Local Similarity 60.3%; Pred. No. 49;
Matches 35; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 1627 TGTTCCTGCTCTTGTACCTGATAGGCATCTCTTCTCAAGGTTAGGAATTTT 1684
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1539 TTTTITTTTTTTTTTTTTTTTGTGGGATCTCACTTATGGAGAGACGTTAT 1482

RESULT 73
LOCUS BD060364/c 267 bp DNA linear PAT 27-AUG-2002
DEFINITION Secreted expressed sequence tags (ESTs).
ACCESSION BD060364
VERSION BD060364.1 GI:22605970
KEYWORDS JP 2001518793-A/724.
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 267)
Jacobs,K., McCoy,J.M., Lavallie,E.R., Racie,L.A., Merberg,D.,
Trecay,M., Spaulding,V. and Agostino,M.J.
Secreted expressed sequence tags (ESTs)
Patent: JP 2001518793-A 724 16-OCT-2001;
GENETICS INSTITUTE INC
COMMENT PN JP 2001518793-A/724
PD 16-OCT-2001
PF 10-APR-1998 JP 1998543070
PR 10-APR-1997 US 08/873112
PI KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI
DAVID MERBERG,
PI MAURICE TREACY,VITKI SPAULDING,MICHAEL J AGOSTINO PC
C12N15/12,C12N5/10,C07K14/47,C12Q1/68,A61K38/17 CC Strandedness:
Double;
CC Topology: Linear;
FH Key Location/Qualifiers.
1..267
/organism="Zea mays"

/protein_id="genomic DNA"
/db_xref="taxon:4577"
Query Match 0.9%; Score 21; DB 1; Length 267;
Best Local Similarity 49.5%; Pred. No. 50;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 1637 GCTTCTGTGACCTGTAGGATCTCTTTCTCAAGGTTAGGAAATTTCTTTTGGTT 1696
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 243 GATGCATTTGACCTCAACACTCTCTCAGTATCCCATTTCTGTGGATTTCTTTCTCAATC 184
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1697 TTCTTGAATAATTTTCCCTGCTTTGACCTGCCTTCTTCCCTTCTC 1745
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 183 TTCTTCAAAAGTCCACTTTGGCTGTTCTTTTCCGCCCATTCAC 135
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 74
LOCUS AF306917 280 bp DNA linear VRT 23-JAN-2001
DEFINITION Brachyramphus brevirostris haplotype KME ribosomal protein 40 gene,
intron 5 and partial sequence.
ACCESSION AF306917
VERSION AF306917.1 GI:12382289
KEYWORDS Brachyramphus brevirostris
ORGANISM Brachyramphus brevirostris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauia; Aves; Neognathae; Charadriiformes; Alcidae;
Brachyramphus.
1 (bases 1 to 280)
Pacheco,N.M. and Friesen,V.L.
A molecular investigation of hybridization in Brachyramphus
murrelets
Unpublished
REFERENCE 2 (bases 1 to 280)
Pacheco,N.M. and Friesen,V.L.
Direct Submission
TITLE Submitted (21-SEP-2000) Department of Biology, Queen's University,
Kingston, ON K7L 3N6, Canada
JOURNAL
FEATURES source
1..280
/organism="Brachyramphus brevirostris"
/mol_type="genomic DNA"
/db_xref="taxon:28693"
/haplotype="KME"
/product="ribosomal protein 40"
/notes="coding region not determined"
15..263
/number=5
intron

Query Match 0.9%; Score 21; DB 1; Length 280;
Best Local Similarity 51.6%; Pred. No. 50;
Matches 48; Conservative 0; Mismatches 45; Indels 0; Gaps 0;

QY 1106 ACTTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 154 AGTCCTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 1166 TCTGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1198
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 214 TTCGGTGGGAGACTTAGGCTACTCTCTCTGT 246
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 75
LOCUS AF306913 280 bp DNA linear VRT 23-JAN-2001
DEFINITION Brachyramphus brevirostris haplotype KMA ribosomal protein 40 gene,
intron 5 and partial sequence.
ACCESSION AF306913
VERSION AF306913.1 GI:12382285
KEYWORDS Brachyramphus brevirostris
SOURCE Brachyramphus brevirostris

```


Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

213	TGCTTTGGCTCACCCATCTCTCTGGCACAGCATGACATCTGTGACTTCTGTAGGT	272
Db		
2181	ACATATTGTCCTGGTTGTTATTG	2203
Qy		
273	AGACTTTGGCACAGTTCTCAATTG	295
Db		

E63001/c	E63001	1206 bp	DNA	linear	PAT 31-JAN-2002
LOCUS	Hemocoagulation factor VII modification.				
DEFINITION	E63001				
ACCESSION	E63001.1	GI:18633643			
VERSION	JP 2001061479-A/5.				
KEYWORDS	synthetic construct				
SOURCE	synthetic construct				
ORGANISM	artificial sequences.				
REFERENCE	1 (bases 1 to 1206)				
AUTHORS	Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.				
TITLE	Hemocoagulation factor VII modification				
JOURNAL	Patent: JP 2001061479-A 5 13-MAR-2001;				
COMMENT	JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE				
	OS Artificial Sequence				
	PN JP 2001061479-A/5				
	PD 13-MAR-2001				
	PF 24-AUG-1999	JP 1999237610			
	PR				
	PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO				
	NAKAGAKI,				
	PI SADAAKI IWANAGA				

A61K37/465	
CC	Location/Qualifiers
FH	Key

```

source
FT
FEATURES
source
Location/Qualifiers
1..1206
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

```

[illegible]

E83002
 E83002.1 GI:18633544
 JP 2001061479-A/6.
 synthetic construct
 synthetic construct
 artificial sequences.
 1 (bases 1 to 1206)
 Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.
 Hemocoagulation factor VII modification
 Patent: JP 2001061479-A 6 13-MAR-2001
 JURIDICAL FOUNDATION THE CHEMO-SOFT THERAPEUTIC RESEARCH INSTITUTE

CONTENTS

CS	Structural sequences
PN	JP 2001061479-A/6
PD	13-MAR-2001

PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1206
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1206
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATATGATTCATTTGG 498
Db 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATTCATCTGTGG 386
RESULT 85
E62997/c
LOCUS E62997 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62997
VERSION E62997.1 GI:18633639
KEYWORDS JP 2001061479-A/1.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 1 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS blood coagulation factor VII
PN JP 2001061479-A/1
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='blood coagulation factor VII'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATATGATTCATTTGG 498
Db 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATTCATCTGTGG 386
RESULT 86
E62998/c
LOCUS E62998 1221 bp DNA linear PAT 31-JAN-2002

DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62998
VERSION E62998.1 GI:18633640
KEYWORDS JP 2001061479-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 2 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/2
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATATGATTCATTTGG 498
Db 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATTCATCTGTGG 386
RESULT 87
E62999/c
LOCUS E62999 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 3 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/3
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1..1221
/organism="synthetic construct"

/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTAATTCATTTGG 498
Db 444 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGTGG 386

RESULT 88
E63000/c
LOCUS 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63000
VERSION E63000.1 GI:18633642
KEYWORDS JP 2001061479-A/4.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima.K., Mizuguchi.J., Yuguchi.M., Nakagaki.T. and Iwanaga.S.
TITLE Hemocoagulation Factor VII modification
JOURNAL Patent: JP 2001061479-A 4 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR
PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.
FEATURES
source Location/Qualifiers
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 68;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTAATTCATTTGG 498
Db 444 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGTGG 386

RESULT 89
AR112953/c
LOCUS 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132729.
ACCESSION AR112953
VERSION AR112953.1 GI:14093275
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
JOURNAL Patent: US 6132729-A 13 17-OCT-2000;
FEATURES
source Location/Qualifiers
1..1440

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTAATTCATTTGG 498
Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGTGG 601

RESULT 90
AR112969/c
LOCUS 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132730.
ACCESSION AR112969
VERSION AR112969.1 GI:14093291
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
JOURNAL Patent: US 6132730-A 13 17-OCT-2000;
FEATURES
source Location/Qualifiers
1..1440
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTAATTCATTTGG 498
Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGTGG 601

RESULT 91
I19358/c
LOCUS 1440 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 3 from patent US 5504064.
ACCESSION I19358
VERSION I19358.1 GI:1599713
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Morrissey,J.H. and Comp,P.C.
TITLE Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JOURNAL Patent: US 5504064-A 3 02-APR-1996;
FEATURES
source Location/Qualifiers
1..1440
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTAATTCATTTGG 498
Db 659 TTGCTGGCATTCTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGTGG 601

RESULT 92
I19360/c
LOCUS 1440 bp DNA linear PAT 07-OCT-1996

```
DEFINITION Sequence 3 from patent US 5504067.
ACCESSION I19360
VERSION I19360.1 GI:1599715
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Morrissey, J.H. and Comp, P.C.
TITLE Treatment of bleeding with modified tissue factor in combination with FVII
JOURNAL Patent: US 5504067-A 3 02-APR-1996;
FEATURES
    source
        1..1440
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCAATTGG 498
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGGTATTTTCCACATGGATTCCACTGTGG 601
RESULT 93
BD194674/c
LOCUS BD194674 1440 bp DNA linear PAT 17-JUL-2003
DEFINITION Tissue factor methods and compositions for coagulation and tumor treatment.
ACCESSION BD194674
VERSION BD194674.1 GI:33004420
KEYWORDS JP 2002514201-A/3.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe, P.E., King, S.W. and Gao, B.
TITLE Tissue factor methods and compositions for coagulation and tumor treatment
JOURNAL Patent: JP 2002514201-A 3 14-MAY-2002;
COMMENT BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PF 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920, 27-JAN-1997 US 60/036205 PR
PI PHILIP E THORPE, STEVEN W KING, BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
tumor treatment
FH Key Location/Qualifiers
FT source 1..1440
    /organism="Mammalian".
FEATURES
    source
        1..1440
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCAATTGG 498
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGGTATTTTCCACATGGATTCCACTGTGG 601
RESULT 94
AX565990/c
LOCUS AX565990 6098 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 2 from Patent WO02077218.
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Persson, B.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)
FEATURES
    source
        1..6098
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Plasmid DNA pLN174"
Query Match 0.9%; Score 20.6; DB 1; Length 6098;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCAATTGG 498
Db 728 TTGCTGGCAATTCCTTTTCTAGAAATAGGTATTTTCCACATGGATTCCACTGTGG 670
RESULT 95
AX839180/c
LOCUS AX839180 394 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 23 from Patent WO03076610.
ACCESSION AX839180
VERSION AX839180.1 GI:39922629
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Bracco, L., Brinkman, B. and Coignard, F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 23 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
FEATURES
    source
        1..394
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 0.9%; Score 20.4; DB 1; Length 394;
Best Local Similarity 52.3%; Pred. No. 73;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
Qy 38 CAATGGTTGTGATGTTGGTAGAGTATCTCATACAGAGATAGACTAGATGCTCTCTGGG 97
Db 272 CACTGGCTAGAGAGGGGACTAGAGAAGCAGAGAGAGGGGGGATATGGAGATTCTCTGAT 213
Qy 98 ACATAGGTAAGCTTTTCCAGAGAGACT 123
Db 212 GCAGTGGCAGCTGTGAGGCCCACT 187
RESULT 96
AF465269/c
LOCUS AF465269 1416 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus coagulation factor IX precursor (F9) mRNA, complete cds.
ACCESSION AF465269
VERSION AF465269.1 GI:28194009
KEYWORDS
SOURCE Gallus gallus (chicken)
```

ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
REFERENCE 1 (bases 1 to 1416)
AUTHORS Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
TITLE Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
AUTHORS McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
TITLE Direct Submission
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK.

FEATURES
source
1..1416
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
gene
1..1416
/gene="F9"
CDS
1..1416
/gene="F9"
/EC_number="3.4.21.22"
/function="converts factor X to its active form in the
presence of Ca++ ions, phospholipids, and factor VIIa"
/note="vitamin K dependent serine protease; Christmas
factor; contains 2 EGF-like domains; member of peptidase
family S1/trypsin family"
/codon_start=1
/product="coagulation factor IX precursor"
/protein_id="AA033364.1"
/db_xref="GI:28194010"
/translation="MAKPLILSFLCLLEAFLEAGSTVFTEKEASTVLSRTRGNSNR
LEELPGLNERICEKCSFEAREVFENTKTFWKIYIDGQCNPNCKNGAVCK
DVSSEYCPGPGYGCNEIDSTCATNGGCEHFCHDTPOKAVCSAGYKLHEDG
KSCPAVYPCCRITAPEMRGKVTRENTIERWNTAHDEGDADEALDITPPPPPT
TSAAPAKVPLTNTDTRVVGYSVKGLPQVHLVDSRGLGFCGSGIINEKVVVTA
HCLFGDNTAVAGYNTKEDDTEQRQVVKILPYPTNTRNKHNDLLELDQP
LTFNSYVPTICGSDFTNLLNSGFGVSGMSLVRGRSAIVLQVLVFPVDRVTC
YKSTTTLHSMFCAGYTAGGKDTCCGSDGGPYTNSIGETFLTGTWGERCAKPGK
YGIYTKVAKYKWIETRELT"

Query Match 0.9%; Score 20.4; DB 1; Length 1416;
Best Local Similarity 53.8%; Pred. No. 77;
Matches 42; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 24 GGGGCTGAGGCTCAATGGTTGATGCTGAGATATCTCATACAGAGGATAGCACT 83
DB 408 GTGCTCGAGGCCCATTTTCTGACACAGTAGAGTCTATCTCACAGTCTCTGCTCC 349

QY 84 AGATGCTGTCTGGACAT 101
DB 348 ATAACACAGTGGGCACAT 331

RESULT 97
AF272774/c
LOCUS Homo sapiens factor VII active site mutant immunoglobulin mRNA, complete cds.
DEFINITION AF272774.2 GI:28269793
ACCESSION AF272774.2
VERSION
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Targeting tissue factor on tumor vascular endothelial cells and

tumor cells for immunotherapy in mouse models of prostatic cancer
Proc. Natl. Acad. Sci. U.S.A. 98 (21), 12180-12185 (2001)
21477448
11593034
PUBMED
REFERENCE 2 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Direct Submission
JOURNAL Submitted (26-MAY-2000) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
REFERENCE 3 (bases 1 to 2072)
AUTHORS Hu, Z. and Garen, A.
TITLE Direct Submission
JOURNAL Submitted (07-FEB-2003) Department of Molecular Biophysics and
Biochemistry, Yale University, 266 Whitney Ave., New Haven, CT
06520, USA
REMARK
COMMENT Sequence update by submitter
FEATURES
Location/Qualifiers
1..2072
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
22..2061
/note="hViiIasm"
/codon_start=1
/product="factor VII active site mutant immunoglobulin"
/protein_id="AAK58686.2"
/db_xref="GI:28269794"
/translation="MVSQALLRLCLLGLQGLAAVFTQBEAHGVHLHRRRANAFLE
ELRPSLEREKEQCFEAREIFKDAERTKLFWISYSDGQCSLPQNGSGCKDQ
LQSYICFLCPAPKELGSPVFLPPPKPOTLMISRTPEVTGVVDSHEDPEVFN
DGVSTPTVEYPCGKIPILEKRNASKPOGRIVGGKCPKGECPWVLLVNGAQLCGG
TLNITVWVSAHCFDKIKNWNLJAVLGEHDLSEHDGDEQSRRAQVILPSTVPGT
TNHDLALRLQPVVLTIDHVPCLPETFSELTAFRFLSVSGQLDRGATALE
LMVLNPLMTQDCLQSKVDSNTEYMFECAGYSDGSKDCSDGSGGPHATHRG
LMLVLTGVSWGQCATVGFYVTSYVIEWLKLMRSEPRGVLLLRAPFGSAEPK
SCDKHTCPCPAPKELGSPVFLPPPKPOTLMISRTPEVTGVVDSHEDPEVFN
WYDQGEVHNATKPREQYNSYTRVSVLTVHQDLNGKEYKCKVSNKALPAPEK
TISKAGOPRPOVYTLPSRDELTKNOVSLTCLVKGVPSPDIQVWESNGOPENNYK
TTPVLDSDGSEFFLYSKLTVDKSRMQQNVFSCSVMEALHNHYTKSLSLSPGK"

Query Match 0.9%; Score 20.4; DB 1; Length 2072;
Best Local Similarity 61.1%; Pred. No. 77;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 445 TTGCTTTTATCTCGAGACTTGTCTTTGTTGAATATGATTCATTTGG 498
DB 574 TGGCATTTCTTTTCTAGATAGGTATTTTCCACATGATATCACTGTGG 521

RESULT 98
AF272773/c
LOCUS Synthetic construct mutated mouse factor VII molecule
DEFINITION immunoglobulin mRNA, complete cds.
ACCESSION AF272773
VERSION
KEYWORDS AF272773.1 GI:9837149
SOURCE
ORGANISM Synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 2078)
AUTHORS Hu, Z., Sun, Y. and Garen, A.
TITLE Targeting tumor vasculature endothelial cells and tumor cells for
immunotherapy of human melanoma in a mouse xenograft model
Proc. Natl. Acad. Sci. U.S.A. 96 (14), 8161-8166 (1999)
99324206
MEDLINE 10393965
PUBMED
REFERENCE 2 (bases 1 to 2078)
AUTHORS Hu, Z. and Garen, A.
TITLE Intratumoral injection of adenoviral vectors encoding
tumor-targeted immunoglobulins for cancer immunotherapy

JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 97 (16), 9221-9225 (2000)	
MEDLINE	20381364	
REFERENCE	3 (bases 1 to 2078)	
AUTHORS	Hu, Z. and Garen, A.	
TITLE	Direct Submission	
JOURNAL	Submitted (26-MAY-2000) Molecular Biophysics and Biochemistry, Yale University, 266 Whitney Ave, New Haven, CT 06520, USA	

FEATURES	Location/Qualifiers	gene
source	1..2078	
	/organism="synthetic construct"	
	/mol_type="mRNA"	mRNA
	/db_xref="taxon:32630"	
CDS	22..2067	
	/note="mfVflasm; contains active site mutation"	
	/codon_start=1	
	/transl_table=11	
	/product="mutated mouse factor VII molecule immunocojugate"	
	/protein_id="AAG00449.1"	
	/db_xref="GI:9837150"	
	<1..>183	
	/gene="mast"	
	/codon_start=3	
	/product="mastermind"	
	/protein_id="AAO61936.1"	
	/db_xref="GI:28975317"	
	/translation="DLKRLQQQQAAQQQQQQHHAQQQQQQHHPGPKMGVPMWGAGNPA KQKQKQKQNVMTXKQKQKQ"	

Query Match	Score	DB	Length
Best Local Similarity	53.1%	Pred. No. 78;	
Matches	43;	Conservative	0; Mismatches 38; Indels 0; Gaps 0;
Qy	344	TGGTTTCCATAAGTTTCTGAAGTTTCTGTTCTTTCTGTTGTTGTTGTTATCTAGATT	403
Db	111	TGGGTACACCATTTGGGACCATTTGGATGTTGTTGTTGTTGTTGTCATGGTGT	52
Qy	404	TAAGCTGTGGTGGTCAGATAG	424
Db	51	GTTGCTGTTGCTGTTGCATTG	31

Query Match	0.9%;	Score 20.4;	DB 1;	Length 2078;
Best Local Similarity	58.1%;	Pred. No. 77;		
Matches	36;	Conservative 0;	Mismatches 26;	Indels 0;
Gaps	0;			
31	GAGGCTCAATGGTTGTGATGGTGTAGAGTATCTCATACAGAGATGACCTAGATGCT	90		
2046	GAGGCTCTTCCGTGTAGTGGTTGTGCAGACCTCATGCATCACGGAGCATGAGAAGAC	1987		
91	GT 92			
1986	GT 1985			

[illegible]

TITLE	Genetic divergence within the <i>Drosophila mayaguana</i> subcluster, a closely related triad of Caribbean species in the repleta species group
JOURNAL REFERENCE	Unpublished 2 (bases 1 to 183) O'Grady,P.M. II, Durando,C.M., Head,W.B., Wasserman,M., Etges,W. and Desalle,R. Direct Submission
TITLE	Submitted (25-SEP-2002) Invertebrate Zoology, American Museum of Natural History, Central Park West at 79th Street, New York, NY 10024, USA
JOURNAL REFERENCE	CDS
TITLE	variation
JOURNAL REFERENCE	gene
TITLE	source
JOURNAL REFERENCE	1. .214 /organism="Homo sapiens" /mol_type="genomic DNA" /isolate="patient: PS 1" /db_xref="taxon:9606" 24 /_replace="g" 25. .182 /gene="PROS1" <25. >.182 /gene="PROS1"

```

/codon_start=3
/product="protein S"
/protein_id="BAC54134.1"
/db_xref="GI:27531050"
/translation="LSXQASQVLVRKRKRANSLLEETKQGNLERECIEELCNKEARE
VFENDPET"
25. .182
/gene="PROS1"
/number=2
exon

```

	Query Match	Best Local Similarity	0.9%;	Score 20.2;	DB 1;	Length 214;
	Matches	46;	Conservative	0;	Mismatches	43;
					Indels	0;
					Gaps	0;
Qy	290	CTTCTATTCTTGATTTCTATCTCTGGCTCAATTTTTAACTCAGTAGTACGATTGTTGGTTT	349			
Db	150	CTTCTCTCTTTATTTCACACAGTTCTTCGATGCAATCTCTTTCAAGATTACCCCTGTTGGTTT	91			
Qy	350	CCATAAGTTTGTAAAGTTTCTCTGTTGTTTC	378			
Db	90	CTTCAAGTAAAGAAATTTGCACGACGGTTTC	62			

RESULT 101	
AB084901/c	
LOCUS	214 bp DNA linear PRI 07-JAN-2003
DEFINITION	Homo sapiens PROS1 gene for PS22, partial cds.
ACCESSION	AB084901
VERSION	AB084901.1 GI:27531280
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS	1 Hamasaki,N., Kang,D., Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y. and Ono,M.
TITLE	Gene analysis of anticoagulation factors in Japanese thrombotic patients.Genetic background of thrombophilia in Japan
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 214)
AUTHORS	Hamasaki,N. and Inoue,S.
TITLE	Direct Submission
JOURNAL	Submitted (09-MAY-2002) Naotaka Hamasaki, Kyushu University Hospital, Department of clinical chemistry and laboratory medicine; 3-1-1 maidasi, Higasi-ku Fukuokasi, Fukuoka 812-8582, Japan (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770, Fax:81-92-642-5772)

FEATURES	Location/Qualifiers
source	1. .214 /organism="Homo sapiens" /mol_type="genomic DNA" /isolate="16" /db_xref="taxon:9606" 25. .182 /gene="PROS1" /cds <25. .>.182 /gene="PROS1" /codon_start=3 /product="PS22" /protein_id="BAC54254.1" /db_xref="GI:27531281" /translation="LSKQASQVIVRKRRANSLLEETKQGNLERECTETLCNKEARE VFENDPEM" 25. .182 /gene="PROS1" /number=2 181 /gene="PROS1" /replace="c"
gene	
cds	
exon	
variation	

Query Match 0.9%; Score 20.2; DB 1; Length 214;
Best Local Similarity 51.7%; Pred. No. 79;

	Matches	46;	Conservative	0;	Mismatches	43;	Indels	0;	Gaps	0;
Qy	290	CTTCTATTTCTTGATTTCTATCTTGCTCATTTTTAACTCAGTAGAGTGTCTTCGTTTT								349
Db	150	CTTCTCTTTTATTGACAGTCTTCGATGCAATCTCTTTCAAGATTACCCGTGTTGGTTT								91
Qy	350	CCATAAGTTTGTAAAGTTTTCCTGTGTTTC								378
Db	90	CTTCAAGTAAAGAAATTTGCACGACGCTTC								62

RESULT 102	AY022473/c	227 bp	DNA	linear	PLN 07-FEB-2001
LOCUS	AY022473/c				
DEFINITION	Oryza sativa microsatellite MRGA798 containing (AGC) _X 9, closest to marker GI32, genomic sequence.				
ACCESSION	AY022473				
VERSION	AY022473.1	GI:12705689			
KEYWORDS	.				
SOURCE	Oryza sativa				
ORGANISM	Oryza sativa				

REFERENCE	1 (bases 1 to 227)	Submitted (10-JAN-2001) Genomics, Monsanto, 800 North Lindbergh Blvd., Creve Coeur, MO 63167, USA
AUTHORS	Tao, N., Barbazuk, W.B., Liu, J., Wu, K. and Barry, G.F.	Derived from rice genomic sequences generated from the Monsanto Rice Genome Sequencing project. Please see
TITLE	Sample sequence repeats from Monsanto rice genomic sequences	http://www.rice-research.org for more information. The sequence
JOURNAL	Unpublished	data were produced primarily in the laboratories of Dr. Leroy Hood
REFERENCE	2 (bases 1 to 227)	at the University of Washington in Seattle.
AUTHORS	Tao, N., Barbazuk, W.B., Liu, J., Wu, K. and Barry, G.F.	
TITLE	Direct Submission	
JOURNAL	Submitted (10-JAN-2001) Genomics, Monsanto, 800 North Lindbergh Blvd., Creve Coeur, MO 63167, USA	
COMMENT	Derived from rice genomic sequences generated from the Monsanto Rice Genome Sequencing project. Please see	
	http://www.rice-research.org for more information. The sequence	
	data were produced primarily in the laboratories of Dr. Leroy Hood	
	at the University of Washington in Seattle.	

```

FEATURES
source
1. .227
/organism="Oryza sativa"
/mol_type="genomic DNA"
/db_xref="taxon:4530"
1. .227
/note="microsatellite MRG4798"
repeat_region
/rpt_type=tandem
/rpt_unit="agc"

```

	Query Match	0.9%	Score 20.2;	DB 1;	Length 227;
	Best Local Similarity	63.3%;	Pred. No. 79;		
	Matches 31; Conservative	0;	Mismatches 18;	Indels 0;	Gaps 0;
QY	140	TGAAGCCTCTGCTGGCAATATTCTGGGGCTGTGCCTTTTCTCCCTGC	188		
DB	125	TGCTGTGCTGCTGCTGCTGTACTGTCTGTGCTGTGCTCTCTCTCTGC	77		

RESULT	103	
LOCUS	AY023221	
DEFINITION	Oryza sativa microsatellite MRG5546 containing (GCT) _{X9} , closest to marker Gi32, genomic sequence.	227 bp DNA linear PLN 07-FEB-2001
ACCESSION	AY023221	
VERSION	AY023221.1	GI:12706437
KEYWORDS	.	
SOURCE	Oryza sativa	

REFERENCE
1 (bases 1 to 227)
Enhalotoluae; *Oryzae*; *Oryza*.
AUTHORS
Tao, N., Barbazuk, W. B., Liu, J., Wu, K. and Barry, G. F.
TITLE
Simple sequence repeats from Monsanto rice genomic sequences


```
COMMENT Original source text: Human liver DNA.
FEATURES
  source
    Location/Qualifiers
      1..352
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /map="3p11-q11.2"
        /tissue_type="liver"
        join(M57840.1:837..912,135..181)
        /gene="PS-alpha"
        order(M57840.1:913..1014,1..134)
        /gene="PROS1"
        /number=1
        135..292
        /gene="PROS1"
        /note="G00-120-721"
        /number=2

  sig_peptide
  intron
  exon

  Query Match      0.9%; Score 20.2; DB 1; Length 352;
  Best Local Similarity 51.7%; Pred. No. 81;
  Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 290 CTTCTATTCTTGATTCATCTGCTCATTTTAACTCAGTAGTCAGTTGTTGTTT 349
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 260 CTTCTCTTTATTGCACAGTCTCTGATGCAITCTCTTTCAAGATTACCTCTGTTGTTT 201
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 350 CCATAGTTTGTAAAGTTTCTGTGTTTC 378
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 200 CTTCAAGTAAAGATTTCACAGCGCTTC 172
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 107
AR108139/c
LOCUS AR108139 885 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6110721.
ACCESSION AR108139
VERSION AR108139.1 GI:12823626
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
  1 (bases 1 to 885)
AUTHORS Gibbs,C.S., Leung,L.L.K. and Tsiang,M.
TITLE Polypeptides and coagulation therapy
JOURNAL Patent: US 6110721-A 1 29-AUG-2000;
FEATURES
  source
    Location/Qualifiers
      1..885
        /organism="unknown"
        /mol_type="unassigned DNA"

  Query Match      0.9%; Score 20.2; DB 1; Length 885;
  Best Local Similarity 63.3%; Pred. No. 85;
  Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 167 GCGTCGCTCTTCTCCCTGCTCGATTCCTAGGTCAGGTCACCACTG 215
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 489 GCGTCGCTCTCCCTGCTCGGCAGACACACAGGTCAGTACTGCTG 441
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 108
AX401899/c
LOCUS AX401899 1543 bp DNA linear PAT 06-JUN-2002
DEFINITION Sequence 1575 from Patent WO0210453.
ACCESSION AX401899
VERSION AX401899.1 GI:21338079
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE
  1
AUTHORS Mendrick,D., Porter,M.W., Johnson,K.R., Castle,A.L. and
```

```
Elashoff,M.R.
Molecular toxicology modeling
Patent: WO 0210453-A 1575 07-FEB-2002;
Gene Logic, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..1543
        /organism="Rattus norvegicus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10116"
        /note="EMBL/GenBank Accession No. NM_012803"

  Query Match      0.9%; Score 20.2; DB 1; Length 1543;
  Best Local Similarity 68.3%; Pred. No. 86;
  Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCCTTTACTCTAAGTGATGTCTATCCATCGTAGGTG 960
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1408 CATCCCTTTCCCTATGTAGCTGTGATCCATTCAGGTAG 1368
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 109
RNPROC/c
LOCUS RNPROC 1543 bp mRNA linear ROD 12-NOV-2003
DEFINITION Rattus norvegicus mRNA for protein C precursor.
ACCESSION X64336 S40352
VERSION X64336.1 GI:56962
KEYWORDS protein C.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE
  1 (bases 1 to 1543)
AUTHORS Okafuji,T., Maekawa,K., Nawa,K. and Marumoto,Y.
TITLE The cDNA cloning and mRNA expression of rat protein C
JOURNAL Biochim. Biophys. Acta 1131 (3), 329-332 (1992)
MEDLINE 92329550
PUBMED 1627650
REFERENCE
  2 (bases 1 to 1543)
AUTHORS Okafuji,T.
TITLE Direct Submission
JOURNAL Submitted (03-FEB-1992) Okafuji T., Mol Biology Research Lab,
Daiichi Pharmaceutical Co LTD, 16-13 Kitakasai 1-Chome, Edogawa-Ku,
Tokyo 134, JAPAN
COMMENT On Nov 19, 2003 this sequence version replaced gi:251769.
FEATURES
  source
    Location/Qualifiers
      1..1543
        /organism="Rattus norvegicus"
        /mol_type="mRNA"
        /strain="Wistar"
        /db_xref="taxon:10116"
        /clone="28000"
        49..1434
        /codon_start=1
        /product="protein C precursor"
        /protein_id="CAA45617.1"
        /db_xref="GI:56963"
        /db_xref="GOA:P31394"
        /db_xref="SWISS-PROT:P31394"
        /translation="MWQFRIFLLFASTWIGSVSAHPDPVFSSEGAHQVLRVRANS
        FLEVRAGSLRECEMBEICDFEEAEI FQNVEDTLAFWKYFDGQCSTPPLDHQCD
        PCGHTCTIDGLGFGSCSDKGWGRFCQEGKGFQDCRVKNGGCHYCLJEETRRRCR
        CAGYELADDMHCRPTVNFPCGKLWRTDKRKNPKRDI DPDEDELELGPRI VNGTL
        TKQGS PMQAILLD SKKLCACGVLHTSWLTAACLESKLT VRLGEYDLRRDP
        WELDDI KEVLVHPNYTRNSNDIALLSQAPATLSKTIPTICLPNSGLAELSOAG
        QETVVTGYSQDKVDGRRNRTFILFIRIPLARNDCMQWNNVVS EMLCAGLIG
        DTRDACDGDGSGPMVVFVFRGTWFLVGLVSGEGGCLNNIVTITKVGSLIKWIHSTIG
        ERDVSLSKSEKL"
        49..147
        169..1431
        /product="protein C"
        1514..1519
        polyA_signal

  sig_peptide
  mat_peptide
  polyA_signal
```



```

Query Match          0.9%; Score 20.2; DB 1; Length 1543;
Best Local Similarity 68.3%; Pred.No.86;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY    920 CATCCCTTTTACTCTAAGGTGATGTCATCATCGTAGGTGG 960
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB    1408 CATCCCTTTCCCCTATTAGCTGTGGATCCATTGAGGTAG 1368

RESULT 110
AF011899/c
LOCUS       AF011899                855 bp        mRNA         linear   VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a3 (TRYPA3) mRNA, complete cds.
ACCESSION  AF011899
VERSION     AF011899.1 GI:2367496
SOURCE      Petromyzon marinus (sea lamprey)
ORGANISM    Petromyzon marinus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
            Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE   1 (bases 1 to 855)
AUTHORS     Roach,J.C.
TITLE       The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL     Unpublished
REFERENCE   2 (bases 1 to 855)
AUTHORS     Roach,J.C.
TITLE       Direct Submission
JOURNAL     Submitted (01-JUL-1997) Molecular Biotechnology, University of
            Washington, Seattle, WA 98195, USA

FEATURES             Location/Qualifiers
     source           1..855
                     /organism="Petromyzon marinus"
                     /mol_type="mRNA"
                     /db_xref="taxon:7757"
     gene             1..855
                     /dev_stage="ammocoete"
                     /tissue_lib="anterior intestine"
     CDS              1..855
                     /gene="TRYPA3"
                     /genes="TRYPA3"
                     /codon_start=1
                     /product="trypsinogen a3"
                     /protein_id="AAB69655.1"
                     /db_xref="GI:2367497"
                     /translations="MHGLIILALVGAAPMYEDHIVGGSECAAHSPQWVSLNIG
YHFCGGSLSINSOMVSAAHCYQTASRIKSVRIGEHNFVNBSGEQQIQASKAIQHPOYN
SWPINDIMLIKUSSPATLNQYQAIALPSSCVNTGMWCTISWGSGTQTSVGSPFDVLM
CWAQPLVSIDFSCKRNTPGDITNNMI CLGYLEGGKDCSQGSDSGGVVVCNGELQGISVWSG
RGAPNLPGPVYTKVCYNNAWIAQTAAAN"
sig_peptide         1..45
                     /gene="TRYPA3"
                     /evidence=not_experimental
mat_peptide         46..741
                     /gene="TRYPA3"
                     /product="trypsin a3"
                     /evidence=not_experimental

Query Match          0.9%; Score 20; DB 1; Length 855;
Best Local Similarity 65.9%; Pred.No.95;
Matches 29; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY    1540 TTTTAATATCTCTTTTGTTCTATACCTTTTAGTGATTGATTA 1583
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB    855 TTTTTTTTTTTGTAGTAGTCACATTTTATTTCATTGTTA 812

RESULT 111
AR234337
LOCUS       AR234337                1130 bp        DNA         linear   PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6458564.
ACCESSION  AR234337
VERSION     AR234337.1 GI:27277021
SOURCE      .
KEYWORDS    .

```


Cancer Res. (1998) In press
 2 (bases 1 to 268)
 Bignell,G.R., Barfoot,R., Seal,S., Collins,N., Warren,W. and
 Stratton,M.R.
 TITLE
 Low frequency of somatic mutations in the LKB1/Peutz-Jeghers
 syndrome gene in sporadic breast cancer
 Cancer Res. 58 (7), 1384-1386 (1998)
 98196525
 PUBMED
 9537235
 REFERENCE
 3 (bases 1 to 268)
 Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Bignell,G.R.,
 Warren,W., Stratton,M.R. and Aaltonen,L.A.
 DIRECT SUBMISSION
 TITLE
 Submitted (25-MAR-1998) Department of Medical Genetics, Haartman
 Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3),
 Helsinki FIN-00014, Finland
 HELSINKI
 FEATURES
 source
 1. .268
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="19"
 /map="19p13.3"
 41. .228
 /gene="LKB1"
 /number=8
 exon
 Query Match 0.9%; Score 19.8; DB 1; Length 268;
 Best Local Similarity 60.0%; Pred. No. 1e+02;
 Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
 Qy 938 TGAATGCTATCCATGCTAGGTGTCCTTTTGGATGACGAGTAGGATGATCTT 992
 Db 105 TGGTGCTGGCTCGGTGGATGGCAGCTGCTTACGCGGAGGATGTTCTT 51
 RESULT 118
 BD095271/c
 LOCUS
 BD095271 384 bp DNA linear PAT 27-AUG-2002
 DEFINITION
 Structural coordinate and NMR chemical shift of protein and
 utilization thereof.
 ACCESSION
 BD095271
 VERSION
 BD095271.1 GI:22640859
 KEYWORDS
 WO 0142453-A/3
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 384)
 Koda,D., Hiroaki,H. and Sumimoto,H.
 TITLE
 Structural coordinate and NMR chemical shift of protein and
 utilization thereof
 Patent: WO 0142453-A 3 14-JUN-2001;
 BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU
 HIROAKI, HIDEKI SUMIMOTO
 OS
 Homo sapiens (human)
 PN
 WO 0142453-A/3
 PD
 14-JUN-2001
 PF
 01-DEC-2000 WO 2000JP008501
 PR
 06-DEC-1999 JP 99P 346193
 PI
 DAISUKE KODA, HIDEKAZU HIROAKI, HIDEKI SUMIMOTO PC
 C12N15/09, C12N9/02, G06F17/30, G06F17/50, G01N33/68, G01N24/02 CC
 Structural coordinate and NMR chemical shift of protein and CC
 utilization
 CC
 thereof
 FH
 Key
 FT
 source
 1. .336
 Location/Qualifiers
 /organism="Homo sapiens (human)"
 FEATURES
 source
 1. .384
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 19.8; DB 1; Length 384;
 Best Local Similarity 77.4%; Pred. No. 1e+02;
 Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 1674 TAGGAATTTTCTTTTCTTTTGGTTTCTTCTGAA 1704
 Db 178 TAGGAACATTTCTTTTAAAGGTTTATGGA 148
 RESULT 119
 AX814618/c
 LOCUS
 AX814618 394 bp DNA linear PAT 05-DEC-2003
 DEFINITION
 Sequence 56 from Patent WO03064641.
 ACCESSION
 AX814618
 VERSION
 AX814618.1 GI:39103831
 KEYWORDS
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 Bouqueleret,L., Niknejad,A. and Saudrais,C.
 TITLE
 Gene encoding serine proteases
 JOURNAL
 Patent: WO 03064641-A 56 07-AUG-2003;
 Geneprot, Inc. (CH)
 FEATURES
 Location/Qualifiers
 source
 1. .394
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 misc_feature
 1. .394
 /note="exon 14"
 Query Match 0.9%; Score 19.8; DB 1; Length 394;
 Best Local Similarity 60.0%; Pred. No. 1e+02;
 Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
 Qy 1149 GTCTCCCT 1203
 Db 391 GTAGCTGGTCT 337
 RESULT 120
 DLA6882
 LOCUS
 DLA6882 535 bp mRNA linear VRT 12-OCT-1998
 DEFINITION
 Dicertrarchus labrax mRNA for trypsin, partial.
 ACCESSION
 AJ006882
 VERSION
 AJ006882.1 GI:3228220
 KEYWORDS
 trypsin.
 SOURCE
 Dicertrarchus labrax (European sea bass)
 ORGANISM
 Dicertrarchus labrax
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
 Percoidae; Moronidae; Dicertrarchus.
 1
 Peres,A., Zambonino Infante,J.L. and Cahu,C.L.
 TITLE
 Dietary regulation of activities and mRNA levels of trypsin and
 amylase in sea bass (Dicertrarchus labrax) larvae
 JOURNAL
 Fish Physiol. Biochem. 19, 145-152 (1998)
 2 (bases 1 to 535)
 Zambonino Infante,J.L.
 REFERENCE
 Direct Submission
 TITLE
 Submitted (11-JUN-1998) Zambonino Infante J.L., Unite Mixte
 Inra-Iframer de Nutrition des Poissons, Ifremer, BP 70, 29280
 Plouzanee, FRANCE
 FEATURES
 Location/Qualifiers
 source
 1. .535
 /organism="Dicertrarchus labrax"
 /mol_type="mRNA"
 /db_xref="taxon:13489"
 /dev_stage="larvae"

CDS

CDS

```
<1..>535
/EC_number="3.4.21.4"
/codon_start=1
/product="trypsin"
/protein_id="CAA07315.1"
/db_xref="GI:3242120"
/db_xref="GOA:O93594"
/db_xref="SPTREMBL:O93594"
/translation="QVSLNNGYHFCGGSILNENWVVSAAHCYKSRVEVELGEHINRTV
ENTEQPISSRVIRHPRYSYININDIMLIKSLPQYVQVPALPTSCAPAGTMC
TVSGWGNTWSSYADNRKLNQCLNIPILSFKDCDCNSYPGMITDAMFCAGYLEGGKDSQQG
DSGGPVNCGELQGVVSW"
```

	Query Match	0.9%	Score 19.8	DB 1	Length 535
	Best Local Similarity	54.3%	Pred. No. 1e-021		
	Matches 39	Conservative 0	Mismatches 32	Indels 0	Gaps 0
QY	53	TGTTAGAGTATCTCATACAGAGGATGACACTAGATGCTGTCTGGGCATAGGTAGCTTTT	112		
Db	414	TGGCATGATCACTGATGCTATGTTCTGCGCTGGATACTTGGAGGGGCAAGGACTCTTG	473		
QY	113	CCAGAGAGACT	123		
Db	474	CCAGGGTGACT	484		

RESULT 121	BV036036	556 bp	DNA	linear	STS 31-MAY-2003
LOCUS	S212P6822FB7.T0		Mus musculus	STS genomic,	
DEFINITION	tagged site.				
ACCESSION	BV036036				
VERSION	BV036036.1	GI:31119931			
KEYWORDS	STS.				
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
	1 (bases 1 to 556)				
	Wade,C.M., Kulbokas,E.J. III, Kirby,A.W., Zody,M.C., Mullikin,J.C.,				
	Lander,E.S., Lindblad-Toh,K. and Daly,M.J.				
TITLE	The mosaic structure of variation in the laboratory mouse genome				
JOURNAL	Nature 420 (6915), 574-578 (2002)				
MEDLINE	22354684				
PUBMED	12466852				
COMMENT					

Contact: Kerstin Lindblad-Toh
Whitehead Institute for Biomedical Research, Center for Genome
Research
320 Charles Street, Cambridge, MA 02141, USA
Tel: 6172521477
Fax: 6172580903
Email: kersli@genome.wi.mit.edu
Primer A: None
Primer B: None
STS size: 556
Protocol:
WGS-discovery: Paired-end low-coverage whole genome shotgun reads
were generated from 129S1/SvImJ, C3H/HeJ, and BALB/cByJ. The WGS
reads were placed uniquely on the WGS CV3, C57BL/6J assembly and SNP
detection was carried out by SSAHA-SNP. 225,000 reads were
annotated
as STSs and 81,000 SNPs were annotated with alleles from C57BL/6J
and the strain from which the particular read came. The validation
rate for these SNPs was estimated at approximately 98%.

FEATURES
SOURCE

```

location/Qualifiers
1..556
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="CZECHII/E1"
/db_xref="taxon:10090"
/map=- 8 22-490 13020709-13020240"
/clone_lib="CZECHII/E1"

```

STS

```

<1. >.556

Query Match          0.9%; Score 19.8; DB 1; Length 556;
Best Local Similarity 69.2%; Pred. No. 1.1e+02;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy      1860  CTGCGTGGAGATTCTCTCTCTATCTCTCTGTGTTATCTGTCA 1898
          |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
          |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db      346  CTGCTGGAGTTCCTTTTCTTACACAGGTATCTCCCA 384

RESULT 122
PIGFIXA/c
LOCUS      PIGFIXA      813 bp      mRNA      linear      MAM 27-APR-1993
DEFINITION Pig factor IX mRNA, partial cds.
ACCESSION M26235
VERSION    M26235.1 GI:164450
KEYWORDS   factor IX.
SOURCE     Sus scrofa (pig)
ORGANISM   Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

REFERENCE
  1 (bases 1 to 813)
AUTHORS    Sarkar, G., Koeberl, D.D. and Sommer, S.S.
TITLE      Direct sequencing of the activation peptide and the catalytic
            domain of the factor IX gene in six species
JOURNAL    Genomics 6 (1), 133-143 (1990)
MEDLINE    90152675
MEDLINE    2303254
COMMENT    Original source text: Pig liver, cDNA to mRNA.
            Draft entry and computer-readable sequence for [1] kindly provided
            by G.Sarkar, 18-JUL-1989.

```

FEATURES source

```
location/Qualifiers
1. .813
   /organism="Sus scrofa"
   /mol_type="mrna"
   /db_xref="taxon:9823"
```

CDS

```

CDS
/db_xref="CAZ001:5923"
<!.>813
/note="factor IX"
/codon_start=1
/protein_id="AAA31031.1"
/db_xref="GI:164451"
/translation="SHSPTTLTRAEIIFSNVDYENSTEVEPILDSLSTESNQSSDDEIR
IVGNAKPGFPQWLKIDKACGGSINERKWWVTAHCEPGLVPTITVAGEXT
BETEPQRNRIIRAIPIHNSYNAIVNKYSHDIALLELDEPTLNSVYPTICADKQYI
NIFLKFGSGYSGHVRVNGRSRATILQYLKVLVDRATCLRSTKVTIIVNMFCAGFH
EGGQKIGDGGSGVEVEGTSPTIGIISWGRECAVKVGKVTIVKSRVYVW"

```

	Query Match	0.9%	Score 19.8;	DB 1;	Length 813;
	Best Local Similarity	49.5%;	Pred. No. 1.1e+02;		
	Matches	51;	Conservative	0;	Mismatches 52; Indels 0; Gaps 0;
Qy	298	TCTTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAGT	357		
Db	156	TTTGGCGTTTTCCACCAACAATTCGATAAAGTCGTCAGATGTTGGTTGCTTTCAGT	97		
Qy	358	TTGTAAGTTTCTGTTGTTTCTGTTGTTGTTGTTATCTAG	400		
Db	96	GAGCGCTATCAAAATTTGGTTTCAACTTCAGTAGAATTTTCAATAG	54		

RESULT 123
HIMCETX/C

LOCUS	HUMCFIX	873 bp	linear	PRI 01-NOV-1994
DEFINITION	Human coagulation factor IX mRNA, partial cds.			
ACCESSION	M35672			
VERSION	M35672.1 GI:180287			
KEYWORDS	coagulation factor IX; serine protease.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.			
REFERENCE	1 (bases 1 to 873)			

/organism="Mesocricetus auratus"
/mol_type="genomic DNA"
/db_xref="taxon:10036"
<1..>484
/codon_start=2
/product="coagulation factor X"
/protein_id="BAA04757.1"
/db_xref="GI:455393"
/translation="EGNETHEDVDVVKHNFVRETYDFDIADVLRKTPILFRNVAP
ACLPEKDAEATLMTQKSGIVSGFRGTHEGRQSHILKKLEVPYVDRNTCKLSFTI
TQNMFCAGYDAKPEDACQDSGPHVTRFKDTYFVTGIVSWGEGCARCKYGIYTKVT
A"

CDS

Query Match 0.9%; Score 19.6; DB 1; Length 484;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
QY 740 ATTGTGTTGGTGCATGACATTAAGAATTGCAATGCTCTTGTGGGATTTCCTTTGA 799
Db 114 AATATGATGGGGTCTTCAGCTGAGCAGCGGATGCGAAGTCTAGGTCTCCCTCACA 55
QY 800 TGCCTATGATGATTTCTTCCCAATCTCATCTGCTTAGT 837
Db 54 AACTGTGTTGTTTATGACCACGCTCCACCTCATGTGT 17

RESULT 126
AX193364
LOCUS AX193364 596 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 931 from Patent WO0149716.
ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J.,
Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.
TITLE Compounds for immunotherapy and diagnosis of colon cancer and
methods for their use
JOURNAL Patent: WO 0149716-A 931 12-JUL-2001;
CORIXA CORPORATION (US)
FEATURES
source
Location/Qualifiers
1..596
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.6; DB 1; Length 596;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTTGTTTGGTCATAGCAATTAAGAATTCGAATGCTCTTTGG 784
Db 122 GATGTAGCGGAGAGGATGGGTCTGCTGAGTTGGAGAGTGAATGTCGCCCTGG 179

RESULT 127
AX763043
LOCUS AX763043 609 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 37 from Patent WO03040393.
ACCESSION AX763043
VERSION AX763043.1 GI:32257659
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Martinez, R.A. and Sigurdsson, G.T.
TITLE Nucleic acids encoding proteases

JOURNAL Patent: WO 03040393-A 37 15-MAY-2003;
Decode Genetics EHF. (IS)
FEATURES
source
Location/Qualifiers
1..609
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.6; DB 1; Length 609;
Best Local Similarity 54.1%; Pred. No. 1.2e+02;
Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 435 ATTATTTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGTAAATATGATTAAT 494
Db 142 ATTATTTCCCAATATATAGATCATGCTGTGGCCCTTTTGTTCAAATTTCTCCATT 201
QY 495 TTGAGAGAGTTTTCAT 508
Db 202 TGAATGGGAACAT 215

RESULT 128
AX675583
LOCUS AX675583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX675583
VERSION AX675583.1 GI:29333568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigar, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Bohdig, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
Location/Qualifiers
1..882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTTGTTTGGTCATAGCAATTAAGAATTCGAATGCTCTTTGG 784
Db 369 GATGTAGCGGAGAGGATGGGTCTGCTGAGTTGGAGAGTGAATGTCGCCCTGG 312

RESULT 129
AR219285
LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 8 from patent US 6420157.
ACCESSION AR219285
VERSION AR219285.1 GI:23320255
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1142)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;

```

FEATURES
  source      Location/Qualifiers
              1..1142
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.9%; Score 19.6; DB 1; Length 1142;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 727 GAACCTTGGGTGACATTGTGTTGGTCATAGACATTAAAGAAATGCAATGTCCTCTTGG 784
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 456 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTGGAGGAGTGCAATGTCGCCCTGG 399

RESULT 130
AX675581/c
LOCUS      AX675581      1161 bp      DNA      linear      PAT 27-MAR-2003
DEFINITION      Sequence 31 from Patent WO02055704.
ACCESSION      AX675581
VERSION      AX675581.1 GI:29333567
KEYWORDS      Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS      Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
              Spytek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
              Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
              Boldog,F.L., Grosse,W.M., Alsbrook,J.P., Gerlach,V.,
              Edingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
              Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
              Stone,D.J.
TITLE      Proteins, polynucleotides encoding them and methods of using the
              same
JOURNAL      Patent: WO 02055704-A 31 18-JUL-2002;
              Curagen Corporation (US)
FEATURES
  source      Location/Qualifiers
              1..1161
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.9%; Score 19.6; DB 1; Length 1161;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 727 GAACCTTGGGTGACATTGTGTTGGTCATAGACATTAAAGAAATGCAATGTCCTCTTGG 784
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 657 GATGTAGCGGAGNAGTGATGGTCTGCTGAGTTGGAGGAGTGCAATGTCGCCCTGG 600

RESULT 131
AR219284/c
LOCUS      AR219284      1169 bp      DNA      linear      PAT 25-SEP-2002
DEFINITION      Sequence 7 from patent US 6420157.
ACCESSION      AR219284
VERSION      AR219284.1 GI:23320254
KEYWORDS      Unknown.
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 1169)
AUTHORS      Darrow,A., Qi,J. and Andrade-Grodon,P.
TITLE      Zymogen activation system
JOURNAL      Patent: US 6420157-A 7 16-JUL-2002;
FEATURES
  source      Location/Qualifiers
              1..1169
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.9%; Score 19.6; DB 1; Length 1169;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;

```

```

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 727 GAACCTTGGGTGACATTGTGTTGGTCATAGACATTAAAGAAATGCAATGTCCTCTTGG 784
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 483 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTGGAGGAGTGCAATGTCGCCCTGG 426

RESULT 132
BOVPBC/c
LOCUS      BOVPBC      1373 bp      mRNA      linear      MAM 27-APR-1993
DEFINITION      Bovine protein C mRNA.
ACCESSION      K02435
VERSION      K02435.1 GI:163486
KEYWORDS      autoproteolysin IIA; protein C; serine protease.
SOURCE      Bos taurus
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
              Bovidae; Bovinae; Bos.
REFERENCE      1 (bases 1 to 1373)
AUTHORS      Long,G.L., Belagaje,R.M. and MacGillivray,R.T.
TITLE      Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL      Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE      85014826
PUBMED      6091100
COMMENT      Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
              pBC-7.
              The sequence reported in [1] included homopolymeric tails on the 5'
              and 3' ends (not shown here).
FEATURES
  source      Location/Qualifiers
              1..1373
              /organism="Bos taurus"
              /mol_type="mRNA"
              /db_xref="taxon:9913"
              <1..1370
              /notes="protein C prepropeptide"
              /codon_start=3
              /protein_id="AAA30685.1"
              /translation="TSLLLFVTIWGISTPAPDSVPSSSQRAHQVLRIRKANSFLE
              ELRPGNVRECSVEVCFEAFEFQNTEDTMAFWKSYSDGQCEDRPSPGSCDLPC
              GRGKIDGLGPRDCAGWEGFCLHEVRFNSCAENGCGCAHYCMEERRRHSCAP
              GYLEDHOLCVSKVTFFPGRGLGRMEKKTKLRDNTNOVDQDOLDPRIVDQGEAGW
              GESPWQAVLLDSKKLVCGAVLHVSNVLTVACHLSRKKLIVRLGEYDWRRESWYV
              DLDIVLHPNTKTSNDIALRLAKPATLUSQTIVPICLPDSGLSERKLIQVGOR
              TVVTGWGYRDETKRNTFLSFIKVPVPYFNACVHAMENKISENMLCAGILGDPDAC
              EGDSGPMVTFFRGTWFLVGLVSWGEGCGRLNYGYVTKVSRYLDMITYHIKAQEAPL
              ESQVP"
              <1..86
              /notes="protein C signal peptide"
              /product="protein C light chain"
              588..1367
              /product="protein C inactive heavy chain"
              630..1367
              /product="protein C active heavy chain"

Query Match      0.9%; Score 19.6; DB 1; Length 1373;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 2069 ATTTCCTCTTCAAGGACCTTTTATGAATTCATAAATGATGTAGTCTCTTGCCTTGT 2128
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 895 ATGTCGTTGTCATGTTGGTCTCTTGGTATAGTATAGTGGTGGATGATGACCTCTTGTGTC 836

QY 2129 GCTTCAGCTATGTTGCATCTCAGGCGCTATTGTAATA 2166
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 835 AGGTCCACCTCCAGCTCTCCGAGCGCGCATGTCATA 798

RESULT 133
AR109618
LOCUS      AR109618      177 bp      DNA      linear      PAT 14-FEB-2001

```

DEFINITION Sequence 30 from patent US 6114139.

ACCESSION AR109618 GI:12825894

VERSION AR109618.1

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

UNCLASSIFIED.

REFERENCE 1 (bases 1 to 177)

AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.

TITLE G-protein coupled receptor protein and a DNA encoding the receptor

JOURNAL Patent: US 6114139-A 30 05-SEP-2000;

FEATURES Location/Qualifiers

source 1..177

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTATTCCTTGGTTTTCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 134

AR150638

LOCUS AR150638 177 bp DNA linear PAT 08-AUG-2001

DEFINITION Sequence 25 from patent US 6228984.

ACCESSION AR150638

VERSION AR150638.1

KEYWORDS GI:15115229

SOURCE Unknown.

ORGANISM Unknown.

UNCLASSIFIED.

REFERENCE 1 (bases 1 to 177)

AUTHORS Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S. and Kitada,C.

TITLE Polypeptides their production and use

JOURNAL Patent: US 6228984-A 25 08-MAY-2001;

FEATURES Location/Qualifiers

source 1..177

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTATTCCTTGGTTTTCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 135

E16187

LOCUS E16187 177 bp DNA linear PAT 28-JUL-1999

DEFINITION Partial sequence of cDNA encoding G protein-coupled receptor.

ACCESSION E16187

VERSION E16187.1

KEYWORDS GI:5710870

SOURCE JP 1998146192-A/11.

ORGANISM Homo sapiens (human)

UNCLASSIFIED.

REFERENCE 1 (bases 1 to 177)

AUTHORS Shuji,H. and Shoji,F.

TITLE Novel physiologically active substance, process for producing the

JOURNAL Patent: JP 1999009286-A 4 19-JAN-1999;

COMMENT TAKEDA CHEM IND LTD

OS Unidentified

PN JP 1999009286-A/4

PD 19-JAN-1999

PF 27-APR-1998

PR JP 1998117189

PI SHUJI HINUMA, SHOJI FUKUZUMI

PC C12N15/09, A01K67/027, A61K38/00, A61K31/70, A61K14/47, C07K16/18, C12N1/21,

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

OS

PN

PD

PF

PR

PI

HINUMA KUNII, HABATAKE YUUGO, KAWAMATA YUJI, HOSoya MASAKI, PI

FUJII AKIRA,

PI FUKUZUMI MASASHI, KITADA CHIEKO

PC C12N15/09, A61K31/70, A61K38/00, C07H21/00, C07K14/47, C12N5/10, PC

PC A61K35/76, A61K38/00, A61K48/00, C07H21/00, C07K14/47, C12N5/10, PC

C12P21/02,

PC C12Q1/02, G01N33/566, (C12N5/10, C12R1:91), (C12P21/02, C12R1:91);

CC strandedness: Double;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

PH Key

PH Location/Qualifiers

FT source 1..177

FT /organism="Homo sapiens"

FT /tissue_type="pituitary gland".

FT Location/Qualifiers

source 1..177

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="taxon:9606"

Query Match 0.9%; Score 19.4; DB 1; Length 177;

Best Local Similarity 57.4%; Pred. No. 1.2e+02;

Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTGACCTGCTCTTCCCTCTCTATTCCTTGGTTTTCATAGTGTCTCT 1774

DB 7 CTGCTGGTCACTACCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 66

QY 1775 G 1775

DB 67 G 67

RESULT 136

E27213

LOCUS E27213 177 bp DNA linear PAT 18-JUN-2001

DEFINITION Novel physiologically active substance, process for producing the

same and utilization thereof.

ACCESSION E27213

VERSION E27213.1

KEYWORDS GI:13025230

SOURCE JP 1999009286-A/4.

ORGANISM unidentified

UNCLASSIFIED.

REFERENCE 1 (bases 1 to 177)

AUTHORS Shuji,H. and Shoji,F.

TITLE Novel physiologically active substance, process for producing the

JOURNAL Patent: JP 1999009286-A 4 19-JAN-1999;

COMMENT TAKEDA CHEM IND LTD

OS Unidentified

PN JP 1999009286-A/4

PD 19-JAN-1999

PF 27-APR-1998

PR JP 1998117189

PI SHUJI HINUMA, SHOJI FUKUZUMI

PC C12N15/09, A01K67/027, A61K38/00, A61K31/70, A61K14/47, C07K16/18, C12N1/21,

PC	C12N5/10, C12P21/02, G01N33/53, G01N33/577//C12P21/08, (C12N15/09, C12R1:91),
PC	(C12N1/21, C12R1:19), (C12N5/10, C12R1:91), (C12P21/02, C12R1:19),
PC	C12N15/00,
PC	A61K37/02, A61K37/02, C12N5/00, (C12N15/00, C12R1:91), (C12N5/00, C12R1:91)
CC	Strandedness: Double;
CC	Topology: Linear;
FH	Key
FT	source
FT	1. .177
FT	Location/Qualifiers
FT	Location/Qualifiers
FT	1. .177
FT	/organism="Unidentified".
FT	/organism="unidentified"
FT	/mol_type="genomic DNA"
FT	/db_xref="taxon:32644"
Query Match	0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity	57.4%; Pred. No. 1.2e+02;
Matches	35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy	1715 CTGTTTGGACCTCCCTCTTCCTCTTCCTCTATTCCTTTGGTTTTCATAGTCTCT 1774
Db	
Db	7 CTGCTGTCACCTACCTGCTCCCTCTCTGCTGCTCACTCTCTTAGTCCGGGTCTCA 66
Qy	1775 G 1775
Db	67 G 67
RESULT 137	
E28271	
LOCUS	E28271 177 bp DNA linear PAT 18-JUN-2001
DEFINITION	Utilization of peptide.
ACCESSION	E28271
VERSION	E28271.1 GI:13025305
KEYWORDS	JP 1999071300-A/11.
SOURCE	unidentified
ORGANISM	unidentified
REFERENCE	1 (bases 1 to 177)
AUTHORS	Shuji, H., Ryo, F., Yuji, K. and Hirokazu, M.
TITLE	Utilization of peptide
JOURNAL	Patent: JP 1999071300-A 11 16-MAR-1999;
COMMENT	TAKEDA CHEM IND LTD
OS	Unidentified
PN	JP 1999071300-A/11
PD	16-MAR-1999
PF	22-JUN-1998 JP 1998175007
PR	
PI	SHUJI HINUMA, RYO FUJII, YUJI KAWAMATA, HIROKAZU MATSUMOTO PC
A61K38/00	A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, PC
A61K38/00,	
PC	A61K38/00, A61K38/00, C07K7/08, C07K14/705//C12N15/09, C12P21/02,
PC	(C12P21/02, C12R1:91), A61K37/02, A61K37/02, A61K37/02, A61K37/02,
PC	A61K37/02,
PC	A61K37/02, A61K37/02, A61K37/02, A61K37/02, C12N15/00 CC
Strandedness:	Double;
CC	Topology: Linear;
FH	Key
FT	source
FT	1. .177
FT	Location/Qualifiers
FT	Location/Qualifiers
FT	1. .177
FT	/organism="Unidentified".
FT	/organism="unidentified"
FT	/mol_type="genomic DNA"
FT	/db_xref="taxon:32644"
Query Match	0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity	57.4%; Pred. No. 1.2e+02;
Matches	35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy	1715 CTGTTTGGACCTCCCTCTTCCTCTTCCTCTATTCCTTTGGTTTTCATAGTCTCT 1774

```
AR150703
LOCUS AR150703 204 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 127 from patent US 6228984.
ACCESSION AR150703
VERSION AR150703.1 GI:15115294
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 204)
AUTHORS Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S.
and Kitada,C.
TITLE Polypeptides their production and use
JOURNAL Patent: US 6228984-A 127 08-MAY-2001;
FEATURES
    source
        Location/Qualifiers
            1..204
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 19.4; DB 1; Length 204;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1715 CTGCTTTTACCTGCTTCCCTCTCTATTCCTTTCCTTGGTTTTCATGATGTCCT 1774
Db 7 CTGCTGGTCACTACTGCTCTCTCTGCTGGTCACTCTCTCTTACGTCGGGTGTCA 66

QY 1775 G 1775
Db 67 G 67

RESULT 141
AJ586104/c
LOCUS AJ586104 249 bp mRNA linear PLN 23-OCT-2003
DEFINITION Lolium multiflorum partial mRNA for putative 4-coumarate coA ligase
(4cl gene).
ACCESSION AJ586104
VERSION AJ586104.1 GI:37805458
KEYWORDS 4-coumarate coA ligase; 4cl gene.
SOURCE Lolium multiflorum (Italian ryegrass)
ORGANISM Lolium multiflorum
REFERENCE 1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Poae; Lolium.
AUTHORS Bettany,A.J.E. and Morris,P.
TITLE cDNA and genomic clones of Festuca arundinacea and Lolium
multiflorum
JOURNAL Unpublished
AUTHORS 2 (bases 1 to 249)
TITLE Bettany,A.J.E.
JOURNAL Direct Submission
SUBMITTED (13-OCT-2003) Bettany A.J.E., Plant, Animal & Microbial
Science, Inst. Grassland & Environmental Research, Plas Gogerddan,
Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM
FEATURES
    source
        Location/Qualifiers
            1..249
            /organism="Lolium multiflorum"
            /mol_type="mRNA"
            /cultivar="Trident"
            /db_xref="taxon:4521"
            /tissue_type="young leaves with leaf bases"
            /dev_stage="seedlings"
            1..249
            /gene="4cl"
            /gene="4cl"
            <1..249
            /gene="4cl"
            /EC number="6.2.1.12"
            /function="activation of thioester substrates for
phenylpropanoid synthesis"
            /codon_start=3
            /product="putative 4-coumarate coA ligase"

gene
CDS
```

```
/protein id="CAE51882.1"
/db_xref="GI:37805459"
/translation="PFKVKSGCTVVRNAELKVVDPTGASLGRNQPGEICVRGKQI
MLGYLNDPESTKNITDKGWLHTGDIGLVDDDEIFIV"

Query Match
Best Local Similarity 0.9%; Score 19.4; DB 1; Length 249;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1880 TATCTCTGTATTCTGTCAGTCAGGAGCTGTCTCTCTAGGTCCTCTGTGGTTCT 1932
Db 210 TGTCTCCGTTGTCAGCCAGCGCTCTTGTGATGTTGTCTTGTGCGACTCT 158

RESULT 142
AX839191/c
LOCUS AX839191 290 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 34 from Patent WO03076610.
ACCESSION AX839191
VERSION AX839191.1 GI:39922640
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Bracco,L., Brinkman,B. and Coignard,F.
TITLE Variants of human kallikrein-2 and kallikrein-3 and uses thereof
JOURNAL Patent: WO 03076610-A 34 18-SEP-2003;
FEATURES
    source
        Location/Qualifiers
            1..290
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 19.4; DB 1; Length 290;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTCTAACACTCTCGGCCAGGTAGGGGCATCGGCATTCCCTC 276
Db 113 TCTCGCACTCCAGCGCTCCCAATCCGAGAGGATGAGGGGTGCAGCAATCCACG 54

QY 277 TCTCTTCCA 285
Db 53 TCACGGACA 45

RESULT 143
HUMPS02
LOCUS HUMPS02 352 bp DNA linear PRI 10-JAN-1995
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917
VERSION M57841.1 GI:190535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT 2 of 14
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 (bases 1 to 352)
TITLE Schmidt,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
JOURNAL Organization of the human protein S genes
MEDLINE Biochemistry 29 (34), 7845-7852 (1990)
PUBMED 9108444
COMMENT 2148110
FEATURES
    source
        Location/Qualifiers
            1..352
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
```

```

/map="3p11-q11.2"
/tissue_type="liver"
Join(M57840.1:837..912,135..181)
/gene="PS-alpha"
order(M57840.1:913..1014,1..134)
/gene="PROS1"
/number=1
135..292
/gene="PROS1"
/note="G00-120-721"
/number=2

Query Match      0.9%; Score 19.4; DB 1; Length 352;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1309 AAGATAGATATCTTTACATCTGATTTTATCTTAGAATGCTTTCTTCTTCTCCAACTATTG 1368
      |||||
Db 80 AATATATTTACATCGAAATAATGATTATTCATATAAATGATTTCTTCTTCTCAGTTTGTG 139

Qy 1369 TGACAGAAA 1377
      |||||
Db 140 TCAAAGCAA 148

RESULT 144
LOCUS      DOGA2              471 bp      DNA      linear      MAM 09-FEB-1999
DEFINITION Dog gene for protein C (precursor of vitamin K-dependent serine
              protease), partial cds (catalytic region).
ACCESSION  D43751
VERSION     D43751.1 GI:601886
KEYWORDS    protein C; serine protease zymogen; vitamin K-dependent serine
              protease; blood coagulation-related.
SOURCE      Canis familiaris (dog)
ORGANISM    Canis familiaris
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1 (bases 1 to 471)
AUTHORS     Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
              Niho,Y.
TITLE       A comparative study of partial primary structures of the catalytic
              region of mammalian protein C
JOURNAL     Br. J. Haematol. 86 (3), 590-600 (1994)
MEDLINE     94318474
PUBMED      8043441
REFERENCE   2 (bases 1 to 471)
AUTHORS     Murakawa,M.
TITLE       Direct Submission
JOURNAL     Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General
              Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
              Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
FEATURES    Location/Qualifiers
              1..471
                /organism="Canis familiaris"
                /mol_type="genomic DNA"
                /db_xref="taxon:9615"
                <1..>471
                  /function="regulation of blood coagulation"
                  /note="catalytic region"
                  /codon_start=1
                  /product="protein C"
                  /protein_id="BAA07808.1"
                  /db_xref="GI:1304048"
                  /translation="EKGMVDVDEKEVLHPNYSKSTDDIALHLAQAIFQSOTIVP
                  ICLPDSGLARELTQVQETVTVGWYRSTKRNRTFVLFNIPVAPHNECICQAMYN
                  MISNMLCAGILGDSRDACEGSGPVMVTSFRGTWFLVGLVSGEGGCRLLNYGI"

Query Match      0.9%; Score 19.4; DB 1; Length 471;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1191 TGTCTCTCCCTCTTTTGATTTTTTGGCTGGAATTATTTATTTATTCATATTTCTTGAA 1250

```

```

Db 322 TGTTCAGATATCATGTTGTACATGGCCTGGATGCACTCATTTGTGCGGGCCACAGGGA 263
      |||||
Qy 1251 TGTGGGTAA 1259
      |||||
Db 262 TGTGTATAA 254
      |||||

RESULT 145
LOCUS      SHPFIYA          823 bp      mRNA      linear      MAM 27-APR-1993
DEFINITION Sheep factor IX mRNA, partial cds.
ACCESSION  M26233
VERSION     M26233.1 GI:165878
KEYWORDS    factor IX.
SOURCE      Ovis aries (sheep)
ORGANISM    Ovis aries
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
              Bovidae; Caprinae; Ovis.
REFERENCE   1 (bases 1 to 823)
AUTHORS     Sarkar,G., Koerberl,D.D. and Sommer,S.S.
TITLE       Direct sequencing of the activation peptide and the catalytic
              domain of the factor IX gene in six species
JOURNAL     Genomics 6 (1), 133-143 (1990)
MEDLINE     90152675
PUBMED      2303254
COMMENT     Original source text: Sheep liver, cDNA to mRNA.
              Draft entry and computer-readable sequence for [1] kindly provided
              by G.Sarkar, 18-JUL-1989.
FEATURES    Location/Qualifiers
              1..823
                /organism="Ovis aries"
                /mol_type="mRNA"
                /db_xref="taxon:9940"
                <1..>823
                  /note="factor IX"
                  /codon_start=1
                  /protein_id="AAA31520.1"
                  /db_xref="GI:552419"
                  /translation="RASVLHTSKLTRAETIFSNMNYENSEAEIINDVNTQNSQSP
                  DFRVVGGEAARGQFFQVOLLHGEIAAFCGGSIVNEKVVTAHCHIKPGVKITVWAG
                  EHNTKEPTEQRNVRIRAIPIHYNASINKYSHDIALDELDEPLELNSVYVTPICAD
                  REYTNIFLKFGYGVSGWFRNRSASILQYLKPLVDRATCLRTKFTIYHMF
                  AGYHEGKDCQSDSGGPHVTEVGEFTSLGILISWGECAKMGKGIYTKVSYEV"

Query Match      0.9%; Score 19.4; DB 1; Length 823;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 1663 TTTCTAAGGTAGGAAATTTCTTTTGGTTTCTTCTTGAATAATTTTCCCTGCTTTT 1722
      |||||
Db 93 TATTTCAGTTCAGAGAAATTTTCATAGTTCATATTCGAAAAATAGTCTCAGCACCAGGT 34
      |||||

Qy 1723 GACCTGCCT 1731
      |||||
Db 33 GAGCTTCTT 25
      |||||

RESULT 146
LOCUS      BC061135/c          829 bp      mRNA      linear      ROD 25-NOV-2003
DEFINITION Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),
              complete cds.
ACCESSION  BC061135
VERSION     BC061135.1 GI:38511692
KEYWORDS    MGC.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 829)
AUTHORS     Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,

```


602 AGCATTTCTCTGTTTCGTTTGTGTGAGATGACCTACTGTTGGAGAGAAATGGGTT 658
 Db TCCTGCTCCGGTTCCGGTCCCTTCGAATCTCTTGGCTTGGTAGACAGTGGGCT 480

RESULT 149
 HUMEX/c

HUMFX	1126 bp	mRNA	linear	PRI 08-NOV-1994
LOCUS				
DEFINITION	Human factor X mRNA.			
ACCESSION	K01886			
VERSION	K01886.1 GI:182820			
KEYWORDS	Stuart factor; factor X; serine protease.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
AUTHORS	1 (bases 1 to 1126)			
TITLE	Leytus,S.P., Chung,D.W., Kistiel,W., Kurachi,K. and Davie,E.W.			
JOURNAL	Characterization of a cDNA coding for human factor X			
MEDLINE	Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)			
PUBMED	84222026			
COMMENT	6587384			
	Original source text: Human liver, cDNA to mRNA, clone lambda-X-1137.			
	In processing, factor X (Stuart factor) is converted to Xa by cleavage of a glycopeptide from the amino-terminal end of the heavy chain. It then acts as a serine protease in converting prothrombin to thrombin.			

FEATURES

source	Location/Qualifiers
gene	1..1126
mRNA	/organism="Homo sapiens"
	/mol_type="mRNA"
	/db_xref="taxon:9606"
	/map="13q34"
	1..1126
	/gene="F10"
	<1..1126
	/gene="F10"
	/product="factor X mRNA"
CDS	<1..1116
	/gene="F10"
	/note="factor X precursor peptide"
	/codon_start=1
	/protein_id="AAA52486.1"
	/db_xref="GI:182821"
	/db_xref="GDB:G00-119-890"
	/translation="GFEGRNCELFTRKCLSDNGDCDFCHEEQNSVWCARGYTILA DNGKACITPTGPGKQTLERRRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFLD FNFTQPRGDNNTTRI VGGCECKDECPQWALLINENEGFCGGTILSEPYLTA AHCLYQAKREGRDNRTOEGSGEAGVHEVEVVI KHNRFKETYDFDILVLRKTPITPFR MNVAPACLPERDWAESTLMTQKTVIGSGFRTHEKGRQSTRLKALSVFVDRNSCKLS SSFIIQTQNFACGDTKQEDACGDSGGSPHVTFFKDTYFVTGIVSWGEGCARGKGYGI YKTITAFPLINDRSMKTRGLPLPAKSHAPEVITSSPLK"

mat_peptide

/gene="F10"	/product="factor X light chain"
205..1113	/gene="F10"
361..1113	/product="factor X heavy chain"
/gene="F10"	/product="factor Xa heavy chain"

mat_peptide

/gene="F10"	/product="factor X light chain"
205..1113	/gene="F10"
361..1113	/product="factor X heavy chain"
/gene="F10"	/product="factor Xa heavy chain"

mat_peptide

/gene="F10"	/product="factor X light chain"
205..1113	/gene="F10"
361..1113	/product="factor X heavy chain"
/gene="F10"	/product="factor Xa heavy chain"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
 Best Local Similarity 47.9%; Pred. No. 1.3e+02;
 Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

542 TTGCTGAATAGTCTGTAAATATCTCTAGTCCACTTGGTTTATGATCATCAGTTAGCTCC 601
 Db TTTGTGACCGGTGTGCTTGATGACCACTCCACTCGTGCACCGCCTCACGCCCTCC 537

602 AGCATTTCTCTGTTTCGTTTGTGTGAGATGACCTACTGTTGGAGAGAAATGGGTT 658

DEFINITION	Goat gene for protein C (precursor of vitamin k-dependent serine protease), partial cds (catalytic region).
ACCESSION	D43752
VERSION	D43752.1
KEYWORDS	GI:601887 protein C; blood coagulation-related; serine protease zymogen; vitamin K-dependent serine protease.
SOURCE	Capra hircus (goat)
ORGANISM	Capra hircus
REFERENCE	Makaryova, Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Eumalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidae; Bovidae; Caprinae; Capra. 1 (bases 1 to 471) Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and Nihoy. A comparative study of partial primary structures of the catalytic region of mammalian protein C Br. J. Haematol. 86 (3), 590-600 (1994) 94318474 2 (bases 1 to 471) Murakawa,M. Direct Submission Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan [Tel:092-291-3434, Fax:092-291-3266] Location/Qualifiers 1. .471
FEATURES	source

```

1. 471
source
/organism="Capra hircus"
/mol_type="genomic DNA"
/db_xref="taxon:9925"
<1. .>471
CDS
/function="regulation of blood coagulation"
/note="catalytic region"
/codon_start=1
/product="protein C"
/protein_id="BAA07809.1"
/db_xref="GI:1304082"
/translations="ESMEVLDLKEIVREPNYKTSDDNDIALHLAKPATLSQTIVP
ICLPSLSERKLTQVGQETVFTGWGVRDETKKRTSILNFIKIPVVSYNACVHAMEN
KVENMLCAGILGNPRDACEGDSGPMVTFRTGTWFLVGLVSWGEGCGRLNNYGI"

Query Match      0.8%; Score 19.2; DB 1; Length 471;
Best Local Similarity 50.0%; Pred. No. 1.5e+02;
Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

Qy 1826 GACCAAGTATCCATTTCTCTACTGTCTTCTACTGCTGAGATTCTCTTCTATCTC 1885
      |||||
Db 246 GATGGAGTGGGTTTTTCTTGGTCTCGTACGGTAGCCCGAGCTGTCCACGAGTCTC 187
      |||||

Qy 1886 TTGTATTCTGTCACTGAGGCTTGTCTCTGAGGTTCC 1921
      |||||
Db 186 CTGGCCACCTGAGTGAGCTTGCCTGCAGAGAGGCC 151
      |||||

```

RESULT	157
BV094002/c	
LOCUS	
DEFINITION	BV094002 linear STS 15-OCT-2003 RPAMSEQ0005940 Roche Palo Alto Mus musculus STS genomic, sequence tagged site.
ACCESSION	BV094002
VERSION	BV094002.1 GI:37671481
KEYWORDS	STS.
SOURCE	Mus musculus (house mouse)
ORGANISM	Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 596) Usuka,J., Liao,G., Cheng,J., Nguyen,A., Bach,C., Puech,A., McPherson,J.D., Foernzler,D. and Peitz,G. Mus musculus SNPs Unpublished (2003)
AUTHORS	
TITLE	
JOURNAL	
COMMENT	Contact : Jonathan Usuka

Contact: Jonathan Usuka

Roche Palo Alto Genetics and Genomics Department
Roche Palo Alto
3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA
Tel: 6508555807
Email: Jonathan.Usuka@roche.com
Primer A: No primer submitted
Primer B: No primer submitted.
Location/Qualifiers
1. .596
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/map="18-10064-9474-AC126686.3.1.232817"
/clone_lib="Roche Palo Alto"
/notes="SNPs developed from assay sequences derived from 15 different strains of mice (as of October 1, 2003). Those strains include A/J, M/HeJ, ~129/Sv, AKR/J, B10.D2-H2/OSnJ, BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, ~CAST/Bi, DBA/2J, MRL/MpJ, NZB/BinJ, NZW/Lac, SPRET/Ei. ~"
<1. .>596

STS

Query Match 0.8%; Score 19.2; DB 1; Length 596;
Best Local Similarity 49.5%; Pred. No. 1.5e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTCTTGATTTCTATCTGGTCAATTTTAACTCAGTAGTGAGTGTGTGGTTTCCATAAG 356
|||||
Db 555 TTCTGGTCTTNAAGGAGACACCCCTTTCCCAATGTAAGTGTGAATCCATTGTAGGTAG 496
|||||
Qy 357 TTGTGATGTTTCTGTGTTTCTGTGTTCTGTGTTCTGTGTT 393
|||||
Db 495 CTTCACACTTGGTGTAGATGCCATAGTGTGTGTTGTTGT 459
|||||

RESULT 158

RAETHRO 826 bp mRNA linear MAM 08-MAY-1993
LOCUS Oryctolagus cuniculus thrombin mRNA, 3' end.
DEFINITION M81396
VERSION M81396.1 GI:165740
KEYWORDS thrombin.
SOURCE Oryctolagus cuniculus (rabbit)
ORGANISM Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
REFERENCE 1 (bases 1 to 826)
Banfield, D.K. and MacGillivray, R.T.
Partial characterization of vertebrate prothrombin cDNAs:
amplification and sequence analysis of the B chain of thrombin from
nine different species
Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2779-2783 (1992)

JOURNAL 92212913
MEDLINE 1557383
PUBMED
COMMENT Original source text: Oryctolagus cuniculus adult liver cDNA to mRNA.

```

FEATURES             Location/Qualifiers
     1..826
     /organism="Oryctolagus cuniculus"
     /mol_type="mRNA"
     /db_xref="taxon:9986"
     /tissue_type="liver"
     /dev_stage="adult"
     1..826
     /gene="thrombin"
     <1..708
     /gene="thrombin"
     /codon_start=1
     /product="thrombin"
     /protein_id="AAA31477.1"
     /db_xref="GI:165741"
     /translation="QELLCAASLISDRWVLTAARCLLYPPWDKNFTVNDILVRIGKVA
RSRYRNMEXISTLEKIIIPHGYNWRENLRDIALMKLKPVPASDIYHPVCLPDKOI
VTSLIAGHGKRYVTGMCNLEKPMVTNNWNEVPSVLQMNVLPLVERPTCKASTGIRVTD

```



```

/gene="CRYBB2"
/note="forward PCR primer"
49..181
/gene="CRYBB2"
/number=4
complement(223..244)
/note="reverse PCR primer"

primer_bind

Query Match
Best Local Similarity 0.8%; Score 19; DB 1; Length 244;
Matches 28; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 258 GGCACTACCGATTCCCTCTCTCTCCAAACACTTCTATTCT 300
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 193 GCCATCACCTACTCCCTCTCTCTGCCATCATCCTACTTCT 235

RESULT 166
LOCUS AR263850 340 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 28 from patent US 6331427.
ACCESSION AR263850
VERSION AR263850.1 GI:28075854
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 340)
TITLE Robison,K.E.
JOURNAL Protease homologs
FEATURES Patent: US 6331427-A 28 18-DEC-2001;
source Location/Qualifiers
1..340
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 18.8; DB 1; Length 340;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

Qy 570 GTGCCACTTGTTATGACATCATGTTAGCTCCAGCATTCCTGTTTCGTTTGTGTA 629
Db 156 GATACCCCTGAGTTTACACAGAAGTTAGTTTCTACAGAAATGGATTATTGATCACCTGA 97
Qy 630 GATGACCTAACTGTTGA 647
Db 96 GACAAAGCTTCCTGTTGA 79

RESULT 167
LOCUS AR263851/c 340 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 29 from patent US 6331427.
ACCESSION AR263851
VERSION AR263851.1 GI:28075855
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 340)
TITLE Robison,K.E.
JOURNAL Protease homologs
FEATURES Patent: US 6331427-A 29 18-DEC-2001;
source Location/Qualifiers
1..340
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 18.8; DB 1; Length 340;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

Qy 570 GTGCCACTTGTTATGACATCATGTTAGCTCCAGCATTCCTGTTTCGTTTGTGTA 629

```

```

Db      156 GATACCCGAGTTTACACAGAGTAGTTTCTACAGAAATGGATTATGATACCTGA 97
QY      630 GATGACCTCACTGTTGGA 647
Db      96 GACAAAGCTTCCTGTTTGA 79

RESULT 168
DMU58868          352 bp  mRNA  linear  VRT 16-MAY-1997
DEFINITION      Disostichus mawsoni antifreeze glycopeptide precursor (DM-AFGP)
ACCESSION      U58868
VERSION        U58868.1 GI:1399808
KEYWORDS
SOURCE
ORGANISM        Disostichus mawsoni
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
                Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
                Notothenioidae; Nototheniidae; Dissostichus.
REFERENCE
AUTHORS        Chen, L., DeVries, A.L. and Cheng, C.H.
TITLE          Evolution of antifreeze glycoprotein gene from a trypsinogen gene
                in Antarctic notothenioid fish
JOURNAL        Proc. Natl. Acad. Sci. U.S.A. 94 (8), 3811-3816 (1997)
MEDLINE        97268652
PUBMED         9108060
REFERENCE      2 (bases 1 to 352)
AUTHORS        Chen, L., DeVries, A. and Cheng, C.
TITLE          Direct Submission
JOURNAL        Submitted (21-MAY-1996) Liangbiao Chen, Molecular and Integrative
                Physiology, University of Illinois, 524 Burrill Hall, 407 S.
                Goodwin Ave, Urbana, IL 61801, USA
FEATURES
source
1..352
/organism="Disostichus mawsoni"
/mol_type="mRNA"
/db_xref="taxon:36200"
/tissue_type="pancreas"
1..352
/gene="DM-AFGP"
<1..102
/gene="DM-AFGP"
/function="inhibits ice crystal growth"
/codon_start=1
/product="antifreeze glycopeptide precursor"
/protein_id="AAB57730.1"
/db_xref="GI:1399809"
/translation="AATPALNFVATPATATAATAATAATAARG"

Query Match      0.8%; Score 18.8; DB 1; Length 352;
Best Local Similarity 52.6%; Pred. No. 1.8e+02;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY      1978 TAATTCATTATCCACTTCAGTCCTGCAATGTTTACTCATTTCTCCAGTATTAC 2037
Db      249 TAAAGAAATACCAAGTATTATTTCTCACTTCCTCCACCGTTCACAGCCCTGGTTTAA 308
QY      2038 ATTTTCATAGGTTTCCTT 2055
Db      309 TTTTCTGTCCTCTCT 326

RESULT 169
AX193364/c       596 bp  DNA  linear  PAT 15-AUG-2001
LOCUS
DEFINITION      AX193364
ACCESSION      AX193364
VERSION        AX193364.1 GI:15211315
KEYWORDS
SOURCE          Homo sapiens (human)

ORGANISM        Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
AUTHORS        Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J.,
                Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.
TITLE          Compounds for immunotherapy and diagnosis of colon cancer and
                methods for their use
JOURNAL        Patent: WO 0149716-A 931 12-JUL-2001;
                CORIXA CORPORATION (US)
FEATURES
source
1..596
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 18.8; DB 1; Length 596;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY      345 GGTTCCTCAAGTTGTAAGTTTCTGTTGTTTCTGTTGTTGTTGTTGTTATCT 398
Db      376 GCGCTCCATGTGTGTGGCTCTCTCGTGTCTGACAGTGGTGTGCTGACGT 323

RESULT 170
AX675583          882 bp  DNA  linear  PAT 27-MAR-2003
LOCUS
DEFINITION      Sequence 33 from Patent WO02055704.
ACCESSION      AX675583
VERSION        AX675583.1 GI:29333568
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
AUTHORS        Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
                Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
                Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
                Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
                Edingermark, S., Rotherberg, M.E., Billeman, K., Macdougall, J.,
                Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
                Stone, D.J.
TITLE          Proteins, polynucleotides encoding them and methods of using the
                same
JOURNAL        Patent: WO 02055704-A 33 18-JUL-2002;
                Curagen Corporation (US)
FEATURES
source
1..882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 18.8; DB 1; Length 882;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY      345 GGTTCCTCAAGTTGTAAGTTTCTGTTGTTTCTGTTGTTGTTGTTGTTATCT 398
Db      115 GCGCTCCATGTGTGTGGCTCTCTCGTGTCTGACAGTGGTGTGCTGCTGACGT 168

RESULT 171
AX675581          1161 bp  DNA  linear  PAT 27-MAR-2003
LOCUS
DEFINITION      Sequence 31 from Patent WO02055704.
ACCESSION      AX675581
VERSION        AX675581.1 GI:29333567
KEYWORDS
SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```


QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 175
AR081819/c
LOCUS 168 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 28 from patent US 5972645.
ACCESSION AR081819
VERSION AR081819.1 GI:10008545
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea serine protease nucleic acid molecules
JOURNAL Patent: US 5972645-A 28 26-OCT-1999;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; 59; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACACGACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 176
AR098999/c
LOCUS 168 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6077687.
ACCESSION AR098999
VERSION AR098999.1 GI:12808765
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L. and Gaines,P.J.
TITLE Flea aminopeptidase nucleic acid molecules and uses thereof
JOURNAL Patent: US 6077687-A 28 20-JUN-2000;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; 59; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACACGACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 177
AR116830/c

LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6139840.
ACCESSION AR116830
VERSION AR116830.1 GI:14097736
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.
TITLE Methods of eliciting an antibody response using flea protease proteins and homologs thereof
JOURNAL Patent: US 6139840-A 28 31-OCT-2000;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; 59; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACACGACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 178
AR127061/c
LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6180383.
ACCESSION AR127061
VERSION AR127061.1 GI:14113654
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea leucine aminopeptidase proteins and uses thereof
JOURNAL Patent: US 6180383-A 28 30-JAN-2001;
FEATURES Location/Qualifiers
source 1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; 59; Indels 0; Gaps 0;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1646 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTCTTGAAA 1705
Db 150 ATCAGGATAACACGACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91

QY 1706 ATATTTTCCGCTTTTGACCTGCTCTTCCCTTCTCTATTCCTTTGGTT 1758
Db 90 AGTTTGGCTAGTCCAGTTAAACAATAGGTACCTTTACATATTCAGTTGTT 38

RESULT 179
AR141647/c
LOCUS 168 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6146870.
ACCESSION AR141647
VERSION AR141647.1 GI:15101163
KEYWORDS
SOURCE Unknown.


```
RESULT 183
AY135778S1/c
LOCUS      Gorilla gorilla HCR (HCR) gene, exon 14.      189 bp      DNA      linear      PRI 23-SEP-2002
DEFINITION Gorilla gorilla HCR (HCR) gene, exon 14.
ACCESSION AY135791
VERSION   AY135791.1 GI:23296123
KEYWORDS  14 of 18
SEGMENT   Gorilla gorilla (gorilla)
SOURCE    Gorilla gorilla
ORGANISM  Gorilla gorilla
REFERENCE 1 (bases 1 to 189)
AUTHORS  Asumalahti,K. and Kere,J.
TITLE     HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and orangutan
JOURNAL   Unpublished
REFERENCE 2 (bases 1 to 189)
AUTHORS  Asumalahti,K. and Kere,J.
TITLE     Direct Submission
JOURNAL   Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum, University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki FIN-00014, Finland
FEATURES  Location/Qualifiers
            source
            1..189
            /organism="Gorilla gorilla"
            /mol_type="genomic DNA"
            /db_xref="taxon:9593"
            1..189
            /gene="HCR"
            /number=14
            exon

Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTGCTGCGCAATACTTCTGGGCTGCTGCTTCTCCCT 185
      |||||
DB 52 TCTGCTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTGCTGCT 4

RESULT 184
AY135796S1/c
LOCUS      Pongo pygmaeus HCR (HCR) gene, exon 14.      189 bp      DNA      linear      PRI 23-SEP-2002
DEFINITION Pongo pygmaeus HCR (HCR) gene, exon 14.
ACCESSION AY135809
VERSION   AY135809.1 GI:23296145
KEYWORDS  14 of 18
SEGMENT   Pongo pygmaeus (orangutan)
SOURCE    Pongo pygmaeus
ORGANISM  Pongo pygmaeus
REFERENCE 1 (bases 1 to 189)
AUTHORS  Asumalahti,K. and Kere,J.
TITLE     HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and orangutan
JOURNAL   Unpublished
REFERENCE 2 (bases 1 to 189)
AUTHORS  Asumalahti,K. and Kere,J.
TITLE     Direct Submission
JOURNAL   Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum, University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki FIN-00014, Finland
FEATURES  Location/Qualifiers
            source
            1..189
            /organism="Pongo pygmaeus"
            /mol_type="genomic DNA"
            /db_xref="taxon:9600"
            1..189
            /gene="HCR"
            /number=14
            exon

Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTGCTGCGCAATACTTCTGGGCTGCTGCTTCTCCCT 185
      |||||
DB 52 TCTGCTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTGCTGCT 4

RESULT 185
AY135783S1/c
LOCUS      AR047835
DEFINITION Sequence 1 from patent US 5817798.
ACCESSION AR047835
VERSION   AR047835.1 GI:5969300
KEYWORDS  Unknown.
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 200)
AUTHORS  Gundling,G.J.
TITLE     Rapid RNA isolation procedure in the presence of a transition metal ion
JOURNAL   Patent: US 5817798-A 1 06-OCT-1998;
FEATURES  Location/Qualifiers
            source
            1..200
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 18.6; DB 1; Length 200;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTTAACACTTCTGGGCCAGGTAGGSCACTACCGCATTC 273
      |||||
DB 60 TCTCGACTCCAGCTCCCAATCCAGATGAGGTAGGGTGACGACCAATCC 4

RESULT 186
AX260845
LOCUS      AX260845
DEFINITION Sequence 496 from Patent WO0173027.
ACCESSION AX260845
VERSION   AX260845.1 GI:16509812
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS  Meagher,M.J., Xu,J. and King,G.E.
TITLE     Compositions and methods for therapy and diagnosis of colon cancer
JOURNAL   Patent: WO 0173027-A 496 04-OCT-2001;
CORIXA CORPORATION (US)
FEATURES  Location/Qualifiers
            source
            1..222
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 222;
Best Local Similarity 53.4%; Pred. No. 2e+02;
Matches 39; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 414 TGGTCAGATAGACATAGAGTATTATTTCAATTGCTTTTATCTGTCGAGACTTGTG 473
      |||||
DB 138 TGGTTGGGTGCTCAGAGAGATGTTTCCGGCTTAGTCCCTGTGGGGATGCTTTG 197
      |||||
QY 474 TTTTGAATATATGT 486
      |||||
DB 198 TTATGCAGAAAGT 210
      |||||
```

```
Query Match      0.8%; Score 18.6; DB 1; Length 189;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 137 TCTTGAAGCCTGCTGCGCAATACTTCTGGGCTGCTGCTTCTCCCT 185
      |||||
DB 52 TCTGCTCCAGCTGCTGGCCACCTTGCTCAGCTGCTGCGCTGCTGCT 4

RESULT 195
AR047835/c
LOCUS      AR047835
DEFINITION Sequence 1 from patent US 5817798.
ACCESSION AR047835
VERSION   AR047835.1 GI:5969300
KEYWORDS  Unknown.
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 200)
AUTHORS  Gundling,G.J.
TITLE     Rapid RNA isolation procedure in the presence of a transition metal ion
JOURNAL   Patent: US 5817798-A 1 06-OCT-1998;
FEATURES  Location/Qualifiers
            source
            1..200
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 18.6; DB 1; Length 200;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 217 TCTCTCTCCCTTCTTAACACTTCTGGGCCAGGTAGGSCACTACCGCATTC 273
      |||||
DB 60 TCTCGACTCCAGCTCCCAATCCAGATGAGGTAGGGTGACGACCAATCC 4

RESULT 186
AX260845
LOCUS      AX260845
DEFINITION Sequence 496 from Patent WO0173027.
ACCESSION AX260845
VERSION   AX260845.1 GI:16509812
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS  Meagher,M.J., Xu,J. and King,G.E.
TITLE     Compositions and methods for therapy and diagnosis of colon cancer
JOURNAL   Patent: WO 0173027-A 496 04-OCT-2001;
CORIXA CORPORATION (US)
FEATURES  Location/Qualifiers
            source
            1..222
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 222;
Best Local Similarity 53.4%; Pred. No. 2e+02;
Matches 39; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 414 TGGTCAGATAGACATAGAGTATTATTTCAATTGCTTTTATCTGTCGAGACTTGTG 473
      |||||
DB 138 TGGTTGGGTGCTCAGAGAGATGTTTCCGGCTTAGTCCCTGTGGGGATGCTTTG 197
      |||||
QY 474 TTTTGAATATATGT 486
      |||||
DB 198 TTATGCAGAAAGT 210
      |||||
```



```

RESULT 187
HS88A12F
LOCUS          HS88A12F          241 bp      DNA          linear          PRI 22-OCT-1995
DEFINITION    H.sapiens CpG island DNA genomic MseI fragment, clone 88a12,
forward read cp388a12.ft1a.
ACCESSION    Z63614
VERSION      Z63614.1 GI:1035992
KEYWORDS     CpG island; genomic MseI fragment.
SOURCE       Homo sapiens
ORGANISM     Homo sapiens (human)

REFERENCE
AUTHORS      MacDonald,M., Huckle,E., Wilkinson,P. and Micklem,G.
TITLE        Direct Submission
JOURNAL      Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
MEDLINE     CB10 lRQ, England. E-mail contact: humquery@sanger.ac.uk
PUBMED      8012384

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..241
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="88a12"
/sex="male"
/tissue type="blood"
/clone_lib="CGI-1"
/dev_stage="adult"

Query Match          0.8%; Score 18.6; DB 1; Length 241;
Best Local Similarity 55.4%; Pred. No. 2e+02;
Matches 36; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

Qy 1710 TTTCCCTGCTTTGACCTGCTTCCCTTCCTCTATCTTCCTTGGTTTTCATAGTG 1769
Db 175 TTTCTCCGCTCGTCGGAGGCGCTTCCCGTCGAGTTGCATTATTTTCAAGGAG 234

Qy 1770 TCCTCT 1774
Db 235 GTTWT 239

RESULT 188
AR162089
LOCUS          AR162089          289 bp      DNA          linear          PAT 17-OCT-2001
DEFINITION    Sequence 17 from patent US 6258558.
ACCESSION    AR162089
VERSION      AR162089.1 GI:16229155
KEYWORDS     CpG island; genomic MseI fragment.
SOURCE       Homo sapiens
ORGANISM     Homo sapiens (human)

REFERENCE
AUTHORS      Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE        Method for selection of proteins using RNA-protein fusions
JOURNAL      Patent: US 6258558-A 17 10-JUL-2001;
MEDLINE     US 6258558-A 17 10-JUL-2001;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..289
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="162089"
/sex="male"
/tissue type="blood"
/clone_lib="CGI-1"
/dev_stage="adult"

Query Match          0.8%; Score 18.6; DB 1; Length 289;
Best Local Similarity 21.4%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTTGTTCCTCAAG 356
Db 115 TTTCTGCTCTTAAGGGAGACACCTTTTCCCAATGTAAGTGAATCCATTTGAGTAG 174

Qy 357 TTTCTGATTTTCTGTTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTT 393
Db 175 CTTCCCACTTTGGTGTAGATGCCATAGTTGTTGTTGT 211

RESULT 191
AX524284
LOCUS          AX524284          427 bp      DNA          linear          PAT 21-NOV-2002
DEFINITION    Sequence 314 from Patent EP1236798.
ACCESSION    AX524284
VERSION      AX524284.1 GI:25169380
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus (house mouse)

REFERENCE
AUTHORS      Hoefler,M., Hofmann,M., Kaiser,C., Kranz,H., Loebbert,R. and
Schlueter,T.
TITLE        Gene library and method for its production
JOURNAL      Patent: EP 1236798-A 314 04-SEP-2002;
MEDLINE     EP 1236798-A 314 04-SEP-2002;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match          0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTTGTTCCTCAAG 356
Db 115 TTTCTGCTCTTAAGGGAGACACCTTTTCCCAATGTAAGTGAATCCATTTGAGTAG 174

Qy 357 TTTCTGATTTTCTGTTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTT 393
Db 175 CTTCCCACTTTGGTGTAGATGCCATAGTTGTTGTTGT 211

RESULT 191
AX524284
LOCUS          AX524284          427 bp      DNA          linear          PAT 21-NOV-2002
DEFINITION    Sequence 314 from Patent EP1236798.
ACCESSION    AX524284
VERSION      AX524284.1 GI:25169380
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus (house mouse)

REFERENCE
AUTHORS      Hoefler,M., Hofmann,M., Kaiser,C., Kranz,H., Loebbert,R. and
Schlueter,T.
TITLE        Gene library and method for its production
JOURNAL      Patent: EP 1236798-A 314 04-SEP-2002;
MEDLINE     EP 1236798-A 314 04-SEP-2002;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match          0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTTGTTCCTCAAG 356
Db 115 TTTCTGCTCTTAAGGGAGACACCTTTTCCCAATGTAAGTGAATCCATTTGAGTAG 174

Qy 357 TTTCTGATTTTCTGTTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTT 393
Db 175 CTTCCCACTTTGGTGTAGATGCCATAGTTGTTGTTGT 211

```

```

Matches 12; Conservative 27; Mismatches 17; Indels 0; Gaps 0;

Qy 1110 GTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
Db 4 GGRGRCRARATRTTRACRTRATRTTRARCRARATRTTRARCRARATRTTRARCRARATRTGRNR 59

RESULT 189
AR166614
LOCUS          AR166614          289 bp      DNA          linear          PAT 17-OCT-2001
DEFINITION    Sequence 17 from patent US 6281344.
ACCESSION    AR166614
VERSION      AR166614.1 GI:16242009
KEYWORDS     Nucleic acid-protein fusion molecules and libraries
SOURCE       Patent: US 6281344-A 17 28-AUG-2001;
ORGANISM     Location/Qualifiers
Unclassified
1 (bases 1 to 289)
AUTHORS      Szostak,J.W., Roberts,R.W. and Liu,R.
TITLE        Nucleic acid-protein fusion molecules and libraries
JOURNAL      Patent: US 6281344-A 17 28-AUG-2001;
MEDLINE     US 6281344-A 17 28-AUG-2001;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..289
/organism="unknown"
/mol_type="unassigned DNA"

Query Match          0.8%; Score 18.6; DB 1; Length 289;
Best Local Similarity 21.4%; Pred. No. 2.1e+02;
Matches 12; Conservative 27; Mismatches 17; Indels 0; Gaps 0;

Qy 1110 GTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1165
Db 4 GGRGRCRARATRTTRACRTRATRTTRARCRARATRTTRARCRARATRTTRARCRARATRTGRNR 59

RESULT 190
AX524284
LOCUS          AX524284          427 bp      DNA          linear          PAT 21-NOV-2002
DEFINITION    Sequence 314 from Patent EP1236798.
ACCESSION    AX524284
VERSION      AX524284.1 GI:25169380
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus (house mouse)

REFERENCE
AUTHORS      Hoefler,M., Hofmann,M., Kaiser,C., Kranz,H., Loebbert,R. and
Schlueter,T.
TITLE        Gene library and method for its production
JOURNAL      Patent: EP 1236798-A 314 04-SEP-2002;
MEDLINE     EP 1236798-A 314 04-SEP-2002;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match          0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTTGTTCCTCAAG 356
Db 115 TTTCTGCTCTTAAGGGAGACACCTTTTCCCAATGTAAGTGAATCCATTTGAGTAG 174

Qy 357 TTTCTGATTTTCTGTTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTT 393
Db 175 CTTCCCACTTTGGTGTAGATGCCATAGTTGTTGTTGT 211

RESULT 191
AX524284
LOCUS          AX524284          427 bp      DNA          linear          PAT 21-NOV-2002
DEFINITION    Sequence 314 from Patent EP1236798.
ACCESSION    AX524284
VERSION      AX524284.1 GI:25169380
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus (house mouse)

REFERENCE
AUTHORS      Hoefler,M., Hofmann,M., Kaiser,C., Kranz,H., Loebbert,R. and
Schlueter,T.
TITLE        Gene library and method for its production
JOURNAL      Patent: EP 1236798-A 314 04-SEP-2002;
MEDLINE     EP 1236798-A 314 04-SEP-2002;
PUBMED      1166614

COMMENT
Clones are available from the UK MRC Human Genome Mapping Project
Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
http://www.hgmp.mrc.ac.uk/ for details
or contact: bihelp@hgmp.mrc.ac.uk.
FEATURES
source
1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match          0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

Qy 297 TTTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTTGTTCCTCAAG 356
Db 115 TTTCTGCTCTTAAGGGAGACACCTTTTCCCAATGTAAGTGAATCCATTTGAGTAG 174

Qy 357 TTTCTGATTTTCTGTTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTTTCTGTT 393
Db 175 CTTCCCACTTTGGTGTAGATGCCATAGTTGTTGTTGT 211

```

LOCUS AX553022 427 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 314 from Patent WO02074953.
ACCESSION AX553022
VERSION AX553022.1 GI:25897022
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and Schluter, T.
TITLE Gene library and a method for producing the same
JOURNAL Patent: WO 02074953-A 314 26-SEP-2002,
LION Bioscience AG (DE)
FEATURES
source
1..427
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 18.6; DB 1; Length 427;
Best Local Similarity 49.5%; Pred. No. 2.1e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
QY 297 TTCTTGATTCTATCTTGGCTCATTTTAACTCAGTAGGAGTGTGTTGGTTTCCATAAG 356
|||||
DB 115 TTCTGGCTTTAAGGAGACACCCCTTTTCCCAATGTAATCCATTCATTGAGGTAG 174
QY 357 TTGTGAAGTTTCTGTGTTTCTGTTGTTGTTGTTGTTGT 393
|||||
DB 175 CTTCACCTTGTGTAGATGCCATAGTTGTTGGTGT 211

RESULT 192
LOCUS AX277349/c 439 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 7 from Patent WO0174897.
ACCESSION AX277349
VERSION AX277349.1 GI:16548914
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quin, K.E., Spytek, K.A., Rastelli, L. and Herrmann, J.L.
TITLE Novel proteins and nucleic acids encoding same
JOURNAL Patent: WO 0174897-A 7 11-OCT-2001;
Curagen Corporation (US)
FEATURES
source
1..439
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
CDS
<2..295
/note="unnamed protein product"
/codon_start=1
/protein_id="CAD10333.1"
/db_xref="GI:16548915"
/db_xref="REMBL:CAD10333"
/translation="HGNKPGVPLISNKNHRDVGIIISPSMLCAGYLTGVDSQC
GDSGGLVQQRRLKLVGATSFSGICAEVKNPGVTVPSWTSSTSRWRT"
Query Match 0.8%; Score 18.6; DB 1; Length 439;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGTCGCAATCTTCTGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
|||||
DB 174 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGTCCCTGGCAGCTGTCACG 118

RESULT 193
LOCUS AX277375/c 439 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 33 from Patent WO0174897.
ACCESSION AX277375
VERSION AX277375.1 GI:16548940
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quin, K.E., Spytek, K.A., Rastelli, L. and Herrmann, J.L.
TITLE Novel proteins and nucleic acids encoding same
JOURNAL Patent: WO 0174897-A 33 11-OCT-2001;
Curagen Corporation (US)
FEATURES
source
1..439
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 439;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 143 AGCCTCTGTCGCAATCTTCTGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
|||||
DB 174 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGTCCCTGGCAGCTGTCACG 118

RESULT 194
LOCUS MACCFX/c 484 bp DNA linear PRI 05-FEB-1999
DEFINITION Rhesus monkey gene for coagulation factor X, partial cds.
ACCESSION D21214
VERSION D21214.1 GI:415307
KEYWORDS coagulation factor X.
SOURCE
ORGANISM Macaca mulatta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
Cercopithecoidea; Macaca.
1 (bases 1 to 484)
REFERENCE
AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.
TITLE Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X
JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE 94222160
PUBMED 8168596
REFERENCE
AUTHORS Murakawa, M.
TITLE Direct Submission
JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
COMMENT Submitted (18-Oct-1993) to DDBJ by:
Masahiro Murakawa
Division of Hematology
Harasanshin General Hospital
1-8 Taihaku-machi, Hakata-ku
Fukuoka, Fukuoka 812
Japan
Phone: 092-291-3434
Fax : 092-291-3266.
FEATURES
source
1..484
/organism="Macaca mulatta"
/mol_type="genomic DNA"

```
/db_xref="taxon:9544"
<1_>484
/codon_start=2
/product="coagulation factor X"
/protein_id="BAA04755.1"
/db_xref="GI:455395"
/translation="EGGEAVHEVEVIKHNRFKTYDFDIIVLRLKSPITFRMNVAP
ACLPEDMASTLMTQKTVIGSGRTHKGRQSTRLKMLEVPYVDNRNSCKLSFFII
TQMFCAGYHAKQEDACQDGGPHVTRFKDYFVTGIVSWGECARKKGYIYKVT
A"

Query Match      0.8%; Score 18.6; DB 1; Length 484;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 370 TGTGTTCTCTGTTGTTGTTATCTAGATTAAGCTGTGGTGTC 418
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 317 TGTTCGGTGATGATGAAGCTGTGGAGAGCTTGCAGCTGTTGCGGTC 269

RESULT 195
AX775014/c
LOCUS      AX775014      546 bp      DNA      linear      PAT 09-JUL-2003
DEFINITION Sequence 330 from Patent WO03038129.
ACCESSION  AX775014
VERSION     AX775014.1  GI:32486530
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Raponi, M.
TITLE       Methods for assessing and treating leukemia
JOURNAL     Patent: WO 03038129-A 330 08-MAY-2003;
            Ortho-Clinical Diagnostics, Inc. (US)
FEATURES    source
            1..546
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 546;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 143 AGCTCTGCTGGAATCTCTGCGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 336 AGCTCTCTCTTGACACACAGGGGCCCCCGCTGTCCCTGGCAGCTGTCACG 280

RESULT 196
AX335885/c
LOCUS      AX335885      624 bp      DNA      linear      PAT 09-JAN-2002
DEFINITION Sequence 6394 from Patent WO0194629.
ACCESSION  AX335885
VERSION     AX335885.1  GI:18126604
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
            Horrigan, S., Soppet, D.R. and Weaver, Z.
TITLE       Cancer gene determination and therapeutic screening using signature
            gene sets
JOURNAL     Patent: WO 0194629-A 6394 13-DEC-2001;
            Avalon Pharmaceuticals (US)
FEATURES    source
            1..624
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"

/db_xref="taxon:9606"
Query Match      0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 370 TGTGTTCTCTGTTGTTGTTATCTAGATTAAGCTGTGGTGTC 418
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 351 TGTTCGGTGATGATGAAGCTGTGGACAGCTTGCAGCTGTTGCGGTC 303

RESULT 197
HUMFX8/c
LOCUS      HUMFX8      624 bp      DNA      linear      PRI 09-NOV-1994
DEFINITION Human factor X (blood coagulation factor) gene, exon 8.
ACCESSION  L29433 M14327 N00045
VERSION     L29433.1  GI:459809
KEYWORDS    Stuart factor; blood coagulation factor; factor X; glycoprotein;
            serine protease.
SEGMENT     8 of 8
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Leytus, S.P., Foster, D.C., Kurachi, K. and Davie, E.W.
TITLE       Gene for human factor X: a blood coagulation factor whose gene
            organization is essentially identical with that of factor IX and
            protein C
JOURNAL     Biochemistry 25 (18), 5098-5102 (1986)
MEDLINE     87028600
PubMed      3768336
COMMENT     Original source text: Homo sapiens (tissue library: of Lawn et al.,
            and Yoshitake et al.) DNA.
            matp + 13 + 458 factor Xa heavy chain.
FEATURES    source
            1..624
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="13q34"
            /tissue_lib="of Lawn et al., and Yoshitake et al."
            join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,
            L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,
            L00396.1:13..130,13..614)
            /note="preprofactor X"
            /codon_start=1
            /product="coagulation factor X"
            /protein_id="AAA52764.1"
            /db_xref="GI:182831"
            /translation="MGRPLHLVLLSLAGLLGLSLFIRREQANNILARVTRANSF
            LEEMKGLHRECEMEETCSVEAREVEFSDKTNEFNWYKDGQDCQETSPCNQGCK
            DGLGYTCFLEGEGKNCLEFTRKCLSDNGDCDOFCHEEQNSVVCSCARGYTLADN
            GKACITPTGVPCKGKTLERKKSVAQATSSSGEAPDSITWKPYDAADLDPTENPFLL
            DFNQTPERGDNLRIVGGCKGCECPQWALLINEEGFCGGLTSFFYLITAAH
            CLYAKRFRVDRNTEQEGEAVEHVEVIKHNRFKTYDFDIIVLRLKSPITFRMNVAP
            RNVAPACLPEDMASTLMTQKTVIGSGRTHKGRQSTRLKMLEVPYVDNRNSCKL
            SSSFIITQNMFCAGYDKQEDACQDGGPHVTRFKDYFVTGIVSWGECARKKGYG
            IYKVTAFKLWDRSMKTRGLPKAKSHAPEVITSSPLK"
            join(L00395.1:57..257,L00396.1:13..130,13..458)
            /product="coagulation factor X"
            /note="factor X light chain"
            459..611
            /product="activation peptide"
            <1..12
            /note="FX intron G"
            13..624
            /note="FX"
            /number=8

Query Match      0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

Qy 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAACTGCTGGTGC 418
|||||
Db 351 TGTTCGGGTGATGATGAAGCTGCTGGACAGCTTGACAGCTGTGCGGTC 303
|||||

RESULT 198
BD173590/c 711 bp DNA linear PAT 18-FEB-2003
LOCUS Novel serine protease MP493.
DEFINITION BD173590
ACCESSION BD173590
VERSION WO 02059295-A/3
KEYWORDS WO 02059295-A/3
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 711)
Nakamura, Y., Sugano, S., Matsusue, T., Okamoto, A. and Okawa, K.
Novel serine protease MP493
Patent: WO 02059295-A 3 01-AUG-2002;
MOCHIDA PHARMACEUTICAL CO LTD, YUSUKE NAKAMURA, SUMIO SUGANO,
TOMOKAZU MATSUSUE, ATSUSHI OKAMOTO, KAZUFUMI OKAWA
OS Homo sapiens (human)
PN WO 02059295-A/3
PD 01-AUG-2002
PF 23-JAN-2002 WO 2002JP000465
PR 23-JAN-2001 JP 01P 014963
PI YUSUKE NAKAMURA, SUMIO SUGANO, TOMOKAZU MATSUSUE, ATSUSHI
OKAMOTO,
PI KAZUFUMI OKAWA
PC C12N15/09, C12N15/12, C12N9/64, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C07K16/40,
PC C12Q1/02
CC Novel serine protease MP493
FH Key Location/Qualifiers
FT source 1..711
FT /organism='Homo sapiens (human)'.
FT Location/Qualifiers

1..711
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
Query Match 0.8%; Score 18.6; DB 1; Length 711;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 143 AGCCTCTGCTGCAATCTCTGCGGCTGCTGCTTCTCCCTGCTGATCTCTAGG 199
|||||
Db 584 AGCCTCTCTCTTGACACACAGGCGCCCGCTGCTCCCTGGCAGCTGTCACG 528
|||||

RESULT 199
AX827818/c 773 bp DNA linear PAT 12-DEC-2003
LOCUS Sequence 552 from Patent EPI344834.
DEFINITION AX827818
ACCESSION AX827818
VERSION AX827818.1 GI:39838006
KEYWORDS Rattus norvegicus (Norway rat)
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1
Boess, F., Suter-Dick, L. and Wolf, D.
Methods for the toxicity prediction of a compound
Patent: EP 1344834-A 552 17-SEP-2003;
F. HOFFMANN-LA ROCHE AG (CH)
Location/Qualifiers
1..773
/organism='Rattus norvegicus'

Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
Qy 1646 ACCTTGATAGGATCTCTTCTCAGAGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1705
|||||
Db 315 AGCTTGATCAGCATGATGTCATTTTCAGGGTCTTCTCAGAGTTGGATGCTTGATG 256
|||||
Qy 1706 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCCTATTCCTTTGGTTTGGAT 1765
|||||
Db 195 AGTCTCACTTGGATGCGGGACTTAT 171
|||||

/mol_type='unassigned DNA'
/db_xref='taxon:10116'
Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
Qy 1646 ACCTTGATAGGATCTCTTCTCAGAGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1705
|||||
Db 315 AGCTTGATCAGCATGATGTCATTTTCAGGGTCTTCTCAGAGTTGGATGCTTGATG 256
|||||
Qy 1706 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCCTATTCCTTTGGTTTGGAT 1765
|||||
Db 255 ATCTTGGCAGCATTGACAAACTGCTCATTTGCCCTCAGAGCATGATGTTGTCTCTCC 196
|||||
Qy 1766 AGTGTCTCTGCTTCTTCTGATGTTT 1790
|||||
Db 195 AGTCTCACTTGGATGCGGGACTTAT 171
|||||

RESULT 200
RNTY2/c 773 bp mRNA linear ROD 30-MAR-1995
LOCUS Rat mRNA encoding pancreatic trypsinogen II.
DEFINITION RNTY2
ACCESSION V01274
VERSION V01274.1 GI:57410
KEYWORDS complementary DNA; signal peptide; trypsin.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 773)
MacDonald, R.J., Stary, S.J. and Swift, G.H.
Two similar but nonallelic rat pancreatic trypsinogens. Nucleotide
sequences of the cloned cDNAs
J. Biol. Chem. 257 (16), 9724-9732 (1982)
82265624
6896710
Location/Qualifiers

1..773
/organism='Rattus norvegicus'
/mol_type='mRNA'
/db_xref='taxon:10116'
1..773
/product='messenger RNA'
1..718
/note='unnamed protein product; trypsinogen (1 is 3rd base
in codon)'
/codon_start=2
/protein_id='CAA24581.1'
/db_xref='GI:758266'
/db_xref='GOA:P00763'
/db_xref='SWISS-PROT:P00763'
/translation='LVGAAPFPVDDDDKIVGYTCQNSVPYQSLNSGYHFCGSL
INDQVVAACHYKSRIOVRLEHNIIVLEQNEQFVNAKIIKHFNDRKTLNNDIML
IKLSPVKLNARVALPSSCAPAGTQCLI SGWNTLSSGNEPDLQLCLDAPLLPQ
ADCEASYPGKITDNMVCVFLSGGKDCQGDGGPVVNCNGLQGIWVGCGCALPDP
GVYTKVNVVDWIQDTIAAN'
1..25
/note='signal peptide'
773
/note='polyA addition site'

Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
Qy 1646 ACCTTGATAGGATCTCTTCTCAGAGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1705
|||||
Db 315 AGCTTGATCAGCATGATGTCATTTTCAGGGTCTTCTCAGAGTTGGATGCTTGATG 256
|||||
Qy 1706 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCCTATTCCTTTGGTTTGGAT 1765
|||||

```

Db      255 ATCTGGCAGCATTACAACTGCTTCATTCGCTCAAGGACATGATGTTGGCTCTCC 196
Qy      1766 AGTGTCTGCTGCTCCTCGGATGTTT 1790
Db      195 AGTCTCACTGGATCGCGGACTTAT 171

RESULT 201
DOGTYPYPA
LOCUS      Dog pancreatic anionic trypsinogen mRNA.
DEFINITION
ACCESSION M11589
VERSION    M11589.1 GI:164094
KEYWORDS
SOURCE     Canis sp.
ORGANISM   Canis sp.
REFERENCE  1 (bases 1 to 819)
AUTHORS    Pinsky,S.D., LaForge,K.S. and Scheele,G.
TITLE      Differential regulation of trypsinogen mRNA translation:
            trypsinogen isoenzymes in the dog pancreas
JOURNAL    Mol. Cell. Biol. 5 (10), 2669-2676 (1985)
MEDLINE    86284628
PUBMED     3841794
COMMENT    Original source text: Dog pancreas, cDNA to mRNA, clone pT1.
FEATURES   source
            Location/Qualifiers
            1..819
            /organism="Canis sp."
            /mol_type="mRNA"
            /db_xref="taxon:9616"
            1..819
            /product="anionic trypsinogen mRNA"
            15..758
            /note="anionic trypsinogen precursor"
            /codon_start=1
            /protein_id="AAA30899.1"
            /db_xref="GI:164095"
            /translation="MNPILLALFLGAAVATPTDDDKIVGGYTCSENSVPYQVSLNAG
            YHFCGSLISDQWVSAHCYKRIQVRLGEYNIIDVLEGNQEQFINSKAVIRHPNYSNW
            ILNDILMLIKLSPAVLNARVATISLPACAAPTQCLISGWGNTLSGGTNYPELLQC
            LDAPILTQAOCSEASYPQITENMTCAGFLGGKDCSCQDGGPWCNGELQGIVSWG
            YGCAQKNKPGYVTKVCFVDMVQSTIANS"

Query Match      0.8%; Score 18.6; DB 1; Length 819;
Best Local Similarity 50.6%; Pred. No. 2.1e+02;
Matches 45; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy      882 GCTTGCTTCTTAGGGCCATTTGCTTAGAATATCTTTCCATCTTTTACTCTAAGGTGAT 941
Db      531 GCCTCTACCCGCCAGATCAGGAGAACATGTTTCGCGCGCTTCTTGAGGGAGGC 590
Qy      942 GTCATCCATGGTAGGTGCTTTTGG 970
Db      591 AAGGACTCCTGCCAGGCTGACTCTGGTG 619

RESULT 202
PVTRYPSIN
LOCUS      P.vannamei mRNA for trypsin.
DEFINITION
ACCESSION X86369
VERSION    X86369.1 GI:785034
KEYWORDS   trypsin.
SOURCE     Litopenaeus vannamei (Pacific white shrimp)
ORGANISM   Litopenaeus vannamei
            Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
            Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
            Penaeidae; Litopenaeus.
REFERENCE  1
AUTHORS    Klein,B., Le Moulliac,G., Sellos,D. and Van Wormhoudt,A.

```

```

TITLE      Molecular cloning and sequencing of trypsin cDNAs from Penaeus
            vannamei (Crustacea, Decapoda): use in assessing gene expression
            during the moult cycle
JOURNAL    Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)
MEDLINE    96252881
PUBMED     8697100
REFERENCE  2 (bases 1 to 854)
AUTHORS    Van Wormhoudt,A.E.
TITLE      Direct Submission
JOURNAL    CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,
            FRANCE
FEATURES   source
            Location/Qualifiers
            1..854
            /organism="Litopenaeus vannamei"
            /mol_type="mRNA"
            /db_xref="taxon:6689"
            /tissue_type="hepatopancreas"
            /dev_stage="adult"
            3..803
            /EC_number="3.4.21.4"
            /codon_start=1
            /product="trypsin"
            /protein_id="CAA60129.1"
            /db_xref="GI:785035"
            /db_xref="GOA:Q27761"
            /translaton="MKTLLICVLLAGAFAAPSRKPTFRRLKIVGTDATPPGLPYQ
            LSFDISGFAMHFCGASINENWAI CAGHCVOGEDNNPDYLOVAVAGENODVDEGT
            EOTVILSKIIHQEDYNGFTISNDLSLKLSQLSFNDNVRALDIPAGCHAASGDCIVS
            GWGTTSEGGSTPSVLQKVTVPVSDDECRDYGQSDIEDSMICAGVPEGGKDCSCQDGS
            GGPLACSDTASTYLAGIVSWGVCARPGYGVYAEVSYHVDWIKANAV"
            3..41
            sig_peptide

Query Match      0.8%; Score 18.6; DB 1; Length 854;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy      719 TGTTTATGAACCTTGGTGACATTTGTTGGTGTCATAGACATTAAGAA 767
Db      797 TGTTATCAAGTGTGTTTAAACATGACTTACCTTGAAGCAATAAGAA 845

RESULT 203
AF465268/c
LOCUS      Gallus gallus coagulation factor VII precursor (F7) mRNA, complete
DEFINITION
ACCESSION AF465268
VERSION    AF465268.1 GI:28194007
KEYWORDS   Gallus gallus (chicken)
SOURCE     Gallus gallus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE  1 (bases 1 to 1278)
AUTHORS    Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
            Tuddenham,E.G.D. and McVey,J.H.
TITLE      Comparative sequence analysis and molecular evolution of blood
            coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 1278)
AUTHORS    McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE      Direct Submission
JOURNAL    Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
            Centre, The Faculty of Medicine, Imperial College, Hammersmith
            Campus, Du Cane Road, London W12 0NN, UK
FEATURES   source
            Location/Qualifiers
            1..1278
            /organism="Gallus gallus"
            /mol_type="mRNA"
            /db_xref="taxon:9031"

```



```

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGTGGTC 418
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 206
AB6886/c
LOCUS AR340866 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION AR340866
VERSION AR340866.1 GI:6735677
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 1467)
Himmelspach,M. and Eibl,J.
AUTHORS
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL PATENT: WO 983817-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
Location/Qualifiers
source 1..1467
/mol_type="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/db_xref="REMBL:CAB69368"
/translations="MGRPLHLVLLSASLAGLLGLLGLSFLRREQANNILARVTRANSF
LEBMKGHLRECEWFEFTCSYEAREVFEFSDKTNFNWVKYDGDQCTSPCONGKCK
DGLGEVCTCLEGPEGNKCLFTRKLCSLDNGCDQPCHEEQNSVVCSCARGYTLADN
GXACITGTPFCQDILERRKRSVAQTSNGSEAPDSITWKPYDAADLDPENPFLL
DFNQTPFERDNNLIRIVGQCKGECQPCWALLINEENEGFCGGTILSEFYLTAAH
CLYQAKRFVVRDNTQEGGEAVHEVWFKHNRFTKETVDFDIAVLRLKPTTF
RMNVAPACLPDRWASTLTKTQTVISGVRTHKEGRQSTRLKMLEVPPVDRNSCKI
SSSEFIITQNMFCAGYDTKQEDACQSDSGSPHVTFRFXDTVFVTGLVSWGESCARCKYK
IYTKVTAFLKNWIDRSMKTRGLPKAKSHAPVITSSPLK"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGTGGTC 418
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 207
AR316969/c
LOCUS AR316969 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION AR316969
VERSION AR316969.1 GI:33696092
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 1467)
Himmelspach,M., Pfeleiderer,M., Falkner,F.-G., Eibl,J., Dorner,F.
and Schlokot,U.
AUTHORS
TITLE Factor X deletion mutants and analogues thereof
JOURNAL PATENT: US 6562598-A 43 13-MAY-2003;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
Location/Qualifiers
source 1..1467
/mol_type="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/db_xref="REMBL:CAB69368"
/translations="MGRPLHLVLLSASLAGLLGLLGLSFLRREQANNILARVTRANSF
LEBMKGHLRECEWFEFTCSYEAREVFEFSDKTNFNWVKYDGDQCTSPCONGKCK
DGLGEVCTCLEGPEGNKCLFTRKLCSLDNGCDQPCHEEQNSVVCSCARGYTLADN
GXACITGTPFCQDILERRKRSVAQTSNGSEAPDSITWKPYDAADLDPENPFLL
DFNQTPFERDNNLIRIVGQCKGECQPCWALLINEENEGFCGGTILSEFYLTAAH
CLYQAKRFVVRDNTQEGGEAVHEVWFKHNRFTKETVDFDIAVLRLKPTTF
RMNVAPACLPDRWASTLTKTQTVISGVRTHKEGRQSTRLKMLEVPPVDRNSCKI
SSSEFIITQNMFCAGYDTKQEDACQSDSGSPHVTFRFXDTVFVTGLVSWGESCARCKYK
IYTKVTAFLKNWIDRSMKTRGLPKAKSHAPVITSSPLK"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGTGGTC 418
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 208
AR340866/c
LOCUS AR340866 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6573071.
ACCESSION AR340866
VERSION AR340866.1 GI:33732713
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 1467)
Himmelspach,M., Schlokot,U., Dorner,F., Fisch,A. and Eibl,J.
AUTHORS
TITLE Factor X analogues with a modified protease cleavage site
JOURNAL PATENT: US 6573071-A 26 03-JUN-2003;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
Location/Qualifiers
source 1..1467
/mol_type="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/db_xref="REMBL:CAB69368"
/translations="MGRPLHLVLLSASLAGLLGLLGLSFLRREQANNILARVTRANSF
LEBMKGHLRECEWFEFTCSYEAREVFEFSDKTNFNWVKYDGDQCTSPCONGKCK
DGLGEVCTCLEGPEGNKCLFTRKLCSLDNGCDQPCHEEQNSVVCSCARGYTLADN
GXACITGTPFCQDILERRKRSVAQTSNGSEAPDSITWKPYDAADLDPENPFLL
DFNQTPFERDNNLIRIVGQCKGECQPCWALLINEENEGFCGGTILSEFYLTAAH
CLYQAKRFVVRDNTQEGGEAVHEVWFKHNRFTKETVDFDIAVLRLKPTTF
RMNVAPACLPDRWASTLTKTQTVISGVRTHKEGRQSTRLKMLEVPPVDRNSCKI
SSSEFIITQNMFCAGYDTKQEDACQSDSGSPHVTFRFXDTVFVTGLVSWGESCARCKYK
IYTKVTAFLKNWIDRSMKTRGLPKAKSHAPVITSSPLK"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGTGGTC 418
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 209
AX082959/c
LOCUS AX082959 1467 bp DNA linear PAT 28-FEB-2001
DEFINITION Sequence 1 from Patent WO0110896.
ACCESSION AX082959
VERSION AX082959.1 GI:13184880
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
Himmelspach,M. and Schlokot,U.
AUTHORS
TITLE Factor X analog with an improved ability to be activated
JOURNAL PATENT: WO 0110896-A 1 15-FEB-2001;
BAXTER AKTIENGESellschaft (AT)
FEATURES
Location/Qualifiers
source 1..1467
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/db_xref="REMBL:CAB69368"
/translations="MGRPLHLVLLSASLAGLLGLLGLSFLRREQANNILARVTRANSF
LEBMKGHLRECEWFEFTCSYEAREVFEFSDKTNFNWVKYDGDQCTSPCONGKCK
DGLGEVCTCLEGPEGNKCLFTRKLCSLDNGCDQPCHEEQNSVVCSCARGYTLADN
GXACITGTPFCQDILERRKRSVAQTSNGSEAPDSITWKPYDAADLDPENPFLL
DFNQTPFERDNNLIRIVGQCKGECQPCWALLINEENEGFCGGTILSEFYLTAAH
CLYQAKRFVVRDNTQEGGEAVHEVWFKHNRFTKETVDFDIAVLRLKPTTF
RMNVAPACLPDRWASTLTKTQTVISGVRTHKEGRQSTRLKMLEVPPVDRNSCKI
SSSEFIITQNMFCAGYDTKQEDACQSDSGSPHVTFRFXDTVFVTGLVSWGESCARCKYK
IYTKVTAFLKNWIDRSMKTRGLPKAKSHAPVITSSPLK"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTAAAGCTGTGTGGTC 418
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 210
BD070392/c
LOCUS BD070392 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X-analogues with modified protease cleavage site.

```

```

ACCESSION BD070392
VERSION BD070392.1 GI:22615995
KEYWORDS JP 2001513631-A/26.
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dörner,F., Andreas, Fisch and Eibl,J.
TITLE Factor X-analogues with modified protease cleavage site
JOURNAL Patent: JP 2001513631-A 26 04-SEP-2001;
BAXTER AG
COMMENT OS Unidentified
PN JP 2001513631-A/26
PD 04-SEP-2001
PP 27-FEB-1998 JP 1998537062
PR 27-FEB-1997 AT A 335/97
PI MICHELE HIMMELSPACH,UWE SCHLOKAT,FRIEDRICH DÖRNER,ANDREAS PI
FISCH,JOHANN EIBL
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X-analogues with modified protease cleavage site FH
Key CDS Location/Qualifiers
FT 1..1467.
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTCTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156
RESULT 211
BD070435/c
LOCUS BD070435 1467 bp DNA linear PAT 27-AUG-2002
DEFINITION Factor X deletion mutants and analogues thereof.
ACCESSION BD070435
VERSION BD070435.1 GI:22616038
KEYWORDS JP 2001513632-A/43.
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Pfeleiderer,M., Falkner,F.G., Eibl,J., Dörner,F. and
Schlokot,U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: JP 2001513632-A 43 04-SEP-2001;
BAXTER AG
COMMENT OS Unidentified
PN JP 2001513632-A/43
PD 04-SEP-2001
PP 27-FEB-1998 JP 1998537063
PR 27-FEB-1997 AT A 336/97
PI MICHELE HIMMELSPACH,MICHAEL PFLEIDERER,FALKO GÜNTHER FALKNER,
JOHANN EIBL,
PI FRIEDRICH DÖRNER,UWE SCHLOKAT
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X deletion mutants and analogues thereof FH
Key CDS Location/Qualifiers
FT 1..1467.
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="genomic DNA"

```

```

/db_xref="taxon:32644"
Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTCTGTTGTTGTTATCTAGATTAAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156
RESULT 212
AF191307/c
LOCUS AF191307 1514 bp mRNA linear MAM 01-NOV-2000
DEFINITION Sus scrofa protein C mRNA, complete cds.
ACCESSION AF191307
VERSION AF191307.1 GI:11065893
KEYWORDS Sus scrofa (pig)
SOURCE Sus scrofa
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 1514)
AUTHORS Grimm,D.R., Colter,M.B. and Kim,H.
TITLE Cloning of the complete cDNA sequences encoding porcine factor V
and protein C
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1514)
AUTHORS Grimm,D.R., Colter,M.B. and Kim,H.
TITLE Direct Submission
JOURNAL Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
North Pine Drive, Tampa, FL 33612, USA
FEATURES
source
1..1514
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="92N.4; 58/86.2; 12N3.1"
/tissue type="liver"
22..1401
/note="serine protease"
/codon_start=1
/product="protein C"
/protein_id="AAG28380.1"
/db_xref="GI:11065894"
/translation="MWQLASLLILLIIVAVSTPPVPSVSSORAHQMLRSKRANS
FLEELRPSLEKEETCDREAREIFQNTENTWAFSKYHGDQCAVSPPEHLCD
PCCGRGTCIDGLGFRCDCAQWEGRCLEHVRFSNCSTENGCGAHYCLFEEGRCA
CAPGYRLGDDHLQCEPKVRSPCGRNLNMEKARKNKRKRDTDQVKKEDQIDRLVNGK
QSPMGESPMQVILLDSKKIACGAVLIHVSWVLTAAHCLDDYKKLUTVRLGEYDLRRRE
KWEVDLDIKELVHPNTYRSTSDNDIALRLAEPATFSQTVIPICLPDSGLSERELTR
VQGETVVTGWYRSEAKTRNSFILNFIKVPVAPHNECVQAMHNKISNNMLCAGILGDS
RDCEGDSGGMVASFRTGWTFLVGLVSNVSGEGGRLHNYGVYTKVSRYLWDIWHIRME
EAPHNQVP"
Query Match 0.8%; Score 18.6; DB 1; Length 1514;
Best Local Similarity 51.9%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 1948 CAGATTTCCTTCAGTTTGGTTTCTTTTATTAATTCCTTCAGTTTCAGTCTGCTGAAA 2007
DB 657 CGGATCTATTGGTCTCTCTTTTTCACACTGGTCTGTATCAGCTTCAAGTCTTCTGCG 598
QY 2008 TGTCTTACTCATTTCTCCCTCC 2028
DB 597 TTCTCTCCATCGCATTCCTCC 577
RESULT 213
HUMKALR4
LOCUS HUMKALR4 193 bp DNA linear PRI 06-JAN-1995
DEFINITION Human renal kallikrein, exon 4.
ACCESSION M33108

```


[illegible]

```
/replace="cctccccgcagagaattac"
249
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgggct"

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTCAGGTTCTCTGGTCTTAATTTTCATTTCCAGATTTCCTTCAGTTTG 1965
DB 218 TTGTCTGCACATCTCTCCGCACTGCCCGCTTCTCTCCAGGATGCTCTTGCGTG 159

RESULT 217
HUMMDPBH/c
LOCUS HUMMDPBH 249 bp DNA linear PRI 07-JAN-1995
DEFINITION Human MHC class II HLA DP-beta gene, exon 2 allele DPB5.
ACCESSION M23680
VERSION M23680.1 GI:188070
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 249)
AUTHORS Bugawan,T.I., Horn,G.T., Long,C.M., Mickelson,E., Hansen,J.A.,
Ferrara,G.B., Angelini,G. and Erlich,H.A.
TITLE Analysis of HLA-DP allelic sequence polymorphism using the in vitro
enzymatic DNA amplification of DP-alpha and DP-beta loci
J. Immunol. 141 (11), 4024-4030 (1988)
JOURNAL 89035547
MEDLINE 2460556
PUBMED
COMMENT Original source text: Human DNA allele DPB5.
FEATURES
location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1..249
/gene="HLA-DPB1"
<1..>249
/gene="HLA-DPB1"
/note="MHC DP-beta, allele DPB5"
/codon_start=1
/protein_id="AAA59745.1"
/db_xref="GI:188071"
/db_xref="GDB:G00-120-636"
/translation="LFGQEQCYAFNGTQFLERYLYNREELVRFSDVGEFRAVTEL
GRPEAYWNSQDILEEKRAVDRMCRHNYELDEAVTLQ"

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTCAGGTTCTCTGGTCTTAATTTTCATTTCCAGATTTCCTTCAGTTTG 1965
DB 218 TTGTCTGCACATCTCTCCGCACTGCCCGCTTCTCTCCAGGATGCTCTTGCGTG 159

RESULT 218
HUMMDPBH/c
LOCUS HUMMDPBH 256 bp DNA linear PRI 07-JAN-1995
DEFINITION Human MHC class II HLA DP-beta (allele DPB5), partial cds.
ACCESSION M62333
VERSION M62333.1 GI:188026
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane glycoprotein; major histocompatibility complex.
SOURCE Homo sapiens (human)
```

```
/replace="cctccccgcagagaattac"
249
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgggct"

Query Match      0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTCAGGTTCTCTGGTCTTAATTTTCATTTCCAGATTTCCTTCAGTTTG 1965
DB 218 TTGTCTGCACATCTCTCCGCACTGCCCGCTTCTCTCCAGGATGCTCTTGCGTG 159

RESULT 216
HUMDPBB/c
LOCUS HUMDPBB 249 bp DNA linear PRI 14-APR-2000
DEFINITION Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK2.
ACCESSION D10479
VERSION D10479.1 GI:219606
KEYWORDS HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
Hum. Immunol. 34 (3), 203-211 (1992)
JOURNAL 93053849
MEDLINE 1358867
PUBMED
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsunaga,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.
FEATURES
location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THMI"
/db_xref="taxon:9606"
/chromosomes="6"
/clone="SSK2"
/cell_type="peripheral blood mononuclear cell"
1..249
/gene="DPB1"
<1..>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01282.1"
/db_xref="GI:219607"
/translation="VYQLQEQCYAFNGTQFLERYLYNREELVRFSDVGEFRAVTEL
GRPEAYWNSQDILEEKRAVDRMCRHNYELDEAVTLQ"

exon
1..249
/gene="DPB1"
/number=2
old_sequence
1
/gene="DPB1"
/citation=[1]
```

```

ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 256)
TITLE Bugawan, T.L., Begovich, A.B. and Erlich, H.A.
Rapid HLA-DPB typing using enzymatically amplified DNA and
nonradioactive sequence-specific oligonucleotide probes
JOURNAL Immunogenetics 32 (4), 231-241 (1990)
MEDLINE 91055805
PUBMED 2242906
COMMENT source text: Human DNA allele DPB5.
FEATURES
    Location/Qualifiers
        1..256
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
        1..256
            /map="6p21.3"
        1..256
            /gene="HLA-DPB1"
        1..256
            /gene="HLA-DPB1"
        /codon_start=1
        /product="MHC class II HLA-DP-beta-1"
        /protein_id="AAAS59726.1"
        /map="6p21.3"
        /db_xref="GI:553549"
        /translation="LFGQRCYAFNGTQCFLERYINREELVRFDSVGEFRAVTEL
        GRPEAYWNSQKDIIEKRAVDPDRMCRHNYELDEAVTLQR"

Query Match 0.8%; Score 18.4; DB 1; Length 256;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCCGTGGTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTG 1965
Db 218 TTGTGTCGACATCTCTCCGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGCTG 159

RESULT 219
AF180970/c
LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1 variant
DEFINITION AF180970
VERSION AF180970.1 GI:14279142
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 257)
AUTHORS Xu, A., Huang, H., Liu, Z., Chen, W., Pan, D., Lin, J., Xu, K., Chen, S.,
Wang, X. and Chen, R.
TITLE A novel HLA-DPB1 allele in Chinese people
JOURNAL Unpublished
AUTHORS 2 (bases 1 to 257)
XU, A., HUANG, H., LIU, Z., CHEN, W., PAN, D., LIN, J., XU, K., CHEN, S.,
WANG, X. AND CHEN, R.
Direct Submission
Submitted (26-AUG-1999) Biochemistry, School of Life Science, 135
Xingangxi Road, Guangzhou, Guangdong 510275, P.R.China
FEATURES
    Location/Qualifiers
        1..257
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="6"
            /map="6p21.3"
        <1..>257
            /gene="HLA-DPB1"
            /allele="HLA-DPB1 variant"
        <1..>257
            /gene="HLA-DPB1"

gene
mRNA

```

```

CDS
    /product="MHC class II antigen"
    <1..>257
        /gene="HLA-DPB1"
        /note="membrane protein"
        /codon_start=3
        /product="MHC class II antigen"
        /protein_id="AAKS5808.1"
        /db_xref="GI:14279143"
        /translation="NYLFGQRCYAFNGTQCFLERYINREELVRFDSVGEFRAVTEL
        ELGRPEAYWNSQKDIIEKRAVDPDRMCRHNYELDEAVTLQ"
        1..257
            /gene="HLA-DPB1"
            /number=2

exon
    Query Match 0.8%; Score 18.4; DB 1; Length 257;
    Best Local Similarity 56.7%; Pred. No. 2.3e+02;
    Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGTCCTGAGGTTCCGTGGTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTG 1965
Db 226 TTGTGTCGACATCTCTCCGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGCTG 167

RESULT 220
HUMDPB1KT/c
LOCUS Human MHC class II HLA-DPB1 gene allele DPB1*KT.
DEFINITION HUMDPB1KT
ACCESSION D10882
VERSION D10882.1 GI:219602
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 264)
AUTHORS Ogawa, K., Itho, H., Nakajyo, S., Kobayashi, K., Sekiguchi, S.,
Koshizaka, T., Taguchi, M., Onishi, H., Kobayashi, S. and Inoko, H.
TITLE A novel HLA-DPB1 allele, DPB1*3601 (DPB1*KT)
JOURNAL Tissue Antigens 44 (2), 134-136 (1994)
MEDLINE 95117110
PUBMED 7817379
REFERENCE 2 (bases 1 to 264)
Koshizaka, T.
Direct Submission
Submitted (06-APR-1992) Takuya Koshizaka, Sumitomo Metal
Industries, Ltd.; 14-15 Kobuchi 2-chome, Sagamihara, Kanagawa 229,
Japan (Tel:0427-51-7568, Fax:0427-51-7519)
Submitted (06-APR-1992) to DDBJ by:
Takuya Koshizaka
Sumitomo Metal Industries, Ltd.
14-15 Kobuchi 2-chome
Sagamihara, Kanagawa 229
Japan
Phone: 0427-51-7568
Fax: 0427-51-7519.
FEATURES
    Location/Qualifiers
        1..264
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
        <1..>264
            /codon_start=3
            /product="HLA-DPB1"
            /protein_id="BAA01704.1"
            /db_xref="GI:219603"
            /translation="NYVQLRQECYAFNGTQCFLERYINREELVRFDSVGEFRAVTEL
            ELGRPEAYWNSQKDIIEKRAVDPDRMCRHNYELDEAVTLQR"
            1..264
                /number=2

exon
    Query Match 0.8%; Score 18.4; DB 1; Length 264;
    Best Local Similarity 56.7%; Pred. No. 2.3e+02;

```

```

Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGCTCTGAGGTTCTCTGGTGGTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGCGTG 167

RESULT 221
AF336224/c
LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*3801
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*3801
ACCESSION AF336224
VERSION AF336224.1 GI:13430229
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 283)
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Sequence of complete exon 2 and partial intron 2 of HLA-DPB1*3801
allele
JOURNAL Unpublished
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Direct Submission
JOURNAL Submitted (16-JAN-2001) Biochemistry Department, Zhongshan (Sun
Yat-sen) University, 135 W. Xingang Rd, Guangzhou, Guangdong
510275, P.R. China
FEATURES
source
1..283
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
<1..>283
/gene="HLA-DPB1"
/allele="HLA-DPB1*3801"
<1..>264
/gene="HLA-DPB1"
<1..>264
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAK25779.1"
/db_xref="GI:13430230"
/translation="NYLFQGRQECYFPFNGTQFLERYINREELVRFDSVDGGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNVELDEAVTLQRR"
1..264
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 283;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGCTCTGAGGTTCTCTGGTGGTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGCGTG 167

RESULT 222
AF492638/c
LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*0501
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1*0501
ACCESSION AF492638
VERSION AF492638.1 GI:29422764
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 283)
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Sequence of complete exon 2 and partial intron 2 of HLA-DPB1*3801
allele
JOURNAL Unpublished
AUTHORS Liu,Z., Lin,J., Chen,W., Jia,Z., Pan,D. and Xu,A.
TITLE Direct Submission
JOURNAL Submitted (16-JAN-2001) Biochemistry Department, Zhongshan (Sun
Yat-sen) University, 135 W. Xingang Rd, Guangzhou, Guangdong
510275, P.R. China
FEATURES
source
1..283
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
<1..>283
/gene="HLA-DPB1"
/allele="HLA-DPB1*3801"
<1..>264
/gene="HLA-DPB1"
<1..>264
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAK25779.1"
/db_xref="GI:13430230"
/translation="NYLFQGRQECYFPFNGTQFLERYINREELVRFDSVDGGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNVELDEAVTLQRR"
1..264
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 283;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGCTCTGAGGTTCTCTGGTGGTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 226 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGCGTG 167

RESULT 223
HUMHDPBZ/c
LOCUS Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Kimura,A.
TITLE Unpublished (1991)
JOURNAL Original source text: Homo sapiens (individual isolate SASBE41)
COMMENT DNA.
FEATURES
source
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1

intron

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Sequence-Based DPB Typing Fills the Missing Exon 2 Sequences of
Multiple HLA-DPB1 Alleles
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 285)
AUTHORS Luo,M., Mao,X., Shehzad,I., Jacobson,K., Kwan,L., Shroeder,M. and
Plummer,F.A.
TITLE Direct Submission
JOURNAL Submitted (14-MAR-2002) Medical Microbiology, University of
Manitoba, R507 BMSB, 730 William Avenue, Winnipeg, Manitoba R3E
0M3, Canada
FEATURES
source
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1..>285
/gene="HLA-DPB1"
/allele="HLA-DPB1*0501"
<20..>283
/gene="HLA-DPB1"
/product="MHC class II antigen"
<20..>283
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAO84763.1"
/db_xref="GI:29422765"
/translation="NYLFQGRQECYAFNGTQFLERYINREELVRFDSVDGGEFRAVT
ELGRPEAEYWNQKIDLEKRAVPDRMCRHNVELDEAVTLQRR"
20..283
/gene="HLA-DPB1"
/number=2

Query Match 0.8%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGCTCTGAGGTTCTCTGGTGGTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTG 1965
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGCACATCTCTGCGGCACTGCCGCTTCTCTCCAGGATGCTCTTGCGTG 186

RESULT 223
HUMHDPBZ/c
LOCUS Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Kimura,A.
TITLE Unpublished (1991)
JOURNAL Original source text: Homo sapiens (individual isolate SASBE41)
COMMENT DNA.
FEATURES
source
1..285
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1

intron

```

```

CDS
<20..>283
/codon_start=3
/label=exon 2
/product="MHC HLA DPB1"
/protein_id="AAA36266.1"
/db_xref="GI:553571"
/translation="NYVQLRQECYAFNGTORFLERYLYNREELVRFDSDVGEFRAVT
ELGRPEAEYNNQSDILLEKFAVDRMCRHNYELDEAVTLQR"
intron
284..>285
/number=2

Query Match      0.8%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1906 TTGCTCTGAGGTCCTGTTGGTCTTAATTTTTCATTCAGATTTCCTTCAGTTG 1965
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
245 TTGTTCTGACATCCTGTCGGCACTGCCCGCTTCTCTCCAGGATGTCCTTCTGGCTG 186

RESULT 224
AF312826/c
LOCUS
DEFINITION
Luidia foliolata sea star regeneration-associated protease SRAP
mRNA, complete cds.
ACCESSION
AF312826
VERSION
AF312826.1 GI:13183619
KEYWORDS
SOURCE
Luidia foliolata
ORGANISM
Luidia foliolata
REFERENCE
1 (bases 1 to 804)
AUTHORS
Vickery,M.C., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE
Utilization of a novel deuterostome model for the study of
regeneration genetics: molecular cloning of genes that are
differentially expressed during early stages of larval sea star
regeneration
JOURNAL
Gene 262 (1-2), 73-80 (2001)
MEDLINE
21100442
PUBMED
11179669
AUTHORS
Vickery,M.C.L., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE
Direct Submision
JOURNAL
Submitted (12-OCT-2000) Department of Biology, University of
Alabama at Birmingham, 1300 University Blvd., Birmingham, AL.
35294-1170, USA

FEATURES
source
Location/Qualifiers
1..804
/organism="Luidia foliolata"
/mol_type="mRNA"
/db_xref="taxon:105861"
/dev_stage="larva"
1..804
/notes="serine protease"
/codon_start=1
/product="sea star regeneration-associated protease SRAP"
/protein_id="AAK15274.1"
/db_xref="GI:13183620"
/translation="MLRLVLALAAFYVADCGVQVINFVLNKLIVGDEAVPGSWPQQ
VNFRRYAGDYQFCGGTILSDIEWAVSAACFHNIGNHNTAVVGAHDDSDVSTQT
TVGLGKVFHESVDTSLNDIALIKLSSPSVMSNVNSVCLPTATPTGTCVVTGW
GQDETAVDPTLQOVVPIILSSQCNRTWYGEINDNMICAGFKEGKDSQGSQGG
PFVQSASSEYELVGVSWGYGCADRKPGVTKVLNVSVINNLVARN"

CDS
Query Match      0.8%; Score 18.4; DB 1; Length 804;
Best Local Similarity 59.6%; Pred. No. 2.3e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 623 TTGTTGAGATGACCTAACTGTTGGAGAGATGGGGTATTGAAGTACCCACT 674
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
251 TGGTTGATGTTGCCATAGTATTGAAGCAATGGCGACAGACAGACCCCACT 200

Query Match      0.8%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.3e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 295 ATTCTTGATTCTATCTTGGCTCATTTTAACCTCAGTAGTGAGTTGTTGTTCCATA 354
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
207 AATTGTCGATCTGTGGAGGTTCCATCGTTAATGAAATGGTGTACTGTCGCCA 266

QY 355 AGTTTCTAAGTTTCTGTTGTTCTGTTGTTGTTGTTGTT 394
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
267 CTGCATCAAGCCCTGGTGTAAATTAATTACTGTTGTGAGGT 306

RESULT 226
AF011900/c
LOCUS
DEFINITION
Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
ACCESSION
AF011900
VERSION
AF011900.1 GI:2367498
KEYWORDS
SOURCE
Petromyzon marinus (sea lamprey)
ORGANISM
Petromyzon marinus
REFERENCE
1 (bases 1 to 832)
AUTHORS
Roach,J.C.
TITLE
The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL
Unpublished
AUTHORS
Roach,J.C.
TITLE
Direct Submission
JOURNAL
Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA

FEATURES
Location/Qualifiers
1..832
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/notes="factor IX"
/codon_start=1
/protein_id="AAA31520.1"
/db_xref="GI:552419"
/translation="RASVLHTSKLTRAETIFSNMNVNSESAREIWDNVTSQNSQFD
DFNRVVGDEDAARGQPPWVLLHGEIAAFGGSIIVNEKVVVTAHCIKPGKIVVAG
ENHTPEPEQKENVIRALPHGYNASINKYSHDIALLEDEPLNSIVTICIAAD
REYTNFLKPGYGVSGWRGSRASILQYLVPLVDVRACTLRSTKRTFTYHMFEC
AGYHEGGKDSQCGSDGSPHVTVEGTSFLTGLISWGECAMKGYIYTKVSRVEV"

```

```

RESULT 225
SHPFIIXA
LOCUS
DEFINITION
Sheep factor IX mRNA, partial cds.
ACCESSION
M26233
VERSION
M26233.1 GI:165878
KEYWORDS
factor IX.
SOURCE
Ovis aries (sheep)
ORGANISM
Ovis aries
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
1 (bases 1 to 823)
REFERENCE
AUTHORS
Sarkar,G., Koeberl,D.D. and Sommer,S.S.
TITLE
Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL
Genomics 6 (1), 133-143 (1990)
MEDLINE
90152675
PUBMED
2303254
COMMENT
Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
FEATURES
source
Location/Qualifiers
1..823
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/notes="factor IX"
/codon_start=1
/protein_id="AAA31520.1"
/db_xref="GI:552419"
/translation="RASVLHTSKLTRAETIFSNMNVNSESAREIWDNVTSQNSQFD
DFNRVVGDEDAARGQPPWVLLHGEIAAFGGSIIVNEKVVVTAHCIKPGKIVVAG
ENHTPEPEQKENVIRALPHGYNASINKYSHDIALLEDEPLNSIVTICIAAD
REYTNFLKPGYGVSGWRGSRASILQYLVPLVDVRACTLRSTKRTFTYHMFEC
AGYHEGGKDSQCGSDGSPHVTVEGTSFLTGLISWGECAMKGYIYTKVSRVEV"
Query Match      0.8%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.3e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 295 ATTCTTGATTCTATCTTGGCTCATTTTAACCTCAGTAGTGAGTTGTTGTTCCATA 354
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
207 AATTGTCGATCTGTGGAGGTTCCATCGTTAATGAAATGGTGTACTGTCGCCA 266

QY 355 AGTTTCTAAGTTTCTGTTGTTCTGTTGTTGTTGTTGTT 394
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
267 CTGCATCAAGCCCTGGTGTAAATTAATTACTGTTGTGAGGT 306

RESULT 226
AF011900/c
LOCUS
DEFINITION
Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
ACCESSION
AF011900
VERSION
AF011900.1 GI:2367498
KEYWORDS
SOURCE
Petromyzon marinus (sea lamprey)
ORGANISM
Petromyzon marinus
REFERENCE
1 (bases 1 to 832)
AUTHORS
Roach,J.C.
TITLE
The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL
Unpublished
AUTHORS
Roach,J.C.
TITLE
Direct Submission
JOURNAL
Submitted (01-JUL-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98195, USA

FEATURES
Location/Qualifiers
1..832
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/notes="factor IX"
/codon_start=1
/protein_id="AAA31520.1"
/db_xref="GI:552419"
/translation="RASVLHTSKLTRAETIFSNMNVNSESAREIWDNVTSQNSQFD
DFNRVVGDEDAARGQPPWVLLHGEIAAFGGSIIVNEKVVVTAHCIKPGKIVVAG
ENHTPEPEQKENVIRALPHGYNASINKYSHDIALLEDEPLNSIVTICIAAD
REYTNFLKPGYGVSGWRGSRASILQYLVPLVDVRACTLRSTKRTFTYHMFEC
AGYHEGGKDSQCGSDGSPHVTVEGTSFLTGLISWGECAMKGYIYTKVSRVEV"

```


PUBMED	1346483	GenBank staff at the National Library of Medicine created this entry [NCBI gibbsq 78934] from the original journal article.									
REMARK	This sequence comes from Fig 3A.										
FEATURES	Location/Qualifiers										
source	1..171										
	/organism="Homo sapiens"										
	/mol_type="genomic DNA"										
	/db_xref="taxon:9606"										
Query Match	0.8%;	Score 18.2;	DB 1;	Length 171;							
Best Local Similarity	51.9%;	Pred. No. 2.5e+02;									
Matches	41;	Conservative	0;	Mismatches	38;	Indels	0;	Gaps	0;		
QY	533	CTTTGTGTTTGGTGAATAGTCTGTAATAATCTCTAGGTCACCTTGGTTATGACATCA	592								
Db	84	CTTTGGATTTTGAAGGAAGAACTGTGAATTTTCAGTTTCAACTTGTTCAGAGGGAAA	143								
QY	593	GTTAGTCCAGATTCTC	611								
Db	144	CTTTGAACCATGAGTATTC	162								
RESULT	230										
AX318568											
LOCUS	AX318568	240 bp	DNA	linear	PAT 06-JUL-2002						
DEFINITION	Sequence 73 from Patent WO0177155.										
ACCESSION	AX318568										
VERSION	AX318568.2	GI:21713338									
KEYWORDS											
SOURCE	Homo sapiens (human)										
ORGANISM	Homo sapiens										
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.										
AUTHORS	Fernandes, E., Vernet, C.A., Mishnu, V.S., Leach, M.D., Shimkets, R.A., Zerhusen, B.D. and Kekuda, R.										
TITLE	Orfx polynucleotides and polypeptides										
JOURNAL	Patent: WO 0177155-A 73 18-OCT-2001;										
COMMENT	Curagen Corporation (US)										
FEATURES	On Jul 8, 2002 this sequence version replaced gi:17900986.										
source	1..240										
	/organism="Homo sapiens"										
	/mol_type="unassigned DNA"										
	/db_xref="taxon:9606"										
Query Match	0.8%;	Score 18.2;	DB 1;	Length 240;							
Best Local Similarity	59.2%;	Pred. No. 2.6e+02;									
Matches	32;	Conservative	0;	Mismatches	23;	Indels	0;	Gaps	0;		
QY	1740	TTCTCTATTCTCTTTGGTTTTTTCATAGTCTCTCTGGCTTCCTGGATGTTTTATG	1794								
Db	26	TCCCTCAGATGCTCTGAGTGTGGAGCGAGCCCTCGCTTCCCGATAGTTGGTG	80								
RESULT	231										
AY083553											
LOCUS	AY083553	251 bp	DNA	linear	PRI 13-APR-2002						
DEFINITION	Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.										
ACCESSION	AY083553										
VERSION	AY083553.1	GI:20146915									
KEYWORDS											
SOURCE	Macaca mulatta (rhesus monkey)										
ORGANISM	Macaca mulatta										
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopithecinae; Macaca.										
AUTHORS	1 (bases 1 to 251)										
TITLE	Norgren, R.B. Jr., Zink, M.A., Jia, Y., Ojeda, S.R. and Spindel, E.R.										
JOURNAL	Construction of a targeted rhesus macaque microarray										
REFERENCE	2 (bases 1 to 251)										

Qy	1526	TTTTCCCTTCGATCTTTTAAATATCTCTTTTGTCTATACATTTTAGTGAATTTGATTAT 1588
Db	836	TTTTTTTTTTTAACTTTTCAAAGTTTATTTCGTTTCATGGCATTTACAACCATCATAGTG 777
Qy	1586	ATGCACGTGGGGAGTTTCTTTTCGGTCCATCTATTTGGTGTTTTGTATGCTCTCTG 1644
Db	776	CTTGTGCTCGCAAGTGGCTTCCGAGTGAGTCGCTCAGTTGGCAGCCATGGTGCTGG 718
RESULT 234		
AF542056/c		
LOCUS		
DEFINITION		
AF542056		
ACCESSION		
AF542056.1		
VERSION		
KEYWORDS		
SOURCE		
ORGANISM		
REFERENCE		
AUTHORS		
TITLE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		
REFERENCE		
JOURNAL		
PUBMED		


```
DEFINITION
ACCESSION U49933
VERSION U49933.1 GI:1236620
KEYWORDS
SOURCE
ORGANISM
Oryctolagus cuniculus (rabbit)
Oryctolagus cuniculus
Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
1 (bases 1 to 1558)
Shen,L., He,X. and Dahlback,B.
Molecular cloning of rabbit vitamin K-dependent protein C and
demonstration of its mRNA in the reproductive organs
Unpublished
2 (bases 1 to 1558)
Shen,L., He,X. and Dahlback,B.
Direct Submission
Submitted (26-FEB-1996) Lei Shen, Clinical Chemistry, Lund
University, University Hospital, Malmö S-205 02, Sweden
Location/Qualifiers
1..1558
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AAA92956.1"
/db_xref="GI:1236621"
/translation="IPDDVGYRQKTKASKEGVVSKQDGNLTPRAKANSFLEEL
RPSLLRECEVEVCLDEAKEIFQSVDDTLAFWKYVDGQCAALPSEHPCSSQCGH
GTCAISIGFSCQCHGWGSGFCQYEVRENSVDNGGCAHYCLEEEAGRSCSCAPY
ELADHLQCEPAVPCGGLKWKIRKRNVDLEQVDEMDVDEPRIDGKLTFRG
DEPQVILDSKKLACGAVLHVSVLTAHCEPKKLFVRLGYDILRRKRWELD
LNIOEVLHPNTSRSTIDIALRLAQPATLSOTIVPICLPDGLAELRLMAQOET
VVTGWGSHSSKEAKRNTFILNFTVPAPQNECEOVMSNIISENMLCAGILGDRR
DACDGDGSGPMVASFGTWFLVGLVSGWGGDLNNYGVYKVSRYLDWIRSHIEKE
AAPESPAP"
<1..108
/feature="putative; leader peptide"
109..1374
/product="vitamin K-dependent protein C"
/feature="putative"
sig_peptide
mat_peptide
Query Match 0.8%; Score 18.2; DB 1; Length 1558;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
QY 920 CATCTTTTACTCTAAGGTGATGTCATCCATGCTAGGT 958
Db 1351 CCTCTTTTCTCGATGTGGCTGTGATCCATGCTGAGGT 1313
RESULT 236
S68634/c
LOCUS
DEFINITION
CRM+ factor IX Strasbourg 2-cross reacting material positive factor
IX Strasbourg 2 (exon 2) [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
S68634
S68634.1 GI:545020
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 199)
de la Salle,C., Charmantier,J.L., Ravanat,C., Ohlmann,P.,
Hartmann,M.L., Schuher,S., Bischoff,R., Ebel,C., Roecklin,D.,
Balland,A. et al.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
TITLE
by factor Xia
JOURNAL Nouv. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
MEDLINE 94126308
PUBMED 8295821
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsq 143652] from the original journal article.
COMMENT G6365 to A transition.
FEATURES
source
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..>168
/notes="cross reacting material positive factor IX
Strasbourg 2; Arg-4 to Gln transition; Method: conceptual
translation with partial peptide sequencing"
/codon_start=1
/product="CRM+ factor IX Strasbourg 2"
/protein_id="AAR29758.1"
/db_xref="GI:545021"
/translation="VFLDHENANKILNQPKRYNSKLEEFVQGNLERECMEKCSPEE
AREVPENTERI"
Query Match 0.8%; Score 18; DB 1; Length 199;
Best Local Similarity 45.2%; Pred. No. 2.9e+02;
Matches 66; Conservative 0; Mismatches 80; Indels 0; Gaps 0;
QY 1634 TATGCTTCTTGACCTGATAGCATCTCTTCTCAAGGTAGGAATTTCTTTTGTG 1693
Db 168 TGTCTTCTCAGTGTCTTCAAAAACCTCTCTGCTCTTCAAAACTACACTTTCTTCCAT 109
QY 1694 GTTTTCTGAAATATTTTCCCTGCTTTTGACTGCTCTTCTCCCTTCTCTATTTCCTT 1753
Db 108 ACATCTCTCTCAAGTTCCTTGAACAACCTTCAATTTACCTGAATATACCTCTT 49
QY 1754 TGGTTTTTGCATAGTGTCTCTGCTT 1779
Db 48 TGGCTGATTCAGAAATTTTGTGGCGT 23
RESULT 237
I14646/c
LOCUS
DEFINITION
Sequence 123 from patent US 5451512.
ACCESSION I14646
VERSION I14646.1 GI:997129
KEYWORDS
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 276)
AUTHORS Apple,R.J., Bugawan,T.L. and Erlich,H.A.
TITLE Methods and reagents for HLA class I A locus DNA typing
JOURNAL Patent: US 5451512-A 123 19-SEP-1995;
FEATURES
source
1..276
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 169 CTGCTGCCCTTCTCTCTGATTCCTAGGTGAGGTAGGCTTACCACTGCTCTCTCTCC 228
Db 238 CTGCGAGCCACTCCACGACGTGCCCTCCAGGTAGGCTCTCCACTGCTCGCTCATGG 179
QY 229 TTCTCTTAACACTT 242
Db 178 GCCGTCTCCCACTT 165
```



```

/db_xref="taxon:9606"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
/product="MHC class I antigen"
join(U90242.1:<1..270,1..>276)
/gene="HLA-A"
/note="variant A*2601"
/codon_start=3
/product="MHC class I antigen"
/protein_id="AAB50149.1"
/db_xref="GI:1905860"
/translation="SHSRYFYTSVSRGCEPRFIAVGVDDTQFVRFDSASQRM
EPAPWIEQEGPEWDRNTRNVKAHSOTDRANLCTLRGYVNCSEDSGHITQRMTCGV
GPDGRFLRGYQODAYDGDYIALNEDLSRWTAADMAAQITQKWEIAHEAQWRAYLE
GTCVWELRYLLENGKETLQRT"
1..276
/gene="HLA-A"
/number=3

Query Match      0.8%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCTTTCTCCCTGTCTGATTCCTAGGTTGAGGTTACCACTCTCTCTCTCCC 228
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
238 CTGGGAGCCACTCCACGACGTCCTCCAGTAGGCTCTCCACTGCTCGGCTCATGG 179
QY 229 TTCTCTAACACTT 242
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 241
AR249144/c
LOCUS      AR249144      290 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 4503 from patent US 6476212.
ACCESSION AR249144
VERSION AR249144.1 GI:27297018
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 290)
AUTHORS Lalgudi,R.V., Ito,I.Y. and Sherman,B.K.
TITLE Polynucleotides and polypeptides derived from corn ear
JOURNAL Patent: US 6476212-A 4503 05-NOV-2002;
FEATURES
source
1..290
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.8%; Score 18; DB 1; Length 290;
Best Local Similarity 51.2%; Pred. No. 2.9e+02;
Matches 42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1671 GGTTAGGAATTTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTTTGCACCTGCC 1730
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
218 GGCCGGAGATCTTGCCCTCTGCTGCTCCAGGAGGCTCGGCTCTCCAGGGCTGAC 159
QY 1731 TTCTTCCCTTCTCTATTCCT 1752
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
158 TGCAGCTCCATCTCTCGGCT 137

RESULT 242
AX312474
LOCUS      AX312474      299 bp      DNA      linear      PAT 14-DEC-2001
DEFINITION Sequence 5459 from Patent WO0150366.
ACCESSION AX312474
VERSION AX312474.1 GI:17897467
KEYWORDS

```

```

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Leach,M.D. and Shinkets,R.A.
TITLE Human polynucleotides and polypeptides encoded thereby
JOURNAL Patent: WO 0190366-A 5459 29-NOV-2001;
Curagen Corporation (US)
FEATURES
Location/Qualifiers
source
1..299
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 18; DB 1; Length 299;
Best Local Similarity 54.5%; Pred. No. 2.9e+02;
Matches 36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 1720 TTGACTGCTTCTCCCTTCTTATTCCTTTGGTTTGCATAGTGTCTGCTT 1779
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
220 TTGCAGTGGCTTCACCCATCTCCTCAATGACTACATGCTTCAGTCTGCCGAAA 279
QY 1780 CCTGGA 1785
Db      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
280 CCTGGA 285

RESULT 243
BTA271156/c
LOCUS      BTA271156      302 bp      mRNA      linear      MAM 27-JUL-2000
DEFINITION Bos taurus partial mRNA for haptoglobin (hp gene).
ACCESSION AJ271156
VERSION AJ271156.1 GI:9581738
KEYWORDS haptoglobin; hp gene.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
Bovidae; Bovinae; Bos.
REFERENCE 1
AUTHORS Lavery,K.S., Gabler,C. and Killian,G.J.
TITLE Expression and localization of haptoglobin in the bovine female
reproductive tract
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 302)
AUTHORS Lavery,K.S.
TITLE Direct Submission
JOURNAL Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science,
Pennsylvania State University, The John O. Alquist Research
Center, Fox Hollow Road, University Park, USA
FEATURES
Location/Qualifiers
source
1..302
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
/sex="female"
/cell_type="epithelial cell"
/tissue_type="oviduct"
/dev_stage="adult"
1..302
/gene="hp"
<1..>302
/gene="hp"
/function="acute phase protein"
/codon_start=3
/product="haptoglobin"
/protein_id="CAC00531.1"
/db_xref="GI:9581739"
/db_xref="GOA:Q9MYV8"
/db_xref="SPTREMBL:Q9MYV8"
/translation="KGSFPWQAKVMSQNLISGATLINERWLLTTAKNLYIGHSSDKK
AKDTPTLRLYVGNQLVEVEKVIHPDHSKVDIGLIKLRQKVPVNDKVPICLPS"

```

Query Match	0.8%;	Score 18;	DB 1;	Length 302;	
Best Local Similarity	52.7%;	Pred. No. 2.9e+02;			
Matches	39;	Conservative	0;	Mismatches 35;	Indels 0;
					Gaps 0;
Qy	1644	GTACCTTGATAGCATCTCTTTCTCAAGGTTAGGAATTTCTTTTGGTTTCTTGA	1703		
Ddb	297	GTAGCAGATGGGCATTACTTTGTCTATTCACAGGTACCTTCTGCTCTGATGAGCC	238		
Qy	1704	AAATATTTTCCCTG	1717		
Ddb	237	CAATGCTACCTTG	224		
RESULT 244					
FRSPLEX2/c					
LOCUS		335 bp	DNA	linear	VRT 28-OCT-2000
DEFINITION		F.rubripes serine protease-like exon (335bp).			
ACCESSION		X95338			
VERSION		X95338.1			
KEYWORDS		GI:1171532			
SOURCE		Takifugu rubripes (Fugu rubripes)			
ORGANISM		Takifugu rubripes			
REFERENCE		1			
AUTHORS		Lim, E.H. and Brenner, S.			
TITLE		Short-range linkage relationships, genomic organisation and sequence comparisons of a cluster of five HSP70 genes in Fugu rubripes			
JOURNAL		Cell. Mol. Life Sci. 55 (4), 668-678 (1999)			
MEDLINE		99284127			
PUBMED		10357235			
REFERENCE		2 (bases 1 to 335)			
AUTHORS		Lim, E.H.			
TITLE		Direct Submission			
JOURNAL		Submitted (17-JAN-1996) E.H. Lim, Molecular Genetics, Dept. of Medicine, Level 5, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK			
FEATURES					
source		Location/Qualifiers			
exon		1..335			
		/organism="Takifugu rubripes"			
		/mol_type="genomic DNA"			
		/db_xref="taxon:31033"			
		80..214			
		/product="serine protease-like protein"			
Query Match		0.8%;	Score 18;	DB 1;	Length 335;
Best Local Similarity		80.8%;	Pred. No. 2.9e+02;		
Matches		21;	Conservative	0;	Mismatches 5;
					Indels 0;
					Gaps 0;
Qy	30	TGAGGCTCCAAATGGTTGTTGATGTGG	55		
Ddb	194	TCAGGATCCACTGGTTGTTGATCAGG	169		
RESULT 245					
AF266240					
LOCUS		Gillichthys seta trypsinogen 2 precursor, mRNA, partial cds.			
DEFINITION		AF266240			
ACCESSION		AF266240.1			
VERSION		GI:10121759			
KEYWORDS		Gillichthys seta			
SOURCE		Gillichthys seta			
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Gobioidi; Gobiidae; Gillichthys			
REFERENCE		1 (bases 1 to 383)			
AUTHORS		Gravey, A.Y., Troll, J.V. and Somero, G.N.			

ACCESSION M35672.1 GI:180287
 VERSION coagulation factor IX; serine protease.
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 JAGADESWARAN,P., Lavelle,D.E., Kaul,R., Mohandas,T. and
 WARREN,S.T.
 Isolation and characterization of human factor IX cDNA:
 identification of Tag I polymorphism and regional assignment
 Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
 MEDLINE 84300526
 PUBMED 6089357
 COMMENT Original source text: Human adult liver, cDNA to mRNA.
 FEATURES
 Location/Qualifiers
 1..873
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /map_xref="Xq26.3-q27.1"
 1..873
 /gene="F9"
 <1..>873
 /gene="F9"
 /notes="coagulation factor IX"
 /codon_start=1
 /protein_id="AA51981.1"
 /db_xref="GI:180288"
 /db_xref="GDB:G00-119-900"
 /translations="NANKILNRPKNYSGLEEFVQGNLEECMEKCKCFEAREVFE
 NTRTEFVKQYVDGDCSNPCINGSGKDDINSYECWCPFGKGNCLDVTCKIK
 NGKCEQFKNSANKVCSCTEYIRLAENKSCPEAVPPGGRVSVSQTSLFRATV
 FPDVTVNSTEATILNDITQSFNDFTRVVGGEDAKGQFPWQVLNGKVDAPCG
 GSVNKKIIVTAACHVETGVTKITVVAGEHNIEBTEHQKRNIRIIPHHNYNAINK
 YNHDIALLEDEPLV"
 gene
 CDS
 Query Match 0.8%; Score 18; DB 1; Length 873;
 Best Local Similarity 64.3%; Pred. No. 2.9e+02;
 Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
 QY 369 CTGTTCTCTGTTGTTGTTGTTGTTATCTAGATTTAAAGCTG 410
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 476 CTGTTTCTGATGGACTATGTAATCTACTAGCTG 517
 RESULT 248
 AF465274/c
 LOCUS Takifugu rubripes 1329 bp mRNA linear VRT 02-FEB-2003
 DEFINITION Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete
 cds.
 ACCESSION AF465274
 VERSION AF465274.1 GI:28194019
 SOURCE
 ORGANISM Takifugu rubripes (Fugu rubripes)
 Takifugu rubripes
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
 Tetraodontidae; Tetraodontidae; Takifugu.
 1 (bases 1 to 1329)
 Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
 Tuddenham,E.G.D. and McVey,J.H.
 Comparative sequence analysis and molecular evolution of blood
 coagulation genes from Gallus gallus and Fugu rubripes
 Unpublished
 2 (bases 1 to 1329)
 McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
 Direct Submission
 Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
 Centre, The Faculty of Medicine, Imperial College, Hammersmith
 Campus, Du Cane Road, London W12 0NN, UK

FEATURES
source

Location/Qualifiers
 1..1329
 /organism="Takifugu rubripes"
 /mol_type="mRNA"
 /db_xref="taxon:31033"
 1..1329
 /EC_number="3.4.21.21"
 /function="serum prothrombinconversion accelerator"
 /note="vitamin K dependent serine protease; similar to
 Fugu rubripes FVII; synthesized in liver; contains 2
 EGF-like domains; member of peptidase family S1/trypsin
 family"
 /codon_start=1
 /product="coagulation factor VIIb precursor"
 /protein_id="AA033369.1"
 /db_xref="GI:28194020"
 /translations="MLIRICCTWILFESATAAAVFERDDASTVLQRRRANGSFLE
 EMQGNLKRCEIEICNEYEAREFDDAQTRKFWETYNRHDPCSNPCQNGYCVSM
 GNTYQCHCPGFGGQRCETKAEDFLKCLYQNGQCFDGSASRKCFAHGXTLAD
 GRCIAEVEFPCCQLPPETGPDTVVVGQTRLVGTNHCPEKCEPQWLVLLHGQSHG
 GVLRPDWVITAAHCVTKQPHLSVAGEHNLNDGDTOKIPVARVFAHEGVSET
 GDKDIALHLNASVTILNRGVI PVCLPTKDLAERELLMTRVHTVSGWKR'INGNEDHG
 VNTAPVSPELRKESVPIIPNQCSTRSQNFDTNMFACAGYLEGNQSCRGDGSPLV
 TLYGSTHFLIGVVGRCENPGYGYITNMGNFVDWANGIMMAANKKST"
 Query Match 0.8%; Score 18; DB 1; Length 1329;
 Best Local Similarity 52.7%; Pred. No. 2.8e+02;
 Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 1491 TCTAATACATCTCCCTTATATGTTATGCTGCTTTTCCCTTGCACTTTTAATTC 1550
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 209 TCGAATACTTCTCGAGTTCTTCGTAGTCAGATCTCTCGATTCATCTCTCTCAGG 150
 QY 1551 TTTCTTTGTTCTAT 1564
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 149 TTTCTTTGTTCTAT 136

RESULT 249
E02492/c

LOCUS DNA encoding protein C mutant.
 DEFINITION
 ACCESSION E02492
 VERSION E02492.1 GI:2170722
 KEYWORDS JP 1990167096-A/1.
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 1 (bases 1 to 1389)
 Hashimoto,T. and Sato,M.
 HUMAN PROTEIN C MUTANT AND ITS PRODUCTION
 Patent: JP 1990167096-A 1 27-JUN-1990;
 HOECHST JAPAN LTD
 COMMENT
 OS Artificial gene
 OC Artificial sequence; Genes.
 OS Homo sapiens (human)
 PN JP 1990167096-A/1
 PD 27-JUN-1990
 PF 13-JUL-1989 JP 1989179140
 PR 26-JUL-1988 JP 88P 184538
 PI HASHIMOTO TAMOTSU, SATO MASAHITO
 PC C12P21/02,C07K13/00,C12N15/12//A61K37/465,(C12P21/02, PC
 C12R1:91);
 CC strandedness: Single;
 CC topology: Linear;
 CC anti-sense: No;
 FH Key Location/Qualifiers
 FH sig_peptide 1..126
 FT /product='signal peptide of protein' FT
 mat_peptide 127..1383
 FT /product='protein c mutant'
 FT CDS 1..1389

Search completed: August 9, 2004, 17:50:01
Job time : 698 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:38:45 ; Search time 892 Seconds
(without alignments)
3.871 Million cell updates/sec

Title: us-10-664-775-5

Perfect score: 2267

Sequence: 1 gatcaactcctctagtgaag.....ttgttaattcttagtgctgat 2267

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	44.2	1.9	2422	1	AAQ80296 cDNA encoding Fact
C 2	44.2	1.9	2422	1	AAV02230 Homo sapiens cDNA
C 3	44.2	1.9	2422	1	AAZ57385 Factor VII encodin
C 4	44.2	1.9	2422	1	AAF57099 Human Factor VII p
C 5	44.2	1.9	2422	1	ADC24226 Human NOV8a encodi
C 6	44.2	1.9	2462	1	AAK15425 DNA encoding coagu
C 7	44.2	1.9	2462	1	AAK12968 DNA encoding Facto
C 8	44.2	1.9	2462	1	AAZ56118 Vitamin-K-dependen
C 9	44.2	1.9	2462	1	AAZ54032 Human factor VII c
C 10	44.2	1.9	2462	1	AAAG9784 DNA encoding coagu
C 11	44.2	1.9	2462	1	ABL87255 Thyroid cancer rel
C 12	44.2	1.9	2462	1	ABN95753 Gene #2251 used to
C 13	44.2	1.9	2483	1	AAAG60064 Factor VII cDNA of
C 14	44.2	1.9	2177	1	AAAG60063 Partial Factor VII
C 15	44.2	1.9	2438	1	AAAG60065 Factor IX/Factor V
C 16	32.4	1.4	300	1	AAZ12625 Human gene express
C 17	25.6	1.1	254	1	AAK16179 Human secreted pro
C 18	25.4	1.1	237	1	AAAG8927 DNA encoding novel
C 19	25.2	1.1	612	1	ABQ47969 Oligonucleotide fo
C 20	25.2	1.1	612	1	ABQ47968 Oligonucleotide fo
C 21	25.2	1.1	1843	1	AAQ54035 Human protein C co
C 22	25.2	1.1	1843	1	AAAF4050 Human protein C ge
C 23	25.2	1.1	1843	1	ABN97175 Gene #3673 used to
C 24	24.2	1.1	267	1	AAK45604 Human bone marrow
C 25	24.2	1.1	267	1	AAK19599 Human brain expres
C 26	24.2	1.1	267	1	ABSA5294 Human liver single
C 27	24.2	1.1	267	1	ABSI9876 Human genome-deriv
C 28	23.8	1.0	868	1	AAK93580 Human cDNA clone r
C 29	23.6	1.0	868	1	AAK31631 Human cDNA 5'-end
C 30	23.4	1.0	433	1	ACH20452 Human adult liver
C 31	23.4	1.0	612	1	ABQ47966 Oligonucleotide fo
C 32	23.4	1.0	612	1	ABQ47967 Oligonucleotide fo
C 33	23	1.0	306	1	AAT40850 Serine protease nf

Human factor X cod	1	1507	1.0	23	34	AAA54031
Human gene express	1	1507	1.0	23	35	ABZ35322
Farnesyl transfer	1	1507	1.0	23	36	ADE84862
Targeting arm #2	1	200	1.0	22.8	37	AAD37041
Human secreted pro	1	1151	1.0	22.8	38	RAD08286
Single nucleotide	1	271	1.0	22.4	39	AACT71343
Probe #1464 for ge	1	476	1.0	22.4	40	AAI11531
Human foetal liver	1	476	1.0	22.4	41	ABA53212
Probe #1496 used t	1	476	1.0	22.4	42	RAI32810
Human breast cell	1	476	1.0	22.4	43	ABA42785
Probe #1452 for ge	1	476	1.0	22.4	44	ABA22986
Human bone marrow	1	476	1.0	22.4	45	AAK26907
Human brain expres	1	476	1.0	22.4	46	AAK01461
Human liver single	1	476	1.0	22.4	47	ABS26497
Probe #1440 used t	1	476	1.0	22.4	48	RAI01449
Human genome-deriv	1	476	1.0	22.4	49	ABS01506
Human secreted pro	1	223	1.0	22.2	50	AAC20296
Probe #9609 for ge	1	301	1.0	22.2	51	RAI19676
Human foetal liver	1	301	1.0	22.2	52	ABA64702
Probe #13557 used	1	301	1.0	22.2	53	AAI44871
Human breast cell	1	301	1.0	22.2	54	ABA46822
Probe #10292 for g	1	301	1.0	22.2	55	ABA31826
Human bone marrow	1	301	1.0	22.2	56	AAK38868
Human brain expres	1	301	1.0	22.2	57	AAK13137
Human liver single	1	301	1.0	22.2	58	ABS38453
Probe #5386 used t	1	301	1.0	22.2	59	AAI05395
Human genome-deriv	1	301	1.0	22.2	60	ABS12949
Factor IX mutation	1	121	1.0	22	61	ABA79626
Factor IX mutation	1	121	1.0	22	62	ABA79623
Factor IX mutation	1	121	1.0	22	63	ABA79622
Factor IX mutation	1	121	1.0	22	64	ABA79634
Factor IX mutation	1	121	1.0	22	65	ABA79627
Factor IX mutation	1	121	1.0	22	66	ABA79631
Factor IX mutation	1	121	1.0	22	67	ABA79635
Factor IX mutation	1	121	1.0	22	68	ABA79638
Factor IX mutation	1	121	1.0	22	69	ABA79630
Factor IX mutation	1	121	1.0	22	70	ABA79639
Factor IX mutation	1	121	1.0	22	71	ABA79619
Factor IX mutation	1	121	1.0	22	72	ABA79618
Factor IX mutation	1	121	1.0	22	73	AAC04575
Human secreted pro	1	385	1.0	22	74	AAK70944
Single nucleotide	1	253	1.0	21.6	75	ABV98470
Human pancreatic c	1	254	1.0	21.6	76	AAV28290
Galanin receptor G	1	283	0.9	21.4	77	AAV32651
Galanin receptor G	1	283	0.9	21.4	78	AAV44930
Rat galanin recept	1	283	0.9	21.4	79	AAK14060
Human cDNA sequenc	1	1129	0.9	21.4	80	AAK21354
Novel human secret	1	1129	0.9	21.4	81	ACD23963
cDNA encoding huma	1	1129	0.9	21.4	82	ACA67104
DNA encoding novel	1	1129	0.9	21.4	83	ACA03713
Human secreted/tra	1	1129	0.9	21.4	84	ABX89251
Human cDNA encodin	1	1129	0.9	21.4	85	ACD41905
Novel human secret	1	1129	0.9	21.4	86	ACA41134
Human PRO polynucl	1	1129	0.9	21.4	87	ADA45740
Human PRO polynucl	1	1129	0.9	21.4	88	ADA76171
Human PRO polynucl	1	1129	0.9	21.4	89	ADA18821
Homo sapiens, Nov	1	1129	0.9	21.4	90	ADA61444
Novel human secret	1	1129	0.9	21.4	91	ADB19229
cDNA encoding huma	1	1129	0.9	21.4	92	ADB27770
Novel human secret	1	1129	0.9	21.4	93	ADA86249
Human PRO polynucl	1	1129	0.9	21.4	94	ADBI5813
Human PRO polynucl	1	1129	0.9	21.4	95	ADA47599
Human PRO polynucl	1	1129	0.9	21.4	96	ADA67394
cDNA encoding huma	1	1129	0.9	21.4	97	ADB30401
Novel human secret	1	1129	0.9	21.4	98	ADA85697
Human PRO polynucl	1	1129	0.9	21.4	99	ADA96909
Human PRO polynucl	1	1129	0.9	21.4	100	ADA79213
Novel human secret	1	1129	0.9	21.4	101	ADA67352
Human PRO polynucl	1	1129	0.9	21.4	102	ADBI6554
Novel human secret	1	1129	0.9	21.4	103	ADA91646
Human PRO polynucl	1	1129	0.9	21.4	104	ADBI4709
Novel human secret	1	1129	0.9	21.4	105	ADBI8670
Human PRO polynucl	1	1129	0.9	21.4	106	ADA93885

c 107	21.4	0.9	1129	1	AD819781	Novel human secret
c 108	21.4	0.9	1129	1	AD813093	Human PRO polynucle
c 109	21.4	0.9	1129	1	AD898534	Novel human secret
c 110	21.4	0.9	1129	1	AD874347	Human PRO polynucle
c 111	21.4	0.9	1129	1	AD824580	Human PRO polynucle
c 112	21.4	0.9	1129	1	AD82104	Human PRO polynucle
c 113	21.4	0.9	1129	1	AD875067	Human PRO polynucle
c 114	21.4	0.9	1129	1	AD885145	Novel human secret
c 115	21.4	0.9	1129	1	AD845593	Novel human secret
c 116	21.4	0.9	1129	1	AD829849	CDNA encoding huma
c 117	21.4	0.9	1129	1	AD80377	Human PRO polynucle
c 118	21.4	0.9	1129	1	AD875619	Human PRO polynucle
c 119	21.4	0.9	1129	1	AD846844	Human PRO polynucle
c 120	21.4	0.9	1129	1	AD825140	Human PRO polynucle
c 121	21.4	0.9	1129	1	AD893316	CDNA encoding huma
c 122	21.4	0.9	1129	1	AD826666	CDNA encoding huma
c 123	21.4	0.9	1129	1	AD830953	CDNA encoding huma
c 124	21.4	0.9	1129	1	AD860881	Homo sapiens. Nov
c 125	21.4	0.9	1129	1	AD824028	Human PRO polynucle
c 126	21.4	0.9	1129	1	AD896357	Human PRO polynucle
c 127	21.4	0.9	1129	1	AD809929	Human PRO polynucle
c 128	21.4	0.9	1129	1	AD895805	Human PRO polynucle
c 129	21.4	0.9	1129	1	AD826114	CDNA encoding huma
c 130	21.4	0.9	1129	1	AD821599	Novel human secret
c 131	21.4	0.9	1129	1	AD87378	Human PRO polynucle
c 132	21.4	0.9	1129	1	AD818118	CDNA encoding huma
c 133	21.4	0.9	1129	1	AD868801	Novel human secret
c 134	21.4	0.9	1129	1	AD87904	Novel human secret
c 135	21.4	0.9	1129	1	AD846292	Novel human secret
c 136	21.4	0.9	1129	1	AD828322	CDNA encoding huma
c 137	21.4	0.9	1129	1	AD828874	CDNA encoding huma
c 138	21.4	0.9	1129	1	AD876826	Human PRO polynucle
c 139	21.4	0.9	1129	1	AD88456	Novel human secret
c 140	21.4	0.9	1129	1	AD897461	Human PRO polynucle
c 141	21.4	0.9	1129	1	AD827218	CDNA encoding huma
c 142	21.4	0.9	1129	1	AD822151	Novel human secret
c 143	21.4	0.9	1129	1	AD866842	Human PRO polynucle
c 144	21.4	0.9	1129	1	AD822703	Human PRO polynucle
c 145	21.4	0.9	1129	1	AD823476	Human PRO polynucle
c 146	21.4	0.9	1129	1	AD892198	Human PRO polynucle
c 147	21.4	0.9	1129	1	AD815261	Novel human secret
c 148	21.4	0.9	1129	1	AD838513	Novel human secret
c 149	21.4	0.9	1129	1	AD837961	Novel human secret
c 150	21.4	0.9	1129	1	AD866433	Novel human secret
c 151	21.4	0.9	1129	1	AD889513	Human PRO polynucle
c 152	21.4	0.9	1129	1	AD890245	Human PRO polynucle
c 153	21.4	0.9	1129	1	AD839346	Novel human secret
c 154	21.4	0.9	1129	1	AD846969	Novel human secret
c 155	21.4	0.9	1129	1	AD886576	Human PRO polynucle
c 156	21.4	0.9	1129	1	AD877181	Novel human secret
c 157	21.4	0.9	1129	1	AD834338	Human PRO polynucle
c 158	21.4	0.9	1129	1	AD835442	Human PRO polynucle
c 159	21.4	0.9	1129	1	AD833786	Human PRO polynucle
c 160	21.4	0.9	1129	1	AD834890	Human PRO polynucle
c 161	21.4	0.9	1129	1	AD835994	Human PRO polynucle
c 162	21.4	0.9	1129	1	AD846389	Novel human secret
c 163	21.4	0.9	1129	1	AD850262	Novel human secret
c 164	21.4	0.9	1129	1	AD871809	Novel human secret
c 165	21.4	0.9	1129	1	AD859788	Novel human secret
c 166	21.4	0.9	1129	1	AD852795	Novel human secret
c 167	21.4	0.9	1129	1	AD857149	Novel human secret
c 168	21.4	0.9	1129	1	AD860340	Novel human secret
c 169	21.4	0.9	1129	1	AD850815	Novel human secret
c 170	21.4	0.9	1129	1	AD85342	Human PRO polynucle
c 171	21.4	0.9	1129	1	AD854440	Novel human secret
c 172	21.4	0.9	1129	1	AD853401	Novel human secret
c 173	21.4	0.9	1129	1	AD858924	Novel human secret
c 174	21.4	0.9	1129	1	AD855802	Novel human secret
c 175	21.4	0.9	1129	1	AD858372	Novel human secret
c 176	21.4	0.9	1129	1	AD803046	Novel human secret
c 177	21.4	0.9	1129	1	AD890038	Novel human secret
c 178	21.4	0.9	1129	1	AD869457	CDNA encoding huma
c 179	21.4	0.9	1129	1	AD848346	Human PRO polynucle
c 180	21.4	0.9	1129	1	ADD09875	Human PRO polynucle
c 181	21.4	0.9	1129	1	ADD04450	Novel human secret
c 182	21.4	0.9	1129	1	AD80406	Novel human secret
c 183	21.4	0.9	1129	1	ADD10913	Human PRO polynucle
c 184	21.4	0.9	1129	1	AD847794	Human PRO polynucle
c 185	21.4	0.9	1129	1	AD879854	Novel human secret
c 186	21.4	0.9	1129	1	ADD09323	Human PRO polynucle
c 187	21.4	0.9	1129	1	ADD41036	Novel human secret
c 188	21.4	0.9	1129	1	ADD52175	CDNA encoding huma
c 189	21.4	0.9	1129	1	ADD52915	CDNA encoding huma
c 190	21.4	0.9	1129	1	ADD53467	Novel human secret
c 191	21.4	0.9	1129	1	ADD51623	CDNA encoding huma
c 192	21.4	0.9	1129	1	ADD02422	Human PRO polynucle
c 193	21.4	0.9	1129	1	ADD01856	Human PRO polynucle
c 194	21.4	0.9	1129	1	ADD54038	Human PRO polynucle
c 195	21.4	0.9	1129	1	ADD92355	Human PRO polynucle
c 196	21.4	0.9	1129	1	ADD91251	Human PRO polynucle
c 197	21.4	0.9	1129	1	AD803865	Human PRO polynucle
c 198	21.4	0.9	1129	1	AD832162	Novel human secret
c 199	21.4	0.9	1129	1	AD822094	CDNA encoding huma
c 200	21.4	0.9	1129	1	AD879318	CDNA encoding huma
c 201	21.4	0.9	1129	1	AD841854	Human PRO polynucle
c 202	21.4	0.9	1129	1	AD817671	Human PRO polynucle
c 203	21.4	0.9	1129	1	AD891803	Human PRO polynucle
c 204	21.4	0.9	1129	1	AD833266	Novel human secret
c 205	21.4	0.9	1129	1	AD833818	Novel human secret
c 206	21.4	0.9	1129	1	AD879870	CDNA encoding huma
c 207	21.4	0.9	1129	1	AD892907	Human PRO polynucle
c 208	21.4	0.9	1129	1	AD819327	Human PRO polynucle
c 209	21.4	0.9	1129	1	AD818775	Human PRO polynucle
c 210	21.4	0.9	1129	1	AD842971	Human PRO polynucle
c 211	21.4	0.9	1129	1	ADD95760	Human PRO polynucle
c 212	21.4	0.9	1129	1	AD822646	CDNA encoding huma
c 213	21.4	0.9	1129	1	AD878764	CDNA encoding huma
c 214	21.4	0.9	1129	1	AD832714	Novel human secret
c 215	21.4	0.9	1129	1	AD842406	Human PRO polynucle
c 216	21.4	0.9	1129	1	AD80422	CDNA encoding huma
c 217	21.4	0.9	1129	1	AD89450	Human PRO polynucle
c 218	21.4	0.9	1129	1	AD840734	Human PRO polynucle
c 219	21.4	0.9	1129	1	AD804533	Human PRO polynucle
c 220	21.4	0.9	1129	1	AD80958	Novel human secret
c 221	21.4	0.9	1129	1	AD876406	Human PRO polynucle
c 222	21.4	0.9	1129	1	AD87770	Human PRO polynucle
c 223	21.4	0.9	1129	1	AD86174	Human PRO polynucle
c 224	21.4	0.9	1129	1	AD875622	CDNA encoding huma
c 225	21.4	0.9	1129	1	AD823198	CDNA encoding huma
c 226	21.4	0.9	1129	1	AD823750	CDNA encoding huma
c 227	21.4	0.9	1129	1	AD824393	Human PRO polynucle
c 228	21.4	0.9	1129	1	AD87218	Human PRO polynucle
c 229	21.4	0.9	1129	1	AD889084	Human PRO polynucle
c 230	21.4	0.9	1129	1	AD818223	Human PRO polynucle
c 231	21.4	0.9	1129	1	AD88532	Human PRO polynucle
c 232	21.4	0.9	6098	1	ABX14193	Plasmid pIN174 for
c 233	21.2	0.9	121	1	ABA79647	Factor IX mutation
c 234	21.2	0.9	121	1	ABA79646	Factor IX mutation
c 235	21.2	0.9	121	1	ABA79642	Factor IX mutation
c 236	21.2	0.9	121	1	ABA79643	Factor IX mutation
c 237	21.2	0.9	305	1	AB868969	Novel murine polyn
c 238	21.1	0.9	286	1	ABL76556	Corn tassell-deri
c 239	21	0.9	267	1	AAV88446	EST clone BA90. H
c 240	21	0.9	372	1	ABX37095	Bovine EST associa
c 241	20.8	0.9	263	1	AAI20194	Probe #10127 for g
c 242	20.8	0.9	263	1	AA65223	Human foetal liver
c 243	20.8	0.9	263	1	AAI45394	Probe #14080 used
c 244	20.8	0.9	263	1	AA47338	Human breast cell
c 245	20.8	0.9	263	1	ABA32324	Human bone marrow
c 246	20.8	0.9	263	1	AAK39361	Human brain expres
c 247	20.8	0.9	263	1	AAK13640	Human liver single
c 248	20.8	0.9	263	1	AB838969	Probe #5889 used t
c 249	20.8	0.9	263	1	AAI05898	Human genome-deri
c 250	20.8	0.9	263	1	AB813468	

[illegible]

[illegible]

CC protease activity of Factor VIIa. The calcium binding domain comprises a
CC gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC construct is used to transfected host cells to produce the protein which,
CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;

Query Match 1.9%; Score 44; DB 1; Length 2438;
Best Local Similarity 63.0%; Pred. No. 5.3e-05;
Matches 68; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1080 GTGTTTGGGATCTCTGTTATCTTGCACTTGCAAGTGTGTGTGTGTGTGTGTGTG 1139
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1995 GTGTGCGTCATGGCATGGCGTGCACTCCATGTGTATATCTGTGTGTGTCATCTGTG 1936

QY 1140 TGT 1187
Db 1935 TGCATATCTATGTGCGGTGTCATCGGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1888

RESULT 16
AAZ12625
ID AAZ12625 standard; cDNA; 300 BP.
XX
AC AAZ12625;
XX
DT 12-OCT-1999 (first entry)
XX
DE Human gene expression product cDNA sequence SEQ ID NO:94.
XX
KW Human; gene; gene expression product; diagnosis; therapy; probe;
KW detection; mapping; tissue typing; profiling; forensic; cancer;
KW genetic analysis; colorectal cancer; breast cancer; lung cancer; ss.
XX
OS Homo sapiens.
XX
XN WO9938972-A2.
PN
XX
PD 05-AUG-1999.
XX
PF 28-JAN-1999; 99WO-US001619.
XX
PR 28-JAN-1998; 98US-0072910P.
PR 24-FEB-1998; 98US-0075954P.
PR 31-MAR-1998; 98US-0080114P.
PR 03-APR-1998; 98US-0080515P.
PR 03-APR-1998; 98US-0080666P.
PR 21-OCT-1998; 98US-0105234P.
PR 28-OCT-1998; 98US-0105877P.
XX
PA (CHIR) CHIRON CORP.
PA (HYSB-) HYSBQ INC.
XX
XX
PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
PI Reinhard C, Glese K, Randazzo F, Kennedy GC, Pot D, Kassam A;
PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
PI Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX
XX WPI; 1999-494092/41.
XX
XX
PT Novel human genes and their expression products which are differentially
PT expressed in different cell types.
XX
XX
XX Claim 1; Page 683; 2479pp; English.
XX
XX The present invention describes a library of human polynucleotides
CC comprising the sequences given in AAZ12532 to AAZ17779. Also described is
CC a method of detecting differentially expressed genes correlated with the
CC cancerous state of a mammalian cell, comprising detecting at least one
CC differentially expressed gene product in a test sample from a cell
CC suspected of being cancerous, where the gene product is encoded by one of
CC the 5248 polynucleotide sequences given in AAZ12532 to AAZ17779. The

CC polynucleotides can be used as a source of primers and probes, which can
CC be used for a variety of purpose, e.g. detection of expression levels,
CC mapping, tissue typing or profiling, forensics, genetic analysis and
CC detection of polymorphisms. Polypeptides encoded by the polynucleotides
CC can be used for raising antibodies for experimental, diagnostic and
CC therapeutic purposes. The polynucleotides may also be used to construct
CC arrays for diagnostics (which may be used to determine function of an
CC encoded protein); and to detect differences in expression levels between
CC two cells (e.g. to identify abnormal or diseased tissue in a human, to
CC identify a genetic predisposition or susceptibility to a disease such as
CC cancer). The polynucleotides of the invention are especially used in the
CC diagnosis, prognosis and management of colorectal cancer, breast cancer,
CC and lung cancer. The polynucleotides can also be used to screen for
CC peptide analogues and antagonists
XX
SQ Sequence 300 BP; 41 A; 84 C; 105 G; 68 T; 0 U; 2 Other;

Query Match 1.4%; Score 32.4; DB 1; Length 300;
Best Local Similarity 78.0%; Pred. No. 0.049;
Matches 39; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1103 TGCACCTTGTGAAGT 1152
Db 89 TCCCTAGGCGCGTGCCTGTGCGTGTGCGTGTGCGTGTGTGTGTGTGTGTGTGT 138

RESULT 17
AAC16179
ID AAC16179 standard; cDNA; 254 BP.
XX
AC AAC16179;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein 5' EST, SEQ ID NO: 20254.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-00200610.
XX
PR 26-FEB-1999; 99US-0122487P.
XX
PA (GEST) GENSET.
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX WPI; 2000-500381/45.
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX
XX Claim 1; SEQ ID NO 20254; 71pp + Sequence Listing; English.
XX
XX The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. No ORF has yet been conclusively
CC identified within the present sequence. The 5' ESTs were prepared from
CC total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
CC sequences usually correspond mainly to the 3' untranslated region (UTR)
CC of the mRNA because they are often obtained from oligo-dT primed cDNA
CC libraries. Such ESTs are not well suited for isolating cDNA sequences
CC derived from the 5' ends of mRNAs and even in those cases where longer
CC cDNA sequences have been obtained, the full 5' UTR is rarely included. 5'
CC ESTs are derived from mRNAs with intact 5' ends and can therefore be used
CC to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used in
CC diagnostic, forensic, gene therapy and chromosome mapping procedures.


```
XX 11-APR-2002.
PD 03-AUG-2000; 2000US-00608408.
XX 21-SEP-2000; 2000US-0234687P.
PF 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488900/53.
PI Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human bone marrow.
DR Example 4; SEQ ID NO 20161; 658pp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX bone marrow. They can be used to measure gene expression in bone marrow
XX samples, which may enable the improved diagnosis and treatment of cancers
XX such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX the probes of the invention
XX
XX Sequence 267 BP; 3 A; 151 C; 4 G; 109 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 24.2; DB 1; Length 267;
Best Local Similarity 45.5%; Pred. No. 7.8;
Matches 86; Conservative 0; Mismatches 103; Indels 0; Gaps 0;
QY 1714 CTTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTTTTCATAGTCTCTC 1773
Db 78 CTTCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 137
QY 1774 TGGCTTCTCTGGATGTTTATGCTGGAATATTTAGACTTAACATTTCTTTGACCAAGG 1833
Db 138 TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 197
QY 1834 TATCCATTTCTTCTATCTTGTCTTCTACCTGCTGAGATTCCTCTCTTATCTCTTGTATTC 1893
Db 198 CTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 257
QY 1894 TGTCACTGA 1902
Db 258 TCTCTGGGA 266
RESULT 25
AAK19599
ID AAK19599 standard; DNA; 267 BP.
XX
XX AAK19599;
AC
XX
XX 05-NOV-2001 (first entry)
DT
XX
XX Human brain expressed single exon probe SEQ ID NO: 19590.
DE
XX
XX Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
KW ss.
XX
XX Homo sapiens.
OS
XX
XX WO200157275-A2.
PN
XX
XX 09-AUG-2001.
PD
XX
XX 30-JAN-2001; 2001WO-US000667.
PF
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR
```

```
XX 02-OCT-2001; 2001WO-US0030589.
XX 02-OCT-2000; 2000US-0237054P.
XX (GENE-) GENE LOGIC INC.
PA Horne D, Alvares C, Peres-Da-Silva S, Vockley JG;
XX WPI; 2002-426119/45.
PI Diagnosing and detecting the progression of liver cancer, hepatocellular
XX carcinoma or metastatic liver tumor in a patient, involves detecting the
XX level of expression of two or more genes in a liver tissue sample.
XX
XX Claim 1; SEQ ID NO 3673; 298pp; English.
XX
XX The invention relates to a novel method for diagnosing and detecting the
XX progression of liver cancer, hepatocellular carcinoma or metastatic liver
XX tumour in a patient, and differentiating metastatic liver cancer from
XX hepatocellular carcinoma in a patient, involving detecting the level of
XX expression of two or more genes represented in ABN93503-ABN97455 in a
XX tissue sample. The method of the invention has hepatotropic, and
XX cytotatic activity. The method is useful for diagnosing and detecting
XX the progression of liver cancer, hepatocellular carcinoma and metastatic
XX liver carcinoma in a patient. The method is useful for identifying
XX expression profiles which serve as useful diagnostic markers as well as
XX markers that can be used to monitor disease states, disease progression,
XX drug toxicity, drug efficacy and drug metabolism. Note: The sequence data
XX for this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 1843 BP; 417 A; 530 C; 564 G; 332 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 25.2; DB 1; Length 1843;
Best Local Similarity 55.8%; Pred. No. 6;
Matches 48; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 1157 GTGTGTGTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGTGTC 1216
Db 1838 GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 1779
QY 1217 GCTTGAATTAATTATTATTCATATT 1242
Db 1778 TCTGTGTGTGTTTATTCCTTTT 1753
RESULT 24
AAK45604
ID AAK45604 standard; DNA; 267 BP.
XX
XX AAK45604;
AC
XX
XX 06-NOV-2001 (first entry)
DT
XX
XX Human bone marrow expressed single exon probe SEQ ID NO: 20161.
DE
XX
XX Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
KW
XX
XX Homo sapiens.
OS
XX
XX WO200157276-A2.
PN
XX
XX 09-AUG-2001.
PD
XX
XX 30-JAN-2001; 2001WO-US000668.
PF
XX
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR
```


[illegible]


```

ID  ABQ47966 standard; DNA; 612 BP.
XX
AC  ABQ47966;
XX
DT  12-JUL-2002 (first entry)
XX
DE  Oligonucleotide for detecting cytosine methylation SEQ ID NO 34557.
XX
KW  Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW  drug; side effect; cancer; central nervous system; cardiovascular;
KW  gastrointestinal; respiratory system; single nucleotide polymorphism;
KW  SNP; cell differentiation; ds.
XX
OS  Homo sapiens.
XX
PN  WO200218632-A2.
XX
PD  07-MAR-2002.
XX
PF  01-SEP-2001; 2001WO-EP010074.
XX
PR  01-SEP-2000; 2000DE-01043826.
PR  05-SEP-2000; 2000DE-01044543.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K, Guetig D;
PI  WPI; 2002-371829/40.
XX
DR  WPI; 2002-371829/40.
XX
PT  Determining the degree of cytosine methylation in genomic DNA, useful for
PT  diagnosis and prognosis, comprises selective hybridization of amplicons
PT  from chemically treated DNA.
XX
PS  Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
CC  This invention describes a novel method for determining the degree of
CC  methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC  genomic sample of DNA. The sample is treated chemically to convert
CC  cytosine (C) but not methylated C, to uracil, then part of the genomic
CC  DNA that contains the target C is amplified to form a labeled amplicon.
CC  The amplicon is hybridised to two classes, each with at least one member,
CC  of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC  degree of hybridisation to both classes is determined from the label on
CC  the amplicon. From the ratio of labels hybridised to the two classes of
CC  oligomers, the degree of methylation is calculated. The method is used:
CC  (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC  and of a wide range of diseases, e.g. cancer, disorders of the central
CC  nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC  particularly by detecting mutations or single nucleotide polymorphisms
CC  (SNP's); and (ii) for differentiation of cell or tissue types and for
CC  investigating cell differentiation. The method allows the methylation
CC  status of many C residues to be determined simultaneously. ABQ13410-
CC  ABQ54121 represent genomic DNA sequences used to illustrate the method
CC  for determining the degree of cytosine methylation described in the
CC  disclosure of the invention
XX
SQ  Sequence 612 BP; 88 A; 72 C; 216 G; 236 T; 0 U; 0 Other;

Query Match      1.0%; Score 23.4; DB 1; Length 612;
Best Local Similarity 46.2%; Pred. No. 15;
Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;

QY  1593 GTGGGAGTTCTTTTCGGGTCCAAATCTATTTGGTGTCTTTGTATGCTTCTGTACCTGA 1652
DB  431 GGGGGTCGTTTTTCGTTTCGGGTGATTCGTTTTTTTGGCGGATGTTTTTATTTTAGG 490
QY  1653 TAGGCATCTCTTCTCAAGTTAGGAATTTCTTTTGGTGTCTTTCTTCTGAAAATATTT 1712
DB  491 TAGCGCTTTTTCGTTTCGGGTCTGATCGCGTATGCGGTTTTTATATAGAAAATACGAT 550
QY  1713 CCTGCTTTGACCTGCTCTTCCCTCTCTATCTCTTCTGTTTTT 1761

```

551 TTGTAAGTATATTTAGGGTGTTTTTTTAAATTTTAAAGGAGGATTTT 599
 RESULT 32
 ABQ47967/c
 ID ABQ47967 standard; DNA; 612 BP.
 XX
 AC ABQ47967;
 XX
 DT 12-JUL-2002 (first entry)
 XX
 DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34558.
 XX
 KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
 KW drug; side effect; cancer; central nervous system; cardiovascular;
 KW gastrointestinal; respiratory system; single nucleotide polymorphism;
 KW SNP; cell differentiation; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200218632-A2.
 XX
 PD 07-MAR-2002.
 XX
 PF 01-SEP-2001; 2001WO-EP010074.
 XX
 PR 01-SEP-2000; 2000DE-01043826.
 PR 05-SEP-2000; 2000DE-01044543.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K, Guetig D;
 PI WPI; 2002-371829/40.
 XX
 DR WPI; 2002-371829/40.
 XX
 PT Determining the degree of cytosine methylation in genomic DNA, useful for
 PT diagnosis and prognosis, comprises selective hybridization of amplicons
 PT from chemically treated DNA.
 XX
 PS Claim 12; 56pp + Sequence Listing; 56pp; German.
 XX
 CC This invention describes a novel method for determining the degree of
 CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
 CC genomic sample of DNA. The sample is treated chemically to convert
 CC cytosine (C) but not methylated C, to uracil, then part of the genomic
 CC DNA that contains the target C is amplified to form a labeled amplicon.
 CC The amplicon is hybridised to two classes, each with at least one member,
 CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
 CC degree of hybridisation to both classes is determined from the label on
 CC the amplicon. From the ratio of labels hybridised to the two classes of
 CC oligomers, the degree of methylation is calculated. The method is used:
 CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
 CC and of a wide range of diseases, e.g. cancer, disorders of the central
 CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
 CC particularly by detecting mutations or single nucleotide polymorphisms
 CC (SNP's); and (ii) for differentiation of cell or tissue types and for
 CC investigating cell differentiation. The method allows the methylation
 CC status of many C residues to be determined simultaneously. ABQ13410-
 CC ABQ54121 represent genomic DNA sequences used to illustrate the method
 CC for determining the degree of cytosine methylation described in the
 CC disclosure of the invention
 XX
 SQ Sequence 612 BP; 236 A; 216 C; 72 G; 88 T; 0 U; 0 Other;

Query Match 1.0%; Score 23.4; DB 1; Length 612;
Best Local Similarity 46.2%; Pred. No. 15;
Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;

QY 1593 GTGGGAGTTCTTTTCGGGTCCAAATCTATTTGGTGTCTTTGTATGCTTCTGTACCTGA 1652
DB 431 GGGGGTCGTTTTTCGTTTCGGGTGATTCGTTTTTTTGGCGGATGTTTTTATTTTAGG 490
QY 1653 TAGGCATCTCTTCTCAAGTTAGGAATTTCTTTTGGTGTCTTTCTTCTGAAAATATTT 1712
DB 491 TAGCGCTTTTTCGTTTCGGGTCTGATCGCGTATGCGGTTTTTATATAGAAAATACGAT 123
QY 1653 TAGGCATCTCTTCTCAAGTTAGGAATTTCTTTTGGTGTCTTTCTTCTGAAAATATTT 1712

Db 122 TACGGCTTTTTCGTCGGTGGTATCGGATGTCGTTTATATTAGAAAATACGAT 63
Qy 1713 CCCGCTTTTACCTGCTTCCTCCCTTCCTCTATCTTCTTGGTTTTT 1761
Db 62 TTGTAAGTATATTAGGGTGTCTTTTATATTTTAAAGGGAGTTTTT 14

RESULT 33
AA40850/c
ID AA40850 standard; cDNA; 306 BP.
XX AC
XX AA40850;
XX DT
XX 16-MAR-1997 (first entry)
XX DE
XX Serine protease nSP8-299 gene.
XX Flea; midgut; serine protease; nSP8-299; recombinant vaccine;
XX domestic animal; infestation; insecticide; protease-inhibitor;
XX controlled release formulation; synergist; ss.
XX Siphonaptera sp.
XX OS
XX Key Location/Qualifiers
XX FT 1. .90
XX FT /tag= a
XX FT /note= "back-translated from N-terminal part of PfSP8-99
XX (AAW01205)"
XX FT 91. .276
XX FT /tag= b
XX FT /note= "Corresponds to nSP8-186 (AA40826, claim 70)"
XX FT 277. .299
XX FT /tag= c
XX FT /note= "back-translated from C-terminal part of PfSP8-99
XX (AAW01205)"
XX PN WO9611706-A1.
XX DT 25-APR-1996.
XX PF 18-OCT-1995; 95WO-US014442.
XX PR 18-OCT-1994; 94US-00326773.
XX PR 07-JUN-1995; 95US-00482130.
XX PR 07-JUN-1995; 95US-00484211.
XX PR 07-JUN-1995; 95US-00485443.
XX PR 07-JUN-1995; 95US-00485455.
XX PA (HESK-) HESKA CORP.
XX PI Grieve RB, Rushlow KE, Hunter SW, Frank GR, Stiegler GL, Heath A;
XX Yamanaka M, Arfsten A, Dale B;
XX WPI; 1996-221762/22.
XX DR P-PSDB; AAW01205.
XX PT DNA encoding Flea serine protease and aminopeptidase - useful in vaccines
XX to protect animals from flea infestation.
XX PS Claim 70; Page 182; 241pp; English.
XX This sequence (nSP8-299) encodes a flea midgut serine protease (PfSP8-
XX 99), and has been isolated from a flea cDNA library by PCR using primers
XX AA40862-63 and hybridisation with probe AA40866, based on conserved
XX serine protease sequences. The sequence contains sequence AA40826 (nSP8
XX -186), which spans 2 conserved serine protease sequences. The sequence
XX shown has been derived from the encoded protein sequence (N- and C-
XX terminal regions) and internal sequence AA40826, since the appropriate
XX page is missing from the specification. The sequence may be used to
XX produce a recombinant vaccine for protection of domestic animals from
XX flea infestation, or in isolation of protease-inhibitors which may be
XX used in controlled release formulations to reduce the flea burden on and

CC around the animal. The inhibitors may be included in insecticidal
CC compositions to increase efficacy of other active compounds, by reducing
CC proteolytic activity in the flea midgut
XX Sequence 306 BP; 83 A; 30 C; 72 G; 56 T; 0 U; 65 Other;
SQ Query Match 1.0%; Score 23; DB 1; Length 306;
Best Local Similarity 58.5%; Pred. No. 17;
Matches 38; Conservative 1; Mismatches 26; Indels 0; Gaps 0;
Qy 248 CCAGGTAGGGGACACTCCGCAATTCCTCTCTTCCAAAACATCTTATTTCTGATTTC 307
Db 280 CYTGCAAGTGTCTTTTCCACATCAATTCCTCTGACACATCTGTGTTTCTACATTC 221
Qy 308 TATCT 312
Db 220 CATTT 216

RESULT 34
AAA54031/c
ID AAA54031 standard; DNA; 1507 BP.
XX AC
XX AAA54031;
XX DT 08-FEB-2001 (first entry)
XX DE Human factor X coding sequence.
XX KW Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;
XX fusion protein; coagulation factor; Factor X; Factor VII; Protein S;
XX Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
XX ds.
XX OS Homo sapiens.
XX PN WO200054787-A1.
XX PD 21-SEP-2000.
XX PF 16-MAR-2000; 2000WO-US006934.
XX PR 16-MAR-1999; 99US-0124609P.
XX PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX (UUNC-) UNIV NORTH CAROLINA.
XX PI High KA, Camire RM, Larson PJ, Stafford DW;
XX WPI; 2000-638152/61.
XX Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent
XX protein useful for treating diseases associated with the protein,
XX comprises sequence encoding propeptide fused to sequence encoding the
XX protein.
XX Disclosure; Fig 6a; 60pp; English.
XX Efficient processing and release of mature two-chain factor X into the
XX circulation requires: removal of the signal sequence; formation of
XX disulfide bonds; modification of amino terminal glutamic acid residues,
XX to gamma-carboxylglutamic acid; modification of one aspartic acid in the
XX first epidermal growth factor (EGF) domain to Beta-hydroxyaspartic acid;
XX addition of N- and O-linked oligosaccharides to the activation peptide;
XX removal of an internal tripeptide to yield two-chain factor X and removal
XX of the propeptide just prior to secretion. While some of these
XX modifications do not appear essential for factor X function the removal
XX of the signal sequence, propeptide, internal tripeptide and full gamma-
XX carboxylation are all steps which are important requisites for the
XX production of biologically active factor X/FXA. Isolated chimeric
XX polynucleotides are described which encode a propeptide fused to a
XX nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The
XX fusion proteins encoded are vitamin K-dependent protein gamma-

disclosure, SEQ ID NO 81; 346pp; English.

The invention relates to a method of determining whether a patient will respond to treatment with a farnesyl transferase inhibitor (FTI), by analyzing the expression of gene that is differentially modulated in the presence of the inhibitor.

XX WO200136440-A1.
XX 25-MAY-2001.
XX 15-NOV-2000; 2000WO-US031282.
XX 19-NOV-1999; 99US-0166414P.
XX 21-JUL-2000; 2000US-0219665P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Komatsoulis GA, Birse CE, Moore PA;
XX WPI; 2001-343795/36.
XX P-PSDB; AAE03821.
XX Isolated nucleic acid molecule encoding a human secreted protein is used
XX in preventing, treating or ameliorating a medical condition.
XX Claim 1; Page 440-441; 553pp; English.
XX AAD08283-AAD08355 represent cDNAs corresponding to 23 human secreted
XX protein genes, and AAE03818-AAE03870 represent the proteins they encode.
XX AAE03871-AAE03896 represent human secreted protein fragments or variants.
XX The secreted proteins and their genes are useful for preventing, treating
XX or ameliorating medical conditions, e.g., by protein or gene therapy.
XX Pathological conditions can be diagnosed by determining the amount of the
XX new protein in a sample or by determining the presence of mutations in
XX the new genes. Specific uses are described for each of the 23 genes,
XX based on the tissues in which they are most highly expressed, and include
XX developing products for the diagnosis or treatment of proliferative
XX disorders, cancer, tumors, foetal and developmental abnormalities,
XX haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
XX diseases (e.g., rheumatoid arthritis), inflammation, allergies,
XX neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
XX cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
XX psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
XX angiogenic disorders, kidney disorders, gastrointestinal disorders,
XX pregnancy-related disorders, endocrine disorders, and infections. The
XX proteins can also be used to aid wound healing and epithelial cell
XX proliferation, to prevent skin aging due to sunburn, to maintain organs
XX before transplantation, for supporting cell culture of primary tissues,
XX to regenerate tissues, to identify their cognate ligands or binding
XX partners, and in chemotaxis, and can be used as a food additive or
XX preservative to modify storage properties. Antibodies specific for a
XX protein of the invention can be used in alleviating symptoms associated
XX with the disorders mentioned above, and in diagnostic immunoassays e.g.,
XX radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The
XX present sequence represents a human secreted protein-encoding cDNA of the
XX invention
XX SQ Sequence 1151 BP; 252 A; 370 C; 336 G; 193 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.6; DB 1; Length 1151;
Best Local Similarity 53.3%; Pred. No. 24;
Matches 48; Conservative 0; Mismatches 42; Indels 0; Gaps 0;
QY 365 TTTTCTGCTGTTCTGTTGTTGTTATCTAGATTAAAGCTGTGGTGCAGATAG 424
Db 1146 TTTTCTGCTGTTCTGTTGTTGTTATCTAGATTAAAGCTGTGGTGCAGATAG 424
QY 425 GACATAGAGTATTATTTCAATTGCTTTTA 454
Db 1086 GAGAACATTAATAAATAAGGTTATTGA 1057
RESULT 39
AAC71343/c
ID AAC71343 standard; DNA; 271 BP.
XX AAC71343;
XX

DT 09-FEB-2001 (first entry)
XX Single nucleotide polymorphism containing sequence #391.
DE XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; ds.
XX Homo sapiens.
XX WO200058519-A2.
XX 05-OCT-2000.
XX 30-MAR-2000; 2000WO-US008440.
XX 31-MAR-1999; 99US-0127248P.
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX (AFFY-) AFFYMETRIX INC.
XX Altshuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
XX Lipshutz RJ, Patil N, Sklar P;
XX WPI; 2000-611722/58.
XX Nucleic acid selected from one of 106 genes comprising single nucleotide
XX polymorphisms, allele-specific oligonucleotides to the genes are useful
XX for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX Claim 1; Fig 5; 214pp; English.
XX The present invention is concerned with a number of human single
XX nucleotide polymorphisms (SNPs) which the inventors identified in human
XX genes. These SNPs can be used in disease diagnosis and prediction of an
XX individual's susceptibility to disease, in forensic and paternity testing
XX and in genetic mapping. In particular, the SNPs of the invention can be
XX used to diagnose susceptibility to diseases of the cardiovascular,
XX endocrine and neurological systems, such as coronary artery disease,
XX schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX diseases. Note: The degenerate codon within the sequence represents the
XX position of an SNP, for example the letter S represents a polymorphism
XX where the nucleotide may be C or G
XX SQ Sequence 271 BP; 82 A; 43 C; 62 G; 83 T; 0 U; 1 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 271;
Best Local Similarity 50.0%; Pred. No. 24;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTATAGGGTTTACGAGGACATATTGTCCTGGTGTGTTATGTCGTGTTTGTG 2215
Db 114 CCATTAAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTAGAAATTG 55
QY 2216 CTTTGCCATATAGCGGCTGAGTTGGATGATTGTAATTCCTAGGTGCTGAT 2267
Db 54 AATTGGCAGCTAAACTGCTTAGAATGCCCGTCCCTCCCTGTAGACTCAT 3
RESULT 40
AA11531/c
ID AA11531 standard; DNA; 476 BP.
XX AA11531;
XX 12-OCT-2001 (first entry)
XX Probe #1464 for gene expression analysis in human cervical cell sample.
DE Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer; ss.
XX

OS Homo sapiens.
XX WO200157278-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000670.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488901/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human cervical epithelial cells.
XX Claim 25; SEQ ID NO 1464; 487pp; English.
XX The present invention relates to human single exon nucleic acid probes
XX (SENP). The present sequence is one such probe. The SENPs are derived
XX from human HeLa cells. The SENPs can be used to produce a single exon
XX microarray, which can be used for measuring human gene expression in a
XX sample derived from human cervical epithelial cells. By measuring gene
XX expression, the probes are therefore useful in grading and/or staging of
XX diseases of the cervix, notably cervical cancer. Note: The sequence data
XX for this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 26;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTCTAATAGGGTTTACGAGGACATATTCTCTGGTTGTTATTGCTGTTTGG 2215
Db 357 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGACGGCTGAGTTGGGATGATTGTAATTTCTAGGTGCTGAT 2267
Db 297 AATTGGCAGTAACTGCTTAGAATGCCCGTCCCTCCCTGTAGATACATCAT 246
RESULT 41
ABAS3212/c
ID ABAS3212 standard; DNA; 476 BP.
XX AC ABAS3212;
XX 01-FEB-2002 (first entry)
XX Human foetal liver single exon nucleic acid probe #1517.
XX Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX Homo sapiens.
XX WO200157277-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000669.
XX (MOLE-) MOLECULAR DYNAMICS INC.

PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483447/52.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human fetal liver.
XX Claim 1; SEQ ID NO 1517; 639pp + Sequence Listing; English.
XX The invention relates to a single exon nucleic acid probe for measuring
XX human gene expression in a sample derived from human foetal liver. The
XX single exon nucleic acid probes may be used for predicting, measuring and
XX displaying gene expression in samples derived from human fetal liver. The
XX present sequence is a single exon nucleic acid probe of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 26;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTCTAATAGGGTTTACGAGGACATATTCTCTGGTTGTTATTGCTGTTTGG 2215
Db 357 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGACGGCTGAGTTGGGATGATTGTAATTTCTAGGTGCTGAT 2267
Db 297 AATTGGCAGTAACTGCTTAGAATGCCCGTCCCTCCCTGTAGATACATCAT 246
RESULT 42
AAI32810/c
ID AAI32810 standard; DNA; 476 BP.
XX AC AAI32810;
XX 17-OCT-2001 (first entry)
XX Probe #1496 used to measure gene expression in human placenta sample.
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX Homo sapiens.
XX WO200157272-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000663.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI WPI; 2001-488997/53.
DR Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
XX Claim 25; SEQ ID NO 1496; 654pp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP).
CC The present sequence is one such probe. The probes are useful for
CC producing a microarray for predicting, measuring and displaying gene
CC expression in samples derived from human placenta. The probes are useful
CC for antenatal diagnosis of human genetic disorders
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2156 CTATGTAATAGGGTTTAGCAGGACATATGTCCTGGTGTATTCCTGTTGTTTG 2215
Db 357 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGGATGATGTAATTCCTAGTGCTGAT 2267
Db 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246
RESULT 43
ABA42785/c
ID ABA42785 standard; DNA; 476 BP.
AC ABA42785;
XX
XX 01-FEB-2002 (first entry)
XX Human breast cell single exon nucleic acid probe #1480.
XX
XX Human; microarray; single exon probe; gene expression; breast; disease;
XX cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
PT for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
XX Claim 1; SEQ ID NO 1480; 327pp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon

CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting the
CC probes with a collection of detectably labelled nucleic acids derived
CC from mRNA of human breast, and then measuring the label bound to each
CC probe of the microarray. The probes are useful for verifying the
CC expression of regions of genomic DNA predicted to encode proteins. They
CC are useful for gene discovery, and for determining predisposition and/or
CC assessing breast disease. Gene expression analysis is useful for
CC this invention presents a far greater diversity of probes for measuring
CC gene expression, with far less bias than expressed sequence tag
CC microarrays. The method is suitable for rapid production of functional
CC information from genomic sequence. The present sequence is a single exon
CC nucleic acid probe of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2156 CTATGTAATAGGGTTTAGCAGGACATATGTCCTGGTGTATTCCTGTTGTTTG 2215
Db 357 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGGATGATGTAATTCCTAGTGCTGAT 2267
Db 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246
RESULT 44
ABA22986/c
ID ABA22986 standard; DNA; 476 BP.
AC ABA22986;
XX
XX 23-JAN-2002 (first entry)
XX
XX Probe #1452 for gene expression analysis in human heart cell sample.
XX
XX Human; gene expression; heart; microarray; vascular system; probe;
XX cardiovascular disease; hypertension; cardiac arrhythmia;
XX congenital heart disease; ss.
XX
XX Homo sapiens.
XX
XX WO200157274-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488999/53.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX hearts.
XX
XX Claim 1; SEQ ID NO 1452; 530pp; English.

XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: the sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACGAGGACATATTGCTCGTGTGTTATTCTGTGTTTGG 2215
DB 357 CCATTTAAACATGATGGATCGATCCACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGCGCTGAGTTTGGGATGATTGTAATTTAGGTGCTGAT 2267
DB 297 AATTGGCAGTAACTGCTTAGAATGCCCGGTCCTCCCTGTAGATCTCAT 246
RESULT 45
AAK26907/c
ID AAK26907 standard; DNA; 476 BP.
XX
AC AAK26907;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed single exon probe SEQ ID NO: 1464.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
XX Example 4; SEQ ID NO 1464; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of

CC the probes of the invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACGAGGACATATTGCTCGTGTGTTATTCTGTGTTTGG 2215
DB 357 CCATTTAAACATGATGGATCGATCCACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
QY 2216 CTTTGGCATATAGCGCTGAGTTTGGGATGATTGTAATTTAGGTGCTGAT 2267
DB 297 AATTGGCAGTAACTGCTTAGAATGCCCGGTCCTCCCTGTAGATCTCAT 246
RESULT 46
AAK01461/c
ID AAK01461 standard; DNA; 476 BP.
XX
AC AAK01461;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe SEQ ID NO: 1452.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
XX Example 4; SEQ ID NO 1452; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTACGAGGACATATTGCTCGTGTGTTATTCTGTGTTTGG 2215


```
Db 357 CCAATTAAACATGGATTGGACTCACCACATGATCTCCATCTTTGAGATAGGTTAAGAATTG 298
Qy 2216 CTTTGGCATATAGACGGCTGAGTTGGAGATGATTTGTAATTTAGTGTGCTGAT 2267
Db 297 AATTGGCAGGTAAACTGCTTAGAATGCCGGTCCCTCCCTCTAGATACTCAT 246

RESULT 47
ID ABS26497 standard; DNA; 476 BP.
XX AC ABS26497;
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID No 1487.
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.
XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX DR Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human adult liver.
XX PS Claim 1; SEQ ID NO 1487; 658pp; English.
XX CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX CC measuring human gene expression in a sample derived from human adult
XX CC liver, comprising one of 13109 defined nucleotide sequences given in the
XX CC specification (or complements/ fragments). The probe hybridises at high
XX CC stringency to a nucleic acid molecule expressed in the human adult liver.
XX CC (I) may be used for predicting, measuring and displaying gene expression
XX CC in samples derived from human adult liver. The genes identified may be
XX CC involved in genetic liver diseases such as cirrhosis,
XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX CC associated with coronary heart disease. ABS25011-ABS51005 represent human
XX CC liver single exon nucleic acid probes of the invention. Note: The
XX CC sequence information for this patent does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2156 CTAATGTAATAGGGTTTACGAGGACATATGCTCGTGTGTTGTTCTGTTGTTTGG 2215
Db 357 CCAATTAAACATGGATTGGACTCACCACATGATCTCCATCTTTGAGATAGGTTAAGAATTG 298

RESULT 48
ID AAI01449 standard; DNA; 476 BP.
XX AC AAI01449;
XX DT 09-OCT-2001 (first entry)
XX DE Probe #1440 used to measure gene expression in human breast sample.
XX KW Probe; human; breast disease; breast cancer; development disorder; ss;
XX KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX OS Homo sapiens.
XX PN WO200157270-A2.
XX PD 09-AUG-2001.
XX PF 29-JAN-2001; 2001WO-US000661.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX DR Novel single exon nucleic acid probe used to measuring gene expression in
XX PT a human breast.
XX PS Claim 25; SEQ ID NO 1440; 322pp; English.
XX CC The present invention relates to novel single exon nucleic acid probes.
XX CC The present sequence is one such probe. The probes are useful for
XX CC measuring human gene expression in a human breast sample, where the probe
XX CC hybridises at high stringency to a nucleic acid expressed in the human
XX CC breast. The probes are useful for predicting, diagnosing, grading,
XX CC staging, monitoring and prognosing diseases of the human breast,
XX CC particularly those diseases with polygenic aetiology. The diseases
XX CC include: breast cancer, disorders of development, inflammatory diseases
XX CC of the breast, fibrocystic changes, proliferative breast disease and non-
XX CC carcinoma tumours. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2156 CTAATGTAATAGGGTTTACGAGGACATATGCTCGTGTGTTGTTCTGTTGTTTGG 2215
Db 357 CCAATTAAACATGGATTGGACTCACCACATGATCTCCATCTTTGAGATAGGTTAAGAATTG 298

RESULT 49
ID AAI01449 standard; DNA; 476 BP.
XX AC AAI01449;
XX DT 09-OCT-2001 (first entry)
XX DE Probe #1440 used to measure gene expression in human breast sample.
XX KW Probe; human; breast disease; breast cancer; development disorder; ss;
XX KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX OS Homo sapiens.
XX PN WO200157270-A2.
XX PD 09-AUG-2001.
XX PF 29-JAN-2001; 2001WO-US000661.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX DR Novel single exon nucleic acid probe used to measuring gene expression in
XX PT a human breast.
XX PS Claim 25; SEQ ID NO 1440; 322pp; English.
XX CC The present invention relates to novel single exon nucleic acid probes.
XX CC The present sequence is one such probe. The probes are useful for
XX CC measuring human gene expression in a human breast sample, where the probe
XX CC hybridises at high stringency to a nucleic acid expressed in the human
XX CC breast. The probes are useful for predicting, diagnosing, grading,
XX CC staging, monitoring and prognosing diseases of the human breast,
XX CC particularly those diseases with polygenic aetiology. The diseases
XX CC include: breast cancer, disorders of development, inflammatory diseases
XX CC of the breast, fibrocystic changes, proliferative breast disease and non-
XX CC carcinoma tumours. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2156 CTAATGTAATAGGGTTTACGAGGACATATGCTCGTGTGTTGTTCTGTTGTTTGG 2215
Db 357 CCAATTAAACATGGATTGGACTCACCACATGATCTCCATCTTTGAGATAGGTTAAGAATTG 298
```

analysis, and for identifying exons in a gene, particularly using human lung derived mRNA and for the study of lung diseases such as asthma, lung cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, primary ciliary dyskinesia, lymphangioleiomyomatosis, pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary dyskinesia, pulmonary hypertension and hyaline membrane disease. The present sequence is a single exon probe of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 1.0%; Score 22.4; DB 1; Length 476; Best Local Similarity 50.0%; Pred. No. 26; Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

2156 CTATTGTAATAGGGTTTGTAGCAGGACATATTGCTCGTGTGTTATTGTCGTGTTTGTG 2215
|||||
357 CCAITTAACATGGATTGACATCACTGATCTCATCTTTGAGATAGTTAAGAAATTG 298
|||||
2216 CTTTGGCATATAGACGGCTGAGTTTGGGATGATGTAATTCTAGTGTGAT 2267
|||||
297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACATCAT 246
|||||

RESULT 50
AAC20296
ID AAC20296 standard; cDNA; 223 BP.
AC AAC20296;
XX
XX 06-OCT-2000 (first entry)
DT
DE Human secreted protein 5' EST, SEQ ID NO: 24371.
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX
XX Homo sapiens.
XX
XX EP1033401-A2.
XX
XX 06-SEP-2000.
XX
XX 21-FEB-2000; 2000EP-00200610.
XX
XX 26-FEB-1999; 99US-0122487P.
XX (GIST) GENSET.
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX WPI; 2000-500381/45.
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
XX obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
XX diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX
XX Claim 1; SEQ ID NO 24371; 71pp + Sequence Listing; English.
XX
XX The present sequence is one of a large number of 5' ESTs derived from
XX mRNAs encoding secreted proteins. No ORF has yet been conclusively
XX identified within the present sequence. The 5' ESTs were prepared from
XX total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
XX sequences usually correspond mainly to the 3' untranslated region (UTR)
XX of the mRNA because they are often obtained from oligo-dT primed cDNA
XX libraries. Such ESTs are not well suited for isolating cDNA sequences
XX derived from the 5' ends of mRNAs and even in those cases where longer
XX cDNA sequences have been obtained, the full 5' UTR is rarely included.

CC lung derived mRNA and for the study of lung diseases such as asthma, lung cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, primary ciliary dyskinesia, lymphangioleiomyomatosis, pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary dyskinesia, pulmonary hypertension, and hyaline membrane disease.

Human genome-derived single exon probe from lung SEQ ID No 1497.

Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesia; pulmonary hypertension;
KW hyaline membrane disease.

Homo sapiens.
WO200186003-A2.
15-NOV-2001.
30-JAN-2001; 2001WO-US000665.
04-FEB-2000; 2000US-0180312P.
26-MAY-2000; 2000US-0207456P.
30-JUN-2000; 2000US-00608408.
03-AUG-2000; 2000US-00632366.
21-SEP-2000; 2000US-0234687P.
27-SEP-2000; 2000US-0236359P.
04-OCT-2000; 2000GB-00024263.
(MOLE-) MOLECULAR DYNAMICS INC.
Penn SG, Hanzel DK, Chen W, Rank DR;
WPI; 2002-114183/15.
Spatially-addressable set of single exon nucleic acid probes, used to measure gene expression in human lung samples.
Claim 1; SEQ ID NO 1497; 634pp; English.
The invention relates to a spatially-addressable set of single exon nucleic acid probes for measuring gene expression in a sample derived from human lung comprising single exon nucleic acid probes having one of 12614 nucleic acid sequences mentioned in the specification, or their complements or the 12387 open reading frames derived from the 12614 probes. Also included are a microarray comprising the novel set of probes; the novel set of probes which hybridise at high stringency to a nucleic acid expressed in the human lung; measuring gene expression in a sample derived from human lung, comprising (a) contacting the array with a collection of detectably labeled nucleic acids derived from human lung mRNA, and (b) measuring the label detectably bound to each probe of the array; identifying exons in a eukaryotic genome, comprising (a) algorithmically predicting at least one exon from genomic sequences of the eukaryote; and (b) detecting specific hybridisation of detectably labeled nucleic acids from eukaryotic lung mRNA, to a single exon probe, having a fragment identical to the predicted exon, the probe is included in the above mentioned microarray; assigning exons to a single gene, comprising (a) identifying exons from genomic sequence by the method above and (b) measuring the expression of each of the exons in several tissues and/or cell types using hybridisation to a single exon microarrays having a probe with the exon, where a common pattern of expression of the exons in the tissues and/or cell types indicates that the exons should be assigned to a single gene; a peptide comprising one of 12011 sequences, mentioned in the specification, or encoded by the probes/open reading frames (ORF). The probes are used for gene expression


```
Db          217 TCTAGCT 211
|||
RESULT 53
AAI44871/c
ID AAI44871 standard; DNA; 301 BP.
XX
XX
AC AAI44871;
XX
XX 17-OCT-2001 (first entry)
XX
XX Probe #13557 used to measure gene expression in human placenta sample.
XX
XX Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX
XX Homo sapiens.
XX
XX WO200157272-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48897/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human placenta.
XX
XX Claim 25; SEQ ID NO 13557; 654pp; English.
XX
XX The present invention relates to single exon nucleic acid probes (SENP).
XX The present sequence is one such probe. The probes are useful for
XX producing a microarray for predicting, measuring and displaying gene
XX expression in samples derived from human placenta. The probes are useful
XX for antenatal diagnosis of human genetic disorders
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCGGCTTCTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCNGGCTT 1779
Db 277 TCTCGCGCTGTACCTCTCGCCTCAATTTCTTCCCTCTCTCCTCTCTCTGCGCT 218
QY 1780 CCTGGAT 1786
Db 217 TCTAGCT 211
|||
RESULT 54
ABA46822/c
ID ABA46822 standard; DNA; 301 BP.
XX
XX
AC ABA46822;
XX
XX 01-FEB-2002 (first entry)
XX
XX
```

```
DE
XX
XX Human breast cell single exon nucleic acid probe #5517.
XX
XX Human; microarray; single exon probe; gene expression; breast; disease;
XX cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
XX for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
XX Claim 4; SEQ ID NO 5517; 327pp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human breast and BT 474 cells. The method involves contacting the
XX probes with a collection of detectably labelled nucleic acids derived
XX from mRNA of human breast, and then measuring the label bound to each
XX probe of the microarray. The probes are useful for verifying the
XX expression of regions of genomic DNA predicted to encode proteins. They
XX are useful for gene discovery, and for determining predisposition and/or
XX prognosing breast disease. Gene expression analysis is useful for
XX assessing the toxicity of chemical agents on cells. The microarray of
XX this invention presents a far greater diversity of probes for measuring
XX gene expression, with far less bias than expressed sequence tag
XX microarrays. The method is suitable for rapid production of functional
XX information from genomic sequence. The present sequence is a single exon
XX nucleic acid probe of the invention. Note: The sequence data for this
XX patent did not form part of the printed specification, but was obtained
XX in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCGGCTTCTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCNGGCTT 1779
Db 277 TCTCGCGCTGTACCTCTCGCCTCAATTTCTTCCCTCTCTCCTCTCTCTGCGCT 218
QY 1780 CCTGGAT 1786
Db 217 TCTAGCT 211
|||
RESULT 55
ABA31826/c
ID ABA31826 standard; DNA; 301 BP.
XX
XX
AC ABA31826;
XX
XX
```



```
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX SQ
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCTGCTTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1779
Db 277 TCTGCGCTGTACCTCGCCTCAATTTCTTCCCTCTCTCTCTCTCTCTCTCT 218
QY 1780 CTTGGAT 1786
Db 217 TCTAGCT 211
RESULT 58
ABS38453/c
ID ABS38453 standard; DNA; 301 BP.
XX AC ABS38453;
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID No 13443.
XX Human; single exon nucleic acid probe; liver; cirrhosis;
XX hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX coronary heart disease; ss.
XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX SQ
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 27;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1720 TTGACCTGCTTCCCTCCCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1779
Db 277 TCTGCGCTGTACCTCGCCTCAATTTCTTCCCTCTCTCTCTCTCTCTCTCT 218
QY 1780 CTTGGAT 1786
Db 217 TCTAGCT 211
RESULT 59
AAI05395/c
ID AAI05395 standard; DNA; 301 BP.
XX AC AAI05395;
XX DT 09-OCT-2001 (first entry)
XX DE Probe #5386 used to measure gene expression in human breast sample.
XX Probe; human; breast disease; breast cancer; development disorder; ss;
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX OS Homo sapiens.
XX PN WO200157270-A2.
XX PD 09-AUG-2001.
XX PF 29-JAN-2001; 2001WO-US000661.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX PA
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX Claim 4; SEQ ID NO 13443; 658pp; English.
XX The invention relates to a single exon nucleic acid probe (SEN) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis,
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABG25011-ABS51005 represent human
XX liver single exon nucleic acid probes of the invention. Note: The
XX sequence information for this patent does not appear in the printed
XX specification but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
```


Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic; antilipemic; ss.

Homo sapiens.

WO200173002-A2.

04-OCT-2001.

27-MAR-2001; 2001WO-US009761.

27-MAR-2000; 2000US-0192176P.

27-MAR-2000; 2000US-0192179P.

01-JUN-2000; 2000US-0208538P.

30-OCT-2000; 2000US-0244989P.

(UYDE) UNIV DELAWARE.

Kmiec EB, Gamper HB, Rice MC;

WPI; 2001-639230/73.

Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.

Claim 7; Page 184; 294pp; English.

The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGTCCTGGTGTGTTATTGTTGTTTGG 2215
DB 88 CCATTAAACATGATGGACTCACACTGTCCTCACTTTGAGTAGGTTAAGAAATTG 29

QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 28 AATTGGCAGCTAACTGCTTAGAATG 3

RESULT 62
ID ABA79623
XX ID ABA79623 standard; DNA; 121 BP.
AC ABA79623;

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic; antilipemic; ss.

Homo sapiens.

WO200173002-A2.

04-OCT-2001.

27-MAR-2001; 2001WO-US009761.

27-MAR-2000; 2000US-0192176P.

27-MAR-2000; 2000US-0192179P.

01-JUN-2000; 2000US-0208538P.

30-OCT-2000; 2000US-0244989P.

(UYDE) UNIV DELAWARE.

Kmiec EB, Gamper HB, Rice MC;

WPI; 2001-639230/73.

Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.

Claim 7; Page 184; 294pp; English.

The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGTCCTGGTGTGTTATTGTTGTTTGG 2215
DB 88 CCATTAAACATGATGGACTCACACTGTCCTCACTTTGAGTAGGTTAAGAAATTG 29

QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 28 AATTGGCAGCTAACTGCTTAGAATG 3

RESULT 62
ID ABA79623
XX ID ABA79623 standard; DNA; 121 BP.
AC ABA79623;

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic; antilipemic; ss.

Homo sapiens.

WO200173002-A2.

04-OCT-2001.

27-MAR-2001; 2001WO-US009761.

27-MAR-2000; 2000US-0192176P.

27-MAR-2000; 2000US-0192179P.

01-JUN-2000; 2000US-0208538P.

30-OCT-2000; 2000US-0244989P.

(UYDE) UNIV DELAWARE.

Kmiec EB, Gamper HB, Rice MC;

WPI; 2001-639230/73.

Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.

Claim 7; Page 184; 294pp; English.

The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2156 CTATTGTAATAGGTTTACGAGGACATATTGTCCTGGTGTGTTATTGTTGTTTGG 2215
DB 88 CCATTAAACATGATGGACTCACACTGTCCTCACTTTGAGTAGGTTAAGAAATTG 29

QY 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
DB 28 AATTGGCAGCTAACTGCTTAGAATG 3

RESULT 62
ID ABA79623
XX ID ABA79623 standard; DNA; 121 BP.
AC ABA79623;

RESULT 63	
ABA79622/c	
ID	ABA79622 standard; DNA, 121 BP.
XX	
AC	ABA79622;
XX	
DT	24-JAN-2002 (first entry)
XX	
DE	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2468.
XX	
KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW	Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW	antileptic; ss.
XX	
OS	Homo sapiens.
XX	
FN	WO200173002-A2.
XX	
PD	04-OCT-2001.
XX	
XX	27-MAR-2001; 2001WO-US009761.
PF	
XX	
PR	27-MAR-2000; 2000US-0192176P.
XX	
PR	27-MAR-2000; 2000US-0192179P.
XX	
PR	01-JUN-2000; 2000US-0208538P.
XX	
PR	30-OCT-2000; 2000US-0244989P.
XX	
XX	
PA	(UYDE) UNIV DELAWARE.
XX	
XX	
PI	Kmiec EB, Gamper HB, Rice MC;
XX	
DR	WPI; 2001-639230/73.
XX	
PT	Oligonucleotide for targeted alterations of genetic sequences and for
PT	treating cystic fibrosis, comprises at least one mismatch and chemical
PT	modification.
XX	
XX	
PS	Claim 7; Page 184; 294pp; English.
XX	
CC	The present invention provides single-stranded oligonucleotides which can
CC	be used for the targeted alteration of genomic sequences, where the
CC	oligonucleotide has at least one mismatch compared with the genomic
CC	sequence to be altered. In particular, these sequences are directed at
CC	the following genes: adenosine deaminase, p53, beta-globin,
CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC	(CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC	various syndromes. The present sequence is one of the gene correcting
CC	oligonucleotides of the invention
XX	
SQ	Sequence 121 BP: 37 A; 23 C; 24 G; 37 T; 0 U; 0 Other:

	Query Match	1.0%	Score 22	DB 1	Length 121
	Best Local Similarity	53.5%	Pred.No. 26		
	Matches 46	Conservative 0	Mismatches 40	Indels 0	Gaps 0
QY	2156	CTATTGTAATAGGTTTTAGCAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTTTG	2215		
Db	87	CCATTTAAACATGGATGGAACTACACATGATCTTCATCTTTGACATAGGTTAAGAAATTC	28		

QY	2216	CTTTGGCATATAGACGCGCTGAGTTG	2241
Db	27	AATTGGCAACGTAAACTGCTTGAATG	2
RESULT 64			
ABA79634/C			
ID	ABA79634	standard; DNA; 121 BP.	
XX			
AC	ABA79634;		
XX			
DT	24-JAN-2002	(first entry)	
XX			
DE	Factor IX mutation correcting oligonucleo-		
XX			
KW	Human; gene therapy; adenosine deaminase		
KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic		
KW	cystic fibrosis; cyclin-dependent kinase inhibitor 2A; CDH1		
KW	adenomatous polyposis of the colon; Factor IX		
KW	haemophilia; alpha thalassemia; haemoglobin		
KW	mismatch repair; MSH2; MSH6; hyperlipidaemia		
KW	familial hypercholesterolaemia; UGT1; syndrome		
KW	UDP-glucuronosyltransferase; amyloid precursor		
KW	Alzheimer's disease; cytosstatic; antitoxic		
KW	antileptic; ss.		
XX			
OS	Homo sapiens.		
XX			
FN	WO200173002-A2.		
XX			
PD	04-OCT-2001.		
XX			
PF	27-MAR-2001; 2001WO-US0039761.		
XX			
PR	27-MAR-2000; 2000US-0192176P.		
FR	27-MAR-2000; 2000US-0192179P.		
PR	01-JUN-2000; 2000US-0208538P.		
PR	30-OCT-2000; 2000US-0244989P.		
XX			
PA	(UYDE) UNIV DELAWARE.		
XX			
Pf	Kniec EB, Gamper HB, Rice MC;		
XX			
DR	WPI; 2001-639230/73.		
XX			
PT	Oligonucleotide for targeted alterations		
PT	treating cystic fibrosis, comprises at least		
PT	modification.		
XX			
PS	Claim 7; Page 184; 294pp; English.		
XX			
CC	The present invention provides single-strand		
CC	be used for the targeted alteration of ge-		
CC	oligonucleotide has at least one mismatch		
CC	sequence to be altered. In particular, the		
CC	following genes: adenosine deaminase,		
CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-		
CC	(CDKN2A), APC, Factor V, Factor VIII, Fac-		
CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2)		
CC	apolipoprotein E (APOE), LDL receptor (LDL		
CC	(UGT1), amyloid precursor protein (APC),		
CC	prenilin-2 (PSEN2). These can be used i		
CC	such as cancer, adenosine deaminase defic		
CC	haemophilia, hypercholesterolaemia, thal		
CC	Alzheimer's disease, melanoma, adenomatou		
CC	various syndromes. The present sequence i		
CC	oligonucleotides of the invention		
XX			
QQ	Sequence 121 BP; 37 A; 23 C; 23 G; 38 T;		

```
Query Match      1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
```

Qy	2156	CTATTGTAAATAGGTTTACAGGGACATATTGCTCTGGTGTGTTATGCTGTGTTTGTG	2215
Db	86	CCATTTAAACATGAATGGACTCACCTGAATCTCCATCTTTGAGATAGTTAGAAATTTG	27
Qy	2216	CTTTGGCATATAGACGGCTGAGTTG	2241
Db	26	AAATTGGCACGTAAACTGCTTAGAATG	1

RESULT 65
ABA79627
ID ABA79627 standard; DNA; 121 BP.
XX
XX ABA79627;
XX AC
XX AC
XX DT
24-JAN-2002 (first entry)
XX
XX
Factor IX mutation correcting oligonucleotide SEQ ID NO: 2473.

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CTRR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGL1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antickling; antinaemic; haemostatic; antileptic; ss.

OS	Homo sapiens.
XX	
PN	WO200173002-A2.
XX	
PD	04-OCT-2001.

XX	27-MAR-2001;	2001WO-US009761.
PF		
XX		
PR	27-MAR-2000;	2000US-0192176P.
PR	27-MAR-2000;	2000US-0192179P.
PR	01-JUN-2000;	2000US-0208538P.
PR	30-OCT-2000;	2000US-0244989P.

AA (UYDE) UNIV DELAWARE.
PA

PI Kniec EB. Gamber HB. Rice MC:

WPI: 2001-639230/73.

PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.

PS Claim 7; Page 184; 294pp; English.

The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CTRF, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention.

Sequence 121 BP: 37 A; 25 C; 23 G; 36 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels

Qy 2156 CTAATTGTAATAGGGTTTTAGCAGGGACATATGTCCTGGTGTGTTATGTCGTGTTTTTG 2215

ph 34 CCAATTTAAACATGGATTGGCACTCACACGTATCTCCATCTTTGAGATAGGTTAAGAAATTG 93

Qy 2216 CTTTGGCATATAGACGGCTGAGTTTG 2241
||| ||| ||| ||| ||| |||
nb 94 ATTGGCAGTAACCTGTAGAATG 119

RESULT 66
ABA79631
ID ABA79631 standard: DNA: 121 BP.

AC ABA79631:

24-JAN-2002 (first entry)

Factor IX mutation correcting oligonucleotide SEQ ID NO: 2477.

Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CTRR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGL1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic; antileptic; ss.

OS Homo sapiens.

PN WO200173002-A2.

PD 04-OCT-2001.

PF 27-MAR-2001; 2001WO-US009761.

PR 27-MAR-2000; 2000US-0192176P.

PR 01-JUN-2000; 2000US-0208538P.

100

XX

XX

XX

PT treating cystic fibrosis, comprises at least one mismatch and chemical PT modification.

PS Claim 7; Page 184; 294pp; English.

The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFT8, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
SQ Sequence 121 BP; 37 A; 26 C; 23 G; 35 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATGCTCTGTTGTTATGTCGTGTTTGG 2215
DB 33 CCAATTAAACATGATTGGACTCACACTGCTCCTCACTCTTTGAGATAGGTTAAGAAATG 92
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
DB 93 AATTGGCAGCTAAACTGCTTAGAATG 118
RESULT 67
ABA79635
ID ABA79635 standard; DNA; 121 BP.
XX ABA79635;
XX
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2481.
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
XX antileptic; ss.
XX Homo sapiens.
XX
XX
XX PN WO200173002-A2.
XX
XX PD 04-OCT-2001.
XX
XX PF 27-MAR-2001; 2001WO-US009761.
XX
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX
XX PA (UYDE) UNIV DELAWARE.
XX
XX PI Kmiec EB, Gamper HB, Rice MC;
XX
XX DR WPI; 2001-639230/73.
XX
XX PT Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX PS Claim 7; Page 184; 294pp; English.
XX
XX CC The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus

CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
SQ Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGTTTACGAGGACATATGCTCTGTTGTTATGTCGTGTTTGG 2215
DB 36 CCAITTAACATGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATG 95
QY 2216 CTTTGGCATATAGCGCTGAGTTG 2241
DB 96 AATTGGCAGCTAAACTGCTTAGAATG 121
RESULT 68
ABA79638/c
ID ABA79638 standard; DNA; 121 BP.
XX ABA79638;
XX
XX 24-JAN-2002 (first entry)
XX
XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2484.
XX
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
KW antileptic; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200173002-A2.
XX
XX PD 04-OCT-2001.
XX
XX PF 27-MAR-2001; 2001WO-US009761.
XX
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX
XX PA (UYDE) UNIV DELAWARE.
XX
XX PI Kmiec EB, Gamper HB, Rice MC;
XX
XX DR WPI; 2001-639230/73.
XX
XX PT Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX PS Claim 7; Page 185; 294pp; English.
XX
XX CC The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the

[illegible]

XX Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
PT genetic analysis.
XX
PS Claim 1; Fig 5; 214pp; English.
XX
CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases. Note: The degenerate codon within the sequence represents the
CC position of an SNP, for example the letter S represents a polymorphism
CC where the nucleotide may be C or G
XX
SQ Sequence 253 BP; 92 A; 41 C; 58 G; 61 T; 0 U; 1 Other;
Query Match 1.0%; Score 21.6; DB 1; Length 253;
Best Local Similarity 53.6%; Pred. No. 39;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
Qy 1629 TTTTGTATGCTTCTTGACCTTGATAGGCATCTCTTCTCAAGTTAGGAATTTTCTT 1688
Db 141 TATGGGTATTTTATGCTCTGTATCTCTTCTGGCACTCTTCGTGTCACTAAGGGTA 82
Qy 1689 TTTTGGTTTCTTGAAATATTTT 1712
Db 81 TCTTGGCTTCTGGAGAGATTTT 58
RESULT 75
ABV98470/c
ID ABV98470 standard; cDNA; 254 BP.
AC ABV98470;
XX
DT 14-JAN-2003 (first entry)
DE Human pancreatic cancer expressed cDNA SEQ ID NO 3878.
XX
XX Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW cytosstatic; tumour; gene; ss.
OS Homo sapiens.
XX
PN WO200260317-A2.
XX
PD 08-AUG-2002.
XX
PF 30-JAN-2002; 2002WO-US0002781.
XX
PR 30-JAN-2001; 2001US-0265305P.
PR 31-JAN-2001; 2001US-0265882P.
PR 09-FEB-2001; 2001US-0267568P.
PR 21-MAR-2001; 2001US-0278651P.
PR 28-APR-2001; 2001US-0287112P.
PR 16-MAY-2001; 2001US-0291631P.
PR 12-JUL-2001; 2001US-0305484P.
PR 20-AUG-2001; 2001US-0313999P.
PR 27-NOV-2001; 2001US-0333626P.
XX
XX (CORI-) CORIXA CORP.
XX
PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
XX WPI; 2002-627435/67.
XX
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for

PT diagnosing, preventing and/or treating cancer, particularly pancreatic
PT cancer.
XX
PS Claim 1; SEQ ID NO 3878; 300pp + Sequence Listing; English.
XX
CC The invention relates to an isolated polynucleotide (I) comprising: (a)
CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
CC complements of (a); (c) sequences consisting of at least 20 contiguous
CC residues of (a); (d) sequences that hybridize to (a), under moderately
CC stringent conditions; (e) sequences having at least 75% or 90% identity
CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
CC in a patient and compositions comprising polypeptides, polynucleotides,
CC antibodies, fusion proteins, T cell populations and antigen presenting
CC cells expressing the polypeptide are useful in treating pancreatic cancer
CC and stimulating an immune response. The polynucleotides can be used as
CC probes or primers for nucleic acid hybridisation, in the design and
CC preparation of ribozyme molecules for inhibiting expression of the tumour
CC polypeptides and proteins in the tumour cells, in vaccines and for gene
CC therapy. Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 254 BP; 61 A; 74 C; 84 G; 35 T; 0 U; 0 Other;
Query Match 1.0%; Score 21.6; DB 1; Length 254;
Best Local Similarity 47.7%; Pred. No. 39;
Matches 63; Conservative 0; Mismatches 69; Indels 0; Gaps 0;
Qy 1836 TCCATTTCTTCTATCTTGTCTTCACTGCTGAGATTCTCTTCTATCTCTTGTATCTG 1895
Db 247 TCAGTTCCCTCTCTTGTGCGCTTGCCTCAGGATGCGGTCCCTTCTCTCGCCCTT 188
Qy 1896 TCAGTGAGGCTTGTCTCTGAGGTTCTCTGTTGGGTTCTTAATTTTTCATTTCCAGATTTC 1955
Db 187 CCAGGCGCGTTGTCAATGTTGAGGATGCGGTCCCTTACAGTGGCCCTCGCAGGTTTCC 128
Qy 1956 CTTCAAGTTTGGG 1967
Db 127 CTGCAGTATGAG 116
RESULT 76
AAV28290
ID AAV28290 standard; cDNA; 283 BP.
XX
AC AAV28290;
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
XX WO9829440-A1.
XX
PN 09-JUL-1998.
XX
PD 18-DEC-1997; 97WO-US023891.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
XX (MERI) MERCK & CO INC.
XX (UYTE-) UNIV TEXAS HEALTH SCI SAN ANTONIO.
XX
PI Tan CP, Kolakowski LF;
XX WPI; 1998-388038/33.
XX
XX P-PSDB; AAW61461.
XX

Query Match 0.9%; Score 21.4; DB 1; Length 283;

DT 08-MAY-2002 (first entry)

DE Rat galanin receptor 2 (GALR2) cDNA probe.
 XX Galanin receptor 2; GALR2; probe; ss; rat; obesity; pain; anorectic;
 KW cognitive disorder; analgesic; neuroprotective.
 XX Rattus sp.
 XX US6337206-B1.
 XX 08-JAN-2002.
 XX 18-DEC-1997; 97US-00993424.
 XX 18-DEC-1997; 97US-00993424.
 XX (MERI) MERCK & CO INC.
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX Tan C, Kolakowski LF;
 XX WPI; 2002-163241/21.
 XX New nucleic acid encoding mouse galanin receptor 2, useful in assays for
 PT identifying galanin receptor 2 ligands for treating obesity, pain and
 PT cognitive disorders.
 XX Disclosure; Fig 6; 48pp; English.
 XX The invention relates to mouse galanin receptor 2 (GALR2) and the nucleic
 CC acid encoding the novel polypeptide. The sequences are useful in assays
 CC for identifying GALR2 ligands that are useful for treating obesity, pain
 CC and cognitive disorders. The sequences are also useful for identifying
 CC agonists, antagonists, suppressors or inducers of GALR2. This sequence
 CC represents a cDNA probe used to isolate rat GALR2, used in the methods of
 CC the invention
 XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;
 SQ

Query Match 0.9%; Score 21.4; DB 1; Length 283;
 Best Local Similarity 61.8%; Pred. No. 45;
 Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTTCTCTGTCGATTCCTAGGTGAGGGTTACCACTGCTC 218
 Db 112 TCGGGCGCTGCTGCTGCGCTGTCCTCTACGTGGGCGAGGCTGCACCTACGC 166

RESULT 80
 AAS21354/c
 ID AAS21354 standard; cDNA; 1129 BP.
 XX AAS21354;
 AC AAS21354;
 XX 24-OCT-2001 (first entry)
 DT Human cDNA sequence encoding for PRO4327 polypeptide.
 DE Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
 XX prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
 KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
 KW A-peptide; factor VIIA; gene therapy; ss.
 XX Homo sapiens.
 OS WO20010466-A2.
 XX 07-JUN-2001.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 01-DEC-1999; 99WO-US028301.
 XX 01-DEC-1999; 99WO-US028634.
 XX 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 09-DEC-1999; 99US-0170262P.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030939.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2001-408281/43.
 DR P-PSDB; AAU12282.
 XX Isolated , secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
 PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
 PT breast, prostate, cervical.
 XX Claim 3; Fig 221; 813pp; English.
 XX AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO
 CC polypeptides. The PRO polypeptides are useful to detect other PRO
 CC polypeptides, to link bioactive molecules to cells expressing PRO
 CC polypeptides, to modulate biological activities of cells expressing PRO
 CC polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample. Some
 CC of the 275 sequences are also useful to stimulate the release of tumour
 CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 CC differentiation of chondrocytes, the proliferation or gene expression in
 CC pericyte cells, the release of proteoglycans from cartilage, the
 CC proliferation of inner ear utricular supporting cells or of T-
 CC lymphocytes, the release of a cytokine from peripheral blood monocytes
 CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
 CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
 CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 CC VIIA. The PRO polypeptides can be used in assays to identify molecules
 CC involved in binding interactions. The polynucleotides encoding PRO
 CC polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy

```
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAAATTTTCCAGATTCTTCAGTTTGGGTTTGGTTT 1975
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTATTTTATTTTTCAGCTGGCACACAGGCTGGGTTTATTT 1083

RESULT 81
ACD23963/c
ID ACD23963 standard; cDNA; 1129 BP.
XX AC ACD23963;
XX DT 26-AUG-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PR04327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX OS Homo sapiens.
XX UN US2003032156-A1.
XX PD 13-FEB-2003.
XX PF 06-MAY-2002; 2002US-00140474.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 04-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
102-DEC-1999; 99WO-US028551.
102-DEC-1999; 99WO-US028564.
102-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030311.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
11-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
10-MAR-2000; 2000WO-US005841.
10-MAR-2000; 2000WO-US006319.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015284.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US020231.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
14-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001US-00908273.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
```

```

XX WPI; 2003-341980/32.
DR P-PSDB; ABO17726.
XX
PT New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 2; Fig 221; 560pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1975
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 82
ACA67104/C
ID ACA67104 standard; cDNA; 1129 BP.
XX
AC ACA67104;
XX
DT 23-JUN-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #11.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;
KW antidiabetic; anorectic; vulnerable; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003004311-A1.
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.

```

```

PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059283P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077751P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.

```


XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-148238/14.
DR P-PSDB; ABUS9761.
XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX PS Claim 2; Fig 221; 659pp; English.
XX CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumors. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing of
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or Crohn's
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This sequence
CC encodes a novel human PRO protein
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1975
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 85
ACD41905/c
ID ACD41905 standard; cDNA; 1129 BP.
XX AC ACD41905;
XX 05-SEP-2003 (first entry)
DT XX
DE Human secreted/transmembrane protein (PRO) cDNA #111.
XX Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;
XX cytosolic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
XX proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
XX PMBC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
XX chondrocyte cell proliferation; chondrocyte cell differentiation;
XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell; A-peptide; factor VIIA.
XX

OS Homo sapiens.
XX US2003036179-A1.
XX 20-FEB-2003.
XX 10-MAY-2002; 2002US-00142431.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 20-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 02-OCT-1999; 99WO-US022089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 14-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030939.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 11-FEB-2000; 2000WO-US000376.
XX 18-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 22-FEB-2000; 2000WO-US004342.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US020231.
XX 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US000520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US021016.
PR 29-JUN-2001; 2001US-00921735.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-466355/44.
DR P-PSDB; ABO24951.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 221; 659pp; English.
XX The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptide),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the
CC specification, or of the DNA deposited under any of the American Type
CC Culture Collection (ATCC) Accession Numbers listed in the specification.
CC Also included are a vector comprising the novel nucleic acid, a host cell
CC comprising the vector, producing a PRO polypeptide, the isolated PRO
CC polypeptides detailed above, a chimeric molecule comprising the PRO
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC antibody, detecting a PRO polypeptide in a sample suspected of containing
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulating at least one biological activity of a cell
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC modulating the uptake of glucose or FFA by skeletal muscle cells or
CC adipocyte cells, stimulating the proliferation or differentiation of
CC chondrocyte cells (or proliferation of or gene expression in pericyte


```
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 03-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 24-FEB-2000; 2000WO-US005601.
PR 01-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006684.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-687639/65.
XX P-PSDB; ADA76172.
XX
XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTTGGTTTGT 1975
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083
RESULT 89
ADA18921/C
ID ADA18921 standard; cDNA; 1129 BP.
XX
```

AC ADA18821;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
XX US2003054517-A1.
XX
XX 20-MAR-2003.
XX
XX 08-MAY-2002; 2002US-00141755.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001WO-US006566.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00806889.
PR 05-APR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-521854/49.
XX P-PSDB; ADA18822.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumors.
XX
XX Claim 2; Fig 221; 660pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
XX prostate, rectal, cervical and liver tumours). The polynucleotides are
XX useful in molecular biology, including uses as hybridisation probes, in
XX chromosome and gene mapping, in generating antisense RNA and DNA and in
XX gene therapy. The polynucleotides may also be used in preparing PRO

PR	29-OCT-1998;	98WO-US0202991;
PR	29-OCT-1998;	98WO-US0202992;
PR	29-OCT-1998;	98WO-US0204855;
PR	29-NOV-1998;	98WO-US0204856;
PR	01-DEC-1998;	98WO-US0205108;
PR	05-JAN-1999;	98WO-US000106;
PR	08-MAR-1999;	99WO-US0050528;
PR	10-MAR-1999;	99WO-US005190;
PR	20-APR-1999;	99WO-US008615;
PR	14-MAY-1999;	99WO-US010733;
PR	02-JUN-1999;	99WO-US012252;
PR	01-SEP-1999;	99WO-US0201111;
PR	08-SEP-1999;	99WO-US020594;
PR	13-SEP-1999;	99WO-US020944;
PR	15-SEP-1999;	99WO-US021090;
PR	15-SEP-1999;	99WO-US021547;
PR	05-OCT-1999;	99WO-US023089;
PR	29-NOV-1999;	99WO-US028214;
PR	30-NOV-1999;	99WO-US028311;
PR	30-NOV-1999;	99WO-US028403;
PR	01-DEC-1999;	99WO-US028301;
PR	01-DEC-1999;	99WO-US028634;
PR	02-DEC-1999;	99WO-US028551;
PR	02-DEC-1999;	99WO-US028564;
PR	02-DEC-1999;	99WO-US028565;
PR	16-DEC-1999;	99WO-US030095;
PR	20-DEC-1999;	99WO-US030911;
PR	20-DEC-1999;	99WO-US030999;
PR	22-DEC-1999;	99WO-US030720;
PR	23-DEC-1999;	99WO-US031243;
PR	30-DEC-1999;	99WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	16-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US003565;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004914;
PR	24-FEB-2000;	2000WO-US005004;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	02-MAR-2000;	2000WO-US005841;
PR	10-MAR-2000;	2000WO-US006319;
PR	15-MAR-2000;	2000WO-US006884;
PR	20-MAR-2000;	2000WO-US007377;
PR	21-MAR-2000;	2000WO-US007532;
PR	30-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US013042;
PR	03-JUN-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015264;
PR	28-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US022031;
PR	24-AUG-2000;	2000WO-US023522;
PR	08-NOV-2000;	2000WO-US023328;
PR	10-NOV-2000;	2000WO-US030952;
PR	01-DEC-2000;	2000WO-US030873;
PR	10-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-U0747259;
PR	28-FEB-2001;	2000WO-US034956;
PR	28-FEB-2001;	2000US-U0796498;
PR	01-MAR-2001;	2001WO-US006520;
PR	28-FEB-2001;	2001WO-US006666;
PR	09-MAR-2001;	2001US-U0802706;
PR	14-MAR-2001;	2001US-U080689;
PR	22-MAR-2001;	2001US-U0816744;
PR	05-APR-2001;	2001US-U0828366;
PR	10-MAY-2001;	2001US-U0854208;
PR	10-MAY-2001;	2001US-U0854280;
PR	18-MAY-2001;	2001US-U0860326;
PR	25-MAY-2001;	2001US-U0866028;
PR	25-MAY-2001;	2001US-U0866034;
PR	25-MAY-2001;	2001WO-US017092;

Query Match	0.9%;	Score 21.4;	DB 1;	Length 1129;
Best Local Similarity	66.0%;	Pred. No. 56;		
Matches 31; Conservative	0;	Mismatches 16;	Indels 0	

RESULT 90
ADA61444/c
ID ADA61444 standard; cDNA; 1129 BP.

07-OCT-1998:


```
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00919692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00909827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695926/66.
DR P-PSDB; ADA67395.
XX
XX Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
XX Claim 2; Fig 221; 660pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the release of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCACGATTCCTTCAGTTGGTTTGT 1975
```


PF	16-APR-2002;	2002US-00123907.	
XX	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014532.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	16-SEP-1998;	98WO-US019177.	
PR	17-SEP-1998;	98WO-US019330.	
PR	07-OCT-1998;	98WO-US019437.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	10-MAR-1999;	99WO-US005190.	
PR	10-MAR-1999;	2000WO-US006319.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028301.	
PR	01-DEC-1999;	99WO-US028634.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028564.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	
PR	22-DEC-1999;	99WO-US030720.	
PR	30-DEC-1999;	99WO-US031243.	
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US000565.	
PR	18-FEB-2000;	2000WO-US0004341.	
PR	18-FEB-2000;	2000WO-US0004342.	
PR	22-FEB-2000;	2000WO-US0004914.	
PR	24-FEB-2000;	2000WO-US0005004.	
PR	01-MAR-2000;	2000WO-US0005601.	
PR	02-MAR-2000;	2000WO-US0005746.	
PR	02-MAR-2000;	2000WO-US0005841.	
PR	15-MAR-2000;	2000WO-US0006884.	
PR	21-MAR-2000;	2000WO-US0007377.	
PR	30-MAR-2000;	2000WO-US0007532.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	11-AUG-2000;	2000WO-US022031.	
PR	23-AUG-2000;	2000WO-US023522.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	08-NOV-2000;	2000WO-US030952.	
PR	10-NOV-2000;	2000WO-US030873.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000WO-US034956.	
SQ	20-DEC-2000;	2000WO-US034956.	
XX	28-FEB-2001;	2001US-00796498.	
PR	28-FEB-2001;	2001WO-US006520.	
PR	01-MAR-2001;	2001WO-US006666.	
PR	09-MAR-2001;	2001US-00802706.	
PR	14-MAR-2001;	2001US-00808689.	
PR	22-MAR-2001;	2001US-00816744.	
PR	05-APR-2001;	2001US-00828366.	
PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001US-00854280.	
PR	18-MAY-2001;	2001US-00860216.	
PR	25-MAY-2001;	2001US-00866028.	
PR	25-MAY-2001;	2001US-00866034.	
PR	01-JUN-2001;	2001WO-US017092.	
PR	01-JUN-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001WO-US019692.	
PR	21-JUN-2001;	2001US-00887879.	
PR	22-JUN-2001;	2001WO-US020116.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2	

ADA74347/c
ID ADA74347 standard; cDNA; 1129 BP.
XX
AC ADA74347;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003068798-A1.
PN
XX
XX 10-APR-2003.
PD
XX
XX 07-MAY-2002; 2002US-00140928.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625490/59.
DR P-PSDB; ADA74348.
XX
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating bone disorders, arthritis, heart
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear uricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
XX	
XX	US2003082701-A1.
XX	
PN	01-MAY-2003.
XX	
PD	
XX	
PF	23-APR-2002; 2002US-00128686.
XX	
XX	31-AUG-1998; 98US-0098525P.
PR	16-SEP-1998; 98US-0100634P.
PR	02-JUN-1999; 99WO-US012252.
PR	25-AUG-1999; 99US-00380137.
PR	30-MAR-2000; 2000WO-US008439.
PR	02-JUN-2000; 2000WO-US015264.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
XX	
WPI	2003-755110/71.
DR	P-PSDB; ADA82105.
DR	
XX	
PT	PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT	tumor or for tissue typing.
XX	
PS	Claim 2; Fig 221; 637pp; English.

```
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match          0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY      1929 TTCTTAATTTTTCATTCCAGATTTCCCTTCACGTTGGGTTTTGTTT 1975
        ||||| ||||| ||||| ||||| | ||||| ||||| |||||
Db       1129 TTTTNTTTTTTTTTTTTTCAGCTGCACACAGGCTGGGTTTTATT 1083

RESULT 113
ADA75067/c
ID ID ADA75067 standard; cDNA; 1129 BP.
XX
AC ADA75067;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
UN US2003073216-A1.
PD 17-APR-2003.
```

30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US0202031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 05-APR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 05-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 XX
 XX
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-765392/72.
 DR P-PSDB; ADA75068.
 XX
 PT New secreted and transmembrane PRO polypeptides useful for stimulating
 PT the release of tumor necrosis factor alpha in human blood and detecting
 PT the presence of tumor in a mammal.
 XX
 PS Claim 2; Fig 221; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TTTCTAATTTTTCATTCAGATTTTCCTTCAGTTGGTGGTTTGGTTT 1975
 |||||
 DB 1129 TTTTCTTTTTCATTCAGCTGGCAGACAGCTGGTGGTTTATT 1083
 RESULT 114
 ADA85145/c
 ID ADA85145 standard; cDNA; 1129 BP.
 XX
 AC ADA85145;
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW

KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW	gene therapy; chromosome identification; chromosome marker.
XX	
OS	Homo sapiens.
XX	
XX	US2003082695-A1.
PN	
XX	01-MAY-2003.
PD	
XX	
PF	22-APR-2002; 2002US-00127846.
XX	
PR	03-MAR-2000; 2000US-0187202P.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-786909/74.
DR	P-PSDB; ADA85146.
XX	
PT	New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT	composition for treating e.g. tumor by gene therapy, or for tissue
PT	typing.
XX	
PS	Claim 2; Fig 221; 637pp; English.
XX	
CC	The invention describes 305 nucleic acids encoding PRO (secreted and
CC	transmembrane) polypeptides (I). (I) is useful for stimulating the
CC	release of TNF-alpha from human blood, for modulating the uptake of
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating the proliferation or differentiation of chondrocyte cells,
CC	for stimulating the proliferation of or gene expression in pericyte
CC	cells, for stimulating the release of proteoglycans from cartilage, for
CC	stimulating the proliferation of inner ear utricular supporting cells,
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC	the release of a cytokine from PBM cells, for inhibiting the binding of
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC	cells, for stimulating proliferation of endothelial cells, for detecting
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC	are useful for isolating genomic and cDNA nucleotide sequences or
CC	antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC	in assays to identify other proteins or molecules involved in binding
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC	and gene mapping, in generation of antisense RNA and DNA, in the
CC	preparation of PRO polypeptide, for generating transgenic animals or
CC	knockout animals which in turn are useful in the development and
CC	screening of therapeutically useful reagents, in gene therapy, for
CC	chromosome identification, as chromosome marker, and for generating
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC	detecting its expression in specific cells, tissues or serum, and for
CC	affinity purification of PRO from recombinant cell culture or natural
CC	sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC	a novel human secreted and transmembrane PRO polypeptide.
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match 0.9%; Score 21.4; DB 1; Length 1129;
	Best Local Similarity 66.0%; Pred. No. 56;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTCTTT 1975
Db	1129 TTTTITTTTTTTTTTTCAGTCGCGACACAGCGTGGTTTTATT 1083
RESULT 115	
ADA84593/c	

cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTGGTTTCTTTT 1975
Db 1129 TTTTTCATTTTTCATTTTCAGTTGGTTTCTTTTATT 1083

RESULT 118
ADA75619/C
ID ADA75619 standard; cDNA; 1129 BP.
XX ADA75619;
AC ADA75619;
XX 20-NOV-2003 (first entry)
XX Human PRO polynucleotide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003082703-A1.
XX 01-MAY-2003.
XX 23-APR-2002; 2002US-00128691.
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755115/71.
XX P-PSDB; ADA75620.
XX New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte

23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US049556.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755115/71.
XX P-PSDB; ADA80378.
XX New PRO polypeptides useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors.
XX Claim 2; Fig 221; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003092147-A1.

XX 15-MAY-2003.

XX 11-APR-2002; 2002US-00121051.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US007733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 12-MAR-2001; 2001US-00808689.

PR 24-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019892.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-777249/73.

DR P-PSDB; ADB26667.

XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or

PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart

PT attack, various coagulation disorders, tumors.

XX Claim 2; Fig 221; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US000528.
PR 10-MAR-1999; 98WO-US0005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020844.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021147.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028401.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854290.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755114/71.
P-PSDB; ADA95806.

New isolated PRO polypeptides, useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTAATTTTTCATTTCCAGATTCCTTCAGTTGGTTTGT 1975

Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
RESULT 129
ADB26114/c
ID ADB26114 standard; cDNA; 1129 BP.
XX ADB26114;
AC ADB26114;
XX
XX
XX 20-NOV-2003 (first entry)
DE cDNA encoding human PRO polypeptide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003082760-A1.
XX
XX 01-MAY-2003.
XX
XX 12-APR-2002; 2002US-00121056.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908927.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-777204/73.
DR P-PSDB; ADB26115.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.

SQ	Sequence	1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match	0.9%; Score 21.4; DB 1; Length 1129;	
Best Local Similarity	66.0%; Pred. No. 56;	
Matches	31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;	
QY	1929 TTCTTAATTTTTTCATTCCAGATTTCCTTCAGTTTGGGTTTGTTT 1975 	
DB	1129 TTTTNTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTATT 1083 	
RESULT 131		
ADA77378/C		
ID	ADA77378 standard; cDNA; 1129 BP.	
XX		
AC	ADA77378;	
XX		
DT	20-NOV-2003 (first entry)	
XX		
DE	Human PRO polynucleotide #111.	
XX		
KW	Human; Gene: ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; macrovascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003068797-A1.	
XX		
PD	10-APR-2003.	
XX		
PF	07-MAY-2002; 2002US-00140921.	
XX		
PR	31-MAR-1997; 98WO-US005230. PR 12-JUN-1998; 98WO-US012456. PR 14-JUL-1998; 98WO-US014552. PR 28-AUG-1998; 98WO-US017888. PR 10-SEP-1998; 98WO-US018824. PR 14-SEP-1998; 98WO-US019093. PR 14-SEP-1998; 98WO-US019094. PR 14-SEP-1998; 98WO-US019177. PR 16-SEP-1998; 98WO-US019330. PR 17-SEP-1998; 98WO-US019437. PR 07-OCT-1998; 98WO-US021141. PR 29-OCT-1998; 98WO-US022991. PR 29-OCT-1998; 98WO-US022992. PR 20-NOV-1998; 98WO-US024855. PR 01-DEC-1998; 98WO-US025108. PR 05-JAN-1999; 99WO-US000106. PR 08-MAR-1999; 99WO-US005028. PR 10-MAR-1999; 99WO-US005190. PR 20-APR-1999; 99WO-US008615. PR 14-MAY-1999; 99WO-US010733. PR 02-JUN-1999; 99WO-US012252. PR 01-SEP-1999; 99WO-US020111. PR 08-SEP-1999; 99WO-US020594. PR 13-SEP-1999; 99WO-US020944. PR 15-SEP-1999; 99WO-US021090. PR 15-SEP-1999; 99WO-US021547. PR 05-OCT-1999; 99WO-US023089. PR 29-NOV-1999; 99WO-US028214. PR 30-NOV-1999; 99WO-US028313. PR 30-NOV-1999; 99WO-US028409. PR 01-DEC-1999; 99WO-US028401. PR 01-DEC-1999; 99WO-US028634. PR 02-DEC-1999; 99WO-US028551.	

PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	29-OCT-1998;	98WO-US022991.

AC ADB28322;
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082699-A1.
XX 01-MAY-2003.
XX 22-APR-2002; 2002US-00127851.
XX 17-JUN-1998; 98US-0089599P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-NOV-1999; 99WO-US028313.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777202/73.
XX P-PSDB; ADB28323.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCAGATTTCTTCAGTTTCGGTTTCTTT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTCGGTCACAGCTGGGTTTATT 1083
RESULT 137
ADB28874/C
ID ADB28874 standard; cDNA; 1129 BP.
XX
XX ADB28874;
XX AC
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082706-A1.
XX 01-MAY-2003.
XX 24-APR-2002; 2002US-00131836.
XX 09-DEC-1999; 99US-0170262P.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E;
PI Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777203/73.
XX P-PSDB; ADB28875.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCACAGATTCCTTCAGTTGGGTTTGTGTT 1975

DB 1129 TTTTTTTTTTTTTTTTTTCAGCTGGCACAGCTGGGTTTATT 1083

RESULT 138

ADA76826/c

ID ADA76826 standard; cDNA; 1129 BP.

XX AC

ADA76826;

XX AC

DT 20-NOV-2003 (first entry)

XX XX

DE Human PRO polynucleotide #111.

XX KW

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX KW

OS Homo sapiens.

XX OS

PN US2003059909-A1.

XX PN

PD 27-MAR-2003.

XX PD

PF 10-MAY-2002; 2002US-00143032.

XX PF

PR 31-MAR-1997; 97WO-US005230.

XX PR

PR 12-JUN-1998; 98WO-US012456.

XX PR

PR 14-JUL-1998; 98WO-US014552.

XX PR

PR 28-AUG-1998; 98WO-US017888.

XX PR

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.

Sequence 1129 BP: 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

PR 16-DEC-1999; 39WC-03030000

XX 19-APR-2002; 2002US-00125926.
 XX 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755106/71.
 DR P-PSDB; ADA97462.
 XX Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX Claim 2; Fig 221; 666pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 Qy 1929 TTCCTAATTTTTCATTCAGATTCTCTTCAGTTGGTGTGTTT 1975
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGTGTGTTTATT 1093
 RESULT 141
 ADB27218/c
 ID ADB27218 standard; cDNA; 1129 BP.
 XX
 AC ADB27218;
 XX

DT 20-NOV-2003 (first entry)
 XX cDNA encoding human PRO polypeptide #111.
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX US2003022239-A1.
 XX 30-JAN-2003.
 XX 12-APR-2002; 2002US-00121049.
 XX 18-JUN-1997; 97US-0049911P.
 PR 26-AUG-1997; 97US-0056974P.
 PR 17-SEP-1997; 97US-0059113P.
 PR 17-SEP-1997; 97US-0059115P.
 PR 17-SEP-1997; 97US-0059117P.
 PR 17-SEP-1997; 97US-0059122P.
 PR 17-SEP-1997; 97US-0059184P.
 PR 18-SEP-1997; 97US-0059352P.
 PR 19-SEP-1997; 97US-0059588P.
 PR 19-SEP-1997; 97US-0059836P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 17-OCT-1997; 97US-0062285P.
 PR 17-OCT-1997; 97US-0062287P.
 PR 17-OCT-1997; 97US-0063755P.
 PR 24-OCT-1997; 97US-0062814P.
 PR 24-OCT-1997; 97US-0062816P.
 PR 24-OCT-1997; 97US-0063045P.
 PR 24-OCT-1997; 97US-0063082P.
 PR 24-OCT-1997; 97US-0063127P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063561P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063733P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 24-NOV-1997; 97US-0066453P.
 PR 24-NOV-1997; 97US-0066511P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 11-DEC-1997; 97US-0069212P.
 PR 11-DEC-1997; 97US-0069278P.
 PR 11-DEC-1997; 97US-0069334P.
 PR 16-DEC-1997; 97US-0069694P.
 PR 23-JAN-1998; 98US-0072320P.
 PR 04-FEB-1998; 98US-0073612P.
 PR 09-FEB-1998; 98US-0074086P.
 PR 09-FEB-1998; 98US-0074082P.
 PR 12-MAR-1998; 98US-0077791P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 25-MAR-1998; 98US-0079294P.
 PR 27-MAR-1998; 98US-0079663P.
 PR 27-MAR-1998; 98US-0079728P.
 PR 31-MAR-1998; 98US-0080165P.

PR	15-SEP-1998;	98US-0100390P.
PR	16-SEP-1998;	98US-006334P.
PR	16-SEP-1998;	98US-005019330.
PR	17-SEP-1998;	98US-0100710P.
PR	17-SEP-1998;	98US-0100658P.
PR	17-SEP-1998;	98WO-US019437.
PR	23-SEP-1998;	98US-0101474P.
PR	23-SEP-1998;	98US-0103477P.
PR	24-SEP-1998;	98US-0103741P.
PR	07-OCT-1998;	98US-0103315P.
PR	07-OCT-1998;	98US-0103328P.
PR	07-OCT-1998;	98WO-US021141.
PR	13-OCT-1998;	98US-0104080P.
PR	20-OCT-1998;	98US-0104987P.
PR	20-OCT-1998;	98US-0105169P.
PR	28-OCT-1998;	98US-0106030P.
PR	29-OCT-1998;	98WO-US022991.
PR	29-OCT-1998;	98US-0106464P.
PR	03-NOV-1998;	98US-0106856P.
PR	10-NOV-1998;	98US-0106934P.
PR	10-NOV-1998;	98US-0107783P.
PR	17-NOV-1998;	98US-0108775P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	20-NOV-1998;	98US-0108923P.
PR	20-NOV-1998;	98US-0109304P.
PR	20-NOV-1998;	98WO-US024855.
PR	01-DEC-1998;	98WO-US025108.
PR	16-DEC-1998;	98US-0112743P.
PR	16-DEC-1998;	98US-0112850P.
PR	22-DEC-1998;	98US-0113296P.
PR	22-DEC-1998;	98US-0113299P.
PR	22-DEC-1998;	98US-0113300P.
PR	22-DEC-1998;	98US-0113333P.
PR	22-DEC-1998;	98US-0113314P.
PR	22-DEC-1998;	98US-0113315P.
PR	22-DEC-1998;	98US-0113510P.
PR	22-DEC-1998;	98US-0113511P.
PR	23-DEC-1998;	98US-0113605P.
PR	23-DEC-1998;	98US-0113621P.
PR	05-JAN-1999;	98WO-US000106.
PR	12-JAN-1999;	98US-0115549P.
PR	12-JAN-1999;	98US-0115557P.
PR	12-JAN-1999;	98US-0115560P.
PR	12-JAN-1999;	98US-0115562P.
PR	12-JAN-1999;	98US-0115564P.
PR	12-JAN-1999;	98US-0115630P.
PR	12-JAN-1999;	98US-0115705P.
PR	12-JAN-1999;	98US-0115733P.

Qy	1929	TTCTTAATTTT	TTTCATTC	CAGATTT	CCTTC	CAGATTT	CGGTTT	GT	1975
D _b	1129	TTTTTTTTTTT	TTTTTTTTT	TTTTC <td>CAGTGG <td>CAC <td>CAGGCT</td> <td>TTTTAT</td> <td>1083</td> </td></td>	CAGTGG <td>CAC <td>CAGGCT</td> <td>TTTTAT</td> <td>1083</td> </td>	CAC <td>CAGGCT</td> <td>TTTTAT</td> <td>1083</td>	CAGGCT	TTTTAT	1083

RESULT 142	
ADB22151/c	
ID	ADB22151 standard; cDNA; 1129 BP.
XX	
XX	
AC	ADB22151;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO4327 cDNA.
XX	
KW	Human; secreted and transmembrane protein; PRO; gene; ss;
KW	Tumour necrosis factor alpha release; TNF-alpha release;
KW	Glucose uptake modulator; FFA uptake modulator;

[illegible]

15-MAY-1998	R	98US-00856976P
15-MAY-1998	R	98US-00857047P
22-MAY-1998	R	98US-00864140P
22-MAY-1998	R	98US-00864300P
28-MAY-1998	R	98US-00871060P
04-JUN-1998	R	98US-00880260P
10-JUN-1998	R	98US-00887300P
10-JUN-1998	R	98US-00887410P
11-JUN-1998	R	98US-00888510P
12-JUN-1998	R	98US-00888525P
17-JUN-1998	R	98US-00895320P
17-JUN-1998	R	98US-00895390P
18-JUN-1998	R	98US-00899070P
19-JUN-1998	R	98US-00899470P
23-JUN-1998	R	98US-00903490P
24-JUN-1998	R	98US-00904290P
24-JUN-1998	R	98US-00904450P
26-JUN-1998	R	98US-00905380P
26-JUN-1998	R	98US-00905830P
01-JUL-1998	R	98US-00915190P
02-JUL-1998	R	98US-00919820P
07-JUL-1998	R	98US-00931590P
14-JUL-1998	R	98US-00931330P
14-JUL-1998	R	98US-00931430P
30-JUL-1998	R	98US-00946510P
04-AUG-1998	R	98US-00952850P
04-AUG-1998	R	98US-00953010P
04-AUG-1998	R	98US-00953020P
04-AUG-1998	R	98US-00953250P
11-AUG-1998	R	98US-00961460P
11-AUG-1998	R	98US-00963290P
12-AUG-1998	R	98US-00967680P
17-AUG-1998	R	98US-00967730P
17-AUG-1998	R	98US-00967910P
17-AUG-1998	R	98US-00968910P
18-AUG-1998	R	98US-00969690P
18-AUG-1998	R	98US-00969690P
19-AUG-1998	R	98US-00971410P
20-AUG-1998	R	98US-00972180P
26-AUG-1998	R	98US-00979510P
26-AUG-1998	R	98US-00979860P
28-AUG-1998	R	98US-00981780P
31-AUG-1998	R	98US-00985250P
01-SEP-1998	R	98US-00987500P
09-SEP-1998	R	98US-00995360P
09-SEP-1998	R	98US-00995980P
09-SEP-1998	R	98US-00996010P
09-SEP-1998	R	98US-00997920P
10-SEP-1998	R	98US-00998030P
10-SEP-1998	R	98US-00998160P
10-SEP-1998	R	98US-00998180P
14-SEP-1998	R	98US-01002620P
14-SEP-1998	R	98US-01002630P
14-SEP-1998	R	98US-01003900P
14-SEP-1998	R	98US-01003940P
15-SEP-1998	R	98US-01006340P
16-SEP-1998	R	98US-01007130P
17-SEP-1998	R	98US-01007100P
17-SEP-1998	R	98US-01008580P
23-SEP-1998	R	98US-01014930P
23-SEP-1998	R	98US-01014740P
23-SEP-1998	R	98US-01014770P
24-SEP-1998	R	98US-01017410P

[illegible][illegible][illegible]

10-JUN-1998	98US-0086888P	98US-0086888P
11-JUN-1998	98US-0088858P	98US-0088858P
12-JUN-1998	98WO-US0112456P	98WO-US0112456P
13-JUN-1998	98US-0089532P	98US-0089532P
14-JUN-1998	98US-0089599P	98US-0089599P
15-JUN-1998	98US-0089907P	98US-0089907P
16-JUN-1998	98US-0089947P	98US-0089947P
17-JUN-1998	98US-0090349P	98US-0090349P
18-JUN-1998	98US-0090423P	98US-0090423P
19-JUN-1998	98US-0090445P	98US-0090445P
20-JUN-1998	98US-0090538P	98US-0090538P
21-JUN-1998	98US-0090863P	98US-0090863P
22-JUN-1998	98US-0091360P	98US-0091360P
23-JUN-1998	98US-0091519P	98US-0091519P
24-JUN-1998	98US-0091982P	98US-0091982P
25-JUN-1998	98WO-US014552P	98WO-US014552P
26-JUN-1998	98US-0093339P	98US-0093339P
27-JUN-1998	98US-0094651P	98US-0094651P
28-JUN-1998	98US-0095285P	98US-0095285P
29-JUN-1998	98US-0095301P	98US-0095301P
30-JUN-1998	98US-0095302P	98US-0095302P
01-AUG-1998	98US-0095325P	98US-0095325P
02-AUG-1998	98US-0096143P	98US-0096143P
03-AUG-1998	98US-0096146P	98US-0096146P
04-AUG-1998	98US-0096323P	98US-0096323P
05-AUG-1998	98US-0096768P	98US-0096768P
06-AUG-1998	98US-0096773P	98US-0096773P
07-AUG-1998	98US-0097511P	98US-0097511P
08-AUG-1998	98US-0097951P	98US-0097951P
09-AUG-1998	98US-0097986P	98US-0097986P
10-AUG-1998	98WO-US017888P	98WO-US017888P
11-AUG-1998	98US-0098525P	98US-0098525P
12-AUG-1998	98US-0098750P	98US-0098750P
13-AUG-1998	98US-0099536P	98US-0099536P
14-AUG-1998	98US-0099598P	98US-0099598P
15-AUG-1998	98US-0099601P	98US-0099601P
16-AUG-1998	98US-0099792P	98US-0099792P
17-AUG-1998	98US-0099803P	98US-0099803P
18-AUG-1998	98US-0099812P	98US-0099812P
19-AUG-1998	98WO-US018824P	98WO-US018824P
20-AUG-1998	98US-0100262P	98US-0100262P
21-AUG-1998	98US-0100263P	98US-0100263P
22-AUG-1998	98WO-US019093P	98WO-US019093P
23-AUG-1998	98WO-US019094P	98WO-US019094P
24-AUG-1998	98WO-US019177P	98WO-US019177P
25-AUG-1998	98US-0100390P	98US-0100390P
26-AUG-1998	98US-0100634P	98US-0100634P
27-AUG-1998	98WO-US019330P	98WO-US019330P
28-AUG-1998	98US-0100710P	98US-0100710P
29-AUG-1998	98US-0100858P	98US-0100858P
30-AUG-1998	98US-0019437P	98US-0019437P
31-AUG-1998	98US-0101474P	98US-0101474P
01-SEP-1998	98US-0101477P	98US-0101477P
02-SEP-1998	98US-0101741P	98US-0101741P

[illegible]

17-JUN-1998	98US-0089352P	98US-0089907P
18-JUN-1998	98US-0089908P	98US-0089909P
19-JUN-1998	98US-0089947P	98US-0089948P
23-JUN-1998	98US-0090343P	98US-0090344P
24-JUN-1998	98US-0090429P	98US-0090445P
24-JUN-1998	98US-0090445P	98US-0090538P
24-JUN-1998	98US-0090538P	98US-0090538P
26-JUN-1998	98US-0090863P	98US-0090863P
26-JUN-1998	98US-0091360P	98US-0091360P
02-JUL-1998	98US-0091519P	98US-0091519P
07-JUL-1998	98US-0091982P	98US-0091982P
14-JUL-1998	98WO-US014552	98WO-US014552
20-JUL-1998	98US-0093339P	98US-0093339P
30-JUL-1998	98US-0094651P	98US-0094651P
04-AUG-1998	98US-0095285P	98US-0095285P
04-AUG-1998	98US-0095301P	98US-0095301P
11-AUG-1998	98US-0096143P	98US-0096143P
12-AUG-1998	98US-0096146P	98US-0096146P
12-AUG-1998	98US-0096329P	98US-0096329P
17-AUG-1998	98US-0096769P	98US-0096769P
17-AUG-1998	98US-0096773P	98US-0096773P
17-AUG-1998	98US-0096791P	98US-0096791P
17-AUG-1998	98US-0096891P	98US-0096891P
17-AUG-1998	98US-0096895P	98US-0096895P
18-AUG-1998	98US-0096960P	98US-0096960P
18-AUG-1998	98US-0097141P	98US-0097141P
20-AUG-1998	98US-0097218P	98US-0097218P
26-AUG-1998	98US-0097951P	98US-0097951P
26-AUG-1998	98US-0097986P	98US-0097986P
28-AUG-1998	98WO-US017888	98WO-US017888
31-AUG-1998	98US-0098525P	98US-0098525P
01-SEP-1998	98US-0098750P	98US-0098750P
01-SEP-1998	98US-0098536P	98US-0098536P
09-SEP-1998	98US-0099598P	98US-0099598P
09-SEP-1998	98US-0099601P	98US-0099601P
10-SEP-1998	98US-0099792P	98US-0099792P
10-SEP-1998	98US-0099803P	98US-0099803P
10-SEP-1998	98US-0099816P	98US-0099816P
10-SEP-1998	98WO-US018824	98WO-US018824
14-SEP-1998	98US-0100262P	98US-0100262P
14-SEP-1998	98US-0100263P	98US-0100263P
14-SEP-1998	98WO-US019093	98WO-US019093
14-SEP-1998	98WO-US019094	98WO-US019094
14-SEP-1998	98WO-US019177	98WO-US019177
15-SEP-1998	98US-0100390P	98US-0100390P
16-SEP-1998	98US-0100634P	98US-0100634P
16-SEP-1998	98WO-US019330	98WO-US019330
17-SEP-1998	98US-0100710P	98US-0100710P
17-SEP-1998	98US-0100858P	98US-0100858P
17-SEP-1998	98US-0101437P	98US-0101437P
23-SEP-1998	98US-0101474P	98US-0101474P
23-SEP-1998	98US-0101477P	98US-0101477P
24-SEP-1998	98US-011741P	98US-011741P

[illegible][illegible]

PR	24-JUN-1998	98US-00901358P	98US-00901358P
PR	26-JUN-1998	98US-00908633P	98US-00908633P
PR	01-JUL-1998	98US-00913606P	98US-00913606P
PR	02-JUL-1998	98US-00915191P	98US-00915191P
PR	07-JUL-1998	98US-00919822P	98US-00919822P
PR	14-JUL-1998	98WO-US014552	98WO-US014552
PR	20-JUL-1998	98US-00933339P	98US-00933339P
PR	20-JUL-1998	98US-00946512P	98US-00946512P
PR	30-AUG-1998	98US-00952855P	98US-00952855P
PR	04-AUG-1998	98US-00953011P	98US-00953011P
PR	04-AUG-1998	98US-00953022P	98US-00953022P
PR	11-AUG-1998	98US-00953253P	98US-00953253P
PR	11-AUG-1998	98US-00956143P	98US-00956143P
PR	11-AUG-1998	98US-00961465P	98US-00961465P
PR	12-AUG-1998	98US-00963239P	98US-00963239P
PR	17-AUG-1998	98US-00967698P	98US-00967698P
PR	17-AUG-1998	98US-00967733P	98US-00967733P
PR	17-AUG-1998	98US-00967911P	98US-00967911P
PR	17-AUG-1998	98US-00966891P	98US-00966891P
PR	17-AUG-1998	98US-00968925P	98US-00968925P
PR	18-AUG-1998	98US-00969606P	98US-00969606P
PR	20-AUG-1998	98US-00971411P	98US-00971411P
PR	20-AUG-1998	98US-00972181P	98US-00972181P
PR	26-AUG-1998	98US-00979516P	98US-00979516P
PR	26-AUG-1998	98US-00979862P	98US-00979862P
PR	28-AUG-1998	98WO-US017888	98WO-US017888
PR	31-AUG-1998	98US-00985253P	98US-00985253P
PR	01-SEP-1998	98US-00987505P	98US-00987505P
PR	09-SEP-1998	98US-00995363P	98US-00995363P
PR	09-SEP-1998	98US-00995988P	98US-00995988P
PR	09-SEP-1998	98US-00996011P	98US-00996011P
PR	10-SEP-1998	98US-00997922P	98US-00997922P
PR	10-SEP-1998	98US-00998033P	98US-00998033P
PR	10-SEP-1998	98US-00998161P	98US-00998161P
PR	14-SEP-1998	98WO-US018824	98WO-US018824
PR	14-SEP-1998	98US-01002623P	98US-01002623P
PR	14-SEP-1998	98US-01002633P	98US-01002633P
PR	14-SEP-1998	98WO-US019093	98WO-US019093
PR	14-SEP-1998	98WO-US019094	98WO-US019094
PR	14-SEP-1998	98WO-US019177	98WO-US019177
PR	15-SEP-1998	98US-01003909P	98US-01003909P
PR	16-SEP-1998	98US-01006344P	98US-01006344P
PR	16-SEP-1998	98WO-US019330	98WO-US019330
PR	17-SEP-1998	98US-01007101P	98US-01007101P
PR	17-SEP-1998	98US-01008589P	98US-01008589P
PR	17-SEP-1998	98WO-US019437	98WO-US019437
PR	23-SEP-1998	98US-01014749	98US-01014749
PR	23-SEP-1998	98US-01014777P	98US-01014777P
PR	24-SEP-1998	98US-01117419P	98US-01117419P

PR	01-JUN-1998	98US-00931519P
PR	02-JUN-1998	98US-00931982P
PR	07-JUL-1998	98US-00931982P
PR	14-JUL-1998	98WO-US014552
PR	20-JUL-1998	98US-00933339P
PR	30-JUL-1998	98US-0094651P
PR	04-AUG-1998	98US-0095285P
PR	04-AUG-1998	98US-0095285P
PR	04-AUG-1998	98US-0095301P
PR	04-AUG-1998	98US-0095302P
PR	11-AUG-1998	98US-0095325P
PR	11-AUG-1998	98US-00956143P
PR	11-AUG-1998	98US-0096146P
PR	12-AUG-1998	98US-00963239P
PR	17-AUG-1998	98US-0096768P
PR	17-AUG-1998	98US-0096773P
PR	17-AUG-1998	98US-0096791P
PR	17-AUG-1998	98US-00968891P
PR	17-AUG-1998	98US-0096895P
PR	17-AUG-1998	98US-0096960P
PR	18-AUG-1998	98US-0097141P
PR	20-AUG-1998	98US-0097218P
PR	20-AUG-1998	98US-0097551P
PR	26-AUG-1998	98US-0097958P
PR	26-AUG-1998	98US-0097958P
PR	28-AUG-1998	98WO-US017888
PR	31-AUG-1998	98US-0098525P
PR	01-SEP-1998	98US-0098750P
PR	09-SEP-1998	98US-0099536P
PR	09-SEP-1998	98US-0099598P
PR	09-SEP-1998	98US-0099601P
PR	10-SEP-1998	98US-0099792P
PR	10-SEP-1998	98US-0099803P
PR	10-SEP-1998	98US-0099816P
PR	10-SEP-1998	98WO-US018824
PR	14-SEP-1998	98US-0100263P
PR	14-SEP-1998	98US-0100263P
PR	14-SEP-1998	98WO-US019093
PR	14-SEP-1998	98WO-US019094
PR	14-SEP-1998	98WO-US019177
PR	15-SEP-1998	98US-0100390P
PR	15-SEP-1998	98US-0100634P
PR	16-SEP-1998	98WO-US019330
PR	16-SEP-1998	98US-0100710P
PR	17-SEP-1998	98US-0100858P
PR	17-SEP-1998	98US-05019437
PR	23-SEP-1998	98US-0101474P
PR	23-SEP-1998	98US-0101477P
PR	24-SEP-1998	98US-011741P
PR	24-SEP-1998	98US-011741P

PR	07-JUL-1998	98WO-US014552
PR	14-JUL-1998	98US-0039351P
PR	20-JUL-1998	98US-00394651P
PR	30-JUL-1998	98US-00395285P
PR	04-AUG-1998	98US-00395301P
PR	04-AUG-1998	98US-00395302P
PR	04-AUG-1998	98US-00395325P
PR	11-AUG-1998	98US-00396143P
PR	11-AUG-1998	98US-00396146P
PR	12-AUG-1998	98US-00396329P
PR	17-AUG-1998	98US-00396769P
PR	17-AUG-1998	98US-00396773P
PR	17-AUG-1998	98US-00396791P
PR	17-AUG-1998	98US-00396895P
PR	17-AUG-1998	98US-00396895P
PR	18-AUG-1998	98US-00396960P
PR	18-AUG-1998	98US-00397141P
PR	20-AUG-1998	98US-00397218P
PR	26-AUG-1998	98US-00397951P
PR	26-AUG-1998	98US-00397986P
PR	28-AUG-1998	98WO-US017888
PR	31-AUG-1998	98US-00398525P
PR	01-SEP-1998	98US-00398750P
PR	01-SEP-1998	98US-00398536P
PR	09-SEP-1998	98US-00398598P
PR	09-SEP-1998	98US-00398601P
PR	09-SEP-1998	98US-00398792P
PR	10-SEP-1998	98US-00398803P
PR	10-SEP-1998	98US-00398816P
PR	10-SEP-1998	98WO-US018824
PR	10-SEP-1998	98US-0100262P
PR	14-SEP-1998	98US-0100263P
PR	14-SEP-1998	98WO-US019093
PR	14-SEP-1998	98WO-US019094
PR	14-SEP-1998	98WO-US019177
PR	15-SEP-1998	98US-0100303P
PR	16-SEP-1998	98US-0100364P
PR	16-SEP-1998	98WO-US019330
PR	17-SEP-1998	98US-0100710P
PR	17-SEP-1998	98US-0100858P
PR	17-SEP-1998	98WO-US019437
PR	23-SEP-1998	98US-0101474P
PR	23-SEP-1998	98US-0101477P
PR	24-SEP-1998	98US-011741P

[illegible]

PR	04-AUG-1998;	98US-0095301P;
PR	04-AUG-1998;	98US-0095302P;
PR	04-AUG-1998;	98US-0095325P;
PR	11-AUG-1998;	98US-0096143P;
PR	11-AUG-1998;	98US-0096146P;
PR	12-AUG-1998;	98US-0096322P;
PR	17-AUG-1998;	98US-0096768P;
PR	17-AUG-1998;	98US-0096773P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096892P;
PR	18-AUG-1998;	98US-0096960P;
PR	20-AUG-1998;	98US-0097141P;
PR	20-AUG-1998;	98US-0097218P;
PR	26-AUG-1998;	98US-0097951P;
PR	26-AUG-1998;	98US-0097986P;
PR	28-AUG-1998;	98US-0098178P;
PR	31-AUG-1998;	98US-0098525P;
PR	01-SEP-1998;	98US-0098750P;
PR	01-SEP-1998;	98US-0099536P;
PR	09-SEP-1998;	98US-0099598P;
PR	10-SEP-1998;	98US-0099601P;
PR	10-SEP-1998;	98US-0099792P;
PR	10-SEP-1998;	98US-0099803P;
PR	10-SEP-1998;	98US-0099816P;
PR	10-SEP-1998;	98US-0099824P;
PR	14-SEP-1998;	98US-0100262P;
PR	14-SEP-1998;	98US-0100263P;
PR	14-SEP-1998;	98US-0100343P;
PR	14-SEP-1998;	98US-0100390P;
PR	14-SEP-1998;	98US-0100390P;
PR	16-SEP-1998;	98US-0100710P;
PR	16-SEP-1998;	98US-0100710P;
PR	17-SEP-1998;	98US-0100858P;
PR	17-SEP-1998;	98US-0100943P;
PR	23-SEP-1998;	98US-0101474P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-011741P;

04-AUG-1998	98US-00953325P
05-AUG-1998	98US-00961434P
11-AUG-1998	98US-0096146P
11-AUG-1998	98US-0096329P
12-AUG-1998	98US-0096769P
17-AUG-1998	98US-0096773P
17-AUG-1998	98US-0096791P
17-AUG-1998	98US-0096891P
17-AUG-1998	98US-0096895P
18-AUG-1998	98US-0096960P
19-AUG-1998	98US-0097141P
20-AUG-1998	98US-0097218P
26-AUG-1998	98US-0097951P
26-AUG-1998	98US-0097986P
28-AUG-1998	98US-0097988P
31-AUG-1998	98US-0098523P
01-SEP-1998	98US-0098750P
09-SEP-1998	98US-0099536P
09-SEP-1998	98US-0099598P
09-SEP-1998	98US-0099601P
10-SEP-1998	98US-0099792P
10-SEP-1998	98US-0099803P
10-SEP-1998	98US-0099816P
10-SEP-1998	98US-0099824P
14-SEP-1998	98US-0100262P
14-SEP-1998	98US-0100263P
14-SEP-1998	98US-0100993
14-SEP-1998	98US-0100994
14-SEP-1998	98US-0101977P
15-SEP-1998	98US-0100390P
16-SEP-1998	98US-0100634P
16-SEP-1998	98US-01009330
17-SEP-1998	98US-0100710P
17-SEP-1998	98US-0100858P
17-SEP-1998	98US-01019437P
23-SEP-1998	98US-0101474P
23-SEP-1998	98US-0101477P
24-SEP-1998	98US-0111741P

11-AUG-1998	98US-0096145P
12-AUG-1998	98US-0096323P
17-AUG-1998	98US-0096769P
17-AUG-1998	98US-0096773P
17-AUG-1998	98US-0096791P
17-AUG-1998	98US-0096891P
17-AUG-1998	98US-0096895P
18-AUG-1998	98US-0096960P
20-AUG-1998	98US-0097141P
20-AUG-1998	98US-0097218P
26-AUG-1998	98US-0097951P
26-AUG-1998	98US-0097986P
28-AUG-1998	98MO-US017888
31-AUG-1998	98MO-US017888
01-SEP-1998	98US-0098523P
01-SEP-1998	98US-0098750P
09-SEP-1998	98US-0099538P
09-SEP-1998	98US-0099596P
09-SEP-1998	98US-0099598P
10-SEP-1998	98US-0099601P
10-SEP-1998	98US-0099792P
10-SEP-1998	98US-0099803P
10-SEP-1998	98US-0099816P
10-SEP-1998	98MO-US018824
14-SEP-1998	98US-0100262P
14-SEP-1998	98US-0100263P
14-SEP-1998	98MO-US019093
14-SEP-1998	98MO-US019094
14-SEP-1998	98MO-US019177
15-SEP-1998	98US-0100390P
16-SEP-1998	98US-0100634P
16-SEP-1998	98MO-US019330
17-SEP-1998	98US-01007130
17-SEP-1998	98US-0100858P
17-SEP-1998	98MO-US019437
23-SEP-1998	98US-0101474P
23-SEP-1998	98US-0101477P
24-SEP-1998	98US-011741P

12-AUG-1998	98US-0096768P
17-AUG-1998	98US-0096773P
17-AUG-1998	98US-0096791P
17-AUG-1998	98US-0096891P
17-AUG-1998	98US-0096895P
17-AUG-1998	98US-0096960P
18-AUG-1998	98US-0097141P
19-AUG-1998	98US-0097218P
20-AUG-1998	98US-0097951P
26-AUG-1998	98US-0097986P
28-AUG-1998	98US-0097988P
31-AUG-1998	98US-0098525P
01-SEP-1998	98US-0098750P
09-SEP-1998	98US-0099536P
09-SEP-1998	98US-0099598P
09-SEP-1998	98US-0099601P
10-SEP-1998	98US-0099792P
10-SEP-1998	98US-0099803P
10-SEP-1998	98US-0099818P
10-SEP-1998	98US-0099824P
14-SEP-1998	98US-0100263P
14-SEP-1998	98US-0100262P
14-SEP-1998	98US-0100263P
14-SEP-1998	98US-0100309P
14-SEP-1998	98US-0100390P
15-SEP-1998	98US-0100634P
16-SEP-1998	98US-01009330P
17-SEP-1998	98US-0100710P
17-SEP-1998	98US-0100858P
17-SEP-1998	98US-01019437
23-SEP-1998	98US-0101474P
23-SEP-1998	98US-0101477P
24-SEP-1998	98US-011741P

PR	17-AUG-1998	98US-00967919P
PR	17-AUG-1998	98US-00968919P
PR	17-AUG-1998	98US-00968919P
PR	18-AUG-1998	98US-00969609P
PR	18-AUG-1998	98US-00971419P
PR	20-AUG-1998	98US-00972189P
PR	20-AUG-1998	98US-00979519P
PR	26-AUG-1998	98US-00979869P
PR	26-AUG-1998	98MO-US017888P
PR	28-AUG-1998	98US-00985219P
PR	31-AUG-1998	98US-00985709P
PR	01-SEP-1998	98US-00995369P
PR	01-SEP-1998	98US-00995989P
PR	09-SEP-1998	98US-00996019P
PR	09-SEP-1998	98US-00997929P
PR	10-SEP-1998	98US-00998039P
PR	10-SEP-1998	98US-00998169P
PR	10-SEP-1998	98MO-US018824P
PR	14-SEP-1998	98US-01002629P
PR	14-SEP-1998	98US-01002639P
PR	14-SEP-1998	98MO-US019093P
PR	14-SEP-1998	98MO-US019094P
PR	14-SEP-1998	98MO-US019177P
PR	15-SEP-1998	98US-01003909P
PR	16-SEP-1998	98US-01006349P
PR	16-SEP-1998	98MO-US019330P
PR	16-SEP-1998	98US-01007109P
PR	17-SEP-1998	98US-01008589P
PR	17-SEP-1998	98MO-US019437P
PR	23-SEP-1998	98US-01014749P
PR	23-SEP-1998	98US-01014779P
PR	24-SEP-1998	98US-0117419P

PR	17-AUG-1998	98US-0096895P
PR	18-AUG-1998	98US-0096960P
PR	19-AUG-1998	98US-0097141P
PR	20-AUG-1998	98US-0097218P
PR	20-AUG-1998	98US-0097951P
PR	26-AUG-1998	98US-0097986P
PR	28-AUG-1998	98US-0098017P
PR	31-AUG-1998	98US-0098253P
PR	01-SEP-1998	98US-0098750P
PR	09-SEP-1998	98US-0099536P
PR	09-SEP-1998	98US-0099598P
PR	09-SEP-1998	98US-0099601P
PR	10-SEP-1998	98US-0099792P
PR	10-SEP-1998	98US-0099803P
PR	10-SEP-1998	98US-0099816P
PR	10-SEP-1998	98US-0099822P
PR	14-SEP-1998	98US-0100262P
PR	14-SEP-1998	98US-0100263P
PR	14-SEP-1998	98US-0099309P
PR	14-SEP-1998	98US-0099309P
PR	14-SEP-1998	98US-0099309P
PR	14-SEP-1998	98US-0099309P
PR	15-SEP-1998	98US-0100390P
PR	16-SEP-1998	98US-0100634P
PR	16-SEP-1998	98US-0099330P
PR	17-SEP-1998	98US-0100710P
PR	17-SEP-1998	98US-0100858P
PR	17-SEP-1998	98US-0099194P
PR	23-SEP-1998	98US-0101473P
PR	23-SEP-1998	98US-0101477P
PR	24-SEP-1998	98US-0117417P
PR	24-SEP-1998	98US-0117417P

PR	19-AUG-1998;	98US-0097141P
PR	20-AUG-1998;	98US-0097218P
PR	26-AUG-1998;	98US-0097951P
PR	26-AUG-1998;	98US-0097986P
PR	28-AUG-1998;	98WO-US017888
PR	28-AUG-1998;	98US-0098525P
PR	31-AUG-1998;	98US-0098750P
PR	01-SEP-1998;	98US-0099536P
PR	09-SEP-1998;	98US-0099598P
PR	09-SEP-1998;	98US-0099601P
PR	10-SEP-1998;	98US-0099792P
PR	10-SEP-1998;	98US-0099803P
PR	10-SEP-1998;	98US-0099816P
PR	10-SEP-1998;	98WO-US018824
PR	14-SEP-1998;	98US-0100262P
PR	14-SEP-1998;	98US-0100263P
PR	14-SEP-1998;	98WO-US019093
PR	14-SEP-1998;	98WO-US019094
PR	14-SEP-1998;	98WO-US019177
PR	15-SEP-1998;	98US-0100390P
PR	16-SEP-1998;	98US-0100634P
PR	16-SEP-1998;	98WO-US019330
PR	17-SEP-1998;	98US-0100710P
PR	17-SEP-1998;	98US-0100858P
PR	17-SEP-1998;	98WO-US019437
PR	23-SEP-1998;	98WO-0100474P
PR	23-SEP-1998;	98US-0101477P
PR	24-SEP-1998;	98US-0101741P

26-AUG-1998;	98US-0097951P;
26-AUG-1998;	98US-0097986P;
28-AUG-1998;	98WO-US017868;
31-AUG-1998;	98US-0098523P;
01-SEP-1998;	98US-0098750P;
09-SEP-1998;	98US-0099536P;
09-SEP-1998;	98US-0099598P;
09-SEP-1998;	98US-0099601P;
10-SEP-1998;	98US-0099792P;
10-SEP-1998;	98US-0099803P;
10-SEP-1998;	98US-0099816P;
10-SEP-1998;	98WO-US018824;
14-SEP-1998;	98US-0100262P;
14-SEP-1998;	98US-0100263P;
14-SEP-1998;	98WO-US019093;
14-SEP-1998;	98WO-US019094;
14-SEP-1998;	98WO-US019177;
15-SEP-1998;	98US-0100390P;
16-SEP-1998;	98US-0100634P;
17-SEP-1998;	98WO-US019330;
17-SEP-1998;	98US-0100710P;
17-SEP-1998;	98US-0100858P;
17-SEP-1998;	98WO-US019437;
23-SEP-1998;	98US-0101474P;
23-SEP-1998;	98US-0101477P;
24-SEP-1998;	98US-0111741P;

28-AUG-1998	PR	98WO-US017898
29-AUG-1998	PR	98WO-US008525P
31-AUG-1998	PR	98US-US0098750P
01-SEP-1998	PR	98US-US0098750P
09-SEP-1998	PR	98US-US009536P
09-SEP-1998	PR	98US-US009536P
09-SEP-1998	PR	98US-US009598P
09-SEP-1998	PR	98US-US009601P
10-SEP-1998	PR	98US-US009792P
10-SEP-1998	PR	98US-US009803P
10-SEP-1998	PR	98US-US009816P
10-SEP-1998	PR	98WO-US018824
14-SEP-1998	PR	98US-US002623P
14-SEP-1998	PR	98US-US0100263P
14-SEP-1998	PR	98WO-US019093
14-SEP-1998	PR	98WO-US019094
14-SEP-1998	PR	98WO-US019177
14-SEP-1998	PR	98US-US000390P
15-SEP-1998	PR	98US-US000634P
16-SEP-1998	PR	98WO-US019330
16-SEP-1998	PR	98WO-US019330
17-SEP-1998	PR	98US-US000710P
17-SEP-1998	PR	98US-US000858P
17-SEP-1998	PR	98US-US019437
17-SEP-1998	PR	98WO-US019437
23-SEP-1998	PR	98US-US01474P
23-SEP-1998	PR	98US-US01477P
23-SEP-1998	PR	98US-US01741P
24-SEP-1998	PR	98US-US01741P

01-SEP-1998	98US-0098750P
02-SEP-1998	98US-0098753P
03-SEP-1998	98US-0098756P
04-SEP-1998	98US-0098759P
05-SEP-1998	98US-0098761P
06-SEP-1998	98US-0098762P
07-SEP-1998	98US-0098765P
08-SEP-1998	98US-0098768P
09-SEP-1998	98US-0098771P
10-SEP-1998	98US-0098774P
11-SEP-1998	98US-0098777P
12-SEP-1998	98US-0098780P
13-SEP-1998	98US-0098783P
14-SEP-1998	98US-0098786P
15-SEP-1998	98US-0098789P
16-SEP-1998	98US-0098792P
17-SEP-1998	98US-0098795P
18-SEP-1998	98US-0098798P
19-SEP-1998	98US-0098801P
20-SEP-1998	98US-0098804P
21-SEP-1998	98US-0098807P
22-SEP-1998	98US-0098810P
23-SEP-1998	98US-0098813P
24-SEP-1998	98US-0098816P
25-SEP-1998	98US-0098819P
26-SEP-1998	98US-0098822P
27-SEP-1998	98US-0098825P
28-SEP-1998	98US-0098828P
29-SEP-1998	98US-0098831P
30-SEP-1998	98US-0098834P
01-OCT-1998	98US-0098837P
02-OCT-1998	98US-0098840P
03-OCT-1998	98US-0098843P
04-OCT-1998	98US-0098846P
05-OCT-1998	98US-0098849P
06-OCT-1998	98US-0098852P
07-OCT-1998	98US-0098855P
08-OCT-1998	98US-0098858P
09-OCT-1998	98US-0098861P
10-OCT-1998	98US-0098864P
11-OCT-1998	98US-0098867P
12-OCT-1998	98US-0098870P
13-OCT-1998	98US-0098873P
14-OCT-1998	98US-0098876P
15-OCT-1998	98US-0098879P
16-OCT-1998	98US-0098882P
17-OCT-1998	98US-0098885P
18-OCT-1998	98US-0098888P
19-OCT-1998	98US-0098891P
20-OCT-1998	98US-0098894P
21-OCT-1998	98US-0098897P
22-OCT-1998	98US-0098900P
23-OCT-1998	98US-0098903P
24-OCT-1998	98US-0098906P
25-OCT-1998	98US-0098909P
26-OCT-1998	98US-0098912P
27-OCT-1998	98US-0098915P
28-OCT-1998	98US-0098918P
29-OCT-1998	98US-0098921P
30-OCT-1998	98US-0098924P
31-OCT-1998	98US-0098927P
01-NOV-1998	98US-0098930P
02-NOV-1998	98US-0098933P
03-NOV-1998	98US-0098936P
04-NOV-1998	98US-0098939P
05-NOV-1998	98US-0098942P
06-NOV-1998	98US-0098945P
07-NOV-1998	98US-0098948P
08-NOV-1998	98US-0098951P
09-NOV-1998	98US-0098954P
10-NOV-1998	98US-0098957P
11-NOV-1998	98US-0098960P
12-NOV-1998	98US-0098963P
13-NOV-1998	98US-0098966P
14-NOV-1998	98US-0098969P
15-NOV-1998	98US-0098972P
16-NOV-1998	98US-0098975P
17-NOV-1998	98US-0098978P
18-NOV-1998	98US-0098981P
19-NOV-1998	98US-0098984P
20-NOV-1998	98US-0098987P
21-NOV-1998	98US-0098990P
22-NOV-1998	98US-0098993P
23-NOV-1998	98US-0098996P
24-NOV-1998	98US-0098999P
25-NOV-1998	98US-0099002P
26-NOV-1998	98US-0099005P
27-NOV-1998	98US-0099008P
28-NOV-1998	98US-0099011P
29-NOV-1998	98US-0099014P
30-NOV-1998	98US-0099017P
01-DEC-1998	98US-0099020P
02-DEC-1998	98US-0099023P
03-DEC-1998	98US-0099026P
04-DEC-1998	98US-0099029P
05-DEC-1998	98US-0099032P
06-DEC-1998	98US-0099035P
07-DEC-1998	98US-0099038P
08-DEC-1998	98US-0099041P
09-DEC-1998	98US-0099044P
10-DEC-1998	98US-0099047P
11-DEC-1998	98US-0099050P
12-DEC-1998	98US-0099053P
13-DEC-1998	98US-0099056P
14-DEC-1998	98US-0099059P
15-DEC-1998	98US-0099062P
16-DEC-1998	98US-0099065P
17-DEC-1998	98US-0099068P
18-DEC-1998	98US-0099071P
19-DEC-1998	98US-0099074P
20-DEC-1998	98US-0099077P
21-DEC-1998	98US-0099080P
22-DEC-1998	98US-009

[illegible][illegible]

10-SEP-1998;	PR	98US-00093816P
10-SEP-1998;	PR	98US-00018824A
10-SEP-1998;	PR	98WO-US010822P
14-SEP-1998;	PR	98US-000262P
14-SEP-1998;	PR	98US-0100263P
14-SEP-1998;	PR	98WO-US010903P
14-SEP-1998;	PR	98WO-US010904A
14-SEP-1998;	PR	98WO-US010917P
14-SEP-1998;	PR	98US-0100390P
15-SEP-1998;	PR	98US-0100643P
16-SEP-1998;	PR	98WO-US019330P
16-SEP-1998;	PR	98WO-US019330P
17-SEP-1998;	PR	98US-0100710P
17-SEP-1998;	PR	98US-0100858P
17-SEP-1998;	PR	98WO-US019437P
17-SEP-1998;	PR	98US-0101474P
23-SEP-1998;	PR	98US-0101477P
24-SEP-1998;	PR	98US-0101741P
24-SEP-1998;	PR	98US-0101741P

PR	14-SEP-1998	98US-01002622
PR	14-SEP-1998	98US-01002630
PR	14-SEP-1998	98WO-US019093
PR	14-SEP-1998	98WO-US019094
PR	14-SEP-1998	98WO-US019177
PR	14-SEP-1998	98US-01003309
PR	15-SEP-1998	98US-01006340
PR	16-SEP-1998	98WO-US019330
PR	16-SEP-1998	98US-01007100
PR	17-SEP-1998	98US-01008580
PR	17-SEP-1998	98WO-US019437
PR	17-SEP-1998	98US-01008580
PR	23-SEP-1998	98US-01014740
PR	23-SEP-1998	98US-01014770
PR	23-SEP-1998	98US-01017410
PR	23-SEP-1998	98US-01017410

	PR	98WO-US019093
14-SEP-1998	PR	98WO-US019094
14-SEP-1998	PR	98WO-US019177
14-SEP-1998	PR	98US-OI00390P
15-SEP-1998	PR	98US-OI00634P
16-SEP-1998	PR	98WO-US019330
16-SEP-1998	PR	98US-OI00710P
17-SEP-1998	PR	98US-OI00858P
17-SEP-1998	PR	98US-OI019437
17-SEP-1998	PR	98WO-US019437
23-SEP-1998	PR	98US-OI01474P
23-SEP-1998	PR	98US-OI01477P
23-SEP-1998	PR	98US-OI01741P
24-SEP-1998	PR	98US-OI01741P

98WU-US0119177 PR
98WU-US010390P PR
98US-US0019039 PR
98US-US006343P PR
98WU-US0119330 PR
98US-US007107R PR
98US-US008583P PR
98WU-US0119437 PR
98WU-US0104474 PR
98US-US011477P PR
98US-US011477P PR
98US-US011477P PR
98US-US011477P PR
98US-US011477P PR

PR 16-SEP-1998; 98US-0100634P;
PR 16-SEP-1998; 98WO-US019330;
PR 17-SEP-1998; 98US-0100710P;
PR 17-SEP-1998; 98US-0100858P;
PR 17-SEP-1998; 98WO-US019437;
PR 23-SEP-1998; 98US-0101474P;
PR 23-SEP-1998; 98US-0101477P;
PR 24-SEP-1998; 98US-0101741P;
PR 24-SEP-1998;

PR	17-SEP-1998;	98US-0100710P.
PR	17-SEP-1998;	98US-0100858P.
PR	17-SEP-1998;	98WO-US019437.
PR	23-SEP-1998;	98US-0101474P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101741P.

PR	17-SEP-1998;	98WO-US019437.
PR	23-SEP-1998;	98US-0101474P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101741P.

PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101741P.

CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTTGGTTTGT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTTCGACACAGCGCTGTTTATT 1083
RESULT 144
ADB22703/c
ID ADB22703 standard; cDNA; 1129 BP.
XX
AC ADB22703;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US200307711-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127829.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-755066/71.
DR P-PSDB; ADB22704.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, as diagnostic markers for the presence of a disease
PT condition, or as therapeutic targets for treating tumors, diabetes,
PT obesity or arthritis.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 03-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-0086034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-695925/66.
DR P-PSDB; ADA66843.
XX
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT release of tumor necrosis factor-alpha from human blood and detecting the
PT presence of a tumor in a mammal.
XX
XX Claim 2; Fig 221; 60pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumor in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumors, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	PR	29-OCT-1998;	98WO-US022991.
CC	be used in preparing PRO polypeptides by recombinant techniques and in	PR	29-OCT-1998;	98WO-US022992.
CC	generating either transgenic animals or knock-out animals which are	PR	29-NOV-1998;	98WO-US024855.
CC	useful in the development and screening of therapeutically useful	PR	01-DEC-1998;	98WO-US025108.
CC	reagents. The PRO polypeptides or antibodies are used in preparing a	PR	05-JAN-1999;	99WO-US000106.
CC	medicament for treating a condition responsive to the polypeptides or	PR	08-MAR-1999;	99WO-US005028.
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	PR	10-MAR-1999;	99WO-US005190.
CC	of human microvascular endothelial cells, for modulating the uptake of	PR	20-APR-1999;	99WO-US008615.
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	PR	14-MAY-1999;	99WO-US010733.
CC	stimulating differentiation of adipocyte cells, for stimulating	PR	02-JUN-1999;	99WO-US012252.
CC	proliferation of or gene expression in pericyte cells, for stimulating	PR	01-SEP-1999;	99WO-US020111.
CC	the proliferation of inner ear cellular supporting cells or T-lymphocyte	PR	08-SEP-1999;	99WO-US020594.
CC	cells, for inducing endothelial cell tube formation and for treating	PR	13-SEP-1999;	99WO-US020944.
CC	various bone and/or cartilage disorders such as sports injuries and	PR	15-SEP-1999;	99WO-US021090.
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans	PR	15-SEP-1999;	99WO-US021547.
CC	from cartilage are useful for treating sports-related joint problems,	PR	05-OCT-1999;	99WO-US023089.
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO	PR	29-NOV-1999;	99WO-US028214.
CC	polypeptides are also useful for treating various mammalian haemoglobin-	PR	30-NOV-1999;	99WO-US028409.
CC	associated disorders such as various thalassemias and conditions which	PR	01-DEC-1999;	99WO-US028301.
CC	may benefit from enhanced local immune system cell infiltration. This	PR	01-DEC-1999;	99WO-US028634.
CC	sequence represents a human PRO polynucleotide of the invention. Note:	PR	02-DEC-1999;	99WO-US028551.
CC	The sequence data for this patent is also available in electronic format	PR	02-DEC-1999;	99WO-US028564.
CC	from USPTO at seqdata.uspto.gov/sequence.html.	PR	02-DEC-1999;	99WO-US028565.
XX		PR	16-DEC-1999;	99WO-US030095.
XX	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;	PR	20-DEC-1999;	99WO-US030911.
XX		PR	20-DEC-1999;	99WO-US030999.
XX	Query March 0.9%; Score 21.4; DB 1; Length 1129;	PR	22-DEC-1999;	99WO-US030720.
XX	Best Local Similarity 66.0%; Pred No. 56;	PR	30-DEC-1999;	99WO-US031243.
XX	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;	PR	30-DEC-1999;	99WO-US031274.
Qy	1929 TTCTTAATTTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975	PR	05-JAN-2000;	2000WO-US000219.
Db	1129 TTTTITTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTTTATT 1083	PR	06-JAN-2000;	2000WO-US000277.
		PR	06-JAN-2000;	2000WO-US000376.
RESULT 148		PR	11-FEB-2000;	2000WO-US003565.
ADB38513/c		PR	18-FEB-2000;	2000WO-US004341.
ID	ADB38513 standard; cDNA; 1129 BP.	PR	18-FEB-2000;	2000WO-US004342.
XX		PR	22-FEB-2000;	2000WO-US004414.
XX		PR	24-FEB-2000;	2000WO-US004914.
AC	ADB38513;	PR	24-FEB-2000;	2000WO-US005004.
XX		PR	01-MAR-2000;	2000WO-US005601.
XX		PR	02-MAR-2000;	2000WO-US005746.
DT	04-DEC-2003 (first entry)	PR	02-MAR-2000;	2000WO-US005841.
XX		PR	10-MAR-2000;	2000WO-US006319.
XX		PR	15-MAR-2000;	2000WO-US006884.
DE	Novel human secreted and transmembrane protein PRO4327 cDNA.	PR	20-MAR-2000;	2000WO-US007377.
XX		PR	21-MAR-2000;	2000WO-US007532.
KW	Human; secreted and transmembrane protein; PRO; Gene: ss;	PR	30-MAR-2000;	2000WO-US008439.
KW	Tumour necrosis factor alpha release; TNF-alpha release;	PR	17-MAY-2000;	2000WO-US013705.
KW	glucose uptake modulator; FFA uptake modulator;	PR	22-MAY-2000;	2000WO-US014942.
KW	cell proliferation stimulator; cell differentiation stimulator;	PR	30-MAY-2000;	2000WO-US014941.
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	PR	02-JUN-2000;	2000WO-US015264.
KW	lung tumore; colon tumour; breast tumour; prostate tumour; rectal tumour;	PR	28-JUL-2000;	2000WO-US020710.
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	PR	11-AUG-2000;	2000WO-US022031.
KW	gene therapy; chromosome identification; chromosome marker.	PR	23-AUG-2000;	2000WO-US023322.
XX		PR	24-AUG-2000;	2000WO-US023328.
OS	Homo sapiens.	PR	08-NOV-2000;	2000WO-US030952.
XX		PR	10-NOV-2000;	2000WO-US030873.
XX		PR	01-DEC-2000;	2000WO-US032678.
PN	US2003082766-A1.	PR	20-DEC-2000;	2000WO-US034956.
XX		PR	20-DEC-2000;	2000WO-US034956.
PD	01-MAY-2003.	PR	28-FEB-2001;	2001US-00796498.
XX		PR	28-FEB-2001;	2001WO-US006520.
XX		PR	01-MAR-2001;	2001WO-US006666.
XX		PR	09-MAR-2001;	2001WO-US006706.
PR	31-MAR-1997; 97WO-US005230.	PR	14-MAR-2001;	2001US-00802706.
PR	12-JUN-			

PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019892.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786921/74.
 DR P-PSDB; ADB38514.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 PS Claim 2; Fig 221; 660pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 G; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1929 TCTTAAATTTTTCATTCAGATTCTTCAGTTGGCTTTGTTT 1975
 Db 1129 TTTTATTTTTCATTCAGATTCTTCAGTTGGCTTTGTTT 1083
 RESULT 149

ADB37961/c
 ID ADB37961 standard; cDNA; 1129 BP.
 XX
 AC ADB37961;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003087347-A1.
 PN
 XX 08-MAY-2003.
 PD
 XX 19-APR-2002; 2002US-00125921.
 PF
 XX 17-AUG-1998; 98US-0096791P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786938/74.
 DR P-PSDB; ADB37962.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PT
 PS Claim 2; Fig 221; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCAGATTTTCCTTCAGTTGGGTTTGTGTT 1975
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083
RESULT 150
ADB66433/c
ID ADB66433 standard; cDNA; 1129 BP.
XX
AC ADB66433;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
DN US2003082689-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127831.
XX
PR 31-MAR-1997; 99WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-1999;
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US021066.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

ADB90245/c
 ID ADB90245 standard; cDNA; 1129 BP.
 XX
 AC ADB90245;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Human PRO polynucleotide #111.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear intricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003082762-A1.
 PN
 XX
 XX 01-MAY-2003.
 XX
 XX 15-APR-2002; 2002US-00123235.
 PF
 XX 31-MAR-1997; 97WO-US005230.
 XX 12-JUN-1998; 98WO-US012456.
 XX 14-JUL-1998; 98WO-US014552.
 XX 28-AUG-1998; 98WO-US017888.
 XX 10-SEP-1998; 98WO-US018824.
 XX 14-SEP-1998; 98WO-US019093.
 XX 14-SEP-1998; 98WO-US019094.
 XX 14-SEP-1998; 98WO-US019094.
 XX 16-SEP-1998; 98WO-US019330.
 XX 17-SEP-1998; 98WO-US019437.
 XX 27-OCT-1998; 98WO-US021141.
 XX 29-OCT-1998; 98WO-US022991.
 XX 29-OCT-1998; 98WO-US022992.
 XX 29-OCT-1998; 98WO-US024855.
 XX 01-DEC-1998; 98WO-US025108.
 XX 05-JAN-1999; 99WO-US000106.
 XX 08-MAR-1999; 99WO-US005028.
 XX 10-MAR-1999; 99WO-US005190.
 XX 20-APR-1999; 99WO-US008615.
 XX 14-MAY-1999; 99WO-US010733.
 XX 02-JUN-1999; 99WO-US012252.
 XX 01-SEP-1999; 99WO-US020111.
 XX 08-SEP-1999; 99WO-US020594.
 XX 13-SEP-1999; 99WO-US020944.
 XX 15-SEP-1999; 99WO-US021090.
 XX 15-SEP-1999; 99WO-US021547.
 XX 05-OCT-1999; 99WO-US023089.
 XX 29-NOV-1999; 99WO-US028214.
 XX 30-NOV-1999; 99WO-US028313.
 XX 30-NOV-1999; 99WO-US028409.
 XX 01-DEC-1999; 99WO-US028301.
 XX 01-DEC-1999; 99WO-US028634.
 XX 02-DEC-1999; 99WO-US028551.
 XX 02-DEC-1999; 99WO-US028564.
 XX 02-DEC-1999; 99WO-US028565.
 XX 16-DEC-1999; 99WO-US030095.
 XX 20-DEC-1999; 99WO-US030911.
 XX 20-DEC-1999; 99WO-US030999.
 XX 22-DEC-1999; 99WO-US030720.
 XX 30-DEC-1999; 99WO-US031124.
 XX 30-DEC-1999; 99WO-US031274.
 XX 05-JAN-2000; 2000WO-US000219.
 XX 06-JAN-2000; 2000WO-US000277.
 XX 06-JAN-2000; 2000WO-US000376.
 XX 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023528.
 PR 10-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 18-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US015692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 08-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-743899/70.
 DR P-PSDB; ADB90245.
 DR
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, and in the detection and treatment of tumor in a mammal.
 FT
 XX
 XX Claim 2; Fig 221; 649pp; English.
 PS
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis

PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00870992.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001US-00921066.
PR 29-JUN-2001; 2001US-00921066.
PR 09-JUL-2001; 2001US-00921735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00924419.
PR 16-DEC-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786919/74.
XX P-PSDB; ADB39347.
XX
XX New secreted and transmembrane PRO polypeptide useful for detecting the
XX presence of tumor in a mammal, or modulating the uptake of glucose or
XX free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumor in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTTCCAGATTCCTTCAGTTGGGTTTGT 1975

DB 1129 TTTTTCATTTTTCATTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 154
ADB46969/c
ID ADB46969 standard; cDNA; 1129 BP.
XX
XX ADB46969;
XX
XX 04-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX US2003082687-A1.
XX
XX 01-MAY-2003.
XX
XX 19-APR-2002; 2002US-00125930.
XX
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786904/74.
XX P-PSDB; ADB46970.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 221; 627pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumor in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ


```
PR 19-DEC-2003; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755109/71.
DR P-PSDB; ADB77182.
XX
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTCCAGATTTTCCTTCAGTTGGGTTTGTGTT 1975
Db 1129 TTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGCTTTTATT 1083
RESULT 157
ADB34338/c
XX ID ADB34338 standard; cDNA; 1129 BP.
XX AC ADB34338;
XX
XX 04-DEC-2003 (first entry)
XX
XX Human PRO polynucleotide SEQ ID NO 221.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
```

```
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003077717-A1.
XX
XX 24-APR-2003.
XX
XX 24-APR-2002; 2002US-00131818.
XX
XX 07-OCT-1998; 98US-0103328P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 30-NOV-1999; 99WO-US028313.
XX 18-FEB-2000; 2000WO-US004342.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755072/71.
XX P-PSDB; ADB34339.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumors). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting the proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
```


CC invention.

XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other; 0;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1975
||| ||||| ||| ||| ||| ||||| |||
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 167
ADC57149/c
ID ADC57149 standard; cDNA; 1129 BP.
XX
AC ADC57149;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID221.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
OS Homo sapiens.
XX
XX US2003087366-A1.
XX
XX 08-MAY-2003.
XX
XX 23-APR-2002; 2002US-00128694.
XX
XX 02-MAR-2000; 2000WO-US005841.
XX 30-MAY-2000; 2000WO-US014941.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801151/75.
XX P-PSDB; ADC571150.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides and hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytoskeletal activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a

PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.

XX

XX Claim 2; SEQ ID NO 221; 637pp; English.

CC This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides and hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
and receptors may be of use as pharmaceutical and diagnostic agents, such
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors
and proteins, along with the cDNA sequences encoding them. The novel
proteins of the invention may have cytosolic activities through the
stimulation of chondrocytes. The nucleic acids of the invention may be
useful for the manufacture of a medicament for diagnosing or treating a
tumour in a mammal. In addition, they may be useful for measuring or
detecting the expression of a tumour associated gene. The present
sequence is a cDNA sequence which encodes a human PRO protein of the
invention.

XX

SEQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTCAGTTGGGTTTGTTT 1975
|||||
DB 1129 TTTTTTTTTTTTTTTTACGTGGGCACAGCGCTGGTTTATT 1083
|||||

RESULT 173

ID ADC58924/c

XX ADC589224 standard; cDNA; 1129 BP.

XX ADC58924;

DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein cDNA Seq ID221.

KW human; PRO; membrane bound protein; membrane bound receptor;
cell proliferation; cell migration; cell differentiation;
mitogenic factor; survival factor; cytotoxic factor;
differentiation factor; neuropeptide; hormone; cell receptor;
receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

OS Homo sapiens.

XX

XX US2003087359-A1.

PX

PD 08-MAY-2003.

XX

XX 22-APR-2002; 2002US-00127834.

XX

PR 17-SEP-1998; 98US-0100710P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801144/75.
XX P-PSDB; ADC58925.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides or hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytotatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred.No.56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps

Qy 1929 TTCTTAATTTTTTCATTCCAGATTCTCCTCAGTTTGGGTTTGTTT 1975
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTNTTTTTTTTTTTTCACCTCGGCACACAGGCTGGGTATT 1083

RESULT 174
ADC55802/c
ID ADC55802 standard; cDNA; 1129 BP.
XX
XX AC ADC55802;
XX
XX 18-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein cDNA Seq ID221.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
XX US2003087360-A1.
XX
XX 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127836.
XX
XX 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR

immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.

Homo sapiens.

US2003092104-A1.

15-MAY-2003.

24-APR-2002; 2002US-00131817.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

16-SEP-1998; 98WO-US019177.

17-SEP-1998; 98WO-US019330.

27-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
05-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen BE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801169/75.
P-PSDB; ADP03047.
New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.
Claim 2; Fig 221; 638pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for

stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGTGTGTTT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 188
ADD52175/c
ID ADD52175 standard; cDNA; 1129 BP.

AC ADD52175;
XX
DT 15-JAN-2004 (first entry)
DE cDNA encoding human PRO polypeptide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
XX US2003194769-A1.
XX 16-OCT-2003.
XX 21-MAY-2002; 2002US-00152374.
XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-852593/79.

P-PSDB; ADD52176.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for detection of tumors, modulating the uptake of glucose or free fatty acids and stimulating the release of proteoglycans from cartilage.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGTGTGTTT 1975
DB 1129 TTTTTCATTTTTCATTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 189
ADD52175/c
ID ADD52915 standard; cDNA; 1129 BP.
XX
AC ADD52915;
XX
DT 15-JAN-2004 (first entry)
DE cDNA encoding human PRO polypeptide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

immune system cell infiltration.

Homo sapiens.

US2003194792-A1.

16-OCT-2003.

15-APR-2002; 2002US-00123156.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US00028.

10-MAR-1999; 99WO-US005190.

10-MAR-1999; 2000WO-US006319.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028401.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.

18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US004914.

24-FEB-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005746.

02-MAR-2000; 2000WO-US005841.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.

08-NOV-2000; 2000WO-US030952.

10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.

20-DEC-2000; 2000US-00747259.

20-DEC-2000; 2000WO-US034956.

28-FEB-2001; 2001US-00796498.

28-FEB-2001; 2001WO-US006520.

01-MAR-2001; 2001WO-US006666.

09-MAR-2001; 2001US-00802706.

14-MAR-2001; 2001US-00808689.

22-MAR-2001; 2001US-00816744.

05-APR-2001; 2001US-00828366.

10-MAY-2001; 2001US-00854208.

10-MAY-2001; 2001US-00854280.

18-MAY-2001; 2001US-00860216.

25-MAY-2001; 2001US-00866028.

25-MAY-2001; 2001US-00866034.

25-MAY-2001; 2001US-0087092.

01-JUN-2001; 2001US-00872035.

01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.

14-JUN-2001; 2001US-00882636.

19-JUN-2001; 2001US-00886342.

20-JUN-2001; 2001US-00891962.

21-JUN-2001; 2001US-00887879.

22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.

09-JUL-2001; 2001WO-US021735.

18-JUL-2001; 2001US-00908827.

06-AUG-2001; 2001US-00924419.

09-AUG-2001; 2001US-00927796.

16-AUG-2001; 2001US-00931836.

19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-852599/79.

DR P-PSDB; ADD52916.

XX

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PT PRO4978, useful in chromosome and gene mapping, in generating antisense

PT RNA and DNA, and in the treatment of cancer.

XX

PS Claim 2; Fig 221; 638pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1929 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1975
 1129 TTTTNTTTTTTTTTTTTTCAGTGGCACAGGCTGGGTTTATT 1083

RESULT 193
 ID ADD01856/c
 XX AC ADD01856;
 XX DT 15-JAN-2004 (first entry)
 XX DE Human PRO polynucleotide #111.
 XX DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 XX DE tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 XX DE cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 XX DE liver; microvascular endothelial cell; pericyte; FFA;
 XX DE skeletal muscle cell; adipocyte cell; pericyte cell;
 XX DE inner ear utricular supporting cell; T-lymphocyte cell;
 XX DE endothelial cell tube formation; bone disorder; cartilage disorder;
 XX DE sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 XX DE rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 XX DE immune system cell infiltration.
 OS Homo sapiens.
 XX US2003203430-A1.
 XX PD 30-OCT-2003.
 XX PF 23-APR-2002; 2002US-00128685.
 XX PR 11-AUG-1998; 98US-0096143P.
 XX PR 02-JUN-1999; 99WO-US012252.
 XX PR 30-MAR-2000; 2000US-00380137.
 XX PR 30-MAR-2000; 2000WO-US008439.
 XX PR 01-DEC-2000; 2000WO-US032678.
 XX PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875637/81.
 DR P-PSDB; ADD01857.
 XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
 XX generating antisense RNA and DNA, and in gene therapy.
 XX Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; SEQ ID NO 221; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SEQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTGTGTTT 1975

Db 1129 TTTTTCATTTTTCAGTGGCAGACAGGCTGGTGTGTTTATT 1083

RESULT 195

ADD92355/c

ID ADD92355 standard; cDNA; 1129 BP.

XX AC ADD92355;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199030-A1.

XX PD 23-OCT-2003.

XX

PF 28-MAY-2002; 2002US-00156841.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-900159/82.

DR P-PSDB; ADD92356.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 221; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SEQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGTGTGTTT 1975

Db 1129 TTTTTCATTTTTCAGTGGCAGACAGGCTGGTGTGTTTATT 1083

RESULT 196

ADD91251/c

ID ADD91251 standard; cDNA; 1129 BP.

XX AC ADD91251;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.
XX DE
XX DE
XX DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS
XX OS Homo sapiens.
XX PN
XX PN US2003199055-A1.
XX XX
XX PD 23-OCT-2003.
XX PF
XX PF 12-APR-2002; 2002US-00121063.
XX PR
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 20-APR-1999; 2000WO-US006319.
XX PR 14-MAY-1999; 99WO-US008615.
XX PR 02-JUN-1999; 99WO-US010733.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 15-SEP-1999; 99WO-US021547.
XX PR 05-OCT-1999; 99WO-US023089.
XX PR 29-NOV-1999; 99WO-US028214.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 30-NOV-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028401.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 02-DEC-1999; 99WO-US028565.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.
XX PR 22-DEC-1999; 99WO-US030720.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US000356.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 24-FEB-2000; 2000WO-US004914.
XX PR 24-FEB-2000; 2000WO-US005004.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005746.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 15-MAR-2000; 2000WO-US006884.
XX PR 20-MAR-2000; 2000WO-US007377.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 17-MAY-2000; 2000WO-US013705.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 30-MAY-2000; 2000WO-US014941.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 28-JUL-2000; 2000WO-US020710.
XX PR 11-AUG-2000; 2000WO-US022031.
XX PR 23-AUG-2000; 2000WO-US023522.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 08-NOV-2000; 2000WO-US030952.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000US-00747259.
XX PR 20-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001US-00796496.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 01-MAR-2001; 2001WO-US006665.
XX PR 09-MAR-2001; 2001US-00802706.
XX PR 14-MAR-2001; 2001US-00808689.
XX PR 22-MAR-2001; 2001US-00816744.
XX PR 05-APR-2001; 2001US-00828366.
XX PR 10-MAY-2001; 2001US-00854208.
XX PR 18-MAY-2001; 2001US-00860216.
XX PR 25-MAY-2001; 2001US-00866028.
XX PR 25-MAY-2001; 2001US-00866034.
XX PR 25-MAY-2001; 2001WO-US017092.
XX PR 01-JUN-2001; 2001US-00872035.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 05-JUN-2001; 2001US-00874503.
XX PR 14-JUN-2001; 2001US-00882636.
XX PR 19-JUN-2001; 2001US-00886342.
XX PR 20-JUN-2001; 2001WO-US019692.
XX PR 21-JUN-2001; 2001US-00887879.
XX PR 22-JUN-2001; 2001WO-US020116.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-JUL-2001; 2001WO-US021735.
XX PR 18-JUL-2001; 2001US-00908827.
XX PR 06-AUG-2001; 2001US-00924419.
XX PR 09-AUG-2001; 2001US-00927796.
XX PR 16-AUG-2001; 2001US-00931836.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-300165/82.
XX P-PSDB; ADD91252.
XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX PS Claim 2; SEQ ID NO 221; 636pp; English.
XX PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as

PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00862636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 29-JUN-2001; 2001WO-US021735.
PR 09-JUL-2001; 2001US-00908827.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900167/82.
DR P-PSDB; ADE03866.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCCTTAATTTTTCATTTCCAGATTTCTTCAGTTGGGTTTGT 1975
DB 1129 TTTTTCATTTTTCATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 198
ADE32162/c
ID ADE32162 standard; cDNA; 1129 BP.
XX
AC ADE32162;
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003194765-A1.
XX
PD 16-OCT-2003.
XX
PF 09-MAY-2002; 2002US-00142889.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-999784/82.
DR P-PSDB; ADE32163.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 221; 636pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and

PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900166/82.
DR P-PSDB; ADE22095.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 221; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
SQ

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1929 TTCTTAATTTTTCATTCACGATTTTCCTTCAGTTGGGTTTGGTTT 1975
DB 1129 TTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTATT 1083

RESULT 200
ADD79318/c
ID ADD79318 standard; cDNA; 1129 BP.
XX
XX AC ADD79318;
XX
XX DT 29-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003203428-A1.
XX
XX 30-OCT-2003.
XX
XX 22-APR-2002; 2002US-00127852.
XX
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875635/81.
DR P-PSDB; ADD79319.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

PR	01-DEC-1998;	98WO-US025108.	PR	14-JUN-2001;	2001US-00882636.
PR	05-JAN-1999;	99WO-US000106.	PR	19-JUN-2001;	2001US-00886342.
PR	08-MAR-1999;	99WO-US005028.	PR	20-JUN-2001;	2001WO-US019692.
PR	10-MAR-1999;	99WO-US005190.	PR	21-JUN-2001;	2001US-00887879.
PR	20-MAR-1999;	2000WO-US006319.	PR	22-JUN-2001;	2001WO-US020116.
PR	20-APR-1999;	99WO-US008615.	PR	29-JUN-2001;	2001WO-US021066.
PR	14-MAY-1999;	99WO-US010733.	PR	09-JUL-2001;	2001WO-US021735.
PR	02-JUN-1999;	99WO-US012252.	PR	18-JUL-2001;	2001US-00908827.
PR	01-SEP-1999;	99WO-US020111.	PR	06-AUG-2001;	2001US-00924419.
PR	08-SEP-1999;	99WO-US020594.	PR	09-AUG-2001;	2001US-00927796.
PR	13-SEP-1999;	99WO-US020944.	PR	16-AUG-2001;	2001US-00931836.
PR	15-SEP-1999;	99WO-US021090.	PR	19-DEC-2001;	2001US-00028072.
PR	15-SEP-1999;	99WO-US021547.	XX		
PR	05-OCT-1999;	99WO-US023089.	PA	(GETH) GENENTECH INC.	
PR	29-NOV-1999;	99WO-US028214.	XX		
PR	30-NOV-1999;	99WO-US028313.	PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PR	30-NOV-1999;	99WO-US028409.	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PR	01-DEC-1999;	99WO-US028401.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
PR	01-DEC-1999;	99WO-US028634.	XX		
PR	02-DEC-1999;	99WO-US028551.	DR	WPI; 2003-900155/82.	
PR	02-DEC-1999;	99WO-US028564.	DR	P-PSDB; ADE17672.	
PR	02-DEC-1999;	99WO-US028565.	XX		
PR	16-DEC-1999;	99WO-US030095.	PT	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	
PR	20-DEC-1999;	99WO-US030911.	PT	useful for treating pericyte-associated tumors, diabetes and various bone	
PR	20-DEC-1999;	99WO-US030999.	PT	and/or cartilage disorders, e.g. arthritis.	
PR	22-DEC-1999;	99WO-US030720.	XX		
PR	30-DEC-1999;	99WO-US031243.	PS	Claim 2; SEQ ID NO 221; 637pp; English.	
PR	30-DEC-1999;	99WO-US031274.	XX		
PR	05-JAN-2000;	2000WO-US000219.	CC	The invention relates to isolated human PRO polypeptides (secreted and	
PR	06-JAN-2000;	2000WO-US000277.	CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
PR	06-JAN-2000;	2000WO-US000376.	CC	invention also relates to an antibody which specifically binds to a PRO	
PR	11-FEB-2000;	2000WO-US003565.	CC	polypeptide, a method for stimulating the release of tumour necrosis	
PR	18-FEB-2000;	2000WO-US004341.	CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
PR	22-FEB-2000;	2000WO-US004414.	CC	proliferation or differentiation of chondrocyte cells and a method for	
PR	24-FEB-2000;	2000WO-US004914.	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	
PR	24-FEB-2000;	2000WO-US005004.	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
PR	01-MAR-2000;	2000WO-US005601.	CC	polynucleotides are useful in molecular biology, including uses as	
PR	02-MAR-2000;	2000WO-US005746.	CC	hybridisation probes, in chromosome and gene mapping, in generating	
PR	02-MAR-2000;	2000WO-US013705.	CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
PR	15-MAR-2000;	2000WO-US005841.	CC	be used in preparing PRO polypeptides by recombinant techniques and in	
PR	20-MAR-2000;	2000WO-US006884.	CC	generating either transgenic animals or knock-out animals which are	
PR	20-MAR-2000;	2000WO-US007377.	CC	useful in the development and screening of therapeutically useful	
PR	21-MAR-2000;	2000WO-US007532.	CC	reagents. The PRO polypeptides or antibodies are used in preparing a	
PR	30-MAR-2000;	2000WO-US008439.	CC	medicament for treating a condition responsive to the polypeptides or	
PR	17-MAY-2000;	2000WO-US013705.	CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	
PR	22-MAY-2000;	2000WO-US014042.	CC	of human microvascular endothelial cells, for modulating the uptake of	
PR	30-MAY-2000;	2000WO-US014941.	CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
PR	02-JUN-2000;	2000WO-US015264.	CC	stimulating differentiation of adipocyte cells, for stimulating	
PR	28-JUL-2000;	2000WO-US020710.	CC	proliferation of or gene expression in pericyte cells, for stimulating	
PR	11-AUG-2000;	2000WO-US022031.	CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	
PR	24-AUG-2000;	2000WO-US023522.	CC	cells, for inducing endothelial cell tube formation and for treating	
PR	24-AUG-2000;	2000WO-US023328.	CC	various bone and/or cartilage disorders such as sports injuries and	
PR	08-NOV-2000;	2000WO-US030952.	CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans	
PR	10-NOV-2000;	2000WO-US030873.	CC	from cartilage are useful for treating sports-related joint problems,	
PR	01-DEC-2000;	2000WO-US032678.	CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO	
PR	20-DEC-2000;	2000US-00747259.	CC	polypeptides are also useful for treating various mammalian haemoglobin-	
PR	20-DEC-2000;	2000WO-US034956.	CC	associated disorders such as various thalassemias and conditions which	
PR	28-FEB-2001;	2001US-00796498.	CC	may benefit from enhanced local immune system cell infiltration. This	
PR	28-FEB-2001;	2001WO-US006520.	CC	sequence represents a human PRO polynucleotide of the invention. Note:	
PR	01-MAR-2001;	2001WO-US006666.	CC	The sequence data for this patent is also available in electronic format	
PR	09-MAR-2001;	2001US-00802706.	CC	from USPTO at seqdata.uspto.gov/sequence.html .	
PR	14-MAR-2001;	2001US-00808689.	XX		
PR	22-MAR-2001;	2001US-00816744.	SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;	
PR	05-APR-2001;	2001US-00828366.		Query Match 0.9%; Score 21.4; DB 1; Length 1129;	
PR	10-MAY-2001;	2001US-00854208.		Best Local Similarity 66.0%; Pred. No. 56;	
PR	10-MAY-2001;	2001US-00854280.		Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;	
PR	18-MAY-2001;	2001US-00860216.			
PR	23-MAY-2001;	2001US-00866028.			
PR	25-MAY-2001;	2001US-00866034.			
PR	25-MAY-2001;	2001US-00866034.			
PR	01-JUN-2001;	2001WO-US017092.			
PR	01-JUN-2001;	2001US-00872035.			
PR	01-JUN-2001;	2001WO-US017800.			
PR	05-JUN-2001;	2001US-00874503.			
QY	1929	TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTGGGTTTGT 1975			
Db	1129	TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083			

RESULT 203
ADD91803/C
ID ADD91803 standard; cDNA; 1129 BP.
XX
AC ADD91803;
XX
DT 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX OS
XX US2003199053-A1.
XX
XX PD 23-OCT-2003.
XX
XX PE 12-APR-2002; 2002US-00121053.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard AJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900164/82.
DR P-PSDB, ADD91804.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 221; 636pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC	CC	and gene mapping, in generation of antisense RNA and DNA, in the	PR	01-SEP-1999;	99WO-US0201111;
CC	CC	preparation of PRO polypeptide, for generating transgenic animals or	PR	08-SEP-1999;	99WO-US0205944;
CC	CC	knockout animals which in turn are useful in the development and	PR	13-SEP-1999;	99WO-US0205944;
CC	CC	screening of therapeutically useful reagents, in gene therapy, for	PR	15-SEP-1999;	99WO-US0210990;
CC	CC	chromosome identification, as chromosome marker, and for generating	PR	15-SEP-1999;	99WO-US021547;
CC	CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.	PR	05-OCT-1999;	99WO-US023089;
CC	CC	detecting its expression in specific cells, tissues or serum, and for	PR	29-NOV-1999;	99WO-US028214;
CC	CC	affinity purification of PRO from recombinant cell culture or natural	PR	30-NOV-1999;	99WO-US028313;
CC	CC	sources. (I) and (II) are useful for tissue typing. This sequence encodes	PR	30-NOV-1999;	99WO-US028409;
CC	CC	a novel human secreted and transmembrane PRO polypeptide.	PR	01-DEC-1999;	99WO-US028301;
XX	XX		PR	01-DEC-1999;	99WO-US028634;
SQ	SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;	PR	02-DEC-1999;	99WO-US028551;
			PR	02-DEC-1999;	99WO-US028564;
			PR	02-DEC-1999;	99WO-US028565;
			PR	16-DEC-1999;	99WO-US030095;
			PR	20-DEC-1999;	99WO-US030911;
			PR	20-DEC-1999;	99WO-US030999;
			PR	22-DEC-1999;	99WO-US030720;
			PR	30-DEC-1999;	99WO-US031243;
			PR	30-DEC-1999;	99WO-US031274;
			PR	05-JAN-2000;	2000WO-US000219;
			PR	06-JAN-2000;	2000WO-US000277;
			PR	06-JAN-2000;	2000WO-US000376;
			PR	11-FEB-2000;	2000WO-US003565;
			PR	18-FEB-2000;	2000WO-US004342;
			PR	18-FEB-2000;	2000WO-US004342;
			PR	22-FEB-2000;	2000WO-US004414;
			PR	24-FEB-2000;	2000WO-US004914;
			PR	24-FEB-2000;	2000WO-US005004;
			PR	01-MAR-2000;	2000WO-US005601;
			PR	02-MAR-2000;	2000WO-US005746;
			PR	02-MAR-2000;	2000WO-US005841;
			PR	15-MAR-2000;	2000WO-US006884;
			PR	20-MAR-2000;	2000WO-US007377;
			PR	21-MAR-2000;	2000WO-US007532;
			PR	30-MAR-2000;	2000WO-US008439;
			PR	17-MAY-2000;	2000WO-US013705;
			PR	22-MAY-2000;	2000WO-US014042;
			PR	30-MAY-2000;	2000WO-US014941;
			PR	02-JUN-2000;	2000WO-US015264;
			PR	28-JUL-2000;	2000WO-US020710;
			PR	11-AUG-2000;	2000WO-US020231;
			PR	23-AUG-2000;	2000WO-US023522;
			PR	24-AUG-2000;	2000WO-US023328;
			PR	08-NOV-2000;	2000WO-US030352;
			PR	10-NOV-2000;	2000WO-US030873;
			PR	01-DEC-2000;	2000WO-US032678;
			PR	20-DEC-2000;	2000US-00747259;
			PR	20-DEC-2000;	2000WO-US034956;
			PR	28-FEB-2001;	2001US-00796498;
			PR	28-FEB-2001;	2001WO-US006566;
			PR	01-MAR-2001;	2001WO-US006666;
			PR	09-MAR-2001;	2001US-00802706;
			PR	14-MAR-2001;	2001US-00808689;
			PR	22-MAR-2001;	2001US-00816744;
			PR	05-APR-2001;	2001US-00828366;
			PR	10-MAY-2001;	2001US-00854208;
			PR	10-MAY-2001;	2001US-00854280;
			PR	18-MAY-2001;	2001US-00860216;
			PR	25-MAY-2001;	2001US-00866028;
			PR	25-MAY-2001;	2001US-00866034;
			PR	25-MAY-2001;	2001WO-US017092;
			PR	01-JUN-2001;	2001US-00872035;
			PR	01-JUN-2001;	2001WO-US017800;
			PR	05-JUN-2001;	2001US-00874503;
			PR	14-JUN-2001;	2001US-00882636;
			PR	19-JUN-2001;	2001US-00886342;
			PR	20-JUN-2001;	2001WO-US019692;
			PR	21-JUN-2001;	2001US-00887879;
			PR	22-JUN-2001;	2001WO-US020116;
			PR	29-JUN-2001;	2001WO-US021066;
			PR	09-JUL-2001;	2001WO-US021735;
			PR	18-JUL-2001	

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTGGGTTTGT 1975

Db 1129 TTTTITTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 214

ADE32714/c

ID ADE32714 standard; cDNA; 1129 BP.

XX AC ADE32714;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003194766-A1.

XX PD 16-OCT-2003.

XX PF 14-MAY-2002; 2002US-00145874.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-899785/82.

XX DR P-PSDB; ADE32715.

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 221; 636pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1929 TTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTGGGTTTGT 1975

Db 1129 TTTTITTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 215

ADE42406/c

ID ADE42406 standard; cDNA; 1129 BP.

XX AC ADE42406;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199032-A1.

XX XX 23-OCT-2003.

XX	28-MAY-2002; 2002US-00156844.
PF	
XX	
XX	03-MAR-2000; 2000US-0187202P.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-900161/82.
DR	P-PSDB; ADE42407.
XX	
PT	Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT	useful for treating pericyte-associated tumors, diabetes and various bone
PT	and/or cartilage disorders, e.g. arthritis.
XX	
FS	Claim 2; Fig 221; 636pp; English.
XX	
CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	invention also relates to an antibody which specifically binds to a PRO
CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	proliferation or differentiation of chondrocyte cells and a method for
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	polynucleotides are useful in molecular biology, including uses as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	be used in preparing PRO polypeptides by recombinant techniques and in
CC	generating either transgenic animals or knock-out animals which are
CC	useful in the development and screening of therapeutically useful
CC	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	medicament for treating a condition responsive to the polypeptides or
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
CC	of human microvascular endothelial cells, for modulating the uptake of
CC	glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating differentiation of adipocyte cells, for stimulating
CC	proliferation of or gene expression in pericyte cells, for stimulating
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC	cells, for inducing endothelial cell tube formation and for treating
CC	various bone and/or cartilage disorders such as sports injuries and
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC	polypeptides are also useful for treating various mammalian haemoglobin-
CC	associated disorders such as various thalassemias and conditions which
CC	may benefit from enhanced local immune system cell infiltration. This
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent is also available in electronic format
CC	from USPTO at seqdata.uspto.gov/sequence.html.
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match 0.9%; Score 21.4; DB 1; Length 1129;
	Best Local Similarity 66.0%; Pred. No. 56;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Oy	1929 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTTGGGTTTGTGTT 1975
Db	1129 TTTTNTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 216	
ID ADD80422/c	
ID ADD80422 standard; cDNA; 1129 BP.	
XX AC ADD80422;	
XX	

20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX
(GETH) GENENTECH INC.
XX PA
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX XX
WPI; 2004-0089956/01.
P-PSDB; ADD76407.
XX XX
XX New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT a tumor.
XX XX
XX Claim 2; Fig 221; 638pp; English.
XX XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 56;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTGTTT 1975
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTTTTTTTTTTTTTTTTTTCAGTCGCACACAGCGCTGGGTTTTATT 1083

RESULT 222
ADD87770/C

ID ADD87770 standard; cDNA; 1129 BP.
XX AC ADD87770;
XX DT
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #111.
DE XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
XX OS
XX FN US2003092113-A1.
XX PD 15-MAY-2003.
XX PF 16-MAY-2002; 2002US-00147523.
XX PR 09-DEC-1999; 99US-0170262P.
XX FR 01-DEC-2000; 2000WO-US032678.
XX ER 19-DEC-2001; 2001US-00028072.
XX PA (GENTECH) GENENTECH INC.
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart FA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2004-020237/02.
XX DR P-PSDB; ADD87771.
XX PT New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.
XX PS Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US0005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US0008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.

05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 22-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-041356/04.
 DR P-PSDB; ADE88533.
 XX Novel secreted and transmembrane polypeptides, PRO useful for treating
 PT bone disorders, arthritis, heart attack, injuries, tumors, and
 PT stimulating release of TNF-alpha from human blood.
 XX Claim 2; SEQ ID NO 221; 638pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 56;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1929 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTGTTTGT 1975
 |||||
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACAGGCTGGTTTATT 1083
 |||||

PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX
XX Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2156 CTATTGTAATAGGGTTTTCAGGAGGACATATTGCTCGTGTGTTATTCCTGTTGTTTGG 2215
DB 39 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 98
XX
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
DB 99 AATTGGCACGTAACCTGCTTAG 120
XX
RESULT 234
ABA79646/C
ID ABA79646 standard; DNA; 121 BP.
XX
XX ABA79646;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2492.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX

PI Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 185; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 36 A; 22 C; 24 G; 39 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
XX
QY 2156 CTATTGTAATAGGGTTTTCAGGAGGACATATTGCTCGTGTGTTATTCCTGTTGTTTGG 2215
DB 83 CCATTTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 24
XX
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
DB 23 AATTGGCACGTAACCTGCTTAG 2
XX
RESULT 235
ABA79642/C
ID ABA79642 standard; DNA; 121 BP.
XX
XX ABA79642;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2488.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX

```
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PA (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 185; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX Sequence 121 BP; 36 A; 22 C; 24 G; 39 T; 0 U; 0 Other;
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGGGACATATTCCTCGTGTGTTATGTCGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
24 CCATTAAACATGGATTGGACTCACAATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 25
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
24 AATTGSCACGTAACGCTTAG 3
RESULT 236
ABA79643
XX ID ABA79643 standard; DNA; 121 BP.
XX AC ABA79643;
XX XX
XX 24-JAN-2002 (first entry)
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2489.
XX Human; gene therapy: adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APC; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cystostatic; antislaking; antianaemic; haemostatic;
XX antilipemic; ss.
XX Homo sapiens.
XX OS
XX WO200173002-A2.
XX PN
XX 04-OCT-2001.
XX PD

XX PF 27-MAR-2001; 2001WO-US009761.
XX XX
XX PR 27-MAR-2000; 2000US-01921176P.
XX PR 27-MAR-2000; 2000US-01921179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX XX
XX PA (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 185; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;
XX Query Match 0.9%; Score 21.2; DB 1; Length 121;
XX Best Local Similarity 53.7%; Pred. No. 43;
XX Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2156 CTATTGTAATAGGGTTTTCAGGGGACATATTCCTCGTGTGTTATGTCGTGTTTGG 2215
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
38 CCATTAAACATGGATTGGACTCACAATGATCTCCATCTTTGAGATAGGTTAAGAAATTG 97
QY 2216 CTTTGGCATATAGCGGCTGAG 2237
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
98 AATTGSCACGTAACGCTTAG 119
RESULT 237
ABS68969/c
XX ID ABS68969 standard; DNA; 305 BP.
XX AC ABS68969;
XX XX
XX 21-NOV-2002 (first entry)
XX Novel murine polynucleotide isolated using gene trap technology #32.
XX Mouse; gene trapped sequence; GTS; functional genomic analysis;
XX phage display system; gene chip; temporal gene expression;
XX tissue specific gene expression; antisense inhibition; gene targeting;
XX development disorder; cell differentiation disorder; aging; cancer;
XX autoimmune disease; lupus; inflammatory disorder; skin disorder;
XX degenerative disorder; ds.
XX Mus musculus.
XX OS
XX US2002102543-A1.
XX PN
XX
```

PN US2001051335-A1.
XX
PD 13-DEC-2001.
XX
PF 16-APR-1999; 99US-00294093.
XX
PR 21-APR-1998; 98US-0082587P.
XX
XX (IALG/) LALGUDI R V.
PA (ITOL/) ITO L Y.
PA (SHER/) SHERMAN B K.
XX
PI Lalgudi RV, Ito LY, Sherman BK;
XX
XX WPI; 2002-163647/21.
XX
XX Novel purified corn tassell-derived polynucleotide useful for determining
PT altered gene expression, to recover regulatory elements and to follow
PT inheritance of desirable characteristics through hybrid breeding
PT programs.
XX
XX Claim 1; SEQ ID NO 6030; 201pp; English.
XX
XX The present sequence describes a purified corn tassell-derived
XX polynucleotide sequence (cdps) comprising a nucleic acid sequence
XX selected from those given in ABL70627 to ABL76833. The cdps sequences
XX encode corn tassell-derived polypeptides (CDPs). The cdps sequences (I)
XX can be used for determining altered gene expression, to recover
XX regulatory elements and to follow inheritance of desirable
XX characteristics through hybrid breeding programs. (I) are also useful in
XX the evaluation, and alteration of desired characteristics associated with
XX growth and development, disease resistance, environmental adaptability,
XX quality and yield, and as molecular markers for studying inheritance of
XX multigenic traits in a plant breeding program. (I) can be used to produce
XX a tassell-specific profile of gene transcription, a transcript image, to
XX clone regulatory elements for use in transformation vectors, to express a
XX polypeptide, to identify, isolate or extend identical or related corn
XX tassell nucleic acid sequences from DNA libraries, in nucleic acid
XX hybridisation or amplification technologies, as query sequences to
XX determine homology of known sequences, as probe for use in Southern or
XX Northern hybridisation, and to identify the presence of and/or to
XX determine the degree of similarity between two (or more) nucleic acid
XX sequences
XX
XX Sequence 286 BP; 96 A; 73 C; 89 G; 27 T; 0 U; 1 Other;
SQ
Query Match 0.9%; Score 21.1; DB 1; Length 286;
Best Local Similarity 46.0%; Pred. No. 54;
Matches 104; Conservative 0; Mismatches 119; Indels 3; Gaps 1;
QY 1698 TTTTGGTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTTCTTCCCTTCTCTA 1747
Db 261 TTTGTCTTGGTTCGCGGACTTTCGCGGTGCTGCGGTGCTTCTTCTTCTTCTT 202
QY 1748 TTCCCTTGGTTTTCGATAGTCTCTGCTTCTTCTGCTTCTTCTGCTGATTTT 1807
Db 201 CTCCACGATGCCCTCTTGTCTGCTCCCGTCTCTTCTTGTGCTGCTCCCTCTT 142
QY 1808 AGACTTAACATTTTCTTGAACCAAGTATCCATTTCTTCTATCTTCTTCTCTGCTGA 1867
Db 141 GTGGTGTCTCTCGCCCTT---CTTGTGCTGCTGCTCTCTCTTGTGCTGCTGCTG 85
QY 1868 GATTCTCTCTCTATCTCTTGTATTCTGTTCAGTGAGGCTTGTCTCT 1913
Db 84 GAGCGTCTCTCGAATCTTGTGATGATGATGATGATGATGATGATGATGATGATG 39
RESULT 239
AAV88246/c
ID AAV88246 standard; cDNA; 267 BP.
XX
XX AAV88246;
AC
XX

PD 01-AUG-2002.
XX
PF 30-NOV-2000; 2000US-00728445.
XX
PR 01-DEC-1999; 99US-0168358P.
XX
XX (FRIE/) FRIEDRICH G.
PA (ZAMB/) ZAMBROWICZ B.
PA (SAND/) SANDS A T.
XX
PI Friedrich G, Zambrowicz B, Sands AT;
XX
XX WPI; 2002-690598/74.
XX
XX Novel murine polynucleotides that individually identify novel genes into
PT which a retroviral gene trap vector has integrated, useful in genomic
PT analysis and in discovery, development of therapeutic and diagnostic
PT agents.
XX
XX Claim 1; Page 36; 296pp; English.
XX
XX The invention describes an isolated murine polynucleotide (I) comprising
XX a contiguous stretch of at least 60 nucleotides of one of 265-677
XX nucleotide 891 OMNIBANK gene trapped sequences (GTSS) (S), given in the
XX specification. The novel genes and cells are useful in functional genomic
XX analysis and in the discovery and development of new therapeutic and
XX diagnostic agents and methods. (I) is useful for identifying the coding
XX regions of the murine genome, to isolate cDNAs, genomic clones, or full-
XX length genes/polynucleotides or homologues, heterologues, paralogues, or
XX orthologues that are capable of hybridising to one or more of the GTSS
XX under stringent conditions. (I) can be incorporated into a phage display
XX system that can be used to screen for proteins, or other ligands, that
XX are capable of binding an amino acid sequence encoded by an
XX oligonucleotide or polynucleotide sequence in at least one of the TS
XX sequences. (I) is useful in addressable arrays, such as gene chips, to
XX identify and characterise temporal and tissue specific gene expression,
XX to identify the gene of interest from many sources and for genetic
XX manipulations such as antisense inhibition and gene targeting. Decreasing
XX the level of expression of (I) and/or down regulating the activity of
XX peptides or proteins encoded by (I) is useful for treating development
XX and cell differentiation disorders, aging, cancer, autoimmune disease,
XX lupus, inflammatory disorders, skin disorders and degenerative disorders.
XX This sequence represents a murine cDNA isolated using gene trap
XX technology
XX
XX Sequence 305 BP; 72 A; 96 C; 66 G; 70 T; 0 U; 1 Other;
SQ
Query Match 0.9%; Score 21.2; DB 1; Length 305;
Best Local Similarity 60.3%; Pred. No. 51;
Matches 35; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
QY 148 CTGCTGCAATACTCTGGGGTGTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 205
Db 284 CTGCTCTCAGAACTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTG 227
RESULT 238
ABL76656/c
ID ABL76656 standard; cDNA; 286 BP.
XX
XX ABL76656;
AC
XX
XX 14-MAY-2002 (first entry)
XX
XX Corn tassell-derived polynucleotide (cdps) SEQ ID NO:6030.
XX
XX Corn; corn tassell-derived polynucleotide; cdps; hybrid breeding; CDPs;
XX inheritance; characteristic; growth; development; disease resistance;
XX environmental adaptability; quality; yield; molecular marker;
XX multigenic trait; plant breeding; corn tassell; gene; ss.
XX
XX Zea mays.
OS
XX

DT 12-FEB-1999 (first entry)
 XX EST clone EA90.
 DE
 XX
 XX Expressed sequence tag; secreted protein; haematopoiesis regulator;
 KW tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
 KW chemotaxis; chemokines; haemostasis; gene therapy; thrombolysis;
 KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9845437-A2.
 PN
 XX
 XX 15-OCT-1998.
 PD
 XX
 XX 10-APR-1998; 98WO-US006956.
 PF
 XX
 XX 10-APR-1997; 97US-00837312.
 PR
 XX
 XX (GEMY) GENETICS INST INC.
 PA
 XX
 XX Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
 PI Spaulding V, Agostino MJ;
 PI
 XX WPI; 1999-070078/06.
 DR
 XX
 XX New polynucleotides encoding human secreted proteins - derived from e.g.
 PT human blood, kidney, foetal lung, placenta, testes, brain, ovary,
 PT pituitary, retina and colon cDNA libraries.
 PT
 XX
 XX Claim 1; Page 332; 641pp; English.
 PS
 XX
 XX The present sequence represents an expressed sequence tag (EST), and is a
 CC polynucleotide of the invention. The polynucleotides of the invention are
 CC all secreted EST sequences isolated from a variety of human tissue
 CC sources. The EST sequences and proteins encoded by them are predicted to
 CC have useful biological activities which would make them suitable for
 CC treating, preventing or ameliorating medical conditions in humans and
 CC animals, although no supporting data is given. Suggested activities
 CC include nutritional activity, immune stimulating or suppressing activity,
 CC haematopoiesis regulating activity, tissue growth activity,
 CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
 CC activity. The EST sequences are also stated to be useful for gene therapy
 XX
 XX Sequence 267 BP; 75 A; 45 C; 90 G; 57 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 21; DB 1; Length 267;
 Best Local Similarity 49.5%; Pred. No. 56;
 Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1637 GCTTCTGTACCTGTATAGGACATCTTCTCAAGGTTAGGAATTTTCTTTTGGTT 1696
 DB 243 GATGCATTGACCTCAACACTCTCTCAGTATCCCATTTCTGTGGATTCTTCTCAATC 184
 QY 1697 TTCTTGAAATATTTTCCCTGTTTGGCTTTCGCTTCTTCCCTTCCTC 1745
 DB 183 TTCTTCAAAAAGTCACCTTGGCTGTCTTCTTCTTCCGCCATTGCAC 135
 RESULT 240
 ID ABX37095/c
 XX ABX37095 standard; cDNA; 372 BP.
 XX
 AC ABX37095;
 XX
 XX 20-FEB-2003 (first entry)
 DT
 DE
 XX Bovine EST associated with lactation/muscle/fat deposition #2260.
 XX
 XX Bovine; ss; EST; expressed sequence tag; lactation; LMPD;
 KW muscle deposition; fat deposition; genome mapping; gene identification;

gene analysis; cattle breeding.
 KW
 XX Bos Taurus.
 OS
 XX
 XX US2002137139-A1.
 PN
 XX
 XX 26-SEP-2002.
 PD
 XX
 XX 24-SEP-2001; 2001US-00960352.
 PF
 XX
 XX 12-JAN-1999; 99US-0115707P.
 PR
 XX
 XX 11-JAN-2000; 2000US-00480902.
 XX
 XX (BYAT/) BYATT J C.
 PA (MATH/) MATHIALAGAN N.
 PA (TAON/) TAO N.
 PA (WARR/) WARREN W C.
 XX
 XX Byatt JC, Mathialagan N, Tao N, Warren WC;
 PI
 XX WPI; 2003-110599/10.
 DR
 XX
 XX New nucleic acid associated with lactation, and muscle and fat
 PT deposition, useful for genome mapping, gene identification and analysis,
 PT cattle breeding, or for genetically improving cattle.
 PT
 XX
 XX Claim 2; SEQ ID NO 2260; 245pp; English.
 PS
 XX
 XX The invention relates to a purified nucleic acid molecule associated with
 CC lactation or muscle and fat deposition (designated LMPD), derived from
 CC cattle, and the LMPD nucleic acid can specifically hybridise to a second
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
 CC appearing as ABX34836-ABX4947, or complements of them. Also included are
 CC ; (1) a transformed cell having a nucleic acid comprising an LMPD nucleic
 CC acid linked to a promoter and a 3' non-translated sequence that
 CC functions in the cell to cause termination of transcription and addition
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
 CC (2) determining a level or pattern of a molecule in a bovine cell or
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a
 CC complementary nucleic acid molecule obtained from the bovine cell or
 CC tissue, where hybridisation between the marker nucleic acid and the
 CC complementary nucleic acid permits the detection of the molecule; and (b)
 CC detecting the level or pattern of the complementary nucleic acid, where
 CC the detection of the complementary nucleic acid is predictive of the
 CC level or pattern of the molecule. The LMPD nucleic acid is used for
 CC determining a level or pattern of a molecule in a bovine cell or tissue.
 CC It is useful for genome mapping, gene identification and analysis, cattle
 CC breeding, preparation of constructs for use in cattle gene expression, or
 CC for genetically improving cattle. The present sequence is one of the
 CC 15112 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The
 CC present sequence was not shown in the specification but was obtained in
 CC electronic format from the USPTO web site:
 CC seqdata.uspto.gov/sequence.html?DocID=20020137139
 XX
 XX Sequence 372 BP; 113 A; 73 C; 87 G; 99 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 21; DB 1; Length 372;
 Best Local Similarity 56.5%; Pred. No. 60;
 Matches 39; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
 QY 1663 TTTCTCAAGGTTAGGAATTTTCTTTTGGTTTCTTTTGTGAAATATTTTCCCTGCTTT 1722
 DB 317 TATTTGAGCCTCAGAAGAATTTTCATAGTTCTGATTGGAAAAATAGTCTCAGACGGGT 258
 QY 1723 GACCTGCGCT 1731
 DB 257 GAGCTTCTT 249
 RESULT 241
 ID AAI20194/c
 ID AAI20194 standard; DNA; 263 BP.

Human; foetal liver; gene expression; single exon nucleic acid probe; ss
Homo sapiens.
WO200157277-A2.
09-AUG-2001.
30-JAN-2001; 2001WO-US000669.
04-FEB-2000; 2000US-0180312P.
26-MAY-2000; 2000US-0207456P.
30-JUN-2000; 2000US-00608408.
03-AUG-2000; 2000US-00632366.
21-SEP-2000; 2000US-0234687P.
27-SEP-2000; 2000US-0236359P.
04-OCT-2000; 2000GB-00024263.
(MOLE-) MOLECULAR DYNAMICS INC.
Penn SG, Hanzel DK, Chen W, Rank DR;
WPI; 2001-483447/52.
Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human fetal liver.
Claim 4; SEQ ID NO 13528; 639pp + Sequence Listing; English.
The invention relates to a single exon nucleic acid probe for measuring human gene expression in a sample derived from human foetal liver. The single exon nucleic acid probes may be used for predicting, measuring and displaying gene expression in samples derived from human fetal liver. The present sequence is a single exon nucleic acid probe of the invention. Note: the sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;
Query Match 0.9%; Score 20.8; DB 1; Length 263; Best Local Similarity 52.3%; Pred. No. 64; Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0
QY 1708 ATTATTCCTGCTTTTGACCTGCCTTCTGCCCTTCTATTCCCTGTGGTTTTGTCATAG 176
Db 251 AATTTCTTTCTCCTCTCCTCTCTCTCGGTCTAGCTCCGCTGCTTTTCCAGTTG 192
QY 1768 TGTCCTGGCTTCCTCGAATGTTTATGC 1795
Db 191 CTCTCCAGTCCAGTTGTTCTTTTGGCG 164
RESULT 243
AAI45394/C
ID AAI45394 standard; DNA; 263 BP.
XX AAI45394;
AC AAI45394;
DT 17-OCT-2001 (first entry)
XX Probe #14080 used to measure gene expression in human placenta sample.
DE Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
KW Homo sapiens.
XN Homo sapiens.
OS WO200157272-A2.
PD 09-AUG-2001.
PF 30-JAN-2001; 2001WO-US000663.

[illegible]

```
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1708 ATTTCCTGCTTTGACCTGCTTCTTCCCTTCTCTATCTCTTTGGTTTGGCATAG 1767
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 251 AATTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 192
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1768 TGTCTCTGGCTTCTCGGATGTTTATGC 1795
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 191 CTTCTCCAGTTCAGTTGTCTTTTGGCGC 164

RESULT 248
ABS38969/c
ID ABS38969 standard; DNA; 263 BP.
XX
AC ABS38969;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver single exon probe, SEQ ID No 13959.
XX
KW Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632166.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-48898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 4; SEQ ID NO 13959; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABS25011-ABS51005 represent human
CC liver single exon nucleic acid probes of the invention. Note: The
CC sequence information for this patent does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
```

```
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1708 ATTTCCTGCTTTGACCTGCTTCTTCCCTTCTCTATCTCTTTGGTTTGGCATAG 1767
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 251 AATTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 192
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1768 TGTCTCTGGCTTCTCGGATGTTTATGC 1795
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 191 CTTCTCCAGTTCAGTTGTCTTTTGGCGC 164

RESULT 249
AAI05898/c
ID AAI05898 standard; DNA; 263 BP.
XX
AC AAI05898;
XX
DT 09-OCT-2001 (first entry)
XX
DE Probe #5889 used to measure gene expression in human breast sample.
XX
KW Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632166.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 25; SEQ ID NO 5889; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes.
CC The present sequence is one such probe. The probes are useful for
CC measuring human gene expression in a human breast sample, where the probe
CC hybridises at high stringency to a nucleic acid expressed in the human
CC breast. The probes are useful for predicting, diagnosing, grading,
CC staging, monitoring and prognosing diseases of the human breast,
CC particularly those diseases with polygenic aetiology. The diseases
CC include: breast cancer, disorders of development, inflammatory diseases
CC of the breast, fibrocystic changes, proliferative breast disease and non-
CC carcinoma tumours. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;

Query Match          0.9%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 64;
```



```
RESULT 2
US-08-021-615A-3/c
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-021-615A-3
```

```
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAAATATGTAATTCATTTGG 498
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGTAGTATTTTCCACATGGATATTCACACTGG 601
```

```
RESULT 3
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
```

```
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-321-777-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAAATATGTAATTCATTTGG 498
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGTAGTATTTTCCACATGGATATTCACACTGG 601

RESULT 4
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
```



```
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATATGTAATTTGG 498
Db 659 TTGCTGGCATTCTTTTCTAGTAATAGTATTTTCCACATGGATATTTCAACTGTGG 601

RESULT 5
US-09-009-656-13/c
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATATGTAATTTGG 498
Db 659 TTGCTGGCATTCTTTTCTAGTAATAGTATTTTCCACATGGATATTTCAACTGTGG 601

RESULT 6
PCT-US93-04493-3/c
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
```

```
;
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cdna"
; OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3

Query Match          0.7%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATGTCCTTTATCTGTCGAGACTTGCTTGTGTTTGAATATGATTCAAATTTGG 498
Db 659 TTGCTGCGCAATTCCTTTCTTAGAATAGGTATTTTCCACATGGATATTCAACTGTGG 601

RESULT 7
US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cdna"
; OTHER INFORMATION: /citation= ([1])
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cdna"
US-08-021-615A-3

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
```

```
;
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cdna"
US-07-882-202A-3

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1749 TCCTTTGGTTTTTCATAGTGTCTCTGGCTTCCTCGCTTCCTGGATG 1787
Db 58 TCCTCTGCTTCTCTGGGCTTCAGGCGCTCGCTGGCTG 96

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cdna"
US-08-021-615A-3

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
```

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 9

US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cdna"
US-08-321-777-3

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 10

US-09-009-217-13
; Sequence 13, Application US/09009217

; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATG 1787
|||||
Db 58 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 11

US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433


```
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match          0.6%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 65;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 147 TCTGTCGGCAATACCTCTGGGGCT 170
DB 25 TCAGCTGGTCATCTCTGGGGCT 2

RESULT 15
US-08-849-248-6
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match          0.6%; Score 12.6; DB 1; Length 141;
Best Local Similarity 55.8%; Pred. No. 73;
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1382 TTCTAAGTCAGTAGTCGCGCTGACATCTGTAGTCTCTTGGGA 1424
DB 97 TGCACGAGGGGTACTCTCTGCTGGCAGACGGGGTGTCTTGGCA 139

RESULT 16
US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-558-027-4

Query Match          0.5%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 45;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 893 AGGGCCATTGCTTAGAATA 912
DB 31 AGCCCATTCCTAGACTA 12

RESULT 17
US-08-293-778-17/c
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
```

;; PRIOR APPLICATION DATA: US/08/104,509
;; APPLICATION NUMBER: DK 3235/87
;; FILING DATE: 25-JUN-1987
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/434,149
;; FILING DATE: 13-NOV-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/DK88/00103
;; FILING DATE: 24-JUN-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/898,248
;; FILING DATE: 12-JUN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Agriis, Cheryl H.
;; REGISTRATION NUMBER: 34,086
;; REFERENCE/DOCKET NUMBER: 3129.224-US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-867-0123
;; TELEFAX: 212-867-0298
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 27 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.5%; Score 11.2; DB 1; Length 27;
Best Local Similarity 81.2%; Pred. No. 63;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1776 GCTTCCTGGAGTGT 1791
Db 23 GCGTCTGGAGATTT 8

RESULT 18
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149

;; FILING DATE: 13-NOV-1989
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/DK88/00103
;; FILING DATE: 24-JUN-1988
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/898,248
;; FILING DATE: 12-JUN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Agriis, Cheryl H.
;; REGISTRATION NUMBER: 34,086
;; REFERENCE/DOCKET NUMBER: 3129.224-US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-867-0123
;; TELEFAX: 212-867-0298
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 27 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2075 TCITCAAGGAC 2085
Db 11 TCITCAAGGAC 21

RESULT 19
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCAGGCTCTGGGAC 26

RESULT 20
US-08-756-506-13/c
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.

```
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Sawislak, Deborah A
; REGISTRATION NUMBER: 37,438
; REFERENCE/DOCKET NUMBER: 95-28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6672
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC6337
; US-08-756-506-13

Query Match 0.5%; Score 10.6; DB 1; Length 45;
Best Local Similarity 57.6%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 241 TTCTGGCCAGGCTAGGGCACTACCGCATCC 273
Db 35 TGCTGCAAGCGGCAAGCGCGCAACTCCTCC 3

RESULT 21
US-08-756-506-13
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506
```

```
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Sawislak, Deborah A
; REGISTRATION NUMBER: 37,438
; REFERENCE/DOCKET NUMBER: 95-28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6672
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC6337
; US-08-756-506-13

Query Match 0.5%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 642 GTTGAGAGAAATGGGTATTGAAGTAGC 669
Db 10 GTTGGCGCGCTTGGCCGTTGCAGCACC 37

RESULT 22
US-07-998-972A-7/c
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```


; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-07-998-972A-7

Query Match	0.4%	Score 10;	DB 1;	Length 35;
Best Local Similarity	72.2%	Pred. No. 2e+02;		
Matches 13;	Conservative 0;	Mismatches 5;	Indels	

Qy 1390 GCAGTAGTCTGGCCCTGAC 1407
Db 21 GGAGTTGGCTCGCCCGGAC 4

RESULT 23

```

US-08-463-953-7/C
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent-In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463.953

```

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels

QY 1390 GCAGTAGTCTGGCCTGAC 1407
 |||||
 Db 21 GGAGTTGGCTCGCCGGAC 4

RESULT 24

US-08-462-261-7/c

```

; Sequence 7, Application US/00462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZCL324
; US-08-462-261-7

```

Query Match	0.4%	Score 10;	DB 1;	Length 35;
Best Local Similarity	72.2%	Pred. No. 28+02;		
Matches 13;	Conservative	0;	Mismatches 5;	Indels 0;
				Gaps 0;

Qy 1390 GCAGTAGTCTGGCCTGAC 1407
||| ||| ||| |||
Db 21 GGAGTTGGCTCGCCGGAC 4

RESULT 25

```

PCT-US92-11357-7/C
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

```

ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/11357
FILING DATE: 19921230
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1390 GCAGTAGTCTGGCGTCGAC 1407
DB 21 GGAGTTGGCTGCCGGAC 4

RESULT 26
US-08-293-778-16/c
Sequence 16, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSER: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agris, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cdna
US-08-293-778-16

Query Match 0.4%; Score 9.8; DB 1; Length 27;
Best Local Similarity 66.7%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 553 GTCGTAAATATCTCTAGGTC 573
DB 21 GTCCTGAAGATCTCCCGGC 1

RESULT 27
US-08-293-778-17
Sequence 17, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSER: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988

;; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.4%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2075 TCTTCAAGGAC 2085
Db 11 TCTTCCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 48
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 31-DEC-1991
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCCTGGATG 1787
Db 21 CTTCCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 48
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 31-DEC-1991
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTTCCTGGATG 1787
Db 21 CTTCCTGGAGG 31

RESULT 30
US-08-462-261-7

;; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match 0.4%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2075 TCTTCAAGGAC 2085
Db 11 TCTTCCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 48
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 31-DEC-1991
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```
; Sequence 7, Application US/08462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-462-261-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTCTCTGGATG 1787
Db 21 CTCTCTGGAGG 31

RESULT 31
PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```

```
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1777 CTCTCTGGATG 1787
Db 21 CTCTCTGGAGG 31

RESULT 32
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

Query Match 0.4%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 259 GCACTACGCGATTCCTCT 277
Db 13 GCCGTGCGCGAGCTCTCT 31

RESULT 33
```

US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsesen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 259 GCCTACCGCATTCCTCT 277
Db 24 GCCGTGCGACGCTCTCT 6

RESULT 34
US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086

; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-22

Query Match 0.4%; Score 9.2; DB 1; Length 26;
Best Local Similarity 78.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1908 GTCTCTGAGGTTC 1921
Db 25 GTCTCCGACCTTC 12

RESULT 35
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086

; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-20
Query Match 0.4%; Score 9.2; DB 1; Length 27;
Best Local Similarity 78.8%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 3;
QY 240 CTTCTGGCGCAGGG 253
Db 2 CTGCTGGACCTGGG 15
RESULT 36
US-08-955-636-8/c
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8
Query Match 0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 3.8e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 17;
QY 136 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 42 TTCTGGAGGAGCTCGTCCACAGCCTGGAGCGG 7
RESULT 37
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-20

; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match      0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred.No. 4.5e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy      158 TACTTCTGGGGCTGCTGC 175
Db      2 TCCTAGAGGAGCTCGGC 19

Search completed: August 9, 2004, 16:57:15
Job time : 12 secs
```

```
Query Match      0.4%; Score 8.6; DB 1; Length 27;
Best Local Similarity 60.9%; Pred.No. 4.2e+02;
Matches 14; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
```

```
Qy      509 AGGGTCTGACAGAGGTACAG 531
Db      27 AGGCCCGTGGCCCGCCAGTCCAG 5
```

```
RESULT 39
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9
```

```
Query Match      0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred.No. 4.5e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
Qy      158 TACTTCTGGGGCTGCTGC 175
Db      35 TCCTAGAGGAGCTCGGC 18
```

```
RESULT 40
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
```


c 107 9.2 0.4 34 1 US-09-951-121A-3
c 108 9.2 0.4 34 1 US-10-295-682-2
c 109 9.2 0.4 34 1 US-10-295-682-3
c 110 9.2 0.4 36 1 US-10-281-727-2
c 111 9.2 0.4 36 1 US-10-281-727-3
c 112 9 0.4 33 1 US-09-951-121A-14
c 113 9 0.4 33 1 US-09-951-121A-15
c 114 9 0.4 33 1 US-10-295-682-14
c 115 9 0.4 33 1 US-10-295-682-15
c 116 8.8 0.4 42 1 US-09-803-810-8
c 117 8.8 0.4 42 1 US-10-298-330-8
c 118 8.2 0.4 31 1 US-10-017-122-4
c 119 7.8 0.3 34 1 US-09-951-121A-2
c 120 7.8 0.3 34 1 US-09-951-121A-3
c 121 7.8 0.3 34 1 US-10-295-682-2
c 122 7.8 0.3 34 1 US-10-295-682-3

ALIGNMENTS

RESULT 1
US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens

US-10-411-037-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;

Best Local Similarity 59.3%; Pred. No. 2.3;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTTCG 498

DB 558 TTGCTGGCATTTCCTTTTCTAGAAATAGGATATTTTCCACATGGATATTTCAACTGTG 500

RESULT 2

US-10-411-026-7/c

; Sequence 7, Application US/10411026

; Publication No. US20040063911A1

; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;

Best Local Similarity 59.3%; Pred. No. 2.3;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTTCG 498

DB 558 TTGCTGGCATTTCCTTTTCTAGAAATAGGATATTTTCCACATGGATATTTCAACTGTG 500

RESULT 3

US-10-410-962-7/c

; Sequence 7, Application US/10410962

; Publication No. US20040077836A1

; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527

US-10-410-962-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;

Best Local Similarity 59.3%; Pred. No. 2.3;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTTCAATTTCG 498

DB 558 TTGCTGGCATTTCCTTTTCTAGAAATAGGATATTTTCCACATGGATATTTCAACTGTG 500


```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGCGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 7
US-10-411-012-7/c
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGCGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 8
US-10-287-994-7/c
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
```

```
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCOUJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match          0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 440 TTCAATTGCTTTTATCTGTCGACACTGCTTTGTTTGAATAATGATTTCAATTGG 498
Db 558 TTTCGTGCGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 9
US-10-410-913-7/c
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCOUJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match      0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 500

RESULT 10
US-10-375-741-13/c
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Bojing
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE OF INVENTION: TREATMENT
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 2.4;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 659 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 601

RESULT 11
US-10-617-619-12/c
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
```

```
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match      0.9%; Score 20.6; DB 1; Length 2040;
Best Local Similarity 59.3%; Pred. No. 3.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 500

RESULT 12
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.9%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred. No. 3.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTAATTCAAATTTGG 498
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 624 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCAACTGTGG 566

RESULT 13
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
```

```

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

```

Query Match	0.9%	Score 19.4;	DB 1;	Length 1361;
Best Local Similarity	55.1%;	Pred. No. 6.2;		
Matches 38;	Conservative	0;	Mismatches 31;	Indels 0;
Gaps 0;				

Qy 2208 TGTTTTGC 2216
db 1252 AGCTTTTGC 1244

```

RESULT 14
US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqdist version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

```

	Query Match	0.8%;	Score 17.2;	DB 1;	Length 1361;
	Best Local Similarity	51.3%;	Pred. No. 26;		
	Matches 40;	Conservative 0;	Mismatches 38;	Indels 0;	Gaps 0;
Qy	6	CTCCTCTAGTGAAGGTGGGGTCTGAGGCTCCAATGGTTGTCATGCTGTAGATGATCT	65		
Db	441	CTCCTCTCCCTCGAGGCCCGAACTGTGAGACGCTTGAATATCCATCTGGAATAATACCT	500		
Qy	66	CATACAGAGGATAGCACT	83		
Db	501	ATTCTAGAAAAAGAAAT	518		

```

RESULT 15
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq. Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076

```

```

; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483

```

Query Match 0.7%; Score 17; DB 1; length 483;
Best Local Similarity 59.3%; Pred. NO. 19;
Matches 29; Conservative 0; Mismatches 20; Indels 0;

QY 1749 TCTTTGGTTTTGCATAGTGTCTGGCTTCCTGGATGTTTATGCT 1797
Db 122 TCTCTGGCTTCCTGGCTTCAGGCGTCTGGCTGCAGTCTTCGT 170

```

RESULT 16
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Derfres, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A
; FILE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

```

Query Match 0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0;

Qy 1749 TCCTTTGGTTTTGCATAGTGTCTGGCTTCCTGGATGTTTTATGCCT 1799

Db 23 TCCTTTGGCTTTGCTTTGGGCTTCAGGGTGGCTGGCTGCAGTCTTGGT 71

RESULT 17
US-10-411-026-7
; Sequence 7, Application US/10411026

```
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-026-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 18
US-10-410-962-7
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-026-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 19
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: ALPHA
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 20
US-10-410-930-7
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
```

```
; Publication No. US 60/407,527
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: ALPHA
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTCGATGTTTATGCCT 1797
      |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGTCTTCGT 71

RESULT 20
US-10-410-930-7
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
```



```
; APPLICANT: DePress, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: BETA
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTCTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 21
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePress, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: FSH
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
```

```
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTCTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 22
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePress, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryne
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; PRIOR APPLICATION NUMBER: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCCTTGGTTTTCATAGTCTCTCGGCTTCCTCGATGTTTATGCCT 1797
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 23 TCCCTGCTCTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 23
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DePress, Shawn
; APPLICANT: Zopf, David
```

```
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; FILE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
Db 23 TCCTCGCCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 24
US-10-410-913-7
; Sequence 7; Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
```

```
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
Db 23 TCCTCGCCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 25
US-10-617-619-12
; Sequence 12; Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455,200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match      0.7%; Score 17; DB 1; Length 2040;
Best Local Similarity 59.2%; Pred. No. 24;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1749 TCCTTTGGTTTTCATAGTCTCTGGCTTCTCTGGATGTTTATGCCT 1797
Db 23 TCCTCGCCTTCTGCTTGGGCTTCAGGGCTGCTGCTGCAGTCTTCGT 71

RESULT 26
US-09-782-587B-2/c
; Sequence 2; Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAU
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match          0.7%; Score 16.6; DB 1; Length 1338;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1216 GCCTGGAATTATTATTATTCATATTTCTTGAATGTG 1254
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 567 GCCTGGGTTTGTAGCGTTCCGCTTTCTAGAATGGG 529

RESULT 27
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match          0.7%; Score 16.6; DB 1; Length 1357;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1216 GCCTGGAATTATTATTATTCATATTTCTTGAATGTG 1254
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 580 GCCTGGGTTTGTAGCGTTCCGCTTTCTAGAATGGG 542

RESULT 28
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
```

```
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 31;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1749 TCCTTTGGTTTTGCATAGTCTCTCGCTTCCTGGATG 1787
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTG 96

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.7%; Score 16.6; DB 1; Length 2106;
Best Local Similarity 64.1%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1749 TCCTTTGGTTTTGCATAGTCTCTCGCTTCCTGGATG 1787
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTG 61

RESULT 30
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; TITLE OF INVENTION: FROM VARIOUS cDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match          0.7%; Score 16.4; DB 1; Length 483;
Best Local Similarity 55.2%; Pred. No. 30;
Matches 32; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 686 AGGTCAATATGTAATTTAGCTGTAGCTGTCTGTTTATGAACATTGGTGACATTG 743
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 415 AGGACTGGAGCTGGTCTTTCAGGAGGCCGCCATCTTGGCATGACTTGGAGCACATG 358

RESULT 31
US-10-029-386-9623
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David K.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match          0.7%; Score 14.8; DB 1; Length 555;
Best Local Similarity 56.0%; Pred. No. 75;
Matches 28; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 254 TAGGGGCACTACGGATCCCTCTCTCTCCAAACACTTCTATTTCTTGA 303
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 12 TGGGGAGTCTCCACCTTCCGTGACTGCTGCAGGAGTCTCTGGGTCATCA 61

RESULT 32
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David K.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match          0.6%; Score 14.6; DB 1; Length 222;
Best Local Similarity 54.7%; Pred. No. 69;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 1893 CTGTCACTGAGGCTTGTCTCTGAGGTTCTCTGTGGTCTCTTAATTTTTCATT 1945
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 152 CTGCCGACGAGCGTTCTCTGAGAGGACGCTGCGCTTCTGCGCTTCTCAAT 100

RESULT 33
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David K.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match          0.6%; Score 14.6; DB 1; Length 555;
Best Local Similarity 54.7%; Pred. No. 79;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 1893 CTGTCACTGAGGCTTGTCTCTGAGGTTCTCTGTGGTCTCTTAATTTTTCATT 1945
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 188 CTGCCGACGAGCGTTCTCTGAGAGGACGCTGCGCTTCTGCGCTTCTCAAT 136

RESULT 34
US-10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
```

```
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272.665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22
```

```
Query Match          0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
```

```
Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
      ||||| ||||| ||||| ||||| |||||
Db 58 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 24
```

RESULT 35

```
US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273.321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22
```

```
Query Match          0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
```

```
Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
      ||||| ||||| ||||| ||||| |||||
Db 58 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 24
```

RESULT 36

```
Query Match          0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
```

```
US-10-272-756-22/c
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272.756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22
```

```
Query Match          0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
```

```
Qy 1719 TTTTGACCTGCCTTCTCCCTTCCTCTATTCCTT 1753
      ||||| ||||| ||||| ||||| |||||
Db 58 TGTGGGCTCCACTGTCCCTTCGAGGAGTCCTT 24
```

RESULT 37

```
US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273.228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22
```

```
Query Match          0.6%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 35;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
```



```
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 1753
    ||||| ||||| ||||| ||||| ||||| |||||
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 42
US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 1753
    ||||| ||||| ||||| ||||| ||||| |||||
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 43
US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 1753
    ||||| ||||| ||||| ||||| ||||| |||||
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 44
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1719 TTTTGACCTGCCTTCTTCCCTTCTCTATTCCTT 1753
    ||||| ||||| ||||| ||||| ||||| |||||
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 45
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; SOFTWARE: FastSeq for Windows Version 4.0
```



```
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match          0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1719 TTTTGACCTGCCTCTTCCCTTCTCTATTCCTT 1753
Db      ||||| ||||| ||||| ||||| ||||| ||||| |||||
38 TGTGGCCCTCCACTGTCCCTCTGCAGGAGTCCTT 4

RESULT 46
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIITA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match          0.6%; Score 14.2; DB 1; Length 1338;
Best Local Similarity 70.4%; Pred. No. 38;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTCTCTGGGCTGCTG 174
Db      ||||| ||||| ||||| ||||| ||||| ||||| |||||
22 CTCCTGTGCTCTCTCTGGGCTGCTGAG 48

RESULT 47
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIITA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
```

```
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match          0.6%; Score 14.2; DB 1; Length 1357;
Best Local Similarity 70.4%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTCTCTGGGCTGCTG 174
Db      ||||| ||||| ||||| ||||| ||||| ||||| |||||
35 CTCCTGTGCTCTCTCTGGGCTGCTGAG 61

RESULT 48
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: ABOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match          0.5%; Score 12; DB 1; Length 222;
Best Local Similarity 58.3%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 763 AAGAATTGCAATGCTCTCTGTGTGATTTTCCTTTG 798
Db      ||||| ||||| ||||| ||||| ||||| ||||| |||||
112 ACGAAGGCCAGCGCTCTCTCAGAGAAGCCGCTCGTTCG 147

RESULT 49
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
```

```
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.5%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.6%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1913 TGAGGTTCCCTGTTGGGTTCTTAA 1935
    ||||| ||||| ||||| |||||
DB 29 TGGGCTTCCCTCGGTACGAA 7

RESULT 50
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1987 TTCCACTTTCAGGTCCTG 2004
    ||||| ||||| ||||| |||||
DB 26 TCCACCTTCGTTCCCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1987 TTCCACTTTCAGGTCCTG 2004
    ||||| ||||| ||||| |||||
DB 26 TCCACCTTCGTTCCCTG 9

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCCTCTCTGCGC 155
    ||||| ||||| ||||| |||||
DB 10 TAAACGCTTCTCGAGAGCTCGGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
```

APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
APPLICANT: Pingel, Hans K
APPLICANT: Klausen, Niels K
TITLE OF INVENTION: Factor VII Glycoforms
FILE REFERENCE: 6207.510-US
CURRENT FILING DATE: 2002-10-02
PRIORITY APPLICATION NUMBER: US/09/969,357
PRIORITY FILING DATE: 2000-10-02
PRIORITY APPLICATION NO. PA 2000 01456
PRIORITY FILING DATE: 2001-02-16
PRIORITY APPLICATION NO. PA 2001 00262
PRIORITY FILING DATE: 2001-03-14
PRIORITY APPLICATION NO. PA 2001 00430
PRIORITY FILING DATE: 2001-05-14
PRIORITY APPLICATION NO. PA 2001 00751
PRIORITY FILING DATE: 2000-10-02
PRIORITY APPLICATION NO. PA 2000 01456
PRIORITY FILING DATE: 2000-10-10
PRIORITY APPLICATION NO. PA 2001 00262
PRIORITY FILING DATE: 2001-02-26
PRIORITY APPLICATION NO. PA 2001 00430
PRIORITY FILING DATE: 2001-03-16
PRIORITY APPLICATION NO. PA 2001 00751
NUMBER OF SEQ ID NOS: 2
SOFTWARE: Patent in version 3.2
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCTCTGCTGGC 155
DB 10 TAAACGCTTTCTCTGGAGGAGCTGCGCC 38

RESULT 54
US-10-254-394-2
Sequence 2, Application US/10254394
Publication No. US20030096366A1
GENERAL INFORMATION:
APPLICANT: Knudsen, Ida Molgaard
TITLE OF INVENTION: Method for Production of Recombinant
Proteins in Eukaryote Cells
FILE REFERENCE: 6480.500-US
CURRENT APPLICATION NUMBER: US/10/254,394
PRIORITY FILING DATE: 2002-09-25
PRIORITY APPLICATION NUMBER: PCT/DK01/00632
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PCT/DK01/00634
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PA 2002 00460
PRIORITY FILING DATE: 2002-03-26
PRIORITY APPLICATION NUMBER: 60/374,855
PRIORITY FILING DATE: 2002-10-04
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTCTTGAAGCCTCTGCTGGC 155
DB 10 TAAACGCTTTCTCTGGAGGAGCTGCGCC 38

RESULT 55
US-10-272-665-22
Sequence 22, Application US/10272665
Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
FILE REFERENCE: 24736-2033E
CURRENT APPLICATION NUMBER: US/10/272,665
PRIORITY FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: 09/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:
OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2150 CAGGCGCTATTCTAATAGGTTTTCAGGAGGACATAT 2186
DB 23 CAAGGACTCTCTGACAGGGGGACAGTGGAGGCCACAT 59

RESULT 56
US-10-273-321-22
Sequence 22, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
FILE REFERENCE: 24736-2033B
CURRENT APPLICATION NUMBER: US/10/273,321
PRIORITY FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: 09/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:

```
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCCTGCAAGGGGGGACAGTGGAGGCCACAT 59

RESULT 57
US-10-272-756-22
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCCTGCAAGGGGGGACAGTGGAGGCCACAT 59

RESULT 58
US-10-273-228-22
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
```

```
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match      0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 CAAGGACTCCTGCAAGGGGGGACAGTGGAGGCCACAT 59

RESULT 59
US-10-272-665-107
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match      0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGGAGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCCTGCAAGGGGGGACAGTGGAGGCCACAT 39

RESULT 60
US-10-273-321-107
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
```



```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 65
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 66
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match          0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 2150 CAGGGCCTATTGTAATAGGGTTTTCAGCAGGGACATAT 2186
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 67
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1389 TGCAGTAGTCTGGCCTGACATCTG 1412
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 31 TGCAGGAGTCTTTCGCCCATCCG 8

RESULT 68
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
```



```
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 4 CACGTTGAGGACCTGGA 20

RESULT 73
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 33 CACGTTGAGGACCTGGA 17

RESULT 76
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 4 CACGTTGAGGACCTGGA 20

RESULT 74
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1990 CACTTTCAGGTCCTGAA 2006
Db 33 CACGTTGAGGACCTGGA 17

RESULT 74
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
RESULT 77
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGTGGGAC 26

RESULT 78
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGTGGGAC 26

RESULT 79
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCCTTGTATCTTGCACTTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 80
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCCTTGTATCTTGCACTTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 81
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
```



```
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6224.200-US
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 16 GAAAGTGGGGTCT 30
Db 16 GGAAGTGGGAGACT 30

RESULT 85
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 16 GAAAGTGGGGTCT 30
Db 17 GGAAGTGGGAGACT 3

RESULT 87
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; CURRENT APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTCTCCAGGT 23

RESULT 88
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2123 CCTGTGCTTCAGCT 2137
Db 28 CCTGGTCTCCAGGT 14

RESULT 89
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1c No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
```

```
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2123 CCTGTGCTTCAGCT 2137
Db 28 CCTGGTGTCCAGGT 14

RESULT 91
US-10-255-032-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```

```
US-10-295-682-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2123 CCTGTGCTTCAGCT 2137
Db 9 CCTGGTGTCCAGGT 23

RESULT 92
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2123 CCTGTGCTTCAGCT 2137
Db 28 CCTGGTGTCCAGGT 14

RESULT 93
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 94
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 95
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; TITLE OF INVENTION: Proteins in Eukaryote Cells
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 34 GCAGCTCTCCAGAAAGCGTTTATAGCGCG 4

RESULT 96
US-10-109-498-5/c
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match          0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 579 GTGTGTGAGGTCAATATGTGATTTTAGCTGTAGC 712
Db 34 GTCAGTGAGGACCAACGGGACAGTCGACGGCGGAGC 1

RESULT 97
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
```

```

; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match          0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 679 GTGTGTCAGGTCATATGTGATTTAGTGTAGC 712
Db 2  GTCAGTAGGACACCGGACAGTCGACGGCGAGC 35

RESULT 98
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.4%; Score 9.8; DB 1; Length 54;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 117 AGAGACTTCATAA 129
Db 1  AGAGTCTTCGTAA 13

RESULT 99
US-10-272-665-23
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTGAGGT 689
Db 4  CCCACTACCGGGGCACGTGGT 24

RESULT 100
US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTGAGGT 689
Db 4  CCCACTACCGGGGCACGTGGT 24

RESULT 101
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
```


; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 7; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
DB 4 CCCACTACCGGGCAGGTGT 24

RESULT 102

US-10-273-228-23
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 7; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
DB 4 CCCACTACCGGGCAGGTGT 24

RESULT 103

US-10-109-498-5
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22

; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 6; Gaps 0;

QY 1587 TGCACGTGGGGAGTTTCT 1605
DB 9 TGCACGTCCCGTGTCT 27

RESULT 104

US-10-109-498-6/C
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 6; Gaps 0;

QY 1587 TGCACGTGGGGAGTTTCT 1605
DB 27 TGCACGTCCCGTGTCT 9

RESULT 105

US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA

; ORGANISM: Homo sapiens		Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;	
US-10-017-122-4			
Query Match 0.4%; Score 9.2; DB 1; Length 31;			
Best Local Similarity 56.7%; Pred. No. 9.6e+02;			
Matches 17; Conservative 0; Mismatches 13; Indels 0; Gaps 0;			
QY 1608 TCCGGTCCATCTATTGTTGGTGTGTTGATG 1637			
Db 2 TCCTGTCGGTCCATGAGGGGTACTCTCTG 31			
RESULT 106			
US-09-951-121A-2			
; Sequence 2, Application US/09951121A			
; Publication No. US20030104978A1			
; GENERAL INFORMATION:			
; APPLICANT: Persson, Egon			
; APPLICANT: Olsen, Ole Hvilsted			
; TITLE OF INVENTION: Human Coagulation Factor VII Variants			
; FILE REFERENCE: 6224.200-US			
; CURRENT APPLICATION NUMBER: US/09/951.121A			
; CURRENT FILING DATE: 2001-09-13			
; PRIOR APPLICATION NUMBER: PA 2000 01361			
; PRIOR FILING DATE: 2000-09-13			
; PRIOR APPLICATION NUMBER: 60/236,455			
; PRIOR FILING DATE: 2000-09-29			
; NUMBER OF SEQ ID NOS: 17			
; SOFTWARE: FastSEQ for Windows Version 4.0			
; SEQ ID NO 2			
; LENGTH: 34			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Synthetic			
US-09-951-121A-2			
Query Match 0.4%; Score 9.2; DB 1; Length 34;			
Best Local Similarity 63.6%; Pred. No. 9.7e+02;			
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;			
QY 1112 GAAGTGTGTGTGTGTGTGTG 1133			
Db 3 GAATTGGGGGGCGCGGTGTG 24			
RESULT 107			
US-09-951-121A-3/c			
; Sequence 3, Application US/09951121A			
; Publication No. US20030104978A1			
; GENERAL INFORMATION:			
; APPLICANT: Persson, Egon			
; APPLICANT: Olsen, Ole Hvilsted			
; TITLE OF INVENTION: Human Coagulation Factor VII Variants			
; FILE REFERENCE: 6224.200-US			
; CURRENT APPLICATION NUMBER: US/09/951.121A			
; CURRENT FILING DATE: 2001-09-13			
; PRIOR APPLICATION NUMBER: PA 2000 01361			
; PRIOR FILING DATE: 2000-09-13			
; PRIOR APPLICATION NUMBER: 60/236,455			
; PRIOR FILING DATE: 2000-09-29			
; NUMBER OF SEQ ID NOS: 17			
; SOFTWARE: FastSEQ for Windows Version 4.0			
; SEQ ID NO 3			
; LENGTH: 34			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Synthetic			
US-09-951-121A-3			
Query Match 0.4%; Score 9.2; DB 1; Length 34;			
Best Local Similarity 63.6%; Pred. No. 9.7e+02;			
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;			
QY 1112 GAAGTGTGTGTGTGTGTG 1133			
Db 3 GAATTGGGGGGCGCGGTGTG 11			
RESULT 108			
US-10-295-682-2			
; Sequence 2, Application US/10295682			
; Publication No. US20030100740A1			
; GENERAL INFORMATION:			
; APPLICANT: Persson, Egon			
; APPLICANT: Olsen, Ole Hvilsted			
; TITLE OF INVENTION: Human Coagulation Factor VII Variants			
; FILE REFERENCE: 6224.200-US			
; CURRENT APPLICATION NUMBER: US/10/295.682			
; CURRENT FILING DATE: 2002-11-15			
; PRIOR APPLICATION NUMBER: PA 2000 01361			
; PRIOR FILING DATE: 2000-09-13			
; PRIOR APPLICATION NUMBER: 60/236,455			
; PRIOR FILING DATE: 2000-09-29			
; NUMBER OF SEQ ID NOS: 17			
; SOFTWARE: FastSEQ for Windows Version 4.0			
; SEQ ID NO 2			
; LENGTH: 34			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Synthetic			
US-10-295-682-2			
Query Match 0.4%; Score 9.2; DB 1; Length 34;			
Best Local Similarity 63.6%; Pred. No. 9.7e+02;			
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;			
QY 1112 GAAGTGTGTGTGTGTGTG 1133			
Db 3 GAATTGGGGGGCGCGGTGTG 24			
RESULT 109			
US-10-295-682-3/c			
; Sequence 3, Application US/10295682			
; Publication No. US20030100740A1			
; GENERAL INFORMATION:			
; APPLICANT: Persson, Egon			
; APPLICANT: Olsen, Ole Hvilsted			
; TITLE OF INVENTION: Human Coagulation Factor VII Variants			
; FILE REFERENCE: 6224.200-US			
; CURRENT APPLICATION NUMBER: US/10/295.682			
; CURRENT FILING DATE: 2002-11-15			
; PRIOR APPLICATION NUMBER: PA 2000 01361			
; PRIOR FILING DATE: 2000-09-13			
; PRIOR APPLICATION NUMBER: 60/236,455			
; PRIOR FILING DATE: 2000-09-29			
; NUMBER OF SEQ ID NOS: 17			
; SOFTWARE: FastSEQ for Windows Version 4.0			
; SEQ ID NO 3			
; LENGTH: 34			
; TYPE: DNA			
; ORGANISM: Artificial Sequence			
; FEATURE:			
; OTHER INFORMATION: Synthetic			
US-10-295-682-3			
Query Match 0.4%; Score 9.2; DB 1; Length 34;			
Best Local Similarity 63.6%; Pred. No. 9.7e+02;			
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;			
QY 1112 GAAGTGTGTGTGTGTGTG 1133			
Db 32 GAATTGGGGGGCGCGGTGTG 11			

RESULT 110
 US-10-281-727-2
 ; Sequence 2, Application US/10281727
 ; Publication No. US20030130191A
 ; GENERAL INFORMATION:
 ; APPLICANT: Persson, Egon
 ; APPLICANT: Olsen, Ole Hvilsted
 ; TITLE OF INVENTION: Human Coagulation Factor VII
 ; TITLE OF INVENTION: Polypeptides
 ; FILE REFERENCE: 6410.200-US
 ; CURRENT APPLICATION NUMBER: US/10/281,727
 ; CURRENT FILING DATE: 2002-10-28
 ; PRIOR APPLICATION NUMBER: PA 2001 01627
 ; PRIOR FILING DATE: 2001-11-02
 ; PRIOR APPLICATION NUMBER: 60/335,383
 ; PRIOR FILING DATE: 2001-11-15
 ; NUMBER OF SEQ ID NOS: 7
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 2
 ; LENGTH: 36
 ; TYPE: DNA
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
 US-10-281-727-2

Query Match 0.4%; Score 9.2; DB 1; Length 36;
 Best Local Similarity 78.6%; Pred. No. 9.7e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATGCAGCAGTA 981
 ||| |||||
 Db 2 TGCCTGCAGCAGGA 15

RESULT 111
 US-10-281-727-3/c
 ; Sequence 3, Application US/10281727
 ; Publication No. US20030130191A
 ; GENERAL INFORMATION:
 ; APPLICANT: Persson, Egon
 ; APPLICANT: Olsen, Ole Hvilsted
 ; TITLE OF INVENTION: Human Coagulation Factor VII
 ; TITLE OF INVENTION: Polypeptides
 ; FILE REFERENCE: 6410.200-US
 ; CURRENT APPLICATION NUMBER: US/10/281,727
 ; CURRENT FILING DATE: 2002-10-28
 ; PRIOR APPLICATION NUMBER: PA 2001 01627
 ; PRIOR FILING DATE: 2001-11-02
 ; PRIOR APPLICATION NUMBER: 60/335,383
 ; PRIOR FILING DATE: 2001-11-15
 ; NUMBER OF SEQ ID NOS: 7
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 3
 ; LENGTH: 36
 ; TYPE: DNA
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
 US-10-281-727-3

Query Match 0.4%; Score 9.2; DB 1; Length 36;
 Best Local Similarity 78.6%; Pred. No. 9.7e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATGCAGCAGTA 981
 ||| |||||
 Db 35 TGCCTGCAGCAGGA 22

RESULT 112

US-09-951-121A-14
 ; Sequence 14, Application US/09951121A
 ; Publication No. US20030104978A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Persson, Egon
 ; APPLICANT: Olsen, Ole Hvilsted
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants
 ; FILE REFERENCE: 6224.200-US
 ; CURRENT APPLICATION NUMBER: US/09/951,121A
 ; CURRENT FILING DATE: 2001-09-13
 ; PRIOR APPLICATION NUMBER: PA 2000 01361
 ; PRIOR FILING DATE: 2000-09-13
 ; PRIOR APPLICATION NUMBER: 60/236,455
 ; PRIOR FILING DATE: 2000-09-29
 ; NUMBER OF SEQ ID NOS: 17
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 14
 ; LENGTH: 33
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic
 US-09-951-121A-14

Query Match 0.4%; Score 9; DB 1; Length 33;
 Best Local Similarity 60.0%; Pred. No. 1.1e+03;
 Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGTTGAGGTTTACCACCTGCT 217
 ||| |||||
 Db 4 TACTCGGATGGCGGCAAGGACTCCT 28

RESULT 113
 US-09-951-121A-15/c
 ; Sequence 15, Application US/09951121A
 ; Publication No. US20030104978A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Persson, Egon
 ; APPLICANT: Olsen, Ole Hvilsted
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants
 ; FILE REFERENCE: 6224.200-US
 ; CURRENT APPLICATION NUMBER: US/09/951,121A
 ; CURRENT FILING DATE: 2001-09-13
 ; PRIOR APPLICATION NUMBER: PA 2000 01361
 ; PRIOR FILING DATE: 2000-09-13
 ; PRIOR APPLICATION NUMBER: 60/236,455
 ; PRIOR FILING DATE: 2000-09-29
 ; NUMBER OF SEQ ID NOS: 17
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 15
 ; LENGTH: 33
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic
 US-09-951-121A-15

Query Match 0.4%; Score 9; DB 1; Length 33;
 Best Local Similarity 60.0%; Pred. No. 1.1e+03;
 Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGTTGAGGTTTACCACCTGCT 217
 ||| |||||
 Db 30 TACTCGGATGGCGGCAAGGACTCCT 6

RESULT 114
 US-10-295-682-14
 ; Sequence 14, Application US/10295682
 ; Publication No. US20030100740A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Persson, Egon

```
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGCTGAGGCTTACCCTGCT 217
Db 4 TACTCGGATGGCGCAAGGACTCCT 28

RESULT 115
US-10-295-682-15/c
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGCTGAGGCTTACCCTGCT 217
Db 30 TACTCGGATGGCGCAAGGACTCCT 6

RESULT 116
US-09-803-810-8/c
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
```

```
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 136 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 42 TTCTTGAAGGAGCTCCGTCCAGCAGCCTGGAGCGG 7

RESULT 117
US-10-298-330-8/c
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 136 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171
Db 42 TTCTTGAAGGAGCTCCGTCCAGCAGCCTGGAGCGG 7

RESULT 118
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
```

US-10-017-122-4

Query Match 0.4%; Score 8.2; DB 1; Length 31;
Best Local Similarity 61.9%; Pred. No. 1.4e+03;
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1372 CAGAAAGTTTCTTAAGTCA 1392
Db 31 CAGAGAGTACCCCTCATGGCA 11

RESULT 119

US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTTGGTGCATA 756
Db 31 TTTGGGGCACA 21

RESULT 120

US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTTGGTGCATA 756
Db 4 TTTGGGGCACA 14

RESULT 121

US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTTGGTGCATA 756
Db 31 TTTGGGGCACA 21

RESULT 122

US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 TTTGGTGCATA 756
Db 4 TTTGGGGCACA 14

Mon Aug 9 17:56:37 2004

Search completed: August 9, 2004, 16:58:13
Job time : 32 secs

10664775-5.rnpb

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:58:32 ; Search time 3 Seconds
(without alignments)
4.164 Million cell updates/sec

Title: us-10-664-775-5
Perfect score: 2267
Sequence: 1 gatcactcctctagtgaag.....ttgtaattctagtgctgat 2267

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 4 segs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database: rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	0.9	1201	1	AL531727
C 2	19.8	0.9	645	1	AI116939
C 3	18	0.8	1201	1	AL531727
C 4	17	0.7	300	1	AU099140
C 5	16.3	0.7	609	1	AI099321
C 6	14.4	0.6	609	1	AI099321
C 7	13.8	0.6	645	1	AI116939
C 8	13.6	0.6	300	1	AU099140

ALIGNMENTS

RESULT 1
AL531727/c
LOCUS
DEFINITION
AL531727 Homo sapiens FETAL LIVER Homo sapiens CDNA clone
CS0DM003YI01 5-PRIME, mRNA sequence.
ACCESSION
AL531727.2 GI:31069559
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens

REFERENCE
1 (bases 1 to 1201)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
Li.W.B., Gruber,C., Jessee,J. and Polayes,D.
TITLE
Full-length cDNA libraries and normalization
JOURNAL
Unpublished (2001)
CONTACT
On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DM003AE01QPI&cluster=7252.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DM003AE01QPI.
Location/Qualifiers

1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DM003YI01"
/tissue_type="FETAL LIVER"
/dev stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/note="Organ: liver; Vector: pCMVSPORT_6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."
FEATURES
source

source

Query Match 0.9%; Score 20.6; DB 1; Length 1201;
Best Local Similarity 59.3%; Pred. No. 0.31;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTGTGTTGAATATGATTCATTTGG 498
DB 648 TTGCTGGCAATTTCTTTTCTAGATAGGTAATTTTCCACATGGATATCAACTGTGG 590

RESULT 2

AI116939/c

LOCUS

DEFINITION

AI116939.1 GI:3517263

PRECUSOR (HUMAN); mRNA sequence.

EST.

Mus musculus (house mouse)

Mus musculus

ORGANISM

REFERENCE

AUTHORS

1 (bases 1 to 645)

Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,

Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,

Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,

Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and

Waterston,R.

The WashU-HMI Mouse EST Project

Unpublished (1996)

CONTACT: Marra M/Mouse EST Project

WashU-HMI Mouse EST Project

Washington University School

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@watson.wustl.edu

This clone is available royalty-free through LLNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930178

Seq primer: custom primer used

High quality sequence stop: 483.

Location/Qualifiers

1. 645

/organism="Mus musculus"

/mol_type="mRNA"

/strain="C57BL"

/db_xref="taxon:10090"

/clone="IMAGE:1481822"

FEATURES
source


```

/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGG); Site 2: DraIII (CACCATGG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCCTACTG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACGTGTG, 3' site CACCATGG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTGAGCACA."

Query Match      0.9%; Score 19.8; DB 1; Length 645;
Best Local Similarity 69.2%; Pred. No. 0.87;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1860 CTGCTGAGATCTCTCTATCTCTGTATCTGTCTGTCATCTGCA 1898
Db 586 CTGCTGAGTTCTTTTCTTACACAGCATTTCTCCCA 548

RESULT 3
AL531727 1201 bp mRNA linear EST 23-MAY-2003
LOCUS AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone
DEFINITION CSODM003YI01 5-PRIME, mRNA sequence.
ACCESSION AL531727
VERSION AL531727.2 GI:31069559
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1201)
Li W.B., Gruber C., Jesse J., and Polayes D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL On Feb 13, 2001 this sequence version replaced gi:12795220.
COMMENT Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seque@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODM003AE01QP1&cluster=7252.f. Contact :
Peng Liang Email: fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paradise Avenue Genoscope sequence ID : CSODM003AE01QP1.
Location/Qualifiers
1. .1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODM003YI01"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

Query Match      0.8%; Score 18; DB 1; Length 1201;
Best Local Similarity 52.4%; Pred. No. 1.1;

```

```

Matches 22; Conservative 7; Mismatches 13; Indels 0; Gaps 0;

Qy 1665 TCTCAAGGTTAGGAATTTCTTTTGTGTTCTTCTGAAAA 1706
Db 1148 TCCCAAAWHAGGAKAAATTTTTCGGTWTWYGAGGAAA 1189

RESULT 4
AU099140 300 bp mRNA linear EST 05-APR-2001
LOCUS AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVI2463, mRNA sequence.
ACCESSION AU099140
VERSION AU099140.1 GI:13550269
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 300)
Suzuki Y., Tsunoda T., Taira H., Mizushima-Sugano J., Sese J.,
Hata H., Ota T., Isogai T., Tanaka T., Nakamura Y., Morishita S.,
Okubo K., Suyama A. and Sugano S.
In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
Oligo-capping method
Unpublished (2001)
JOURNAL Contact: Yutaka Suzuki
COMMENT Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki Y., Yoshitomo-Nakagawa K., Maruyama K., Suyama A. and
Sugano S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
Location/Qualifiers
1. 300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match      0.7%; Score 17; DB 1; Length 300;
Best Local Similarity 59.2%; Pred. No. 6.6;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1749 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1797
Db 57 TCCTCTGCTTCTGCTTGGCTTCAGGCTGCTGCTGCTGCTTCTGCT 105

RESULT 5
AI099321/c 609 bp mRNA linear EST 20-AUG-1998
LOCUS ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:482509 5' similar to gb:M1232 COAGULATION FACTOR VII
PRECURSOR (HUMAN); mRNA sequence.
ACCESSION AI099321
VERSION AI099321.1 GI:3448846
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 609)
Marra M., Hillier L., Allen M., Bowles M., Dietrich N., Dubuque T.,
Geisel S., Kucaba T., Lacy M., Le M., Martin J., Morris M.,
Schellenberg K., Steptoe M., Tan F., Underwood K., Moore B.,
Theising B., Wylie T., Lennon G., Soares B., Wilson R. and
Waterston R.

```


Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
MGI:930178

Seq primer: custom primer used
High quality sequence stop: 483.

FEATURES

source
1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1481822"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [GTGGCCCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGCG and 3' end
primer CGACCTGCAGCTGCAGCACA."

Query Match 0.6%; Score 13.8; DB 1; Length 645;
Best Local Similarity 56.4%; Pred. No. 7.7; Indels 2; Gaps 1;
Matches 44; Conservative 0; Mismatches 32;
QY 2117 TCCTTGCTGTGCTTCAGCTATCTTCATCTTCAGGCG--CTATTGTAATAGGGTTTA 2174
DB 50 TCTCTGCTTCTTCAGCTCCAGGGACCTCTAGGAGCTGCAGTTTCATAACCCAGGA 109
QY 2175 GCAGGACATATTTCTCT 2192
DB 110 GGAAGCACATGGTGTCTCT 127

RESULT 8

AU099140/c
LOCUS 300 bp mRNA linear EST 05-APR-2001
DEFINITION AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVII2463, mRNA sequence.

ACCESSION AU099140
VERSION AU099140.1 GI:13550269
KEYWORDS EST.

SOURCE Homo sapiens (human)

REFERENCE 1 (bases 1 to 300)
AUTHORS Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J.,
Hata,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S.,
Okubo,K., Suyama,A. and Sugano,S.

TITLE In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
Oligo-capping method

JOURNAL

COMMENT Unpublished (2001)
Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yusuzuki@ims.u-tokyo.ac.jp
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
Sugano,S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),

149-156 (1997).
FEATURES Location/Qualifiers
source 1..300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match 0.6%; Score 13.6; DB 1; Length 300;
Best Local Similarity 61.1%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 756 AGACATTAAAGAATTGCAATGTCCTCTTGGTGGATT 791
DB 277 AGAATCCAGAACAGCTTCGTCCTCCGCGTCCTT 242

Search completed: August 9, 2004, 16:58:35
Job time : 3 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:59:13 ; Search time 728 Seconds
(without alignments)
3.781 Million cell updates/sec

Title: us-10-664-775-4

Perfect score: 2279

Sequence: 1 gatcacctcctagtgaag.....ttgtaattctagggtgtgat 2279

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 250 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	44.7	2.0	289	1	AR162089
C 2	44.7	2.0	289	1	AR166614
C 3	43	1.9	2422	1	AR030786
C 4	43	1.9	2422	1	AR045090
C 5	43	1.9	2422	1	AR052946
C 6	43	1.9	2422	1	AR122899
C 7	43	1.9	2422	1	AR127821
C 8	43	1.9	2462	1	AR095304
C 9	43	1.9	2462	1	AR103988
C 10	43	1.9	2462	1	AX335083
C 11	43	1.9	2462	1	AX409604
C 12	43	1.9	2462	1	HUMVII
C 13	43	1.9	2483	1	E01076
C 14	43	1.9	2483	1	I07990
C 15	41.6	1.8	2177	1	E01075
C 16	41.6	1.8	2438	1	I07991
C 17	37.4	1.6	1573	1	BC040125
C 18	32.4	1.4	300	1	BD211952
C 19	28	1.2	1403	1	BC009726
C 20	27.2	1.2	1792	1	BC034377
C 21	25.2	1.1	1843	1	AR390799
C 22	25.2	1.1	1843	1	AX411026
C 23	25.2	1.1	1843	1	HSPTC
C 24	24.4	1.1	251	1	AY083553
C 25	24	1.1	1499	1	MUSCP
C 26	24	1.1	1580	1	AF318182
C 27	24	1.1	1603	1	BC013896
C 28	23.8	1.0	364	1	AR425705
C 29	23.8	1.0	364	1	BD121258
C 30	23.8	1.0	394	1	AX839180
C 31	23.8	1.0	868	1	BD124660
C 32	23.8	1.0	868	1	BD126609
C 33	23.6	1.0	1671	1	AY040345

ACCESSION:AR425705
ACCESSION:BD121258
ACCESSION:AF465274
ACCESSION:AX774765
ACCESSION:M57285
ACCESSION:AX395271
ACCESSION:AB062462
ACCESSION:AB062463
ACCESSION:AX265077
ACCESSION:AX265078
ACCESSION:AX265081
ACCESSION:AX265082
ACCESSION:AX265085
ACCESSION:AX265086
ACCESSION:AX265089
ACCESSION:AX265090
ACCESSION:AX265093
ACCESSION:AX265094
ACCESSION:AX265094
ACCESSION:AX265073
ACCESSION:AX265074
ACCESSION:MX3108
ACCESSION:K02050
ACCESSION:AX892787
ACCESSION:BD028320
ACCESSION:AX839163
ACCESSION:AF306920
ACCESSION:AF011898
ACCESSION:AF011352
ACCESSION:BC061149
ACCESSION:BC061149
ACCESSION:AX839181
ACCESSION:AX464088
ACCESSION:AX359106
ACCESSION:AX565990
ACCESSION:AX265102
ACCESSION:AX265102
ACCESSION:AX265097
ACCESSION:AX265098
ACCESSION:BC046125
ACCESSION:BD060364
ACCESSION:BD060364
ACCESSION:AR162089
ACCESSION:AR166614
ACCESSION:AF515269
ACCESSION:D21215
ACCESSION:AX524243
ACCESSION:AX552981
ACCESSION:E63001
ACCESSION:E63002
ACCESSION:E62997
ACCESSION:E62998
ACCESSION:E62999
ACCESSION:E63000
ACCESSION:AR112953
ACCESSION:AR112969
ACCESSION:I19358
ACCESSION:I19360
ACCESSION:BD194674
ACCESSION:AX565990
ACCESSION:AX908508
ACCESSION:BD044041
ACCESSION:AF306917
ACCESSION:AF306917
ACCESSION:AF306913
ACCESSION:AF306914
ACCESSION:AF306915
ACCESSION:AF306919
ACCESSION:AF306919
ACCESSION:AX839180
ACCESSION:AF465269
ACCESSION:AF272774
ACCESSION:AF272774
ACCESSION:AY155152
ACCESSION:AB083386
ACCESSION:AB084901
ACCESSION:AY022473
ACCESSION:AY023221

C 107	20.2	0.9	272	1	HUMPROS01	18.6	0.8	168	1	1B2435	182435	ACCESSION:M36565 J
C 108	20.2	0.9	352	1	HUMPS02	18.6	0.8	174	1	HUMPROS01	182435	ACCESSION:M36565 J
C 109	20.2	0.9	885	1	AR108139	18.6	0.8	189	1	AY135778S1	182435	ACCESSION:AY135791
C 110	20.2	0.9	1543	1	AX401899	18.6	0.8	189	1	AY135778S1	182435	ACCESSION:AY135791
C 111	20.2	0.9	1543	1	RNPROC	18.6	0.8	200	1	AR047835	182435	ACCESSION:AR047835
C 112	20	0.9	855	1	AF011899	18.6	0.8	222	1	AX260845	182435	ACCESSION:AX260845
C 113	20	0.9	1130	1	AR234337	18.6	0.8	241	1	HS88A12F	182435	ACCESSION:HS88A12F
C 114	20	0.9	1142	1	AR219285	18.6	0.8	427	1	AX524284	182435	ACCESSION:AX524284
C 115	20	0.9	1142	1	AR219285	18.6	0.8	427	1	AX524284	182435	ACCESSION:AX524284
C 116	20	0.9	1169	1	AR219284	18.6	0.8	439	1	AX553022	182435	ACCESSION:AX553022
C 117	20	0.9	1169	1	AR219284	18.6	0.8	439	1	AX553022	182435	ACCESSION:AX553022
C 118	19.8	0.9	254	1	AX587861	18.6	0.8	546	1	MACCFX	182435	ACCESSION:MACCFX
C 119	19.8	0.9	268	1	HSUBK1FU7	18.6	0.8	546	1	MACCFX	182435	ACCESSION:MACCFX
C 120	19.8	0.9	384	1	BD095271	18.6	0.8	439	1	AX277349	182435	ACCESSION:AX277349
C 121	19.8	0.9	394	1	AX814618	18.6	0.8	439	1	AX277349	182435	ACCESSION:AX277349
C 122	19.8	0.9	535	1	DLA6882	18.6	0.8	773	1	AX827818	182435	ACCESSION:AX827818
C 123	19.8	0.9	556	1	BV036036	18.6	0.8	773	1	RNTRY2	182435	ACCESSION:RNTRY2
C 124	19.8	0.9	813	1	PIGFIYA	18.6	0.8	819	1	DOGTRYP	182435	ACCESSION:DOGTRYP
C 125	19.8	0.9	873	1	HUMCFIX	18.6	0.8	854	1	PVTRYPIN	182435	ACCESSION:PVTRYPIN
C 126	19.8	0.9	1850	1	MMU44795	18.6	0.8	854	1	PVTRYPIN	182435	ACCESSION:PVTRYPIN
C 127	19.6	0.9	484	1	HAMCFX	18.6	0.8	1278	1	AF465268	182435	ACCESSION:AF465268
C 128	19.6	0.9	596	1	AX193364	18.6	0.8	1443	1	HUMFXM	182435	ACCESSION:HUMFXM
C 129	19.6	0.9	609	1	AX763043	18.6	0.8	1467	1	A86886	182435	ACCESSION:A86886
C 130	19.6	0.9	882	1	AX675583	18.6	0.8	1467	1	A86886	182435	ACCESSION:A86886
C 131	19.6	0.9	1142	1	AR219285	18.6	0.8	1467	1	AR316969	182435	ACCESSION:AR316969
C 132	19.6	0.9	1161	1	AX675581	18.6	0.8	1467	1	AR340866	182435	ACCESSION:AR340866
C 133	19.6	0.9	1169	1	AR219284	18.6	0.8	1467	1	AX082959	182435	ACCESSION:AX082959
C 134	19.6	0.9	1373	1	BOVPBC	18.6	0.8	1467	1	BD070392	182435	ACCESSION:BD070392
C 135	19.4	0.9	177	1	AR109618	18.6	0.8	1514	1	BD070435	182435	ACCESSION:BD070435
C 136	19.4	0.9	177	1	AR150638	18.6	0.8	1514	1	AF191307	182435	ACCESSION:AF191307
C 137	19.4	0.9	177	1	E16187	18.4	0.8	193	1	HUMKALR4	182435	ACCESSION:HUMKALR4
C 138	19.4	0.9	177	1	E27213	18.4	0.8	249	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 139	19.4	0.9	177	1	E28271	18.4	0.8	249	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 140	19.4	0.9	177	1	AR300928	18.4	0.8	249	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 141	19.4	0.9	204	1	AR109885	18.4	0.8	249	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 142	19.4	0.9	204	1	AR150703	18.4	0.8	256	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 143	19.4	0.9	249	1	AX86104	18.4	0.8	256	1	HUMDPB1A	182435	ACCESSION:HUMDPB1A
C 144	19.4	0.9	290	1	AX839191	18.4	0.8	257	1	AF180970	182435	ACCESSION:AF180970
C 145	19.4	0.9	352	1	HUMPS02	18.4	0.8	257	1	AF180970	182435	ACCESSION:AF180970
C 146	19.4	0.9	471	1	DOGA2	18.4	0.8	264	1	HUMDPB1KT	182435	ACCESSION:HUMDPB1KT
C 147	19.4	0.9	823	1	SHPTIXA	18.4	0.8	279	1	AF306907	182435	ACCESSION:AF306907
C 148	19.4	0.9	829	1	BC061135	18.4	0.8	279	1	AF306907	182435	ACCESSION:AF306907
C 149	19.4	0.9	1146	1	AR095306	18.4	0.8	279	1	AF306907	182435	ACCESSION:AF306907
C 150	19.4	0.9	1126	1	AR095306	18.4	0.8	283	1	AF306912	182435	ACCESSION:AF306912
C 151	19.4	0.9	1126	1	HUMFX	18.4	0.8	283	1	AF306912	182435	ACCESSION:AF306912
C 152	19.4	0.9	1404	1	AX3124	18.4	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 153	19.4	0.9	1414	1	HUMCFX	18.4	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 154	19.4	0.9	1551	1	AX147505	18.4	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 155	19.4	0.9	1850	1	MMU44795	18.4	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 156	19.4	0.9	1869	1	BC061149	18.4	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 157	19.2	0.8	281	1	MUSACROS02	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 158	19.2	0.8	471	1	GOT3	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 159	19.2	0.8	596	1	BV094002	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 160	19.2	0.8	826	1	RABTHRO	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 161	19.2	0.8	1302	1	AF465270	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 162	19.2	0.8	1341	1	AF532184	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 163	19.2	0.8	1619	1	OCUT7477	18.2	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 164	19	0.8	244	1	HSCRYB2S3	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 165	18.8	0.8	340	1	AR263850	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 166	18.8	0.8	340	1	AR263851	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 167	18.8	0.8	352	1	DMU58868	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 168	18.8	0.8	596	1	AX193364	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 169	18.8	0.8	882	1	AX675583	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 170	18.8	0.8	1161	1	AX675581	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 171	18.8	0.8	1505	1	AX523898	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 172	18.8	0.8	1671	1	AY040345	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 173	18.6	0.8	168	1	AR077689	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 174	18.6	0.8	168	1	AR081819	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 175	18.6	0.8	168	1	AR098999	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 176	18.6	0.8	168	1	AR116830	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 177	18.6	0.8	168	1	AR127061	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 178	18.6	0.8	168	1	AR141647	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638
C 179	18.6	0.8	168	1	AR151537	18	0.8	285	1	AF492638	182435	ACCESSION:AF492638

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

1 (bases 1 to 1573)

Strausberg,R.
Direct Submission
Submitted (22-NOV-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA

NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabbs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbio.org
contact: amadan@systemsbio.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Ketteman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAX Plate: 84 Row: m Column: 9
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 9961350.

FEATURES
 source
 1..1573
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:5764698"
 /tissue_type="Brain, adult, 6 pooled whole brains"
 /clone_lib="NIH_MGC_114"
 /lab_host="DH10B"
 /note="vector: pCMV-SPORTc"

Query Match 1.6%; Score 37.4; DB 1; Length 1573;
Best Local Similarity 51.5%; Pred. No. 0.0032;
Matches 86; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

Qy 1518 TTTATATTGAATGGTCCTTTTTCCCTGCACTTTTAATAATCTCTCTCTCTCTATA 1577
Db 1564 TT 1505
Qy 1578 CTTTAGTGATTGATTATGACATGTGGGAGTTCTTTCCGTCACAATCTATTG 1637
Db 1504 TTTTTTTTTTTTTTTTTTTTTTTTTTTGGTGGCATCTCATTAAATGGAGGACGTTATGAC 1445
Qy 1638 GTGTTTTGTGATGCTCTTGACTGATAGGCACTCTTTCTCAAG 1684
Db 1444 CTCGGGGCATGGCTCTGGCTTGGCCATGGCAAAGCCCTGGTTTCATGG 1398

RESULT 18
BD211952 300 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel human genes and gene expression products ii.
ACCESSION BD211952
VERSION BD211952.1 GI:33021722
KEYWORDS JP 2002519000-A/94.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 300)
Williamis,L.T., Escobedo,J., Immis,M.A., Garcia,P.D., Klinger,J.S.,
Reinhard,C., Giese,K., Randazzo,F., Kennedy,G.C., Pot,D.,
Kassam,A., Lanson,G., Drmanac,R., Crkvenjakov,R., Dickson,M.,
Drmanac,S., Labat,I., Leshkowitz,D., Kita,D., Garcia,V., Jones,L.W.,
and Crain,B.S.
Novel human genes and gene expression products ii
Patent: JP 2002519000-A 94 02-JUL-2002;
CHIRON CORP.HYSEQ INC

TITLE
JOURNAL

OS Homo sapiens (human)
PN JP 2002519000-A/94
PD 67-JUL-2002
PF 28-JAN-1999 JP 2000556580
PR 28-JAN-1998 US 60/072910,24-FEB-1998 US 60/075954 PR
31-MAR-1998 US 60/080114,03-APR-1998 US 60/080515 PR
03-APR-1998 US 60/080666,21-OCT-1998 US 60/105234 PR
28-OCT-1998 US 60/105877
PI LOUIS T WILLIAMS,JAIME ESCOBEDO,MICHAEL A INNIS,PABLO PI
DOMINGUEZ GARCIA,
PI JULIE SUDDUTH KLINGER,CHRISTOPH REINHARD,KLAUSE GIESE,FILIPPO
PI RANDAZZO,
PI GIULIA C KENNEDY,DAVID POT,ALTAF KASSAM,GEORGE LAMSON,RADOJE
PI DPMANAC,
PI RADOMIR CRKVENJAKOV,MARK DICKSON,SNEZANA DRMANAC,IVAN LABAT,
PI DENA LESHKOWITZ,DAVID KITA,VERONICA GARCIA,LEE WILLIAM JONES,
PI BIRJIT STACHE CRAIN
PC C12N15/09,C12N15/09,C07K14/47,C07K14/82,C07K16/18,C12N1/15,PC
C12N1/19,
PC C12N1/21,C12N5/10,C12Q1/68,C12N15/00,C12N5/00,C12N15/00 CC n
=A,T,C or G
FH key Location/Qualifiers
FT misc feature (1)..{300}.
Location/Qualifiers
1..300
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.4%; Score 32.4; DB 1; Length 300;
Best Local Similarity 78.0%; Pred. No. 0.057;
Matches 39; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1103 TGCACCTGTGCACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1152
DB 89 TCCCCCTAGGCGCCCTGCTGTGCGTGTGCGTGTGCGTGTGTGTGTGTGTGTGT 138
RESULT 19
BC009726/c
LOCUS 1403 bp mRNA linear PRI 12-NOV-2003
DEFINITION Homo sapiens protease, serine, 22, mRNA (cDNA clone MGC:9599
IMAGE:3899480), complete cds.
ACCESSION BC009726
VERSION BC009726.1 GI:16307274
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1403)
Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L.H., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Heieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Schectel,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carinci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalon,D.K., Muzny,D., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahey,J., Helton,E., Kettman,M., Maman,A., Rodrigues,S.,
Sanchez,A., Whiting,M., Maman,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalls,D.E.,
Scherch,A., Schein,J.F., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257

mat_peptide /product="activation peptide" 644.1393 /product="serine protease"

Query Match 1.1%; Score 24; DB 1; Length 1499; Best Local Similarity 46.9%; Pred. No. 9.5; Mismatches 85; Indels 0; Gaps 0; Matches 75; Conservative 0;

QY 1891 CTATCTCTGTTTCTGTCAGTGGCTTGTCTGAGGTTCCTGTTGGTTCCTTAATT 1950
 DB 715 CTCTCTGAGTCCAGAGGATGCTGCGCAAGACTGCACCTGCTGTCAGCGT 656

QY 1951 TTTCATTTCCAGATTCCTTCAGTTGGTGTGTTTATTAATTCATTTCCATTTT 2010
 DB 655 TCGGTTGACTATCTTGGATCTGTTCCAGTTTCATCTTAAAGTCTGTCTGCTGTTGAG 596

QY 2011 GTCCTGAATGTTTACTCATTTTCTCCAGTATTACA 2050
 DB 595 GATCTTGGCTTCTTCTATCCACCTCCCGAGTTTCCCA 556

RESULT 26
 AF318182/c
 LOCUS
 DEFINITION Mus musculus anticoagulant protein C mRNA, complete cds.
 ACCESSION AF318182
 VERSION AF318182.1 GI:12802522
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 1580)
 Korf, I.
 Complete sequence of UC72A01
 Unpublished
 2 (bases 1 to 1580)
 Korf, I.
 Direct Submission
 Submitted (02-NOV-2000) Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, MO 63108, USA
 FEATURES
 source
 1. .1580
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="C57BL"
 /db_xref="dbEST:AA986009"
 /db_xref="taxon:10090"
 72..1454
 /codon_start=1
 /product="anticoagulant protein C"
 /protein_id="AAK07918.1"
 /db_xref="GI:12802523"
 /translations="MQFRVFLIMTGWISIPAHDPDPVFSSEHAHQVLRVRANS
 FLEMPGSLERMEICDLERAEQFONVEDTLAFWKYFDGDCSPAPLDHQCDSD
 PCCHGTCDIGISFSCDKHGEGFCQELRPDCRVNNGSCLYCLEESNGRCA
 CAGYELADDMKCKSTVNPFCGLKRWIEKKILKRDLDLEDELPDRIYNGILF
 KQDGPQAILLDSKKLACGVLITHTSVLTAHCVGFKLTVRIGEDYELRRRDHW
 ELDDIKELIIVHPNTRSSNDIALRLAQPATLSKTIVIPICLPNNGLAELTQAGQ
 ETVTGMYGQSDRIKQGRNRITLPIRIPLVARNECVEMKNVSENNMLCAGIIGD
 TRACDGDSDGPMVFRPGTWFLVGLVSGEGCGHTNNYGIYTKVGSYLKWIHSYIE
 KGVSLKSKQL"

Query Match 1.1%; Score 24; DB 1; Length 1580; Best Local Similarity 46.9%; Pred. No. 9.5; Mismatches 85; Indels 0; Gaps 0; Matches 75; Conservative 0;

QY 1891 CTATCTCTGTTTCTGTCAGTGGCTTGTCTGAGGTTCCTGTTGGTTCCTTAATT 1950
 DB 776 CTCTCTGAGTCCAGAGGATGCTGCGCAAGACTGTACCCCTGCTTCGTCAGCGT 717
 QY 1951 TTTCATTTCCAGATTCCTTCAGTTGGTGTGTTTATTAATTCATTTCCATTT 2010

Db 716 TCGGTTGACTATCTTGGATCTGGTTCCAGTTTCATCTTCTAAGTCTGTCTCGTTTGAG 657
 QY 2011 GTCCTGAATGTTTACTCATTTTCTCTCCAGTATTACA 2050
 Db 656 GATCTTGGGTTTCTTCTCTATCCACCTCCCGAGTTTCCCA 617

RESULT 27
 BC013896
 LOCUS
 DEFINITION Mus musculus protein C, mRNA linear ROD 03-OCT-2003 complete cds.
 ACCESSION BC013896
 VERSION BC013896.1 GI:15530229
 SOURCE MGC.
 ORGANISM Mus musculus (house mouse)
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 1603)
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.P., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S., Carninci, P., Brange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Wray, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Hellon, E., Kettelman, M., Madan, A., Rodriguez, S., Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalusz, D.E., Scherch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 22388257
 12477932
 2 (bases 1 to 1603)
 Strausberg, R.
 Direct Submission
 Submitted (07-SEP-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA
 REMARK
 COMMENT NIH-MGC Project URL: <http://mgc.nci.nih.gov>
 Contact: MGC help desk
 Email: cgaps-remail.nih.gov
 Tissue Procurement: Jeffrey E. Green, M.D.
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Institute for Systems Biology
<http://www.systemsbio.org>
 contact: amadan@systemsbiology.org
 Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
 Series: IRAC Plate: 18 Row: n Column: 8
 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6579476.
 Location/Qualifiers
 1. .1603
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="FVB/N"
 /db_xref="taxon:10090"


```
/clone="MGC:13870 IMAGE:4211329"
/tissue_type="Liver, normal. 5 month old male mouse."
/clone_lib="NCI CGAP_Li9"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"
1..1603
/gene="Proc"
/note="synonym: PC"
/db_xref="LocusID:19123"
/db_xref="GI:15530230"
100..1482
/codon_start=1
/product="protein C"
/protein_id="AAH13896.1"
/db_xref="GI:15530230"
/db_xref="LocusID:19123"
/translation="MWQFRVLLLMSTWGISSIPAHDPVPFSSSEHAHQVLRVRANS
FLEMRPGSLRECHMEECIFEEAEIQFQNVEDTAFWIKYFDGQCSAPPLDHQCD
PCCGHGTCIDIGSFSCSDKGWEGKFCQQLRFQDCRVNNGGCLHYCLEESNGRCA
CAPGYELADHMRCKSTVNFPCGKLGRWIEKRILKRDITDLELDPDRIVNGTTLT
KQGPSWQAILLDDSKKLACCGVLHTSWLTAACHVEGTGKLTVRLEGVLDLRRDHW
ELDLIDKEILVHPNVTSSSDNDIALLRLAQPATLSKTIPICLPNGLAQLTQAGQ
ETVVTGQYQSDRIKDGRRNRTFILFIRIELVARNECEVKKNVVSENMLCAGIIGD
TRDACDGSQGMVFFRGITWFLVGLVSWEGGCHTNNGYIYTKVSYLKIWIHSYIE
KGVSLKSKQL"
175..357
/note="GLA; Region: Domain containing Gla
(gamma-carboxylglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
/note="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
730..1431
/note="Tryp_SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 1.1%; Score 24; DB 1; Length 1603;
Best Local Similarity 46.9%; Pred. No. 9.5;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1891 CTATCTCTGATCTCTGATGAGGCTTGCTCTGAGGTTCCTGTTGGGTCTTAATT 1950
Db 804 CTCTCTCTGAGTCCAGAGGATGCTGCCAAGGACTGTCACCTGCTTCGTCAGCGT 745
QY 1951 TTTCATTCAGATTTCCTCAGTTGGGTTGTTGTTATTAATTTCACTTTTCA 2010
Db 744 TCGTTGACTATCTTGATCTGGTTCAGTTTCATCTTCAAGTCTGTCTGTTTGG 685
QY 2011 GTCTGAAATGTTTACTCATTTTCCTCCAGTATTACA 2050
Db 684 GATCTGCGTTTCTCTATCCACCTCCCAAGTTCCCA 645

RESULT 28
AR425705
LOCUS 364 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 17202 from patent US 6639063.
ACCESSION AR425705
VERSION AR425705.1 GI:40180815
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 364)
```

```
AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.
TITLE ESR's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES
    source
        1..364
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match 1.0%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 9.7;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 194 CCTAGGTTGAGGGTTACCACTGCTCTCTCTCCCTTCTTCAACACTTCTTCTG 253
Db 27 MCKSSRSYGRSSCCGSMGWSGCSKRSRSCRCMKSMWSMMYMRSMKYKSTCASC 86
QY 254 TAGGGGCACCTACCGCATTCCTCTCTCTTCCAAACACTTCTATTTCTTG 302
Db 87 YKGGKMACMTCWSTGMYRYNASYWCYSYARYTTCYSKYRMWKYCYR 135

RESULT 29
BD121258
LOCUS 364 bp DNA linear PAT 18-SEP-2002
DEFINITION EST and encoded human protein..
ACCESSION BD121258
VERSION BD121258.1 GI:23216168
KEYWORDS JP 2002010789-A/13335.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
    Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.
TITLE EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 13335 15-JAN-2002;
GENSET CORP
COMMENT OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PF 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPTISTE DUNAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
C12N1/21,
PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source 1..364
    /organism="Homo sapiens (human)"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"

FEATURES
    source
        1..364
            /organism="Homo sapiens"
            /mol_type="genomic DNA"

Query Match 1.0%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 9.7;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 194 CCTAGGTTGAGGGTTACCACTGCTCTCTCTCCCTTCTTCAACACTTCTTCTG 253
Db 27 MCKSSRSYGRSSCCGSMGWSGCSKRSRSCRCMKSMWSMMYMRSMKYKSTCASC 86
QY 254 TAGGGGCACCTACCGCATTCCTCTCTTCCAAACACTTCTATTTCTTG 302
Db 87 YKGGKMACMTCWSTGMYRYNASYWCYSYARYTTCYSKYRMWKYCYR 135

RESULT 30
AX839180
```

[illegible]

```
AY040345/c
LOCUS       AY040345               1671 bp      mRNA      linear      VRT 25-JUL-2001
DEFINITION   Danio rerio coagulation factor VII mRNA, complete cds.
ACCESSION    AY040345
VERSION      AY040345.1  GI:15020317
KEYWORDS     Danio rerio (zebrafish)
SOURCE       Danio rerio
ORGANISM     Danio rerio
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
              Cypriniformes; Cyprinidae; Danio.
REFERENCE    1 (bases 1 to 1671)
AUTHORS      Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
              Phan,T., Thankavel,B. and Jagadeeswaran,P.
              Direct Submission
              Submitted (14-JUN-2001) Cellular and Structural Biology, University
              Of Texas Health Science Center at San Antonio, 7703 Floyd Curl
              Drive, San Antonio, TX 78229, USA
              Location/Qualifiers
              1..1671
                 /organism="Danio rerio"
                 /mol_type="mRNA"
                 /db_xref="taxon:7955"
              1..1302
                 /codon_start=1
                 /product="coagulation factor VII"
                 /protein_id="AAK74192.1"
                 /db_xref="GI:15020318"
                 /translation="MSLLVFLSLWSLHYCHSAAFVHRDEAHEVLIRSKRANGWFE
              ELATGNLCRLCEKESYEAREVFTEATNEFWKIYDVKHCCASPCHDGLCTQ
              NADSYNCLCPGSGRHCQSIGDVLDSCLHDNGGCEHFCFTEODGRNCSADGYLD
              NSQKCRSHVFPFGCVPLLOAGKAADHQVLDLSRIVGSECEPKGHPQVLKYGEK
              GFCGGVYKPTWLTAAHCLKLVKFLRIVAGEHDLVDEGEQLIQVDMTHFAY
              VSTADSLALLRLPTPIVYSYAVFVCLPLREMAERLWAVSKHTVSGWKGKSEDP
              TSLRLDLRLPRITQECQVSNLTLSNNFCAGYIEGRQDSCKGSDGSGFLVTRYRDT
              AFLLGVSNKGKARGSGYITRVSNYLQWIRQTNTTIH"
              1.0%; Score 23.6; DB 1; Length 1671;
              Best Local Similarity 54.7%; Pred. No. 12;
              Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 1319 TGNAGATAGATATCTTTCACTGATTTTATCTTAGAATGCTCTTTCTTCTCCTCAACTAT 1378
Db 1436 TTAATATAAATATTTTATTTTCAATAAATTTTGTCTATTTTACAAACATTAATAT 1377

QY 1379 TGTGACAGAAAGTTTCTTAAGTCCA 1404
Db 1376 AATAGTAATAATTTGTAAATGTGTTCA 1351

RESULT 34
AR425705/c
LOCUS       AR425705               364 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 17202 from patent US 6639063.
ACCESSION    AR425705
VERSION      AR425705.1  GI:40180815
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
              1 (bases 1 to 364)
              Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
              EST's and encoded human proteins
              Patent: US 6639063-A 17202 28-OCT-2003;
              Location/Qualifiers

Query Match
Best Local Similarity 1.0%; Score 23.6; DB 1; Length 1671;
Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 1319 TGNAGATAGATATCTTTCACTGATTTTATCTTAGAATGCTCTTTCTTCTCCTCAACTAT 1378
Db 1436 TTAATATAAATATTTTATTTTCAATAAATTTTGTCTATTTTACAAACATTAATAT 1377

QY 1379 TGTGACAGAAAGTTTCTTAAGTCCA 1404
Db 1376 AATAGTAATAATTTGTAAATGTGTTCA 1351

RESULT 34
AR425705/c
LOCUS       AR425705               364 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 17202 from patent US 6639063.
ACCESSION    AR425705
VERSION      AR425705.1  GI:40180815
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
              1 (bases 1 to 364)
              Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
              EST's and encoded human proteins
              Patent: US 6639063-A 17202 28-OCT-2003;
              Location/Qualifiers

Query Match
Best Local Similarity 1.0%; Score 23; DB 1; Length 364;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

QY 660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTAATTTAGCTGTAGCTGTGCTT 719
Db 277 WTGRSMWKKSTYKRWSRAGSWMTGYRMSKMWGTGSTRCTSKKKRKGSTSSKYASTSGK 218

QY 720 GTTTTATGAACCTTGGGTGACATTTGTTTGGTGACATGACATTAAGAATTCATGCTCT 779
Db 217 SSKYMSCTCRSSKKCRYSATYYISCMWKKYCMMSATYSGCMWRYCYSCMWSRYSCT 158

QY 780 CTGTGGTGATTTT 792
Db 157 SYSRGKCSCTGWK 145

RESULT 35
BD121258/c
LOCUS       BD121258               364 bp      DNA      linear      PAT 18-SEP-2002
DEFINITION   EST and encoded human protein.
ACCESSION    BD121258
VERSION      BD121258.1  GI:23216168
KEYWORDS     JP 2002010789-A/13335.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
              1 (bases 1 to 364)
              Edwards,J.B.D.M., Jobert,S. and Giordano,J.E.
              EST and encoded human protein
              Patent: JP 2002010789-A 13335 15-JAN-2002;
              GENSET CORP

COMMENT      OS Homo sapiens (human)
              PN JP 2002010789-A/13335
              PD 15-JAN-2002
              PF 07-AUG-2000 JP 2000280989
              PR 05-AUG-1999 US 60/147499
              PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
              GIORDANO
              PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
              C12N1/21,
              PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
              C12N15/00
              CC EST and encoded human protein
              FH Key Location/Qualifiers
              FT source
                 1..364
                 /organism="Homo sapiens"
                 /mol_type="genomic DNA"
                 /db_xref="taxon:9606"

FEATURES
source
1..364
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.0%; Score 23; DB 1; Length 364;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

QY 660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTAATTTAGCTGTAGCTGTGCTT 719
Db 277 WTGRSMWKKSTYKRWSRAGSWMTGYRMSKMWGTGSTRCTSKKKRKGSTSSKYASTSGK 218

QY 720 GTTTTATGAACCTTGGGTGACATTTGTTTGGTGACATGACATTAAGAATTCATGCTCT 779
Db 217 SSKYMSCTCRSSKKCRYSATYYISCMWKKYCMMSATYSGCMWRYCYSCMWSRYSCT 158

QY 780 CTGTGGTGATTTT 792
Db 157 SYSRGKCSCTGWK 145
```

```
AY040345/c
LOCUS       AY040345               1671 bp      mRNA      linear      VRT 25-JUL-2001
DEFINITION   Danio rerio coagulation factor VII mRNA, complete cds.
ACCESSION    AY040345
VERSION      AY040345.1  GI:15020317
KEYWORDS     Danio rerio (zebrafish)
SOURCE       Danio rerio
ORGANISM     Danio rerio
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
              Cypriniformes; Cyprinidae; Danio.
REFERENCE    1 (bases 1 to 1671)
AUTHORS      Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
              Phan,T., Thankavel,B. and Jagadeeswaran,P.
              Direct Submission
              Submitted (14-JUN-2001) Cellular and Structural Biology, University
              Of Texas Health Science Center at San Antonio, 7703 Floyd Curl
              Drive, San Antonio, TX 78229, USA
              Location/Qualifiers
              1..1671
                 /organism="Danio rerio"
                 /mol_type="mRNA"
                 /db_xref="taxon:7955"
              1..1302
                 /codon_start=1
                 /product="coagulation factor VII"
                 /protein_id="AAK74192.1"
                 /db_xref="GI:15020318"
                 /translation="MSLLVFLSLWSLHYCHSAAFVHRDEAHEVLIRSKRANGWFE
              ELATGNLCRLCEKESYEAREVFTEATNEFWKIYDVKHCCASPCHDGLCTQ
              NADSYNCLCPGSGRHCQSIGDVLDSCLHDNGGCEHFCFTEODGRNCSADGYLD
              NSQKCRSHVFPFGCVPLLOAGKAADHQVLDLSRIVGSECEPKGHPQVLKYGEK
              GFCGGVYKPTWLTAAHCLKLVKFLRIVAGEHDLVDEGEQLIQVDMTHFAY
              VSTADSLALLRLPTPIVYSYAVFVCLPLREMAERLWAVSKHTVSGWKGKSEDP
              TSLRLDLRLPRITQECQVSNLTLSNNFCAGYIEGRQDSCKGSDGSGFLVTRYRDT
              AFLLGVSNKGKARGSGYITRVSNYLQWIRQTNTTIH"
              1.0%; Score 23.6; DB 1; Length 1671;
              Best Local Similarity 54.7%; Pred. No. 12;
              Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 1319 TGNAGATAGATATCTTTCACTGATTTTATCTTAGAATGCTCTTTCTTCTCCTCAACTAT 1378
Db 1436 TTAATATAAATATTTTATTTTCAATAAATTTTGTCTATTTTACAAACATTAATAT 1377

QY 1379 TGTGACAGAAAGTTTCTTAAGTCCA 1404
Db 1376 AATAGTAATAATTTGTAAATGTGTTCA 1351

RESULT 34
AR425705/c
LOCUS       AR425705               364 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 17202 from patent US 6639063.
ACCESSION    AR425705
VERSION      AR425705.1  GI:40180815
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
              1 (bases 1 to 364)
              Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
              EST's and encoded human proteins
              Patent: US 6639063-A 17202 28-OCT-2003;
              Location/Qualifiers

Query Match
Best Local Similarity 1.0%; Score 23; DB 1; Length 1671;
Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 1319 TGNAGATAGATATCTTTCACTGATTTTATCTTAGAATGCTCTTTCTTCTCCTCAACTAT 1378
Db 1436 TTAATATAAATATTTTATTTTCAATAAATTTTGTCTATTTTACAAACATTAATAT 1377

QY 1379 TGTGACAGAAAGTTTCTTAAGTCCA 1404
Db 1376 AATAGTAATAATTTGTAAATGTGTTCA 1351

RESULT 34
AR425705/c
LOCUS       AR425705               364 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 17202 from patent US 6639063.
ACCESSION    AR425705
VERSION      AR425705.1  GI:40180815
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
              Unclassified.
              1 (bases 1 to 364)
              Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
              EST's and encoded human proteins
              Patent: US 6639063-A 17202 28-OCT-2003;
              Location/Qualifiers

Query Match
Best Local Similarity 1.0%; Score 23; DB 1; Length 364;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

QY 660 TTGAAGTAGCCCACTATCTGTGTGAGGTCAATATGTAATTTAGCTGTAGCTGTGCTT 719
Db 277 WTGRSMWKKSTYKRWSRAGSWMTGYRMSKMWGTGSTRCTSKKKRKGSTSSKYASTSGK 218

QY 720 GTTTTATGAACCTTGGGTGACATTTGTTTGGTGACATGACATTAAGAATTCATGCTCT 779
Db 217 SSKYMSCTCRSSKKCRYSATYYISCMWKKYCMMSATYSGCMWRYCYSCMWSRYSCT 158

QY 780 CTGTGGTGATTTT 792
Db 157 SYSRGKCSCTGWK 145
```



```
Query Match      1.0%; Score 23; DB 1; Length 1507;
Best Local Similarity 60.3%; Pred. No. 17;
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1634 TTTGGTGTGTTGTATGCTCTTGTACCTTGATAGGCATCTCTTTCTCAAGGTTAGGAAT 1693
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1506 TTTTGTGTTTGTGTTTGTGTTTGTGTTGATGGATCTCACTTAAATGAGAGGACGT 1447
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 1694 TTT 1696
      |||
Db 1446 TAT 1444

RESULT 39
AX395271/c
LOCUS AX395271 200 bp DNA linear PAT 18-MAY-2002
DEFINITION Sequence 8 from Patent WO0203787.
ACCESSION AX395271
VERSION AX395271.1 GI:21066295
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Allen,K.D. and Leviten,M.W.
TITLE Transgenic mice containing targeted gene disruptions
JOURNAL Patent: WO 0203787-A 8 17-JAN-2002;
Deltagen, Inc. (US)
FEATURES
source
Location/Qualifiers
1..200
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Targeting Vector"

Query Match      1.0%; Score 22.8; DB 1; Length 200;
Best Local Similarity 46.8%; Pred. No. 17;
Matches 72; Conservative 0; Mismatches 82; Indels 0; Gaps 0;

QY 3 TCACTCCTCTAGTCAAGGTGGGGTCTGAGGCTCCAATGGTTGTTGATGTGTAGTA 62
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 198 TCCTCTCTCTGTATCCAGGTGTGATGCGGCATCCCTGTGGGTGTTGTGTGCGCTG 139
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 63 TCTCATACAGAGGATACACTAGATGCTGTCTGGGACATAGTAAGCTTCCAGAGAC 122
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 138 TCTGTCCATGCTGCTATACCCAGTGTGCTTTGTATCCAGTCCCGAACTACAGGGAGCC 79
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 123 TTCATATATATTTTCTTGAGGCTCTGTGGCA 156
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 78 TTGTGTACACGCGCTGGCTTGTCTCTGTAGCGCA 45
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 40
AB062458S3/c
LOCUS AB062458S3 210 bp DNA linear PRI 07-JUN-2001
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,
isolate:504.
ACCESSION AB062462
VERSION AB062462.1 GI:14270094
KEYWORDS Pan troglodytes (chimpanzee)
SEGMENT Pan troglodytes
SOURCE Pan troglodytes
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1
AUTHORS Satta,Y.
TITLE Comparison of DNA and protein polymorphisms between humans and
chimpanzees
JOURNAL Genes Genet. Syst. (2001) In press
AUTHORS Satta,Y.
REFERENCE 2 (bases 1 to 210)
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 41
AB062459S3/c
LOCUS AB062459S3 210 bp DNA linear PRI 31-MAY-2001
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,
isolate:505.
ACCESSION AB062463
VERSION AB062463.1 GI:14270118
KEYWORDS Pan troglodytes (chimpanzee)
SEGMENT Pan troglodytes
SOURCE Pan troglodytes
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1
AUTHORS Satta,Y.
TITLE Comparison of DNA and protein polymorphisms between humans and
chimpanzees
JOURNAL Genes Genet. Syst. (2001) In press
AUTHORS Satta,Y.
REFERENCE 2 (bases 1 to 210)
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="504"
/db_xref="taxon:9598"
/sex="female"
/note="CDS is reported in Acc#:AB062470"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 41
AB062459S3/c
LOCUS AB062459S3 210 bp DNA linear PRI 31-MAY-2001
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,
isolate:505.
ACCESSION AB062463
VERSION AB062463.1 GI:14270118
KEYWORDS Pan troglodytes (chimpanzee)
SEGMENT Pan troglodytes
SOURCE Pan troglodytes
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1
AUTHORS Satta,Y.
TITLE Comparison of DNA and protein polymorphisms between humans and
chimpanzees
JOURNAL Genes Genet. Syst. (2001) In press
AUTHORS Satta,Y.
REFERENCE 2 (bases 1 to 210)
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 41
AB062459S3/c
LOCUS AB062459S3 210 bp DNA linear PRI 31-MAY-2001
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,
isolate:505.
ACCESSION AB062463
VERSION AB062463.1 GI:14270118
KEYWORDS Pan troglodytes (chimpanzee)
SEGMENT Pan troglodytes
SOURCE Pan troglodytes
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1
AUTHORS Satta,Y.
TITLE Comparison of DNA and protein polymorphisms between humans and
chimpanzees
JOURNAL Genes Genet. Syst. (2001) In press
AUTHORS Satta,Y.
REFERENCE 2 (bases 1 to 210)
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 41
AB062459S3/c
LOCUS AB062459S3 210 bp DNA linear PRI 31-MAY-2001
DEFINITION Pan troglodytes F9 gene for coagulation factor XI, exon 4,
isolate:505.
ACCESSION AB062463
VERSION AB062463.1 GI:14270118
KEYWORDS Pan troglodytes (chimpanzee)
SEGMENT Pan troglodytes
SOURCE Pan troglodytes
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1
AUTHORS Satta,Y.
TITLE Comparison of DNA and protein polymorphisms between humans and
chimpanzees
JOURNAL Genes Genet. Syst. (2001) In press
AUTHORS Satta,Y.
REFERENCE 2 (bases 1 to 210)
TITLE Direct Submission
JOURNAL Submitted (29-MAY-2001) Yoko Satta, The Graduate University for
Advanced Studies, Department of Biosystems Science; 1560-35
Kaniyamaguchi, Hayama, Kanagawa 240-0193, Japan
(E-mail:satta@mailsv.soken.ac.jp, Tel:81-468-58-1574,
Fax:81-468-58-1544)
FEATURES
source
Location/Qualifiers
1..210
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/isolate="505"
/db_xref="taxon:9598"
/sex="male"
/note="CDS is reported in Acc#:AB062471"
97..210
/gene="F9"
/product="coagulation factor XI"
/number=4

exon

Query Match      1.0%; Score 22.8; DB 1; Length 210;
Best Local Similarity 54.9%; Pred. No. 17;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGCTTTTACGAGGACATATTGTCCTGGTGTATTGTCGTGTTTG 2227
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 133 CCATTAAACATGATTGGACTACACTGATCTCCATCTTTTGAGATAGGTTAAGAAATG 74
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 CTTTGGCATATAGACGGCTGAG 2249
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 73 AATTGGCACATAAATGCTTAG 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTCTCTGTGTTTGG 2227
Db 133	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 74
QY 2228	CTTTGGCATATAGACGGCTGAGT 2249
Db 73	AATTGGCACATAAACTGCTTAG 52
RESULT 42	
AX265077/c	AX265077
LOCUS	Sequence 2468 from Patent WO0173002. 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265077
ACCESSION	AX265077
VERSION	AX265077.1 GI:16513876
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2468 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
	1..121
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTCTGTGTTTGG 2227
Db 87	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 28
QY 2228	CTTTGGCATATAGACGGCTGAGTTG 2253
Db 27	AATTGGCACGTAAACTGCTTAGAATG 2
RESULT 43	
AX265078	AX265078
LOCUS	Sequence 2469 from Patent WO0173002. 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265078
ACCESSION	AX265078
VERSION	AX265078.1 GI:16513877
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2469 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
	1..121
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTCTGTGTTTGG 2227
Db 35	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 94
QY 2228	CTTTGGCATATAGACGGCTGAGTTG 2253
Db 95	AATTGGCACGTAAACTGCTTAGAATG 120
RESULT 44	
AX265081/c	AX265081
LOCUS	Sequence 2472 from Patent WO0173002. 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265081
ACCESSION	AX265081
VERSION	AX265081.1 GI:16513880
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2472 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
	1..121
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY 2168	CTATTGTAATAGGGTTTATAGCAGGACATATTGTCCTGGTTGTTATTCTGTGTTTGG 2227
Db 88	CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 29
QY 2228	CTTTGGCATATAGACGGCTGAGTTG 2253
Db 28	AATTGGCACGTAAACTGCTTAGAATG 3
RESULT 45	
AX265082	AX265082
LOCUS	Sequence 2473 from Patent WO0173002. 121 bp DNA linear PAT 26-OCT-2001
DEFINITION	AX265082
ACCESSION	AX265082
VERSION	AX265082.1 GI:16513881
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL	Patent: WO 0173002-A 2473 04-OCT-2001;
FEATURES	UNIVERSITY OF DELAWARE (US)
source	Location/Qualifiers
	1..121
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match 1.0%; Score 22; DB 1; Length 121;	
Best Local Similarity 53.5%; Pred. No. 26;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	

```
QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227
Db 34 CCAITTAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 93
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
Db 94 AATTGGCAGCTAAACTGCTTAGAATG 119

RESULT 46
AX265085/c
LOCUS AX265085 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2476 from Patent WO0173002.
ACCESSION AX265085
VERSION AX265085.1 GI:16513884
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2476 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227
Db 89 CCAITTAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 30
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
Db 29 AATTGGCAGCTAAACTGCTTAGAATG 4

RESULT 47
AX265086
LOCUS AX265086 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2477 from Patent WO0173002.
ACCESSION AX265086
VERSION AX265086.1 GI:16513885
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2477 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227
```

```
Db 33 CCAITTAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 92
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
Db 93 AATTGGCAGCTAAACTGCTTAGAATG 118

RESULT 48
AX265089/c
LOCUS AX265089 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2480 from Patent WO0173002.
ACCESSION AX265089
VERSION AX265089.1 GI:16513888
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2480 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227
Db 86 CCAITTAACATGATGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 27
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
Db 26 AATTGGCAGCTAAACTGCTTAGAATG 1

RESULT 49
AX265090
LOCUS AX265090 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2481 from Patent WO0173002.
ACCESSION AX265090
VERSION AX265090.1 GI:16513889
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2481 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 26;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227
```


Db 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 95

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 96 AATTGGCAGTAAACTGCTTAGAATG 121

RESULT 50

AX265093/c

LOCUS AX265093 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2484 from Patent WO0173002.

ACCESSION AX265093

VERSION AX265093.1 GI:16513892

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2484 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

Location/Qualifiers

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATGCTCGGTTGTTATTGTCGTGTTTGG 2227

Db 86 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 27

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 26 AATTGGCAGTAAACTGCTTAGAATG 1

RESULT 51

AX265094

LOCUS AX265094 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2485 from Patent WO0173002.

ACCESSION AX265094

VERSION AX265094.1 GI:16513893

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2485 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

Location/Qualifiers

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATGCTCGGTTGTTATTGTCGTGTTTGG 2227

Db 36 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 95

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 96 AATTGGCAGTAAACTGCTTAGAATG 121

RESULT 52

AX265073/c

LOCUS AX265073 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2464 from Patent WO0173002.

ACCESSION AX265073

VERSION AX265073.1 GI:16513872

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2464 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

Location/Qualifiers

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATGCTCGGTTGTTATTGTCGTGTTTGG 2227

Db 91 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 32

QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253

Db 31 AATTGGCAGTAAACTGCTTAGAATG 6

RESULT 53

AX265074

LOCUS AX265074 121 bp DNA linear PAT 26-OCT-2001

DEFINITION Sequence 2465 from Patent WO0173002.

ACCESSION AX265074

VERSION AX265074.1 GI:16513873

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.

TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides

JOURNAL Patent: WO 0173002-A 2465 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)

FEATURES

Location/Qualifiers

1. .121

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.0%; Score 22; DB 1; Length 121;

Best Local Similarity 53.5%; Pred. No. 26;

Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGTTTATAGCAGGACATATGCTCGGTTGTTATTGTCGTGTTTGG 2227

Db 31 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 90

84236100	Medline
6329734	PUBMED
COMMENT	
Original source text: Human: cDNA to liver mRNA, clones cVII, cVI, 108.1, and DB.1; 4X lymphoblastoid cell line (GM1416B) DNA, clone lambda-HIX-4; genomic DNA library of Lawn et al., clones lambda-HIX-1,2,3.	
See segment 1.	
FEATURES	
source	Location/Qualifiers
1..240	
/organism="Homo sapiens"	
/mol_type="genomic DNA"	
/db_xref="taxon:9606"	
/map="Xq26.3-q27.1"	
prim_transcript	<1..>240
/gene="F9"	
/note="fix mRNA"	
<1..64	
/gene="F9"	
/note="fix intron 3"	
65..178	
/gene="F9"	
/note="G00-119-900"	
/number=4	
179..>240	
/gene="F9"	
/note="fix intron 4"	
Query Match 1.0%; Score 22; DB 1; Length 240;	
Best Local Similarity 53.5%; Pred.No. 28;	
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
Qy 2168	CTATTGTAATAGGGTTTATGACGGGACATATGTCCTGGTGTATTCTCTGTGTTTTG 222
Db 101	CCATTAAACATGAATGGACTACACTGATCTCCATCTTTTGAGATAGTTAAGAAATTG 42
Qy 2228	CTTTGGCATATAGCGGCTGAGTTG 2253
Db 41	AATGGCACGTAAACTGCTTAGAATG 16
RESULT 56	
AX892787/c	
LOCUS	385 bp DNA linear PAT 18-DEC-2003
DEFINITION	Sequence 8650 from Patent EP1033401.
ACCESSION	AX892787
VERSION	AX892787.1 GI:40047671
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
REFERENCE	1
AUTHORS	Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE	Expressed sequence tags and encoded human proteins
JOURNAL	Patent: EP 1033401-A 8650 06-SEP-2000;
Genset (FR)	
FEATURES	
source	Location/Qualifiers
1..385	
/organism="Homo sapiens"	
/mol_type="unassigned DNA"	
/db_xref="taxon:9606"	
Query Match 1.0%; Score 22; DB 1; Length 385;	
Best Local Similarity 57.1%; Pred.No. 28;	
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;	

TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 860)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA
FEATURES Location/Qualifiers
 1..860
 /organism="Petrymyzon marinus"
 /mol_type="mRNA"
 /db_xref="taxon:7757"
 /dev_stage="ammocoete"
 /tissue_lib="anterior intestine"
 1..860
 /genes="TRYP2"
 6..749
 /genes="TRYP2"
 /codon_start=1
 /product="trypsinogen a2"
 /protein_id="AAB69654.1"
 /db_xref="GI:2367495"
 /translation="MHGLILALLVGVAAAPYMYEDHIVGSECAHHSQPVQVSLNIG
 YHFCGSLINSQWVSAHCVQASRISVRIGEHNI FVNEGTEQIOQASKAIOHPQYN
 SWIINDIMLIKSSPATLNOYAOAIAPSSCVNTGVMCTISGWGETQTSIGSPDVLN
 CVOAPVLSDTSCRNSYPGDI TNNMICLGYLGGKDCQGDGSGGPPVVCNGELQGVSWG
 RGCAPLPYPGVYTKVCYNWIAQTIAAN"
 6..50
 /genes="TRYP2"
 /evidence=not_experimental
 51..746
 /genes="TRYP2"
 /product="trypsin a2"
 /evidence=not_experimental

gene
CDS

sig_peptide
 0.9%; Score 21.6; DB 1; Length 860;
 Best Local Similarity 68.2%; Pred. No. 38;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

mat_peptide
 0.9%; Score 21.6; DB 1; Length 861;
 Best Local Similarity 68.2%; Pred. No. 38;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Query Match
Best Local Similarity 0.9%; Score 21.6; DB 1; Length 860;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1552 TTTTAAATATCTTCTTTGTTCTATATCTTTTAGTGATTGATTA 1595
 |||||
Db 860 TTTTATATATGTTTCACATTTTATCAITTTGTTA 817
 |||||

RESULT 61
AF011352/c
LOCUS Petromyzon marinus trypsinogen A1 mRNA, complete cds.
DEFINITION Petromyzon marinus trypsinogen A1 mRNA, complete cds.
ACCESSION AF011352
VERSION AF011352.1 GI:2293477
KEYWORDS Petromyzon marinus (sea lamprey)
SOURCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
ORGANISM Petromyzoniformes; Petromyzontidae; Petromyzon.
REFERENCE
AUTHORS Roach, J.C.
TITLE The molecular evolution of the vertebrate trypsinogenase
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 861)
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (25-JUN-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA
FEATURES Location/Qualifiers
 1..861
 /organism="Petrymyzon marinus"
 /mol_type="mRNA"
 /db_xref="taxon:7757"
 /tissue_type="anterior intestine"
 /dev_stage="ammocoete"
 6..749
 /codon_start=1
 /product="trypsinogen A1"

CDS

/protein_id="AAB65411.1"
 /db_xref="GI:2293478"
 /translation="MHGLILALLVGVAAAPYMYEDHIVGSECAHHSQPVQVSLNIG
 YHFCGSLINSQWVSAHCVQASRISVRIGEHNI FVNEGTEQIOQASKAIOHPQYN
 SWIINDIMLIKSSPATLNOYAOAIAPSSCVNTGVMCTISGWGETQTSIGSPDVLN
 CVOAPVLSDTSCRNSYPGDI TNNMICLGYLGGKDCQGDGSGGPPVVCNGELQGVSWG
 RGCAPLPYPGVYTKVCYNWIAQTIAAN"
 6..50
 /evidence=not_experimental
 51..746
 /product="trypsin A1"
 /evidence=not_experimental

sig_peptide
 0.9%; Score 21.6; DB 1; Length 861;
 Best Local Similarity 68.2%; Pred. No. 38;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

mat_peptide
 0.9%; Score 21.6; DB 1; Length 861;
 Best Local Similarity 68.2%; Pred. No. 38;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Query Match
Best Local Similarity 0.9%; Score 21.6; DB 1; Length 861;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1552 TTTTAAATATCTTCTTTGTTCTATATCTTTTAGTGATTGATTA 1595
 |||||
Db 860 TTTTATATATGTTTCACATTTTATCAITTTGTTA 817
 |||||

RESULT 62
BC061149/c
LOCUS Mus musculus coagulation factor VII, mRNA (cdna clone MGC:74281
DEFINITION Mus musculus coagulation factor VII, mRNA (cdna clone MGC:74281
ACCESSION BC061149
VERSION BC061149.1 GI:38511701
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE 1 (bases 1 to 1869)
AUTHORS Klausner, R.D., Collins, F.S., Wagner, L.H., Derge, J.G.,
 Klausner, R.D., Collins, F.S., Wagner, L.H., Derge, J.G.,
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
 Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
 Scheetz, T.E., Brownstein, M.J., Udwin, T.B., Toshiyuki, S.,
 Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
 Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J.,
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
 Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
 Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S.,
 Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bouffard, G.C., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalls, D.E.,
 Scherch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 22388257
 12477932
REFERENCE 2 (bases 1 to 1869)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-2003) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 NIH-MGC Project URL: http://mgc.nci.nih.gov
 Contact: MGC help desk
 Email: cgapbs-r@mail.nih.gov
 Tissue Procurement: Dr. Michael Brownstein
 cDNA Library Preparation: Michael Brownstein / Ted Usdin
 Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome

Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: <http://www-shgc.stanford.edu>
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 53 Row: n Column: 1
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6753805.

FEATURES
source
1..1869
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:74281 IMAGE:30305571"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10B"
/note="Vector: pDNR-LIB"
1..1869
/gene="E7"
/note="Synonyms: FVII, mfVII"
/db_xref="LocusID:14068"
/db_xref="MGI:109325"
10..1350
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAH61149.1"
/db_xref="GI:38511702"
/db_xref="LocusID:14068"
/translation="VWPAQHLLLCFLQLQPLGTAVFTTQEEAHGVHLRQRANS
LLEELWPGLEECNEQSFEEAIFKSPERTQFVIWSDQCSNPNQNGGTC
QHLKSYVCFCLDEGRNCKSKNQLICANENGCDQYCRDHVTKRTCSCHEDYT
LPDEVSCKPVEYPCGRIPVVEKNSRQGRIVGNVCPKQCPQAVLAKINGLL
CGAVLDAAWIVTAHCFDNIWGNITVMEGHDFSEKDGDEQVRVTVQVIMPKYI
RGKINHDIALLRLMTQDCLRHAKHSNTPKITEFMFCAGYMDSTKDKGDSGGPHAT
ALELMSIEVPLWMTQDCLRHAKHSNTPKITEFMFCAGYMDSTKDKGDSGGPHAT
YHGTWLTGWSWNGECAAIGHGVYTRVSQYIDWLVRHMDSKLQGVFRLPL"
79..264
/note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
268..378
/note="EGF CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:cd00054"
589..1302
/note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.9%; Score 21.6; DB 1; Length 1869;
Best Local Similarity 68.2%; Pred. No. 39;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 1693 TTTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTTGA 1736
Db 1860 TTTTCTTTTGGTTTCTTGAATAATTTCTCATTTAATTTGA 1817

RESULT 63
AX839181
LOCUS AX839181 328 bp DNA linear PAT 15-DEC-2003
DEFINITION Sequence 24 from Patent WO03076610.
ACCESSION AX839181
VERSION AX839181.1 GI:39922630
KEYWORDS Homo sapiens (human)
SOURCE

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Bracco, L., Brinkman, B. and Coignard, F.
Variants of human kallikrein-2 and kallikrein-3 and uses thereof
Patent: WO 03076610-A 24 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)
FEATURES
source
1..328
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 328;
Best Local Similarity 52.9%; Pred. No. 40;
Matches 46; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
Qy 2136 CTGTGCTTACGCTATGTTGCAATTCAGGGCTATTGTAAAGGTTTACAGGACA 2195
Db 190 CTGGTGACCCCACTGGGTCTCTCAGCTGCCCATCAGGAAGTAGTAGGGGCC 249
Qy 2196 TATTGTCTCTGTTGTTATTGTCTGTGT 2222
Db 250 TGGGGTCTGGGGAGCAGGTGTCTGTGT 276

RESULT 64
AX464088/c
LOCUS AX464088 1129 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 221 from Patent WO0140466.
ACCESSION AX464088
VERSION AX464088.1 GI:21899060
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
Secreted and transmembrane polypeptides and nucleic acids encoding
same
Patent: WO 0140466-A 221 07-JUN-2001;
Genentech Inc. (US)
FEATURES
source
1..1129
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 43;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1987
Db 1129 TTTTCTTTTCTTTTTCATTTCCAGCTGGCACACAGCTGGTTTATT 1083

RESULT 65
AY359106/c
LOCUS AY359106 1129 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DNA99391 MPN (UNC1884) mRNA, complete cds.
ACCESSION AY359106
VERSION AY359106.1 GI:37183328
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
1 (bases 1 to 1129)
Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
Stinson,J., Vagts,A., Wadland,R., Watanabe,C., Wieand,D., Woods,K.,
Xie,M.H., Yamsuaka,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
Goddard,A., Wood,W.I. and Godowski,P.
The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
Genome Res. 13 (10), 2265-2270 (2003)

JOURNAL
PUBMED
12975309
REFERENCE
AUTHORS
2 (bases 1 to 1129)
Clark,H.F.
TITLE
Direct Submission
JOURNAL
Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES
source
1..1129
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clones="DNA99391"
1..1129
/locus tag="UNQ1884"
36..908
/locus tag="UNQ1884"
/notes="PRO4327"
/codon_start=1
/product="MPN"
/protein_id="AA089464.1"
/db_xref="GI:37183329"
/translation="MRPAAVPLLLLCFQSRKAKATACGRPRMLNRMVGGDTQSG
EWQVSIQNGSHFQCGSLIAEQWLTAACHCFNTSETSLYQLVLCARQLVQGPDA
MYARVQESNPILYQTASSADVALVEAPVPTNYILPVLDPDSVI PETGMNCWV
TGMSPEEDLPEPR LLOKLAVPIIDTPKCNLLYSKDTFEGYQPKTIKNDMLCAGFE
EGKKDCKGSGGGLVCLVQSWLQAGVISGSGCARQNRPGVIIRVTAHHNIHRLI
PKLQFQPARLGGQK"

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 43;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGTGTTT 1987
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCGCTGGTTTATT 1083

RESULT 66
AX565990
LOCUS
AX565990 6098 bp DNA linear PAT 29-NOV-2002
DEFINITION
Sequence 2 from Patent WO02077218.
ACCESSION
AX565990
VERSION
AX565990.1 GI:26001242
KEYWORDS
synthetic construct
synthetic construct
artificial sequences.
ORGANISM
1
Persson,E.
AUTHORS
TITLE
Coagulation factor vii derivatives
JOURNAL
Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)

FEATURES
source
1..6098
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Plasmid DNA pLN174"

Query Match 0.9%; Score 21.4; DB 1; Length 6098;
Best Local Similarity 49.5%; Pred. No. 44;
Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 1642 TTCTATGCTTCTTGTACCTTGATAGGCACTCTTCTCAAGGTTAGGAAATTTTCTT 1701
DB 4429 TTTTACGGTTCCTGGCTTTTGTGCGCTTTTGTCTACATGTTCTTCTCGGTTATCC 4488
QY 1702 TTTGGTTTCTGAAATATTTTCCCGTCTTTGACCTGCTTCTTCCCT 1752
DB 4489 CTTGATCTGGATAACCGTATTACCGCTTTGAGTGAGTGATACCGCT 4539

RESULT 67
AX265101/c
LOCUS
AX265101 121 bp DNA linear PAT 26-OCT-2001
DEFINITION
Sequence 2492 from Patent WO0173002.
ACCESSION
AX265101
VERSION
AX265101.1 GI:16513900
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
1
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
TITLE
Kniec,E.B., Gamper,H.B. and Rice,M.C.
targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL
Patent: WO 0173002-A 2492 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.2; DB 1; Length 121;
Best Local Similarity 53.7%; Pred. No. 42;
Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGTTTTCAGCGGACATATTGCTCGTTGTTATGTCGTGTTTG 2227
DB 83 CCATTAAACATGATGGACTCACACTGATCTCCATCTTGAGATAGGTAAGAAATG 24
QY 2228 CTTGGCATATACGGCTGAG 2249
DB 23 AATTGGCAGCGTAAACTGCTTAG 2

RESULT 68
AX265102
LOCUS
AX265102 121 bp DNA linear PAT 26-OCT-2001
DEFINITION
Sequence 2493 from Patent WO0173002.
ACCESSION
AX265102
VERSION
AX265102.1 GI:16513901
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
1
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
TITLE
Kniec,E.B., Gamper,H.B. and Rice,M.C.
targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL
Patent: WO 0173002-A 2493 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 21.2; DB 1; Length 121;

[illegible]

AX524243
LOCUS AX524243 341 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 273 from Patent EP1236798.
ACCESSION AX524243
VERSION AX524243.1 GI:25169339
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .341
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.9%; Score 20.6; DB 1; Length 341;
Best Local Similarity 53.0%; Pred. No. 64;
Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2133 TGCCTTGTGCTTCAGCTATGTTGCTATCTCAGGCGCTATTGTTATAGGTTTACGAGGG 2192
Db 213 TGTCTTGTGCTTCAGCTATCTCCTGCACACGATGACATCTGTGACTTTCGTAGGT 272
QY 2193 ACATATGTCCTGTTGTTATTG 2215
Db 273 AGACTTTGGCAGACTTCTCATTG 295
RESULT 78
AX552981
LOCUS AX552981 341 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 273 from Patent WO02074953.
ACCESSION AX552981
VERSION AX552981.1 GI:25896981
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .341
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.9%; Score 20.6; DB 1; Length 341;
Best Local Similarity 53.0%; Pred. No. 64;
Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
QY 2133 TGCCTTGTGCTTCAGCTATGTTGCTATCTCAGGCGCTATTGTTATAGGTTTACGAGGG 2192
Db 213 TGTCTTGTGCTTCAGCTATCTCCTGCACACGATGACATCTGTGACTTTCGTAGGT 272
QY 2193 ACATATGTCCTGTTGTTATTG 2215
Db 273 AGACTTTGGCAGACTTCTCATTG 295
RESULT 79
E63001/c

E63001
LOCUS E63001 1206 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63001
VERSION E63001.1 GI:18633643
KEYWORDS JP 2001061479-A/5.
SOURCE synthetic construct
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1 (bases 1 to 1206)
Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
Hemocoagulation factor VII modification
Patent: JP 2001061479-A 5 13-MAR-2001;
JURIDICAL FOUNDATION THE CEMO SERO THERAPEUTIC RESEARCH INSTITUTE
OS Artificial Sequence
PN JP 2001061479-A/5
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR
PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1. .1206
/organism="Artificial Sequence".
FEATURES
source
1. .1206
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTGTTGAAATATGTTCAATTTGG 498
Db 444 TTTGCTGGCATTCTCTTTTCTAGAAATAGGTAATTTTCCACATGGATATTCACCTGG 386
RESULT 80
E63002/c
LOCUS E63002 1206 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63002
VERSION E63002.1 GI:18633644
KEYWORDS JP 2001061479-A/6.
SOURCE synthetic construct
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1 (bases 1 to 1206)
Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
Hemocoagulation factor VII modification
Patent: JP 2001061479-A 6 13-MAR-2001;
JURIDICAL FOUNDATION THE CEMO SERO THERAPEUTIC RESEARCH INSTITUTE
OS Artificial Sequence
PN JP 2001061479-A/6
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR
PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1. .1206
/organism="Artificial Sequence".
FEATURES
source
1. .1206

ACCESSION	B62998
VERSION	B62998.1 GI:18633640
KEYWORDS	JP 2001061479-A/2.
SOURCE	synthetic construct
ORGANISM	synthetic construct
	artificial sequences.
REFERENCE	1 (bases 1 to 1221)
AUTHORS	Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE	Hemocoagulation factor VII modification
JOURNAL	Patent: JP 2001061479-A 2 13-MAR-2001;
	JURIDICAL FOUNDATION THE CHERO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT	OS Artificial Sequence

RESULT 84

LOCUS	AR112969/c	LOCUS	AR112969	1440 bp	DNA	linear	PAT 16-MAY-2001
DEFINITION	Sequence 13 from patent US 6132730.	DEFINITION	Sequence 13 from patent US 6132730.				
ACCESSION	AR112969	ACCESSION	AR112969				
VERSION	AR112969.1	VERSION	AR112969.1	GI:14093291			
KEYWORDS		KEYWORDS					
SOURCE	Unknown.	SOURCE	Unknown.				
ORGANISM	Unknown.	ORGANISM	Unknown.				
REFERENCE	Unclassified.	REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 1440)	AUTHORS	1 (bases 1 to 1440)				
TITLE	Thorpe,P.E., King,S.W. and Gao,B.	TITLE	Thorpe,P.E., King,S.W. and Gao,B.				
JOURNAL	Combined tissue factor and factor VIIA methods and compositions for coagulation and tumor treatment	JOURNAL	Combined tissue factor and factor VIIA methods and compositions for coagulation and tumor treatment				
FEATURES	Patent: US 6132730-A 13 17-OCT-2000;	FEATURES	Patent: US 6132730-A 13 17-OCT-2000;				
source	Location/Qualifiers	source	Location/Qualifiers				
	1..1440		1..1440				
	/organism="unknown"		/organism="unknown"				
	/mol_type="unassigned DNA"		/mol_type="unassigned DNA"				
Query Match	0.9%; Score 20.6; DB 1; Length 1440;	Query Match	0.9%; Score 20.6; DB 1; Length 1440;				
Best Local Similarity	59.3%; Pred. No.69;	Best Local Similarity	59.3%; Pred. No.69;				
Matches	35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;	Matches	35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;				
Cy	440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATAATGATGATTCATTGTTGG 498	Cy	440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATAATGATGATTCATTGTTGG 498				
Db	659 TTTCGTGGCATTTCTTTTTCIAGATAGTATTTTCCACATGGATATTCACACTGTGG 601	Db	659 TTTCGTGGCATTTCTTTTTCIAGATAGTATTTTCCACATGGATATTCACACTGTGG 601				
RESULT 87		RESULT 87					
LOCUS	II9358/c	LOCUS	II9358	1440 bp	DNA	linear	PAT 07-OCT-1996
DEFINITION	Sequence 3 from patent US 5504064.	DEFINITION	Sequence 3 from patent US 5504064.				
ACCESSION	II9358	ACCESSION	II9358				
VERSION	II9358.1	VERSION	II9358.1	GI:1599713			
KEYWORDS		KEYWORDS					
SOURCE	Unknown.	SOURCE	Unknown.				
ORGANISM	Unknown.	ORGANISM	Unknown.				
REFERENCE	Unclassified.	REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 1440)	AUTHORS	1 (bases 1 to 1440)				
TITLE	Morrissey,J.H. and Comp.P.C.	TITLE	Morrissey,J.H. and Comp.P.C.				
JOURNAL	Treatment of bleeding with modified tissue factor in combination with an activator of FVII	JOURNAL	Treatment of bleeding with modified tissue factor in combination with an activator of FVII				
FEATURES	Patent: US 5504064-A 3 02-APR-1996;	FEATURES	Patent: US 5504064-A 3 02-APR-1996;				
source	Location/Qualifiers	source	Location/Qualifiers				
	1..1440		1..1440				
	/organism="unknown"		/organism="unknown"				
	/mol_type="unassigned DNA"		/mol_type="unassigned DNA"				
Query Match	0.9%; Score 20.6; DB 1; Length 1440;	Query Match	0.9%; Score 20.6; DB 1; Length 1440;				
Best Local Similarity	59.3%; Pred. No.69;	Best Local Similarity	59.3%; Pred. No.69;				
Matches	35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;	Matches	35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;				
Cy	440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATAATGATGATTCATTGTTGG 498	Cy	440 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATAATGATGATTCATTGTTGG 498				
Db	659 TTTCGTGGCATTTCTTTTTCIAGATAGTATTTTCCACATGGATATTCACACTGTGG 601	Db	659 TTTCGTGGCATTTCTTTTTCIAGATAGTATTTTCCACATGGATATTCACACTGTGG 601				
RESULT 88		RESULT 88					
LOCUS	II9360/c	LOCUS	II9360	1440 bp	DNA	linear	PAT 07-OCT-1996
DEFINITION	Sequence 3 from patent US 5504067.	DEFINITION	Sequence 3 from patent US 5504067.				
ACCESSION	II9360	ACCESSION	II9360				
VERSION	II9360.1	VERSION	II9360.1	GI:1599715			
KEYWORDS		KEYWORDS					
SOURCE	Unknown.	SOURCE	Unknown.				
ORGANISM	Unknown.	ORGANISM	Unknown.				
REFERENCE	Unclassified.	REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 1440)	AUTHORS	1 (bases 1 to 1440)				
TITLE	Morrissey,J.H. and Comp.P.C.	TITLE	Morrissey,J.H. and Comp.P.C.				
JOURNAL	Treatment of bleeding with modified tissue factor in combination with FVII	JOURNAL	Treatment of bleeding with modified tissue factor in combination with FVII				
FEATURES	Patent: US 5504067-A 3 02-APR-1996;	FEATURES	Patent: US 5504067-A 3 02-APR-1996;				
	Location/Qualifiers		Location/Qualifiers				

source 1.1440
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTTCAATTGG 498
Db 659 TTGCTGGCAATCTCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 601
RESULT 89
BD194674 1440 bp DNA linear PAT 17-JUL-2003
LOCUS Tissue factor methods and compositions for coagulation and tumor
treatment.
DEFINITION BD194674
ACCESSION BD194674.1 GI:33004420
VERSION JP 2002514201-A/3.
KEYWORDS unidentified
SOURCE unclassified
ORGANISM 1 (bases 1 to 1440)
REFERENCE Thorpe,P.E., King,S.W. and Gao,B.
AUTHORS Tissue factor methods and compositions for coagulation and tumor
TITLE treatment
JOURNAL Patent: JP 2002514201-A 3 14-MAY-2002;
COMMENT BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PF 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920,27-JAN-1997 US 60/036205 PR
27-MAR-1997 US 60/042427
PI PHILIP E THORPE,STEVEN W KING,BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
FH Key Location/Qualifiers
FT source 1.1440
FT /organism="Mammalian".
FEATURES
source 1.1440
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 69;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTTCAATTGG 498
Db 659 TTGCTGGCAATCTCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 601
RESULT 90
AX565990/c 6098 bp DNA linear PAT 29-NOV-2002
LOCUS Sequence 2 from Patent WO02077218.
DEFINITION AX565990
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Persson,E.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)

Location/Qualifiers
1..6098
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Plasmid DNA pLN174"
Query Match 0.9%; Score 20.6; DB 1; Length 6098;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATTGCTTTATCTGTCGAGACTTGTCTTTGTTTGAATAATGTTCAATTGG 498
Db 728 TTGCTGGCAATCTCTTTTCTAGATAGGATTTTCCACATGGATATTCACCTGG 670
RESULT 91
AX908508 223 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 24371 from Patent EP1033401.
DEFINITION AX908508
ACCESSION AX908508
VERSION AX908508.1 GI:40064588
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 24371 06-SEP-2000;
Genset (FR)
FEATURES
source 1..223
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.4; DB 1; Length 223;
Best Local Similarity 58.1%; Pred. No. 71;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1102 TTGCACTTGTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1161
Db 4 TTGCACTTGTGTGAGTTGTGGAGCGCCTTGAGTCTCAGTACGAGTGTGCGTGTG 63
QY 1162 TG 1163
Db 64 AG 65
RESULT 92
BD044041 223 bp DNA linear PAT 27-AUG-2002
LOCUS Sequence tag and encoded human protein.
DEFINITION BD044041
ACCESSION BD044041
VERSION BD044041.1 GI:22585783
KEYWORDS JP 2001269182-A/20287.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 20287 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/20287
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PI 26-FEB-1999 US 60/122487
JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCLAIR,JEAN YVES

[illegible]

QY	38	CAATGGTTGTTGATGTGCTAGAGTATCTCATACAGAGGATAGCACATAGATGTGTCTGGG	97
DB	272	CACTGGCTAGAGAGGCACTAGAGAAGGACAGAGAGGGGGGATATGAGATTCTCTGAT	213
QY	98	ACATAGGTAAGCTTTCCAGAGACT	123
DB	212	GCAGTGGCAGCTGTGAGGACCCACT	187
RESULT 99			
LOCUS	AF465269	1416 bp	mRNA linear VRT 02-FEB-2003
DEFINITION	Gallus gallus coagulation factor IX precursor (F9) mRNA, complete cds.		
ACCESSION	AF465269		
VERSION	AF465269.1	GI:28194009	
KEYWORDS	Gallus gallus (chicken)		
SOURCE	Gallus gallus		
ORGANISM	Gallus gallus		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus		
AUTHORS	1 (bases 1 to 1416) Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G., Tuddenham,E.G.D. and McVey,J.H.		
TITLE	Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes		
JOURNAL	Unpublished		
AUTHORS	2 (bases 1 to 1416) McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.		
TITLE	Direct Submission		
JOURNAL	Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK		
FEATURES	Location/Qualifiers		
source	1..1416		
gene	/organism="Gallus gallus"		
CDS	/mol_type="mRNA"		
	/db_xref="taxon:9031"		
	1..1416		
	/gene="F9"		
	1..1416		
	/gene="F9"		
	/EC number="3.4.21.22"		
	/function="converts factor X to its active form in the presence of Ca++ ions, phospholipids, and factor VIIa"		
	/note="vitamin K dependent serine protease; christmas factor; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"		
	/codon_start=1		
	/product="coagulation factor IX precursor"		
	/protein_id="AA033364.1"		
	/db_xref="GI:28194010"		
	/translation="MAKIPULISFCLEAPLGAESTVFIENKEASTVLSRTRRGNRNL LEELIPGNLERECIEKCFEAREVFENTKEPMFKIYIDGDCNSNPCKNGAVCK DGVSVECMPCGGRNCEIDSTCATKNGCGRHDTPOKAVCSAGYKLHSDG KCKPAPVPCGRITAPENRGKVKTENTIERNIHADEGAHDALDITTEPPPTT TSAAPAKIPIITKNDTRVGVYDSVKQLPWQVHLVDSRLGFCGSSINERKMWVTA HCLPGDNVAVAGENTDEKDEQRQVKKLIPYPTNRTNRKHNHNDIALLELDQ LFFNSVPTICIGSRDPTNNLSNGPFGTSGWGMLYGRSAIVQLVLPVFPVDRVTC LKSTSTLIHSMFCAGYTAGGCTCGGDSGGPYTNSIGETWFLTGVTSWGECAKPGK YGIYTKVAKYVKWIRETRLT"		
Query Match	0.9%	Score 20.4;	DB 1; Length 1416;
Best Local Similarity	53.8%	Pred. No. 77;	
Matches	42; Conservative	0; Mismatches	36; Indels 0; Gaps 0;
QY	24	GGGCTCGAGGCTCCCAATGGTTGCTAGTGGTAGAGTATCTCATACAGAGGATAGCACT	83
DB	408	GTGCTCGAGCCCCCATTTTCGTAGACACAGTAGAGTCTATCTCAGTTCCTGCTCC	349
QY	84	AGATGCTGCTGGGACAT	101

gene

FEATURES	Location/Qualifiers
source	1. .272
	/organism="Homo sapiens"
	/mol_type="genomic DNA"
	/db_xref="taxon:9606"
	/chromosome="3"
	/map="3p11-q11.2"
exon	28. .185
	/gene="PROS1"
	/note="protein S alpha; G00-120-721; putative"
	/number=2
Query Match	0.9%; Score 20.2; DB 1; Length 272;
Best Local Similarity	51.7%; Pred. No. 81;
Matches	46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
QY	290 CTTCTATTTCTTGATTCTATCTTGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTT 349
DB	
QY	153 CTTCTCTTTATTGACAGTCTCTTCATGCAATCTCTTTCAAGATTACCTGTTGGTTT 94
DB	
QY	350 CCATAAGTTTGTAAAGTTTCTGTGTTTC 378
DB	
QY	93 CTTCAAGTAAGAATTTCACGACGCTTC 65
DB	
RESULT 108	
HUMPS02/c	352 bp DNA linear PRI 10-JAN-1995
LOCUS	HUMPS02
DEFINITION	Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION	M57841.102917
VERSION	M57841.1 GI:190535
KEYWORDS	S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT	2 of 14
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE	1 (bases 1 to 352)
JOURNAL	Schmidl,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
MEDLINE	Organization of the human protein S genes
PUBMED	Biochemistry 29 (34), 7845-7852 (1990)
COMMENT	9108444
FEATURES	2148110
source	Original source text: Human liver DNA.
	Location/Qualifiers
	1. .352
	/organism="Homo sapiens"
	/mol_type="genomic DNA"
	/db_xref="taxon:9606"
	/map="3p11-q11.2"
	/tissue type="liver"
sig_peptide	join(M57840.1:837..912,135..181)
intron	/gene="PS-alpha"
	order(M57840.1:913..1014,1..134)
	/gene="PROS1"
	/number=1
exon	135..292
	/gene="PROS1"
	/note="G00-120-721"
	/number=2
Query Match	0.9%; Score 20.2; DB 1; Length 352;
Best Local Similarity	51.7%; Pred. No. 82;
Matches	46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;
QY	290 CTTCTATTTCTTGATTCTATCTTGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTT 349
DB	
QY	260 CTTCTCTTTATTGACAGTCTTCGATGCAATCTCTTTCAAGATTACCTGTTGGTTT 201
DB	
QY	350 CCATAAGTTTGTAAAGTTTCTGTGTTTC 378
DB	
QY	200 CTTCAAGTAAGAATTTCACGACGCTTC 172
DB	

```

RESULT 109
ARI08139/c
LOCUS      ARI08139      885 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6110721.
ACCESSION  ARI08139
VERSION     ARI08139.1 GI:12823626
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 885)
AUTHORS     Gibbs,C.S., Leung,L.L.K. and Tsiang,M.
TITLE       Polypeptides and coagulation therapy
JOURNAL     Patent: US 6110721-A 1 29-AUG-2000;
FEATURES    Location/Qualifiers
            source
              1..885
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.9%; Score 20.2; DB 1; Length 885;
Best Local Similarity 63.3%; Pred. No. 85;
Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 167 GGCTGCGCTTCTCCCTGTCGATTCCTAGGCTGAGGTTACCACTG 215
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 489 GGCTGCGCTTCTCCCTGTCGCGCAGACACACAGGGTGATGTAGTCACTG 441

RESULT 110
AX401899/c
LOCUS      AX401899      1543 bp      DNA      linear      PAT 06-JUN-2002
DEFINITION Sequence 1575 from Patent WO0210453.
ACCESSION  AX401899
VERSION     AX401899.1 GI:21338079
KEYWORDS
SOURCE      Rattus norvegicus (Norway rat)
ORGANISM    Rattus norvegicus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
            Rattus.
REFERENCE   1
AUTHORS     Mendrick,D., Porter,M.W., Johnson,K.R., Castile,A.L. and
            Elashoff,M.R.
TITLE       Molecular toxicology modeling
JOURNAL     Patent: WO 0210453-A 1575 07-FEB-2002;
            Gene Logic, Inc. (US)
FEATURES    Location/Qualifiers
            source
              1..1543
              /organism="Rattus norvegicus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10116"
              /note="EMBL/GenBank Accession No. NM_012803"

Query Match      0.9%; Score 20.2; DB 1; Length 1543;
Best Local Similarity 68.3%; Pred. No. 86;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCCTTTACTAGGTGATGCTCTCATCGTAGGTTG 960
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1408 CATCCCTTTCCCTATGTAGCTGTGGATCCATTGAGGTAG 1368

RESULT 111
RNPROC/c
LOCUS      RNPROC      1543 bp      mRNA      linear      ROD 12-NOV-2003
DEFINITION Rattus norvegicus mRNA for protein C precursor.
ACCESSION  X64336 S40352
VERSION     X64336.1 GI:56962
KEYWORDS    protein C.
SOURCE      Rattus norvegicus (Norway rat)
ORGANISM    Rattus norvegicus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE   1 (bases 1 to 1543)
AUTHORS     Okafuji,T., Maekawa,K., Nawa,K. and Marumoto,Y.
TITLE       The cDNA cloning and mRNA expression of rat protein C
JOURNAL     Biochim. Biophys. Acta 1131 (3), 329-332 (1992)
MEDLINE     92329550
PUBMED      1627650
REFERENCE   2 (bases 1 to 1543)
AUTHORS     Okafuji,T.
TITLE       Direct Submission
JOURNAL     Submitted (03-FEB-1992) Okafuji T., Mol Biology Research Lab,
            Daiichi Pharmaceutical Co LTD, 16-13 Kitakasai 1-Chome, Edogawa-ku,
            Tokyo 134, JAPAN
            On Nov 19, 2003 this sequence version replaced gi:251769.
FEATURES    Location/Qualifiers
            source
              1..1543
              /organism="Rattus norvegicus"
              /mol_type="mRNA"
              /strain="Wistar"
              /db_xref="taxon:101116"
              /clone="28000"
              49..1434
              /codon_start=1
              /product="protein C precursor"
              /protein_id="CAA45617.1"
              /db_xref="GI:56963"
              /db_xref="GOA:P31394"
              /db_xref="SWISS-PROT:P31394"
              /translation="MQPRIFLLPASTWIGISGVSAHPDPVFSSEGAHQVLRVRANS
              FLEEVAGSLERECMEICDFEAQEIFQNVEDTLAFWKYFDQDQSTPLDHCDS
              PCGHGTCTDGLGFGSCDKWEGFQCOEFGDCRVKNGGCYHCLBETRGRRCR
              CAPGYELADDDHMCRTVAFPCGKLWKRTDKKRNKRDIDPDELELGPRIVNGTL
              TKQDSPWAAILDLSKKLACGGVLIHTSWLTAACHLESSKLTVPRLGEVLRERDP
              WELDLDIKEVLVHPNVTNSNDIALRLSQPATLSKTIIVPICLPSGLAELSQAG
              QETVVTGWGYSQSKVDGRNRFTILFIRIPLAARNDCQVWNVVSVENMLCAGIIG
              DTRDACDGGSGPMVFFRGITWELVGLVSMGEGCHLNLYGVYTKVGSYLKWIHSYIG
              ERDVSUKSPKL"
              49..147
              sig_peptide
              mat_peptide
              169..1431
              /product="protein C"
              polyA_signal
              1514..1519

Query Match      0.9%; Score 20.2; DB 1; Length 1543;
Best Local Similarity 68.3%; Pred. No. 86;
Matches 28; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCCCTTTACTAGGTGATGCTCTCATCGTAGGTTG 960
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1408 CATCCCTTTCCCTATGTAGCTGTGGATCCATTGAGGTAG 1368

RESULT 112
AF011899/c
LOCUS      AF011899      855 bp      mRNA      linear      VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a3 (TRYP3) mRNA, complete cds.
ACCESSION  AF011899
VERSION     AF011899.1 GI:2367496
KEYWORDS
SOURCE      Petromyzon marinus (sea lamprey)
ORGANISM    Petromyzon marinus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
            Petromyzontiformes; Petromyzontidae; Petromyzon.
            1 (bases 1 to 855)
            Roach,J.C.
            The Molecular Evolution of the Vertebrate Trypsinogens
            Unpublished
            2 (bases 1 to 855)
            Roach,J.C.
            Direct Submission
            Submitted (01-JUL-1997) Molecular Biotechnology, University of
            Washington, Seattle, WA 98195, USA
            Location/Qualifiers
            REFERENCE
            AUTHORS
            TITLE
            JOURNAL
            REFERENCE
            AUTHORS
            TITLE
            JOURNAL
            FEATURES
  
```

source	1. .855	/organism="Petromyzon marinus"	/mol_type="mRNA"	/db_xref="taxon:7757"	/dev_stage="amocoete"	/tissue_lib="anterior intestine"	1. .855	/gene="TRYPA3"	/gene="TRYPA3"	1. .744	/codon_start=1	/product="trypsinogen a3"	/protein_id="AAB69655.1"	/db_xref="GI:2367497"	/translation="MHGLILALLGVAAAPVYEDHIVGSGCAHSPWQVSLNIG YHFCGSLNSQWVSAHQYQASRISVRIGHNIPVNEGTEQOQKASKAIOHPQYN SWTIDNDIMLKSLSPATLQYQAIALPSQVNTGVMTCTISGWGTQISVSGPDVLM CVOAPVLSDTSCRNSYPGDIITNNMICLGYLEGKQSCQSGGPPVNGELQIVSWG RGCALPNYPGVYTKVCNNAMIAQTIAAN"	1. .45	/gene="TRYPA3"	/evidence=not_experimental	46. .741	/gene="TRYPA3"	/product="trypsin a3"	/evidence=not_experimental	Query Match	0.9%; Score 20; DB 1; Length 855;	Best Local Similarity	65.9%; Pred. No. 96;	Mismatches	0; Gaps	0;	1552	TTTTAATATCTTTCTTCTTCTATACCTTTAGTGAAATGATTA 1595	855	TTTTTTTTTTTGTAGTAGTTCACATTTTATTCATTGGTTA 812	RESULT 113	AR234337	LOCUS	AR234337	Sequence 8 from patent US 6458564.	AR234337	ACCESSION	VERSION	AR234337.1	GI:27277021	KEYWORDS	Unknown.	SOURCE	Unknown.	ORGANISM	Unclassified.	REFERENCE	1 (bases 1 to 1130)	Darrow, A., Qi, J. and Andrade-Grodon, P.	DNA	1130 bp	DNA	linear	PAT 20-DEC-2002	715	TGCTTTGTTTATGAACCTTGGGTGACATTTGTTTGGTGATGACATTAGAATTGCAAT 774	1059	TGCTTTATTTGTGAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAAT 1118	RESULT 114	AR219285	LOCUS	AR219285	Sequence 8 from patent US 6420157.	AR219285	ACCESSION	VERSION	AR219285.1	GI:23320255	KEYWORDS	Unknown.	SOURCE	Unknown.	ORGANISM	Unclassified.	REFERENCE	1 (bases 1 to 1142)	Darrow, A., Qi, J. and Andrade-Grodon, P.	DNA	1142 bp	DNA	linear	PAT 25-SEP-2002	715	TGCTTTGTTTATGAACCTTGGGTGACATTTGTTTGGTGATGACATTAGAATTGCAAT 774	1098	TGCTTTATTTGTGAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAAT 1154
gene	1. .855	/organism="Petromyzon marinus"	/mol_type="mRNA"	/db_xref="taxon:7757"	/dev_stage="amocoete"	/tissue_lib="anterior intestine"	1. .855	/gene="TRYPA3"	/gene="TRYPA3"	1. .744	/codon_start=1	/product="trypsinogen a3"	/protein_id="AAB69655.1"	/db_xref="GI:2367497"	/translation="MHGLILALLGVAAAPVYEDHIVGSGCAHSPWQVSLNIG YHFCGSLNSQWVSAHQYQASRISVRIGHNIPVNEGTEQOQKASKAIOHPQYN SWTIDNDIMLKSLSPATLQYQAIALPSQVNTGVMTCTISGWGTQISVSGPDVLM CVOAPVLSDTSCRNSYPGDIITNNMICLGYLEGKQSCQSGGPPVNGELQIVSWG RGCALPNYPGVYTKVCNNAMIAQTIAAN"	1. .45	/gene="TRYPA3"	/evidence=not_experimental	46. .741	/gene="TRYPA3"	/product="trypsin a3"	/evidence=not_experimental	Query Match	0.9%; Score 20; DB 1; Length 855;	Best Local Similarity	65.9%; Pred. No. 96;	Mismatches	0; Gaps	0;	1552	TTTTAATATCTTTCTTCTTCTATACCTTTAGTGAAATGATTA 1595	855	TTTTTTTTTTTGTAGTAGTTCACATTTTATTCATTGGTTA 812	RESULT 113	AR234337	LOCUS	AR234337	Sequence 8 from patent US 6458564.	AR234337	ACCESSION	VERSION	AR234337.1	GI:27277021	KEYWORDS	Unknown.	SOURCE	Unknown.	ORGANISM	Unclassified.	REFERENCE	1 (bases 1 to 1130)	Darrow, A., Qi, J. and Andrade-Grodon, P.	DNA	1130 bp	DNA	linear	PAT 20-DEC-2002	715	TGCTTTGTTTATGAACCTTGGGTGACATTTGTTTGGTGATGACATTAGAATTGCAAT 774	1059	TGCTTTATTTGTGAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAAT 1118	RESULT 114	AR219285	LOCUS	AR219285	Sequence 8 from patent US 6420157.	AR219285	ACCESSION	VERSION	AR219285.1	GI:23320255	KEYWORDS	Unknown.	SOURCE	Unknown.	ORGANISM	Unclassified.	REFERENCE	1 (bases 1 to 1142)	Darrow, A., Qi, J. and Andrade-Grodon, P.	DNA	1142 bp	DNA	linear	PAT 25-SEP-2002	715	TGCTTTGTTTATGAACCTTGGGTGACATTTGTTTGGTGATGACATTAGAATTGCAAT 774	1098	TGCTTTATTTGTGAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAAT 1154

```
RESULT 117
AF515269/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AF515269
Danio rerio coagulation factor VIII mRNA, complete cds.
AF515269.1 GI:25005098
Danio rerio (zebrafish)
Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
Cypriniformes; Cyprinidae; Danio.
1 (bases 1 to 1722)
Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.
Comprehensive analysis of blood coagulation pathways in teleostei:
Evolution of coagulation factor genes and identification of
zebrafish factor VIII
Blood Cells Mol. Dis. (2002) In press
2 (bases 1 to 1722)
Jagadeeswaran, P. and Hanumanthaiah, R.
Direct Submission
Submitted (24-MAY-2002) Cellular & Structural Biology, University
of Texas Health Science Center at San Antonio, 7703 Floyd Curl
Drive, San Antonio, TX 78229, USA
Location/Qualifiers
1..1722
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
27..1358
/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AA071000.1"
/db_xref="GI:25005099"
/translation="MTGAAVLLCVLTSTSAVFLSKDEASALLQFRFRANSGLFLE
EMAGNLRECEVEICDYEAREVFEEDRTKOPWLSYSNKEPCLNPNRNGTCVYL
ADSYCLCESEYGEKYEKLETLKQVNGCEQFCDSGARRSCSACGVALADD
GTSVCQVDPCKIPQKNTSONQFLGHCPRGCPQVLLIDYNGESVCGGALLGG
PWLITAAHCQVQDITFLKAVTGDEHLDVLDGSEEPYSAVFIFHPETIDSLA
LKLRLVPSRLSYAVPICLPTPOLARSELMAARFHTLSGNGRTAGNLRERKLGKP
ASGTLQRLAVPLPAACQGNANTANNFCAGYEGDHASCGRHDSGLVTRYGETSFL
TGVSWSGRGCGPGGYWYTKVENFLIMDVTMKTNTEDKSEQIANVSKN"

Query Match 0.9%; Score 20; DB 1; Length 1722;
Best Local Similarity 50.0%; Pred. No. 97;
Matches 50; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

QY 964 TTTTGGATGCACAGTAGGATGATCTTTGTTTATATCCATTCCTGTTACCCAGATCT 1023
Db 1354 TTTTGTGGAACATAGCAATCTGCTCGCTCTTCTTCAGTGTGTCTTCATAACC 1295

QY 1024 TTTTGTAGCAANTTAAGATCATGATGATGATGA 1063
Db 1294 GTGTCCATCCAGATCAGGAAGTCTCCACTTTAGTGAGA 1255

RESULT 118
AX587861/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AX587861
Sequence 331 from Patent WO0246467.
AX587861
AX587861.1 GI:27656555
synthetic construct
synthetic construct
artificial sequences.
1
REFERENCE
AUTHORS
Bertucci, F., Houlgatte, R., Birnbaum, D., Nguyen, C., Viens, P. and
Fert, V.
Gene expression profiling of primary breast carcinomas using arrays

Query Match 0.9%; Score 19.8; DB 1; Length 268;
Best Local Similarity 60.0%; Pred. No. 1e+02;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

of candidate genes
Patent: WO 0246467-A 331 13-JUN-2002;
Ipsogen (FR)
Location/Qualifiers
1..254
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"
1..254
/notes="3' terminal sequence, macrophage stimulating
(hepatocyte growth factor-like) (MST1) gene."

Query Match 0.9%; Score 19.8; DB 1; Length 254;
Best Local Similarity 51.7%; Pred. No. 1e+02;
Matches 45; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1148 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1207
Db 136 TGTCTTCACGGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 77

QY 1208 TCCTCCCTCTTTGATTTTGGCTGG 1234
Db 76 GCCCAGCCTTGATGCCATATGCCCTGG 50

RESULT 119
HSLKB1PJ7/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

HSLKB1PJ7
Homo sapiens Peutz-Jeghers syndrome protein (LKB1) gene, exon 8.
AF055326
AF055326.1 GI:3063582
7 of 8
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 268)
Avizienyte, E., Roth, S., Loukola, A., Hemminki, A., Lothe, R. A.,
Stenwig, A. E., Fossa, S. D., Salovaara, R. E. and Aaltonen, L. A.
Somatic mutations in LKB1 are rare in sporadic colorectal and
testicular tumors
Cancer Res. (1998) In press
2 (bases 1 to 268)
Bignell, G. R., Barfoot, R., Seal, S., Collins, N., Warren, W. and
Stratton, M. R.
Low frequency of somatic mutations in the LKB1/Peutz-Jeghers
syndrome gene in sporadic breast cancer
Cancer Res. 58 (7), 1384-1386 (1998)
98196525
9537235
3 (bases 1 to 268)
Avizienyte, E., Roth, S., Loukola, A., Hemminki, A., Bignell, G. R.,
Warren, W., Stratton, M. R. and Aaltonen, L. A.
Direct Submission
Submitted (25-MAR-1998) Department of Medical Genetics, Haartman
Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3),
Helsinki FIN-00014, Finland
Location/Qualifiers
1..268
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="19"
/map="19p13.3"
41..228
/gene="LKB1"
/number=8

exon

Query Match 0.9%; Score 19.8; DB 1; Length 268;
Best Local Similarity 60.0%; Pred. No. 1e+02;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
```

```
QY 938 TGATGTCATCATGAGTGGTGTCTTTTGGATGCAGCAGTAGGATGGATCTT 992
Db 105 TGGTGTCTGGGCTGGTGGATGGCACTGTGTCTTACGCGGAGGATGTTCTT 51

RESULT 120
BD095271/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

384 bp DNA linear PAT 27-AUG-2002
Structural coordinate and NMR chemical shift of protein and
utilization thereof.
BD095271
BD095271.1 GI:22640859
WO 0142453-A/3.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Koda,D., Hiroaki,H. and Sumimoto,H.
Structural coordinate and NMR chemical shift of protein and
utilization thereof
Patent: WO 0142453-A 3 14-JUN-2001;
BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU
HIROAKI, HIDEKI SUMIMOTO
OS Homo sapiens (human)
PN WO 0142453-A/3
PD 14-JUN-2001
PF 01-DEC-2000 WO 2000JP008501
PR 06-DEC-1999 JP 99P 346193
PI DAISUKE KODA,HIDEKAZU HIROAKI,HIDEKI SUMIMOTO PC
C12N15/09,C12N9/02,G06F17/30,G06F17/50,G01N33/68,G01N24/02 CC
Structural coordinate and NMR chemical shift of protein and CC
utilization
CC thereof
FH Key
FT source
FT Location/Qualifiers
1. .336
/organism="Homo sapiens (human)".

FEATURES
source
1. .384
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 19.8; DB 1; Length 384;
Best Local Similarity 77.4%; Pred. NO. 1e+02;
Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1686 TAGGAATTTTCTTTTGGTTTCTTGAA 1716
Db 178 TAGGGAACATTTCTTTAAGGTTTATGGAA 148

RESULT 121
AX814618/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .394
/organism="Homo sapiens"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.8; DB 1; Length 394;
Best Local Similarity 77.4%; Pred. NO. 1e+02;
Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1686 TAGGAATTTTCTTTTGGTTTCTTGAA 1716
Db 178 TAGGGAACATTTCTTTAAGGTTTATGGAA 148

RESULT 121
AX814618/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .394
/organism="Homo sapiens"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 19.8; DB 1; Length 394;
Best Local Similarity 77.4%; Pred. NO. 1e+02;
Matches 24; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1686 TAGGAATTTTCTTTTGGTTTCTTGAA 1716
Db 178 TAGGGAACATTTCTTTAAGGTTTATGGAA 148
```

```
misc_feature 1. .394
/db_xref="taxon:9606"
/note="exon 14"

Query Match 0.9%; Score 19.8; DB 1; Length 394;
Best Local Similarity 60.0%; Pred. NO. 1e+02;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 1161 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTCCCT 1215
Db 391 GTAGCTGGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCT 337

RESULT 122
DLA6882
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .535
/organism="Dicentrarchus labrax"
/mol_type="mRNA"
/db_xref="taxon:13489"
/dev_stage="larvae"
<1. ->535
/EC_number="3.4.21.4"
/codon_start=1
/product="trypsin"
/protein_id="CAA07315.1"
/db_xref="GI:3242120"
/db_xref="GOA:O93594"
/db_xref="SPTREMBL:O93594"
/translation="QVLSNGVHFVCGSLVNNWVSAAHYKSRVVEVLGEHNIRVT
ENTEQFISRVIRHERYSYNDIDNIMLIKSLKPKATLQYQVLPALPTSCAPAGTMC
TVSGWGNSTSTADNRKIQCLNIPILSFKDCDINSYFGMTDMFCAGYLEGGKDCQ9
DSGGPVVVCNGELQGVVSW"

Query Match 0.9%; Score 19.8; DB 1; Length 535;
Best Local Similarity 54.9%; Pred. NO. 1.1e+02;
Matches 39; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 53 TGGTAGAGTATCTCATACAGAGATAGCATTAGTGTCTGTGGACATAGTAACTTT 112
Db 414 TGGCATGATCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 473

QY 113 CCAGAGAGACT 123
Db 474 CCAGGGTGACT 484

RESULT 123
BV036036
LOCUS
DEFINITION
S212P6822FB7.T0 CZECHII/EI Mus musculus S1S genomic, sequence
```

COMMENT
Original source text: Pig liver, cDNA to mRNA.


```

ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Eisingermark,S., Rothenberg,M.E., Ellerman,K., MacDougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
CORIXA CORPORATION (US)
FEATURES
source
1. .596
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 596;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTCATAGACATTAAAGATTGCAATGCTCTTGG 784
|||
Db 122 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGGATGCAATGTCGCCCTGG 179
|||

RESULT 129
AX763043
LOCUS AX763043 609 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 37 from Patent WO03040393.
ACCESSION AX763043
VERSION AX763043.1 GI:32257659
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Martinez,R.A. and Sigurdsson,G.T.
TITLE Nucleic acids encoding proteases
JOURNAL Patent: WO 03040393-A 37 15-MAY-2003;
Decode Genetics EHF. (IS)
FEATURES
source
1. .609
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 609;
Best Local Similarity 54.1%; Pred. No. 1.2e+02;
Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
QY 435 ATTATTCAATTCCTTTATCTGTCGAGACTTGCCTTTGTTTGAATAATGATTCAATT 494
|||
Db 142 ATTATTGCCATATATTAGATCATGCTGGCCCTTTGTTTGGCAATTTCTTCATT 201
|||
QY 495 TTGGAGAGTTTCAT 508
|||
Db 202 TGGAAATGGGAACAT 215
|||

RESULT 130
AX765583/c
LOCUS AX765583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX765583
VERSION AX765583.1 GI:29333568
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1. .882
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTCATAGACATTAAAGATTGCAATGCTCTTGG 784
|||
Db 369 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGGATGCAATGTCGCCCTGG 312
|||

RESULT 131
AR219285/c
LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 8 from patent US 6420157.
ACCESSION AR219285
VERSION AR219285.1 GI:23320255
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1142)
AUTHORS Barrow,A., Qi,J. and Andrade-Grodon,P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;
Decode Genetics EHF. (IS)
FEATURES
source
1. .1142
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 19.6; DB 1; Length 1142;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTCATAGACATTAAAGATTGCAATGCTCTTGG 784
|||
Db 456 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGGATGCAATGTCGCCCTGG 399
|||

RESULT 132
AX675581/c
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1. .882
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTCATAGACATTAAAGATTGCAATGCTCTTGG 784
|||
Db 456 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGGATGCAATGTCGCCCTGG 399
|||

RESULT 133
AX675581/c
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,
Syttek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,
Vernet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,
Boldog,F.L., Grosse,W.M., Alsobrook,J.P., Gerlach,V.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1. .882
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACCTGGGTGACATTCGTGTTGGTCATAGACATTAAAGATTGCAATGCTCTTGG 784
|||
Db 456 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGGATGCAATGTCGCCCTGG 399
|||

```

Edingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,
Malyankar,U., Millet,I., Peyman,J., Smithson,G., Gunther,E. and
Stone,D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1. .1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.6; DB 1; Length 1161;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACTTGGTGACATTGCTTTGGTGCATAGACATTGAATGCAATGCTCTTGG 784
Db 657 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGAGTGCAATGTCGCCCTGG 600
RESULT 133
AR219284/c
LOCUS AR219284 1169 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 7 from patent US 6420157.
ACCESSION AR219284
VERSION AR219284.1 GI:23320254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 1169)
AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 7 16-JUL-2002;
FEATURES
source
1. .1169
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 19.6; DB 1; Length 1169;
Best Local Similarity 58.6%; Pred. No. 1.2e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 727 GAACTTGGTGACATTGCTTTGGTGCATAGACATTGAATGCAATGCTCTTGG 784
Db 483 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTTGGAGAGTGCAATGTCGCCCTGG 426
RESULT 134
BOVPBC/c
LOCUS BOVPBC 1373 bp mRNA linear MAM 27-APR-1993
DEFINITION Bovine protein C mRNA.
ACCESSION K02435
VERSION K02435.1 GI:163486
KEYWORDS autoproteolysin IIA; protein C; serine protease.
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
REFERENCE
1 (bases 1 to 1373)
AUTHORS Long,G.L., Belagaje,R.M. and Macgillivray,R.T.
TITLE Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE 85014826
PUBMED 6091100
COMMENT Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
pBC-7.
The sequence reported in [1] included homopolymeric tails on the 5'
and 3' ends (not shown here).
FEATURES
Location/Qualifiers

1. .1373
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
CDS
1. .1370
/note="protein C prepropeptide"
/codon_start=3
/protein_id="AAA30685.1"
/db_xref="GI:163487"
translation="TSLLLFTVIMGISSTAPPDSVFSSSORAHQVLRIRKANSFLE
BLRPNVERECSEEEFEAREIFQNTEDTMAFWSKYSDGDQCDRPSGSPCDLPCC
GRKCIDGLGFRCDCAEGWGRFCLHEVRFSNGSAENGCAHYCMBEERRHSCAP
GYLEDHQLCVSKVTRPCGRIGRMEKKRKLKRDITNOVDKQDOLDPRIVDGQAGW
GESPWQVLLDSKKLVCGAVLIHVSWLTVAHCLDSRKLIVRLGEYDMRWESWEV
DLIDKEIIVHENYTKSTSDNDIALLRLAKPATLSOTIPICLPSGLSERKLTQVQE
TVVWGVRDETRKRTFVLSFKIVPVVYNACVHAKMENKLSENMLCAGILGDPDACC
ESGSGPMVTFRTGTFVLVLSWGECCGRLYNGVYTKVSRYLWDIYGHIIKAQEAFL
ESQVP"
sig_peptide 1. .86
/note="protein C signal peptide"
mat_peptide 117. .581
/product="protein C light chain"
mat_peptide 588. .1367
/product="protein C inactive heavy chain"
mat_peptide 630. .1367
/product="protein C active heavy chain"
Query Match 0.9%; Score 19.6; DB 1; Length 1373;
Best Local Similarity 50.0%; Pred. No. 1.2e+02;
Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
QY 2081 ATTTCCTCTTCAAGGACCTTTTATGAATTCATAAAATGATGTTAAGGTCCTTGCTTGT 2140
Db 895 AFGTCGTGTCACCTGGTCTCTTGGTATAGTAGGTGGATGATGACCTCTTGATGTC 836
QY 2141 GCTTCAGCTATGTTGCATCTTCAGGCGCTATTGTATA 2178
Db 835 AGGTCCACCTCCAGCTCTCCAGCGCGCATGTCATA 798
RESULT 135
AR109618
LOCUS AR109618 177 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 30 from patent US 6114139.
ACCESSION AR109618
VERSION AR109618.1 GI:12825894
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 177)
AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 30 05-SEP-2000;
FEATURES
source
1. .177
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1727 CTGCTTTTGACCTGCTCTTCCCTCTCTTATTCCTCTTGGTTTGGCATAGTGTCT 1786
Db 7 CTGCTGGTACCTACCTGCTCTCTCTGCTGTCATCTCTCTGCTACGTCGGGTGCA 66
QY 1787 G 1787
Db 67 G 67
RESULT 136


```
RESULT 139
E28271
LOCUS      E28271      177 bp      DNA      linear      PAT 18-JUN-2001
DEFINITION Utilization of peptide.
ACCESSION E28271
VERSION   E28271.1 GI:13025305
KEYWORDS  JP 1990071300-A/11.
SOURCE    unidentified
ORGANISM  unclassified.
REFERENCE  1 (bases 1 to 177)
AUTHORS   Shuji.H., Ryo.F., Yuji.K. and Hirokazu.M.
TITLE     Utilization of peptide
JOURNAL   Patent: JP 1990071300-A 11 16-MAR-1999;
          TAKEDA CHEM IND LTD
COMMENT   OS Unidentified
          PN JP 1990071300-A/11
          PD 16-MAR-1999
          PF 22-JUN-1998 JP 1998175007
          PR
          PI SHUJI HINUMA, RYO FUJII, YUJI KAWAMATA, HIROKAZU MATSUMOTO PC
          A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, PC
          A61K38/00.
          PC A61K38/00, A61K38/00, C07K7/08, C07K14/705//C12N15/09, C12P21/02,
          PC (C12P21/02, C12R1:91), A61K37/02, A61K37/02, A61K37/02, A61K37/02,
          PC A61K37/02,
          PC A61K37/02, A61K37/02, A61K37/02, C12N15/00 CC
          CC Topology: Linear;
          FH Key Location/Qualifiers
          FT source 1..177
          FT Location/Qualifiers
          FEATURES
          source
          1..177
          /organism="unidentified"
          /mol_type="genomic DNA"
          /db_xref="taxon:32644"

Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67

RESULT 140
AR300928
LOCUS      AR300928      177 bp      mRNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION   AR300928.1 GI:31698601
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 177)
AUTHORS   Hinuma,S., Ito,Y. and Fujii,R.
TITLE     G protein coupled receptor protein production, and use thereof
JOURNAL   Patent: US 6538107-A 30 25-MAR-2003;
          Location/Qualifiers
          FEATURES
          source
          1..177
          /organism="unknown"
          /mol_type="mRNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67

RESULT 141
AR109885
LOCUS      AR109885      204 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 310 from patent US 6114139.
ACCESSION AR109885
VERSION   AR109885.1 GI:12826161
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 204)
AUTHORS   Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Obgi,K.
TITLE     G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL   Patent: US 6114139-A 310 05-SEP-2000;
          Location/Qualifiers
          FEATURES
          source
          1..204
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 204;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67

RESULT 142
AR150703
LOCUS      AR150703      204 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 127 from patent US 6228984.
ACCESSION AR150703
VERSION   AR150703.1 GI:15115294
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 204)
AUTHORS   Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S.
          and Kitada,C.
TITLE     Polypeptides their production and use
JOURNAL   Patent: US 6228984-A 127 08-MAY-2001;
          Location/Qualifiers
          FEATURES
          source
          1..204
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 204;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67
```

```
RESULT 143
AR300928
LOCUS      AR300928      177 bp      mRNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION   AR300928.1 GI:31698601
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 177)
AUTHORS   Hinuma,S., Ito,Y. and Fujii,R.
TITLE     G protein coupled receptor protein production, and use thereof
JOURNAL   Patent: US 6538107-A 30 25-MAR-2003;
          Location/Qualifiers
          FEATURES
          source
          1..177
          /organism="unknown"
          /mol_type="mRNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67

RESULT 144
AR300928
LOCUS      AR300928      177 bp      mRNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION   AR300928.1 GI:31698601
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE  1 (bases 1 to 177)
AUTHORS   Hinuma,S., Ito,Y. and Fujii,R.
TITLE     G protein coupled receptor protein production, and use thereof
JOURNAL   Patent: US 6538107-A 30 25-MAR-2003;
          Location/Qualifiers
          FEATURES
          source
          1..177
          /organism="unknown"
          /mol_type="mRNA"

Query Match 0.9%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.3e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1727 CTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTGGTTTGGTCATAGTGTCTCT 1786
Db 7 CTGCTGGTCACCTACCTGCTTCCCTCTCTGCTGGTCATCCTCTCTTACGTCGGGTGCA 66

QY 1787 G 1787
Db 67 G 67
```

RESULT 143
AJ586104/c
LOCUS
DEFINITION
Lolium multiflorum partial mRNA for putative 4-coumarate coA ligase (4cl gene).
AJ586104 249 bp mRNA linear PLN 23-OCT-2003
AJ586104.1 GI:37805458
4-coumarate coA ligase; 4cl gene.
Lolium multiflorum (Italian ryegrass)
Lolium multiflorum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae; Poae; Lolium.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
REFERENCE
AUTHORS
TITLE
JOURNAL
Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM
Location/Qualifiers
1. .249
/organism="Lolium multiflorum"
/mol_type="mRNA"
/cultivar="Trident"
/db_xref="taxon:4521"
/tissue_type="young leaves with leaf bases"
/dev_stage="seedlings"
1. .249
/gene="4cl"
/gene="4cl"
/EC_number="6.2.1.12"
/function="activation of thioester substrates for phenylpropanoid synthesis"
/codon_start=3
/product="putative 4-coumarate coA ligase"
/protein_id="CAE51882.1"
/db_xref="GI:37805459"
/translation="PFKVKSGSGTGVVNAFLKVVDPDTGASLGRNOPGEICVRGKQI
MLGYLNDPESTKNTIDKDWLHTGDI GLVDDDEIFIV"
Query Match 0.9%; Score 19.4; DB 1; Length 249;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Qy 1892 TATCTTTGATTCTGCAGTGAGCGTGTCTCTGAGGTTCTCTGTGGTTCT 1944
|||||
Db 210 TGTCTCGGTGTGCAGCGCCGCTCTGTGCGATGGTCTTCTGTCGACTCT 158
|||||
RESULT 144
AX839191/c
LOCUS
DEFINITION
Sequence 34 from Patent WO03076610.
AX839191 290 bp DNA linear PAT 15-DEC-2003
AX839191.1 GI:39922640
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
TITLE
JOURNAL
Bracco, L., Brinkman, B. and Coignard, F.
Variants of human kallikrein-2 and kallikrein-3 and uses thereof
Patent: WO 03076610-A 34 18-SEP-2003;
Exonhit Therapeutics S.A. (FR)

FEATURES
source
Location/Qualifiers
1. .290
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 19.4; DB 1; Length 290;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
Qy 217 TCTCTCTCCCTTTCTCTAACACTTCTGGGCCAGGGTAGGGCAGTACCGCAATCCCTC 276
|||||
Db 113 TCTGCACTCCAGCCTCCCAACATCGAGACAGGATGAGGGGTGCAGCCCAATCCACG 54
|||||
Qy 277 TCTCTTCCA 285
|||||
Db 53 TCACGGACA 45
|||||
RESULT 145
HUMPS02
LOCUS
DEFINITION
Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION
M57841 J02917
VERSION
M57841.1 GI:190535
KEYWORDS
S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT
2 of 14
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 352)
AUTHORS
Schmidel, D.K., Tatro, A.V., Phelps, L.G., Tomczak, J.A. and Long, G.L.
TITLE
Organization of the human protein S genes
JOURNAL
Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE
91084444
PUBMED
2148110
COMMENT
Original
source text: Human liver DNA.
FEATURES
source
Location/Qualifiers
1. .352
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="3p11-q11.2"
/tissue_type="liver"
join(M57840.1:837..912,135..181)
/genes="PS-alpha"
order(M57840.1:913..1014,1..134)
/gene="PROS1"
/number=1
135..292
/gene="PROS1"
/note="G00-120-721"
/number=2
Query Match 0.9%; Score 19.4; DB 1; Length 352;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
Qy 1321 AAGTAGATATCTTTTACATCTGATTTATCTTAGAATGTCTTTCTTCCAACTATTG 1380
|||||
Db 80 AATATATTTTACATGGAAATGATTAATTCATATAACTGATTGTTCTTCAGTTTG 139
|||||
Qy 1381 TGACAGAAA 1389
|||||
Db 140 TCAAAGCAA 148
|||||
RESULT 146
DOG2/c
LOCUS
DEFINITION
Dog gene for protein C (precursor of vitamin K-dependent serine protease), partial cds (catalytic region).
471 bp DNA linear MAM 09-FEB-1999

```

ACCESSION D43751
VERSION D43751.1 GI:601886
KEYWORDS protein C; serine protease zymogen; vitamin K-dependent serine
SOURCE protease; blood coagulation-related.
ORGANISM Canis familiaris (dog)
Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and
Niho, Y.
A comparative study of partial primary structures of the catalytic
region of mammalian protein C
Br. J. Haematol. 86 (3), 590-600 (1994)
JOURNAL 94318474
MEDLINE PUBMED
AUTHORS 2 (bases 1 to 471)
MURAKAWA, M.
Direct Submission
Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
Location/Qualifiers
1..471
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"
<1..>471
/function="regulation of blood coagulation"
/note="catalytic region"
/codon_start=1
/product="protein C"
/protein_id="BAA07808.1"
/db_xref="GI:1304048"
/translation="EKGEIMVDIKELVHPNYSKSTDDIALHLAQPAIRSOTIVP
ICLPDGLAERETQVQETVTVGWYRSEKTEKTFVLFNFINVPAPNECICQAMYN
MISENNLCAGILGDSRDACEGDSGGPMVTSFRGTWFLVGLVSGEGCGRLHNYGI"
Query Match 0.9%; Score 19.4; DB 1; Length 471;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 1203 TGTCTCTCCCTTCGATTTTGGCCCTGGGAATTATTATTATTCATATTTCTTGAA 1262
|||||
Db 322 TGTCTCAGATATATGTTGTACATGCGCTGGATGCACCTATTTGCGGGGCCACAGGA 263
QY 1263 TGTGGGTAA 1271
|||||
Db 262 TGTGTATAA 254
SHPFXA
LOCUS Sheep factor IX mRNA, partial cds.
DEFINITION
ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX.
SOURCE Ovis aries (sheep)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
1 (bases 1 to 823)
Sarkar, G., Koerber, D.D. and Sommer, S.S.
Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
Genomics 6 (1), 133-143 (1990)
JOURNAL 90152675
MEDLINE PUBMED
AUTHORS 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
FEATURES
source
1..823
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/note="factor IX"
/codon_start=1
/protein_id="AAA31520.1"
/db_xref="GI:552419"
/translation="RASVLHTSKLTRAETIFSNMNVNSAEIINDVNTOSNQSF
DNRVVGGEADAAGOPQVLLHGHIAECGGSIVNEKVVTAAHCIKPQKITVVG
ENTKEPTEQKRNVRIPAIPHGNASINKYSHDIALEDEPLNYSVVTFCIAD
REYTNIFKFGYGVISRWGRVFNRRGSASILQYLVPLVDATCLRSTKPTIYNHMF
AGYHGGKDCSQDGGPHVTEGTSFLTIGTISWGECEAMKGYGIYTKVSRSEYV"
Query Match 0.9%; Score 19.4; DB 1; Length 823;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 1675 TTCTCAAGGTAGGAAATTTTCTTTTGGTTTCTTGAAATATTTTCCTGCTTT 1734
|||||
Db 93 TATTTTCAGCTTCAGAAATTTTCATATTCATATTTGGAATAATAGTCTCAGCAGG 34
QY 1735 GACCTGCCT 1743
|||||
Db 33 GAGCTTCTT 25
RESULT 148
BC061135/c
LOCUS Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),
complete cds.
DEFINITION
ACCESSION BC061135
VERSION BC061135.1 GI:38511692
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 829)
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.P., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Schetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S.,
Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalusz, D.E.,
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
JOURNAL 22388257
MEDLINE PUBMED
AUTHORS 2 (bases 1 to 829)
Strausberg, R.
Direct Submission
Submitted (03-NOV-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
REMARK

```

COMMENT

Contact: MGC help desk
 Email: cgabbs-r@mail.nih.gov
 Tissue procurement: Dr. Michael Brownstein
 cDNA Library Preparation: Michael Brownstein / Ted Usdin
 Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome
 Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: <http://www-shgc.stanford.edu>
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.

Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
 Series: IRAL Plate: 53 Row: 0 Column: 2
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 6755892.

FEATURES

source
 1. .829
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="MGC:74265 IMAGE:30306436"
 /tissue_type="Liver, mouse"
 /clone_lib="NIH MGC 177"
 /lab_host="DH10B"
 /note="Vector: pDNR-LTB"
 1. .829
 /gene="Try4"
 /notes="synonyms: 0910001B19Rik, Tc"
 /db_xref="LocustID:22074"
 /db_xref="MGI:102757"
 14. .754
 /codon_start=1
 /product="trypsin 4"
 /protein_id="AAH61135.1"
 /db_xref="GI:38511693"
 /db_xref="LocustID:22074"
 /translation="MRALFLALVGAFAFFVDDDKIVGGYTCRENSVPYQVLSNG
 YHFCGSLINDQVVAACHYKSRQVRLGHNINVLGNQFVNSAKIKHPNFSR
 TLNDDMLKASPTLNLARVATVALPSSCAPAGTQCLISGWNLTLSFGVNPDLIQC
 LDAPLLPADCEASYPGKTNMNCVGFLEGGKDSQSGDGGPVVNCGLQIGVNSGY
 GCALXNDPGVYTKVCNVVDWIQNTIAAN"
 misc_feature
 83. .739
 /notes="Tryp_SPC; Region: Trypsin-like serine protease"
 /db_xref="CDD:cd00190"

Query Match 0.9%; Score 19.4; DB 1; Length 829;
 Best Local Similarity 60.4%; Pred. No. 1.3e+02;
 Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1693 TTTTCTTTTGGTTTCTGAAATATTTCCCTGCTTTGACCTGCCTC 1745
 |||||
 Db 817 TTTTCTTTTGGTTTCTGAAATATTTCCCTGCTTTGACCTGCCTC 765

RESULT 149
 AR095306/c
 LOCUS Human factor X mRNA. 1126 bp DNA linear PAT 08-SEP-2000
 DEFINITION
 AR095306
 ACCESSION
 AR095306.1 GI:10023064
 VERSION
 AR095306.1
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 1126)
 AUTHORS Thorpe,P.E. and Edgington,T.S.
 TITLE Methods for the specific coagulation of vasculature
 JOURNAL Patent: US 6004555-A 27 21-DEC-1999;
 FEATURES
 Location/Qualifiers
 1. .1126

/organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
 Best Local Similarity 47.9%; Pred. No. 1.4e+02;
 Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTCTAATATCTCTAGGTCCACTGGTTTATGACATCAGTAGCTCC 601
 |||||
 Db 596 TTGTGAACCGGTGTGTGATGACCACTCCACTCGTGCACCGCTCACCGCCCTCC 537
 |||||
 QY 602 AGCAATTCCTCTGTTTCGTTTGTGAGATGACCTAACTGTGGAGAGAAATGGGT 658
 |||||
 Db 536 TCTGTCCTCGTGTTCGGTCCCTTCGAATCTCTGGCTTGGTAGAGACAGTGGGCT 480
 |||||

RESULT 150
 AR103990/c
 LOCUS Human factor X mRNA. 1126 bp DNA linear PAT 14-FEB-2001
 DEFINITION
 AR103990
 ACCESSION
 AR103990.1 GI:12816698
 VERSION
 AR103990.1
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 1126)
 AUTHORS Thorpe,P.E. and Edgington,T.S.
 TITLE Methods and compositions for the specific coagulation of
 vasculature
 JOURNAL Patent: US 6093399-A 27 25-JUL-2000;
 FEATURES
 Location/Qualifiers
 source
 1. .1126
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
 Best Local Similarity 47.9%; Pred. No. 1.4e+02;
 Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 542 TTGGTGAATAGTCTCTAATATCTCTAGGTCCACTGGTTTATGACATCAGTAGCTCC 601
 |||||
 Db 596 TTGTGAACCGGTGTGTGATGACCACTCCACTCGTGCACCGCTCACCGCCCTCC 537
 |||||
 QY 602 AGCAATTCCTCTGTTTCGTTTGTGAGATGACCTAACTGTGGAGAGAAATGGGT 658
 |||||
 Db 536 TCTGTCCTCGTGTTCGGTCCCTTCGAATCTCTGGCTTGGTAGAGACAGTGGGCT 480
 |||||

RESULT 151
 HUMFX/c
 LOCUS Human factor X mRNA. 1126 bp mRNA linear PRI 08-NOV-1994
 DEFINITION
 ACCESSION K01886
 VERSION K01886.1 GI:182820
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1126)
 AUTHORS Leytus,S.P., Chung,D.W., Kisiel,W., Kurachi,K. and Davie,E.W.
 TITLE Characterization of a cDNA coding for human factor X
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)
 MEDLINE
 84222026
 PUBMED
 6587384
 COMMENT
 Original source text: Human liver, cDNA to mRNA, clone
 lambda-X-1137.

In processing, factor X (Stuart factor) is converted to Xa by
 cleavage of a glycopeptide from the amino-terminal end of the heavy
 chain. It then acts as a serine protease in converting prothrombin
 to thrombin.
 Location/Qualifiers


```

source
1. .1126
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q34"
1. .1126
/gene="F10"
<1. .1126
/gene="F10"
/product="factor X mRNA"
<1. .1116
/gene="F10"
/feature="factor X precursor peptide"
/codon_start=1
/protein_id="AAA52486.1"
/db_xref="GI:182821"
/db_xref="GDB:G00-119-890"
/translation="GPEGKNCLELFTFKLCLSDNGDCDFCHEEQNSVWCSCARGYTLA
DNGKACIPGPGYPCGQITERRKRSVAQATSSSGEAPDSITWKPYDAADLPTNPFD
LLDFNQTQPERGDNNTIRIVGGCEKDCGCPQWALLINEENSGFCGTTLSBFYILTA
AHLCYAKREFEGDNRTEQREGGEAVHEVWLKHNFTKETVDFDIADVLRKLPITFR
MNVAPACLPERDWAESTLMTQKTGIVSGFGRTHKGRQSTRLKMLEVYPYVDNSCKLS
SYFTVFNPCFAGYDQKBDACDGGSGGHVTRFKDTYFVTGIVSWGEGCARGKGYGI
SFKTQAFLLKIDRSMKTRGLPKAKSHAPEVITSSPLK"
<1. .1195
/gene="F10"
/product="factor X light chain"
205. .1113
/gene="F10"
/product="factor X heavy chain"
361. .1113
/gene="F10"
/product="factor Xa heavy chain"

Query Match 0.9%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.4e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

Qy 542 TTGGTGAATAGTCTGTAAATATCTCTAGGTCCACTTGGTTTATGACATCAGTTAGCTCC 601
Db 596 TTGTGNAACGGTGTGCTTGATGACACCTCCACCTCGTGACCGCTCACCGCCCTCC 537

Qy 602 AGCATTTCTCTGTTTCGTTTTTTTGTGTGAGANGACCTAACTGTTGGAGAGAAATGGGT 658
Db 536 TCCTGTCCGTGTTCCGGTCCCTTCCGAATCTCTTGGCTTGTGAGACAGTGGGT 480

RESULT 152
A93124/c
LOCUS
DEFINITION Sequence 15 from Patent WO9747737.
ACCESSION A93124
VERSION A93124.1 GI:6741514
KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.
REFERENCE
1 (bases 1 to 1404)
AUTHORS Kopecki, E. and Hopfner, K.
TITLE RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL Patent: WO 9747737-A 15 18-DEC-1997;
KOPETZKI ERHARD (DE); BOEHRINGER MANNHEIM GMBH (DE)
FEATURES
source
1. .1404
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

Qy 542 TTGGTGAATAGTCTGTAAATATCTCTAGGTCCACTTGGTTTATGACATCAGTTAGCTCC 601

```



```

CDS
<1..>471
/function="regulation of blood coagulation"
/note="catalytic region"
/codon_start=1
/product="protein C"
/protein_id="BAA07809.1"
/db_xref="GI:1304082"
/translations="ESWEVDLDIKEIVRPNTKSTNDIALHLAKPATLSOTIVP
ICLPDGLSERKLTQGVETVTKGVRDETKGNRTSILNFIKIPVSYNACHAMEN
KVENMLCAGILGNPRDACEGSDSGGFFRGTFWFLVGLVSWGEGCGRLNNGI"

Query Match      0.8%; Score 19.2; DB 1; Length 471;
Best Local Similarity 50.8%; Pred. No. 1.5e+02;
Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 1838 GACCAGGATCATTCCTATCTCTGCTTCTTCACTGCCTGAGATCTCTCTTATATCTC 1897
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 246 GATGAGGTCGGTCTTCTTCTGCTCTGCTACGGTAGCCCGCTGTCCACAGATCTC 187

QY 1898 TTGTATTCTGTCAGTGAGGCTTGCTCTGAGGTTCC 1933
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 186 CTGCCGACCTGATGAGCTTGCGCTCAGAGAGGCC 151

RESULT 159
BV094002/c
LOCUS      596 bp DNA linear STS 15-OCT-2003
DEFINITION RPAMSE0005940 Roche Palo Alto Mus musculus STS genomic, sequence
            tagged site.
ACCESSION  BV094002
VERSION     BV094002.1 GI:37671481
KEYWORDS   STS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
REFERENCE  1 (bases 1 to 596)
AUTHORS    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
            Usuka, J., Liao, G., Cheng, J., Nguyen, A., Bach, C., Puech, A.,
            McPherson, J. D., Foernzler, D. and Peltz, G.
TITLE      Mus musculus SNPs
JOURNAL    Unpublished (2003)
COMMENT    Contact: Jonathan Usuka
            Roche Palo Alto Genetics and Genomics Department
            Roche Palo Alto
            3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA
            Tel: 6508555807
            Email: Jonathan.Usuka@roche.com
            Primer A: No primer submitted
            Primer B: No primer submitted.

FEATURES             Location/Qualifiers
     source           1..596
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:10090"
                     /map="18-10064-9474-AC126686.3.1.232817"
                     /clone_lib="Roche Palo Alto"
                     /note="SNPs developed from assay sequences derived from 15
                     different strains of mice (as of October 1, 2003). Those
                     strains include A/J, A/HeJ, -129/Sv, AKR/J, B10.D2-H2/cSnJ,
                     BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J,
                     MRL/MpJ, NZB/BinJ, NZW/Lac, SPRET/Ei.~"
     STS              <1..>596

Query Match      0.8%; Score 19.2; DB 1; Length 596;
Best Local Similarity 49.8%; Pred. No. 1.5e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTTGATTTCTATCTGCTCATTTTAACTCAGTAGTGAGTGTGTTGGTTTCCATAG 356
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 555 TTCTGCTCTNAGGGAGACACCTTTTCCCAATGTAACGTGTAATCCATTTGAGGTAG 496

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393

```

```

Db 495 CTCCACATTGGTGAGATGCCATAGTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 459
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 160
RABTHRO
LOCUS      826 bp mRNA linear MAM 08-MAY-1993
DEFINITION Oryctolagus cuniculus thrombin mRNA, 3' end.
ACCESSION  M81396
VERSION     M81396.1 GI:165740
KEYWORDS   thrombin.
SOURCE     Oryctolagus cuniculus (rabbit)
ORGANISM   Oryctolagus cuniculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
            1 (bases 1 to 826)
REFERENCE  Banfield, D.K. and Macgillivray, R.T.
            Partial characterization of vertebrate prothrombin cDNAs:
            amplification and sequence analysis of the B chain of thrombin from
            nine different species
JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2779-2783 (1992)
MEDLINE    92212913
PUBMED     1557383
COMMENT    Original source text: Oryctolagus cuniculus adult liver cDNA to
            mRNA.

FEATURES             Location/Qualifiers
     source           1..826
                     /organism="Oryctolagus cuniculus"
                     /mol_type="mRNA"
                     /db_xref="taxon:9986"
                     /tissue_type="liver"
                     /dev_stage="adult"
     gene             1..826
                     /gene="thrombin"
     CDS              <1..708
                     /gene="thrombin"
                     /codon_start=1
                     /product="thrombin"
                     /protein_id="AAA31477.1"
                     /db_xref="GI:165741"
                     /translation="OELLCAASLISDRWVLTAAHCLLYPPWPKNFVNDILVRIGKYA
                     RSYERNMEKISTLEKIIIPHPYNNRENLDRIALMKLKPFAFSYDIHPVCLPDQKI
                     VTSLOAGHKGRVTGNLKEWTVNNVQPSVLQMVNPLVVERPICKASTGIRVTD
                     NMFCAGYKPEEGKRGCDACSGDSGGFFVMKNPNRNRYQMGIVSWGEGCDRGKYGFTT
                     HVRLLKWKWKWVDFEG"
                     /length=826
                     /genes="thrombin"
     3'UTR           706..816
                     /gene="thrombin"

Query Match      0.8%; Score 19.2; DB 1; Length 826;
Best Local Similarity 51.1%; Pred. No. 1.5e+02;
Matches 45; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 998 CATATCCATTCTGTTACCCAGTATCTTTTCTAGAGAAATTAAGATCATTGAGTCATTGA 1057
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 714 CACACACATCTGGGCTCTCTCACTCGAGTGTACAGAACCAACCCAGTCAAGAATTGT 773
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 1058 TGTTCAGATTATCAATGACGACGTGTTT 1085
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 774 TTTTGTGTTGTGTCCTAAACGGTGGTT 801
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 161
AF465270
LOCUS      1302 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus anticoagulant protein C precursor (PROC) mRNA,
            complete cds.
ACCESSION  AF465270
VERSION     AF465270.1 GI:28194011
KEYWORDS   Gallus gallus (chicken)
SOURCE     Gallus gallus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;

```

```

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1302)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
TITLE
JOURNAL
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
FEATURES
source
1..1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1302
/gene="PROC"
1..1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/notes="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLTITIGVLLAACSSPVCHASIFYKYDANQVILKIRKANSFL
BELKPGSVRECNERNCPFEASEIFETKEATLEFWSKYVDGQCAQKPCSNACKDN
IGSYCIDKMGEGACQYEVKYNKCSVDNGGCOHFCKEDPAKQRCVCSAGSYLTN
DHNMCTPVVEFCGVRKMDYTEGKAEPNIRLIGNSGGGFSFPMVLONLKGKFLCG
GVLIHPSVLTAAHCVEGTGLRGLRIENSEGTIRKVKYRHENYTKLISD
NDIAMLHAEPMYKNYALPCLPTFDLAEBLTTKGRQMLVIGWSTSDENRYSAL
LSYIETPIVPKNECAQVMTNTISDNMLCAGSLGDRKDCSGSDSGGFMATKYKDTWFLV
GLVNSGEGGCKEKFVTVKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1055 TGATGTGAGAAATATCAATGACGAGTGTGTTGGATTCTTGTATCTTGGCACTTCTGAA 1114
Db 617 TTATGCTGAAATCTGAAGGGAAGTTCTGTGTGAGGTGTTCTCATCCATCCGCTCT 676

QY 1115 GTGT 1118
Db 677 GGGT 680

RESULT 162
AF532184 1341 bp mRNA linear ROD 21-AUG-2002
LOCUS
DEFINITION Rattus norvegicus coagulation factor VII mRNA, complete cds.
ACCESSION AF532184
VERSION AF532184.1 GI:22347744
KEYWORDS
SOURCE
ORGANISM Rattus norvegicus (Norway rat)

REFERENCE
Murphy,K. and Ramaker,M.
TITLE Nucleotide sequence of the cDNA encoding rat coagulation factor VII
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1341)
Murphy,K. and Ramaker,M.

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1302)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
TITLE
JOURNAL
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
FEATURES
source
1..1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1302
/gene="PROC"
1..1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/notes="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLTITIGVLLAACSSPVCHASIFYKYDANQVILKIRKANSFL
BELKPGSVRECNERNCPFEASEIFETKEATLEFWSKYVDGQCAQKPCSNACKDN
IGSYCIDKMGEGACQYEVKYNKCSVDNGGCOHFCKEDPAKQRCVCSAGSYLTN
DHNMCTPVVEFCGVRKMDYTEGKAEPNIRLIGNSGGGFSFPMVLONLKGKFLCG
GVLIHPSVLTAAHCVEGTGLRGLRIENSEGTIRKVKYRHENYTKLISD
NDIAMLHAEPMYKNYALPCLPTFDLAEBLTTKGRQMLVIGWSTSDENRYSAL
LSYIETPIVPKNECAQVMTNTISDNMLCAGSLGDRKDCSGSDSGGFMATKYKDTWFLV
GLVNSGEGGCKEKFVTVKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1055 TGATGTGAGAAATATCAATGACGAGTGTGTTGGATTCTTGTATCTTGGCACTTCTGAA 1114
Db 617 TTATGCTGAAATCTGAAGGGAAGTTCTGTGTGAGGTGTTCTCATCCATCCGCTCT 676

QY 1115 GTGT 1118
Db 677 GGGT 680

RESULT 162
AF532184 1341 bp mRNA linear ROD 21-AUG-2002
LOCUS
DEFINITION Rattus norvegicus coagulation factor VII mRNA, complete cds.
ACCESSION AF532184
VERSION AF532184.1 GI:22347744
KEYWORDS
SOURCE
ORGANISM Rattus norvegicus (Norway rat)

REFERENCE
Murphy,K. and Ramaker,M.
TITLE Nucleotide sequence of the cDNA encoding rat coagulation factor VII
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1341)
Murphy,K. and Ramaker,M.

Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
JOURNAL
REFERENCE 2 (bases 1 to 1302)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
TITLE
JOURNAL
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
Location/Qualifiers
FEATURES
source
1..1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1302
/gene="PROC"
1..1302
/gene="PROC"
/EC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/notes="vitamin K dependent serine protease;
autoprothrombin Iia; coagulation factor XIV; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AA033365.1"
/db_xref="GI:28194012"
/translation="MWKLTITIGVLLAACSSPVCHASIFYKYDANQVILKIRKANSFL
BELKPGSVRECNERNCPFEASEIFETKEATLEFWSKYVDGQCAQKPCSNACKDN
IGSYCIDKMGEGACQYEVKYNKCSVDNGGCOHFCKEDPAKQRCVCSAGSYLTN
DHNMCTPVVEFCGVRKMDYTEGKAEPNIRLIGNSGGGFSFPMVLONLKGKFLCG
GVLIHPSVLTAAHCVEGTGLRGLRIENSEGTIRKVKYRHENYTKLISD
NDIAMLHAEPMYKNYALPCLPTFDLAEBLTTKGRQMLVIGWSTSDENRYSAL
LSYIETPIVPKNECAQVMTNTISDNMLCAGSLGDRKDCSGSDSGGFMATKYKDTWFLV
GLVNSGEGGCKEKFVTVKVSQYLEWQHINKKSGSWRG"

Query Match 0.8%; Score 19.2; DB 1; Length 1341;
Best Local Similarity 58.9%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 1 GATCACTCCTCTAGTGAAGGTGGGGTCTGAGGCTCCCAATGGTTGTCATGTGGT 56
Db 751 GAACACGACTTCAGTGAGAAGGAGGAGGACTGAGCAAGTACGGCTGCTGGAACAGGT 806

RESULT 163
OCU77477/c
LOCUS
DEFINITION Oryctolagus cuniculus coagulation factor VII mRNA, complete cds.
ACCESSION U77477 S56300
VERSION U77477.1 GI:1698964
KEYWORDS
SOURCE
ORGANISM Oryctolagus cuniculus (rabbit)
Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
1 (bases 1 to 1619)
Brothers,A.B., Clarke,B.J., Sheffield,W.P. and Blajchman,M.A.
Complete nucleotide sequence of the cDNA encoding rabbit
coagulation factor VII
Thromb. Res. 69 (2), 231-238 (1993)
93190306
8383365
2 (bases 1 to 1619)
Ruiz,S.R., Blajchman,M.A. and Clarke,B.J.
Direct Submission
Submitted (05-NOV-1996) Pathology, McMaster University, 1200 Main
St. West, Hamilton, ONT L8N 3Z5, Canada
On Feb 8, 2002 this sequence version replaced gi:266294.
Location/Qualifiers
source
1..1619
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"
22..1356
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAB37326.1"
/db_xref="GI:1698965"
/translation="MAPQARGLGCLSLAQASLAAVFTQBEAHSVLRQRANSFL
EBLRPGSLRECKELCSFEAREVFQSTERTKQFTWYNDGDQCSASNPCCNGSCSD
QIQSYICFLADFEKNCENKNDQICMVENGCGEQYCDHVSQSCRCHEGYTLL
PAGVSCPTFYDPCGVPALEKRGASNPQRIVGGKVCPEKCEPQAAALMNGSTLLCG
GSLDTHWVWSAAHCFDLKSLSLRNLTIVIGEDHLSHEGDEQVHVQAQLMPKYVPG
KTDHDIALLRLQLQPAALTNNVPLCLPERNFSESTLITFRFSVSGWGQLLYRGALAR"

Direct Submission
Submitted (24-JUL-2002) Biotechnology, Bristol-Myers Squibb, P.O.
Box 80336, Wilmington, DE 19880-0336, USA
Location/Qualifiers
FEATURES
source
1..1341
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strains="Sprague-Dawley"
/db_xref="taxon:10116"
1..1341
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAM95967.1"
/db_xref="GI:22347745"
/translation="MVPQTHGLLLYFLQLQPLGAVVFTQBEAHSVLRQRANS
LLEELWSSLRERECNEECFEAREBIFKSPERTKQFTWYNDGDQCSASNPCCNGGTC
QDHLSKYVCFCLDFQPEKNCENKNEQICANENGDCDQYCRDHVGTQRTSCHEQYV
LQPDVESCCKPVYPCGRIPVVEKRNFSQGRIVGGKVCPEKCEPQAAALMNGSTLLCG
CGAVLLDTRWIVTAAHCFDKFKLVNITWVLGEHDFSEKGEQVRLVEQVLLMPKRYT
RGRDHDIALVRLHRPVTFTDYVVPVLCI-PERAFSENTLASIRFSVSGWGQLLDRGAT
ALELMVIEVPRMLTQDCLLEHAKHSANTPRITENMECAGYMDGTCKDCKSDSGPHATH
YHGTWYLTGVVSWGEGCAIGHIVITRVSQIYDMLVIMDSKLVGISRVSL"

```

AGNARDS	Dissostichus mawsoni
SOURCE	Dissostichus mawsoni
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Notothenioidi; Nototheniidae; Dissostichus. 1 (bases 1 to 352).
REFERENCE	Chen, L., DeVries, A.L. and Cheng, C.H. Evolution of antifreeze glycoprotein gene from a trypsinogen gene in Antarctic notothenioid fish
AUTHORS	Proc. Natl. Acad. Sci. U.S.A. 94 (8), 3811-3816 (1997)
TITLE	97268652
JOURNAL	
MEDLINE	

PUBMED 9108060
REFERENCE 2 (bases 1 to 352)
AUTHORS Chen, L., DeVries, A. and Cheng, C.
TITLE Direct Submision
JOURNAL Physiology (21-MAY-1996) Liangbiao Chen, Molecular and Integrative
Physiology, University of Illinois, 524 Burrill Hall, 407 S.
Goodwin Ave, Urbana, IL 61801, USA
FEATURES
source
1..352
Location/Qualifiers
/organism="Dioscovich mawsoni"
/mol_type="mRNA"
/db_xref="taxon:36200"
/tissue_type="pancreas"
1..352
/gene="DM-AFGP"
1..102
/gene="DM-AFGP"
/function="inhibits ice crystal growth"
/codon_start=1
/product="antifreeze glycoprotein precursor"
/protein_id="AAB57730.1"
/db_xref="GI:1399809"
/translation="AATPALNFVATPATAATAATAATAATAAARG"
Query Match 0.8%; Score 18.8; DB 1; Length 352;
Best Local Similarity 52.3%; Pred. No. 1.9e+02;
Matches 41; Conservative 0; Mismatches 37; Indels 0; Gaps 0;
QY 1990 TAATTCATTTCCACATTCAGGTCCTGAAATGTTTACATTTCTCCAGTATTTAC 2049
DB 249 TAAAGAAATACAGTTATTTCTTCACTTCTCCACATGGTTCAGACCCCTGGTTT 308
QY 2050 ATTTTCATAGGTTCTTT 2067
DB 309 TTTTCTGCTCTCTCT 326
RESULT 168
AX193364/c
LOCUS AX193364 596 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 931 from Patent WO0149716.
ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J.,
Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.
TITLE Compounds for immunotherapy and diagnosis of colon cancer and
methods for their use
JOURNAL Patent: WO 0149716-A 931 12-JUL-2001;
CORIXA CORPORATION (US)
FEATURES
source
1..596
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.8; DB 1; Length 596;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 345 GGTTTCCATAAGTTTCTGTAAGTTTCTGTTCTGTTCTGTTCTGTTCTGTTCT 398
DB 376 GCGGTCCATGTGTGTGGTCTCTCGTCTGAGCAGGGGTGCTGTCAGCT 323
RESULT 169
AX675583
LOCUS AX675583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:293333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Boidog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..1161
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.8; DB 1; Length 1161;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 345 GGTTTCCATAAGTTTCTGTAAGTTTCTGTTCTGTTCTGTTCTGTTCTGTTCT 398
DB 403 GCGGTCCATGTGTGTGGTCTCTCGTCTGAGCAGGGGTGCTGTCAGCT 456

DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX675583
VERSION AX675583.1 GI:293333568
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Boidog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..882
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.8; DB 1; Length 882;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 345 GGTTTCCATAAGTTTCTGTAAGTTTCTGTTCTGTTCTGTTCTGTTCTGTTCT 398
DB 115 GCGGTCCATGTGTGTGGTCTCTCGTCTGAGCAGGGGTGCTGTCAGCT 168
RESULT 170
AX675581
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:293333567
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Boidog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES
source
1..1161
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.8; DB 1; Length 1161;
Best Local Similarity 59.3%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 345 GGTTTCCATAAGTTTCTGTAAGTTTCTGTTCTGTTCTGTTCTGTTCTGTTCT 398
DB 403 GCGGTCCATGTGTGTGGTCTCTCGTCTGAGCAGGGGTGCTGTCAGCT 456

Qy 1658 ACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91
Qy 1718 ATATTTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 175
AR098999/c
LOCUS 168 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6077687.
ACCESSION AR098999
VERSION AR098999.1 GI:12808765
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L.
TITLE Flea aminopeptidase nucleic acid molecules and uses thereof
JOURNAL Patent: US 6077687-A 28 20-JUN-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0;

Qy 1658 ACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91
Qy 1718 ATATTTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 176
AR116830/c
LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6139840.
ACCESSION AR116830
VERSION AR116830.1 GI:14097736
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.
TITLE Methods of eliciting an antibody response using flea protease proteins and homologs thereof
JOURNAL Patent: US 6139840-A 28 31-OCT-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0;

Qy 1658 ACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91
Qy 1718 ATATTTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 177
AR127061/c
LOCUS 168 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 28 from patent US 6180383.
ACCESSION AR127061
VERSION AR127061.1 GI:14113654
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea leucine aminopeptidase proteins and uses thereof
JOURNAL Patent: US 6180383-A 28 30-JAN-2001;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0;

Qy 1658 ACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91
Qy 1718 ATATTTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 178
AR141647/c
LOCUS 168 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6146870.
ACCESSION AR141647
VERSION AR141647.1 GI:15101163
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 168)
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and Stiegler,G.L.
TITLE Flea protease proteins
JOURNAL Patent: US 6146870-A 28 14-NOV-2000;
FEATURES
source Location/Qualifiers
1..168
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02; Mismatches 59; Indels 0; Gaps 0;
Matches 54; Conservative 0;

Qy 1658 ACCTTGATAGGCACTCTTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAA 1717
Db 150 ATCAGGATAACAGCACAAATCATATTTTGGTAATATTAGTCCTTCATTCCATATAT 91
Qy 1718 ATATTTTCCCTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGGCACTGAGTCCAGTTAAACAATAGGTACCTTTACATATTGCAGTTGTT 38

RESULT 179
AR151537/c
LOCUS 168 bp DNA linear PAT 08-AUG-2001

```
DEFINITION Sequence 28 from patent US 6232096.
ACCESSION AR151537
VERSION AR151537.1 GI:15117587
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Griever,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L.,
Gaines,P.J. and Silver,G.
TITLE Flea serine protease nucleic acid molecules and uses thereof
JOURNAL Patent: US 6232096-A 28 15-MAY-2001;
FEATURES
    source
        1..168
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1658 ACCTTGATAGGCATCTTCTCAAGTTAGGAATTTCTTTTGGTTTCTTGAAA 1717
Db 150 ATCAGGATAACCGACAAATCATATTTTGGGTAATTATTAGTCCTTCATTCATATAT 91
QY 1718 ATATTTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGCACGTAGTCAGTCCAGTACATAGTACCTTTACATATTCAGTTGTT 38

RESULT 180
182435/c
LOCUS AY135778S14 168 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 28 from patent US 5712143.
ACCESSION 182435
VERSION 182435.1 GI:3210732
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Griever,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and
Stiegler,G.L.
TITLE Flea protease proteins, nucleic acid molecules, and uses thereof
JOURNAL Patent: US 5712143-A 28 27-JAN-1998;
FEATURES
    source
        1..168
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1658 ACCTTGATAGGCATCTTCTCAAGTTAGGAATTTCTTTTGGTTTCTTGAAA 1717
Db 150 ATCAGGATAACCGACAAATCATATTTTGGGTAATTATTAGTCCTTCATTCATATAT 91
QY 1718 ATATTTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGCACGTAGTCAGTCCAGTACATAGTACCTTTACATATTCAGTTGTT 38

RESULT 181
HUMPRS01/c
LOCUS HUMPRS01 174 bp DNA linear PRI 08-JAN-1995
DEFINITION Human protein s pseudogene beta (PS-beta), exon 1.
ACCESSION M36565 J02918
VERSION M36565.1 GI:190309
KEYWORDS S protein.
SEGMENT 1 of 12
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

DEFINITION Sequence 28 from patent US 6232096.
ACCESSION AR151537
VERSION AR151537.1 GI:15117587
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Griever,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L.,
Gaines,P.J. and Silver,G.
TITLE Flea serine protease nucleic acid molecules and uses thereof
JOURNAL Patent: US 6232096-A 28 15-MAY-2001;
FEATURES
    source
        1..168
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 1658 ACCTTGATAGGCATCTTCTCAAGTTAGGAATTTCTTTTGGTTTCTTGAAA 1717
Db 150 ATCAGGATAACCGACAAATCATATTTTGGGTAATTATTAGTCCTTCATTCATATAT 91
QY 1718 ATATTTTCCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTTGGTT 1770
Db 90 AGTTTGCACGTAGTCAGTCCAGTACATAGTACCTTTACATATTCAGTTGTT 38

RESULT 180
182435/c
LOCUS AY135778S14 168 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 28 from patent US 5712143.
ACCESSION 182435
VERSION 182435.1 GI:3210732
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 168)
AUTHORS Griever,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and
Stiegler,G.L.
TITLE Flea protease proteins, nucleic acid molecules, and uses thereof
JOURNAL Patent: US 5712143-A 28 27-JAN-1998;
FEATURES
    source
        1..168
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 0.8%; Score 18.6; DB 1; Length 174;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 310 TCTTGCTCATTTTAACTCAGTAGTGAGTGTGTTGTTTCCATAAGTTTGAAGTT 366
Db 116 TCTTCATGATCTCTCTTCAAGATTACCTGTTGGTTCTTCAAGTAAGAAGACTT 60

RESULT 182
AY135778S1/c
LOCUS AY135778S14 189 bp DNA linear PRI 23-SEP-2002
DEFINITION Gorilla gorilla HCR (HCR) gene, exon 14.
ACCESSION AY135791
VERSION AY135791.1 GI:23296123
KEYWORDS
SEGMENT 14 of 18
SOURCE Gorilla gorilla (gorilla)
ORGANISM Gorilla gorilla
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
REFERENCE 1 (bases 1 to 189)
AUTHORS Asumalahti,K. and Kere,J.
TITLE HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
orangutan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 189)
AUTHORS Asumalahti,K. and Kere,J.
TITLE Direct Submission
JOURNAL Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
FIN-00014, Finland
FEATURES
    source
        1..189
        /organism="Gorilla gorilla"
        /mol_type="genomic DNA"
        /db_xref="taxon:9593"

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 174)
AUTHORS Ploos van Amstel,H.K., Reitsma,P.H., van der Logt,C.P. and
Bertina,R.M.
TITLE Intron-exon organization of the active human protein S gene PS
alpha and its pseudogene PS beta: duplication and silencing during
primate evolution
JOURNAL Biochemistry 29 (34), 7853-7861 (1990)
MEDLINE 91084445
PUBMED 2148111
COMMENT Original source text: Human DNA.
Draft entry and computer-readable sequence for [Biochemistry 29,
7853-4861 (1990)] kindly submitted
by H.K.Ploos van Amstel, 13-JUL-1990.
FEATURES
    source
        1..174
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /map="3p21-cen"
    prim_transcript <1..>174
    exon 11..>168
        /note="protein S pseudogene beta mRNA and introns"
        /gene="PROS2"
        /note="protein S pseudogene beta; G00-120-757"
        /number=1
        /pseudo
    exon 11..168
        /gene="PROS2"
        /note="protein S pseudogene beta, exon 1 (AA at 11);
        G00-120-757; putative"
        169..>174
        /gene="PROS2"
        /note="intron 2"

Query Match 0.8%; Score 18.6; DB 1; Length 174;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 310 TCTTGCTCATTTTAACTCAGTAGTGAGTGTGTTGTTTCCATAAGTTTGAAGTT 366
Db 116 TCTTCATGATCTCTCTTCAAGATTACCTGTTGGTTCTTCAAGTAAGAAGACTT 60

RESULT 182
AY135778S1/c
LOCUS AY135778S14 189 bp DNA linear PRI 23-SEP-2002
DEFINITION Gorilla gorilla HCR (HCR) gene, exon 14.
ACCESSION AY135791
VERSION AY135791.1 GI:23296123
KEYWORDS
SEGMENT 14 of 18
SOURCE Gorilla gorilla (gorilla)
ORGANISM Gorilla gorilla
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
REFERENCE 1 (bases 1 to 189)
AUTHORS Asumalahti,K. and Kere,J.
TITLE HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and
orangutan
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 189)
AUTHORS Asumalahti,K. and Kere,J.
TITLE Direct Submission
JOURNAL Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum,
University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki
FIN-00014, Finland
FEATURES
    source
        1..189
        /organism="Gorilla gorilla"
        /mol_type="genomic DNA"
        /db_xref="taxon:9593"
```

FEATURES
source

```

FEATURES
  source
    Location/Qualifiers
      1..241
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /clone="88a12"
        /sex="male"
        /tissue_type="blood"
        /clone_lib="CGI-1"
        /dev_stage="adult"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 241;
  Mismatches 36; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1722 TTCTCCGCTCTTACCTGCTCTTCCCTCTCTCTATTCCTTGTGTTTTCATAGTG 1781
Db 175 TTCTCCGCTCTTACCTGCTCTTCCCTCTCTCTATTCCTTGTGTTTTCATAGTG 1781

QY 1782 TCTCT 1786
Db 235 GTTT 239

RESULT 187
AX524284
LOCUS AX524284 427 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 314 from Patent EP1236798.
ACCESSION AX524284
VERSION AX524284.1 GI:25169380
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
  AUTHORS Hoefer, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
  Schluter, T.
  TITLE Gene library and method for its production
  JOURNAL Patent: EP 1236798-A 314 04-SEP-2002;
  LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

RESULT 188
AX553022
LOCUS AX553022 427 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 314 from Patent WO02074953.
ACCESSION AX553022
VERSION AX553022.1 GI:25897022
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
  AUTHORS Hoefer, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
  Schluter, T.
  TITLE Gene library and method for its production
  JOURNAL Patent: EP 1236798-A 314 04-SEP-2002;
  LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

RESULT 189
AX277349/c
LOCUS AX277349/c 439 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 7 from Patent WO0174897.
ACCESSION AX277349
VERSION AX277349.1 GI:16548914
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quinn, K.E.,
  Spytek, K.A., Rastelli, L. and Herrmann, J.L.
  TITLE Novel proteins and nucleic acids encoding same
  JOURNAL Patent: WO 0174897-A 7 11-OCT-2001;
  Curagen Corporation (US)
FEATURES
  source
    Location/Qualifiers
      1..439
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="CAD10333.1"
        /db_xref="GI:16548915"
        /translation="HGKPGVPLISNKICNHRDVGIIISPSMLCAGVLTGGVDSQ
        GDSGGPLVCQERRLWKLVGATGFGICAEVKNKPGVTVSPSPSTGTSRWRET"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 439;
  Mismatches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCTGGCAATCTTCTGGGCTCTGCTCTTCTCCCTGCTGATTCCTAGG 199
Db 174 AGCCTCTCTCTTGACACACACAGGGGCCCCCGCTGTCCTCCCTGGCAGCTGCCAG 118

RESULT 190
AX277375/c
LOCUS AX277375/c 439 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 33 from Patent WO0174897.
ACCESSION AX277375
VERSION AX277375.1 GI:16548940
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Vernet, C.A., Burgess, C.E., Fernandes, E., Taupier, R.J., Quinn, K.E.,
  Spytek, K.A., Rastelli, L. and Herrmann, J.L.
  TITLE Novel proteins and nucleic acids encoding same
  JOURNAL Patent: WO 0174897-A 7 11-OCT-2001;
  Curagen Corporation (US)
FEATURES
  source
    Location/Qualifiers
      1..439
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="CAD10333.1"
        /db_xref="GI:16548915"
        /translation="HGKPGVPLISNKICNHRDVGIIISPSMLCAGVLTGGVDSQ
        GDSGGPLVCQERRLWKLVGATGFGICAEVKNKPGVTVSPSPSTGTSRWRET"

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Schlueter, T.
Gene library and a method for producing the same
Patent: WO 02074953-A 314 26-SEP-2002;
LION Bioscience AG (DE)
FEATURES
  source
    Location/Qualifiers
      1..427
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  Best Local Similarity 0.8%; Score 18.6; DB 1; Length 427;
  Mismatches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 297 TTCTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTGAGTTGTTGGTTTCCATAAG 356
Db 115 TTCTGCTCTTAAGGAGACACCCCTTTCCCAATGTAAGTGAATCCATTGAGGTAG 174

QY 357 TTGTGAAGTTTCTGTGTTCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 393
Db 175 CTCCACATTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 211

```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Vernet,C.A., Burgess,C.E., Fernandes,E., Taupier,R.J., Quinn,K.E.,
Spytek,K.A., Rastelli,L. and Herrmann,J.L.
TITLE Novel proteins and nucleic acids encoding same
JOURNAL Patent: WO 0174897-A 33 11-OCT-2001;
Curagen Corporation (US)
FEATURES
source
Location/Qualifiers
1..439
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 439;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCGCAATCTCTGGGCTGCTGCTTCTCCCTGCTGATTCCTAGG 199
|||||
Db 174 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGCTCCCTGGCAGCTGCCAG 118

RESULT 191
MACCFX/c 484 bp DNA linear PAT 05-FEB-1999
LOCUS Rhesus monkey gene for coagulation factor X, partial cds.
DEFINITION
ACCESSION D21214
VERSION D21214.1 GI:415307
KEYWORDS coagulation factor X.
SOURCE Macaca mulatta (rhesus monkey)
ORGANISM
Macaca mulatta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopitheciidae;
Cercopitheciinae; Macaca.
1 (bases 1 to 484)
Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
Niho,Y.
TITLE Analysis of the partial nucleotide sequences and deduced primary
structures of the protease domains of mammalian blood coagulation
factors VII and X
JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE 94222160
PUBMED 8168596
REFERENCE
2 (bases 1 to 484)
Murakawa,M.
Direct Submission
TITLE Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
JOURNAL Submitted (18-Oct-1993) to DDBJ by:
Masahiro Murakawa
Division of Hematology
Harasanshin General Hospital
1-8 Taihaku-machi, Hakata-ku
Fukuoka, Fukuoka 812
Japan
Phone: 092-291-3434
Fax : 092-291-3266.
FEATURES
source
Location/Qualifiers
1..484
/organism="Macaca mulatta"
/mol_type="genomic DNA"
/db_xref="taxon:9544"
<1..>484
/codon_start=2
/product="coagulation factor X"
/protein_id="BA04755.1"
/db_xref="GI:455395"
/translation="EGGEAVHEVVIKHNFTKETYDPDIIVLRKSLPTERMNVAP
ACLPKRDWAEIITLTKTIGVSGFTRHKGQSTRLKMLEVYVDNRNSCKLSSEFII
TQNMFCAGYHAKQEDACQSGSGPHVTRFKDTYFVTGIVSWGEGCARKKGIYIKTV
A"
CDS

Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAGCTGTGGTGGTC 418
|||||
Db 351 TGTTCCTGGTGATGATGAAGCTGCTGGAGAGCTTGACAGCTGTTCGGGTC 303

RESULT 192
AX775014/c 546 bp DNA linear PAT 09-JUL-2003
LOCUS AX775014
DEFINITION Sequence 330 from Patent WO03038129.
ACCESSION AX775014
VERSION AX775014.1 GI:32486530
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Raponi,M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 03038129-A 330 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)
FEATURES
source
Location/Qualifiers
1..546
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 546;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 143 AGCCTCTGCTGGCAATCTCTGGGCTCTCTGCTTCCTCCCTGCTGATTCCTAGG 199
|||||
Db 336 AGCCTCTCTCTTGACACACACAGGGGGCCCCCGCTGCTCCCTGGCAGCTGCCAG 280

RESULT 193
AX335885/c 624 bp DNA linear PAT 09-JAN-2002
LOCUS AX335885
DEFINITION Sequence 6394 from Patent WO0194629.
ACCESSION AX335885
VERSION AX335885.1 GI:18126604
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Young,P.E., Augustus,M., Carter,K.C., Ebner,R., Endress,G.,
Horrigan,S., Soppet,D.R. and Weaver,Z.
TITLE Cancer gene determination and therapeutic screening using signature
gene sets
JOURNAL Patent: WO 0194629-A 6394 13-DEC-2001;
Avalon Pharmaceuticals (US)
FEATURES
source
Location/Qualifiers
1..624
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAGCTGTGGTGGTC 418
|||||
Db 351 TGTTCCTGGTGATGATGAAGCTGCTGGAGAGCTTGACAGCTGTTCGGGTC 303
```

```
RESULT 194
HUMFX8/c
LOCUS
DEFINITION Human factor X (blood coagulation factor) gene, exon 8.
ACCESSION L29433.1
VERSION L29433.1 GI:459809
KEYWORDS Stuart factor; blood coagulation factor; factor X; glycoprotein;
serine protease.
SEGMENT
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 624)
AUTHORS Leytus S.P., Foster D.C., Kurachi K. and Davie E.W.
TITLE Gene for human factor X: a blood coagulation factor whose gene
organization is essentially identical with that of factor IX and
protein C
JOURNAL Biochemistry 25 (18), 5098-5102 (1986)
MEDLINE 87026600
PUBMED 3768336
COMMENT Original source text: Homo sapiens (tissue library: of Lawn et al.,
and Yoshitake et al.) DNA.
matp + 13 + 458 factor Xa heavy chain.
FEATURES
source
1..624
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="13q34"
/tissue_lib="of Lawn et al., and Yoshitake et al."
Join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,
L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,
L00396.1:13..130,13..614)
/notes="preprofactor X"
/codon_start=1
/product="coagulation factor X"
/protein_id="AAA52764.1"
/db_xref="GI:182831"
/translation="MRPLHLVLLSLAGLLGLLGLSFLRREQNNILARVTRANSF
LEMKKGLHRECMETCSYEAREVFEDSKTNFKNKYKDGQDCETSPCQNGKCK
DLGLEYTCLEGFEGKNCLEFLFRKLSLNDGCDQFCHBEQSNVVCARGVTLADN
GKACIPGYPCKQTLERRKRSVAQATSSGEAPDSITWKPYDAADLDPTENPFDLL
DFNQTPQERDNNLIRIVGQCKDCGCPQWALLINEEGFCGGTILSEFYLLTAHH
CLYQARFRVGRDNRTEQEGEAEVHEVVKHNRFTKETVDPIALRLKTPTF
RMNVAPACILPERDVAETLMTQKTGIVSGFGRTHKGRQSTRLMLEVPYVDRNSCKL
SSSFILIQMFCGIDYTKQEDACQDGGSGPHVTFRKDTYFVTGIVSWGEGCARKGKYG
IYKVTAFLLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"
Join(L00395.1:157..257,L00396.1:13..130,13..458)
/product="coagulation factor X"
/notes="factor X light chain"
mat_peptide
459..611
/product="activation peptide"
intron
<1..12
/notes="FX intron G"
exon
13..624
/notes="FX"
/number=8
Query Match 0.8%; Score 18.6; DB 1; Length 624;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTTCGTTGTTGTTGTTGTTATCTAGATTAAAGTCGTGGTC 418
Db 351 TGTCTGGGTGATGATGAAGCTCTCGACAGCTTGCAGCTGTTGCGGTC 303
RESULT 195
BD173590/c
LOCUS
DEFINITION Novel serine protease MP493.
ACCESSION BD173590
VERSION BD173590
KEYWORDS Novel serine protease MP493.
SEGMENT
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 711)
AUTHORS Nakamura Y., Sugano S., Matsusue T., Okamoto A. and Okawa K.
TITLE Novel serine protease MP493
JOURNAL MOCHIDA PHARMACEUTICAL CO LTD, YUSUKE NAKAMURA, SUMIO SUGANO,
TOMOKAZU MATSUSUE, ATSUSHI OKAMOTO, KAZUFUMI OKAWA
COMMENT OS Homo sapiens (human)
PN WO 02059295-A/3
PD 01-AUG-2002
PF 23-JAN-2002 WO 2002JP000465
PI 23-JAN-2001 JP 01P 014963
PI YUSUKE NAKAMURA, SUMIO SUGANO, TOMOKAZU MATSUSUE, ATSUSHI
OKAMOTO,
PI KAZUFUMI OKAWA
PC C12N15/09; C12N15/12, C12N9/64, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C07K16/40,
PC C12Q1/02
CC Novel serine protease MP493
FH Key Location/Qualifiers
FT source
1..711
Location/Qualifiers
/organism="Homo sapiens (human)"
source
1..711
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.6; DB 1; Length 711;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 143 AGCCTCTGCTGCAATACATCTCTGGGCTGCTGCTCTCTCCCTGCTGATCTCAGG 199
Db 594 AGCCTCTCTCTTGACACACACAGGGGCCCCCGCTGCTCCCTGGCAGCTGTCCACG 528
RESULT 196
AX827818/c
LOCUS
DEFINITION Sequence 552 from Patent EP1344834.
ACCESSION AX827818
VERSION AX827818.1 GI:39838006
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE
1
AUTHORS Boess F., Suter-Dick L. and Wolf D.
TITLE Methods for the toxicity prediction of a compound
JOURNAL Patent: EP 1344834-A 552 17-SEP-2003;
F. HOFFMANN-LA ROCHE AG (CH)
FEATURES
source
1..773
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"
Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
QY 1658 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGTGTTTCTTGAAA 1717
Db 315 AGCTTCATCAGCATGATGTCATGTTTCAGGGTCTTCTCTATCGAAGTTGGATGCTTGATG 256
```

```
VERSION BD173590.1 GI:28414921
KEYWORDS WO 02059295-A/3.
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 711)
AUTHORS Nakamura Y., Sugano S., Matsusue T., Okamoto A. and Okawa K.
TITLE Novel serine protease MP493
JOURNAL MOCHIDA PHARMACEUTICAL CO LTD, YUSUKE NAKAMURA, SUMIO SUGANO,
TOMOKAZU MATSUSUE, ATSUSHI OKAMOTO, KAZUFUMI OKAWA
COMMENT OS Homo sapiens (human)
PN WO 02059295-A/3
PD 01-AUG-2002
PF 23-JAN-2002 WO 2002JP000465
PI 23-JAN-2001 JP 01P 014963
PI YUSUKE NAKAMURA, SUMIO SUGANO, TOMOKAZU MATSUSUE, ATSUSHI
OKAMOTO,
PI KAZUFUMI OKAWA
PC C12N15/09; C12N15/12, C12N9/64, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C07K16/40,
PC C12Q1/02
CC Novel serine protease MP493
FH Key Location/Qualifiers
FT source
1..711
Location/Qualifiers
/organism="Homo sapiens (human)"
source
1..711
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.6; DB 1; Length 711;
Best Local Similarity 57.9%; Pred. No. 2.1e+02;
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 143 AGCCTCTGCTGCAATACATCTCTGGGCTGCTGCTCTCTCCCTGCTGATCTCAGG 199
Db 594 AGCCTCTCTCTTGACACACACAGGGGCCCCCGCTGCTCCCTGGCAGCTGTCCACG 528
RESULT 196
AX827818/c
LOCUS
DEFINITION Sequence 552 from Patent EP1344834.
ACCESSION AX827818
VERSION AX827818.1 GI:39838006
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE
1
AUTHORS Boess F., Suter-Dick L. and Wolf D.
TITLE Methods for the toxicity prediction of a compound
JOURNAL Patent: EP 1344834-A 552 17-SEP-2003;
F. HOFFMANN-LA ROCHE AG (CH)
FEATURES
source
1..773
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"
Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. No. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
QY 1658 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGTGTTTCTTGAAA 1717
Db 315 AGCTTCATCAGCATGATGTCATGTTTCAGGGTCTTCTCTATCGAAGTTGGATGCTTGATG 256
```

Qy	1718	ATATTTCCTCGCTTTTGACCTGCTCTTCCCTCTCTATCTCTTGTTTGGTTTTCAT	1777
Db	255	ATCTTGGCAGCATTTGACAACTGCTCATGCCCTCAAGACATGTATGTTGTGCTCTCCC	196
Qy	1778	AGTGCTCTCGGCTTCTCGGATGTTT	1802
Db	195	AGTCTCACTTGGATGCGGACTTAT	171

RESULT	197
RNTRY2/c	
LOCUS	RNTRY2
DEFINITION	Rat mRNA encoding pancreatic trypsinogen II.
ACCESSION	V01274
VERSION	V01274.1 GI:57410
KEYWORDS	complementary DNA; signal peptide; trypsin.
SOURCE	Rattus norvegicus (Norway rat)
ORGANISM	Rattus norvegicus Eukaryota; Metazoa; Mammalia; Eutheria; Rodentia; Sciuromorphi; Muridae; Murinae;
	Rattus

REFERENCE
1 (bases 1 to 773)
AUTHORS
MacDonald, R. J., Stary, S. J. and Swift, G. H.
TITLE
Two similar but nonallelic rat pancreatic trypsinogens. Nucleotide
sequences of the cloned cDNAs
J. Biol. Chem. 257 (16), 9724-9732 (1982)
JOURNAL
MEDLINE
82265624
6996710
EJMED

```

FEATURES             Location/Qualifiers
     1..773
         /organism="Rattus norvegicus"
         /mol_type="mRNA"
         /db_xref="taxon:10116"
     <1..773
         /product="messenger RNA"
     <1..718
         /note="unnamed protein product; trypsinogen (1 is 3rd base
         in codon)"

```

```

/codon_start=2
/protein_id="CAA24581.1"
/db_xref="GI:758266"
/db_xref="GOA:P00763"
/db_xref="SWISS-PROT:P00763"
/translation="LVGAAYAFVDDDDKIVGVTVCOENSVFYQVLSNSGVHFCGSL
INDQWVSAACHYKSRIVQRLEGHNVLEGNQFVNAAKIIKHPNEDRKLNNIDMI
IKLSPPYKLNARVATVLPSCAPAFQTLKSGWNTLSGVEPDFLLQCLDAPLPPQ
ADCEASYFGKTIIDNVVCVFLGEGKDSQQGSDSGVFCVNGCBLQIVSGWGYGCAIPDNF

```

```
sig_peptide      GVTKVCNYVDWIQDTIAAN"
                  <1..25
                  /note="signal peptide"
polyA_site       773
                  /note="polyA addition site"
```

Query Match 0.8%; Score 18.6; DB 1; Length 773;
Best Local Similarity 45.5%; Pred. NO. 2.1e+02;
Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;

QY	1658	ACCTGATAGGCATCTCTTTCTCAAGGTTAGGAAATTTTCTTTTTGGTTTTCTTTGAAA	17117
DB	315	AGCTTGATCAGCATGATGTCATGTTTCAGGTCCTTCTCATCGAAGTTGGATGCTTGATG	256

Qy ATATTTCCTCGTTTGACCTGCGTCTTCCGCTCCTCATTTGCCTTGTTTTGGCAT 1777
 |||||
Dd ATCTTGGGAGATTACAAACTGTCTCATTTGCCCTCAAGGACATTTGCTGTCTCCC 196
 |||||

QY	1778	AGTGCTCTGGCTTCTCTGGATGTTT	1802
Dh	195	AGTCTACCTTGGATCGGGACTTAT	171

LOCUS	DOGTYPYA	819 bp	mRNA	linear	MAN 27-APR-1995
RESULT 198					
DOGTYPYA					
LOCUS					

DEFINITION	Dog pancreatic anionic trypsinogen mRNA.
ACCESSION	M11589
VERSION	M11589.1
KEYWORDS	GI:164094
SOURCE	Canis sp.
ORGANISM	Canis sp.
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

REFERENCE	AUTHORS	TITLE	JOURNAL
1 (bases 1 to 819)	Pinsky, S. D., LaForge, K. S. and Scheele, G.	Differential regulation of trypsinogen mRNA translation: full-length mRNA sequences encoding two oppositely charged trypsinogen isoenzymes in the dog pancreas	Mol. Cell. Biol. 5 (10), 2659-2676 (1985)

MEDLINE	86284628	
PUBMED	3841794	
COMMENT	Original	source text: Dog pancreas, cDNA to mRNA, clone pT1.
FEATURES	Location/Qualifiers	
source	1..819	

```

/organism="Canis sp."
/mol_type="mRNA"
/db_xref="taxon:9616"
1. .819
/product="anionic trypsinogen mRNA"
15. .758
/notes="anionic trypsinogen precursor"
/codon_start=1
/protein_id="AAA30899.1"
/db_xref="GI:164095"
/translation="MNPILLILFLGRAVATPTDDDKIYGGVTCENSVPYOVSLNAG
YHFCGSLSDQWVFAAHCKYRIQVRLEGEYNIDLENGEINISAKVIRHNNYSW
ILDNDIMLILKSSPAVLNARVATISLPRACAEPTQCLISGNGNTSSGNTYPELLQC
LDAPILTAQCEASYPGQITENNICKAFLEGKDGKSDCGDGGGVPWCNGELQIGIVSWG
GCAPKKEGTYTKVCNFDVNTOSTIAANS"

```

Query Match 0.8%; Score 18.6; DB 1; Length 813;
 Best Local Similarity 50.6%; Pred. No. 2.1e+02;
 Matches 45; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 882 GCTTGCTTCTTAGGGCAATTTGCTTAGAATACTTTTTCCATCCTTTTACTCTTAAGGTGAT 941

531 GCTTCATTGCCCGGGCGGCTCATGGGAATGCATCATTTTGGCGGCTTCTTCGSGGAGCC 590

DB 6CTCTATCATCGGTAGGTTGCTCTTTTGG 970
QY 942 GTCTATCATCGGTAGGTTGCTCTTTTGG 970
DB 591 AAGGACTCTGCCAGGTGACTCTGGTGG 619
DB 531 GCTCTCTATCATCGGTAGGTTGCTCTTTTGG 970

RESULT 199
PUTRYPESIN

LOCUS PVRVPSIN 854 bp
LINEAR
mRNA
INV 01-OCT-1995

SOURCE	ORGANISM
Litopenaeus vannamei (Pacific white shrimp)	
Litopenaeus vannamei	
Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;	
Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;	

Penaeidae; Litopenaeus.
1

REFERENCE
AUTHORS
Klein,B., Le Moullac,G., Sellos,D. and Van Wormhoudt,A.
TITLE
Molecular cloning and sequencing of trypsin cDNAs from penaeus
monodon (Crustacea: Decapoda): use in assessing gene expression

JOURNAL
MEDLINE
96252881
PUBMED 8697100

2 (bases 1 to 854)
 Van Wormhoudt, A.E.
 Direct Submission
 Submitted (18-APR-1995) A.E. Van Wormhoudt, College de France /
 CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,
 FRANCE

LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M. and Eibl, J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Patent: WO 9838317-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/translation="MGRPLHLVLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKKGHLRECEMTCSEAEAREVFEDSKTNEFNKYNKDGOCETSPCONQKCK
DGLGYCTCLGEGKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPFGPKQTLERKRSVAQATSSGSEAPDSITWKPYDAADLPDENPFDLL
DFNQTPGRGNLITRIVGGQCKGCEPQWALLINEENEGCGTLLSEFYLITAAH
CLYQAKRFVVRGDRNTEQEGEAVEVVEVVKHNRFTKETDYDFDIARLKTPTIF
RMVAPACLPERDWAESTLMTQKTVISGFGRTHEKGRQSTRKMLEVYPVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDSGGPHVTRPKDVFVTVGIVSWGESCARKGYG
IYTKVTAFLKWDIDSMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.8%; Score 18.6; DB 1; Length 1443;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1170 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1122
RESULT 202
A86859/c
LOCUS A86859 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 43 from Patent WO9838318.
ACCESSION A86859
VERSION A86859.1 GI:6735650
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Falkner, F. and Himmelspach, M.
TITLE FACTOR X DELETION MUTANTS AND ANALOGUES THEREOF
JOURNAL Patent: WO 9838318-A 43 03-SEP-1998;
FALKNER FALKO GUENTER (AT); HIMMELSPACH MICHELE (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69367.1"
/db_xref="GI:6735651"
/translation="MGRPLHLVLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKKGHLRECEMTCSEAEAREVFEDSKTNEFNKYNKDGOCETSPCONQKCK
DGLGYCTCLGEGKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPFGPKQTLERKRSVAQATSSGSEAPDSITWKPYDAADLPDENPFDLL
DFNQTPGRGNLITRIVGGQCKGCEPQWALLINEENEGCGTLLSEFYLITAAH
CLYQAKRFVVRGDRNTEQEGEAVEVVEVVKHNRFTKETDYDFDIARLKTPTIF
RMVAPACLPERDWAESTLMTQKTVISGFGRTHEKGRQSTRKMLEVYPVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDSGGPHVTRPKDVFVTVGIVSWGESCARKGYG
IYTKVTAFLKWDIDSMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 203
A86886/c
LOCUS A86886 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION A8316969
VERSION A8316969.1 GI:33696092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M., Pfeleiderer, M., Falkner, F.-G., Eibl, J., Dörner, F. and Schlokat, U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: US 6562598-A 43 13-MAY-2003;
FEATURES
source
1..1467
/organism="unknown"
/mol_type="mRNA"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 203
A86886/c

LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M. and Eibl, J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Patent: WO 9838317-A 26 03-SEP-1998;
HIMMELSPACH MICHELE (AT); EIBL JOHANN (AT)
FEATURES
source
1..1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1..1467
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/translation="MGRPLHLVLSASLAGLLLSGLFIRREQANNILARVTRANSF
LEEMKKGHLRECEMTCSEAEAREVFEDSKTNEFNKYNKDGOCETSPCONQKCK
DGLGYCTCLGEGKNCLEFTRKLCSLDNGDCDFCHEONSVVCSARGVTLADN
GKACIPFGPKQTLERKRSVAQATSSGSEAPDSITWKPYDAADLPDENPFDLL
DFNQTPGRGNLITRIVGGQCKGCEPQWALLINEENEGCGTLLSEFYLITAAH
CLYQAKRFVVRGDRNTEQEGEAVEVVEVVKHNRFTKETDYDFDIARLKTPTIF
RMVAPACLPERDWAESTLMTQKTVISGFGRTHEKGRQSTRKMLEVYPVDRNSCKL
SSSFIITQMFACAGYDTKQEDACQDSGGPHVTRPKDVFVTVGIVSWGESCARKGYG
IYTKVTAFLKWDIDSMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 204
A8316969/c
LOCUS A8316969 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION A8316969
VERSION A8316969.1 GI:33696092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach, M., Pfeleiderer, M., Falkner, F.-G., Eibl, J., Dörner, F. and Schlokat, U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: US 6562598-A 43 13-MAY-2003;
FEATURES
source
1..1467
/organism="unknown"
/mol_type="mRNA"

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 205
A86886/c

Query Match 0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 370 TGTGTTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 418
DB 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 1156
RESULT 205
A86886/c

```

AR340866/c
LOCUS       AR340866               1467 bp    mRNA          linear          PAT 17-AUG-2003
DEFINITION   Sequence 26 from patent US 6573071.
ACCESSION   AR340866
VERSION     AR340866.1  GI:33732713
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 1467)
AUTHORS     Himmelspach,M., Schlokot,U., Dornier,F., Fisch,A. and Eibl,J.
TITLE       Factor X analogues with a modified protease cleavage site
JOURNAL     Patent: US 6573071-A 26 03-JUN-2003;
FEATURES
source      1. .1467
/mol_type="mRNA"
/mol_type="unknown"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGGTC 418
      |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 206
AX082959/c
LOCUS       AX082959               1467 bp    DNA          linear          PAT 28-FEB-2001
DEFINITION   Sequence 1 from Patent WO0110896.
ACCESSION   AX082959
VERSION     AX082959.1  GI:13184880
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE       Himmelspach,M. and Schlokot,U.
JOURNAL     Factor X analog with an improved ability to be activated
            Patent: WO 0110896-A 1 15-FEB-2001;
            Baxter Aktiengesellschaft (AT)
FEATURES
source      1. .1467
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGGTC 418
      |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 207
BD070392/c
LOCUS       BD070392               1467 bp    DNA          linear          PAT 27-AUG-2002
DEFINITION   Factor X-analogues with modified protease cleavage site.
ACCESSION   BD070392
VERSION     BD070392.1  GI:22615995
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1 (bases 1 to 1467)
AUTHORS     Himmelspach,M., Schlokot,U., Dornier,F., Andreas, Fisch and Eibl,J.
TITLE       Factor X-analogues with modified protease cleavage site
JOURNAL     Patent: JP 2001513631-A 26 04-SEP-2001;
            BAXTER AG

```

```

COMMENT      OS Unidentified
PN JP 2001513631-A/26
PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537062
PR 27-FEB-1997 AT A 335/97
PI MICHELE HIMMELSPACH,UWE SCHLOKAT,FRIEDRICH DORNER,ANDREAS FI
FISCH,JOHANN EIBL
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X-analogues with modified protease cleavage site FH
Key Location/Qualifiers
FT CDS 1..1467.
source      1. .1467
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGGTC 418
      |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 208
BD070435/c
LOCUS       BD070435               1467 bp    DNA          linear          PAT 27-AUG-2002
DEFINITION   Factor X deletion mutants and analogues thereof.
ACCESSION   BD070435
VERSION     BD070435.1  GI:22616038
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 1467)
AUTHORS     Himmelspach,M., Pfeleiderer,M., Falkner,F.G., Eibl,J., Dornier,F. and
            Schlokot,U.
TITLE       Factor X deletion mutants and analogues thereof
JOURNAL     Patent: JP 2001513632-A 43 04-SEP-2001;
            BAXTER AG
COMMENT      OS Unidentified
PN JP 2001513632-A/43
PD 04-SEP-2001
PF 27-FEB-1998 JP 1998537063
PR 27-FEB-1997 AT A 336/97
PI MICHELE HIMMELSPACH,MICHAEL PFLEIDERER,FALKO GUNTER FALKNER,
FISCH,JOHANN EIBL,
PC C12N15/57,C12N9/64,A61K38/48
CC Strandedness: Single;
CC Topology: Linear;
CC Factor X deletion mutants and analogues thereof FH
Key Location/Qualifiers
FT CDS 1..1467.
source      1. .1467
/mol_type="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match      0.8%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 370 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAAAGCTGTGGTGGTC 418
      |||||
Db 1204 TGTTCGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGGTC 1156

```

RESULT 209
AF191307/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Sus scrofa (pig)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
1 (bases 1 to 1514)
Grimm,D.R., Colter,M.B. and Kim,H.
Cloning of the complete cDNA sequences encoding porcine factor V
and protein C
Unpublished
2 (bases 1 to 1514)
Grimm,D.R., Colter,M.B. and Kim,H.
Direct Submission
Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
North Pine Drive, Tampa, FL 33612, USA
Location/Qualifiers
1..1514
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="92N.4; 58/86.2; 12N3.1"
/tissue_type="liver"
22..1401
/note="serine protease"
/codon_start=1
/product="protein C"
/protein_id="AAG28380.1"
/db_xref="GI:11065894"
/translation="MWOLASLLILLIIWVSTPPVPPSSORAHOMLSKRANS
FLEELRPSLEKEETCDREARELFONTENTWAFMSKYHDGQCAVPPPEHLCD
PCGGRTGIDHGGFCDCQAGWEGFCLHEVRFNCSTENGCGCAHYCLEESGGRCA
CAPGYLDHDIQCEPKVSPCQRLNGRKKRDKRDIDQDKEDQIDPRLVNGK
QSPWGESPWQVILLDSKKLACGAVLIHVSWLTAHCLDDYKLTFRIGVYDLRRRE
KWEVDIDKEFLVHNTRYTSNDNIALRLAEPATFSQTIPIICLPDSGLSERLTR
VQGETVTGWSVRSKATNRKSFILNFVKVPVAPHNECVQAMENKISENNMLCAGILGDS
RDACGDSGSPVASFRTGFWLVLVGLVSGEGGRLHNYGVYTKVSYLDWIRHME
EAFHNQVP"
Query Match 0.8%; Score 18.6; DB 1; Length 1514;
Best Local Similarity 51.9%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
CDS
QY 1960 CAGATTTCCTCAGTTGGGTTTGTATTATTTCTATTTCCACTTTCAGGCTCCTGAAA 2019
DB 657 CGGATCTATTGTCTCTTTTGTCAACTGGTCTGTATCAGCTTCAAGTTCTTGG 598
QY 2020 TGTTTTACTCATTTCTCTCC 2040
DB 597 TTCTTCTCATGCGATTCCC 577
RESULT 210
HUMKALR4
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SEGMENT
SOURCE
ORGANISM
Human renal kallikrein, exon 4.
M33108
M33108.1 GI:186648
kallikrein; kininogenase.
4 of 5
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 193)
Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N.,
Nakanishi,S., Callen,D.F., Baker,E., Hyland,V.J., Sutherland,G.R.
and Richards,R.I.
Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTGTAGGTCCTCGTTGGGTTCTTAATTTTTCATTTCCAGATTCTTCAGTTTG 1977

TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT
FEATURES
source
Structure and chromosomal localization of the human renal
kallikrein gene
Biochemistry 27 (9), 3124-3129 (1988)
88269498
2898948
Original
Location/Qualifiers
1..193
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="19q13.3"
prim_transcript <1..>193
/gene="KLK1"
/note="kallikrein mRNA and introns"
intron <1..>29
/gene="KLK1"
/note="kallikrein intron C"
exon 30..166
/gene="KLK1"
/note="C00-120-118"
intron number=4
167..>193
/gene="KLK1"
/note="kallikrein intron D"
Query Match 0.8%; Score 18.4; DB 1; Length 193;
Best Local Similarity 69.4%; Pred. No. 2.3e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1944 TTAATTTTTCATTTCCAGATTCTTCAGTTGGG 1979
DB 23 TTCGTAGTCTCATTTCCAGATCATCCAGTGTGTG 58
RESULT 211
HUMDPB1A/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Human DPB1 protein gene, partial cds.
M77674
M77674.1 GI:181735
DPB1 protein.
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 249)
Gao,X., Veale,A. and Serjeantson,S.
AB1: a novel HLA-DPB1 allele found in one third of an Australian
population
Immunogenetics 36 (1), 64-66 (1992)
92267574
1587554
Original
Location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
/cell_type="lymphocyte"
/tissue_type="blood"
1..249
/gene="HLA-DPB1"
misc_feature 1..249
/gene="HLA-DPB1"
/note="G00-120-636"
Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTGTAGGTCCTCGTTGGGTTCTTAATTTTTCATTTCCAGATTCTTCAGTTTG 1977

Db 218 TTGTCTGCACATCTGTCGGCAGCTGCCCGCTTCTCCTCCAGGATGCTCTTGGCTG 159

RESULT 212
HUMDPBA/c
LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK1.
DEFINITION D10478
ACCESSION D10478.1 GI:219604
VERSION HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
KEYWORDS histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE 93053849
PUBMED 1358867
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsunaga,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.

FEATURES
source
1. .249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THKK"
/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK1"
/cell_type="peripheral blood mononuclear cell"
1. .249
/gene="DPB1"
<1. .>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01281.1"
/db_xref="GI:219604"
/translation="LFGQKQECVPFNGTQRFLELYLNREELVRPDSVGEFRAVTEL
GRPEAYWNSQKIDLEEKRAVPDRMCRHNYELDEAVTLQ"
1. .249
/gene="DPB1"
/number=2
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cctccccgcagagaattac"
249
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgaggct"

Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTCAGGTTCTGTTGGGTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTG 1977

Db 218 TTGTCTGCACATCTGTCGGCAGCTGCCCGCTTCTCCTCCAGGATGCTCTTGGCTG 159

RESULT 213
HUMDPBB/c
LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK2.
DEFINITION D10479
ACCESSION D10479.1 GI:219606
VERSION HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
KEYWORDS histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K.,
Akaza,T., Mitomi,Y. and Juji,T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with
HLA-DR/DQ and two 'new' alleles
JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE 93053849
PUBMED 1358867
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsunaga,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DDBJ by:
Katsushi Tokunaga
Dept. of Transfusion Medicine and
Immunohematology, Faculty of Medicine
The University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.

FEATURES
source
1. .249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THMI"
/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK2"
/cell_type="peripheral blood mononuclear cell"
1. .249
/gene="DPB1"
<1. .>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01282.1"
/db_xref="GI:219607"
/translation="VVLQECYAEVNGTQRFLELYLNREELVRPDSVGEFRAVTEL
GRPEAYWNSQKIDLEEKRAVPDRMCRHNYELDEAVTLQ"
1. .249
/gene="DPB1"
/number=2
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cctccccgcagagaattac"
249
old_sequence 1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgaggct"

Query Match 0.8%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
QY 1918 TTGTCTCAGGTTCTGTTGGGTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTG 1977

Db 218 TTGTCCTGCACATCCTCTCCGGCACTGCCCGCTTCTCCTCCAGATGTCCTCTCGCTG 159

RESULT 214
HUMHDPBH/c
LOCUS Human MHC class II HLA DP-beta gene, exon 2 allele DPB5. PRI 07-JAN-1995
DEFINITION Human MHC class II HLA DP-beta gene, exon 2 allele DPB5.
ACCESSION M23680
VERSION 1 GI:188070
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 249)
AUTHORS Bugawan,T.I., Horn,G.T., Long,C.M., Mickelson,E., Hansen,J.A., Ferrara,G.B., Angelini,G. and Erlich,H.A.
TITLE Analysis of HLA-DP allelic sequence polymorphism using the in vitro enzymatic DNA amplification of DP-alpha and DP-beta loci
J. Immunol. 141 (11), 4024-4030 (1988)
MEDLINE 89035547
PUBMED 2460556
COMMENT Original source text: Human DNA allele DPB5.
FEATURES
source
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1..249
/gene="HLA-DPB1"
1..249
/gene="HLA-DPB1"
/note="MHC DP-beta, allele DPB5"
/number=2
/codon_start=1
/protein_id="AAA59745.1"
/db_xref="GI:188071"
/db_xref="GDB:G00-120-636"
/translation="LFQHQECYAFNGTQFLERYIYRNEELVRFDSVGFRAVTEL
GREAEVWNSQKILEKRAVPDRMCRHNYELDEAVTLQ"
Query Match 0.88; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.74; Pred. No. 2.3e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1918 TTGTCCTGAGGTTCCGTGGGTCTTAATTTTTCATTTCCAGATTTCTTCAGTTTG 1977
Db 218 TTGTCCTGCACATCCTCTCCGGCACTGCCCGCTTCTCCTCCAGATGTCCTCTCGCTG 159

RESULT 215
HUMHDPBH/c
LOCUS Human MHC class II HLA DP-beta (allele DPB5), partial cds.
DEFINITION Human MHC class II HLA DP-beta (allele DPB5), partial cds.
ACCESSION M62333
VERSION M62333.1 GI:188026
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane glycoprotein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 256)
AUTHORS Bugawan,T.I., Begovich,A.B. and Erlich,H.A.
TITLE Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes
Immunogenetics 32 (4), 231-241 (1990)
MEDLINE 91055805
PUBMED 2242906
COMMENT Original source text: Human DNA allele DPB5.

```

/gene="HLA-DPB1"
/number=2

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 257;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCTCTGAGTTCCTGTTGGGTCTTAATTTTTCATTTCCAGATTCTCTCAGTTTG 1977
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dd 226 TTGTGTTGACATCTCTGTCGGCACTGCCGCTTCTCTCCAGGATGCTCTTCTGGCTG 167
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 217
HUMDPB1KT/c
LOCUS HUMDPB1KT 264 bp DNA linear PRI 14-APR-2000
DEFINITION Human MHC classII HLA-DPB1 gene allele DPB1*KT.
ACCESSION D10882
VERSION D10882.1 GI:219602
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral
membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 264)
AUTHORS Ogawa,K., Itho,H., Nakajyo,S., Kobayashi,K., Sekiguchi,S.,
Koshizaka,T., Taguchi,M., Onishi,H., Kobayashi,S. and Inoko,H.
TITLE A novel HLA-DPB1 allele, DPB1*3601 (DPB1*KT)
JOURNAL Tissue Antigens 44 (2), 134-136 (1994)
MEDLINE 95117110
PUBMED 7817379
REFERENCE 2 (bases 1 to 264)
AUTHORS Koshizaka,T.
TITLE Direct Submission
JOURNAL Submitted (06-APR-1992) Takuya Koshizaka, Sumitomo Metal
Industries, Ltd.; 14-15 Kobuchi 2-chome, Sagamihara, Kanagawa 229,
Japan (Tel:0427-51-7568, Fax:0427-51-7519)
COMMENT Submitted (06-APR-1992) to DDBJ by:
Takuya Koshizaka
Sumitomo Metal Industries, Ltd.
14-15 Kobuchi 2-chome
Sagamihara, Kanagawa 229
Japan
Phone: 0427-51-7568
Fax: 0427-51-7519.
Location/Qualifiers
1. .264
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1..>264
/codon_start=3
/product="HLA-DPB1"
/protein_id="BAA01704.1"
/db_xref="GI:219603"
/translations="NTVIQRQCYAFNGTQRFERYIYNREELVRFSDVGEFRAV
ELGRPEAYMNSQKILEKRAVPDRVCRHNYELDEAVTIQR"
1. .264
/number=2

exon

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 264;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCTCTGAGTTCCTGTTGGGTCTTAATTTTTCATTTCCAGATTCTCTCAGTTTG 1977
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dd 226 TTGTGTTGACATCTCTGTCGGCACTGCCGCTTCTCTCCAGGATGCTCTTCTGGCTG 167
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 218
AF306907
LOCUS AF306907 279 bp DNA linear VRT 23-JAN-2001
DEFINITION Brachyramphus marmoratus haplotype MMC ribosomal protein 40 gene,

```

REFERENCE 2 (bases 1 to 283)

```
/gene="HGA-DPBT"
```

```

CDS
    /product="MHC class II antigen"
    <20..>283
    /gene="HLA-DPB1"
    /codon_start=3
    /product="MHC class II antigen"
    /protein_id="AA084763.1"
    /db_xref="GI:29422765"
    /translation="NYVQLQESYAFNGTQFLERYIYNRELVRFDSDVGEFRAVT
    ELGRPEAEYWNQKDIIEKRAVPDRMCRHNVELDAVTLQRR"
    exon
        20..283
        /gene="HLA-DPB1"
        /number=2

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 285;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCCTCAGGTCCTGGTGGGTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTTG 1977
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGACATCCTGTCGCGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGCTG 186

RESULT 223
HUMHDPBZ/c
LOCUS HUMHDPBZ 285 bp DNA linear PRI 13-JUL-1993
DEFINITION Human MHC HLA-DPB1 gene, exon 2, clone DPB new A.
ACCESSION M83912
VERSION M83912.1 GI:188106
KEYWORDS Lymphocyte antigen; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 285)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
COMMENT Kimura A.
JOURNAL Unpublished (1991)
COMMENT Original source text: Homo sapiens (individual isolate SASBE41)
DNA.

FEATURES
    source
        1..285
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /isolate="SASBE41"
        /db_xref="taxon:9606"
        /map="6p"
        /cell_type="granulocyte"
        <1..79
        /number=1
        <20..>283
        /codon_start=3
        /label=exon 2
        /product="MHC HLA DPB1"
        /protein_id="AAA36266.1"
        /db_xref="GI:553571"
        /translation="NVYQLQESYAFNGTQFLERYIYNRELVRFDSDVGEFRAVT
        ELGRPEAEYWNQKDIIEKRAVPDRMCRHNVELDAVTLQRR"
        284..>285
        /number=2

    intron
        <1..79
        /number=1
        <20..>283
        /codon_start=3
        /label=exon 2
        /product="MHC HLA DPB1"
        /protein_id="AAA36266.1"
        /db_xref="GI:553571"
        /translation="NVYQLQESYAFNGTQFLERYIYNRELVRFDSDVGEFRAVT
        ELGRPEAEYWNQKDIIEKRAVPDRMCRHNVELDAVTLQRR"
        284..>285
        /number=2

    intron
        <1..79
        /number=1
        <20..>283
        /codon_start=3
        /label=exon 2
        /product="MHC HLA DPB1"
        /protein_id="AAA36266.1"
        /db_xref="GI:553571"
        /translation="NVYQLQESYAFNGTQFLERYIYNRELVRFDSDVGEFRAVT
        ELGRPEAEYWNQKDIIEKRAVPDRMCRHNVELDAVTLQRR"
        284..>285
        /number=2

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 285;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCCTCAGGTCCTGGTGGGTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTTG 1977
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGACATCCTGTCGCGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGCTG 186

RESULT 224
AF312826/c
LOCUS AF312826 804 bp mRNA linear INV 02-MAR-2001
DEFINITION Luidia foliolata sea star regeneration-associated protease SRAP
mRNA, complete cds.

/product="MHC class II antigen"
<20..>283
/gene="HLA-DPB1"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AA084763.1"
/db_xref="GI:29422765"
/translation="NYVQLQESYAFNGTQFLERYIYNRELVRFDSDVGEFRAVT
ELGRPEAEYWNQKDIIEKRAVPDRMCRHNVELDAVTLQRR"
exon
    20..283
    /gene="HLA-DPB1"
    /number=2

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 285;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1918 TTGTCCTCAGGTCCTGGTGGGTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTTG 1977
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 245 TTGTGTCGACATCCTGTCGCGCACTGCCGCTTCTCTCCAGGATGTCCTTCTGCTG 186

RESULT 225
SHPFIKA
LOCUS SHPFIKA 823 bp mRNA linear MAM 27-APR-1993
DEFINITION Sheep factor IX mRNA, partial cds.
ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX.
SOURCE Ovis aries (sheep)
ORGANISM Ovis aries
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
REFERENCE 1 (bases 1 to 823)
AUTHORS Sarkar, G., Koerber, D.D. and Sommer, S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL Genomics 6 (1), 133-143 (1990)
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
Location/Qualifiers
    source
        1..823
        /organism="Ovis aries"
        /mol_type="mRNA"
        /db_xref="taxon:105861"
        /dev_stage="larva"
        1..804
        /note="serine protease"
        /codon_start=1
        /product="sea star regeneration-associated protease SRAP"
        /protein_id="AAK15274.1"
        /db_xref="GI:13183620"
        /translation="MLRLVLCALAAAFVYADCGVQVNPVINKIVGDEAVPGSWPQW
        VWERKQWAGDYQFCGGLTISDEWVSAACHFNNGYNINHYAVGADHDSVDSTQCT
        TVGLGKVFVHESYDTSLNDLALIKLSPVSNYSNVSLCTAATPTGTCVTVGWN
        GQETHAVDDPTLQQVVPVPISSBQCNRAIYWGGEINDMICAGFKGGKDCQCGDSGG
        PFVCSASGEYELVGVSWGYGCADARKPGVAKVLYVSVWINNIVARN"

Query Match
Best Local Similarity 0.8%; Score 18.4; DB 1; Length 804;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 623 TTGTCGATGACCTAAGTGTGGAGAGATGGGGTATTGAAGTAGCCCACT 674
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 251 TGGTTGATGTTGCCATAGTTATGGAAGCAATGGCGCAGACAGACGCCCACT 200

RESULT 226
SHPFIKA
LOCUS SHPFIKA 823 bp mRNA linear MAM 27-APR-1993
DEFINITION Sheep factor IX mRNA, partial cds.
ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX.
SOURCE Ovis aries (sheep)
ORGANISM Ovis aries
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
REFERENCE 1 (bases 1 to 823)
AUTHORS Sarkar, G., Koerber, D.D. and Sommer, S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL Genomics 6 (1), 133-143 (1990)
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
Location/Qualifiers
    source
        1..823
        /organism="Ovis aries"
        /mol_type="mRNA"
        /db_xref="taxon:105861"
        /dev_stage="larva"
        1..804
        /note="serine protease"
        /codon_start=1
        /product="sea star regeneration-associated protease SRAP"
        /protein_id="AAK15274.1"
        /db_xref="GI:13183620"
        /translation="MLRLVLCALAAAFVYADCGVQVNPVINKIVGDEAVPGSWPQW
        VWERKQWAGDYQFCGGLTISDEWVSAACHFNNGYNINHYAVGADHDSVDSTQCT
        TVGLGKVFVHESYDTSLNDLALIKLSPVSNYSNVSLCTAATPTGTCVTVGWN
        GQETHAVDDPTLQQVVPVPISSBQCNRAIYWGGEINDMICAGFKGGKDCQCGDSGG
        PFVCSASGEYELVGVSWGYGCADARKPGVAKVLYVSVWINNIVARN"

```


/evidence=not_experimental

Query Match 0.8%; Score 18.4; DB 1; Length 832;
Best Local Similarity 78.6%; Pred. No. 2.3e+02;
Matches 22; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

CDS

QY 1697 TCTTTTGGTTTCTTCTGAAATATTTT 1724
DB 832 TTTTCTTTTCTTTTATTTCAATATTTT 805

RESULT 227
AF465275/c 1293 bp mRNA linear VRT 02-FEB-2003
LOCUS Takifugu rubripes coagulation factor VIIC precursor, mRNA, complete
DEFINITION AF465275
ACCESSION AF465275
VERSION AF465275.1 GI:28194021
KEYWORDS Takifugu rubripes (Fugu rubripes)
SOURCE Takifugu rubripes
ORGANISM Takifugu rubripes
REFERENCE 1 (bases 1 to 1293)
AUTHORS Tuddenham, E.G.D. and McVey, J.H.
TITLE Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
AUTHORS McVey, J.H., Davidson, C.J., Lal, K., Snell, P., Elgar, G.,
TITLE Direct Submission
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK

FEATURES
source
1..1293
/organism="Takifugu rubripes"
/mol_type="mRNA"
/db_xref="taxon:31033"
CDS
1..1293
/EC_number="3.4.21.21"
/function="serum prothrombin conversion accelerator"
/note="vitamin K dependent serine protease; similar to factor VII precursor; synthesized in liver; similar to Fugu rubripes FVII and FVIIb; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"
/codon_start=1
/product="coagulation factor VIIC precursor"
/protein_id="AA033370.1"
/db_xref="GI:28194022"
/translation="MAFSRGTGRKLFKILFITYVCSGFFPAGVFMKPEANVFLH
RTNRANFLFEELKAGNLEKEIEKSYEAEIFALPQLEAFWRTYTAADQCKLSP
CKNGATCTRRFFETACKCANGHNCVDRVLTNSGCRVNGGCHFCRFPDRSYVC
FCAPGYRLDKDMSCTCLPOYKPCGRQLILFSPRVINGLIPCPCGHCQWAMLSNNIYT
CGTIIILSEQWLTAHCVWRKPAHLENTVVGEDHREIPEKTEQHRVILKVLHPEGYNK
TSSDKDLAMKLKRLPVGLYVVPICPAQNSCTSTILANIROSTVSGWGLSRGPP
ATILQRLTLPRVLPQECRLHKLITRNMLCAGLKTGGDADCEGSGGLVITYIEKTH
FLTGVSWSGKCANENLYGVYVRVTNFDLWIGNIATN"

Query Match 0.8%; Score 18.4; DB 1; Length 1293;
Best Local Similarity 69.4%; Pred. No. 2.3e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

CY 1762 CCTTGGTTTTTCATAGTGTCTCTGCTTCCTGGA 1797
DB 115 CCTCGGGTTTTTCCATAAAACCTCCGCTTCGGAA 80

RESULT 228
AX523898

/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/note="factor IX"
/codon_start=1
/protein_id="AAA31520.1"
/db_xref="GI:552419"
/translation="RASVLHTSKLTRAETIFSNMNYNSEAEIINDVNTQSQSPD
DNRVVGEDDARQOPQWLLHGEIAAFPCGSIWKRWVTAACHIKPGVKITVAG
BHNTEKPEPTQKRWIRAI PVHGYNASINKYSHDIALLEDEPLELNSYVTPICAD
REYNIFLKFGTGYVSGWRVNRGRSASILQYLKVLPLVDRATCLRSKFTLYNHMFC
AGYHEGGKDSQCGSGGPHVTEVGTSLTGLISWGECAAMKGIYIKVSRREV"

Query Match 0.8%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.3e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

CDS

QY 295 ATTCTTGATTTCTATCTGGCTCATTTTAACTCAGTAGTGGTGTGGTTCCATA 354
DB 207 AATTGCTGATTTCTGTGGAGTTTCCATCGTTAATGAAAAATGGTTGTAAC 266
QY 355 AGTTTGTAAGTTTCTGTGTTTCTGCTGTTGTTGTTGTT 394
DB 267 CTGATCAAGCTGGTGTTAAATTAATCTGTTGTTGAGGT 306

RESULT 226
AF011900/c 832 bp mRNA linear VRT 09-SEP-1997
LOCUS Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
DEFINITION AF011900
ACCESSION AF011900
VERSION AF011900.1 GI:2367498
KEYWORDS Petromyzon marinus (sea lamprey)
SOURCE Petromyzon marinus
ORGANISM Petromyzon marinus
REFERENCE 1 (bases 1 to 832)
AUTHORS Roach, J.C.
TITLE The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL Unpublished
AUTHORS Roach, J.C.
TITLE Direct Submission
JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA

FEATURES
source
1..832
/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="ammocoete"
/tissue_lib="anterior intestine"
<1..832
/gene="TRYPB1"
/db_xref="GI:2367499"
/translation="LIFALLVGTAAAPWYEDHIVGVVECAHSPQWQVSLNIGTHF
CGGLISSEWVWSAAHCYQTSIVRIGEHNFIVTEGTQRIQASKAIRHPQYSAT
INDMLILSSPATINQYAAVPLSPSCVGTGVMCTISGGETQTSVSGPDVIMCVQ
APVLSITCRNSVPGDITNNMICLGLYEGGKDSQCGDSGPPVVCNGQLQGVISWGRGC
ALNYPGVYTKVCNYSNWIATMAAN"
<1..37
/gene="TRYPB1"
/evidence=not_experimental
38..733
/gene="TRYPB1"
/product="trypsin B1"

sig_peptide
mat_peptide

LOCUS AX523898 1505 bp DNA linear PAT 24-OCT-2002
DEFINITION Sequence 105 from Patent WO02064799.
ACCESSION AX523898
VERSION AX523898.1 GI:24412662
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Seldon, R.F., Miller, A.M. and Treco, D.S.
AUTHORS Optimized messenger rna
TITLE Patent: WO 02064799-A 105 22-AUG-2002;
JOURNAL TRANSLARYOTIC THERAPIES, INC. (US)
FEATURES
Location/Qualifiers
source
1..1505
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.4; DB 1; Length 1505;
Best Local Similarity 59.6%; Pred. No. 2.3e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Qy 1815 ATTTAGACTTAACTTTCTTTGACCAAGGTATCCATTTCTTCTATCTTCT 1866
|||||
Db 1425 AATTGAAATTAACAGGCGCTCTCACTAACTAATCACATTTCCCATCTTTCT 1476
|||||
RESULT 229
S78934
LOCUS S78934 171 bp DNA linear PRI 07-MAY-1993
DEFINITION (Factor IXMadrin 2) (exon IV and intron d) [human, Genomic Mutant,
171 nt].
ACCESSION S78934
VERSION S78934.1 GI:244109
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 171)
AUTHORS Solera, J., Magallon, M., Martin-Villar, J. and Coloma, A.
TITLE Factor IXMadrin 2: a deletion/insertion in factor IX gene which
abolishes the sequence of the donor junction at the exon IV-intron
d splice site
JOURNAL Am. J. Hum. Genet. 50 (2), 434-437 (1992)
MEDLINE 92133619
PUBMED 1346483
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI Gibbsq 78934] from the original journal article.
This sequence comes from Fig 3A.
FEATURES
Location/Qualifiers
source
1..171
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.2; DB 1; Length 171;
Best Local Similarity 51.9%; Pred. No. 2.5e+02;
Matches 41; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
Qy 533 CTTTGTGTTTGGTGAATAGTCTGTAAATATCTCTAGGTCCACTTGGTTTATGACATCA 592
|||||
Db 84 CTTTGTGTTTGAAGGAAGAACTGTGAATTTCCAGTTTCAACTTTTTCAGAGGAAA 143
|||||
Qy 593 GTTAGCTCCAGCAATTTCTC 611
|||||
Db 144 CTTTGAACCATGAGTATTC 162
|||||
RESULT 230
AX318568

LOCUS AX318568 240 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 73 from Patent WO0177155.
ACCESSION AX318568
VERSION AX318568.2 GI:21713338
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Fernandes, E., Vernet, C.A., Mishnu, V.S., Leach, M.D., Shimkets, R.A.,
Zerhusen, B.D. and Kekuda, R.
AUTHORS Orfx polynucleotides and polypeptides
TITLE Patent: WO 0177155-A 73 18-OCT-2001;
JOURNAL Curagen Corporation (US)
COMMENT On Jul 8, 2002 this sequence version replaced gi:17900986.
FEATURES
Location/Qualifiers
source
1..240
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 18.2; DB 1; Length 240;
Best Local Similarity 58.2%; Pred. No. 2.6e+02;
Matches 32; Conservative 0; Mismatches 23; Indels 0; Gaps 0;
Qy 1752 TTCTCTATTCCTTTGGTTTTCATAGTGTCTGCTTCTCTGATGTTTATG 1806
|||||
Db 26 TCCCTCAGATGCTCTGAGTGTGGAGCGAGGCCCTGCTCCCGATAGTTGGTG 80
|||||
RESULT 231
AY083553
LOCUS AY083553 251 bp DNA linear PRI 13-APR-2002
DEFINITION Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.
ACCESSION AY083553
VERSION AY083553.1 GI:20146915
KEYWORDS
SOURCE Macaca mulatta (rhesus monkey)
ORGANISM Macaca mulatta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
Cercopithecinae; Macaca.
REFERENCE
1 (bases 1 to 251)
AUTHORS Norgren, R.B. Jr., Zink, M.A., Jia, Y., Ojeda, S.R. and Spindel, E.R.
TITLE Construction of a targeted thesus macaque microarray
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 251)
AUTHORS Norgren, R.B. Jr., Zink, M.A., Jia, Y., Ojeda, S.R. and Spindel, E.R.
TITLE Direct Submission
JOURNAL Submitted (11-MAR-2002) Molecular and Cellular Biology Core, Oregon
Regional Primate Research Center, 505 NW 185th Avenue, Beaverton,
OR 97006, USA
FEATURES
Location/Qualifiers
source
1..251
/organism="Macaca mulatta"
/mol_type="genomic DNA"
/db_xref="taxon:9544"
<1..>251
/genes="GAP43"
<1..>251
/genes="GAP43"
/product="growth associated protein 43"
<1..>251
/genes="GAP43"
3'UTR
Query Match 0.8%; Score 18.2; DB 1; Length 251;
Best Local Similarity 55.8%; Pred. No. 2.6e+02;
Matches 35; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1006 TTCTGTACCCAGTATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTGATGTTGAGA 1065
|||||
Db 147 TTTTGTCTTGGTGTGTTATGGCGAGTTTGGTATGATCAATCATTTGGGA 206
|||||


```

peptidase expressed primarily by the pancreas
J. Biol. Chem. 5, 3363-3371 (2003)
12441343
REFERENCE
2 (bases 1 to 987)
Bhagwandin,V.J. and Caughey,G.H.
Direct Submission
JOURNAL
Submitted (29-AUG-2002) Cardiovascular Research Institute,
University of California San Francisco, 90 Medical Center Way,
Surge Building, Room 206, Box 0911, San Francisco, CA 94143, USA
Location/Qualifiers
1..987
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6"
/db_xref="taxon:10090"
/chromosome="17"
/map="17p6.32"
/tissue_type="bladder"
1..987
/notes="membrane anchored tryptic serine protease;
marapsin; similar to human pancreasin"
/codon_start=1
/product="pancreasin"
/protein_id="AA027572.1"
/db_xref="GI:27323337"
/translation="MSQPHIALLLPLLLRSCTEGARTLRACGHPKMFNRNMVGGNA
LEGEPWQVSIQRNGHFCGSLIAPTWLITRAHCFNSNTSDISYQVLGALKLQPGP
PHALYVYQVSNPOYQWASSADVALVEQPVFTWVILPCLPDPVIFESGMN
CWYTWGSPSEQDLNPRVLQKAVPIIDTPKCNLLYNKDVESDFOLATIKDDMLCA
GFAEGKDKAGDSGPLVCLVDQSNVQAGVISWEGCARRRNPGVIIRVSHKWHI
QIPELQFQGRAGTQQQKDSQQLAGNSAPCLAAHAWVALGALLRLIV"

Query Match 0.8%; Score 18.2; DB 1; Length 987;
Best Local Similarity 48.5%; Pred. No. 2.6e+02;
Matches 50; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 298 TCTGATTCTACTTGGCGTCATTTTAACTCAGTAGTAGTGTGTTGTTCCATAAGT 357
DB 608 TCAACATCTTTGTGTACACAGAGTGCATCTGGCGGTGTCAATGATGGCACAGCAAGT 549
QY 358 TTGTAAGTTTCTGTTCTTCTGTTGTTGTTGTTATCTAG 400
DB 548 TTTCGAGGACCCGTGGGTGGTAGTCGGTCTGTCTCACTGG 506

OCU49933 1558 bp mRNA linear MAM 27-MAR-1996
Oryctolagus cuniculus vitamin K-dependent protein C precursor mRNA,
partial cds.
U49933
U49933.1 GI:1236620
Oryctolagus cuniculus (rabbit)
Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
1 (bases 1 to 1558)
Shen,L., He,X. and Dahlback,B.
Molecular cloning of rabbit vitamin K-dependent protein C and
demonstration of its mRNA in the reproductive organs
Unpublished
2 (bases 1 to 1558)
Shen,L., He,X. and Dahlback,B.
Direct Submission
JOURNAL
Submitted (26-FEB-1996) Lei Shen, Clinical Chemistry, Lund
University, University Hospital, Malmö S-205 02, Sweden
Location/Qualifiers
1..1558
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"

FEATURES
source
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AAA92956.1"
/db_xref="GI:1236621"
/translation="IPDDVGYRNQKTASKEGVVSVKCDGPNLTPRAKRAANSFLEEL
RPSLRERCEVERVCOLEAKEIFQSVDDTLAFWKYVDGDOCAALPSEHPSCSQCGH
CADIISIGFSCQCHGWGSGFCOYEVFNSGVNDGCGCAHYCLEEAGRSQSCAPY
ETADHLOCEPAVRPCCGFLGKMKRIEKGKGVKRDLEQVDENDEVPRLIDGKLFRG
DSPWVILLDSKKLACAGVLHVSWLTAHCEEPKGLFVRLGEYDURRKERWELD
LVNTEGVLHNSYRSTTDIALRLAQPATLSQTIPICLPDNGLAERLQAQGET
VNTGWYHSRREKEAKRNRTFTLNFITVPAPQNECEQWMSNIISENMLCAGILGDR
DADGSDSGPMVASFRTGFWLVLGWSGCGDLNNYGVYTKSVRYLDMWHSIEEKE
AAEPSPAP"
<1..108
/notes="putative; leader peptide"
sig_peptide
109..1374
/mat_peptide
/product="vitamin K-dependent protein C"
/notes="putative"

Query Match 0.8%; Score 18.2; DB 1; Length 1558;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCTTTTACTTAAAGTGATGTCTATCCATGCTAGGT 958
DB 1351 CTTCTTTTCTCGATGTGCTGTGATCCAGTCGAGGT 1313

RESULT 236
S68634 199 bp DNA linear PRI 17-AUG-2001
CRM+ factor IX Strasbourg 2=cross reacting material positive factor
IX Strasbourg 2 {exon 2} [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
S68634
S68634.1 GI:545020
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 199)
de la Salle,C., Charnantier,J.L., Ravanat,C., Ohlmann,P.;
Hartmann,M.L., Schuhler,S., Bischoff,R., Ebel,C., Roecklin,D.,
Balland,A. et al.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
by factor XIA
Nov. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
94126308
8295821
GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsq 143652] from the original journal article.
G6365 to A transition.
COMMENT
Location/Qualifiers
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..158

FEATURES
source
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AAA92956.1"
/db_xref="GI:1236621"
/translation="IPDDVGYRNQKTASKEGVVSVKCDGPNLTPRAKRAANSFLEEL
RPSLRERCEVERVCOLEAKEIFQSVDDTLAFWKYVDGDOCAALPSEHPSCSQCGH
CADIISIGFSCQCHGWGSGFCOYEVFNSGVNDGCGCAHYCLEEAGRSQSCAPY
ETADHLOCEPAVRPCCGFLGKMKRIEKGKGVKRDLEQVDENDEVPRLIDGKLFRG
DSPWVILLDSKKLACAGVLHVSWLTAHCEEPKGLFVRLGEYDURRKERWELD
LVNTEGVLHNSYRSTTDIALRLAQPATLSQTIPICLPDNGLAERLQAQGET
VNTGWYHSRREKEAKRNRTFTLNFITVPAPQNECEQWMSNIISENMLCAGILGDR
DADGSDSGPMVASFRTGFWLVLGWSGCGDLNNYGVYTKSVRYLDMWHSIEEKE
AAEPSPAP"
<1..108
/notes="putative; leader peptide"
sig_peptide
109..1374
/mat_peptide
/product="vitamin K-dependent protein C"
/notes="putative"

Query Match 0.8%; Score 18.2; DB 1; Length 1558;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCTTTTACTTAAAGTGATGTCTATCCATGCTAGGT 958
DB 1351 CTTCTTTTCTCGATGTGCTGTGATCCAGTCGAGGT 1313

RESULT 236
S68634 199 bp DNA linear PRI 17-AUG-2001
CRM+ factor IX Strasbourg 2=cross reacting material positive factor
IX Strasbourg 2 {exon 2} [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
S68634
S68634.1 GI:545020
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 199)
de la Salle,C., Charnantier,J.L., Ravanat,C., Ohlmann,P.;
Hartmann,M.L., Schuhler,S., Bischoff,R., Ebel,C., Roecklin,D.,
Balland,A. et al.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
by factor XIA
Nov. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
94126308
8295821
GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsq 143652] from the original journal article.
G6365 to A transition.
COMMENT
Location/Qualifiers
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..158

FEATURES
source
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AAA92956.1"
/db_xref="GI:1236621"
/translation="IPDDVGYRNQKTASKEGVVSVKCDGPNLTPRAKRAANSFLEEL
RPSLRERCEVERVCOLEAKEIFQSVDDTLAFWKYVDGDOCAALPSEHPSCSQCGH
CADIISIGFSCQCHGWGSGFCOYEVFNSGVNDGCGCAHYCLEEAGRSQSCAPY
ETADHLOCEPAVRPCCGFLGKMKRIEKGKGVKRDLEQVDENDEVPRLIDGKLFRG
DSPWVILLDSKKLACAGVLHVSWLTAHCEEPKGLFVRLGEYDURRKERWELD
LVNTEGVLHNSYRSTTDIALRLAQPATLSQTIPICLPDNGLAERLQAQGET
VNTGWYHSRREKEAKRNRTFTLNFITVPAPQNECEQWMSNIISENMLCAGILGDR
DADGSDSGPMVASFRTGFWLVLGWSGCGDLNNYGVYTKSVRYLDMWHSIEEKE
AAEPSPAP"
<1..108
/notes="putative; leader peptide"
sig_peptide
109..1374
/mat_peptide
/product="vitamin K-dependent protein C"
/notes="putative"

Query Match 0.8%; Score 18.2; DB 1; Length 1558;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 920 CATCTTTTACTTAAAGTGATGTCTATCCATGCTAGGT 958
DB 1351 CTTCTTTTCTCGATGTGCTGTGATCCAGTCGAGGT 1313

RESULT 236
S68634 199 bp DNA linear PRI 17-AUG-2001
CRM+ factor IX Strasbourg 2=cross reacting material positive factor
IX Strasbourg 2 {exon 2} [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
S68634
S68634.1 GI:545020
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 199)
de la Salle,C., Charnantier,J.L., Ravanat,C., Ohlmann,P.;
Hartmann,M.L., Schuhler,S., Bischoff,R., Ebel,C., Roecklin,D.,
Balland,A. et al.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
by factor XIA
Nov. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
94126308
8295821
GenBank staff at the National Library of Medicine created this
entry [NCBI gibbsq 143652] from the original journal article.
G6365 to A transition.
COMMENT
Location/Qualifiers
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..158

FEATURES
source
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AAA92956.1"
/db_xref="GI:1236621"
/translation="IPDDVGYRNQKTASKEGVVSVKCDGPNLTPRAKRAANSFLEEL
RPSLRERCEVERVCOLEAKEIFQSVDDTLAFWKYVDGDOCAALPSEHPSCSQCGH
CADIISIGFSCQCHGWGSGFCOYEVFNSGVNDGCGCAHYCLEEAGRSQSCAPY
ETADHLOCEPAVRPCCGFLGKMKRIEKGKGVKRDLEQVDENDEVPRLIDGKLFRG
DSPWVILLDSKKLACAGVLHVSWLTAHCEEPKGLFVRLGEYDURRKERWELD
LVNTEGVLHNSYRSTTD
```

Query Match 0.8%; Score 18; DB 1; Length 199;
 Best Local Similarity 45.2%; Pred. No. 2.9e+02;
 Matches 66; Conservative 0; Mismatches 80; Indels 0; Gaps 0;

QY 1646 TATGCTTCTTACCTGTAGGATCTCTTCTCAAGTTAGGAATTTTCTTTTGG 1705
 DB 168 TGTCTTTTCAAGTGTTCCTCAAAACTTCTCGTCTCTTCAAAACTACACTTTCTCCAT 109
 QY 1706 GTTTCTTCTGAAATATTTTCCCTGCTTTTGAAGTCTCTTCTCCCTTCTCTATTCCTT 1765
 DB 108 ACAATCTCTCAAGTTCCTTGAACAACCTTCCAACTTACCTGAATTATACCTCTT 49
 QY 1766 TGGTTTTCATGATGCTCTCTGCTT 1791
 DB 48 TGGCTGATTCAGAAATTTTGTGGCGT 23

RESULT 237
 I14646/c
 LOCUS
 DEFINITION Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*3401 variant
 ACCESSION AY267909.1
 VERSION 1
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens (human)

REFERENCE 1 (bases 1 to 276)
 AUTHORS Apple, R.J., Bugawan, T.L., and Erlich, H.A.
 TITLE Methods and reagents for HLA class I A locus DNA typing
 JOURNAL Patent: US 5451512-A 123 19-SEP-1995;
 FEATURES
 source
 1..276
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.8%; Score 18; DB 1; Length 276;
 Best Local Similarity 52.7%; Pred. No. 2.9e+02;
 Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCCTTCTCCCTGTCTGATTCCTAGGGTGAGGGTTACCACTGCTCTCTCTCCC 228
 DB 238 CTGCGGAGCCTCTCAGCAGCTGCGCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG 179
 QY 229 TTTCTCTAACACTT 242
 DB 178 GCGGTCTCCCACTT 165

RESULT 238
 AY267909S2/c
 LOCUS
 DEFINITION Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*3401 variant
 ACCESSION AY267910
 VERSION 1
 KEYWORDS
 SEGMENT 2 of 2
 SOURCE Homo sapiens (human)

REFERENCE 1 (bases 1 to 276)
 AUTHORS Steiner, N.K., Fernandez-Vina, M., and Hurley, C.K.
 TITLE Novel HLA-A Allele
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 276)
 AUTHORS Steiner, N.K., Fernandez-Vina, M., and Hurley, C.K.
 TITLE Direct Submission
 JOURNAL Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown University Medical Center, 3970 Reservoir Rd. NW, Washington, DC 20007, USA
 FEATURES
 Location/Qualifiers

source
 1..276
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /isolate="GN00431"
 /db_xref="taxon:9606"
 order (AY267909.1:1..270,1..276)
 /gene="HLA-A"
 /alleles="HLA-A*3401 variant"
 join (AY267909.1:1..270,1..276)
 /gene="HLA-A"
 /product="MHC class I antigen"
 join (AY267909.1:1..270,1..276)
 /gene="HLA-A"
 /codon_start=3
 /product="MHC class I antigen"
 /protein_id="AAP32699.1"
 /db_xref="GI:30525805"
 /translation="SHSMRYFYTSVSRPGEPRFIAGVYDDTQFVRFSDAASQRM
 EPRAPWIRQEGPEYWDNRTRKVAQSQTDRVDLGLTRGYNQSDGSHITIQMYGCDV
 GPDGRLRGYQDDAYDGKDYLSLNEDLSRSLTAADMAAQITQRKWEHAEQWRAYLE
 GTCVLEWLRRYLENGKETLQRT"
 1..276
 /gene="HLA-A"
 /number=3

Query Match 0.8%; Score 18; DB 1; Length 276;
 Best Local Similarity 52.7%; Pred. No. 2.9e+02;
 Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 169 CTGCTGCCCTTCTCCCTGTCTGATTCCTAGGGTGAGGGTTACCACTGCTCTCTCTCCC 228
 DB 238 CTGCGGAGCCTCTCAGCAGCTGCGCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG 179
 QY 229 TTTCTCTAACACTT 242
 DB 178 GCGGTCTCCCACTT 165

RESULT 239
 HSA507648/c
 LOCUS
 DEFINITION Homo sapiens partial HLA-A gene for MHC class I antigen, HLA-A*34
 allele, exon 3.
 ACCESSION AJ507648
 VERSION AJ507648.1
 KEYWORDS HLA-A gene; HLA-A*34 allele; human leucocyte antigen A; major histocompatibility complex; MHC class I antigen.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 Lebedeva, T.V., Huang, A., Janzen, M. and Yu, N.
 TITLE Identification of novel HLA Class I alleles using single allele sequencing
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 276)
 Lebedeva, T.V.
 TITLE Direct Submission
 JOURNAL Submitted (10-SEP-2002) Lebedeva T.V., HLA laboratory, American Red Cross New England Region, 180 Rustcraft Rd, Dedham, MA 02026, USA
 FEATURES
 Location/Qualifiers
 source
 1..276
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="6"
 /map="6p21.3"
 1..276
 /gene="HLA-A"
 1..276
 /gene="HLA-A"
 /number=3

gene
 1..276
 /gene="HLA-A"
 /number=3

exon
 1..276
 /gene="HLA-A"
 /number=3

		/allele="HLA-A*34"		/usedin=AJ507647:HLA-A*34_CDS			
Query Match		0.8%; Score 18; DB 1; Length 276;					
Best Local Similarity		52.7%; Pred. No. 2.9e+02;					
Matches		39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;					
Qy	169	CTGCTGCCTTCTCCCTCTCTGATTCTCTAGGTTGAGGTTACCACTGCTCTCTCTCTCC	228				
Db	238	CTGGGAGCCACTCCACGACGTGCCCTCCAGGTAGGCTCTCCACTGCTCCGCTCATGG	179				
Qy	229	TTTCTCTAACTTT 242					
Db	178	GCGCTCTCCACTT 165					
RESULT 240							
HSHLAAGN2/c							
LOCUS		HSHLAAGN2		276 bp DNA linear PRI 20-OCT-2000			
DEFINITION		Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and partial cds.					
ACCESSION		U90243					
VERSION		U90243.1 GI:1905858					
KEYWORDS		2 of 2					
SEGMENT		Homo sapiens (human)					
SOURCE		Homo sapiens					
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE		1 (bases 1 to 276)					
AUTHORS		Hurley,C.K., Steiner,N., Kosman,C., Mitton,W., Koester,R., Bei,M., Bush,J., McCormack,J., Hahn,A., Henson,V., Hoyer,R., Wade,J.A., Hartzman,R.J. and Ng,J.					
TITLE		Novel HLA-A and HLA-B alleles					
JOURNAL		Tissue Antigens 52 (1), 84-87 (1998)					
MEDLINE		98378282					
PUBMED		9714480					
REFERENCE		2 (bases 1 to 276)					
AUTHORS		Bei,M. and Hurley,C.K.					
TITLE		Direct Submission					
JOURNAL		Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown University Medical Center, 3970 Reservoir Rd. NW, Washington, DC 20007, USA					
FEATURES		Location/Qualifiers					
source		1..276					
		/organism="Homo sapiens"					
		/mol_type="genomic DNA"					
		/isolate="GN00158"					
gene		/db_xref="taxon:9606"					
		/join(U90242.1:<1..270,1..>276)					
mRNA		/gene="HLA-A"					
		/join(U90242.1:<1..270,1..>276)					
		/gene="HLA-A"					
		/product="MHC class I antigen"					
CDS		/join(U90242.1:<1..270,1..>276)					
		/gene="HLA-A"					
		/note="variant A*2601"					
		/codon_start=3					
		/product="MHC class I antigen"					
		/protein_id="AAB50149.1"					
		/db_xref="GI:1905860"					
		/translation="SHSMRYFTYTSVRPGRGEPRFIAVGVDYDQFVRFSDAASQRM EPRAPWLEQSGPEYNDNRNKAHSQTDRLNGLTGLRGYNQSDGSHITQRYMGCDV GPDGRFLRGYQDDAYDKDYIALNEDLRSWADMAAQITQRKWEIHAEEQWRYALE GTCVWLRRLYLENGKETLQRT"					
exon		1..276					
		/gene="HLA-A"					
		/number=3					
Query Match		0.8%; Score 18; DB 1; Length 276;					
Best Local Similarity		52.7%; Pred. No. 2.9e+02;					
Matches		39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;					
Qy	1732	TTTGACCTGCTTCTCCCTCTCTGATTCTCTATTCCTTTGGTTTTCATAGTGTCTCTGCTT	1791				
Db	220	TTGCAGCTGGCTTCACCCATCTCCTTCAATGACTACATGCTCCAGTCTCCCTCCCGAAA	279				
Qy	1792	CCTGGA 1797					
RESULT 241							
AR249144/c							
LOCUS		AR249144		290 bp DNA linear PAT 20-DEC-2002			
DEFINITION		Sequence 4503 from patent US 6476212.					
ACCESSION		AR249144					
VERSION		AR249144.1 GI:27297018					
KEYWORDS		Unknown.					
SOURCE		Unknown.					
ORGANISM		Unclassified.					
REFERENCE		1 (bases 1 to 290)					
AUTHORS		Lalgudi,R.V., Ito,L.Y. and Sherman,B.K.					
TITLE		Polynucleotides and polypeptides derived from corn ear					
JOURNAL		Patent: US 6476212-A 4503 05-NOV-2002;					
FEATURES		Location/Qualifiers					
source		1..290					
		/organism="unknown"					
		/mol_type="genomic DNA"					
Query Match		0.8%; Score 18; DB 1; Length 290;					
Best Local Similarity		51.2%; Pred. No. 2.9e+02;					
Matches		42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;					
Qy	1683	GGTAGGAATTTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTTTGACCTGCC	1742				
Db	218	GCGCGGAGATCTTGCCTCTCTGCTCCAGGAGGCTCGGCTCTCCAGGCTGAC	159				
Qy	1743	TTCTTCCCTTCCCTATTCTT 1764					
Db	158	TGCAGTCCATCTCTCGGCT 137					
RESULT 242							
AX312474							
LOCUS		AX312474		299 bp DNA linear PAT 14-DEC-2001			
DEFINITION		Sequence 5459 from Patent WO0190366.					
ACCESSION		AX312474					
VERSION		AX312474.1 GI:17897467					
KEYWORDS		Homo sapiens (human)					
SOURCE		Homo sapiens					
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.					
REFERENCE		1					
AUTHORS		Leach,M.D. and Shimkets,R.A.					
TITLE		Human polynucleotides and polypeptides encoded thereby					
JOURNAL		Patent: WO 0190366-A 5459 29-NOV-2001;					
FEATURES		Curagen Corporation (US)					
source		1..299					
		/organism="Homo sapiens"					
		/mol_type="unassigned DNA"					
		/db_xref="taxon:9606"					
Query Match		0.8%; Score 18; DB 1; Length 299;					
Best Local Similarity		54.5%; Pred. No. 2.9e+02;					
Matches		36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;					

Db 280 COTGGA 285

RESULT 243
BTA271156/c 302 bp mRNA linear MAM 27-JUL-2000
LOCUS Bta taurus partial mRNA for haptoglobin (hp gene).
DEFINITION AJ271156
ACCESSION AJ271156.1 GI:9581738
VERSION haptoglobin; bp gene.
KEYWORDS Bos taurus (cow)
SOURCE
ORGANISM

REFERENCE
1 Lavery K.S., Gabler, C. and Killian, G.J.
AUTHORS Expression and localization of haptoglobin in the bovine female
TITLE reproductive tract
JOURNAL Unpublished
AUTHORS 2 (bases 1 to 302)
Lavery, K.S.
TITLE Direct Submission
JOURNAL Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science,
Pennsylvania State University, The John O. Almquist Research
Center, Fox Hollow Road, University Park, USA

FEATURES
source
1. .302
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
/sex="female"
/cell_type="epithelial cell"
/tissue_type="oviduct"
/dev_stage="adult"
1. .302
/gene="hp"
/genes="hp"
/function="acute phase protein"
/codon_start=3
/product="haptoglobin"
/protein_id="CAC00531.1"
/db_xref="GI:9581738"
/db_xref="GOA:Q9MYV8"
/db_xref="SPTREMBL:Q9MYV8"
/translations="KGSFPQAKWVSOHNLISGATLINERWLLTTAKNLYLGHSSDKK
AKDITPLRLVVGKNQLVEKVLVHEDHSKVDIGLIKLRQKVPVNDKWPICLPS"

Query Match 0.8%; Score 18; DB 1; Length 302;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 1656 GTACCTTGATAGGCATCTCTTCCTCAAGGTTAGGAATTTTCTTTTGGTTTCTTGA 1715
Dy 297 GTAGGAGATGGGATACCTTGTCTATGACAGTACTCTCTGCTGAGTTGATGAGCC 238
Qy 1716 AAATATTTTCCTG 1729
Dy 237 CAATGCTACCTTG 224

RESULT 244
FRSPLX2/c 335 bp DNA linear VRT 28-OCT-2000
LOCUS F. rubripes serine protease-like exon (335bp).
DEFINITION F. rubripes serine protease-like exon (335bp).
ACCESSION X95338
VERSION X95338.1 GI:1171532
KEYWORDS Takifugu rubripes (Fugu rubripes)
SOURCE Takifugu rubripes
ORGANISM Takifugu rubripes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;

REFERENCE
1 Lim, E.H. and Brenner, S.
AUTHORS Short-range linkage relationships, genomic organisation and
TITLE sequence comparisons of a cluster of five HSP70 genes in Fugu
rubripes
JOURNAL Cell. Mol. Life Sci. 55 (4), 668-678 (1999)
MEDLINE 99284127
PUBMED 10357235
REFERENCE 2 (bases 1 to 335)
Lim, E.H.
AUTHORS Direct Submission
TITLE Submitted (17-JAN-1996) E.H. Lim, Molecular Genetics, Dept. of
JOURNAL Medicine, Level 5, Addenbrookes Hospital, Hills Road, Cambridge CB2
20Q, UK

FEATURES
source
1. .335
/organism="Takifugu rubripes"
/mol_type="genomic DNA"
/db_xref="taxon:31033"
80. .214
/product="serine protease-like protein"

Query Match 0.8%; Score 18; DB 1; Length 335;
Best Local Similarity 80.8%; Pred. No. 2.9e+02;
Matches 21; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 30 TGAGGCTCCAATGGTTGTGATGTGG 55
Dy 194 TCAGGATCCACTGTTGTGATCAGG 169

RESULT 245
AF266240 383 bp mRNA linear VRT 15-FEB-2001
LOCUS Gillichthys seta trypsinogen 2 precursor, mRNA, partial cds.
DEFINITION AF266240
ACCESSION AF266240
VERSION AF266240.1 GI:10121759
KEYWORDS Gillichthys seta
SOURCE Gillichthys seta
ORGANISM Gillichthys seta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
Gobioidae; Gobiidae; Gillichthys.
REFERENCE 1 (bases 1 to 383)
AUTHORS Gracey, A.Y., Troll, J.V. and Somero, G.N.
TITLE Hypoxia-induced gene expression profiling in the euryoxic fish
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 98 (4), 1993-1998 (2001)
MEDLINE 21117151
PUBMED 11172064
REFERENCE 2 (bases 1 to 383)
AUTHORS Gracey, A.Y., Troll, J.V. and Somero, G.N.
TITLE Direct Submission
JOURNAL Submitted (10-MAY-2000) Biological Sciences, Stanford University,
Hopkins Marine Station, Oceanview Blvd., Pacific Grove, CA 93950,
USA

FEATURES
source
1. .383
/organism="Gillichthys seta"
/mol_type="mRNA"
/db_xref="taxon:79683"
/tissue_type="liver"
33. .5383
/codon_start=1
/product="trypsinogen 2 precursor"
/protein_id="AAGI3359.1"
/db_xref="GI:10121760"
/translation="MRLVPIILLIGAFAEDDKIVGVCECTPHSOAHQVSLNSGVHFC
GGSLVNAEWVWSAAHCKYSRVEKRLGHNLRLTEGTQFISSSRVIRHPNYSYINIDN
DIMLTKLSKPANLNL"

```
Query Match      0.8%; Score 18; DB 1; Length 383;
Best Local Similarity 52.7%; Pred. No. 2.9e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 301 TGATTCTATCTTGGCTCAATTTAACTCATAGTAGTGAGTTGTTGGTTTCCATAAGTTG 360
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 155 TCACCTCTGTGGAGGCTCTCTGCTCAACGCGGAATGGTGTGTCTGCTCACTGCTA 214

QY 361 TAGTTTCTGTG 374
    ||||| |||||
Db 215 CAACTCTCGTGTG 228

RESULT 246
AX921761
LOCUS AX921761
DEFINITION Sequence 101 from Patent WO2068649.
ACCESSION AX921761
VERSION AX921761.1 GI:40215332
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS
JOURNAL
FEATURES
    source
        Location/Qualifiers
            1..815
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.8%; Score 18; DB 1; Length 815;
Best Local Similarity 64.3%; Pred. No. 2.9e+02;
Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 1770 TTTTGATGATGCTCTGGCTTCTCGATGATTTTATGCTGG 1811
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 39 TCTTGCAAGTGTGGCTGCGCTGAGCTGCTGGAGGATGCCGG 80

RESULT 247
HUMCFIX
LOCUS HUMCFIX
DEFINITION Human coagulation factor IX mRNA, partial cds.
ACCESSION M35672
VERSION M35672.1 GI:180287
KEYWORDS coagulation factor IX; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 873)
AUTHORS Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and
Warren,S.T.
TITLE Isolation and characterization of human factor IX cDNA:
JOURNAL Identification of Tag I polymorphism and regional assignment
MEDLINE Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
PUBMED 84300526
COMMENT Original source text: Human adult liver, cDNA to mRNA.
FEATURES
    source
        Location/Qualifiers
            1..873
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /map="Xq26.3-q27.1"
            1..873
                /gene="F9"
                <1..->873

Query Match      0.8%; Score 18; DB 1; Length 873;
Best Local Similarity 64.3%; Pred. No. 2.9e+02;
Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 369 CTGTTTCTGTTGTTGTTGTTGTTATCTAGATTTAAAGCTG 410
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 476 CTGTTTCTGATGGACTATGTAATTTCTACTGAAGCTG 517

RESULT 248
AF465274/c
LOCUS AF465274
DEFINITION Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete
cds.
ACCESSION AF465274
VERSION AF465274.1 GI:28194019
KEYWORDS
SOURCE Takifugu rubripes (Fugu rubripes)
ORGANISM Takifugu rubripes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
Tetraodontoidea; Tetraodontidae; Takifugu.
REFERENCE 1 (bases 1 to 1329)
AUTHORS Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
TITLE Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1329)
AUTHORS McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE Direct Submission
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
    source
        Location/Qualifiers
            1..1329
                /organism="Takifugu rubripes"
                /mol_type="mRNA"
                /db_xref="taxon:31033"
            1..1329
                /EC_number="3.4.21.21"
                /function="serum prothrombinconversion accelerator"
                /note="vitamin K dependent serine protease; similar to
                Fugu rubripes FVII; synthesized in liver; contains 2
                EGF-like domains; member of peptidase family S1/trypsin
                family"
                /codon_start=1
                /product="coagulation factor VIIb precursor"
                /protein_id="AA033369.1"
                /db_xref="GI:28194020"
                /translation="MLIRICCTVWILFSATAAAVEFDDASTVLQRRRRANSFLE
                EMQGNLKRCEIEICNVEEAREVEDAQTKFETYNRHDPSCVMPCONNGVCVSM
                GNTYQCHCEPGQRCETKAEDFLKLQYQOCQHFCDGSGASRCKFCACGTYLAD
                GRQCIAEVEFPGQLPPETPDQTVVGOTRLVGNHCPKGCPEWVLVOLHQSHCG
                GVLIREDWITAHCVTGKQPQLSLVVAHEHNLNDNDGTEQKIPARVFAHEGYVSET
                GDKIALLHLINASVTINRGI PVCLPTKDLAEELLMTYHTVSGWGKRTNGDGHG
                VNTAFVSPFLKFSVP11PNQCSDHRSQNFETDNNMFCAGYLEGNQCSRGDGDGSPV
                TLYGSTHFLIGVVGRCGCPNPGYGVYTNMGNFVDWANGINMAANKST"
```


Query Match 0.8%; Score 18; DB 1; Length 1329;
Best Local Similarity 52.7%; Pred. No. 2.8e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 1503 TCTATATACATCGCCTTATATGTTAAATGGTCTTTTTCCTTGTCATCTTTTAATATTC 1562
DB 209 TCGATATCTTCGAGCTTCCTGAGTTCGAGATCTCTCGATGCAATCTCTCTTCAGG 150

QY 1563 TTCTCTTGTCTCAT 1576
DB 149 TTTCCTTGTGCAT 136

RESULT 249
E02492/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

E02492
DNA encoding protein C mutant.
E02492
E02492.1 GI:2170722
JP 1990167096-A/1.
synthetic construct
artificial sequences.
1 (bases 1 to 1389)
Hashimoto,T. and Sato,M.
HUMAN PROTEIN C MUTANT AND ITS PRODUCTION
Patent: JP 1990167096-A 1 27-JUN-1990;
HOECHST JAPAN LTD
OS Artificial gene
OC Artificial sequence; Genes.
OS Homo sapiens (human)
PN JP 1990167096-A/1
PD 27-JUN-1990
PF 13-JUL-1989 JP 1989179140
PR 26-JUL-1988 JP 88P 184538
PI HASHIMOTO TAMOTSU, SATO MASAHIRO
PC C12P21/02,C07K13/00,C12N15/12//A61K37/465,(C12P21/02, PC
C12R1:91);
CC strandedness: Single;
CC topology: Linear;
CC anti-sense: No;
FH Key
FH Location/Qualifiers

FT sig_peptide 1..126
FT /product='signal peptide of protein' FT
mat_peptide 127..1383
FT /product='protein c mutant'
FT CDS 1..1389
FT /product='protein c mutant'
FT mutation replace(592..597,')
FT /product='protein c mutant'
FT mutation replace(592..594,')
FT /product='protein c mutant'
FT mutation replace(595..597,')
FT /product='protein c mutant'.
FT Location/Qualifiers
1..1389
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 0.8%; Score 18; DB 1; Length 1389;
Best Local Similarity 60.0%; Pred. No. 2.8e+02;
Matches 30; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1833 TCTTTGACCAAGGTATCCATTTCTTCTATCTTTGTCATCGCTCGAGAT 1882
DB 641 TCAATGAGCGCGGATCTACTTGGTCTTCTTGGTCTTCTGTCGCGAGTT 592

RESULT 250
AX381010/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AX381010
DNA
177 bp
linear
PAT 18-MAR-2002

DEFINITION Sequence 51 from Patent WO0212456.
ACCESSION AX381010
VERSION AX381010.1 GI:19575840
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Drucker,D.J., Rosen,C.F. and Lefebvre,D.L.
TITLE Ampk-related serine/threonine kinase, designated snark
JOURNAL Patent: WO 0212456-A 51 14-FEB-2002;
1149336 ONTARIO INC. (CA)
FEATURES
source
1..177
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 17.8; DB 1; Length 177;
Best Local Similarity 58.5%; Pred. No. 3.2e+02;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATATCTTCTGGGGCTGCTTCTCCTCTGCTGATTCCTAGGG 200
DB 93 CCGCAGGTTGCTGCTGCTGGTGGTGGTTCACCGCTGCTTCTTCATTAGGG 41

Search completed: August 9, 2004, 17:11:25
Job time : 733 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 17:04:56 ; Search time 885 Seconds

(without alignments)
3.922 Million cell updates/sec

Title: us-10-664-775-4

Perfect score: 2279

Sequence: 1 gatcactcctctagtgaaag.....ttgtaattctagggtgctgat 2279

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	43	1.9	2422	1	CDNA encoding Fact
C 2	43	1.9	2422	1	Human adult liver
C 3	43	1.9	2422	1	Factor VII encoding
C 4	43	1.9	2422	1	Human Factor VII p
C 5	43	1.9	2422	1	Human NOV8a encodi
C 6	43	1.9	2462	1	DNA encoding coagu
C 7	43	1.9	2462	1	DNA encoding Facto
C 8	43	1.9	2462	1	Vitamin-K-dependen
C 9	43	1.9	2462	1	Human factor VII c
C 10	43	1.9	2462	1	DNA encoding coagu
C 11	43	1.9	2462	1	Thyroid cancer rel
C 12	43	1.9	2462	1	Gene #2251 used to
C 13	43	1.9	2483	1	Factor VII cDNA of
C 14	41.6	1.8	2177	1	Partial Factor VII
C 15	41.6	1.8	2438	1	Factor IX/Factor V
C 16	32.4	1.4	300	1	Human gene expres
C 17	25.6	1.1	254	1	Human secreted pro
C 18	25.4	1.1	237	1	DNA encoding novel
C 19	25.2	1.1	1843	1	Human protein C co
C 20	25.2	1.1	1943	1	Human protein C ge
C 21	25.2	1.1	1843	1	Gene #3673 used to
C 22	24.2	1.1	267	1	Human bone marrow
C 23	24.2	1.1	267	1	Human brain expres
C 24	24.2	1.1	267	1	Human liver single
C 25	24.2	1.1	267	1	Human genome-deriv
C 26	23.8	1.0	868	1	Human cDNA clone r
C 27	23.8	1.0	868	1	Human cDNA 5'-end
C 28	23.4	1.0	612	1	Oligonucleotide fo
C 29	23.4	1.0	612	1	Oligonucleotide fo
C 30	23	1.0	306	1	Serine protease nf
C 31	23	1.0	1507	1	Human factor X cod
C 32	23	1.0	1507	1	Human gene expres
C 33	23	1.0	1507	1	Farnesyl transfera

C 34	22.8	1.0	200	1	Targetting arm #2
C 35	22.8	1.0	433	1	Human adult liver
C 36	22.8	1.0	1151	1	Human secreted pro
C 37	22.4	1.0	271	1	Single nucleotide
C 38	22.4	1.0	476	1	Probe #1464 for ge
C 39	22.4	1.0	476	1	Human foetal liver
C 40	22.4	1.0	476	1	Probe #1496 used t
C 41	22.4	1.0	476	1	Human breast cell
C 42	22.4	1.0	476	1	Probe #1452 for ge
C 43	22.4	1.0	476	1	Human bone marrow
C 44	22.4	1.0	476	1	Human brain expres
C 45	22.4	1.0	476	1	Human liver single
C 46	22.4	1.0	476	1	Probe #1440 used t
C 47	22.4	1.0	301	1	Human genome-deriv
C 48	22.2	1.0	301	1	Probe #9609 for ge
C 49	22.2	1.0	301	1	Human foetal liver
C 50	22.2	1.0	301	1	Probe #13557 used
C 51	22.2	1.0	301	1	Human breast cell
C 52	22.2	1.0	301	1	Probe #10292 for g
C 53	22.2	1.0	301	1	Human bone marrow
C 54	22.2	1.0	301	1	Human brain expres
C 55	22.2	1.0	301	1	Human liver single
C 56	22.2	1.0	301	1	Probe #5386 used t
C 57	22.2	1.0	301	1	Human genome-deriv
C 58	22	1.0	121	1	Factor IX mutation
C 59	22	1.0	121	1	Factor IX mutation
C 60	22	1.0	121	1	Factor IX mutation
C 61	22	1.0	121	1	Factor IX mutation
C 62	22	1.0	121	1	Factor IX mutation
C 63	22	1.0	121	1	Factor IX mutation
C 64	22	1.0	121	1	Factor IX mutation
C 65	22	1.0	121	1	Factor IX mutation
C 66	22	1.0	121	1	Factor IX mutation
C 67	22	1.0	121	1	Factor IX mutation
C 68	22	1.0	121	1	Factor IX mutation
C 69	22	1.0	121	1	Factor IX mutation
C 70	22	1.0	385	1	Human secreted pro
C 71	22	1.0	612	1	Oligonucleotide fo
C 72	22	1.0	612	1	Oligonucleotide fo
C 73	21.6	0.9	253	1	Single nucleotide
C 74	21.6	0.9	254	1	Human pancreatic c
C 75	21.4	0.9	283	1	Galanin receptor G
C 76	21.4	0.9	283	1	Galanin receptor G
C 77	21.4	0.9	283	1	Galanin receptor G
C 78	21.4	0.9	283	1	Rat galanin recept
C 79	21.4	0.9	1129	1	Human cDNA sequen
C 80	21.4	0.9	1129	1	Novel human secret
C 81	21.4	0.9	1129	1	CDNA encoding huma
C 82	21.4	0.9	1129	1	CDNA encoding huma
C 83	21.4	0.9	1129	1	DNA encoding novel
C 84	21.4	0.9	1129	1	Human secreted/tra
C 85	21.4	0.9	1129	1	Human cDNA encodin
C 86	21.4	0.9	1129	1	Novel human secret
C 87	21.4	0.9	1129	1	Human PRO polynucl
C 88	21.4	0.9	1129	1	Human PRO polynucl
C 89	21.4	0.9	1129	1	Human PRO polynucl
C 90	21.4	0.9	1129	1	Human PRO polynucl
C 91	21.4	0.9	1129	1	Human PRO polynucl
C 92	21.4	0.9	1129	1	Human PRO polynucl
C 93	21.4	0.9	1129	1	Human PRO polynucl
C 94	21.4	0.9	1129	1	Human PRO polynucl
C 95	21.4	0.9	1129	1	Human PRO polynucl
C 96	21.4	0.9	1129	1	Human PRO polynucl
C 97	21.4	0.9	1129	1	Human PRO polynucl
C 98	21.4	0.9	1129	1	Human PRO polynucl
C 99	21.4	0.9	1129	1	Human PRO polynucl
C 100	21.4	0.9	1129	1	Human PRO polynucl
C 101	21.4	0.9	1129	1	Human PRO polynucl
C 102	21.4	0.9	1129	1	Human PRO polynucl
C 103	21.4	0.9	1129	1	Human PRO polynucl
C 104	21.4	0.9	1129	1	Human PRO polynucl
C 105	21.4	0.9	1129	1	Human PRO polynucl
C 106	21.4	0.9	1129	1	Human PRO polynucl

C 107	21.4	0.9	1129	1	ADBI31093	Human PRO polynucle
C 108	21.4	0.9	1129	1	ADCD98534	Novel human secret
C 109	21.4	0.9	1129	1	ADDA74347	Human PRO polynucle
C 110	21.4	0.9	1129	1	ADBA4580	Human PRO polynucle
C 111	21.4	0.9	1129	1	ADAG2104	Human PRO polynucle
C 112	21.4	0.9	1129	1	ADAA75067	Novel human secret
C 113	21.4	0.9	1129	1	ADA85145	Novel human secret
C 114	21.4	0.9	1129	1	ADA84593	Novel human secret
C 115	21.4	0.9	1129	1	ADBA29849	Novel human secret
C 116	21.4	0.9	1129	1	ADAA80377	Novel human secret
C 117	21.4	0.9	1129	1	ADAA75619	Novel human secret
C 118	21.4	0.9	1129	1	ADAA46844	Novel human secret
C 119	21.4	0.9	1129	1	ADBA25140	Novel human secret
C 120	21.4	0.9	1129	1	ADAA93316	Novel human secret
C 121	21.4	0.9	1129	1	ADBA26666	Novel human secret
C 122	21.4	0.9	1129	1	ADBA30953	Novel human secret
C 123	21.4	0.9	1129	1	ADAA60881	Novel human secret
C 124	21.4	0.9	1129	1	ADBA24028	Novel human secret
C 125	21.4	0.9	1129	1	ADAA66357	Novel human secret
C 126	21.4	0.9	1129	1	ADAA80929	Novel human secret
C 127	21.4	0.9	1129	1	ADAA95805	Novel human secret
C 128	21.4	0.9	1129	1	ADBA26114	Novel human secret
C 129	21.4	0.9	1129	1	ADBA21599	Novel human secret
C 130	21.4	0.9	1129	1	ADAA77378	Novel human secret
C 131	21.4	0.9	1129	1	ADBA18118	Novel human secret
C 132	21.4	0.9	1129	1	ADAA86801	Novel human secret
C 133	21.4	0.9	1129	1	ADAA87904	Novel human secret
C 134	21.4	0.9	1129	1	ADAA46292	Novel human secret
C 135	21.4	0.9	1129	1	ADBA28322	Novel human secret
C 136	21.4	0.9	1129	1	ADBA28874	Novel human secret
C 137	21.4	0.9	1129	1	ADAA76826	Novel human secret
C 138	21.4	0.9	1129	1	ADAA84566	Novel human secret
C 139	21.4	0.9	1129	1	ADAA97461	Novel human secret
C 140	21.4	0.9	1129	1	ADBA27218	Novel human secret
C 141	21.4	0.9	1129	1	ADBA22151	Novel human secret
C 142	21.4	0.9	1129	1	ADAA66842	Novel human secret
C 143	21.4	0.9	1129	1	ADBA22703	Novel human secret
C 144	21.4	0.9	1129	1	ADBA23476	Novel human secret
C 145	21.4	0.9	1129	1	ADAA92198	Novel human secret
C 146	21.4	0.9	1129	1	ADBA15261	Novel human secret
C 147	21.4	0.9	1129	1	ADBA38513	Novel human secret
C 148	21.4	0.9	1129	1	ADBA37961	Novel human secret
C 149	21.4	0.9	1129	1	ADBA66433	Novel human secret
C 150	21.4	0.9	1129	1	ADBA89513	Novel human secret
C 151	21.4	0.9	1129	1	ADBA90245	Novel human secret
C 152	21.4	0.9	1129	1	ADBA33346	Novel human secret
C 153	21.4	0.9	1129	1	ADBA46969	Novel human secret
C 154	21.4	0.9	1129	1	ADBA86576	Novel human secret
C 155	21.4	0.9	1129	1	ADBA77181	Novel human secret
C 156	21.4	0.9	1129	1	ADBA34338	Novel human secret
C 157	21.4	0.9	1129	1	ADBA35442	Novel human secret
C 158	21.4	0.9	1129	1	ADBA33786	Novel human secret
C 159	21.4	0.9	1129	1	ADBA34890	Novel human secret
C 160	21.4	0.9	1129	1	ADBA35994	Novel human secret
C 161	21.4	0.9	1129	1	ADBA46389	Novel human secret
C 162	21.4	0.9	1129	1	ADBA50262	Novel human secret
C 163	21.4	0.9	1129	1	ADBA71809	Novel human secret
C 164	21.4	0.9	1129	1	ADBA59788	Novel human secret
C 165	21.4	0.9	1129	1	ADBA52795	Novel human secret
C 166	21.4	0.9	1129	1	ADBA57149	Novel human secret
C 167	21.4	0.9	1129	1	ADBA60340	Novel human secret
C 168	21.4	0.9	1129	1	ADBA50815	Novel human secret
C 169	21.4	0.9	1129	1	ADBA65342	Novel human secret
C 170	21.4	0.9	1129	1	ADBA54440	Novel human secret
C 171	21.4	0.9	1129	1	ADBA53401	Novel human secret
C 172	21.4	0.9	1129	1	ADBA58924	Novel human secret
C 173	21.4	0.9	1129	1	ADBA55802	Novel human secret
C 174	21.4	0.9	1129	1	ADBA58372	Novel human secret
C 175	21.4	0.9	1129	1	ADBA03046	Novel human secret
C 176	21.4	0.9	1129	1	ADBA90038	Novel human secret
C 177	21.4	0.9	1129	1	ADBA69457	Novel human secret
C 178	21.4	0.9	1129	1	ADBA48346	Novel human secret
C 179	21.4	0.9	1129	1	ADBA09875	Novel human secret

C 180	21.4	0.9	1129	1	ADBA04450	Novel human secret
C 181	21.4	0.9	1129	1	ADCD80406	Novel human secret
C 182	21.4	0.9	1129	1	ADBI09113	Human PRO polynucle
C 183	21.4	0.9	1129	1	ADCA7794	Human PRO polynucle
C 184	21.4	0.9	1129	1	ADCA79854	Human PRO polynucle
C 185	21.4	0.9	1129	1	ADDA09323	Novel human secret
C 186	21.4	0.9	1129	1	ADDA10336	Novel human secret
C 187	21.4	0.9	1129	1	ADDA52175	Novel human secret
C 188	21.4	0.9	1129	1	ADDA52915	Novel human secret
C 189	21.4	0.9	1129	1	ADDA53467	Novel human secret
C 190	21.4	0.9	1129	1	ADDA51623	Novel human secret
C 191	21.4	0.9	1129	1	ADDA02422	Novel human secret
C 192	21.4	0.9	1129	1	ADDA01856	Novel human secret
C 193	21.4	0.9	1129	1	ADDA54038	Novel human secret
C 194	21.4	0.9	1129	1	ADDA92355	Novel human secret
C 195	21.4	0.9	1129	1	ADDA91251	Novel human secret
C 196	21.4	0.9	1129	1	ADDA03865	Novel human secret
C 197	21.4	0.9	1129	1	ADDA32162	Novel human secret
C 198	21.4	0.9	1129	1	ADDA22094	Novel human secret
C 199	21.4	0.9	1129	1	ADDA79318	Novel human secret
C 200	21.4	0.9	1129	1	ADDA1854	Novel human secret
C 201	21.4	0.9	1129	1	ADDA17671	Novel human secret
C 202	21.4	0.9	1129	1	ADDA1803	Novel human secret
C 203	21.4	0.9	1129	1	ADDA3266	Novel human secret
C 204	21.4	0.9	1129	1	ADDA33818	Novel human secret
C 205	21.4	0.9	1129	1	ADDA79870	Novel human secret
C 206	21.4	0.9	1129	1	ADDA92907	Novel human secret
C 207	21.4	0.9	1129	1	ADDA19327	Novel human secret
C 208	21.4	0.9	1129	1	ADDA18775	Novel human secret
C 209	21.4	0.9	1129	1	ADDA2971	Novel human secret
C 210	21.4	0.9	1129	1	ADDA95760	Novel human secret
C 211	21.4	0.9	1129	1	ADDA22646	Novel human secret
C 212	21.4	0.9	1129	1	ADDA78764	Novel human secret
C 213	21.4	0.9	1129	1	ADDA32714	Novel human secret
C 214	21.4	0.9	1129	1	ADDA42406	Novel human secret
C 215	21.4	0.9	1129	1	ADDA80422	Novel human secret
C 216	21.4	0.9	1129	1	ADDA89450	Novel human secret
C 217	21.4	0.9	1129	1	ADDA40734	Novel human secret
C 218	21.4	0.9	1129	1	ADDA04533	Novel human secret
C 219	21.4	0.9	1129	1	ADDA80958	Novel human secret
C 220	21.4	0.9	1129	1	ADDA76406	Novel human secret
C 221	21.4	0.9	1129	1	ADDA87770	Novel human secret
C 222	21.4	0.9	1129	1	ADDA86174	Novel human secret
C 223	21.4	0.9	1129	1	ADDA75622	Novel human secret
C 224	21.4	0.9	1129	1	ADDA23198	Novel human secret
C 225	21.4	0.9	1129	1	ADDA23750	Novel human secret
C 226	21.4	0.9	1129	1	ADDA24393	Novel human secret
C 227	21.4	0.9	1129	1	ADDA87218	Novel human secret
C 228	21.4	0.9	1129	1	ADDA89084	Novel human secret
C 229	21.4	0.9	1129	1	ADDA18223	Novel human secret
C 230	21.4	0.9	1129	1	ADDA88532	Novel human secret
C 231	21.4	0.9	6098	1	ADDA14193	Novel human secret
C 232	21.2	0.9	121	1	ADDA79647	Novel human secret
C 233	21.2	0.9	121	1	ADDA79646	Novel human secret
C 234	21.2	0.9	121	1	ADDA79642	Novel human secret
C 235	21.2	0.9	305	1	ADDA68969	Novel human secret
C 236	21.2	0.9	286	1	ADDA76656	Novel human secret
C 237	21.1	0.9	267	1	ADDA83246	Novel human secret
C 238	21.1	0.9	267	1	ADDA83246	Novel human secret
C 239	21.1	0.9	372	1	ADDA37095	Novel human secret
C 240	20.8	0.9	263	1	ADDA20194	Novel human secret
C 241	20.8	0.9	263	1	ADDA65223	Novel human secret
C 242	20.8	0.9	263	1	ADDA45394	Novel human secret
C 243	20.8	0.9	263	1	ADDA47338	Novel human secret
C 244	20.8	0.9	263	1	ADDA32324	Novel human secret
C 245	20.8	0.9	263	1	ADDA33381	Novel human secret
C 246	20.8	0.9	263	1	ADDA13640	Novel human secret
C 247	20.8	0.9	263	1	ADDA38969	Novel human secret
C 248	20.8	0.9	263	1	ADDA10589	Novel human secret
C 249	20.8	0.9	263	1	ADDA13468	Novel human secret
C 250	20.8	0.9	280	1	ADDA22885	Novel human secret

Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	Novel human secret	
--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--

[illegible]

7778

KW pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
 KW vascular adhesion; coagulation factor; factor VII/VIIa; ss.
 OS Homo sapiens.
 XX US5877289-A.
 PN 02-MAR-1999.
 XX 07-JUN-1995; 95US-00479733.
 XX 05-MAR-1992; 92US-00846349.
 PR 02-MAR-1994; 94US-00205330.
 PR 11-JUL-1994; 94US-00273567.
 XX (SCRI) SCRIPPS RES INST.
 PA (TEXA) UNIV TEXAS SYSTEM.
 PA Edgington TS, Thorpe PE;
 XX WPI; 1999-189722/16.
 XX Tissue factor binding ligands - comprising first binding region which
 PT binds to vasculature, particularly of tumours, and tissue factor
 PT construct.
 XX Example 9; Col 125-128; 83pp; English.
 PS The present sequence encodes a coagulation factor. The specification
 CC describes tissue factor binding ligands which comprise a binding region
 CC which binds to vasculature, particularly of tumours, and a tissue factor
 CC construct. The binding ligands can be used for stimulating coagulation in
 CC disease-associated vasculature, particularly for the treatment of
 CC tumours. The products can also be used for treating e.g. benign prostatic
 CC hyperplasia, diabetic-retinopathy, vascular restenosis, arteriovenous
 CC malformations (AVM), meningioma, hemangioma, neovascular glaucoma,
 CC psoriasis, synovitis, dermatitis, endometriosis, angiofibroma, rheumatoid
 CC arthritis, atherosclerotic plaques, corneal graft neovascularisation,
 CC haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic
 CC granuloma retrolental fibroplasia, scleroderma, trachoma, or vascular
 CC adhesions. The products can also be used in binding assays
 XX
 SQ Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;
 Query Match 1.9%; Score 43; DB 1; Length 2462;
 Best Local Similarity 58.0%; Pred. No. 8.5e-05;
 Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1058 TGTGAGAAATATCAATGAGCAGTGTGTTGTGATCTTGTGATCTTGTGCACTTGTGAAGTG 1117
 DB 2007 TGTGCATATCTATGTCGGTGCATCGGTGTGTTGGTATCTCTGTGTGACCATCTG 1948
 QY 1118 TG 1177
 DB 1947 TGTGTGCATCCGTGTGTGTGTCATATCTCTGTGTGTGTGTCATTCGGCGTGTGTGTGCA 1888
 QY 1178 TCTGTGTCTGT 1188
 DB 1887 TCCAATGTGTGT 1877
 RESULT 7
 ID AAA12968/c
 XX AAA12968 standard; DNA; 2462 BP.
 AC AAA12968;
 XX 18-JUL-2000 (first entry)
 DT DNA encoding Factor VII/VIIa, SEQ ID NO:25.
 DE Truncated tissue factor; tTF; human; blood coagulation;
 KW tumour vasculature; bispecific antibody; targeting; cancer;
 KW

KW vascularised tumour; PCR primer; ss.
 XX Homo sapiens.
 XX US6036955-A.
 XX 14-MAR-2000.
 XX 07-JUN-1995; 95US-00479727.
 XX 05-MAR-1992; 92US-00846349.
 PR 02-MAR-1994; 94US-00205330.
 PR 11-JUL-1994; 94US-00273567.
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA (SCRI) SCRIPPS RES INST.
 PA Edgington TS, Thorpe PE;
 PI WPI; 2000-269871/23.
 DR Kit for inducing coagulation in tumor vasculature, useful for treating
 XX malignant or benign growths, contains ligand, linked to coagulation
 XX agent, that targets tumor marker.
 XX Example 9; Col 127-130; 86pp; English.
 XX The invention relates to the induction of blood coagulation specifically
 CC within tumor vasculature. This is achieved by the use of a bispecific
 CC molecule, which comprises a region capable of binding to intratumoral
 CC vascular or stromal cells linked to a coagulation factor or to a region
 CC capable of binding to a coagulation factor. An example of such a
 CC bispecific molecule is a bispecific antibody, where one arm binds a
 CC tumor antigen, and the other arm binds a coagulation factor. The
 CC expression of certain proteins (tumor antigens) is upregulated in tumor
 CC vasculature; such proteins include vascular endothelial growth factor
 CC (VEGF) and members of the fibroblast growth factor (FGF) family. An
 CC antibody or antibody fragment against VEGF or basic FGF (bFGF) may be
 CC incorporated into the bispecific molecule in order to target coagulation
 CC to tumor vasculature. The coagulation factor-binding portion of the
 CC bispecific molecule may be, for example, directed to tissue factor (TF).
 CC A preferred form of TF used in the invention is a truncated form (tTF).
 CC AA81488 which lacks the cytoplasmic and transmembrane domains. Although
 CC tTF can associate with Factor VIIa, the tTF/Factor VIIa complex cannot
 CC alone initiate the coagulation cascade as the complex has to be
 CC associated with a phospholipid surface for coagulation to occur. However,
 CC binding of tTF to tumor vasculature via a tumor antigen/tTF bispecific
 CC antibody brings tTF into close enough proximity with the cell membrane to
 CC enable the initiation of coagulation. Kits for the induction of tumor
 CC vasculature-specific coagulation may be used to treat malignant or benign
 CC diseases associated with a vascular component, particularly cancers, but
 CC also benign growths, prostatic hypertrophy, restenosis, psoriasis,
 CC glaucoma, rheumatoid arthritis. Coagulation is induced selectively in the
 CC tumor vasculature, minimising side effects. Such kits are likely to be
 CC effective against many different types of cancer. Sequences AAA12945-
 CC AAA12952, AAA12954-A12963 and AAA12971-A12972 represent PCR primers used
 CC in exemplifications of the present invention to generate constructs
 CC encoding tTF, tTF variants or tTF dimers
 XX
 SQ Sequence 2462 BP; 590 A; 724 C; 721 G; 427 T; 0 U; 0 Other;
 Query Match 1.9%; Score 43; DB 1; Length 2462;
 Best Local Similarity 58.0%; Pred. No. 8.5e-05;
 Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1058 TGTGAGAAATATCAATGAGCAGTGTGTTGTGATCTTGTGATCTTGTGCACTTGTGAAGTG 1117
 DB 2007 TGTGCATATCTATGTCGGTGCATCGGTGTGTTGGTATCTCTGTGTGACCATCTG 1948
 QY 1118 TG 1177
 DB 1947 TGTGTGCATCCGTGTGTGTGTCATATCTCTGTGTGTGTGTCATTCGGCGTGTGTGTGCA 1888
 QY 1178 TCTGTGTCTGT 1188
 DB 1887 TCCAATGTGTGT 1877

Db 1947 TGATGCAATCCGTTGTGTGCATATCTGTGTGTGCATTGCGTGTGTGTGTGCA 1888

Qy 1178 TCTGTGTCTGT 1188

Db 1887 TCCATGTGTGT 1877

```

RESULT 13
AAN60064/c
ID AAN60064 standard; DNA; 2483 BP.
XX
XX AAN60064;
XX
XX 25-MAR-2003 (revised)
XX DT 31-OCT-2002 (revised)
XX DT 23-MAY-1991 (first entry)
XX
XX Factor VII cDNA of lambda VII2463.
XX
XX Factor VII; Factor VIIa; DNA construct.
XX
XX Unidentified.
XX OS
XX
XX Key Location/Qualifiers
XX CDS 36..1436
XX FT /*tag= a
XX
XX EP200421-A.
XX
XX 10-DEC-1986.
XX
XX 16-APR-1986; 86EP-00302855.
XX
XX 17-APR-1985; 85US-00724311.
XX PR 16-DEC-1985; 85US-00810002.
XX
XX (ZYMO ) ZYMOGENETICS INC.
XX PA
XX
XX Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
XX
XX WPI; 1986-326899/50.
XX DR P-PSDB; AAP60056.
XX
XX DNA construct used to transfect hosts - to produce protein which
XX activates to give factor VIIa.
XX
XX Disclosure; Fig 1B; 55pp; English.
XX PS
XX
XX The partial factor VII cDNA sequence is from cDNA clonl lambda VII2463.
XX It is used in a DNA construct which contains a nucleotide sequence
XX encoding a protein which, on activation, has the same biological activity
XX for blood coagulation as Factor IIa. The nucleotide codes at least
XX partially for Factor VII and comprises sequence encoding a calcium
XX binding domain joined to a second sequence downstream of this encoding a
XX catalytic domain for the serine protease activity of Factor VIIa. The
XX calcium binding domain comprises a gene encoding Factor VII, IX, X,
XX Protein C, prothrombin or Protein S. The construct is used to transfect
XX host cells to produce the protein which, on activation, yields Factor
XX VIIa. (Updated on 31-OCT-2002 to add missing OS field.) (Updated on 25-
XX MAR-2003 to correct PA field.)
XX
XX Sequence 2483 BP; 611 A; 725 C; 720 G; 427 T; 0 U; 0 Other;

```

Db 1947 TGTGTGCATCCGCGTGTGTGCATCTGTGTGTGCATTGGCGGTGTGTGTGCA 1888

Qy 1178 TCTGTGTCTGT 1188

Db 1887 TCCATGTGTGT 1877

RESULT 14	
AAN60063/c	
ID	AAN60063 standard; cDNA; 2177 BP.
XX	
XX	AAN60063;
XX	
XX	25-MAR-2003 (revised)
DT	31-OCT-2002 (revised)
DT	23-MAY-1991 (first entry)
XX	
XX	Partial Factor VII cDNA.
DE	
XX	
XX	Factor VII; Factor VIIa; DNA construct.
KW	
XX	
OS	Homo sapiens.
XX	
XX	
FH	Key Location/Qualifiers
FT	13. .1128
FT	/*tag= a
XX	
PN	EP200421-A.
XX	
XX	10-DEC-1986.
PD	
XX	
XX	16-APR-1986; 86EP-00302855.
PF	
XX	
XX	17-APR-1985; 85US-00724311.
PR	
PR	16-DEC-1985; 85US-00810002.
XX	
XX	(ZYMO) ZYMOGENETICS INC.
PA	
XX	
XX	Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
PI	
XX	
XX	WPI; 1986-326899/50.
DR	
DR	P-PSDE; AAP60055.
XX	
XX	DNA construct used to transfect hosts - to produce protein which
PT	activates to give factor VIIa.
PT	
XX	
PS	Disclosure; Fig 1A; 55pp; English.
XX	
CC	The partial factor VII cDNA sequence is produced by joining portions of
CC	cDNA clones lambda VII115 and lambda VII1923. It is used in a DNA
CC	construct which contains a nucleotide sequence encoding a protein which,
CC	on activation, has the same biological activity for blood coagulation as
CC	Factor Ila. The nucleotide codes at least partially for Factor VII and
CC	Factor Ila. The nucleotide codes at least partially for Factor VII and
CC	comprises a sequence encoding a calcium binding domain joined to a second
CC	sequence downstream of this encoding a catalytic domain for the serine
CC	protease activity of Factor VII. IX, X, Protein C, prothrombin or Protein S. The
CC	gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC	construct is used to transfect host cells to produce the protein which,
CC	on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC	OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX	
XX	Sequence 2177 BP: 569 A; 624 C; 605 G; 379 T; 0 U; 0 Other;

```
Db      1695 TCATATCTCTATGCGGTGCATCGGTGTTTCGCTACTCTGTGTGACCATCTGTGT 1636
QY      1200 CTGTGTTTC 1207
Db      1635 GTGCATCC 1628

RESULT 15
AAN60065/c
ID      AAN60065 standard; DNA; 2438 BP.
XX
AC      AAN60065;
XX
DT      25-MAR-2003 (revised)
DT      31-OCT-2002 (revised)
DT      23-MAY-1991 (first entry)
XX
DE      Factor IX/Factor VII cDNA fusion.
XX
KW      Factor VII; Factor IX; DNA construct.
XX
OS      Unidentified.
XX
FH      Key      Location/Qualifiers
FT      CDS      7..1368
FT      /*tag= a
XX
PN      EP200421-A.
XX
PD      10-DEC-1986.
XX
PF      16-APR-1986; 86EP-00302855.
XX
PR      17-APR-1985; 85US-00724311.
PR      16-DEC-1985; 85US-00810002.
XX
PA      (ZYMO ) ZYMOGENETICS INC.
XX
PI      Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;
XX
DR      WPI; 1986-326899/50.
XX
DR      P-PSDB; AAP60057.
XX
PT      DNA construct used to transfect hosts - to produce protein which
PT      activates to give factor VIIa.
XX
PS      Disclosure; Fig 7; 55pp; English.
XX
CC      The cDNA is a fusion of Factor IX and Factor VII. It is used to express
CC      Factor IX and Factor VII. cDNA encoding Factor VII can be used in DNA
CC      construct which contains a nucleotide sequence encoding a protein which,
CC      on activation, has the same biological activity for blood coagulation as
CC      Factor Ila. The nucleotide codes at least partially for Factor VII and
CC      comprises a sequence encoding a calcium binding domain joined to a second
CC      sequence downstream of this encoding a catalytic domain for the serine
CC      protease activity of Factor VIIa. The calcium binding domain comprises a
CC      gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The
CC      construct is used to transfect host cells to produce the protein which,
CC      on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing
CC      OS field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ      Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;

Query Match      1.8%; Score 41.6; DB 1; Length 2438;
Best Local Similarity 57.8%; Pred. No. 0.0002;
Matches 74; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY      1080 GGTGTGCGATCTGTGTTATCTTCGACTTGTGAAGTGTGTGTGTGTGTGTGTGTG 1139
Db      1995 GTGTGCGTCATGGCATGGTGGTGACGCCAATGATATCTGTGTGTGTCATCTGTGTG 1936
QY      1140 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1199
```

```
Db      1935 TCATATCTCTATGCGGTGCATCGGTGTTTCGCTACTCTGTGTGACCATCTGTGT 1876
QY      1200 CTGTGTTTC 1207
Db      1875 GTGCATCC 1868

RESULT 16
AAZ12625
ID      AAZ12625 standard; cDNA; 300 BP.
XX
AC      AAZ12625;
XX
DT      12-OCT-1999 (first entry)
XX
DE      Human gene expression product cDNA sequence SEQ ID NO:94.
XX
KW      Human; gene; gene expression product; diagnosis; therapy; probe;
KW      detection; mapping; tissue typing; profiling; forensic; cancer;
KW      genetic analysis; colorectal cancer; breast cancer; lung cancer; ss.
XX
OS      Homo sapiens.
XX
PN      WO9938972-A2.
XX
PD      05-AUG-1999.
XX
PF      28-JAN-1999; 99WO-US001619.
XX
PR      28-JAN-1998; 98US-0072910P.
PR      24-FEB-1998; 98US-0075954P.
PR      31-MAR-1998; 98US-0080114P.
PR      03-APR-1998; 98US-0080515P.
PR      03-APR-1998; 98US-0080666P.
PR      21-OCT-1998; 98US-0105234P.
PR      28-OCT-1998; 98US-0105877P.
XX
PA      (CHIR ) CHIRON CORP.
PA      (HYSE-) HYSEQ INC.
XX
PI      Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
PI      Reinhard C, Giese K, Randazzo F, Kennedy GC, Pot D, Kassam A;
PI      Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
PI      Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX
DR      WPI; 1999-494092/41.
XX
PT      Novel human genes and their expression products which are differentially
PT      expressed in different cell types.
XX
PS      Claim 1; Page 683; 2479pp; English.
XX
CC      The present invention describes a library of human polynucleotides
CC      comprising the sequences given in AAZ12532 to AAZ17779. Also described is
CC      a method of detecting differentially expressed genes correlated with the
CC      cancerous state of a mammalian cell, comprising detecting at least one
CC      differentially expressed gene product in a test sample from a cell
CC      suspected of being cancerous, where the gene product is encoded by one of
CC      the 5248 polynucleotide sequences given in AAZ12532 to AAZ17779. The
CC      polynucleotides can be used as a source of primers and probes, which can
CC      be used for a variety of purpose, e.g. detection of expression levels,
CC      mapping, tissue typing or profiling, forensics, genetic analysis and
CC      detection of polymorphisms. Polypeptides encoded by the polynucleotides
CC      can be used for raising antibodies for experimental, diagnostic and
CC      therapeutic purposes. The polynucleotides may also be used to construct
CC      arrays for diagnostics (which may be used to determine function of an
CC      encoded protein); and to detect differences in expression levels between
CC      two cells (e.g. to identify abnormal or diseased tissue in a human, to
CC      identify a genetic predisposition or susceptibility to a disease such as
CC      cancer). The polynucleotides of the invention are especially used in the
CC      diagnosis, prognosis and management of colorectal cancer, breast cancer,
CC      and lung cancer. The polynucleotides can also be used to screen for
```


[illegible]

XX DR WPI; 2000-611722/58.
XX PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
PS Claim 1; Fig 5; 214pp; English.
XX CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases. Note: The degenerate codon within the sequence represents the
CC position of an SNP, for example the letter S represents a polymorphism
XX where the nucleotide may be C or G
SQ Sequence 271 BP; 82 A; 43 C; 62 G; 83 T; 0 U; 1 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 271;
Best Local Similarity 50.0%; Pred. No. 23;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 114 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGCTTAAGAAATTG 55
QY 2228 CTTTGGCATATAGCGGCTGAGTTGGGATGATTGTAATCTAGGTGCTGAT 2279
Db 54 AATTGCACGTAACACTGCTTAGAATGCCCGGTCCTCCCTGTAGATACTCAT 3

RESULT 38
AA111531/c
ID AA111531 standard; DNA; 476 BP.
XX AC AA111531;
XX DT 12-OCT-2001 (first entry)
XX DE Probe #1464 for gene expression analysis in human cervical cell sample.
XX KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer; ss.
XX OS Homo sapiens.
XX FN WO200157278-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000670.
XX PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488901/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing

PT gene expression in human cervical epithelial cells.
XX Claim 25; SEQ ID NO 1464; 487pp; English.
XX CC The present invention relates to human single exon nucleic acid probes
CC (SENPs). The present sequence is one such probe. The SENPs are derived
CC from human HeLa cells. The SENPs can be used to produce a single exon
CC microarray, which can be used for measuring human gene expression in a
CC sample derived from human cervical epithelial cells. By measuring gene
CC expression, the probes are therefore useful in grading and/or staging of
CC diseases of the cervix, notably cervical cancer. Note: The sequence data
CC for this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGCTTAAGAAATTG 298
QY 2228 CTTTGGCATATAGCGGCTGAGTTGGGATGATTGTAATCTAGGTGCTGAT 2279
Db 297 AATTGCACGTAACACTGCTTAGAATGCCCGGTCCTCCCTGTAGATACTCAT 246
RESULT 39
ABA53212/c
ID ABA53212 standard; DNA; 476 BP.
XX AC ABA53212;
XX DT 01-FEB-2002 (first entry)
XX DE Human foetal liver single exon nucleic acid probe #1517.
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX OS Homo sapiens.
XX FN WO200157277-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000669.
XX PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483447/52.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX Claim 1; SEQ ID NO 1517; 639pp + Sequence Listing; English.
XX CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The

CC present sequence is a single exon nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2168 CTATTGTAATAGGTTTACAGGACATATTGCTCGTGTGTTATGTCGTGTTTGG 2227
Db 357 CCATTTAAACATGAGTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGACGGCTGAGTTGGGATGTTGTAATCTAGGTCGTGAT 2279
Db 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246

RESULT 41
AAI32810/c
ID AAI32810 standard; DNA; 476 BP.
XX
AC AAI32810;
XX
DT 17-OCT-2001 (first entry)
XX
DE Probe #1496 used to measure gene expression in human placenta sample.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
XX genetic disorder; ss.
XX
OS Homo sapiens.
XX
FN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-48897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 25; SEQ ID NO 1496; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP).
CC The present sequence is one such probe. The probes are useful for
CC producing a microarray for predicting, measuring and displaying gene
CC expression in samples derived from human placenta. The probes are useful
CC for antenatal diagnosis of human genetic disorders
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 2168 CTATTGTAATAGGTTTACAGGACATATTGCTCGTGTGTTATGTCGTGTTTGG 2227

Db 357 CCATTTAAACATGAGTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGACGGCTGAGTTGGGATGTTGTAATCTAGGTCGTGAT 2279
Db 297 AATTGGCAGTAAACTGCTTAGAATGCCGGTCTCCCTGTAGATACTCAT 246

RESULT 41
ABA42785/c
ID ABA42785 standard; DNA; 476 BP.
XX
AC ABA42785;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human breast cell single exon nucleic acid probe #1480.
XX
KW Human; microarray; single exon probe; gene expression; breast; disease;
KW cancer; ss.
XX
OS Homo sapiens.
XX
FN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000662.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes, useful
PT for measuring gene expression in sample derived from human breast,
XX comprises number of single exon nucleic acid probes.
XX
PS Claim 1; SEQ ID NO 1480; 327pp + Sequence Listing; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting the
CC probes with a collection of detectably labelled nucleic acids derived
CC from mRNA of human breast, and then measuring the label bound to each
CC probe of the microarray. The probes are useful for verifying the
CC expression of regions of genomic DNA predicted to encode proteins. They
CC are useful for gene discovery, and for determining predisposition and/or
CC prognosing breast disease. Gene expression analysis is useful for
CC assessing the toxicity of chemical agents on cells. The microarray of
CC this invention presents a far greater diversity of probes for measuring
CC gene expression, with far less bias than expressed sequence tag
CC microarrays. The method is suitable for rapid production of functional
CC information from genomic sequence. The present sequence is a single exon
CC nucleic acid probe of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;

Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298
QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGTGCTGAT 2279
Db 297 AATTGGCACGTAACCTGCTTAGAATGCCGGTCTCCCTGTAGATCTCAT 246
RESULT 42
ID ABA22986/c
XX ABA22986 standard; DNA; 476 BP.
AC ABA22986;
XX
DT 23-JAN-2002 (first entry)
DE Probe #1452 for gene expression analysis in human heart cell sample.
XX
KW Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human hearts.
XX
PS Claim 1; SEQ ID NO 1452; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for measuring human gene expression in a sample derived from human heart. The present sequence is one such probe. The probes may be used for predicting, measuring and displaying gene expression in samples derived from the human heart via microarrays. By measuring gene expression, the probes are useful for predicting, diagnosing, grading, staging, monitoring and prognosing diseases of the human heart and vascular system e.g. cardiovascular disease, hypertension, cardiac arrhythmias and congenital heart disease. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298

QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGTGCTGAT 2279
Db 297 AATTGGCACGTAACCTGCTTAGAATGCCGGTCTCCCTGTAGATCTCAT 246
RESULT 43
ID AAK26907/c
XX AAK26907 standard; DNA; 476 BP.
AC AAK26907;
XX
DT 06-NOV-2001 (first entry)
DE Human bone marrow expressed single exon probe SEQ ID NO: 1464.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 1464; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid probes which are derived from genomic sequences expressed in the human bone marrow. They can be used to measure gene expression in bone marrow samples, which may enable the improved diagnosis and treatment of cancers such as lymphoma, leukaemia and myeloma. The present sequence is one of the probes of the invention
XX
SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
QY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCAITTAACATGGATTGGACTCACACATGATCTCCATCTTTAGATAGGTTAAGAAATTG 298
QY 2228 CTTTGGCATATAGCGGCTGAGTTTGGGATGATTGTAATTTCTAGTGCTGAT 2279
Db 297 AATTGGCACGTAACCTGCTTAGAATGCCGGTCTCCCTGTAGATCTCAT 246
RESULT 44
ID AAK01461/c
XX AAK01461 standard; DNA; 476 BP.
AC AAK01461;
XX

```
DT 05-NOV-2001 (first entry)
XX Human brain expressed single exon probe SEQ ID NO: 1452.
DE
XX Human, brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
KW ss.
XX Homo sapiens.
XX
XX WO200157275-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483446/52.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
XX brains.
XX
XX Example 4; SEQ ID NO 1452; 650pp + Sequence Listing; English.
XX
XX The present invention provides a number of single exon nucleic acid
XX probes which are derived from genomic sequences expressed in the human
XX brain. They can be used to measure gene expression in brain cell samples,
XX which may enable the diagnosis and improved treatment of nervous system
XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX epilepsy and cancers. The present sequence is one of the probes of the
XX invention
XX
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2168 CTATTGTAATAGGGTTTATAGCAGGACATATGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGACGCTGAGTTGGATGATGTAATTCCTAGTGTCTGAT 2279
Db 297 AATTGGCAGCTAAACTGCTTAGAATGCCCGTCTCCCTGTAGATACTCAT 246
RESULT 45
ABS26497/C
XX ID ABS26497 standard; DNA; 476 BP.
XX
XX ABS26497;
XX
XX 25-FEB-2003 (first entry)
XX
XX Human liver single exon probe, SEQ ID No 1487.
XX
XX Human, single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
XX Homo sapiens.
XX
XX OS
```

```
XX WO200157273-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488898/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX
XX Claim 1; SEQ ID NO 1487; 658pp; English.
XX
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABS25011-ABS51005 represent human
XX liver single exon nucleic acid probes of the invention. Note: The
XX sequence information for this patent does not appear in the printed
XX specification but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.4; DB 1; Length 476;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
Qy 2168 CTATTGTAATAGGGTTTATAGCAGGACATATGTCCTGGTTGTTATTGTCGTGTTTGG 2227
Db 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGACGCTGAGTTGGATGATGTAATTCCTAGTGTCTGAT 2279
Db 297 AATTGGCAGCTAAACTGCTTAGAATGCCCGTCTCCCTGTAGATACTCAT 246
RESULT 46
AAI01449/C
XX ID AAI01449 standard; DNA; 476 BP.
XX
XX AAI01449;
XX
XX 09-OCT-2001 (first entry)
XX
XX Probe #1440 used to measure gene expression in human breast sample.
XX
XX Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
XX Homo sapiens.
XX
XX WO200157270-A2.
XX
```

```
PD 09-AUG-2001.
XX 29-JAN-2001; 2001WO-US000661.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-476286/51.
XX Novel single exon nucleic acid probe used to measuring gene expression in
XX a human breast.
XX Claim 25; SEQ ID NO 1440; 322pp; English.
XX The present invention relates to novel single exon nucleic acid probes.
XX The present sequence is one such probe. The probes are useful for
XX measuring human gene expression in a human breast sample, where the probe
XX hybridizes at high stringency to a nucleic acid expressed in the human
XX breast. The probes are useful for predicting, diagnosing, grading,
XX staging, monitoring and prognosing diseases of the human breast,
XX particularly those diseases with polygenic aetiology. The diseases
XX include: breast cancer, disorders of development, inflammatory diseases
XX of the breast, fibrocystic changes, proliferative breast disease and non-
XX carcinoma tumours. Note: The sequence data for this patent did not form
XX part of the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 25;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
XX
Qy 2168 CTATTGTAATAGGGTTTACGAGGACATATTGCTGCTGTTTATTGTCGTGTTTGG 2227
Db 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 298
Qy 2228 CTTTGGCATATAGCGCTGAGTTGGATGATTTGTAATTCAGTGCTGAT 2279
Db 297 AATTGGCAGTAACTGCTTAGAATGCCCGTCTCCCTGTAGATACATCAT 246
RESULT 47
ABS01506/C
ID ABS01506 standard; DNA; 476 BP.
XX ABS01506;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human genome-derived single exon probe from lung SEQ ID No 1497.
XX
XX Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
XX chronic obstructive pulmonary disease; interstitial lung disease;
XX familial idiopathic pulmonary fibrosis; neurofibromatosis;
XX tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
XX Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
XX pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
XX pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
XX primary ciliary dyskinesia; pulmonary hypertension;
XX hyaline membrane disease.
XX
XX Homo sapiens.
XX
OS
XX
```

```
PN WO200186003-A2.
XX 15-NOV-2001.
XX 30-JAN-2001; 2001WO-US000665.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2002-114183/15.
XX Spatially-addressable set of single exon nucleic acid probes, used to
XX measure gene expression in human lung samples.
XX Claim 1; SEQ ID NO 1497; 634pp; English.
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human lung comprising single exon nucleic acid probes having one of
XX 12614 nucleic acid sequences mentioned in the specification, or their
XX complements or the 12387 open reading frames derived from the 12614
XX probes. Also included are a microarray comprising the novel set of probes
XX; the novel set of probes which hybridise at high stringency to a nucleic
XX acid expressed in the human lung; measuring gene expression in a sample
XX derived from human lung, comprising (a) contacting the array with a
XX collection of detectably labeled nucleic acids derived from human lung
XX mRNA, and (b) measuring the label detectably bound to each probe of the
XX array; identifying exons in a eukaryotic genome, comprising (a)
XX algorithmically predicting at least one exon from genomic sequences of
XX the eukaryote; and (b) detecting specific hybridisation of detectably
XX labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
XX having a fragment identical to the predicted exon, the probe is included
XX in the above mentioned microarray; assigning exons to a single gene,
XX comprising (a) identifying exons from genomic sequence by the method
XX above and (b) measuring the expression of each of the exons in several
XX tissues and/or cell types using hybridisation to a single exon
XX microarrays having a probe with the exon, where a common pattern of
XX expression of the exons in the tissues and/or cell types indicates that
XX the exons should be assigned to a single gene; a peptide comprising one
XX of 12011 sequences, mentioned in the specification, or encoded by the
XX probes/open reading frames (ORF). The probes are used for gene expression
XX analysis, and for identifying exons in a gene, particularly using human
XX lung derived mRNA and for the study of lung diseases such as asthma, lung
XX cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
XX disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
XX tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
XX Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
XX histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
XX Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
XX dyskinesia, pulmonary hypertension and hyaline membrane disease. The
XX present sequence is a single exon probe of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 476 BP; 125 A; 104 C; 99 G; 148 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.4; DB 1; Length 476;
XX Best Local Similarity 50.0%; Pred. No. 25;
XX Matches 56; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
XX
Qy 2168 CTATTGTAATAGGGTTTACGAGGACATATTGCTGCTGTTTATTGTCGTGTTTGG 2227
Db 357 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 298
```

```
QY 2228 CTTTGGCATATAGACGCTGAGTTTGGGATGATTGTAATTTCTAGGTGCTGAT 2279
DB 297 AATTGGACGCTAAACTCTTAGAATGCCCGTCTCCCTCTGTAGATCTCAT 246

RESULT 48
AAI19676/c
ID AAI19676 standard; DNA; 301 BP.
AC AAI19676;
XX
XX
XX 12-OCT-2001 (first entry)
XX
XX Probe #9609 for gene expression analysis in human cervical cell sample.
XX
XX Probe; human; microarray; gene expression; cervical epithelial cell;
XX KW cervical cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157278-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488901/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human cervical epithelial cells.
XX
XX Claim 25; SEQ ID NO 9609; 487pp; English.
XX
XX The present invention relates to human single exon nucleic acid probes
XX (SENPs). The present sequence is one such probe. The SENPs are derived
XX from human HeLa cells. The SENPs can be used to produce a single exon
XX microarray, which can be used for measuring human gene expression in a
XX sample derived from human cervical epithelial cells. By measuring gene
XX expression, the probes are therefore useful in grading and/or staging of
XX diseases of the cervix, notably cervical cancer. Note: The sequence data
XX for this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 26;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1732 TTTGACCTGCTCTTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1791
DB 277 TCTGCGCTGCTTACCTCTGCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCT 218

QY 1792 CTTGGAT 1798
DB 217 TCTAGCT 211

Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

RESULT 49
AAI19676/c
ID AAI19676 standard; DNA; 301 BP.
XX
XX
XX AAI19676;
XX
XX 17-OCT-2001 (first entry)
XX
XX Probe #13557 used to measure gene expression in human placenta sample.
XX KW Probe; microarray; human; placenta; antenatal diagnosis;
```

```
ABAG4702/c
ID ABA64702 standard; DNA; 301 BP.
XX
XX
XX ABA64702;
XX
XX 01-FEB-2002 (first entry)
XX
XX Human foetal liver single exon nucleic acid probe #13007.
XX
XX Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
XX Homo sapiens.
XX
XX WO200157277-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 30-JUN-2000; 2000US-00608408.
XX
XX 03-AUG-2000; 2000US-00632366.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-483447/52.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human fetal liver.
XX
XX Claim 4; SEQ ID NO 13007; 639pp + Sequence Listing; English.
XX
XX The invention relates to a single exon nucleic acid probe for measuring
XX human gene expression in a sample derived from human foetal liver. The
XX single exon nucleic acid probes may be used for predicting, measuring and
XX displaying gene expression in samples derived from human fetal liver. The
XX present sequence is a single exon nucleic acid probe of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 22.2; DB 1; Length 301;
XX Best Local Similarity 58.2%; Pred. No. 26;
XX Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 1732 TTTGACCTGCTCTTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1791
DB 277 TCTGCGCTGCTTACCTCTGCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCT 218

QY 1792 CTTGGAT 1798
DB 217 TCTAGCT 211

Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

RESULT 50
AAI44871/c
ID AAI44871 standard; DNA; 301 BP.
XX
XX
XX AAI44871;
XX
XX 17-OCT-2001 (first entry)
XX
XX Probe #13557 used to measure gene expression in human placenta sample.
XX KW Probe; microarray; human; placenta; antenatal diagnosis;
```

Genetic disorder; ss.
Homo sapiens.
WO200157272-A2.
09-AUG-2001.
30-JAN-2001; 2001WO-US000663.
04-FEB-2000; 2000US-0180312P.
26-MAY-2000; 2000US-0207456P.
30-JUN-2000; 2000US-00608408.
03-AUG-2000; 2000US-00632366.
21-SEP-2000; 2000US-0234687P.
27-SEP-2000; 2000US-0236359P.
04-OCT-2000; 2000GB-00024263.
(MOLE-) MOLECULAR DYNAMICS INC.
Penn SG, Hanzel DK, Chen W, Rank DR;
WPI; 2001-48897/53.
Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human placenta.
Claim 25; SEQ ID NO 13557; 654pp; English.
The present invention relates to single exon nucleic acid probes (SENP). The present sequence is one such probe. The probes are useful for producing a microarray for predicting, measuring and displaying gene expression in samples derived from human placenta. The probes are useful for antenatal diagnosis of human genetic disorders
Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1732 TTGACCTGGCTTCCCTTCCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCTCT 218
QY 1792 CTTGGAT 1798
Db 217 TCTAGCT 211
RESULT 51
ABA46822/c
ID ABA46822 standard; DNA; 301 BP.
AC ABA46822;
DT 01-FEB-2002 (first entry)
DE Human breast cell single exon nucleic acid probe #5517.
KW Human; microarray; single exon probe; gene expression; breast; disease;
KW cancer; ss.
OS Homo sapiens.
OS WO200157271-A2.
PN 09-AUG-2001.
PD 30-JAN-2001; 2001WO-US000662.
PF 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR Genetic disorder; ss.
OS Homo sapiens.
WO200157272-A2.
09-AUG-2001.
30-JAN-2001; 2001WO-US000663.
04-FEB-2000; 2000US-0180312P.
26-MAY-2000; 2000US-0207456P.
30-JUN-2000; 2000US-00608408.
03-AUG-2000; 2000US-00632366.
21-SEP-2000; 2000US-0234687P.
27-SEP-2000; 2000US-0236359P.
04-OCT-2000; 2000GB-00024263.
(MOLE-) MOLECULAR DYNAMICS INC.
Penn SG, Hanzel DK, Chen W, Rank DR;
WPI; 2001-48897/53.
Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human placenta.
Claim 25; SEQ ID NO 13557; 654pp; English.
The present invention relates to single exon nucleic acid probes (SENP). The present sequence is one such probe. The probes are useful for producing a microarray for predicting, measuring and displaying gene expression in samples derived from human placenta. The probes are useful for antenatal diagnosis of human genetic disorders
Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1732 TTGACCTGGCTTCCCTTCCTCTATTCCTTTGGTTTGGCATAGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCTCT 218
QY 1792 CTTGGAT 1798
Db 217 TCTAGCT 211
RESULT 52
ABA31826/c
ID ABA31826 standard; DNA; 301 BP.
AC ABA31826;
DT 23-JAN-2002 (first entry)
DE Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
OS Homo sapiens.
OS WO200157274-A2.
PN 09-AUG-2001.
PD 30-JAN-2001; 2001WO-US000666.
PF The invention relates to a spatially-addressable set of single exon nucleic acid probes for measuring gene expression in a sample derived from human breast and BT 474 cells. The method involves contacting the probes with a collection of detectably labelled nucleic acids derived from mRNA of human breast, and then measuring the label bound to each probe of the microarray. The probes are useful for verifying the expression of regions of genomic DNA predicted to encode proteins. They are useful for gene discovery, and for determining predisposition and/or prognosing breast disease. Gene expression analysis is useful for assessing the toxicity of chemical agents on cells. The microarray of this invention presents a far greater diversity of probes for measuring gene expression, with far less bias than expressed sequence tag microarrays. The method is suitable for rapid production of functional information from genomic sequence. The present sequence is a single exon nucleic acid probe of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTTGACCTGCTTCTCCCTTCTCTATTCTTGGTTTGGCATAGTGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 53
AAK38868/c
ID AAK38868 standard; DNA; 301 BP.
AC AAK38868;
XX
XX 06-NOV-2001 (first entry)
DT Human bone marrow expressed single exon probe SEQ ID NO: 13425.
DE Human; bone marrow expressed exon; gene expression analysis; probe;
XX KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX OS Homo sapiens.
XX PN WO200157276-A2.
XX PD 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000669.
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-0234687P.
PR 21-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTTGACCTGCTTCTCCCTTCTCTATTCTTGGTTTGGCATAGTGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 53
AAK38868/c
ID AAK38868 standard; DNA; 301 BP.
AC AAK38868;
XX
XX 06-NOV-2001 (first entry)
DT Human bone marrow expressed single exon probe SEQ ID NO: 13425.
DE Human; bone marrow expressed exon; gene expression analysis; probe;
XX KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX OS Homo sapiens.
XX PN WO200157276-A2.
XX PD 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000669.
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-0234687P.
PR 21-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX Claim 4; SEQ ID NO 10292; 530pp; English.
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTTGACCTGCTTCTCCCTTCTCTATTCTTGGTTTGGCATAGTGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 54
AAK13137/c
ID AAK13137 standard; DNA; 301 BP.
AC AAK13137;
XX
XX 05-NOV-2001 (first entry)
DT Human brain expressed single exon probe SEQ ID NO: 13128.
DE Human; brain expressed exon; gene expression analysis; probe; microarray;
XX KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX ss.
XX OS Homo sapiens.
XX PN WO200157275-A2.
XX PD 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000667.
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-48899/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX Example 4; SEQ ID NO 13425; 658pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
CC the probes of the invention
XX
XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 26;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
Qy 1732 TTTGACCTGCTTCTCCCTTCTCTATTCTTGGTTTGGCATAGTGTCTCTGGCTT 1791
Db 277 TCTCGCTGCTTACTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCGT 218
Qy 1792 CCTGGAT 1798
Db 217 TCTAGCT 211
RESULT 54
AAK13137/c
ID AAK13137 standard; DNA; 301 BP.
AC AAK13137;
XX
XX 05-NOV-2001 (first entry)
DT Human brain expressed single exon probe SEQ ID NO: 13128.
DE Human; brain expressed exon; gene expression analysis; probe; microarray;
XX KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX ss.
XX OS Homo sapiens.
XX PN WO200157275-A2.
XX PD 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000667.
XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
PT


```

PD XX 04-OCT-2001.
PF XX
PR XX 27-MAR-2001; 2001WO-US009761.
PR XX
PR XX 27-MAR-2000; 2000US-0192176P.
PR XX
PR XX 27-MAR-2000; 2000US-0192179P.
PR XX
PR XX 01-JUN-2000; 2000US-0208538P.
PR XX
PR XX 30-OCT-2000; 2000US-0244989P.
PR XX
PA (UYDE ) UNIV DELAWARE.
XX XX
XX XX Kmiec EB, Gamper HB, Rice MC;
PI XX
PI XX WPI; 2001-639230/73.
DR XX
DR XX
XX XX
XX XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX XX
PS Claim 7; Page 184; 294pp; English.
XX XX
XX XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX XX
SQ Sequence 121 BP; 36 A; 23 C; 25 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

OY 2168 CTATTGTAATAGGGTTTACGAGGACATATTGCTCGTGTCTTATTGCTGTTTTTG 2227
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
88 CCATTAAACATGGATTGGACTCACACTGATCTCCATCTTTGAGATAGTTAAGAAATTG 29

OY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
28 AATTGGCAGTAACTGCTTAGAATG 3

RESULT 59
ID ABA79623
XX
XX ABA79623 standard; DNA; 121 BP.
AC ABA79623;
XX
XX 24-JAN-2002 (first entry)
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2469.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.

```


XX	DT	24-JAN-2002 (first entry)	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2473.
XX	DE	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1, BRCA2, CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1, HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1, APOE; mismatch repair; MSH2, MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytoskeletal; antiscaling; antianaemic; haemostatic; antilepemic; ss.	
XX	OS	Homo sapiens.	
XX	PN	WO200173002-A2.	
XX	PD	04-OCT-2001.	
XX	PF	27-MAR-2001; 2001WO-US009761.	
XX	PR	27-MAR-2000; 2000US-0192176P.	
XX	PR	27-MAR-2000; 2000US-0192179P.	
XX	PR	01-JUN-2000; 2000US-0208538P.	
XX	PR	30-OCT-2000; 2000US-0244989P.	
XX	XX	(UYDE) UNIV DELAWARE.	
XX	PA	Kmiec EB, Gamper HB, Rice MC;	
XX	PI	WPI; 2001-6392330/73.	
XX	PT	Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.	
XX	PS	Claim 7; Page 184; 294pp; English.	
XX	CC	The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention	
XX	XX	Sequence 121 BP; 37 A; 25 C; 23 G; 36 T; 0 U; 0 Other;	
XX	XX	Query Match 1.0%; Score 22; DB 1; Length 121;	
XX	XX	Best Local Similarity 53.5%; Pred. No. 25;	
XX	XX	Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;	
QY	2168	CTATTGTAATAGGTTTACAGGACATATGTCCTGGTGTGTTATGTCGTGTTTGG 2227	
Db	34	CCATTTAAACATGATGGTACTCACATCTCTTTCGATAGGTTAAGAAATTG 93	
QY	2228	CTTTGGCATATAGACGGCTGAGTTTG 2253	
Db	94	AATGGACGTAACCTGCTAGATG 119	

QY	2228	CTTTGGCATATAGACGGCTGAGTTTG	2253	
Db	93	AATTGGCAGCTAACTGCTTAGAATG	118	
RESULT 64				
ABA79635				
ID	ABA79635	standard; DNA; 121 BP.		
XX	AC	ABA79635;		
XX	AC	ABA79635;		
XX	DT	24-JAN-2002 (first entry)		
XX	DE	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2481.		
XX	DE	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;		
KW	KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;		
KW	KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;		
KW	KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;		
KW	KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;		
KW	KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;		
KW	KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;		
KW	KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;		
KW	KW	Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;		
XX	XX	antileptic; ss.		
OS	OS	Homo sapiens.		
XX	XX	WO200173002-A2.		
PN	PN	04-OCT-2001.		
PD	PD	27-MAR-2001; 2001WO-US009761.		
PF	PF	27-MAR-2000; 2000US-0192176P.		
XX	XX	27-MAR-2000; 2000US-0192176P.		
PR	PR	01-JUN-2000; 2000US-0208538P.		
PR	PR	30-OCT-2000; 2000US-0244989P.		
XX	XX	(UYDE) UNIV DELAWARE.		
PA	PA	Xmtec EB, Gamper HB, Rice MC;		
PI	PI	WPI; 2001-639230/73.		
XX	XX	Oligonucleotide for targeted alterations of genetic sequences and for		
PT	PT	treating cystic fibrosis, comprises at least one mismatch and chemical		
PT	PT	modification.		
XX	XX	Claim 7; Page 184; 294pp; English.		
PS	PS	The present invention provides single-stranded oligonucleotides which can		
CC	CC	be used for the targeted alteration of genomic sequences, where the		
CC	CC	oligonucleotide has at least one mismatch compared with the genomic		
CC	CC	sequence to be altered. In particular, these sequences are directed at		
CC	CC	the following genes: adenosine deaminase, p53, beta-globin,		
CC	CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A		
CC	CC	(CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus		
CC	CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,		
CC	CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase		
CC	CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and		
CC	CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases		
CC	CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,		
CC	CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,		
CC	CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and		
CC	CC	various syndromes. The present sequence is one of the gene correcting		
XX	XX	oligonucleotides of the invention		
SQ	SQ	Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;		
		Query Match 1.0%; Score 22; DB 1; Length 121;		
		Best Local Similarity 53.5%; Pred. No. 25;		
		Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;		
QY	2168	CTATTGTAATAGGTTTTCAGGGACATATGTCCTGGTGTCTGTTATGTCCTGTTTGG	2227	
Db	36	CCATTAAACATGGATTGGACTCAGCTCCTCACTTTGAGATAGGTTAAGAAATTG	95	
RESULT 65				
ABA79638/c				
ID	ABA79638	standard; DNA; 121 BP.		
XX	AC	ABA79638;		
XX	AC	ABA79638;		
XX	DT	24-JAN-2002 (first entry)		
XX	DE	Factor IX mutation correcting oligonucleotide SEQ ID NO: 2484.		
XX	DE	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;		
KW	KW	retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;		
KW	KW	cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;		
KW	KW	adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;		
KW	KW	haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;		
KW	KW	mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;		
KW	KW	familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;		
KW	KW	UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;		
KW	KW	Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;		
XX	XX	antileptic; ss.		
OS	OS	Homo sapiens.		
XX	XX	WO200173002-A2.		
PN	PN	04-OCT-2001.		
PD	PD	27-MAR-2001; 2001WO-US009761.		
PF	PF	27-MAR-2000; 2000US-0192176P.		
XX	XX	27-MAR-2000; 2000US-0192176P.		
PR	PR	01-JUN-2000; 2000US-0208538P.		
PR	PR	30-OCT-2000; 2000US-0244989P.		
XX	XX	(UYDE) UNIV DELAWARE.		
PA	PA	Xmtec EB, Gamper HB, Rice MC;		
PI	PI	WPI; 2001-639230/73.		
XX	XX	Oligonucleotide for targeted alterations of genetic sequences and for		
PT	PT	treating cystic fibrosis, comprises at least one mismatch and chemical		
PT	PT	modification.		
XX	XX	Claim 7; Page 185; 294pp; English.		
PS	PS	The present invention provides single-stranded oligonucleotides which can		
CC	CC	be used for the targeted alteration of genomic sequences, where the		
CC	CC	oligonucleotide has at least one mismatch compared with the genomic		
CC	CC	sequence to be altered. In particular, these sequences are directed at		
CC	CC	the following genes: adenosine deaminase, p53, beta-globin,		
CC	CC	retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A		
CC	CC	(CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus		
CC	CC	1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,		
CC	CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase		
CC	CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and		
CC	CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases		
CC	CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,		
CC	CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,		
CC	CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and		
CC	CC	various syndromes. The present sequence is one of the gene correcting		
XX	XX	oligonucleotides of the invention		

```
SQ Sequence 121 BP; 37 A; 23 C; 23 G; 38 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2168 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGCTGTTCTTATTGTCGTTGTTTG 2227
DB 86 CCATTAAACATGGATTGGACTCACACTGATCCTTCATCTTGAGATAGTTAAGAAATG 27
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
DB 26 AATTGGCAGTAAACTGCTTAGAATG 1
RESULT 66
ABA79630/c
ID ABA79630 standard; DNA; 121 BP.
XX AC ABA79630;
XX DT 24-JAN-2002 (first entry)
XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2476.
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
XX KW antilipemic; ss.
XX OS Homo sapiens.
XX PN WO200173002-A2.
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX PA (UYDE ) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX DR WPI; 2001-639230/73.
XX PS Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.
XX CC Claim 7; Page 184; 294pp; English.
XX CC The present invention provides single-stranded oligonucleotides which can
XX CC be used for the targeted alteration of genomic sequences, where the
XX CC oligonucleotide has at least one mismatch compared with the genomic
XX CC sequence to be altered. In particular, these sequences are directed at
XX CC the following genes: adenosine deaminase, p53, beta-globin,
XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC CC various syndromes. The present sequence is one of the gene correcting
CC CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 35 A; 23 C; 26 G; 37 T; 0 U; 0 Other;
Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
QY 2168 CTAATTGTAATAGGGTTTAGCAGGACATATTGTCCTGCTGTTCTTATTGTCGTTGTTTG 2227
DB 89 CCATTAAACATGGATTGGACTCACACTGATCCTTCATCTTGAGATAGTTAAGAAATG 30
QY 2228 CTTTGGCATATAGCGGCTGAGTTTG 2253
DB 29 AATTGGCAGTAAACTGCTTAGAATG 4
RESULT 67
ABA79639
ID ABA79639 standard; DNA; 121 BP.
XX AC ABA79639;
XX DT 24-JAN-2002 (first entry)
XX DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2485.
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX KW Alzheimer's disease; cytosolic; antisickling; antianaemic; haemostatic;
XX KW antilipemic; ss.
XX OS Homo sapiens.
XX PN WO200173002-A2.
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009761.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192179P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX PA (UYDE ) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX DR WPI; 2001-639230/73.
XX PS Oligonucleotide for targeted alterations of genetic sequences and for
XX PT treating cystic fibrosis, comprises at least one mismatch and chemical
XX PT modification.
XX CC Claim 7; Page 185; 294pp; English.
XX CC The present invention provides single-stranded oligonucleotides which can
XX CC be used for the targeted alteration of genomic sequences, where the
XX CC oligonucleotide has at least one mismatch compared with the genomic
XX CC sequence to be altered. In particular, these sequences are directed at
XX CC the following genes: adenosine deaminase, p53, beta-globin,
XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
```

CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 38 A; 23 C; 23 G; 37 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGGTGTATTGTCGTGTTTGG 2227
DB 36 CCATTTAAACATGGATTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 95
QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253
DB 96 AATTGGCAGCTAAACTGCTTAGAATG 121

RESULT 68
ABA79619
ID ABA79619 standard; DNA; 121 BP.
XX
AC ABA79619;
XX
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2465.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
XX antileptic; ss.

XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192176P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX

XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX

XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.

XX Claim 7; Page 184; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the

CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 121 BP; 36 A; 25 C; 25 G; 35 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 121;
Best Local Similarity 53.5%; Pred. No. 25;
Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2168 CTATTGTAATAGGGTTTACGAGGACATATGCTGGTGTATTGTCGTGTTTGG 2227
DB 31 CCATTTAAACATGGATTGGACTCAGCTGATCTCCATCTTTGAGATAGGTTAAGAAATTG 90
QY 2228 CTTTGGCATATAGACGGCTGAGTTTG 2253
DB 91 AATTGGCAGCTAAACTGCTTAGAATG 116

RESULT 69
ABA79618/c
ID ABA79618 standard; DNA; 121 BP.
XX
XX ABA79618;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2464.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
XX antileptic; ss.

XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192176P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX

XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX

XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.

CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNP's); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX
SQ Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;

Query March 1.0%; Score 22; DB 1; Length 612;
Best Local Similarity 49.2%; Pred. No. 34;
Matches 58; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1067 TTATCAATGACGAGTGTGGGATCTTGTATCTTGCACTTGTGAAGTGTGTGTGT 1126
Db 258 TTTCGAGGAGTATGTTTTTTTGTATTTTTTTTAGGAGTTCGGTCGTAGTTTTT 199
QY 1127 GT 1184
Db 198 TTAGGAACGCGTTGGCGGTCGGTCGGTGTAGGACGTCGGTGTGGGTTTTTTTGGGT 141

RESULT 72
ABQ47968
ID ABQ47968 standard; DNA; 612 BP.
AC ABQ47968;
XX
DT 12-JUL-2002 (first entry)
DE
DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.
KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX
OS Homo sapiens.
XX
XX WO200218632-A2.
XX
XX PD 07-MAR-2002.
XX
XX PF 01-SEP-2001; 2001WO-EP010074.
XX
XX PR 01-SEP-2000; 2000DE-01043826.
XX
XX PR 05-SEP-2000; 2000DE-01044543.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
XX
XX WPI; 2002-371829/40.
XX

PT Determining the degree of cytosine methylation in genomic DNA, useful for
PT diagnosis and prognosis, comprises selective hybridization of amplicons
PT from chemically treated DNA.
XX

PS Claim 12; 56pp + Sequence Listing; 56pp; German.

XX This invention describes a novel method for determining the degree of
CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC genomic sample of DNA. The sample is treated chemically to convert
CC cytosine (C) but not methylated C, to uracil, then part of the genomic
CC DNA that contains the target C is amplified to form a labeled amplicon.
CC The amplicon is hybridised to two classes, each with at least one member,
CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the

CC degree of hybridisation to both classes is determined from the label on
CC the amplicon. From the ratio of labels hybridised to the two classes of
CC oligomers, the degree of methylation is calculated. The method is used:
CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC and of a wide range of diseases, e.g. cancer, disorders of the central
CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC particularly by detecting mutations or single nucleotide polymorphisms
CC (SNP's); and (ii) for differentiation of cell or tissue types and for
CC investigating cell differentiation. The method allows the methylation
CC status of many C residues to be determined simultaneously. ABQ13410-
CC ABQ54121 represent genomic DNA sequences used to illustrate the method
CC for determining the degree of cytosine methylation described in the
CC disclosure of the invention
XX

SQ Sequence 612 BP; 89 A; 72 C; 219 G; 232 T; 0 U; 0 Other;
Query March 1.0%; Score 22; DB 1; Length 612;
Best Local Similarity 49.2%; Pred. No. 34;
Matches 58; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1067 TTATCAATGACGAGTGTGGGATCTTGTATCTTGCACTTGTGAAGTGTGTGTGT 1126
Db 355 TTTCGAGGAGTATGTTTTTTTGTATTTTTTTTAGGAGTTCGGTCGTAGTTTTT 414
QY 1127 GT 1184
Db 415 TTAGGAACGCGTTGGCGGTCGGTCGGTGTAGGACGTCGGTGTGGGTTTTTTTGGGT 472

RESULT 73
AAC70944/c
ID AAC70944 standard; DNA; 253 BP.
XX
AC AAC70944;
XX
DT 09-FEB-2001 (first entry)
XX
DE Single nucleotide polymorphism containing sequence #258.
XX
KW Single nucleotide polymorphism; SNP; human; genetic disease;
KW disease susceptibility; cardiovascular system; endocrine system;
KW neurological system; forensic testing; paternity testing; ds.
XX
OS Homo sapiens.
XX
XX WO200058519-A2.
XX
XX PD 05-OCT-2000.
XX
XX PF 30-MAR-2000; 2000WO-US008440.
XX
XX PR 31-MAR-1999; 99US-0127248P.
XX
XX PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
XX PA (AFFY-) AFFYMETRIX INC.
XX
XX PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
XX
XX PI Lipshutz RJ, Patil N, Sklar P;
XX
XX WPI; 2000-611722/58.
XX

PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
PT genetic analysis.
XX

PS Claim 1; Fig 5; 214pp; English.

XX The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be

used to diagnose susceptibility to diseases of the cardiovascular, endocrine and neurological systems, such as coronary artery disease, schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's diseases. Note: the degenerate codon within the sequence represents the position of an SNP, for example the letter S represents a polymorphism where the nucleotide may be C or G

Sequence 253 BP; 92 A; 41 C; 58 G; 61 T; 0 U; 1 Other;

Query Match 0.9%; Score 21.6; DB 1; Length 253;
Best Local Similarity 53.6%; Pred. No. 37;
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 1641 TTTTGTATGCTTCTTCTACCTTGATAGGACATCTTCTCAAGGTAGGAATTTTCTT 1700
Db 141 TATGGTTATTTATGTCTCTGTATCTTCTTGGCAGCTTCTGTTGGTCATTAAGGTA 82

QY 1701 TTTTGGTTTCTTGAATAATTTT 1724
Db 81 TCTTGGCTTCTGGAGATTTT 58

RESULT 74
ABV98470/c
ID ABV98470 standard; cDNA; 254 BP.
XX
AC ABV98470;
XX
DT 14-JAN-2003 (first entry)
XX
DE Human pancreatic cancer expressed cDNA SEQ ID NO 3878.
XX
KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW Cystostatic; tumour; gene; ss.
XX
OS Homo sapiens.
XX
FN WO200260317-A2.
XX
PD 08-AUG-2002.
XX
PF 30-JAN-2002; 2002WO-US002781.
XX
PR 30-JAN-2001; 2001US-0265305P.
PR 31-JAN-2001; 2001US-0265682P.
PR 09-FEB-2001; 2001US-0267568P.
PR 21-MAR-2001; 2001US-0278651P.
PR 28-APR-2001; 2001US-0287112P.
PR 16-MAY-2001; 2001US-0291631P.
PR 12-JUL-2001; 2001US-0305484P.
PR 20-AUG-2001; 2001US-0313999P.
PR 27-NOV-2001; 2001US-0333626P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;
XX
DR WPI; 2002-627435/57.
XX
PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for
PT diagnosing, preventing and/or treating cancer, particularly pancreatic
PT cancer.
XX
PS Claim 1; SEQ ID NO 3878; 300pp + Sequence Listing; English.
XX
CC The invention relates to an isolated polynucleotide (I) comprising: (a)
CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
CC complements of (a); (c) sequences consisting of at least 20 contiguous
CC residues of (a); (d) sequences that hybridize to (a), under moderately
CC stringent conditions; (e) sequences having at least 75% or 90% identity
CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
CC in a patient and compositions comprising polypeptides, polynucleotides,

antibodies, fusion proteins, T cell populations and antigen presenting cells expressing the polypeptide are useful in treating pancreatic cancer and stimulating an immune response. The polynucleotides can be used as probes or primers for nucleic acid hybridisation, in the design and preparation of ribozyme molecules for inhibiting expression of the tumour polypeptides and proteins in the tumour cells, in vaccines and for gene therapy. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 254 BP; 61 A; 74 C; 84 G; 35 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.6; DB 1; Length 254;
Best Local Similarity 47.7%; Pred. No. 37;
Matches 63; Conservative 0; Mismatches 69; Indels 0; Gaps 0;

QY 1848 TCCATTCTTCTATCTTGTCTTCTCACTGCTGAGATTCTCTTCTATCTCTGTATTCTG 1907
Db 247 TCAGTTCCCTCTCTCTGTGGCGGTGCTCAGGCTATGCCACCTTCTCTGCCCCTT 188

QY 1908 TCAGTGAGGCTTGTCTCTGAGGTTCTCTGTGGGTTCTTAATTTTTCATTTCAGATTTC 1967
Db 187 CCAGGCCGCGTTGTCAATGGTGAGGATCGGTCCCTACAGCTGGCCCTGGCAGGTTTCC 128

QY 1968 CTTTCAGTTTGGG 1979
Db 127 CTGCAGTATGAG 116

RESULT 75
AAV28290
ID AAV28290 standard; cDNA; 283 BP.
XX
AC AAV28290;
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
FN WO9829440-A1.
XX
PD 09-JUL-1998.
XX
PF 18-DEC-1997; 97WO-US023891.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
PA (MERI) MERCK & CO INC.
PA (UYTE-) UNIV TEXAS HEALTH SCI SAN ANTONIO.
XX
PI Tan CP, Kolakowski LF;
XX
DR WPI; 1998-388038/33.
DR P-PSDB; AAW61461.
XX
PT New mouse galanin receptor, GALR2, - useful to identify agonists and
PT antagonists to treat conditions involving galanin, e.g. for treating
PT obesity, pain or cognitive disorders.
XX
PS Example 1; Fig 6; 56pp; English.
XX
CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA
CC library. 2 independent clones, named 27A (see AAV28288) and 16.6, were
CC obtained. Clone 27A codes for a novel full-length rat galanin receptor,
CC designated GALR2 (see AAW61461). The invention provides methods for
CC identifying ligands particular to mouse GALR2 (see AAW61463). Such
CC ligands may be useful therapeutically e.g. to treat obesity or cognitive
CC disorders involving excess galanin or to treat pain or anorexia involving

```
CC insufficient galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGTGAGGGTTACCACTGCTC 218
Db 112 TCGGGCCGCTGCTGCGCGCTGTCCCTCTACGTGGCGGAGGGCTGCACCTACGC 166

RESULT 76
AAV32651
ID AAV32651 standard; cDNA; 283 BP.
XX
AC AAV32651;
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
FN WO9829439-A1.
XX
PD 09-JUL-1998.
XX
PF 18-DEC-1997; 97WO-US023890.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
PA (MERI ) MERCK & CO INC.
PA (UYTE-) UNIV TEXAS HEALTH SCI CENT SAN ANTONIO.
PA (UTOR ) UNIV TORONTO.
XX
PI Sullivan K, Kolakowski LF, Odowd B;
XX
DR WPI; 1998-388037/33.
XX
PT New human galanin receptor, GALR2, - useful to identify agonists and
PT antagonists to treat conditions involving galanin, e.g. for treatment of
PT obesity or cognitive disorders.
XX
PS Example 1; Fig 6; 57pp; English.
XX
CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA
CC library. 2 Independent clones, named 27A (see AAV44929) and 16.6, were
CC obtained. Clone 27A codes for a novel full-length rat galanin receptor,
CC designated GALR2 (see AAW61385). The invention provides methods for
CC identifying ligands particular to human GALR2 (see AAW61386). Such
CC ligands may be useful therapeutically e.g. to treat obesity or cognitive
CC disorders involving excess galanin or to treat pain or anorexia involving
CC insufficient galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

PS Example 1; Fig 6; 57pp; English.
XX
CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA
CC library. 2 Independent clones, named 27A (see AAV32648) and 16.6, were
CC obtained. Clone 27A codes for a novel full-length rat galanin receptor,
CC designated GALR2 (see AAW49002). The invention provides methods for
CC identifying ligands particular to GALR2. Such ligands may be useful
CC therapeutically e.g. to treat obesity or cognitive disorders involving
CC excess galanin or to treat pain or anorexia involving insufficient
CC galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGTGAGGGTTACCACTGCTC 218
Db 112 TCGGGCCGCTGCTGCGCGCTGTCCCTCTACGTGGCGGAGGGCTGCACCTACGC 166

RESULT 77
AAV44930
ID AAV44930 standard; cDNA; 283 BP.
XX
AC AAV44930;
```

```
XX
DT 24-NOV-1998 (first entry)
XX
DE Galanin receptor GALR2 DNA probe.
XX
KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW cognitive disorder; therapy; probe; ss.
XX
OS Rattus sp.
XX
FN WO9829441-A1.
XX
PD 09-JUL-1998.
XX
PF 18-DEC-1997; 97WO-US023892.
XX
PR 27-DEC-1996; 96US-0033851P.
XX
PA (MERI ) MERCK & CO INC.
PA (UYTE-) UNIV TEXAS HEALTH SCI CENT SAN ANTONIO.
PA (UTOR ) UNIV TORONTO.
XX
PI Sullivan K, Kolakowski LF, Odowd B;
XX
DR WPI; 1998-388039/33.
XX
PT New human galanin receptor, GALR2, - useful to identify agonists and
PT antagonists to treat conditions involving galanin, e.g. for treatment of
PT obesity or cognitive disorders.
XX
PS Example 1; Fig 6; 57pp; English.
XX
CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA
CC library. 2 Independent clones, named 27A (see AAV44929) and 16.6, were
CC obtained. Clone 27A codes for a novel full-length rat galanin receptor,
CC designated GALR2 (see AAW61385). The invention provides methods for
CC identifying ligands particular to human GALR2 (see AAW61386). Such
CC ligands may be useful therapeutically e.g. to treat obesity or cognitive
CC disorders involving excess galanin or to treat pain or anorexia involving
CC insufficient galanin
XX
SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match      0.9%; Score 21.4; DB 1; Length 283;
Best Local Similarity 61.8%; Pred. No. 43;
Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 164 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGTGAGGGTTACCACTGCTC 218
Db 112 TCGGGCCGCTGCTGCGCGCTGTCCCTCTACGTGGCGGAGGGCTGCACCTACGC 166

RESULT 78
ABK14060
ID ABK14060 standard; cDNA; 283 BP.
XX
AC ABK14060;
XX
DT 08-MAY-2002 (first entry)
XX
DE Rat galanin receptor 2 (GALR2) cDNA probe.
XX
KW Galanin receptor 2; GALR2; probe; ss; rat; obesity; pain; anorectic;
KW cognitive disorder; analgesic; neuroprotective.
XX
OS Rattus sp.
XX
FN US6337206-B1.
XX
PD 08-JAN-2002.
XX
PF 18-DEC-1997; 97US-00993424.
XX
```


ACD23963/c
ID ACD23963 standard; cDNA; 1129 BP.
XX
AC ACD23963;
XX
DT 26-AUG-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003032156-A1.
XX
XX 13-FEB-2003.
XX
XX 06-MAY-2002; 2002US-00140474.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028554.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 23-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032878.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geriensen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-341980/32.
DR P-PSDB; ABO17726.
XX
XX New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 2; Fig 221; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one


```
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
XX XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-352836/33.
DR P-PSDB; ABU80980.
XX
PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.
XX
PS Claim 2; Fig 221; 643pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ACA6994-ACA67268 represent cDNA sequences encoding
CC the human PRO polypeptides of the invention. Note: The sequence data for
CC this patent was obtained in electronic format directly from the USPTO web
CC site at seqdata.uspto.gov/psipdidentry.html
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
Qy 1941 TTCTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGTTTGTGTT 1987
Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1083
RESULT 82
ACA03713/c
ID ACA03713 standard; cDNA; 1129 BP.
XX
AC ACA03713;
XX
DT 23-MAY-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
KW ss.
OS Homo sapiens.
XX
FN US2003036180-A1.
XX
```


PR 14-SEP-1998; 99WO-US019093.
 PR 14-SEP-1998; 99WO-US019094.
 PR 14-SEP-1998; 99WO-US019177.
 PR 16-SEP-1998; 99WO-US019330.
 PR 17-SEP-1998; 99WO-US019437.
 PR 07-OCT-1998; 99WO-US021141.
 PR 29-OCT-1998; 99WO-US022991.
 PR 29-OCT-1998; 99WO-US022992.
 PR 20-NOV-1998; 99WO-US024855.
 PR 01-DEC-1998; 99WO-US025108.
 PR 01-DEC-1998; 99WO-US025109.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-466355/44.
 DR P-PSDB; ABO24951.
 XX
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 221; 659pp; English.
 XX
 CC The invention relates to an isolated nucleic acid comprising at least 80%
 CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
 CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
 CC extracellular domain (with or without its associated signal peptides),
 CC which comprises any of the 275 120-850 residue amino acid sequences,
 CC given in the specification; (b) comprising any of the 275 300-3500
 CC nucleotide sequences, given in the specification; or (c) comprising the
 CC full-length coding sequence of the nucleotide sequences given in the
 CC specification, or of the DNA deposited under any of the American Type
 CC Culture Collection (ATCC) Accession Numbers listed in the specification.
 CC Also included are a vector comprising the novel nucleic acid, a host cell
 CC comprising the vector, producing a PRO polypeptide, the isolated PRO
 CC polypeptides detailed above, a chimaeric molecule comprising the PRO
 CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
 CC antibody, detecting a PRO polypeptide in a sample suspected of containing
 CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
 CC PRO polypeptide, modulating at least one biological activity of a cell
 CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
 CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
 CC modulating the uptake of glucose or FFA by skeletal muscle cells or
 CC adipocyte cells, stimulating the proliferation or differentiation of
 CC chondrocyte cells (or proliferation of or gene expression in pericyte
 CC cells), stimulating the proliferation of inner ear utricular supporting
 CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
 CC binding of A-peptide to factor VIIa, or differentiation of adipocyte
 CC cells, detecting the presence of a tumour in a mammal and an
 CC oligonucleotide probe derived from any of the nucleotide sequences given
 CC in the specification. The polynucleotide is useful in molecular biology,
 CC including uses as hybridisation probes, in chromosome and gene mapping,
 CC in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The PRO polypeptide or the
 CC antibody is used in preparing a medicament for treating a condition

CC responsive to the polypeptide or antibody, such as tumours, and in
 CC various diagnostic assays. The present sequence encodes a PRO polypeptide
 XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCACAGATTCTTCAGTTTGGGTTTCTTT 1987
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083

RESULT 85

ACA04134/c

ID ACA04134 standard; cDNA; 1129 BP.

XX ACA04134;

XX 27-MAY-2003 (first entry)

DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 221.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
 KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
 KW infertility; birth defects; premature aging; AIDS; biosensor;
 KW acquired immunodeficiency syndrome; cancer; diabetic complication;
 KW bioreactor; tumour.

XX Homo sapiens.

XX US2003032155-A1.

XX 13-FEB-2003.

XX 03-MAY-2002; 2002US-00137865.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019177.

XX 17-SEP-1998; 98WO-US019330.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028554.

XX 02-DEC-1999; 99WO-US028555.

PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-0074259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-331925/31.

P-FSDB; ABU69556.


```

PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 22-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-687639/65.
DR P-PSDB; ADA76172.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 221; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
Db 1129 TTTTCTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083

RESULT 88
ADA18821/c
ID ADA18821 standard; cDNA; 1129 BP.
XX
AC ADA18821;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
```

OS Homo sapiens.
XX US2003054517-A1.
XX 20-MAR-2003.
XX 08-MAY-2002; 2002US-00141755.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US022031.
XX 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 22-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-521854/49.
DR P-PSDB; ADA18822.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumors.
XX Claim 2; Fig 221; 660pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO
CC polypeptides by recombinant techniques and in generating either
CC transgenic animals or knock-out animals which are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polypeptides or antibodies are used in preparing a medicament for
CC treating a condition responsive to the polypeptides or antibodies, such
CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC cells, for stimulating the proliferation of or gene expression in
CC pericyte cells, for stimulating the release of proteoglycans from
CC cartilage, for stimulating the proliferation of inner ear utricular
CC supporting cells, for stimulating the release of cytokines from PBMC
CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC inhibiting the differentiation of adipocyte cells and for stimulating the
CC proliferation of endothelial cells. This sequence represents a human PRO

PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-695892/66.
 DR P-PSDB; ADA61445.
 DR
 XX New PRO nucleic acid and encode polypeptides, are useful for
 PT manufacturing a medicament for diagnosing or treating cancer.
 PT
 XX Claim 2; Fig 221; 660pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 Qy 1941 TTCCTAATTTTTCATTCAGATTCTTCAGTTGGGTTTGTGTTT 1987
 Db 1129 TTTTITTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
 RESULT 90
 ADB19229/c
 ID ADB19229 standard; cDNA; 1129 BP.
 XX
 AC ADB19229;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokin.

OS Homo sapiens.
 XX US2003068796-A1.
 PN
 XX
 FD 10-APR-2003.
 XX
 XX 15-APR-2002; 2002US-00123261.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005501.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTATT 1987
Db 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 92
ADA86249/c
ID ADA86249 standard; cDNA; 1129 BP.
XX AC ADA86249;
XX DT 20-NOV-2003 (first entry)
XX XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX DE
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
XX KW Tumour necrosis factor alpha release; TNF-alpha release;
XX KW Glucose uptake modulator; FFA uptake modulator;
XX KW cell proliferation stimulator; cell differentiation stimulator;
XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;
XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX XX
XX XX US2003082711-A1.
XX XX
XX XX 01-MAY-2003.
XX XX
XX XX 16-MAY-2002; 2002US-00147508.
XX XX
XX XX 02-JUL-1998; 98US-0091519P.
XX XX 02-JUN-1999; 99WO-US012252.
XX XX 07-JUL-1999; 99US-0143048P.
XX XX 25-AUG-1999; 99US-00380137.
XX XX 30-MAR-2000; 2000WO-US008439.
XX XX 01-DEC-2000; 2000WO-US032578.
XX XX 19-DEC-2001; 2001US-00028072.
XX XX
XX XX (GETH) GENENTECH INC.
XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX XX WPI; 2003-786914/74.
XX XX P-PSDB; ADA86250.
XX XX
XX XX New PRO nucleic acid, useful for preparing a composition for treating
XX XX e.g., tumor or for tissue typing.
XX XX
XX XX Claim 2; Fig 221; 637pp; English.
XX XX
XX XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX XX release of TNF-alpha from human blood, for modulating the uptake of
XX XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX XX stimulating the proliferation or differentiation of chondrocyte cells,
XX XX for stimulating the proliferation or gene expression in pericyte
XX XX cells, for stimulating the release of proteoglycans from cartilage, for
XX XX stimulating the proliferation of inner ear utricular supporting cells,
XX XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX XX cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTATT 1987
Db 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 93
ADB15813/c

ID ADB15813 standard; cDNA; 1129 BP.

XX AC ADB15813;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX KW liver; microvascular endothelial cell; glucose; FFA;
XX KW skeletal muscle cell; adipocyte cell; pericyte cell;
XX KW inner ear utricular supporting cell; T-lymphocyte cell;
XX KW endothelial cell tube formation; bone disorder; cartilage disorder;
XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003087350-A1.

XX XX 08-MAY-2003.

XX XX 22-APR-2002; 2002US-00127821.

XX XX 04-AUG-1998; 98US-0095301P.

XX XX 02-JUN-1999; 99WO-US012252.

XX XX 25-AUG-1999; 99US-00380137.

XX XX 30-MAR-2000; 2000WO-US008439.

XX XX 01-DEC-2000; 2000WO-US032578.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-786914/74.

XX XX P-PSDB; ADB15814.

XX XX

xx Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
xx
OS Homo sapiens.
xx
xx US2003068794-A1.
xx
xx 10-APR-2003.
xx
xx 15-APR-2002; 2002US-00123155.
xx
xx 31-MAR-1997; 97WO-US005230.
xx 12-JUN-1998; 98WO-US012456.
xx 14-JUN-1998; 98WO-US014552.
xx 28-AUG-1998; 98WO-US017888.
xx 10-SEP-1998; 98WO-US018824.
xx 14-SEP-1998; 98WO-US019093.
xx 14-SEP-1998; 98WO-US019094.
xx 14-SEP-1998; 98WO-US019177.
xx 16-SEP-1998; 98WO-US019330.
xx 17-SEP-1998; 98WO-US019437.
xx 07-OCT-1998; 98WO-US021141.
xx 29-OCT-1998; 98WO-US022991.
xx 29-OCT-1998; 98WO-US022992.
xx 20-NOV-1998; 98WO-US024855.
xx 01-DEC-1998; 98WO-US025108.
xx 05-JAN-1999; 99WO-US000106.
xx 08-MAR-1999; 99WO-US005028.
xx 10-MAR-1999; 99WO-US005190.
xx 20-APR-1999; 99WO-US008615.
xx 14-MAY-1999; 99WO-US010733.
xx 02-JUN-1999; 99WO-US012252.
xx 01-SEP-1999; 99WO-US020111.
xx 08-SEP-1999; 99WO-US020594.
xx 13-SEP-1999; 99WO-US020944.
xx 15-SEP-1999; 99WO-US021090.
xx 15-SEP-1999; 99WO-US021547.
xx 05-OCT-1999; 99WO-US023089.
xx 29-NOV-1999; 99WO-US028214.
xx 30-NOV-1999; 99WO-US028313.
xx 30-NOV-1999; 99WO-US028409.
xx 01-DEC-1999; 99WO-US028301.
xx 01-DEC-1999; 99WO-US028634.
xx 02-DEC-1999; 99WO-US028551.
xx 02-DEC-1999; 99WO-US028564.
xx 02-DEC-1999; 99WO-US028565.
xx 16-DEC-1999; 99WO-US030095.
xx 20-DEC-1999; 99WO-US030911.
xx 20-DEC-1999; 99WO-US030999.
xx 22-DEC-1999; 99WO-US030720.
xx 30-DEC-1999; 99WO-US031243.
xx 30-DEC-1999; 99WO-US031274.
xx 05-JAN-2000; 2000WO-US000219.
xx 06-JAN-2000; 2000WO-US000277.
xx 06-JAN-2000; 2000WO-US000376.
xx 11-FEB-2000; 2000WO-US003565.
xx 18-FEB-2000; 2000WO-US004341.
xx 18-FEB-2000; 2000WO-US004342.
xx 22-FEB-2000; 2000WO-US004414.
xx 24-FEB-2000; 2000WO-US004914.
xx 24-FEB-2000; 2000WO-US005004.
xx 01-MAR-2000; 2000WO-US005601.
xx 02-MAR-2000; 2000WO-US005746.
xx 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US033873.
PR 01-DEC-2000; 2000WO-US032878.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882836.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AT, Sherwood S;
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-708391/67.
P-ESDB; ADB30402.

New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
preparation of a medicament for treating a condition responsive to PRO
polypeptide, and as therapeutic agents e.g. vaccines.

Claim 2; Fig 22i; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTGTTT 1987

DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGGTTTTTATT 1083

RESULT 97

ADA85697/c

ID ADA85697 standard; cDNA; 1129 BP.

AC ADA85697;

DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene: ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082693-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127843.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-786907/74.

XX P-PSDB; ADA85698.

XX

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTGTTT 1987

DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGGTTTTTATT 1083

RESULT 98

ADA96909/c

ID ADA96909 standard; cDNA; 1129 BP.

XX ADA96909;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene: ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082705-A1.

XX 01-MAY-2003.

10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020331.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00897879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755116/71.
DR P-PSDB; ADA79214.
DR XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at segdata.uspto.gov/sequence.html.
XX XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1987
DB 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 100
ADA87352/c
ID ADA87352 standard; cDNA; 1129 BP.
XX ADA87352;
AC
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003087345-A1.
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.

```
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US031011.
PR 20-DEC-1999; 99WO-US031099.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786937/74.
DR P-PSDB; ADA87353.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
XX Claim 2; Fig 221; 638pp; English.
PS
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGTTCCTTTT 1987
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGTTCCTTTTATT 1083

RESULT 101
ADB16554/C
ID ADB16554 standard; cDNA; 1129 BP.
```


KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003077722-A1.
XX
XX 24-APR-2003.
XX
XX 03-MAY-2002; 2002US-00137872.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755077/71.
DR P-PSDB; ADA93886.
DR
XX
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
XX Claim 2; Fig 221; 637pp; English.
PS
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match

0.9%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTGGGTTTGT 1987
Db 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 106

ADBL9781/c
ID ADB19781 standard; cDNA; 1129 BP.
XX
XX ADB19781;
XX
XX 20-NOV-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX US2003082691-A1.
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127838.
XX
XX 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755108/71.
DR P-PSDB; ADB19782.
XX
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage,
CC for stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBM cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or

antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TCTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1987
DB 1129 TTTTATTTTTCATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 107
ID ADB13093/c
XX ADB13093 standard; cDNA; 1129 BP.

AC ADB13093;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082710-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147484.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-786913/74.

XX P-PsDB; ADB13094.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX preparing a composition for treating e.g., tumor, or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TCTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1987
DB 1129 TTTTATTTTTCATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 108

ACD98534/c

ID ACD98534 standard; cDNA; 1129 BP.

XX ACD98534;

XX 26-SEP-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene therapy;
XX chromosome identification; tissue typing; gene; ss.

XX Homo sapiens.

XX US2003044945-A1.

XX 06-MAR-2003.

XX 10-MAY-2002; 2002US-00142419.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCACAGATTTCCTTCAGTTTGGTTTGT 1987
 Db 1129 TTTTITTTTTTTTTTTTTTTCAGCTGGCACACAGCGCTGGTTTATT 1083

RESULT 110
 ADB24580/C
 ID ADB24580 standard; cDNA; 1129 BP.

XX AC ADB24580;

XX 20-NOV-2003 (first entry)
 XX Human PRO polynucleotide SEQ ID NO 221.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US200307713-A1.

XX 24-APR-2003.

XX 22-APR-2002; 2002US-00127839.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-755068/71.

XX P-PSDB; ADB24581.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 XX tumors.

PS Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCACAGATTTCCTTCAGTTTGGTTTGT 1987
 Db 1129 TTTTITTTTTTTTTTTTTTTCAGCTGGCACACAGCGCTGGTTTATT 1083

RESULT 111

ADAB2104/C

ID ADAB2104 standard; cDNA; 1129 BP.

XX AC ADAB2104;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

```
XX US2003082701-A1.
XX PN
XX PD
XX PF 01-MAY-2003.
XX FF 23-APR-2002; 2002US-00128686.
XX PP
XX PR 31-AUG-1998; 98US-0098525P.
XX PR 16-SEP-1998; 98US-0100634P.
XX PR 02-JUN-1999; 98WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PP (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX DR WPI; 2003-755110/71.
XX DR P-PSDB; ADA82105.
XX PT
XX PP tumor or for tissue typing.
XX PS Claim 2; Fig 221; 637pp; English.
XX CC
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC the proliferation of or gene expression in pericyte cells, for stimulating
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent is also available in electronic format
XX CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX SQ Query Match 0.9%; Score 21.4; DB 1; Length 1129;
XX SQ Best Local Similarity 66.0%; Pred. No. 55;
XX SQ Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX SQ
XX SQ 1941 TCTTTAATTTTTCATTTCCAGATTTCTTCAGTTGGTTTGTGTT 1987
XX SQ ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX SQ 1129 TTTTITTTTTTTTTTTTTTTCAGTGGCACACAGGCTGGTATT 1083
```

RESULT 112
ADA75067/c
ID ADA75067 standard; cDNA; 1129 BP.
XX AC ADA75067;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003073216-A1.
XX PD 17-APR-2003.
XX PF 30-MAY-2002; 2002US-00160498.
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 29-OCT-1998; 98WO-US022992.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 20-APR-1999; 99WO-US008615.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 05-OCT-1999; 99WO-US021547.
XX PR 29-NOV-1999; 99WO-US023089.
XX PR 30-NOV-1999; 99WO-US028214.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 30-NOV-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 16-DEC-1999; 99WO-US028565.
XX PR 20-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 22-DEC-1999; 99WO-US030999.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US0003565.
 PR 18-FEB-2000; 2000WO-US0004341.
 PR 22-FEB-2000; 2000WO-US0004342.
 PR 24-FEB-2000; 2000WO-US0004414.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 01-MAR-2000; 2000WO-US0005004.
 PR 01-MAR-2000; 2000WO-US0005601.
 PR 02-MAR-2000; 2000WO-US0005746.
 PR 02-MAR-2000; 2000WO-US0005841.
 PR 10-MAR-2000; 2000WO-US0006319.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR XX
 PR (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 XX
 DR WPI; 2003-765392/72.
 DR P-FSDB; ADA75068.
 XX
 PT New secreted and transmembrane PRO polypeptides useful for stimulating
 PT the release of tumor necrosis factor alpha in human blood and detecting
 PT the presence of tumor in a mammal.
 XX
 PS Claim 2; Fig 221; 638pp; English.
 XX

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTGTTCGTT 1987
 |||||
 Db 1129 TTTTTCATTTTTCATTTTCAGTTTCAGTGGCAGCGCTGGTTTATT 1083
 |||||

RESULT 113
 ADA85145/c
 ID ADA85145 standard; cDNA; 1129 BP.
 XX
 AC ADA85145;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 FN US2003082695-A1.
 XX
 PD 01-MAY-2003.
 XX
 XX 22-APR-2002; 2002US-00127846.
 XX
 XX 03-MAR-2000; 2000US-0187202P.

[illegible]

PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005001.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-C0747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 03-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00919692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-777249/73.
P-PSDB; ADB26667.
Novel isolated PRO polypeptide useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders, tumors.
Claim 2; Fig 221; 660pp; English.
The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung). The colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match	0.9%;	Score 21.4;	DB 1;	Length 1129;
Best Local Similarity	66.0%;	Pred. No. 55;		
Matches 31;	Conservative	0;	Mismatches 16;	Indels 0;
			Gaps	0;

QY	1941	1942	1943	1944	1945	1946	1947	1948	1949	1950	1951	1952	1953	1954	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348
----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

RESULT 122
ADB30953/c
ID ADB30953 standard; cDNA; 1129 BP.

AC ADB30953;

DT 20-NOV-2003 (first entry)

DE cDNA encoding human PRO polypeptide #111.

Human; gene; *ss*; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; PFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

OS Homo sapiens.

PN US2003096386-A1.

PD 22-MAY-2003.

11-APR-2002; 2002US-00121042.

PR 31-MAR-1997; 97WO-US005230.

FA	12-JUN-1998;	98WO-US012456.
PR	14-JUL-1998;	98WO-US014552.

ER 28-AUG-1998; 98WO-US017888;
PR 10-SEP-1998; 98WO-US018824;

PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330

PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141

PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992

PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US024855.

PR 05-JAN-1999; 99WO-US000106.

PR 10-MAR-1999; 99WO-US005190.

PR 14-MAY-1999; 99WO-US010733.

PR 01-SEP-1999; 99WO-US020111.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021547;

03-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.

FK	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.

PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030999.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000365.
PR	11-FEB-2000;	2000WO-US003766.
PR	18-FEB-2000;	2000WO-US004341.
PR	21-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	21-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	10-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	20-MAR-2000;	2000WO-US007532.
PR	31-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	23-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUN-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00736498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00801689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017032.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908927.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00931872.

(GETH) GENENTECH INC.

Baker KP,	Beresini M,	Deforqe L,	Desnovers L,	Filyvaroff E,	Gao W.
-----------	-------------	------------	--------------	---------------	--------

CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match	0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity	66.0%; Pred. No. 55;
Matches 31; Conservative	0; Mismatches 16; Indels 0; Gaps 0;
QY	1941 TTCTTAATTTTTCATTTCAGATTTTCCTTCAGTTTGCGTTTGTGTTT 1987
Db	1129 TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTTTATT 1083
RESULT 127	
ADA95805/c	
ID	ADA95805 standard; cDNA; 1129 BP.
XX	
AC	ADA95805;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Human PRO polynucleotide #111.
XX	
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; adipocyte cell; pericyte cell; endotheial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
OS	Homo sapiens.
XX	
PN	US2003082759-A1.
XX	
PD	01-MAY-2003.
XX	
PF	11-APR-2002; 2002US-00121040.
XX	
PR	31-MAR-1997; 97WO-US005230.
XX	
PR	12-JUN-1998; 98WO-US012456.
XX	
PR	14-JUL-1998; 98WO-US014552.
XX	
PR	28-AUG-1998; 98WO-US017888.
XX	
PR	10-SEP-1998; 98WO-US018824.
XX	
PR	14-SEP-1998; 98WO-US019093.
XX	
PR	14-SEP-1998; 98WO-US019094.
XX	
PR	16-SEP-1998; 98WO-US019177.
XX	
PR	17-SEP-1998; 98WO-US019330.
XX	
PR	07-OCT-1998; 98WO-US021141.
XX	
PR	29-OCT-1998; 98WO-US022991.
XX	
PR	29-OCT-1998; 98WO-US022992.
XX	
PR	20-NOV-1998; 98WO-US024855.
XX	
PR	01-DEC-1998; 98WO-US025108.
XX	
PR	05-JAN-1999; 99WO-US000106.
XX	
PR	08-MAR-1999; 99WO-US005028.
XX	
PR	10-MAR-1999; 99WO-US005190.
XX	
PR	24-APR-1999; 99WO-US008615.
XX	
PR	14-MAY-1999; 99WO-US010733.
XX	
PR	02-JUN-1999; 99WO-US012252.
XX	
PR	01-SEP-1999; 99WO-US020111.
XX	
PR	08-SEP-1999; 99WO-US020594.
XX	
ADAB0923/c	
ID	ADAB0929 standard; cDNA; 1129 BP.
XX	
AC	ADAB0929;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Human PRO polynucleotide #111.
XX	
KW	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endotheial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
OS	Homo sapiens.
XX	
PN	US2003082702-A1.
XX	
PD	01-MAY-2003.
XX	
PF	23-APR-2002; 2002US-00128690.
XX	
PR	02-MAR-2000; 2000WO-US005841.
XX	
PR	30-MAY-2000; 2000WO-US014941.
XX	
PR	01-DEC-2000; 2000WO-US032678.
XX	
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tomas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-755111/71.
DR	P-PSDB; ADA80930.
XX	
PT	New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.
XX	
PS	Claim 2; Fig 221; 637pp; English.
XX	
CC	The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and

XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; hemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX
PN US2003082760-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121056.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 08-MAR-1999; 99WO-US000106.
PR 10-MAR-1999; 99WO-US005028.
PR 20-APR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-777204/73.
DR P-PSDB; ADB26115.
DR
DR
XX
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
XX
PS Claim 2; Fig 221; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

PR	20-APR-1999;	99WO-US0008611
PR	14-MAY-1999;	99WO-US0107733
PR	02-JUN-1999;	99WO-US0112252
PR	01-SEP-1999;	99WO-US0201111
PR	08-SEP-1999;	99WO-US0205094
PR	13-SEP-1999;	99WO-US0209444
PR	15-SEP-1999;	99WO-US0210990
PR	15-SEP-1999;	99WO-US0215447
PR	05-OCT-1999;	99WO-US0223089
PR	29-NOV-1999;	99WO-US0282144
PR	30-NOV-1999;	99WO-US0283113
PR	30-NOV-1999;	99WO-US0284099
PR	01-DEC-1999;	99WO-US0283011
PR	01-DEC-1999;	99WO-US0286344
PR	02-DEC-1999;	99WO-US0285511
PR	02-DEC-1999;	99WO-US0285644
PR	02-DEC-1999;	99WO-US0285654
PR	16-DEC-1999;	99WO-US0300955
PR	20-DEC-1999;	99WO-US0309111
PR	20-DEC-1999;	99WO-US0309999
PR	22-DEC-1999;	99WO-US0307200
PR	22-DEC-1999;	99WO-US0312723
PR	30-DEC-1999;	99WO-US0312744
PR	05-JAN-2000;	2000WO-US0002119
PR	06-JAN-2000;	2000WO-US0002027
PR	06-JAN-2000;	2000WO-US0003766
PR	11-FEB-2000;	2000WO-US0035655
PR	18-FEB-2000;	2000WO-US0043411
PR	18-FEB-2000;	2000WO-US0044342
PR	22-FEB-2000;	2000WO-US0044414
PR	24-FEB-2000;	2000WO-US0044914
PR	01-MAR-2000;	2000WO-US0050044
PR	02-MAR-2000;	2000WO-US0050601
PR	03-MAR-2000;	2000WO-US0050746
PR	10-MAR-2000;	2000WO-US0050584
PR	13-MAR-2000;	2000WO-US0063819
PR	20-MAR-2000;	2000WO-US0073777
PR	21-MAR-2000;	2000WO-US0075332
PR	30-MAR-2000;	2000WO-US0084339
PR	17-MAY-2000;	2000WO-US0113705
PR	22-MAY-2000;	2000WO-US0140422
PR	30-MAY-2000;	2000WO-US0149414
PR	02-JUN-2000;	2000WO-US0152654
PR	28-JUL-2000;	2000WO-US0207100
PR	11-AUG-2000;	2000WO-US0220311
PR	23-AUG-2000;	2000WO-US0235522
PR	08-NOV-2000;	2000WO-US0233328
PR	10-NOV-2000;	2000WO-US0309592
PR	01-DEC-2000;	2000WO-US0308783
PR	20-DEC-2000;	2000WO-US0326788
PR	20-DEC-2000;	2000US-00747259
PR	28-FEB-2001;	2000WO-US034956
PR	01-MAR-2001;	2001US-00736498
PR	18-MAR-2001;	2001WO-US0065200
PR	04-MAR-2001;	2001WO-US0056666
PR	19-MAR-2001;	2001US-00802706
PR	22-MAR-2001;	2001US-008086869
PR	22-MAR-2001;	2001US-008167444
PR	05-APR-2001;	2001US-008283668
PR	10-MAY-2001;	2001US-008542080
PR	18-MAY-2001;	2001WO-US0054280
PR	25-MAY-2001;	2001US-008650216
PR	25-MAY-2001;	2001US-008660288
PR	25-MAY-2001;	2001US-008660334
PR	01-JUN-2001;	2001WO-US0170932
PR	01-JUN-2001;	2001US-008720355
PR	11-JUN-2001;	2001WO-US0178000
PR	05-JUN-2001;	2001US-00874503
PR	19-JUN-2001;	2001US-008826362
PR	21-JUN-2001;	2001US-008863434
PR	21-JUN-2001;	2001WO-US0196992
PR	21-JUN-2001;	2001US-008878799

PR 10-MAR-1999; 99WO-US005190.

cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 33; Conservative 0; Mismatches 16; Indels 0; Gaps 0

Qy 1941 TTCTAAATTTTTCATTCCAGATTCTCTCAGTTGGGTTTGTTT 1987
 ||| ||||| ||| ||||| ||| ||||| ||| ||||| |||
Db 1129 TTTTTTTTTTTTTTTTTCAGCTGCACACAGCGCTGGTTTTATT 1083

RESULT 139
ADA97461/C

ID ADA97461 standard; cDNA; 1129 BP.
XX
AC ADA97461;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082686-A1.
XX
PD 01-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125926.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
FI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI: 2003-755106/71.
 DR P-PSDB; ADA97462.
 XX
 PT Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 XX
 XS Claim 2; Fig 221; 666pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems. PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 OY 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTGTTT 1987
 DB 1129 TTTTTTTTTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1083
 RESULT 140
 ADB27218/c
 ID ADB27218 standard; cDNA; 1129 BP.
 XX
 AC ADB27218;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #111.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX US2003022239-A1.
 XX 30-JAN-2003.
 XX
 XX 12-APR-2002; 2002US-00121049.
 XX
 XX 18-JUN-1997; 97US-0049911P.
 XX 26-AUG-1997; 97US-0056974P.
 XX 17-SEP-1997; 97US-0059113P.
 XX 17-SEP-1997; 97US-0059115P.
 XX 17-SEP-1997; 97US-0059117P.
 XX 17-SEP-1997; 97US-0059122P.
 XX 17-SEP-1997; 97US-0059184P.
 XX 17-SEP-1997; 97US-0059263P.
 XX 19-SEP-1997; 97US-0059352P.
 XX 19-SEP-1997; 97US-0059588P.
 XX 24-SEP-1997; 97US-0059836P.
 XX 17-OCT-1997; 97US-0062250P.
 XX 17-OCT-1997; 97US-0062285P.
 XX 17-OCT-1997; 97US-0062287P.
 XX 17-OCT-1997; 97US-0063755P.
 XX 24-OCT-1997; 97US-0062814P.
 XX 24-OCT-1997; 97US-0062816P.
 XX 24-OCT-1997; 97US-0063045P.
 XX 24-OCT-1997; 97US-0063082P.
 XX 24-OCT-1997; 97US-0063127P.
 XX 27-OCT-1997; 97US-0063327P.
 XX 27-OCT-1997; 97US-0063329P.
 XX 28-OCT-1997; 97US-0063550P.
 XX 28-OCT-1997; 97US-0063561P.
 XX 29-OCT-1997; 97US-0063704P.
 XX 29-OCT-1997; 97US-0063733P.
 XX 29-OCT-1997; 97US-0063735P.
 XX 29-OCT-1997; 97US-0063738P.
 XX 03-NOV-1997; 97US-0064248P.
 XX 07-NOV-1997; 97US-0064809P.
 XX 12-NOV-1997; 97US-0065186P.
 XX 17-NOV-1997; 97US-0065846P.
 XX 21-NOV-1997; 97US-0066364P.
 XX 24-NOV-1997; 97US-0066453P.
 XX 24-NOV-1997; 97US-0066511P.
 XX 24-NOV-1997; 97US-0066770P.
 XX 11-DEC-1997; 97US-0069212P.
 XX 11-DEC-1997; 97US-0069278P.
 XX 11-DEC-1997; 97US-0069334P.
 XX 16-DEC-1997; 97US-0069694P.
 XX 23-JAN-1998; 98US-0072320P.
 XX 04-FEB-1998; 98US-0073612P.
 XX 09-FEB-1998; 98US-0074086P.
 XX 09-FEB-1998; 98US-0074092P.
 XX 12-MAR-1998; 98US-0077791P.
 XX 20-MAR-1998; 98US-0078910P.
 XX 25-MAR-1998; 98US-0079294P.
 XX 27-MAR-1998; 98US-0079663P.
 XX 31-MAR-1998; 98US-0079728P.
 XX 31-MAR-1998; 98US-0080165P.
 XX 09-APR-1998; 98US-0081223P.
 XX 14-APR-1998; 98US-0081695P.
 XX 15-APR-1998; 98US-0081817P.
 XX 15-APR-1998; 98US-0081818P.
 XX 24-APR-1998; 98US-0082999P.
 XX 28-APR-1998; 98US-0083322P.
 XX 29-APR-1998; 98US-0083545P.
 XX 07-MAY-1998; 98US-0084600P.
 XX 07-MAY-1998; 98US-0084627P.
 XX 07-MAY-1998; 98US-0084637P.
 XX 12-MAY-1998; 98US-0085149P.
 XX 13-MAY-1998; 98US-0085323P.
 XX 13-MAY-1998; 98US-0085338P.


```
PR 13-MAY-1998; 98US-00853339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 12-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-0094455P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 11-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097219P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098523P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0098753P.
PR 09-SEP-1998; 98US-0098998P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099729P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099816P.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100393P.
PR 14-SEP-1998; 98US-0100394P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100943P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 27-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103328P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 30-OCT-1998; 98US-0106299P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106858P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0112456P.
PR 15-DEC-1998; 98US-0112456P.
PR 16-DEC-1998; 98US-0112456P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0000106P.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 12-JAN-1999; 99US-0115733P.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCCTAATTTTTCATTTCCAGATTCCTTCAGTTGGGTTTGT 1987
DB 1129 TTTTITTTTTTTTTCAGCTGCACACAGCTGGTTTATT 1083

RESULT 141
ADB22151/c
ID ADB22151 standard; cDNA; 1129 BP.
XX
AC ADB22151;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
OS Homo sapiens.
XX
PN US2003087344-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123905.
```

XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063127P.
PR 17-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 09-APR-1998; 98US-0080165P.
PR 14-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 20-AUG-1998; 98US-0097141P.
PR 26-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 28-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98WO-US017888.
PR 01-SEP-1998; 98US-0098525P.
PR 09-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 15-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 23-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.

PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-01124855.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-0115549P.
PR 12-JAN-1999; 98US-0115549P.
PR 12-JAN-1999; 98US-0115560P.
PR 12-JAN-1999; 98US-0115562P.
PR 12-JAN-1999; 98US-0115564P.
PR 12-JAN-1999; 98US-0115630P.
PR 12-JAN-1999; 98US-0115705P.
PR 20-JAN-1999; 98US-0115733P.
PR 20-JAN-1999; 98US-0115533P.
PR 01-FEB-1999; 98US-0118210P.

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTTT 1987
DB 1129 TTTTITTTTTTTTTTTTTTTTTCAGTGGCACACAGCTGGTTTATT 1083

RESULT 142

ADA66842/c
ID ADA66842 standard; cDNA; 1129 BP.

AC ADA66842;

DT 20-NOV-2003 (first entry)

DE Human PRO polynucleotide #11.

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; hemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

PN US2003068793-A1.

XX 10-APR-2003.

PD 15-APR-2002; 2002US-00123108.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019130.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 01-SEP-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX US2003082712-A1.
 PN
 XX
 PD 01-MAY-2003.
 XX
 XX 16-MAY-2002; 2002US-00147512.
 XX
 XX 15-MAY-1998; 98US-0085697P.
 PR
 XX 08-MAR-1999; 99WO-US005028.
 PR
 XX 25-AUG-1999; 99US-00380138.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786915/74.
 DR
 XX P-PSDB; ADA92199.
 XX
 XX New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 FT
 XX
 XX Claim 2; Fig 221; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC cells, for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the proliferation of inner ear utricular supporting cells,
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 XX a novel human secreted and transmembrane PRO polypeptide.
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 OY 1941 TTCTTAATTTTTCATTCACGATTTCCTTCAGTTGGGTTTGT 1987
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACAGGCTGGGTTTTTAT 1083
 RESULT 146

ADBI5261/c
 ID ADBI5261 standard; cDNA; 1129 BP.
 XX
 AC ADBI5261;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #111.
 XX
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003087352-A1.
 XX
 XX 08-MAY-2003.
 XX
 XX 22-APR-2002; 2002US-00127824.
 XX
 XX 17-AUG-1998; 98US-0096891P.
 PR
 XX 02-JUN-1999; 99WO-US012252.
 PR
 XX 25-AUG-1999; 99US-00380137.
 PR
 XX 30-MAR-2000; 2000WO-US008439.
 PR
 XX 30-MAY-2000; 2000WO-US014941.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786943/74.
 DR
 XX P-PSDB; ADBI5262.
 XX
 XX New PRO nucleic acid, useful for producing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 FT
 XX
 XX Claim 2; Fig 221; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating

RESULT 149
 ADB66433/c
 ID ADB66433 standard; cdna; 1129 BP.
 XX
 AC ADB66433;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cdna.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082689-A1.
 EN
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127831.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012450.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 22-MAR-2001; 2001US-00808689.
 PR 14-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854280.
 PR 15-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI; 2003-786905/74.
 P-FSDB; ADB66434.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 e.g. tumor or for tissue typing.
 XX
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCCTAATTTTTCATTTCCAGATTCTCTCAGTTTGGTTTGTGTT 1987

Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083

RESULT 150

ADB89513/c

ID ADB89513 standard; cDNA; 1129 BP.

AC ADB89513;

DT 04-DEC-2003 (first entry)

DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082698-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127850.

XX 20-AUG-1998; 98US-0097218P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen NE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-743896/70.

XX P-PSDB; ADB89514.

XX New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT of cancer.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCCTAATTTTTCATTTCCAGATTCTCTCAGTTTGGTTTGTGTT 1987

Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083

RESULT 151

ADB90245/c

ID ADB90245 standard; cDNA; 1129 BP.

XX ADB90245;

XX 04-DEC-2003 (first entry)

XX Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;

CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGTGTT 1987
 Db 1129 TTTTCTTTTTCATTTTCAGTGGCACACAGGCTGGTTTATT 1083

RESULT 152

ADB39346/C

ID ADB39346 standard; cDNA; 1129 BP.

XX AC ADB39346;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX FN US2003082764-A1.

XX PD 01-MAY-2003.

XX PF 03-MAY-2002; 2002US-00137868.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014532.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808699.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.

Db 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGCTGGGTTTATT 1083

RESULT 154

ADB86576/c
ID ADB86576 standard; cDNA; 1129 BP.

AC ADB86576;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #111.

XX XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX FN US2003082697-A1.

XX XX 01-MAY-2003.

XX XX 22-APR-2002; 2002US-00127849.

XX XX 20-OCT-1998; 98US-0104987P.

XX XX 01-SEP-1999; 99WO-US020111.

XX XX 18-OCT-1999; 99US-00403297.

XX XX 18-FEB-2000; 2000WO-US004342.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-743895/70.

XX XX P-PSDB; ADB86577.

XX XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis

XX XX and treatment of cancer.

XX XX Claim 2; Fig 221; 637pp; English.

XX XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTAATTTTTCATTTTCAGATTTCCTTCAGTTTGGTTTCTTT 1987
Db 1129 TTTTTCATTTTTCATTTTCAGATTTCCTTCAGTTTGGTTTCTTT 1083

RESULT 155

ADB77181/c

ID ADB77181 standard; cDNA; 1129 BP.

XX AC ADB77181;

XX DT 04-DEC-2003 (first entry)

XX XX Novel human secreted and transmembrane protein PRO4327 CDNA.

XX XX Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX FN US2003082696-A1.

XX XX 01-MAY-2003.

XX XX 22-APR-2002; 2002US-00127848.

XX XX 03-NOV-1998; 98US-0106934P.

XX XX 26-JUL-1999; 99US-0145698P.

XX XX 01-SEP-1999; 99WO-US020111.

XX XX 18-OCT-1999; 99US-00403297.

XX XX 05-JAN-2000; 2000WO-US000219.

XX XX 18-FEB-2000; 2000WO-US004342.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755109/71.
XX P-PSDB; ADB77182.

XX XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.

factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalasaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match	Score	DB 1	Length
0.9%	Score 21.4	DB 1	Length 1129

31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1941 TTCTTAATTTTTCATTTCCAGATTCCCTTCAGTTGGGTTTGT 1987

1129 TTTTCTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTATTATTT 1083

UT 159

ADB34

ADB34890;

04-DEC-20

Human PRO polynucleotide S

Human; gene; ss; PRO; secreted polypeptide

tumour necrosis factor- α ; TNF- α ; monocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; PFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.

US2003077718-A1.

24-APR-2003.

24-APR-2002; 2002US-00131823.

31-MAR-1997; 97WO-US005230.

12-CON-1998; 98WO-US012456;
14-JUL-1998; 98WO-US014552.

PR	28-AUG-1998;	98WO-US017888;
PR	10-SEP-1998;	98WO-US018824;
PR	14-SEP-1998;	98WO-US019093;
PR	14-SEP-1998;	98WO-US019094;
PR	14-SEP-1998;	98WO-US019177;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98WO-US019437;
PR	07-OCT-1998;	98WO-US021141;
PR	29-OCT-1998;	98WO-US022991;
PR	29-OCT-1998;	98WO-US022992;
PR	20-NOV-1998;	98WO-US024855;
PR	01-DEC-1998;	98WO-US025108;
PR	05-JAN-1999;	98WO-US000106;
PR	08-MAR-1999;	98WO-US005028;
PR	10-MAR-1999;	98WO-US005190;
PR	20-APR-1999;	98WO-US008615;
PR	14-MAY-1999;	98WO-US010733;
PR	02-JUN-1999;	98WO-US012252;
PR	01-SEP-1999;	98WO-US020111;
PR	08-SEP-1999;	98WO-US020594;
PR	13-SEP-1999;	98WO-US020944;
PR	15-SEP-1999;	98WO-US021090;
PR	05-OCT-1999;	98WO-US021547;
PR	29-NOV-1999;	98WO-US023089;
PR	30-NOV-1999;	98WO-US028214;
PR	30-NOV-1999;	98WO-US028313;
PR	01-DEC-1999;	98WO-US028409;
PR	01-DEC-1999;	98WO-US028301;
PR	02-DEC-1999;	98WO-US028634;
PR	02-DEC-1999;	98WO-US028551;
PR	02-DEC-1999;	98WO-US028564;
PR	02-DEC-1999;	98WO-US028565;
PR	16-DEC-1999;	98WO-US030095;
PR	20-DEC-1999;	98WO-US030911;
PR	20-DEC-1999;	98WO-US030939;
PR	22-DEC-1999;	98WO-US030720;
PR	30-DEC-1999;	98WO-US031243;
PR	30-DEC-1999;	98WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US003565;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US004914;
PR	01-MAR-2000;	2000WO-US005004;
PR	02-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	10-MAR-2000;	2000WO-US005841;
PR	10-MAR-2000;	2000WO-US006319;
PR	15-MAR-2000;	2000WO-US006884;
PR	20-MAR-2000;	2000WO-US007377;
PR	21-MAR-2000;	2000WO-US007532;
PR	30-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	23-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US014564;
PR	11-JUL-2000;	2000WO-US020710;
PR	18-AUG-2000;	2000WO-US022031;
PR	23-AUG-2000;	2000WO-US023522;
PR	24-AUG-2000;	2000WO-US023328;
PR	08-NOV-2000;	2000WO-US030952;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000US-00764948;
PR	28-FEB-2001;	2001WO-US000520;
PR	01-MAR-2001;	2001WO-US000566;
PR	09-MAR-2001;	2001US-00802370;
PR	14-MAR-2001;	2001US-00803689;

XX	24-APR-2002; 2002US-00131822.	ADCT71809 standard; cDNA; 1129 BP.
XX	19-AUG-1998; 98US-0097141P.	ADCT71809;
PR	02-JUN-1999; 99WO-US012252.	18-DEC-2003 (first entry)
PR	25-AUG-1999; 99US-00380137.	Novel human secreted and transmembrane protein PRO4327 cDNA.
PR	30-MAR-2000; 2000WO-US008439.	Human; secreted and transmembrane protein; PRO; secreted polypeptide;
PR	01-DEC-2000; 2000WO-US032678.	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
PR	19-DEC-2001; 2001US-00028072.	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX	(GETH) GENENTECH INC.	rectum; kidney; cervix; liver; microvascular endothelial cell;
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	glucose uptake modulator; skeletal muscle cell; adipocyte cell;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	cell differentiation; inner ear utricular supporting cell; T-lymphocyte cell;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	pericyte cell; inner ear utricular supporting cell; cartilage disorder;
XX	WPI; 2003-801171/75.	endothelial cell tube formation; bone disorder; osteoarthritis;
DR	P-PSDB; ADC50263.	sports injury; proteoglycan; articular cartilage defect; thalassemia;
DR		rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
XX		immune system cell infiltration; chromosome mapping; gene mapping; ss.
XX		gene therapy; chromosome identification; chromosome marker; gene; ss.
PT	New secreted and transmembrane nucleic acid useful for treating	Homo sapiens.
PT	inflammation, organ failure, atherosclerosis, cardiac injury,	US2003092107-A1.
PT	infertility, birth defects, premature aging, acquired immunodeficiency	15-MAY-2003.
PT	syndrome or cancer.	24-APR-2002; 2002US-00131828.
XX	Claim 2; Fig 221; 637pp; English.	07-OCT-1998; 98US-0103315P.
XX		01-SEP-1999; 99WO-US020111.
CC	The invention relates to isolated human PRO polypeptides (secreted and	18-OCT-1999; 99US-00403297.
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	18-FEB-2000; 2000WO-US004342.
CC	invention also relates to an antibody which specifically binds to a PRO	10-NOV-2000; 2000WO-US030873.
CC	polypeptide, a method for stimulating the release of tumour necrosis	01-DEC-2000; 2000WO-US032678.
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	19-DEC-2001; 2001US-00028072.
CC	proliferation or differentiation of chondrocyte cells and a method for	(GETH) GENENTECH INC.
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
CC	polynucleotides are useful in molecular biology, including uses as	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
CC	hybridisation probes, in chromosome and gene mapping, in generating	WPI; 2003-801172/75.
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	P-PSDB; ADC71810.
CC	be used in preparing PRO polypeptides by recombinant techniques and in	New secreted and transmembrane nucleic acids and polypeptides, designated
CC	generating either transgenic animals or knock-out animals which are	as PRO, useful for treating inflammation, organ failure, atherosclerosis,
CC	useful in the development and screening of therapeutically useful	cardiac injury, infertility, birth defects, premature aging, AIDS, or
CC	reagents. The PRO polypeptides or antibodies are used in preparing a	cancer.
CC	medicament for treating a condition responsive to the polypeptides or	Claim 2; Fig 221; 637pp; English.
CC	antibodies, such as tumours, for stimulating and inhibiting the uptake of	The invention relates to isolated human PRO polypeptides (secreted and
CC	of human microvascular endothelial cells, for modulating the uptake of	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte	invention also relates to an antibody which specifically binds to a PRO
CC	cells, for stimulating differentiation of adipocyte cells, for	polypeptide, a method for stimulating the release of tumour necrosis
CC	stimulating proliferation of or gene expression in pericyte cells, for	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	stimulating the proliferation of inner ear utricular supporting cells or	proliferation or differentiation of chondrocyte cells and a method for
CC	T-lymphocyte cells, for inducing endothelial cell tube formation and for	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	treating various bone and/or cartilage disorders such as sports injuries	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	and arthritis. PRO polypeptides which stimulate the release of	polynucleotides are useful in molecular biology, including uses as
CC	proteoglycans from cartilage are useful for treating sports-related joint	hybridisation probes, in chromosome and gene mapping, in generating
CC	problems, articular cartilage defects, osteoarthritis and rheumatoid	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	arthritis. PRO polypeptides are also useful for treating various	be used in preparing PRO polypeptides by recombinant techniques and in
CC	mammalian haemoglobin-associated disorders such as various thalassemias	generating either transgenic animals or knock-out animals which are
CC	and conditions which may benefit from enhanced local immune system cell	useful in the development and screening of therapeutically useful
CC	infiltration. This sequence represents a human PRO polynucleotide of the	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	invention. Note: The sequence data for this patent is also available in	medicament for treating a condition responsive to the polypeptides or
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html.	antibodies, such as tumours, for stimulating and inhibiting the uptake of
XX	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;	of human microvascular endothelial cells, for modulating the uptake of
SQ		glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
		cells, for stimulating differentiation of adipocyte cells, for
		stimulating proliferation of or gene expression in pericyte cells, for
		stimulating the proliferation of inner ear utricular supporting cells or
		T-lymphocyte cells, for inducing endothelial cell tube formation and for
		treating various bone and/or cartilage disorders such as sports injuries
		and arthritis. PRO polypeptides which stimulate the release of
		proteoglycans from cartilage are useful for treating sports-related joint
		problems, articular cartilage defects, osteoarthritis and rheumatoid
		arthritis. PRO polypeptides are also useful for treating various
		mammalian haemoglobin-associated disorders such as various thalassemias
		and conditions which may benefit from enhanced local immune system cell
		infiltration. This sequence represents a human PRO polynucleotide of the
		invention. Note: The sequence data for this patent is also available in
		electronic format from USPTO at seqdata.uspto.gov/sequence.html.
		Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
		Query Match 0.9%; Score 21.4; DB 1; Length 1129;
		Best Local Similarity 66.0%; Pred. No. 55;
		Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1941 TTCTTAATTTTCATTTCCAGATTCCTTCAGTTTGGTTTGT 1987	
DB	1129 TTTTTTTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083	
		RESULT 163
		ADCT1809/c


```

RESULT 166
ADC571149/c
ID ADC57149 standard; cDNA; 1129 BP.
XX AC ADC57149;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
XX KW cell proliferation; cell migration; cell differentiation;
XX KW mitogenic factor; survival factor; cytotoxic factor;
XX KW differentiation factor; neuropptide; hormone; cell receptor;
XX KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003087366-A1.
XX PD 08-MAY-2003.
XX PF 23-APR-2002; 2002US-00128694.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 30-MAY-2000; 2000WO-US014941.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX DR WPI; 2003-801151/75.
XX DR P-PSDB; ADC571150.
XX PT New PRO nucleic acid, useful for manufacturing a medicament for
XX PT diagnosing or treating tumor.
XX PS Claim 2; SEQ ID NO 221; 637pp; English.
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX CC and transmembrane proteins. Extracellular proteins play important roles
XX CC in the formation, differentiation and maintenance of multicellular
XX CC organisms. The fate of many individual cells (for example proliferation,
XX CC migration or differentiation) is typically governed by information
XX CC received from other cells and the immediate environment. The information
XX CC is often transmitted by secreted polypeptides (for example mitogenic
XX CC factors, survival factors, cytotoxic factors, differentiation factors,
XX CC neuropeptides or hormones) which are received and interpreted by diverse
XX CC cell receptors or membrane bound proteins. These membrane bound proteins
XX CC and receptors may be of use as pharmaceutical and diagnostic agents, such
XX CC as in the blocking of receptor-ligand interactions. The current invention
XX CC provides the amino acid sequences of novel human membrane bound receptors
XX CC and proteins, along with the cDNA sequences encoding them. The novel
XX CC proteins of the invention may have cytostatic activities through the
XX CC stimulation of chondrocytes. The nucleic acids of the invention may be
XX CC useful for the manufacture of a medicament for diagnosing or treating a
XX CC tumour in a mammal. In addition, they may be useful for measuring or
XX CC detecting the expression of a tumour associated gene. The present
XX CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX CC invention.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Qy 1941 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTTGGGTTTCTTTT 1987
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

```

Db 1129 TTTTTCAGTGGCACACAGGCTGGGTTTTTATT 1083
RESULT 167
ADC60340/c
ID ADC60340 standard; cDNA; 1129 BP.
XX AC ADC60340;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX KW rectum; kidney; cervix; liver; microvascular endothelial cell;
XX KW glucose uptake modulator; EPA uptake modulator; cell proliferation;
XX KW cell differentiation; skeletal muscle cell; adipocyte cell;
XX KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
XX KW endothelial cell tube formation; bone disorder; cartilage disorder;
XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
XX KW immune system cell infiltration; chromosome mapping; gene mapping;
XX KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX OS Homo sapiens.
XX PN US2003087367-A1.
XX PD 08-MAY-2003.
XX PF 24-APR-2002; 2002US-00131825.
XX PR 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US017888.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 29-OCT-1998; 98WO-US022992.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 10-MAR-1999; 2000WO-US006319.
XX PR 20-APR-1999; 99WO-US008615.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 08-SEP-1999; 99WO-US020594.
XX PR 13-SEP-1999; 99WO-US020944.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 15-SEP-1999; 99WO-US021547.
XX PR 05-OCT-1999; 99WO-US023089.
XX PR 29-NOV-1999; 99WO-US028214.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 30-NOV-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 16-DEC-1999; 99WO-US028565.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.

```


CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC stimulation of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for a mammal. In addition, they may be useful for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC invention is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
 |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083

RESULT 172
 ADC58924/c
 ID ADC58924 standard; cDNA; 1129 BP.

XX AC ADC58924;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.

XX KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

XX OS Homo sapiens.

XX FN US2003087359-A1.

XX PD 08-MAY-2003.

XX PF 22-APR-2002; 2002US-00127834.

XX PR 17-SEP-1998; 98US-0100710P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-801144/75.

XX DR P-PSDB; ADC58925.

XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide

XX and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 221; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC stimulation of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for a mammal. In addition, they may be useful for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC invention is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1987
 |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083

RESULT 173

ADC5802/c

ID ADC5802 standard; cDNA; 1129 BP.

XX AC ADC5802;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.

XX KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

XX OS Homo sapiens.

XX FN US2003087360-A1.

XX PD 08-MAY-2003.

XX PF 22-APR-2002; 2002US-00127836.

XX PR 17-NOV-1998; 98US-0108802P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 02-JUN-2000; 2000WO-US015264.

XX PR 23-AUG-2000; 2000WO-US023522.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-801145/75.

XX DR P-PSDB; ADC5803.

XX PT New PRO nucleic acid, useful for manufacturing a medicament for

[illegible]

PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 27-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006894.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-JUN-2000; 2000WO-US014941.
 PR 02-JAN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US032759.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808699.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-801169/75.
 DR P-PSDB; ADD03047.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 221; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating the proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Claim 2: Fig 221; 637pp; English.

CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1987
 DB 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGGCTGGTTCATTTATT 1083
 RESULT 187
 ADD52175/c
 ID ADD52175 standard; cDNA; 1129 BP.
 XX ADD52175;
 AC ADD52175;
 DT 15-JAN-2004 (first entry)
 DE cDNA encoding human PRO polypeptide #111.
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS
 XX US2003194769-A1.
 XX 16-OCT-2003.
 XX 21-MAY-2002; 2002US-00152374.
 XX 09-DEC-1999; 99US-0170262P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-852593/79.
 DR P-PSDB; ADD52176.
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 FT acids, useful for detection of tumors, modulating the uptake of glucose
 FT or free fatty acids and stimulating the release of proteoglycans from
 FT cartilage.
 XX Claim 2; Fig 221; 637pp; English.
 PS
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTTTCAGATTTCCTTCAGTTGGGTTTGTGTT 1987
 DB 1129 TTTTTCATTTTTCATTTTCAGCTGGCACACAGGCTGGTTCATTTATT 1083

RESULT 188

ADD52915/c

ID ADD52915 standard; cDNA; 1129 BP.

XX ADD52915;

AC ADD52915;

DT 15-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #111.
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS
 XX US2003194792-A1.
 XX 16-OCT-2003.
 XX 15-APR-2002; 2002US-00123156.
 XX 31-MAR-1997; 97WO-US005230.
 XX 12-JUN-1998; 98WO-US012456.
 XX 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 98WO-US006319.
PR 20-APR-1999; 98WO-US010733.
PR 14-MAY-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US020111.
PR 01-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 23-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 98WO-US000219.
PR 06-JAN-2000; 98WO-US000277.
PR 11-FEB-2000; 98WO-US000376.
PR 18-FEB-2000; 98WO-US003565.
PR 18-FEB-2000; 98WO-US004341.
PR 18-FEB-2000; 98WO-US004342.
PR 22-FEB-2000; 98WO-US004414.
PR 24-FEB-2000; 98WO-US004914.
PR 01-MAR-2000; 98WO-US005004.
PR 01-MAR-2000; 98WO-US005601.
PR 02-MAR-2000; 98WO-US005746.
PR 02-MAR-2000; 98WO-US005841.
PR 15-MAR-2000; 98WO-US006884.
PR 20-MAR-2000; 98WO-US007377.
PR 21-MAR-2000; 98WO-US007532.
PR 30-MAR-2000; 98WO-US008439.
PR 17-MAY-2000; 98WO-US013705.
PR 22-MAY-2000; 98WO-US014042.
PR 30-MAY-2000; 98WO-US014941.
PR 02-JUN-2000; 98WO-US015264.
PR 28-JUL-2000; 98WO-US020710.
PR 11-AUG-2000; 98WO-US022031.
PR 23-AUG-2000; 98WO-US023522.
PR 24-AUG-2000; 98WO-US023328.
PR 08-NOV-2000; 98WO-US030952.
PR 10-NOV-2000; 98WO-US030873.
PR 01-DEC-2000; 98WO-US032678.
PR 20-DEC-2000; 98WO-US00747259.
PR 28-FEB-2001; 98WO-US00796498.
PR 28-FEB-2001; 98WO-US006520.
PR 01-MAR-2001; 98WO-US006666.
PR 09-MAR-2001; 98WO-US00802706.
PR 14-MAR-2001; 98WO-US0080689.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 98WO-US006319.
PR 20-APR-1999; 98WO-US010733.
PR 14-MAY-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US020111.
PR 01-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 23-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 98WO-US000219.
PR 06-JAN-2000; 98WO-US000277.
PR 11-FEB-2000; 98WO-US000376.
PR 18-FEB-2000; 98WO-US003565.
PR 18-FEB-2000; 98WO-US004341.
PR 18-FEB-2000; 98WO-US004342.
PR 22-FEB-2000; 98WO-US004414.
PR 24-FEB-2000; 98WO-US004914.
PR 01-MAR-2000; 98WO-US005004.
PR 01-MAR-2000; 98WO-US005601.
PR 02-MAR-2000; 98WO-US005746.
PR 02-MAR-2000; 98WO-US005841.
PR 15-MAR-2000; 98WO-US006884.
PR 20-MAR-2000; 98WO-US007377.
PR 21-MAR-2000; 98WO-US007532.
PR 30-MAR-2000; 98WO-US008439.
PR 17-MAY-2000; 98WO-US013705.
PR 22-MAY-2000; 98WO-US014042.
PR 30-MAY-2000; 98WO-US014941.
PR 02-JUN-2000; 98WO-US015264.
PR 28-JUL-2000; 98WO-US020710.
PR 11-AUG-2000; 98WO-US022031.
PR 23-AUG-2000; 98WO-US023522.
PR 24-AUG-2000; 98WO-US023328.
PR 08-NOV-2000; 98WO-US030952.
PR 10-NOV-2000; 98WO-US030873.
PR 01-DEC-2000; 98WO-US032678.
PR 20-DEC-2000; 98WO-US00747259.
PR 28-FEB-2001; 98WO-US00796498.
PR 28-FEB-2001; 98WO-US006520.
PR 01-MAR-2001; 98WO-US006666.
PR 09-MAR-2001; 98WO-US00802706.
PR 14-MAR-2001; 98WO-US0080689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-0086028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-0087092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00874503.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00886342.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 23-JUN-2001; 2001US-00887879.
PR 09-JUL-2001; 2001US-00908827.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 06-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-852599/79.
XX PS P-PSDB; ADD52916.
XX CC New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX CC PRO4978, useful in chromosome and gene mapping, in generating antisense
XX CC RNA and DNA, and in the treatment of cancer.
XX CC Claim 2; Fig 221; 638pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
XX CC proliferation of or gene expression in pericyte cells, for stimulating
XX CC the proliferation of inner ear utricular supporting cells and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems, PRO
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence encodes a human PRO polypeptide of the invention. Note: The
XX CC sequence data for this patent is also available in electronic format from
XX CC the USPTO website at seqdata.uspto.gov.

Claim 2; Fig 221; 637pp; English.

CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pzed. No. 55;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 OY 1941 TCTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTGTTT 1987
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
 RESULT 193
 ADD54038/c
 ID ADD54038 standard; cDNA; 1129 BP.
 XX AC ADD54038;
 XX DT 15-JAN-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX WPI; 2003-875637/81.
 OS Homo sapiens.
 XX P-PSDB; ADD01857.
 XX PN New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 XX PT generating antisense RNA and DNA, and in gene therapy.
 XX PS Claim 2; Fig 221; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX OS Homo sapiens.
 XX PN US2003199055-A1.
 XX PD 23-OCT-2003.
 XX PF 12-APR-2002; 2002US-00121063.
 XX PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 01-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 01-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028401.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028554.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003365.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX MPI: 2003-900165/82.
 P-PSDB; ADD91252.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 221; 636pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGGTTT 1987
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTATT 1083

RESULT 196

AD03865/C
ID AD03865 standard; cDNA; 1129 BP.

XX AC AD03865;

XX XX 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX XX US2003199057-A1.

XX XX 23-OCT-2003.

XX PF 15-APR-2002; 2002US-00123213.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 10-MAR-1999; 2000WO-US006319.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028409.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001WO-US006034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone

and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalasasaenias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1125 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTCAGTTGGGTTTTGT 1987
Db 1129 TTTTFTTTTTTTTTTTTTCAGTGCGACACAGGCTGGGTTTATT 1083

RESULT 199
ADD79318/c
ID ADD79318 standard; cDNA; 1129 BP.
XC ADD79318;
AC ADD79318;
XX
DT 29-JAN-2004 (first entry)
DE
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalasasaemia;
KW immune system cell infiltration.
OS Homo sapiens.
PN
US2003203428-A1.

XX PD 30-OCT-2003.

XX PF 22-APR-2002; 2002US-00127852.

XX PR 09-DEC-1999; 99US-0170262P.

PR 01-DEC-2000; 2000WO-US0032678.

PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875635/81.
DR P-PSDB; ADD79319.

XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

XX PS Claim 2; Fig 221; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
the proliferation of or gene expression in pericyte cells, for stimulating
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence encodes a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1941 TTCTTAATTTTTCATTTCAGATTTTCCTCAGTTGGGTTTTGT 1987

Db 1129 TTTTITTTTTTTTTTTTTCAGTGCGACACAGCGTGGGTTTTTAT 1083

RESULT 200
ADE41854/c
ID ADE41854 standard; cDNA: 1129 BP.

XX

11-APR-2002; 2002US-00121046.
PF
XX

PR 31-MAR-1997; 99WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US011252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-0080689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-899790/82.
DR P-PSDB; ADE33819.
DR
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 221; 636pp; English.
PS
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or TPA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

AD E19327/c

ID ADE19327 standard; cDNA; 1129 BP.

XX AC ADE19327;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199025-A1.

XX PD 23-OCT-2003.

XX PF 21-MAY-2002; 2002US-00152385.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-900156/82.

DR P-FSDB; ADE19328.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

PS Claim 2; SEQ ID NO 221; 648pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTTGTTT 1987
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTNTTTTTTTTTTTTTCAGCTGCACACAGCGTGCGTTTATT 1083

RESULT 208
ADE18775/c

ID ADE18775 standard; cDNA; 1129 BP.

XX AC ADE18775;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199026-A1.

XX PD 23-OCT-2003.

XX PF 20-MAY-2002; 2002US-00152393.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-900157/82.

DR P-FSDB; ADE18776.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

PS Claim 2; SEQ ID NO 221; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the

AD E19327/c

ID ADE19327 standard; cDNA; 1129 BP.

XX AC ADE19327;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199025-A1.

XX PD 23-OCT-2003.

XX PF 21-MAY-2002; 2002US-00152385.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-900156/82.

XX DR P-FSDB; ADE19328.

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

XX PS Claim 2; SEQ ID NO 221; 648pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTTGTTT 1987
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTNTTTTTTTTTTTTTCAGCTGCACACAGCGTGCGTTTATT 1083

RESULT 208
ADE18775/c

ID ADE18775 standard; cDNA; 1129 BP.

XX AC ADE18775;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #111.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003199026-A1.

XX PD 23-OCT-2003.

XX PF 20-MAY-2002; 2002US-00152393.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-900157/82.

XX DR P-FSDB; ADE18776.

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

XX PS Claim 2; SEQ ID NO 221; 636pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the

KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

OS US2003199059-A1.

PN 23-OCT-2003.

XX 15-APR-2002; 2002US-00123322.

XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017898.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 17-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 08-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney M, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900168/82.
 P-PSDB; ADD95761.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a

•

WPI: 2003-900161/82.
P-FSDB; ADE42407.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 221; 636pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells or adipocyte cells, for proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1941 TTCTTATTTTTCATTCCAGATTCTCAGTTTCGGGTTTTGTT 1987
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTFTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTTTATT 1083

RESULT 215
ADD80422/c

ID ADD80422 standard; cDNA; 1129 BP.
XX ADD80422;
XX
XX
DT 29-JAN-2004 (first entry)
DE
DE cDNA encoding human PRO polypeptide #111.
XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match
	Best Local Similarity 0.9%; Score 21.4; DB 1; Length 1129;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1941 TTCTATATTTTTCATTTCCGATTTCCCTTCAGTTGGGTTTGT 1987
db	1129 TTTTTCATTTTTTTTTTTTCAGTCGGCACACAGGCTGGTTCAT 1083

RESULT 220	
ADD76406/c	
ID	ADD76406 standard; cDNA; 1129 BP.
XX	
XX	
AC	ADD76406;
XX	
XX	29-JAN-2004 (first entry)
XX	
DE	Human PRO polynucleotide #111.
XX	
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
XX	
PN	US2003100087-A1.
XX	
PD	29-MAY-2003.
XX	
FF	16-APR-2002; 2002US-00123912.
XX	
PR	31-MAR-1997; 97WO-US005230.
PR	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.

PR	25-MAY-2001; 2001WO-US017092.	DB	1129	TTTTTTTTTTTTTTTTTTTTTTTCACTGGCACACAGGCTGGGTTTTATT 1083
PR	01-JUN-2001; 2001US-00872035.			
PR	01-JUN-2001; 2001US-00872035.			
PR	05-JUN-2001; 2001US-008717800.			
PR	14-JUN-2001; 2001US-00874503.			
PR	19-JUN-2001; 2001US-00882636.			
PR	20-JUN-2001; 2001US-00886342.			
PR	20-JUN-2001; 2001US-008919692.			
PR	21-JUN-2001; 2001US-00897879.			
PR	22-JUN-2001; 2001US-00897879.			
PR	29-JUN-2001; 2001US-009020116.			
PR	09-JUL-2001; 2001US-009021066.			
PR	18-JUL-2001; 2001US-00908827.			
PR	06-AUG-2001; 2001US-00924419.			
PR	09-AUG-2001; 2001US-00927796.			
PR	16-AUG-2001; 2001US-00931836.			
PR	19-DEC-2001; 2001US-00028072.			
XX	(GETH) GENENTECH INC.			
XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;			
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;			
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;			
XX	WPI; 2004-008956/01.			
DR	P-PSDB; ADD76407.			
XX	New PRO nucleic acid, useful for recombinantly producing a PRO			
PT	polypeptide and for manufacturing a medicament for diagnosing or treating			
PT	a tumor.			
XX	Claim 2; Fig 221; 638pp; English.			
XX	The invention relates to isolated human PRO polypeptides (secreted and			
CC	transmembrane polypeptides) and the polynucleotides encoding them. The			
CC	invention also relates to an antibody which specifically binds to a PRO			
CC	polypeptide, a method for stimulating the release of tumour necrosis			
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the			
CC	proliferation or differentiation of chondrocyte cells and a method for			
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,			
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The			
CC	polynucleotides are useful in molecular biology, including uses as			
CC	hybridisation probes, in chromosome and gene mapping, in generating			
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also			
CC	be used in preparing PRO polypeptides by recombinant techniques and in			
CC	generating either transgenic animals or knock-out animals which are			
CC	useful in the development and screening of therapeutically useful			
CC	reagents. The PRO polypeptides or antibodies are used in preparing a			
CC	medicament for treating a condition responsive to the polypeptides or			
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation			
CC	of human microvascular endothelial cells, for modulating the uptake of			
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for			
CC	stimulating differentiation of adipocyte cells, for stimulating			
CC	proliferation of or gene expression in pericyte cells, for stimulating			
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte			
CC	cells, for inducing endothelial cell tube formation and for treating			
CC	various bone and/or cartilage disorders such as sports injuries and			
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans			
CC	from cartilage are useful for treating sports-related joint problems, PRO			
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO			
CC	polypeptides are also useful for treating various mammalian haemoglobin-			
CC	associated disorders such as various thalassaemias and conditions which			
CC	may benefit from enhanced local immune system cell infiltration. This			
CC	sequence represents a human PRO polynucleotide of the invention. Note:			
CC	The sequence data for this patent is also available in electronic format			
CC	from USPTO at seqdata.uspto.gov/sequence.html .			
XX	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;			
SQ	Query Match 0.9%; Score 21.4; DB 1; Length 1129;			
	Best Local Similarity 66.0%; Pred. No. 55;			
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;			
OY	1941 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1987			

XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-051576/05.
DR P-PSDB; ADE75623.
XX
XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding
PT it, for use in gene therapy, as diagnostic markers for the presence of a
PT disease condition, or as therapeutic targets for treating tumors,
PT diabetes, or arthritis.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred. No. 55;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX
XX 1941 TTTCTAATTTTTCATTCACAGATTTCCTTCAGTTGGTTTGGTTT 1987
XX 1129 TTTTTCATTTTTCATTTTTCATTCACAGATTTCCTTCAGTTGGTTTGGTTT 1083
XX
XX RESULT 224
XX ADE23198/c
XX ID ADE23198 standard; cDNA; 1129 BP.
XX AC
XX ADE23198;
XX
XX 29-JAN-2004 (first entry)
XX DT

XX cDNA encoding human PRO polypeptide #111.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX US2003092108-A1.
XX 15-MAY-2003.
XX 24-APR-2002; 2002US-00131835.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-020234/02.
XX P-PSDB; ADE23199.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also

10664775-4.rng

Mon Aug 9 17:47:27 2004

```
XX PS Claim 2; SEQ ID NO 221; 638pp; English.
XX CC
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC proliferation of or gene expression in pericyte cells, for stimulating
XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassaemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent is also available in electronic format
XX CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 55;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1941 TTCTTATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1987
Db 1129 TTTTITTTTTTTTTTTTCAGTGGCACACAGCGTGGTTTATT 1093

RESULT 229
ADE18223/C
ID ADE18223 standard; cDNA; 1129 BP.
XX AC
XX AC ADE18223;
XX DT 29-JAN-2004 (first entry)
XX DE
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX KW liver; microvascular endothelial cell; glucose; FFA;
XX KW skeletal muscle cell; adipocyte cell; pericyte cell;
XX KW inner ear utricular supporting cell; T-lymphocyte cell;
XX KW endothelial cell tube formation; bone disorder; cartilage disorder;
XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003194794-A1.
XX XX
```


prothrombin; thrombin; Factor V; Factor VIII; fibrinogen; fibrin; plasma factor; bleeding episode; haemophilia A; haemophilia B; thrombus; intimal hyperplasia; restenosis; cardiogenic embolism; stroke; platelet deposition; percutaneous transluminal coronary angioplasty; PTCA; cancer; tumour; angiodenesis; ischaemia; reperfusion; thrombolysis; rheumatoid arthritis; arteriosclerosis; inflammation; septic shock; hypotension; adult respiratory distress syndrome; ARDS; myocardial infarction; vasotropic; cerebroprotective; antibacterial; immunosuppressive; cardiant; gene therapy; ds; pLN174.

Homo sapiens.
Unidentified.
Synthetic.

Key Location/Qualifiers

CDS 285..1505
/tag= a
/product= "Coagulation Factor VII"
/partial
/transl_except= (pos:300..305,aa:Xaa-Xaa)
/transl_except= (pos:324..326,aa:Xaa)
/transl_except= (pos:330..332,aa:Xaa)
/transl_except= (pos:339..344,aa:Xaa-Xaa)
/transl_except= (pos:357..362,aa:Xaa-Xaa)
/transl_except= (pos:369..371,aa:Xaa)
/transl_except= (pos:387..389,aa:Xaa)
/note= "NO start codon shown. Xaa = gamma carboxylated glutamic acid"

WO200277218-A1.

XX

ED 03-OCT-2002.

XX 21-MAR-2002; 2002WO-DK000189.

XX 22-MAR-2001; 2001DK-00000477.

XX (NOVO) NOVO NORDISK AS.

XX Persson E;

XX WPI; 2003-059374/05.

XX P-PSDB; ABG73119.

XX Novel factor VII polypeptide, its derivatives useful for preparing medicament for treating bleeding episodes, or for enhancing normal hemostatic system, especially for treating hemophilia.

XX Disclosure; Page 82-85; 96pp; English.

XX The invention discloses a human factor VII polypeptide, or a variant or derivative of it, where an amino acid has been modified. This change results in a polypeptide with the same or an increased activity when compared to recombinant wild type human Factor VIIa. Blood coagulation consists of a complex interaction of various blood components that eventually give rise to a fibrin clot. Initiation of the haemostatic process is mediated by the formation of a complex between tissue factor and Factor VIIa (the active form of the Factor VII zymogen). This complex activates Factors IX and X, converting prothrombin to thrombin, which thrombin converts fibrinogen to fibrin resulting in formation of a fibrin clot. The Factor VII zymogen, or its derivative, can be modified in its catalytic centre to inhibit the ability of the Factor VII polypeptide to activate plasma factor X or IX. The factor VII derivative is useful for preparing a medicament for the treatment of bleeding episodes, for the enhancement of the normal haemostatic system, especially for the treatment of haemophilia A or B and for inhibiting thrombus formation. The inactivated factor VII derivatives are useful for treating intimal hyperplasia, restenosis, cardiogenic emboli, platelet deposition disorders, percutaneous transluminal coronary angioplasty (PTCA), stroke, cancer, tumour metastasis, angiodenesis, ischaemia/reperfusion, rheumatoid arthritis, thrombolysis, arteriosclerosis, acute and chronic indications, such as inflammation, septic shock, hypotension, adult

CC respiratory distress syndrome (ARDS) and myocardial infarction. The CC sequence presented is the plasmid, pLN174, which expresses the CC inactivated human coagulation Factor VII polypeptide
XX
SQ Sequence 6098 BP; 1413 A; 1587 C; 1623 G; 1475 T; 0 U; 0 Other;

Query Match 0.9%; Score 21.4; DB 1; Length 6098;
Best Local Similarity 49.5%; Pred. No. 67;
Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 1642 TTGTATGCTTCTGTGACCTTGATAGGATCTTTCTCAAGTTAGGAATTTTCTTT 1701

Db 4429 TTTTACGTTCTGCGCTTTTGCTGCGCTTTTGCTCACATGTTCTTCTCGGTATCC 4488

QY 1702 TTTGGTTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTCTTCCCT 1752

Db 4489 CCTGATTCGTGGATAACGATTATACCGCTTTGAGTGAGCTGATACCGCT 4539

RESULT 232

ABA79647

ID ABA79647 standard; DNA; 121 BP.

XX AC ABA79647;

XX 24-JAN-2002 (first entry)

XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2493.

XX Human; Gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antileptic; ss.

OS Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US009761.

XX 27-MAR-2000; 2000US-0192176P.

XX 27-MAR-2000; 2000US-0192179P.

XX 01-JUN-2000; 2000US-0208538P.

XX 30-OCT-2000; 2000US-0244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.

XX Claim 7; Page 185; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

xx
ps Claim 7; Page 185; 294pp; English.
xx
cc The present invention provides single-stranded oligonucleotides which can
cc be used for the targeted alteration of genomic sequences, where the
cc oligonucleotide has at least one mismatch compared with the genomic

XX		
PT	Oligonucleotide for targeted alterations of genetic sequences and for	
PT	treating cystic fibrosis, comprises at least one mismatch and chemical	
PT	modification.	
XX		
PS	Claim 7; Page 185; 294pp; English.	
XX		
CC	The present invention provides single-stranded oligonucleotides which can	
CC	be used for the targeted alteration of genomic sequences, where the	
CC	oligonucleotide has at least one mismatch compared with the genomic	
CC	sequence to be altered. In particular, these sequences are directed at	
CC	the following genes: adenosine deaminase, p53, beta-globin,	
CC	retinoblastoma, BRCA1, BRCA2, CPTA, cyclin-dependent kinase inhibitor 2A	
CC	(CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus	
CC	1 (HBA1), haemoglobin alpha locus 2 (HBAA2), MLI1, MSH2, MSH6,	
CC	apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase	
CC	(UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and	
CC	presenilin-2 (PSEN2). These can be used in the gene therapy of diseases	
CC	such as cancer, adenosine deaminase deficiency, cystic fibrosis,	
CC	haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,	
CC	Alzheimer's disease, melanoma, adenomatous polyposis of the colon and	
CC	various syndromes. The present sequence is one of the gene correcting	
CC	oligonucleotides of the invention	
XX		
SQ	Sequence 121 BP; 39 A; 24 C; 22 G; 36 T; 0 U; 0 Other;	
	Query Match 0.9%; Score 21.2; DB 1; Length 121;	
	Best Local Similarity 53.7%; Pred. No. 41;	
	Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;	
QY	2168 CTATTGTAATAGGGTTTGTAGCAGGCACATATGTCCTGGTTGTTATCTCTGCTGTTTTTG 2227	
Dd		
	38 CCATTTAAACATGGATTGGACTCACACTGATCTCATCTTTGAGTAGTTTAGAATAATG 97	
QY	2228 CTTTGGCATATPAGCGCTGAG 2249	
Dd		
	98 AATTGGCAGCTAAAACCTGTTAG 119	
RESULT 236		
ABS68969/C		
ID	ABS68969 standard; DNA; 305 BP.	
XX	ABS68969;	
AC		
XX		
DT	21-NOV-2002 (first entry)	
XX		
DE	Novel murine polynucleotide isolated using gene trap technology #32..	
XX		
KW	Mouse; gene trapped sequence; GTS; functional genomic analysis;	
KW	phage display system; gene chip; temporal gene expression;	
KW	tissue specific gene expression; antisense inhibition; gene targeting;	
KW	development disorder; cell differentiation disorder; aging; cancer;	
KW	autoimmune disease; lupus; inflammatory disorder; skin disorder;	
KW	degenerative disorder; ds.	
XX		
OS	Mus musculus.	
XX		
PN	US2002102543-A1.	
XX		
PD	01-AUG-2002.	
XX		
PF	30-NOV-2000; 2000US-0072845.	
XX		
PR	01-DEC-1999; . 99US-0168358P.	
XX		
PA	{FRIE// FRIEDRICH G.	
PA	{ZAMB// ZAMBROWICZ B.	
PA	{SAND// SANDS A T.	
PI	Friedrich G, Zambrowicz B, Sands AT;	
DR	WPI; 2002-690598/74.	

Db	191	CTTCTCCAGTTCACAGTGTGCTTTTTCGCG	164
RESULT 248			
AAI05898/c			
ID	AAI05898	standard; DNA; 263 BP.	
XX			
AC	AAI05898;		
XX			
DT	09-OCT-2001	(first entry)	
XX			
DE	Probe #5889	used to measure gene expression	
XX			
KW	Probe; human; breast disease; breast cancer		
KW	inflammatory disease; proliferative breast		
XX			
OS	Homo sapiens.		
XX			
PN	W0200157270-A2.		
XX			
PD	09-AUG-2001.		
XX			
PF	29-JAN-2001; 2001WO-US000661.		
XX			
PR	04-FEB-2000; 2000US-0180312P.		
PR	26-MAY-2000; 2000US-0207456P.		
PR	30-JUN-2000; 2000US-00608408.		
PR	03-AUG-2000; 2000US-00632366.		
PR	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
XX			
XX	04-OCT-2000; 2000GB-00024263.		
PA	(MOLE-) MOLECULAR DYNAMICS INC.		
XX			
PI	Penn SG, Hanzel DK, Chen W, Rank DR;		
XX			
DR	WPI; 2001-476286/51.		
XX			
PT	Novel single exon nucleic acid probe used		
PT	a human breast.		
XX			
PS	Claim 25; SEQ ID NO 5889; 322pp; English.		
XX			
CC	The present invention relates to novel sin		
CC	The present sequence is one such probe. Th		
CC	measuring human gene expression in a human		
CC	hybridises at high stringency to a nucleic		
CC	breast. The probes are useful for predicti		
CC	staging, monitoring and prognosing diseas		
CC	particularly those diseases with polygenic		
CC	include: breast cancer, disorders of devel		
CC	of the breast, fibrocystic changes, prolif		
CC	carcinoma tumours. Note: The sequence data		
CC	part of the printed specification, but was		
CC	directly from WIPO at ftp.wipo.int/pub/pub		
XX			
XX	Sequence 263 BP; 91 A; 47 C; 102 G; 23 T;		
XX			
Query Match	0.9%	Score 20.8;	
Best Local Similarity	52.3%	Pred. No. 61;	
Matches	46; Conservative	0; Mismatches	
QY	1720	ATTTCCTGCTTTTGACCTGCCTCTCTCCCTCT	
DbD	251	AAATTTCTTTCTCCTCTCTCCCTCTCTCTCTGCGG	
QY	1780	TGTCCTCGCTTCTCGATGCTTTTATGC	1807
DbD	191	CTTCTCCAGTTCAGTGTGCTTTTTCGCG	164
RESULT 249			
ABSI13468/c			

05C JULISA

AC AAL22285;

XX Human breast cancer expressed polynucleotide 14742.

kw Human: breast cancer; cell marker; cytostatic; ss.

OS Homo sapiens.

PN WO200151628-A2.

XX

XX

14-04AN-2000; 2000US-0189167P
14-MAR-2000; 2000US-0189167P

PR 24-MAR-2000; 2000US-0192099F.

PR 15-MAY-2000; 2000US-0205230P.

09-JUN-2000; Z000US-0211313F:

XX

FA (MILITARY) IDENTIFICATION CARD
 vv

PI Lillie J, Xu Y, Wang Y, Su

WPT: 2001-451856/48.

[illegible]

PS Claim 1; page 2657-2658; 3693

CC The invention relates to human

CC (AALU/344-AAL20/83) and medical
CC - tested with breast cancer

CC expression of certain markers

the polymorphs are characterized by different

CC potentially preventing breast

activity

XX SQ Sequence 280 BP; 69 A; 70 C; 74 G; 67 T; 0 U; 0 Other;
 Query Match 0.9%; Score 20.8; DB 1; Length 280;
 Best Local Similarity 51.0%; Pred. No. 62;
 Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
 QY 396 TCTAGATTTAAGCTGTGGTGCAGATAGGACATAGAGTATTATTCAATTGCTTTTAT 455
 Db 91 TCTGGCTCTTGACAAGATAGACCCTGGAACTAGAGAGGAGAGATTCTACTGGTCA 150
 QY 456 CTGTCGAGACTTGTCTTTGTTTGAATATGTATTC 491
 Db 151 CAGACAAGACTCTCTTGATCTGCAATACGACTTCA 186

Search completed: August 9, 2004, 17:19:45
 Job time : 889 secs

